<SEC-DOCUMENT>0001213900-25-104141.txt : 20251030
<SEC-HEADER>0001213900-25-104141.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251030161055
ACCESSION NUMBER:		0001213900-25-104141
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		251435632

	BUSINESS ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0261356-10q_inmune.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:inmb="http://inmunebio.com/20250930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-6288">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Mark One)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-6289">&#9746;</ix:nonNumeric><b>&#160;QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-6290">SEPTEMBER 30,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-6291">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-6292">&#9744;</ix:nonNumeric>&#160;<b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-6293">001-38793</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 100%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-63"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INMUNE BIO INC.</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact name of registrant as specified in its charter)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-76"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-81"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>47-5205835</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State of incorporation)</i></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer <br/>
Identification No.)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-6294">225 NE Mizner Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-6295">Suite 640</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-6296">Boca Raton</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-6297">FL</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-6298">33432</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive office)</i>
(Zip code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-6299">(561)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-6300">710-0512</ix:nonNumeric></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Registrant&#8217;s telephone number, including
area code)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-135"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-139"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INMB</span></ix:nonNumeric></td> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-6301">NASDAQ</ix:nonNumeric> Stock Market LLC</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Indicate
by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period than the registrant was required to file such reports),
and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-6302">Yes</ix:nonNumeric><span style="background-color: white">&#160;</span>&#9746;<span style="background-color: white">&#160;No&#160;</span>&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405
of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant
was required to submit such files).&#160;</span><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-6303">Yes</ix:nonNumeric><span style="background-color: white">&#160;</span>&#9746;<span style="background-color: white">&#160;No&#160;</span>&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-178"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-185"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-191"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td> <td>&#160;</td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Indicate
by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;&#9744;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-6304">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of October 30, 2025, there were <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6305">26,585,258</ix:nonFraction> shares
of our common stock, par value $0.001 per share, outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-Q</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I &#8211; FINANCIAL INFORMATION</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="width: 8%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 83%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Quantitative and Qualitative Disclosure About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">PART II &#8211; OTHER INFORMATION</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Defaults Upon Senior Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Exhibits</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Financial Statements</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share and per share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CURRENT ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6306">27,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6307">20,922</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development tax credit receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-6308">1,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-6309">1,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-6310">760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-6311">228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-6312">472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-6313">331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-6314">30,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-6315">22,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-6316">878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease &#8211; right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6317">1,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6318">307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-6319">746</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-6320">79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Acquired in-process research and development intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-6321">16,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-6322">33,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-6323">39,562</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6324">6,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6325">6,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts payable and accrued liabilities &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6326">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6327">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6328">517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Operating lease, current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6329">457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6330">140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6331">7,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6332">7,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6333">623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6334">244</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-6335">7,980</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-6336">7,465</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6337"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6338">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-6339"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-6340">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-6341"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-6342"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6343"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6344">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6345"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6346">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-6347"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-6348">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-6349"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6350">26,585,258</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-6351"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6352">22,280,451</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-6353">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-6354">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-6355">229,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-6356">195,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6357">764</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6358">575</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-6359">203,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-6360">163,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6361">25,378</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6362">32,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-6363">33,358</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-6364">39,562</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share and per share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;Three&#160;Months&#160;Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-6365">50</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-6366">14</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-6367">2,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-6368">2,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-6369">7,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-6370">7,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-6371">4,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-6372">10,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-6373">18,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-6374">25,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Impairment of acquired in-process research and development intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-6375">16,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-6376">7,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-6377">12,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-6378">41,959</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-6379">33,182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6380">7,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6381">12,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6382">41,909</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6383">33,168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">OTHER INCOME, NET</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-6384">961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-6385">193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-6386">1,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-6387">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6388">6,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6389">12,093</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6390">40,669</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6391">32,864</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net loss per common share &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-6392"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-6393">0.24</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-6394"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-6395">0.60</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-6396"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-6397">1.68</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-6398"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-6399">1.71</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-6400"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-6401">26,585,258</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-6402"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-6403">20,185,676</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-6404"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-6405">24,141,613</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-6406"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-6407">19,176,853</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6408">6,472</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6409">12,093</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6410">40,669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6411">32,864</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other comprehensive loss &#8211; foreign currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6412">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6413">323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6414">189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6415">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6416">6,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6417">12,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6418">40,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6419">33,101</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white">The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6420">22,280,451</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6421">22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6422">195,754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6423">575</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6424">163,104</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6425">32,097</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6426">2,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6427">2,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-6428">649,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6429">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6430">5,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6431">5,273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise of warrants for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-6432">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-6433">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-6434">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6435">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6436">35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6437">9,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6438">9,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance as of March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6439">22,930,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6440">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6441">203,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6442">610</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6443">172,843</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6444">29,673</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6445">1,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6446">1,534</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-6447">3,654,847</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6448">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6449">22,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6450">22,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6451">153</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6452">153</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6453">24,458</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6454">24,458</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6455">26,585,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6456">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6457">226,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6458">763</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6459">197,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6460">28,867</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6461">2,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6462">2,984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6463">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6464">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6465">6,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6466">6,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6467">26,585,258</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6468">27</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6469">229,888</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6470">764</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6471">203,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6472">25,378</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b>The accompanying notes are an integral
part of these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="padding-bottom: 0pt">&#160;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Income (Loss)</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 0pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c40" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6473">17,950,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6474">18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6475">159,143</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6476">799</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6477">121,022</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6478">37,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6479">1,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6480">1,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" unitRef="usd" id="ixv-6481">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" unitRef="usd" id="ixv-6482">130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6483">11,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6484">11,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6485">17,950,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6486">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6487">160,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6488">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6489">132,047</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6490">28,224</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6491">2,350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6492">2,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-6493">198,364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6494">2,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-6495">2,032</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock and warrants issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" scale="0" unitRef="shares" id="ixv-6496">1,557,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6497">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6498">13,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6499">13,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6500">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6501">44</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6502">9,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6503">9,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6504">19,706,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6505">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6506">178,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6507">713</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6508">141,793</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6509">36,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6510">1,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-6511">1,719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock and warrants issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" scale="0" unitRef="shares" id="ixv-6512">2,390,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6513">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6514">12,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" scale="3" unitRef="usd" id="ixv-6515">12,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reclassification from redeemable common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" scale="0" unitRef="shares" id="ixv-6516">75,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" scale="3" unitRef="usd" id="ixv-6517">799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" scale="3" unitRef="usd" id="ixv-6518">799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6519">323</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-6520">323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6521">12,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6522">12,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-6523">22,172,451</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6524">22</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6525">193,575</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6526">1,036</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-6527">153,886</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-6528">38,675</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white">The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6529">40,669</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-6530">32,864</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-6531">6,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-6532">5,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accretion of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" sign="-" unitRef="usd" id="ixv-6533">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="inmb:GainOnSettlementOfAccountsPayable" scale="3" unitRef="usd" id="ixv-6534">626</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-6535">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Impairment of acquired in-process research and development intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-6536">16,514</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development tax credit receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-6537">523</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" sign="-" unitRef="usd" id="ixv-6538">796</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Other tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" unitRef="usd" id="ixv-6539">532</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-6540">226</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" unitRef="usd" id="ixv-6541">141</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" sign="-" unitRef="usd" id="ixv-6542">646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Prepaid expenses &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="inmb:IncreaseDecreaseInPrepaidExpensesRelatedParty" scale="3" sign="-" unitRef="usd" id="ixv-6543">127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" unitRef="usd" id="ixv-6544">667</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd" id="ixv-6545">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-6546">962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-6547">2,689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable and accrued liabilities &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" unitRef="usd" id="ixv-6548">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deferred liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-6549">517</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" unitRef="usd" id="ixv-6550">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-6551">61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-6552">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-6553">19,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-6554">22,348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Purchase of equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-6555">899</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-6556">899</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net proceeds from sale of common stock and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-6557">27,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-6558">27,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Exercise of warrants for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-6559">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Repayments of debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-6560">7,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-6561">27,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-6562">20,289</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact on cash from foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-6563">196</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-6564">237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-6565">6,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-6566">2,296</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-6567">20,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-6568">35,848</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">CASH AND CASH EQUIVALENTS AT END OF PERIOD</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-6569">27,734</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-6570">33,552</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Cash paid for interest expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-6571">661</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Right of use assets obtained in exchange for lease obligations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-6572">702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INMUNE BIO INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-2948"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 1</span> &#8211; ORGANIZATION AND DESCRIPTION
OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INmune Bio Inc. (the &#8220;Company&#8221; or &#8220;INmune Bio&#8221;)
was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical company focused on developing
and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. INmune Bio has three product platforms.&#160;The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases and was used for its Alzheimer&#8217;s
clinical trial (&#8220;XPro&#8221;). The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem cell product currently
being developed to treat recessive dystrophic epidermolysis bullosa (&#8220;RDEB&#8221;). The Natural Killer Cell Priming Platform includes
INKmune aimed at priming the patient&#8217;s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio&#8217;s
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors
and chronic inflammation.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="ixv-2957"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2</span> &#8211; GOING CONCERN </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant
revenue from the commercialization of its product candidates. During the nine months ended September 30, 2025, the Company incurred a
net loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-6573">40.7</ix:nonFraction>&#160;million and had net cash flows used in operating activities of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd" id="ixv-6574">19.6</ix:nonFraction>&#160;million. Given the Company&#8217;s projected
operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations
through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In response to these conditions, management is
currently evaluating different strategies to obtain the required funding of future operations. Financing strategies may include, but are
not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding,
collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. There can be no assurances
that the Company will be able to secure additional financing, or if available, that it will be sufficient to meet its needs or on favorable
terms. Because management&#8217;s plans have not yet been finalized and are not within the Company&#8217;s control, the implementation
of such plans cannot be considered probable. As a result, the Company has concluded that management&#8217;s plans do not alleviate substantial
doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might result from the outcome of this uncertainty.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-2972"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 3</span> &#8211; SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-2977"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Basis
of Presentation</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US
GAAP&#8221;), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. </span>These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-3005"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s product candidates are still
in development and, to date, none of the Company&#8217;s product candidates have been approved for sale.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the Company&#8217;s
research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products. The Company operates in an environment of rapid change in technology and substantial
competition from other pharmaceutical and biotechnology companies.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company relies and expects to continue to
rely on a small number of vendors to manufacture supplies and materials for its use in the clinical trial programs. These programs could
be adversely affected by a significant interruption in these manufacturing services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-3024"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparing financial statements in conformity with
US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-3032"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures certain assets and liabilities
in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following
three categories:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;2: Observable prices that
are based on inputs not quoted on active markets but corroborated by market data.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;3: Unobservable inputs are
used when little or no market data is available.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_6" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities are classified based on
the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification
on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets
or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of
the fair value measurement hierarchy during the years presented.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial instruments
such as cash and cash equivalents, research and development tax credit receivable, other tax receivable, prepaid expenses, and accounts
payable and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-3070"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash
equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation
limits. The Company maintains its cash deposits with major financial institutions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_InProcessResearchAndDevelopmentPolicy-c0_cont_1" escape="true" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="ixv-3079"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Research
and Development Tax Incentive Receivable</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_InProcessResearchAndDevelopmentPolicy-c0_cont_2" id="_InProcessResearchAndDevelopmentPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in Australia (&#8220;AUS&#8221;), participates in the Australian research and development tax incentive program, such that a percentage
of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected
as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is
reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration
can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information
at the time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_InProcessResearchAndDevelopmentPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in the United Kingdom (&#8220;UK&#8221;), participates in the research and development program provided by the United Kingdom tax relief
program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government,
and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax
incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred
and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to
the Company based on available information at the time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-3091"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment is recorded at cost and depreciated
using the straight-line method over the estimated useful lives of the assets and consist of scientific equipment with a <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-6575">5</ix:nonNumeric> year life. Repairs
and maintenance costs are charged to expense as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-3100"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined and the in-process research and development intangible assets will be amortized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair value, an impairment loss is recognized in an amount
equal to that excess.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#8217;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#8217;s fair value
at $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-6576">0</ix:nonFraction>, resulting in a recorded impairment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-6577">16,514,000</ix:nonFraction> which was recorded during the second quarter of 2025.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-3129"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share </i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-3137"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6578">7,195,342</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6579">6,296,807</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6580">3,944,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6581">3,944,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6582">11,139,480</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-6583">10,241,045</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-3187"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-3198"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires
the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can
materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally
require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined
from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate
weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for
forfeitures of stock options as they occur.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-3207"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development
costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies,
clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead
costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development
activities on the Company&#8217;s behalf.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the
periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. </span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-3234"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the liability method of accounting
for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable
to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-3242"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements are presented
in the U.S. dollar (&#8220;$&#8221;), which is the Company&#8217;s reporting currency, while its functional currencies are the U.S. Dollar
for its U.S. based operations, British Pound (&#8220;GBP&#8221;) for its United Kingdom-based operations and Australian Dollars (&#8220;AUD&#8221;)
for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#8217;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-3250"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Information</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has one primary business activity
and operates in one reportable segment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s chief operating decision maker
(&#8220;CODM&#8221;) is its Chief Executive Officer who evaluates performance and makes operating decisions about allocating resources
based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed
by the CODM are consistent with these financial statements and footnotes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-3261"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,&#160;<i>Income
Taxes (Topic 740): Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024 and for interim periods
for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact that
the adoption of ASU 2023-09 may have on its consolidated financial statements.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40):&#160;<i>Disaggregation of Income
Statement Expenses</i>&#160;(&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company&#8217;s current financial position, results of operations or
financial statement disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act
(&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as expensing of U.S. research expenditures
and eligible capital expenditures, the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications
to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The impacts of the
OBBBA are reflected in our results for the quarter ended September 30, 2025, and there was no impact to our income tax expense or effective
income tax rate.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-3284"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 4</span> &#8211; RESEARCH AND DEVELOPMENT
ACTIVITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to AUS tax law, the Company is allowed
an R&amp;D tax credit that reduces a company&#8217;s tax bill in AUS for expenses incurred in R&amp;D subject to certain requirements.
The Company&#8217;s Australian subsidiary submits R&amp;D tax credit requests annually for research and development expenses incurred.
At September 30, 2025 and December 31, 2024, the Company recorded a research and development tax credit receivable of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-6584">1,704,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-6585">1,181,000</ix:nonFraction>,
respectively, for R&amp;D expenses incurred in Australia.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock-c0_cont_2" id="_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Xencor, Inc. License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On October
3, 2017, the Company entered into a license agreement (&#8220;Xencor License Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;),
which discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. On June 10, 2021, the Company
and Xencor entered into a First Amendment to License Agreement pursuant to which, among other things, Section 3.2 of the Xencor License
Agreement was amended to change the due diligence milestones. Pursuant to the Xencor License Agreement, Xencor granted the Company an
exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license
agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor&#8217;s
proprietary protein known as &#8220;XPro&#8221; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants
of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients,
in any dosage or formulation (&#8220;Licensed Products&#8221;). The Company believes the protein has numerous medical applications. Such
additional alternative applications of the technology are available under the Xencor License Agreement. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
also agreed to pay Xencor a&#160;<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="inmb:SaleOfRoyaltyPercentage" scale="-2" unitRef="pure" id="ixv-6586">5</ix:nonFraction>% royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by-
country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid
claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product
in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#8217;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#8217;s fair value
at $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-6587">0</ix:nonFraction>, resulting in a recorded impairment of $<ix:nonFraction contextRef="c78" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-6588">16,514,000</ix:nonFraction> during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.75pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>CORDStrom License Agreement&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2025, the Company and Great Ormond
Street Hospital for Children NHS Foundation Trust (&#8220;GOSH&#8221;) entered into a license agreement for the exclusive commercial use
to clinical trial data associated with a GOSH study investigating the potential of CORDStrom to treat RDEB in pediatric patients (the
&#8220;MissionEB study&#8221;). The Company owns the intellectual property covering CORDStrom, the investigational medicinal product used
in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the manufacturing
of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing authorization
of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include a milestone payment
of up to &#163;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="0" unitRef="gbp" id="ixv-6589">6,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="6" unitRef="usd" id="ixv-6590">8.1</ix:nonFraction> million as of September 30, 2025) due on the first to occur marketing authorization to be
granted by the FDA, EMA or MHRA, which had not occurred as of September 30, 2025. The Company was also required to make an upfront payment
to GOSH of approximately $<ix:nonFraction contextRef="c79" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" unitRef="usd" id="ixv-6591">0.3</ix:nonFraction> million, which the Company paid during July 2025 and recorded in research and development expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the GOSH license agreement, the Company
has an obligation to provide CORDStrom to the MissionEB study at no cost. While Part 1 of the study is completed, Part 2 of the MissionEB
study is currently uninitiated due to a lack of funding by the National Health Services England (&#8220;NHSE&#8221;). It is unknown whether
funding for the study will be allocated by NHSE or its successor agency in the United Kingdom. The Company has not recorded an estimated
obligation for the supply of the MissionEB trial with CORDStrom as it is unknown if the MissionEB trial will resume.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>INKmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2015, the Company entered into
an exclusive license agreement (the &#8220;INKmune License Agreement&#8221;) with Immune Ventures, LLC (&#8220;Immune Ventures&#8221;).
Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate
any improvements or additions to the patents that may be developed in the future. <ix:nonNumeric contextRef="c0" continuedAt="inmb_ScheduleOfMilestonePaymentsTableTextBlock-c0_cont_1" escape="true" name="inmb:ScheduleOfMilestonePaymentsTableTextBlock" id="ixv-6592">In consideration for the patent rights, the Company
agreed to the following milestone payments:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="inmb_ScheduleOfMilestonePaymentsTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6593">25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase II initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6594">250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6595">350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each NDA/EMA filing</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6596">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each NDA/EMA awarded</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6597">9,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company agreed to pay the licensor
a royalty of&#160;<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="inmb:PercentageOfLicensorRoyaltyPatentGrant" scale="-2" unitRef="pure" id="ixv-6598">1</ix:nonFraction>% of net sales during the life of each patent granted to the Company. The License is owned by Immune Ventures. David
Moss, the Company&#8217;s Chief Executive Officer, Mark Lowdell, its Chief Scientific Officer, and RJ Tesi, former Chief Executive Officer
of the Company, are the owners of Immune Ventures. No sales have occurred under this license. During December 2023, the Company initiated
a Phase I trial with INKmune in patients with metastatic castration-resistant prostate cancer. At December 31, 2024 and September 30,
2025, the Company recorded $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-6599"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-6600">25,000</ix:nonFraction></ix:nonFraction>&#160;payable to Immune Ventures within accounts payable and accrued liabilities &#8211; related parties
in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the agreement began on October 29,
2015 and ends on a country-by-country basis on the date of the expiration of the last to expire patent rights where patent rights exists,
unless terminated earlier in accordance with the agreement. Upon the termination of the agreement, we shall have a fully paid up, perpetual,
royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days
from the Company&#8217;s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not
make this payment. On July&#160;20, 2018 and October 30, 2020, the parties amended the agreement under which the Company was required
achieve milestones pursuant to the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2023, the parties executed an additional
amendment to the agreement under which the Company removed the due diligence requirements to achieve reasonable commercial efforts to
bring INKmune to market. This removed all requirements of clinical trial timelines and the filing timelines of an NDA or equivalent. All
other provisions in the INKmune License Agreement shall continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Pittsburg License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2017, the Company entered into an
Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh.
Pursuant to the Assignment and Assumption Agreement (&#8220;Assignment Agreement&#8221;), Immune Ventures assigned all of its rights,
obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh &#8211; Of the Commonwealth System
of Higher Education (&#8220;Licensor&#8221;) and Immune Ventures to INmune Bio (&#8220;Licensee&#8221;), (the &#8220;PITT Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consideration under the PITT Agreement includes:
(i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone
payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company owes annual maintenance fees under
the PITT Agreement in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" unitRef="usd" id="ixv-6601">25,000</ix:nonFraction> payable on June 26 of each year until the first commercial sale. At September 30, 2025, the
Company owed the University of Pittsburgh $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" unitRef="usd" id="ixv-6602">25,000</ix:nonFraction> for annual maintenance fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon first commercial sale of a product making
use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="inmb:PercentageOfNetSalesToPayRoyalties" scale="-2" unitRef="pure" id="ixv-6603">2.5</ix:nonFraction>% of Net Sales each calendar
quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="inmb:ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" id="ixv-3405"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, under the PITT Agreement the Licensee
is required to make milestone payments as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6604">50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6605">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">First commercial sale of product making use of licensed technology</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="inmb:MilestonePayments" scale="3" unitRef="usd" id="ixv-6606">1,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="inmb:AgreementExpirationTerm" id="ixv-6607">The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensee may terminate the PITT Agreement
upon 3 months prior written notice provided all payments under the license are current. The Licensor may terminate the PITT Agreement
upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after
receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to
the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-3451"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 5</span> &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-3456"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">September 30, 2025:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6608">10,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6609">10,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6610">16,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6611">16,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6612">27,238</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6613">27,238</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">December 31, 2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6614">10,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6615">10,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6616">10,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6617">10,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6618">20,588</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6619">20,588</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-3691"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 6</span> &#8211; COMMITMENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In April
2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing
space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-6620">76,000</ix:nonFraction> each quarter during the
first year and $<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-6621">152,000</ix:nonFraction> each quarter during the second year. The lease commencement date is August 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-3699"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">As of September 30, 2025, the
maturities of our lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-6622">68</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-6623">729</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-6624">405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-6625">1,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-6626">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future lease payments</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-6627">1,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: operating lease, current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6628">457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Long-term operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6629">623</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Weighted-average remaining lease term</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-6630">1.7</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-6631">12.0</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2025 the Company recognized $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-6632">134,000</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-6633">229,000</ix:nonFraction>, respectively, of lease expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2024, the Company recognized $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-6634">40,000</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd" id="ixv-6635">120,000</ix:nonFraction>, respectively, of lease expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2025, the Company&#8217;s wholly-owned
subsidiary, INmune Bio International. Ltd., entered into a <ix:nonNumeric contextRef="c112" format="ixt-sec:duryear" name="inmb:CollaborationAgreementTerm" id="ixv-6636">2</ix:nonNumeric>-year collaboration agreement with a vendor whereby it makes fixed payments
to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. <ix:nonNumeric contextRef="c0" continuedAt="_OtherCommitmentsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherCommitmentsTableTextBlock" id="ixv-6637">A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_OtherCommitmentsTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" scale="3" unitRef="usd" id="ixv-6638">1,449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitmentDueInSecondYear" scale="3" unitRef="usd" id="ixv-6639">1,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="3" unitRef="usd" id="ixv-6640">2,626</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-3829"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 7</span> &#8211; RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">UCL</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During
the nine months ended September 30, 2025 and 2024, the Company made payments to UCL of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-6641">132,000</ix:nonFraction> and $<ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-6642">252,000</ix:nonFraction>, respectively, for medical
research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company&#8217;s Chief
Scientific and Manufacturing Officer is a professor at the University of London.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">AmplifyBio</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">At September
30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-6643">26,000</ix:nonFraction> and $<ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-6644">0</ix:nonFraction>, respectively, for medical research performed
on behalf of the Company. During the nine months ended September 30, 2025 and 2024, the Company paid AmplifyBio $<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-6645">41,000</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-6646">324,000</ix:nonFraction>,
respectively. During 2025, AmplifyBio ceased operations. Amplify Bio&#8217;s former CEO is on the board of directors of the Company.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-3850"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 8</span> &#8211; DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During 2021,
the Company entered into a Loan and Security Agreement (the &#8220;Term Loan&#8221;) with Silicon Valley Bank and SVB Innovation Credit
Fund VIII, L.P., together (the &#8220;Lenders&#8221;) in which the Company borrowed $<ix:nonFraction contextRef="c117" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="usd" id="ixv-6647">15</ix:nonFraction> million. The Term Loan was secured by the Company&#8217;s
assets. During December 2024, the Company paid off the Term Loan in full. During February 2025, the Company entered into a letter agreement
with the Lenders whereby the Term Loan was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
three and nine months ended September 30, 2024, the Company recognized interest expense of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd" id="ixv-6648">145,000</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd" id="ixv-6649">752,000</ix:nonFraction>, respectively, related
to the Term Loan</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-3863"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 9</span> &#8211; STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Registered Direct Offerings</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During June 2025, the Company entered into securities
purchase agreements with investors whereby the Company sold <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6650">3,000,000</ix:nonFraction> shares of the common stock in a registered direct offering in exchange
for gross proceeds of $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-6651">18.9</ix:nonFraction> million (net proceeds of approximately $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="inmb:IssuanceOfNetProceeds" scale="6" unitRef="usd" id="ixv-6652">17.4</ix:nonFraction> million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During September 2024, the Company entered into
securities purchase agreements with investors whereby the Company sold&#160;<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6653">2,341,260</ix:nonFraction>&#160;shares of the Company&#8217;s common stock
and warrants to purchase an additional&#160;<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-6654">2,341,260</ix:nonFraction>&#160;shares of the Company&#8217;s common stock in a registered direct offering
in exchange for gross proceeds of $<ix:nonFraction contextRef="c120" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-6655">13.0</ix:nonFraction>&#160;million (net proceeds of approximately $<ix:nonFraction contextRef="c8" decimals="-5" format="ixt:num-dot-decimal" name="inmb:IssuanceOfNetProceeds" scale="6" unitRef="usd" id="ixv-6656">12.0</ix:nonFraction>&#160;million).&#160;Directors&#160;and officers
that participated in the offering paid a combined offering price of $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-6657">6.50</ix:nonFraction>&#160;per share and warrant, and other investors paid a combined
offering price of $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-6658">5.50</ix:nonFraction>&#160;per share and warrant. The warrants are exercisable until March 16, 2030 and the exercise price is $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-6659">6.40</ix:nonFraction>.
The Company determined the warrants were equity classified. The fair value of the warrants was approximately $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" unitRef="usd" id="ixv-6660">9.1</ix:nonFraction>&#160;million and was
calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount
rate of&#160;<ix:nonFraction contextRef="c124" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-6661">3.41</ix:nonFraction>% based on the applicable US Treasury bill rate (2) expected life of&#160;<ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-6662">5.5</ix:nonNumeric>&#160;years, (3) expected volatility of
approximately&#160;<ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-6663">92</ix:nonFraction>% based on the trading history of the Company, and (4)&#160;<ix:nonFraction contextRef="c124" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" unitRef="usd" id="ixv-6664">zero</ix:nonFraction>&#160;expected dividends.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2024, the Company entered into a
securities purchase agreement with an investor whereby the Company sold&#160;<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6665">986,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock and
warrants to purchase an additional&#160;<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-6666">986,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock in a registered direct offering in exchange
for gross proceeds of approximately $<ix:nonFraction contextRef="c127" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-6667">9.7</ix:nonFraction>&#160;million (net proceeds of approximately $<ix:nonFraction contextRef="c127" decimals="-5" format="ixt:num-dot-decimal" name="inmb:IssuanceOfNetProceeds" scale="6" unitRef="usd" id="ixv-6668">8.9</ix:nonFraction>&#160;million). The exercise price of the warrants
is $<ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-6669">9.84</ix:nonFraction>&#160;and the warrants are exercisable until April 29, 2026. The Company determined that the warrants were equity classified.
The fair value of the warrants was approximately $<ix:nonFraction contextRef="c129" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" unitRef="usd" id="ixv-6670">5.8</ix:nonFraction>&#160;million and was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of&#160;<ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-6671">4.97</ix:nonFraction>% based on the applicable US Treasury bill rate
(2) expected life of&#160;<ix:nonNumeric contextRef="c129" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-6672">2.0</ix:nonNumeric>&#160;years, (3) expected volatility of approximately&#160;<ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-6673">77</ix:nonFraction>% based on the trading history of the Company,
and (4)&#160;<ix:nonFraction contextRef="c129" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" unitRef="usd" id="ixv-6674">zero</ix:nonFraction>&#160;expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2024, the Company entered into securities
purchase agreements with investors whereby the Company sold&#160;<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6675">571,592</ix:nonFraction>&#160;shares of the Company&#8217;s common stock and warrants
to purchase an additional&#160;<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6676">571,592</ix:nonFraction>&#160;shares of the Company&#8217;s common stock in a registered direct offering in exchange for
gross proceeds of approximately $<ix:nonFraction contextRef="c130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-6677">4.8</ix:nonFraction>&#160;million (net proceeds of approximately $<ix:nonFraction contextRef="c130" decimals="-5" format="ixt:num-dot-decimal" name="inmb:IssuanceOfNetProceeds" scale="6" unitRef="usd" id="ixv-6678">4.5</ix:nonFraction>&#160;million).&#160;<span style="background-color: white">Directors</span>&#160;and
officers that participated in the offering paid a combined offering price of $<ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-6679">8.445</ix:nonFraction>&#160;per share and warrant, and other investors paid
$<ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-6680">8.32</ix:nonFraction>&#160;per share and warrant. The exercise price of the warrants is $<ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-6681">9.152</ix:nonFraction>, and the warrants are exercisable for two years from the
issuance dates. The Company determined the warrants were equity classified. The fair value of the warrants was approximately $<ix:nonFraction contextRef="c131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" unitRef="usd" id="ixv-6682">3.0</ix:nonFraction>&#160;million
and was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1)
discount rate of&#160;<ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-6683">4.89</ix:nonFraction>% based on the applicable US Treasury bill rate (2) expected life of&#160;<ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-6684">2.0</ix:nonNumeric>&#160;years, (3) expected volatility
of approximately&#160;<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-6685">78</ix:nonFraction>% based on the trading history of the Company, and (4)&#160;<ix:nonFraction contextRef="c127" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" unitRef="usd" id="ixv-6686">zero</ix:nonFraction>&#160;expected dividends.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Common Stock &#8211; At the Market Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During March 2021, the Company entered into a
sales agreement (&#8220;Sales Agreement&#8221;) with BTIG, LLC (&#8220;BTIG&#8221;), as sales agent, to establish an At-The-Market (&#8220;ATM&#8221;)
offering program of up to $<ix:nonFraction contextRef="c134" decimals="-6" format="ixt:num-dot-decimal" name="inmb:AggregateOfferingPriceAmount" scale="6" unitRef="usd" id="ixv-6687">45</ix:nonFraction>&#160;million of common stock, subject to certain limitations on the amount of common stock that may be offered
and sold by the Company set forth in the sales agreement. During August 2023, the Company and BTIG entered into Amendment No. 1 to the
Sales Agreement. The Company is required to pay BTIG a commission of&#160;<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="inmb:PercentageOfGrossProceeds" scale="-2" unitRef="pure" id="ixv-6688">3</ix:nonFraction>% of the gross proceeds from the sale of shares. During the
nine months ended September 30, 2024, the Company issued and sold&#160;<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6689">198,364</ix:nonFraction>&#160;shares of common stock at an average price of $<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6690">10.56</ix:nonFraction>&#160;per
share under the ATM program. The aggregate net proceeds were approximately $<ix:nonFraction contextRef="c137" decimals="-5" format="ixt:num-dot-decimal" name="inmb:IssuanceOfNetProceeds" scale="6" unitRef="usd" id="ixv-6691">2.0</ix:nonFraction>&#160;million after commission expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During August 2024, the Company entered into an
amended and restated at-the-market sales agreement with RBC Capital Markets LLC and BTIG (together, the &#8220;Sales Agents&#8221;) relating
to the offer and sale of shares of our common stock with an aggregate offering price of up to $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="inmb:AggregateOfferingPriceAmount" scale="6" unitRef="usd" id="ixv-6692">75.0</ix:nonFraction>&#160;million. This amended and restated
at-the-market sales agreement replaced the Sales Agreement entered into with BTIG in March 2021, as amended in August 2023. The Company
is required to pay the Sales Agents a commission of&#160;<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="inmb:PercentageOfGrossProceeds" scale="-2" unitRef="pure" id="ixv-6693">3</ix:nonFraction>% of the gross proceeds from the sale of shares.&#160;During the nine months
ended September 30, 2024, the Company issued and sold&#160;<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6694">48,762</ix:nonFraction>&#160;shares of common stock at an average price of $<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6695">6.96</ix:nonFraction>&#160;per share
under the ATM program. The aggregate net proceeds were approximately $<ix:nonFraction contextRef="c120" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd" id="ixv-6696">0.3</ix:nonFraction>&#160;million after commission expenses. During the nine months
ended September 30, 2025, the Company issued and sold&#160;<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6697">1,304,707</ix:nonFraction>&#160;shares of common stock at an average price of $<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-6698">8.01</ix:nonFraction>&#160;per
share under the ATM program. The aggregate net proceeds were approximately $<ix:nonFraction contextRef="c137" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-6699">10.1</ix:nonFraction>&#160;million after commission expenses. At September
30, 2025, the Company had $<ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" unitRef="usd" id="ixv-6700">64.5</ix:nonFraction>&#160;million of common stock available under the amended and restated at-the-market agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During July 2023, the Company sold&#160;<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6701">75,697</ix:nonFraction>&#160;shares of its common
stock at an average price of $<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-6702">10.56</ix:nonFraction>&#160;per share under the ATM program. The aggregate net proceeds were approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="0" unitRef="usd" id="ixv-6703">775,000</ix:nonFraction>&#160;after
offering expenses. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior
to the time the shares were sold.&#160;&#160; The Company reclassified&#160;<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-6704">75,697</ix:nonFraction>&#160;shares, with an aggregate purchase price of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="inmb:AggregatePurchasePrice" scale="0" unitRef="usd" id="ixv-6705">799,000</ix:nonFraction>&#160;of
its common stock as temporary equity presented outside stockholders&#8217; equity as a result of potential rescission rights. As
of September 30, 2024, the rescission rights for these shares lapsed and the shares were reclassified to permanent equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During August 2025, the Company modified stock
option awards held by its former Chief Executive Officer to extend the post-termination exercise period and provide that unvested stock
options shall continue to vest pursuant to the severance agreement, which will result in additional stock-based compensation expense of
up to $<ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-6706">2.4</ix:nonFraction>&#160;million to be expensed over the remaining original vesting term, if any, of the stock option awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-3911"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table summarizes stock option activity during the nine months ended September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Remaining<br/> Contractual<br/> Term<br/> (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-6707">7,203,307</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-6708">8.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-6709">6.49</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-6710">1,218</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-6711">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-6712">7.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" id="ixv-6713">10.0</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-6714">107,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-6715">7.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-6716">7,195,342</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-6717">8.29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-6718">5.80</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-6719">5,379,014</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-6720">8.80</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-6721">4.81</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2025, the Company recognized stock-based compensation expense of approximately $<ix:nonFraction contextRef="c145" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-6722">3.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c146" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-6723">6.6</ix:nonFraction> million, respectively, related
to the vesting of stock options. During the three and nine months ended September 30, 2024, the Company recognized stock-based compensation
expense of approximately $<ix:nonFraction contextRef="c147" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-6724">1.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-6725">5.8</ix:nonFraction> million, respectively, related to the vesting of stock options. As of September 30, 2025,
there was approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-6726">8.0</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options which is expected to
be recognized over a weighted-average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-6727">2.63</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued&#160;warrants to the Company&#8217;s
lenders upon obtaining a loan in June 2021. The warrants have a&#160;<ix:nonNumeric contextRef="c149" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-6728">10</ix:nonNumeric>-year term and an exercise price of $<ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-6729">14.05</ix:nonFraction>. At September 30, 2025,&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-6730"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-6731">45,386</ix:nonFraction></ix:nonFraction>&#160;of
these warrants are outstanding and the intrinsic value of these warrants is $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" unitRef="usd" id="ixv-6732">0</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During April
2024, the Company issued&#160;<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-6733">1,557,592</ix:nonFraction>&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-6734">1,557,592</ix:nonFraction>&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $<ix:nonFraction contextRef="c150" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-6735">9.59</ix:nonFraction>&#160;per share. The intrinsic value of
these warrants was $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" unitRef="usd" id="ixv-6736">0</ix:nonFraction>&#160;as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During September
2024, the Company issued&#160;<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-6737">2,341,260</ix:nonFraction>&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-6738">2,341,160</ix:nonFraction>&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $<ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-6739">6.40</ix:nonFraction>&#160;per share. The intrinsic value of
these warrants was $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" unitRef="usd" id="ixv-6740">0</ix:nonFraction>&#160;as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock-based Compensation by Class of Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-4088"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the components of stock-based
compensation expense in the consolidated statements of operations for the nine months ended September 30, 2025 and&#160;2024 respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6741">1,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6742">677</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6743">2,820</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6744">2,375</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6745">1,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6746">1,042</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6747">3,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6748">3,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6749">2,984</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6750">1,719</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6751">6,594</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-6752">5,848</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Shareholder Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2020, the Board of Directors (the
&#8220;Board&#8221;) of the Company approved and adopted a Rights Agreement, dated as of December 30, 2020, by and between the Company
and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of one preferred share purchase right (each,
a &#8220;Right&#8221;) for each outstanding share of the Company&#8217;s common stock held by stockholders as of the close of business
on January 11, 2021. When exercisable, each right initially would represent the right to purchase from the Company one one-thousandth
of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $<ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-6753">0.001</ix:nonFraction>&#160;per share,
of the Company, at an exercise price of $<ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="inmb:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-6754">300.00</ix:nonFraction>&#160;per one one-thousandth of a Series A Junior Participating Preferred Share, subject
to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered
persons) becomes the beneficial owner of twenty percent&#160;or more of the Company&#8217;s common stock without the approval of the Board.
The Rights Agreement was amended in 2021, 2022, 2023 and 2024 to extend the expiration date and shall expire on December&#160;30, 2025.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="inmb:LegalDisclosureTextBlock" id="ixv-4180"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 10</span> &#8211; LEGAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Dispute</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
had a dispute with a vendor in which the Company believed that the vendor did not properly provide services for which they have invoiced
the Company. The vendor invoiced the Company approximately $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="inmb:OutstandingInvoices" scale="6" unitRef="usd" id="ixv-6755">1.6</ix:nonFraction> million, of which the Company recorded $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="inmb:VendorInvoices" scale="6" unitRef="usd" id="ixv-6756">0.2</ix:nonFraction> million. During August 2025,
the Company and the vendor settled the obligation for approximately $<ix:nonFraction contextRef="c165" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SupplierFinanceProgramObligationDecreaseSettlement" scale="6" unitRef="usd" id="ixv-6757">0.2</ix:nonFraction> million. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes
that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company&#8217;s
consolidated financial statements, these matters are subject to inherent uncertainties and management&#8217;s view of these matters may
change in the future.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form
10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended
to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results
may differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not limited
to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including
competition from much larger competitors; technological advances and failure to successfully develop business relationships.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our objective is to develop
and commercialize our product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. Immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays
a significant role in the development of immune dysfunction. Immune dysfunction can be seen in cancer where Natural Killer (&#8220;NK&#8221;)
cells are impaired and facilitate a tumor&#8217;s evasion of the immune system and subsequent disease progression. Chronic inflammation
is implicated in various diseases, where it impairs the immune system. Our primary focus continues to be treatment of Alzheimer&#8217;s
Disease (&#8220;AD&#8221;) with XPro1595 (&#8220;XPro&#8482; and DN-TNF) and treatment of recessive dystrophic epidermolysis bullosa (&#8220;RDEB&#8221;)
with CORDStrom, a proprietary, pooled, human umbilical cord mesenchymal stromal cell platform. RDEB is a pediatric orphan disease caused
by mutations in the COL7A1 gene which results in highly debilitating skin blistering, dysphagia and failure to thrive with chronic wound
problems that often result in fatal squamous cell carcinoma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">XPro for AD has completed
Phase I and Phase II trials with enrollment of patients at clinical sites in the United Kingdom, EU, Australia and Canada. The INKmune
program has nearly completed an open label Phase II trial in metastatic castrate resistant prostate cancer (&#8220;mCRPC&#8221;). CORDStrom
for the treatment of children with RDEB has completed a pivotal blinded randomized cross-over trial. The data will be submitted for marketing
authorization by filing a Marketing Authorization Application (MAA) in the United Kingdom followed by a Biologics License Application
(&#8220;BLA&#8221;) with the FDA in the US which is anticipated in 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our XPro&#8482;
platform can be used as a CNS (&#8220;central nervous system&#8221;) therapy to target glial activation to prevent progression of AD along
with other inflammatory diseases. The primary focus of the Company&#8217;s development efforts for XPro is AD. In each case, we believe
neutralizing sTNF is a cornerstone to the treatment of neuroinflammation and immune dysfunction in these diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the DN-TNF platform
can be used to treat selected neurodegenerative diseases by reducing neuroinflammation without immunosuppression. The Company believes
the core pathology of cognitive decline is a combination of neurodegeneration and synaptic dysfunction. Neurodegeneration is nerve cell
death that may include demyelination. Synaptic dysfunction means the connections between nerve cells cease to work efficiently and may
decrease in number. The combination of neurodegeneration and synaptic dysfunction causes cognitive decline and behavioral changes associated
with AD. XPro completed a Phase I trial treating patients with Alzheimer&#8217;s disease that was partially funded by a Part-the-Clouds
Award from the Alzheimer&#8217;s Association. We believe XPro targets activated microglia and astrocytes of the brain that produce sTNF
that promotes nerve cell loss, synaptic dysfunction and prevents myelin repair - key elements in the development of dementia. In animal
models, elimination of sTNF prevents nerve cell dysfunction, reverses synaptic pruning and promotes myelin repair. The Phase I trial in
patients with biomarkers of inflammation with AD has been completed. The open label, dose escalation trial was designed to demonstrate
that XPro can safely decrease neuroinflammation in patients with AD and biomarkers of inflammation (ADi). The goal of the Phase 1 trial
was to demonstrate safety in the target population (patients with AD), demonstrate target engagement by showing XPro got into the brain
in therapeutically relevant concentrations and reduced neuroinflammation) and identify the best dose for phase 2. XPro got into the brain
(<b>Figure 1a</b>) and dose dependently decreased biomarker of neuroinflammation in the CSF (<b>Figure 1b</b>) with patients treated with
the highest dose (1mg/kg/week dose) having the greatest reduction in neuroinflammation. A broad analysis of proteomic changes following
treatment of XPro revealed significant changes in CSF proteins related to CNS neuronal function, immune/inflammatory response, Cytoskeletal,
metabolic processes, and dendritic spine morphogenesis and synaptic plasticity. Of note, XPro reduced neuronal injury markers Visinin-like
protein-1 (91%) and Neurofilament light (84%), improved measures of synaptic function as evinced by a 222% increase in Contactin 2 and
a 56% decrease neurogranin. Finally, XPro significantly reduced CSL levels of p-Tau217 (43%) and pTau181 (2%) after 3 months of therapy
(<b>Figure 1c</b>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 25%">&#160;<img alt="" src="image_001.jpg"/></td>
    <td style="width: 25%; text-align: center">&#160;<img alt="" src="image_002.jpg"/></td>
    <td style="width: 50%; text-align: center"><img alt="" src="image_003.jpg"/>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 1:</b> (A) XPro gets into the brain
at therapeutically relevant concentrations. XPro neutralizes 99.9% of soluble TNF when drug levels exceed two logs. (B) XPro dose dependently
reduces CSF inflammation in the brain. CSF composite &#8211; a composite score of change of all cytokines measured in the OLINK Target
48 Cytokine panel. (C) XPro (at 1 mg/kg dose) reduces CSF pTau217 and pTau181 as measure by proteomics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase II study, also known
as AD-02 and MINDFuL, was a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety, tolerability,
and efficacy of XPro1595 in individuals with early Alzheimer&#8217;s disease with biomarkers of inflammation (ADi). The primary goal of
AD02 was to determine if XPro could affect cognition following 6 months of treatment. Participants with a diagnosis of early AD (mild
cognitive impairment or mild AD) were randomized in a 2:1 (XPro:Placebo) ratio to receive either 1.0 mg/kg of XPro1595 or placebo via
weekly subcutaneous injections for 6 months. An enrichment strategy mirroring to the successful strategy used in the Phase I trial was
used to align the mechanism of the drug with the patients AD pathology. <span style="background-color: #FAFAFA">Eligibility required the
presence of at least one inflammatory biomarker&#8212;either high-sensitivity C-reactive protein (hsCRP &gt; 1.5 mg/L), erythrocyte sedimentation
rate (ESR &gt; 10 mm/h), hemoglobin A1c (HbA1c &gt; 6.0% DCCT), or at least one APOE4 allele. </span>The primary endpoint was the Early
and Mild Alzheimer&#8217;s Cognitive Composite (EMACC), with secondary endpoints of Clinical Dementia Rating Scale &#8211; Sum of Boxes
(CDR-SB), Everyday Cognition Scale (E-Cog), Neuropsychiatric Inventory (NPI-12), ADCS-ADL, and biomarkers such as pTau-217 and GFAP. MRI-based
neuroinflammation and brain volumetrics are also evaluated. The AD program had sites in Australia, Canada, the United Kingdom, France,
Germany, Spain, Czech Republic and Slovakia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Full enrollment in the Phase
II AD trial occurred in late 2024 with 208 patients enrolled and top-line data was received during June 2025. In the Phase 2 MINDFuL trial
of XPro&#8482;&#160;in patients with early Alzheimer&#8217;s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat
(mITT) population (n=200) did not meet the primary and key secondary endpoints (<b>figure 1</b>). Efficacy, Demographics and Safety data
are shown below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 1: Phase 2 Study Results &#8211; mITT&#160;population Primary
and Key Secondary Endpoints, Change From Baseline</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 1:</b> As these graphs depict, the primary
and secondary endpoints in this trial were not met as no decline in the placebo groups were observed. A trend was observed in NPI that
favored XPro1595 over placebo. For reference, A higher EMACC score =better, A lower CDR and NPI score is better. EMACC: LS Mean Diff (SE):
-0.018 (0.0414), 90% CI: -0.0860, 0.0509, p-value: 0.672. CDR-SB: LS Mean Diff (SE): -0.11 (0.185), 90% CI: -0.417, 0.195, p-value: 0.5491.
NPI: LS Mean Diff (SE): -0.9 (0.78), 90% CI: -2.18, 0.39, p-value: 0.2499</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prespecified subgroups analyses
suggested a signal that favored XPro in a predetermined population of patients that were both amyloid positive and had a higher burden
of inflammation defined by 2 or more biomarkers of inflammation (from hereon referred to as enriched group). As shown in figure 2, the
mITT placebo group did not decline whereas patients in the enriched group did decline. Decline in the placebo group is required to test
the ability of a treatment to prevent or slow decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 2: Phase 2 Study Results &#8211; Placebo group decline in
the mITT and enriched population </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 2:</b> Placebo patients in the mITT
did not show decline on the EMACC over the 24 week study. In the enriched group, placebo patients did decline over 24 weeks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To evaluate a subgroup after
missing the primary endpoint, we used effect size as the primary metric due to the smaller sample size (n=100). Effect size, measured
by Cohen&#8217;s D, is well-suited for small samples and allows comparisons across different measures (e.g., cognitive tests and biomarkers).
Unlike p-values, which indicate the likelihood of results being due to chance, effect size reflects clinical relevance and is commonly
used for signal detection in Phase 2 studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We defined a promising signal
as a minimum effect size of 0.2, where XPro outperformed placebo on multiple endpoints aligned with our hypothesis and the drug&#8217;s
mechanism of action. Results must also be appropriate for the trial&#8217;s parameters, meaning the observed effects should align with
the trial&#8217;s duration and endpoints. For example, if a clinical measure typically requires a longer time to show meaningful change
than the trial&#8217;s 6-month timeframe, an observed effect on that endpoint would not be considered supportive. Signal detection was
based on the effect size difference in LS mean change from baseline (MMRM model) between XPro and placebo at 6 months, ensuring results
were meaningful, relevant, and appropriate for the trial&#8217;s design and objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using this method, the enriched
population (50% of the total sample, n=100) showed trends toward improvement with XPro on the primary endpoint (EMACC) and a key secondary
endpoint (NPI) (<b>Figure 3a</b>). With the placebo group showing the expected decline on EMACC over six months, a beneficial effect of
XPro became evident. EMACC, which measures cognition (higher scores are better), showed an effect size of 0.27, exceeding the company&#8217;s
threshold of 0.2, though the p-value of 0.16 fell short of the &lt;0.1 target. For neuropsychiatric symptoms (NPI), the enriched population
showed a stronger beneficial effect compared to the overall population, with an effect size of -0.23 and a p-value of 0.2. There was no
effect on CDR-SB, which measures cognition and function (lower scores are better). Within the dose compliant group of patients, there
was an increased benefit seen corresponding to the amount of XPro received during the trial (Figure 3b). We also evaluated the effect
size of additional endpoints (<b>Figure 4</b>). Across most endpoints, XPro showed favorable trends, with effect sizes approaching the
0.2 threshold for clinical relevance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 3a: Phase 2 Study Results &#8211; Enriched population primary
and key secondary endpoints, change from baseline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 3:</b> The enriched population show
effect size &gt;0.2 favoring XPro1595 on the EMACC and NPI. , A higher EMACC score =better, A lower CDR and NPI score is better. EMACC:
LS Mean Diff (SE): 0.086 (0.0603), 90% CI: -0.0146, 0.1857, p-value: 0.1594. CDR-SB: LS Mean Diff (SE): -0.08 (0.307), 90% CI: -0.593,
0.426, p-value: 0.7859. NPI: LS Mean Diff (SE): -1.6 (1.25), 90% CI: -3.71, 0.47, p-value: 0.2003</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 3b: Phase 2 Study Results &#8211; XPro had greater impact
on dose compliant patients</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_008.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 4:</b> Effect size of XPro across multiple endpoints described
as absolute effect sizes (cohen&#8217;s D).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Demographics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/>&#160;</p><div>




</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_010.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Safety</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: #156082">
    <td colspan="4" style="padding: 8pt 0.75pt; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 3pt solid; border-left: white 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: White"><b>Safety:
    Treatment Emergent Adverse Events (TEAEs): Safety Analyses Set</b></span></td></tr>
  <tr style="background-color: #CCD2D8">
    <td style="width: 51%; border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Event, n (%)</b></span></td>
    <td style="border-right: White 1pt solid; width: 16%; border-bottom: White 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placebo (n=67)</b></span></td>
    <td style="width: 15%; border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XPro1595 (n=139)</b></span></td>
    <td style="width: 18%; border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total <br/>
(n=206)</b></span></td></tr>
  <tr style="background-color: #E7EAED">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any TEAE </b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>59 (88.1%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>131 (94.2%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>190 (92.2%)</b></span></td></tr>
  <tr style="background-color: #CCD2D8">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding: 5pt 0.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Any TEAE by Maximum Severity</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mild</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Moderate</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Severe</b></p></td>
    <td style="border-bottom: white 1pt solid; padding: 5pt 0.75pt; border-right: white 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>34 (50.7%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22 (32.8%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3 (4.5%)</b></p></td>
    <td style="border-bottom: white 1pt solid; padding: 5pt 0.75pt; border-right: white 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>73 (52.5%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>56 (40.3%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2 (1.4%)</b></p></td>
    <td style="border-bottom: white 1pt solid; padding: 5pt 0.75pt; border-right: white 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>107 (51.9%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>78 (37.9%)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5 (2.4%)</b></p></td></tr>
  <tr style="background-color: #E7EAED">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any Serious TEAE</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5 (7.5%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8 (5.8%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13 (6.3%)</b></span></td></tr>
  <tr style="background-color: #CCD2D8">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any Treatment-Related Serious TEAE</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2 (1.4%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2 (1.0%)</b></span></td></tr>
  <tr style="background-color: #E7EAED">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any TEAE Leading to Treatment Discontinuation</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2 (3.0%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12 (8.6%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14 (6.8%)</b></span></td></tr>
  <tr style="background-color: #CCD2D8">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any TEAE Leading to Study Withdrawal</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2 (3.0%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12 (8.6%)</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14 (6.8%)</b></span></td></tr>
  <tr style="background-color: #E7EAED">
    <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any TEAE with Fatal Outcome </b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td>
    <td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-top: 5pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes these
findings from the Phase 2 results indicate that XPro may offer benefits to a readily identified subgroup of Alzheimer&#8217;s patients
across all ages with biomarker-defined neuroinflammation, regardless of comorbidities or ApoE4 status and potentially lays the foundation
for advancing XPro as a promising treatment for AD. The Company is planning an end-of-phase 2 meeting with the FDA, which is expected
to occur towards the end of 2025 or early 2026, to determine next steps and expects to be eligible for one of the accelerated pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">CORDStrom,
developed by INmune Bio circa 2020, represents a breakthrough in mesenchymal stromal cell technology. The CORDStrom platform leverages,
among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled human umbilical
cord -derived mesenchymal stromal cells (HucMSCs) as medicines to treat complex inflammatory diseases. CORDStrom products are designed
to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be
produced at low cost and with repeatable specification. Initially developed at the INKmune manufacturing facilities utilizing United Kingdom
academic grant funding, CORDStrom is a product platform that shows promise as a therapy for RDEB and many other debilitating conditions.
While the first generation CORDStrom product is agnostic to indication, the platform enables creation of indication-specific products,
which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing, and other characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
CORDStrom product platform shares many similarities, including raw materials, equipment, and procedures, with the Company&#8217;s INKmune
oncology product, enabling the Company to leverage economies of scale, experienced staff, and other resources to strategically manufacture
both products in a rotational campaign with resource and environmental efficiencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Children
with RDEB have skin that is damaged by even the smallest amount of friction which causes severe blistering, deep wounds, and scars. It
is caused by a fault in a gene that makes collagen, a protein that holds the skin layers together.&#160;There are limited options available
for treatment, none that adequately meet the needs of patients, and the condition gets worse over time with most children reliant on a
wheelchair as they move into their teenage years. Many of those with an RDEB diagnosis will also go on to develop aggressive life-threatening
skin cancer in adulthood caused by the accumulated damage to their skin.&#160;The Company estimates roughly 2,000 people suffer from RDEB
in the US, United Kingdom and EU representing a large unmet opportunity to potentially provide routine clinical care to these children.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
2020, the Company has supplied CORDStrom HucMSCs as an investigational medical product to the&#160;Great Ormond Street Hospital (&#8220;GOSH&#8221;),
London, in connection with the&#160;MissionEB study, which was primarily funded by a grant from the National Institute for Health and
Care Research (&#8220;NIHR&#8221;) in the United Kingdom. INmune Bio was compensated for CORDStrom used in the trial and was not a sponsor
of the Mission EB study. Investigators recently concluded a double blinded, placebo-controlled arm of the study, which evaluated the safety
and efficacy of CORDStrom in 30 pediatric patients (less than 16 years old) in the United Kingdom with intermediate and severe RDEB using
a novel cross-over clinical trial design. Patients were randomized to CORDStrom or placebo arms and received 2, intravenous infusions
two weeks apart and then followed for 9 months. Each child then crossed over to the other arm and received two doses of placebo or CORDStrom
two weeks apart with a further 9-month follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
patients were treated as day-cases and no CORDStrom related serious adverse events were reported through the study. Top-line results showed
the treatment was easily administered, well tolerated and there were beneficial effects across all types of patients receiving CORDStrom
with respect to Itch Man Scale, iscorEB clinician score and iscorEB skin involvement. &#160;Most notably, CORDStrom significantly reduced
itch scores as measured by the Itch Man Scale. In patients with the most severe disease activity, CORDStrom reduced itch at 3 months and
led to a sustained reduction of over 27% at 6 months. These results demonstrate a clinically meaningful reduction in itch severity sustained
over time. Intermediate group patients showed a broader range of improvements, including reduced skin involvement and less pain as well
as large reduction in itch. &#160;The younger patients (less than 10 years old) showed improvements in skin score, indicating better skin
integrity and reduced disease activity. Interviews with patients and caregivers on completing follow up strongly support the clinical
benefits of the therapy; both caregivers and patients were able to correctly identify which treatment had been CORDStrom and which had
been placebo. Those who completed the study are asking to continue on therapy, which the Company intends to pursue as an open-label study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img alt="" src="image_013.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img alt="" src="image_014.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Mission EB data form the basis of a license that was entered into between INmune Bio and GOSH, whereby the Company gains exclusive access
to the clinical study data for commercial uses in exchange for payment of an initiation milestone of approximately $0.3 million which
the Company paid during July 2025 and a single development milestone of approximately &#163;6 million (approximately $8.1 million at
September 30, 2025) due on receipt of first marketing authorization from the FDA, EMA, or MHRA, which has not occurred yet, and an ongoing
commitment to supply CORDStrom to patients enrolled in an open label arm of the Mission EB trial, subject to certain limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
reviewing results of the Mission EB study, the Company initiated a Type C meeting with the FDA to obtain CMC and regulatory feedback and
submitted information, data and requests for Rare Pediatric Disease and Orphan Drug Designations (RPDD/ODD).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA granted RPDD to the Company&#8217;s CORDStrom product on December 13, 2024, ahead of the sunset period under Section 529(b)(5) of
the Federal Food, Drug, and Cosmetic Act. As such, CORDStrom remains eligible to receive a Priority Review Voucher (PRV) if approved by
the FDA on or prior to September 30, 2026, assuming the PRV program is not extended. If granted, a PRV can be redeemed to receive priority
review for a different product. Alternatively, a PRV may be transferred or sold to another organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA granted ODD to the Company&#8217;s CORDStrom product on January 6, 2025. Benefits of ODD include certain tax credits and eligibility
for select grants, waiver of FDA user fees, including the BLA application fees, access to frequent meetings with the FDA for efficient
drug development, and eligibility for seven (7) years of market exclusivity post approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company plans to prepare for and hold a pre-BLA meeting to discuss particulars of its planned BLA submission, with intent to submit a
BLA this year seeking approval of CORDStrom for treatment of RDEB. Concurrently, the Company will also seek to submit MAAs to the EU and
United Kingdom in 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have demonstrated that
INKmune improves the ability of the patient&#8217;s own NK cells to attack their tumor. INKmune interacts with the patient&#8217;s NK
cells to convert them from inert resting NK cells into memory-like NK cells that kill the patient&#8217;s cancer cells. INKmune is designed
to be given to patients after their immune system has recovered after cytotoxic chemotherapy to target the residual disease that remains
after treatment with cytotoxic therapy. We believe INKmune can be used to treat numerous hematologic malignancies and solid tumors including
leukemia, multiple myeloma, lymphoma, lung, ovary, breast, renal and prostate cancer. The Company sponsored a Phase I trial using INKmune
to treat patients with high risk MDS/AML, a form of leukemia in the UK. Due to Covid restrictions only one patient completed treatment
and follow-up in the Phase I trial for MDS; a further three AML patients were treated compassionately. Due to the post-Covid recruitment
problems, the Company decided to terminate further enrollment in the MDS/AML trial in March 2024. Nonetheless, from the four patients
treated and completing follow-up it was determined that INKmune therapy is safe and promotes development of cancer killing memory-like
NK cells that are activated and can kill NK-resistant cancer cells which can be found in the patient&#8217;s circulation for up to 4 months
after completion of treatment. The Company initiated a separate multicenter Phase I/II trial of INKmune in a metastatic castrate resistant
prostate cancer in the US. The open label trial enrolled the first patient in December 2023 and is currently in Phase II across 6 US sites.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase I/II trial using
INKmune to treat patients with metastatic castrate resistant prostate cancer (mCPRC) is an open label trial. Biomarker data from the patients
will be visible as patients are treated. The Company plans to report data from each cohort as it becomes available. Because of the modified
Bayesian design, the Company estimates the trial will be completely enrolled during the fourth quarter of 2025 with top-line data anticipated
approximately 6 months thereafter. Topline data are divided into immunologic and tumor response variables. The most important immunologic
response variable is related to memory-like NK cell persistence. There are 3 important variables to tumor response: i) blood PSA changes;
ii) change in PSMA-PET scan and iii) change in circulating tumor DNA (ctDNA). INKmune is not a hormone-targeting treatment and will not
directly reduce PSA levels but tumor load measured by PSMA-PET and/or ctDNA are expected to decrease with treatment. We do not expect
this 6-month trial to provide survival data.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to incur significant
development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred
losses in each period since our inception, resulting in substantial doubt in our ability to continue as a going concern. We reported a
net loss of $40.7 million for the nine months ended September 30, 2025. As of September 30, 2025 and December 31, 2024, we had cash and
cash equivalents of $27.7 million and $20.9 million, respectively. We expect to continue to incur significant losses for the foreseeable
future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our
product candidates. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability
to generate revenues, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our recurring net losses and
negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after
the issuance of our unaudited condensed consolidated financial statements for the nine months ended September 30, 2025. Until we can generate
sufficient revenue from the commercialization of our product candidates, we expect to finance our operations through the public or private
sale of equity, debt financings or other capital sources, such as government funding, collaborations, strategic alliances, divestment
of non-core assets, or licensing arrangements with third parties. To date, the Company has relied on equity and debt financing to fund
its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><i>Other Developments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The new U.S. administration
has announced or imposed a series of tariffs on U.S. trading partners. In response, several countries have threatened or imposed retaliatory
measures. At this time, we do not anticipate the tariffs and changes in trade policies in place as of the filing of this Quarterly Report
on Form 10-Q to have a significant adverse effect on our business or operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following recent changes more
broadly within the NIH and FDA, we have not noticed any disruption of communications with the NIH and FDA to date and continue to maintain
productive interactions. To date, there has been no impact to the Company&#8217;s operations due to any changes at the NIH or FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expense
consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This
includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings
for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily
consist of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trial and regulatory-related costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing and testing costs and related supplies and materials; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related expenses, including salaries, benefits, travel and stock-based compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our research and development expenses by product candidate for the periods indicated (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>External Costs</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">DN-TNF - Alzheimer&#8217;s disease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,629</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,289</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,759</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">INKmune - High Risk MDS/AML &amp; Prostate cancer and CORDStrom</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,084</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Preclinical and other programs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">518</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued research and development rebate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(150</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,524</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total external costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Internal costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,926</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,592</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,887</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,067</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,330</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,813</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We typically use our employee
resources across our development programs. We track outsourced development costs by product candidate or development program, but we do
not allocate internal costs personnel costs including salaries and stock-based compensation to specific product candidates or development
programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
participate, through our wholly owned subsidiary in Australia, in the Australian research and development tax incentive program, such
that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives
are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
participate, through our wholly owned subsidiary in the United Kingdom, in the research and development program provided by the United
Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United
Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research
and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure
has been incurred and the amount of the consideration can be reliably measured.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantially all our research
and development expenses to date have been incurred in connection with our current and future product candidates. We expect our research
and development expenses to increase significantly for the foreseeable future as we advance an increased number of our product candidates
through clinical development, including the conduct of our planned clinical trials and manufacturing drug to be used in those clinical
trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful
development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required
to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the
development of product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The costs of clinical trials
may vary significantly over the life of a project owing to, but not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per patient trial costs;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of sites included in the clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the countries in which the clinical trials are conducted;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the length of time required to enroll eligible patients;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients that participate in the clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of doses that patients receive;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of comparative agents used in clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the drop-out or discontinuation rates of patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the duration of patient follow-up;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy and safety profile of the product candidate; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing, finishing, labelling and storage drug used in the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect any of our
product candidates to be commercially available for at least the next several years, if ever. We expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year.
We anticipate that our expenses will increase substantially as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue research and development, including preclinical and clinical development of our existing product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially seek regulatory approval for our product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to discover and develop additional product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to comply with regulatory standards and laws;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, leverage and expand our intellectual property portfolio;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add operational, financial and management information systems and personnel; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional legal, accounting and other expenses in operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Three Months Ended September
30, 2025 and 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,067</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,180</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,546</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,219</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 27pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,853</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,286</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,853</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">961</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,472</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,093</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,621</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
were approximately $4.9 million during the three months ended September&#160;30, 2025, compared to approximately $10.1 million during
the three months ended September 30, 2024. The change in research and development expenses during the three months ending September 30,
2025 compared to the three months ending September 30, 2024 is mainly due to the Company incurring $6.4 million less expenses related
to our Alzheimer&#8217;s clinical program due to the Company completing the Phase 2 clinical trial, partially offset by incurring additional
compensation expense of $1.3 million mainly due to costs associated with the termination of employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were approximately $2.5 million during the three months ended September 30, 2025, compared to $2.2 million during the three months
ended September 30, 2024. The increase in general and administrative expenses was mainly due to the Company incurring $0.6 million higher
stock-based compensation during 2025, partially offset by $0.2 million lower professional fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Expense, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
September 30, 2025, the Company recorded $1.0 million of other income, of which approximately $0.6 million was gain on forgiveness of
payables from two vendors and approximately $0.4 million was due to interest income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
September 30, 2024, the Company&#8217;s other income consisted of interest income partially offset by interest expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Nine Months Ended September
30, 2025 and 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,483</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Impairment of acquired in-process research and development intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0.25in">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,777</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,909</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33,168</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,741</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(40,669</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(32,864</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,805</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company recognized revenue from a license agreement that was terminated during 2025. During the nine months ended
September 30, 2024, the Company recognized revenue from the sale of MSC&#8217;s.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses were approximately $18.3 million
and $25.8 million during the nine months ended September&#160;30, 2025 and 2024, respectively. The change in research and development
expenses during the nine months ending September 30, 2025 compared to the nine months ending September&#160;30, 2024 is mainly due to
the Company incurring $9.5 million less Alzheimer&#8217;s clinical program expenses due to the trial being completed in 2025, partially
offset by the Company incurring $1.3 million of additional compensation expense primarily in connection with the termination of employees
and recording $1.0 million less accrued rebate during the nine months ended September 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses were approximately $7.1 million
and $7.4 million during the nine months ended September 30, 2025 and 2024, respectively. The decrease in general and administrative expenses
during the nine months ended September 30, 2025 was mainly due to the Company incurring $0.3 million lower investor relations expense
and $0.1 million lower professional fees, partially offset by $0.3 million higher stock-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of acquired in-process research
and development intangible assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed
to meet the primary endpoint, though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company
has halted immediate plans to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these
studies. As part of preparing its interim unaudited condensed consolidated financial statements, the Company determined that the intangible
asset&#8217;s fair value was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the
asset&#8217;s fair value at $0, resulting in a recorded impairment of $16.5 million during the second quarter of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other Income, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company recorded $1.2 million of other income, of which $0.6 million was due to the Company earning interest income
on its cash investments and $0.6 million was gain on forgiveness of payables. During the nine months ended September 30, 2024, the Company
earned $0.3 million of other income consisting of interest income partially offset by interest expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Liquidity
is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate
on an ongoing basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred a net loss of
$40.7 million and $32.9 million for the nine months ended September 30, 2025 and 2024, respectively. Net cash used in operating activities
was $19.6 million and $22.3 million for the nine months ended September 30, 2025 and 2024, respectively. Since inception, we have funded
our operations primarily with proceeds from the sales of our common stock. As of September 30, 2025, we had cash and cash equivalents
of $27.7 million. We anticipate that operating losses and net cash used in operating activities will increase over the next few years
as we advance our products under development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ending
September 30, 2025, the Company sold 1,304,707 shares of common stock at an average price of $8.01 for gross proceeds of approximately
$10.4 million under the ATM offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During June 2025, the Company
entered into securities purchase agreements with investors whereby the Company sold 3,000,000 shares of the common stock in a registered
direct offering in exchange for gross proceeds of $18.9 million (net proceeds of approximately $17.4 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services,
costs incurred to manufacture our drugs under development, compensation and related expenses, legal, patent and other regulatory expenses
and general overhead costs. We believe our use of CROs provides us with flexibility in managing our spending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company incurs significant research and development expenses in Australia and the United Kingdom. Fluctuations in the rate of exchange
between the United States dollar and the pound&#160;sterling as well as the Australian dollar could adversely affect our financial results,
including our expenses as well as assets and liabilities. We currently do not hedge foreign currencies but will continue to assess whether
that strategy is appropriate. As of September 30, 2025, the cash balance held by our foreign subsidiaries with currencies other than the
United States dollar was approximately $0.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
recurring net losses and negative cash flows from operations, as well as forecast of continued losses and negative cash flows from operations,
raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed
consolidated financial statements for the nine months ended September 30, 2025. Until we can generate sufficient revenue from the commercialization
of our product candidates, we expect to finance our operations through the public or private sale of equity, debt financing or other capital
sources, such as government funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with
third parties. Our cash and cash equivalents were $27.7 million and total current assets were $30.7 million at September 30, 2025, which
the Company is projecting will be insufficient to sustain its operations through one year following the date that the financial statements
are issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additional
capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on
terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates
or cease operations. If we raise additional funds through the issuance of additional debt or equity securities it could result in dilution
to our existing stockholders, increased fixed payment obligations and these securities may have rights senior to those of our common stock
and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business,
financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Financing
strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financing or funds from other capital
sources, such as government or grant funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements
with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that
it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.
If we raise additional funds through the public or private sale of equity or debt financings, it could result in dilution to our existing
stockholders or increased fixed payment obligations and these securities may have rights senior to those of our common stock and could
contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to
incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial
condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Net cash and cash equivalents (used in) provided by:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19,638</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(22,348</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(899</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,059</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on cash from foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(196</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(237</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,922</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,848</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,734</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,552</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Activities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating activities used
approximately $19.6 million of cash during the nine months ended September 30, 2025, resulting mainly from our loss of $40.7 million,
changes in our net operating assets and liabilities of $1.5 million, and gain on forgiveness of accounts payable of $0.6 million, partially
offset by an intangibles impairment expense of $16.5 million and non-cash stock-based compensation of $6.6 million. The change in our
net operating assets and liabilities was mainly due to an increase in other assets of $0.7 million, an increase in research and development
tax credit receivable of $0.5 million, an increase in other tax receivable of $0.5 million and a decrease in deferred liabilities of $0.5
million, partially offset by a decrease in accounts payable and accrued liabilities of $1.0 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating activities used
approximately $22.3 million of cash during the nine months ended September 30, 2024, resulting from our loss of $32.9 million, partially
offset by changes in our net operating assets and liabilities of $4.6 million and non-cash stock-based compensation of $5.8 million. The
change in our net operating assets and liabilities was mainly due to an increase in accounts payable and accrued liabilities of $2.7 million,
a decrease in research and development tax receivable of $0.8 million, a decrease in prepaid expenses of $0.6 million and a decrease in
other tax receivable of $0.2 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company acquired $0.9 million of equipment to be used in its CORDStrom clinical program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company sold 1,304,707 shares of common stock under its ATM program for net proceeds of $10.1 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During June 2025, the Company
sold 3,000,000 shares of its common stock in a registered direct offering in exchange for gross proceeds of $18.9 million (net proceeds
of $17.4 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2024, the Company sold 247,126 shares of its common stock under its ATM programs for net proceeds of approximately $2.4
million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2024, the Company sold 3,898,852 shares of its common stock and 3,898,852 warrants to purchase its common stock in registered
direct offerings for net proceeds of approximately $25.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2024, the Company repaid $7.5 million of its debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Critical Accounting Estimates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our discussion and analysis
of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have
been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results
may differ from these estimates. Our critical accounting estimates are discussed in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, and there have been no material changes during the nine months ended September&#160;30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Quantitative and Qualitative Disclosures About Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Item 305(e) of
Regulation S-K (&#167; 229.305(e)), the Company is not required to provide the information required by this Item as it is a &#8220;smaller
reporting company,&#8221; as defined by Rule 229.10(f)(1).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Evaluation of Disclosure Controls and Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
management, with the participation of our Principal Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the &#8220;Exchange Act&#8221;)) at the end of the period covered by this Quarterly Report on Form 10-Q.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance
that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated
to management, including our Principal Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives,
and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Changes in Internal Control over Financial
Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
were no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently a party
to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may,
however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not required for smaller reporting
companies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Recent Sales of Unregistered Securities;
Use of Proceeds from Registered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Defaults Upon Senior Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Mine Safety Disclosures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Other Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c6" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-6758"><ix:nonNumeric contextRef="c6" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-6759"><ix:nonNumeric contextRef="c6" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-6760"><ix:nonNumeric contextRef="c6" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-6761">Not applicable</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. Exhibits </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b>&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea026135601ex31-1_inmune.htm">Rule 13a-14(a)/ 15d-14(a) Certification of Principal Executive Officer*</a></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea026135601ex31-2_inmune.htm">Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer*</a></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea026135601ex32-1_inmune.htm">Section 1350 Certification of Principal Executive Officer**</a></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea026135601ex32-2_inmune.htm">Section 1350 Certification of Chief Financial Officer**</a></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished&#8239;herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIGNATURES</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INmune Bio Inc. </b></span></td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 30, 2025</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Moss</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Moss</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 30, 2025 </span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cory Ellspermann</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>Chief Financial Officer</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">36</p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-7" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-9" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-10" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-11" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-13" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-20" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-21" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-22" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-23" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-31" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-32" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-33" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-38" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-39" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-40" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-41" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-42" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-43" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-45" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-46" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-50" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-51" name="inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-52" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-53" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-54" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-55" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-56" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-57" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-59" name="inmb:GainOnSettlementOfAccountsPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-60" name="us-gaap:Depreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-61" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-62" name="inmb:IncreaseDecreaseInPrepaidExpensesRelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-64" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-65" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-66" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:RepaymentsOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-68" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-69" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-70" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-71" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-72" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-73" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-74" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-75" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-76" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-77" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-78" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-79" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-80" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-81" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c110" id="hidden-fact-82" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-83" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-84" name="inmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-88" name="inmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-6855">0001711754</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-6856">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-6857">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-6858">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="inmb-20250930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:GreatOrmondStreetHospitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseOneInitiationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseTwoInitiationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseThreeInitiationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentNdaEmaFilingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentNdaEmaAwardedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:EachPhaseInitiationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:EachPhaseIIIInitiationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:UCLMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:UCLMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:AmplifyBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:AmplifyBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-30</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-30</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-31</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:ATMProgramMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:ATMProgramMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-31</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:AmendedAndRestatedAttheMarketAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-01</xbrli:startDate>
    <xbrli:endDate>2025-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-30</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-01</xbrli:startDate>
    <xbrli:endDate>2025-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][lf+D1kpeRLDoxsXw8fotgB+aKEfEKTzvBBL5ep8hYBhRA6EobR+NJsquQsy6QxYnbf/jrYz7w39zJtDKjwNLopfptYM/BKSPQki3IVVg1T0jTQmyzmPLcnuY+SFZfD4qT3yEZ6EhZt5dX1E08HRYR+FXvtcgLz6JQuGB1I/Bw9DMw4SkVKGkM8EDoFamVkj34+fvl/7cwfZzKdre2ykvHfiWD441nyCvGpFlWxbvfNDJY/M0JjKyfGUfGif9RT25Zki8WiKkeiOiwnHJc4Ban76h9bEh2qdAMjD1l5L9/dsstlakpM8eGSwVLAUL2JRzeGj4uFbVc+TIjb5EuPYL0w4=] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="gbp">
  <xbrli:measure>iso4217:GBP</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea026135601ex31-1_inmune.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David Moss, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of INmune Bio Inc.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Moss</FONT></TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Moss</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(Principal executive officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea026135601ex31-2_inmune.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Cory Ellspermann, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of INmune Bio Inc.;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cory Ellspermann</FONT></TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Chief Financial Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(Principal Financial Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>








</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ea026135601ex32-1_inmune.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of INmune Bio Inc. &nbsp;(the
&ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission on the
date hereof (the &ldquo;Report&rdquo;), I, David Moss, Chief Executive Officer of the Company, certify to my knowledge and in my capacity,
pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Moss</FONT></TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Moss</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">Chief Executive Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ea026135601ex32-2_inmune.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of INmune Bio Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, Cory Ellspermann, Chief Financial Officer of the Company, certify to my knowledge and in my capacity, pursuant to 18 U.S.C. &sect;
1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cory Ellspermann</FONT></TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">Chief Financial Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">(Principal Financial Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>inmb-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:inmb="http://inmunebio.com/20250930" targetNamespace="http://inmunebio.com/20250930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20250930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20250930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20250930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20250930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet" id="inmb_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals" id="inmb_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ConsolidatedIncomeStatement" id="inmb_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ConsolidatedIncomeStatementAlt0" id="inmb_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ShareholdersEquityType2or3" id="inmb_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ConsolidatedCashFlow" id="inmb_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/OrganizationandDescriptionofBusiness" id="inmb_r_OrganizationandDescriptionofBusiness">
        <link:definition>995306 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/GoingConcern" id="inmb_r_GoingConcern">
        <link:definition>995307 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPolicies" id="inmb_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivity" id="inmb_r_ResearchandDevelopmentActivity">
        <link:definition>995309 - Disclosure - Research and Development Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/FairValueMeasurements" id="inmb_r_FairValueMeasurements">
        <link:definition>995310 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/Commitments" id="inmb_r_Commitments">
        <link:definition>995311 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/RelatedPartyTransactions" id="inmb_r_RelatedPartyTransactions">
        <link:definition>995312 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/Debt" id="inmb_r_Debt">
        <link:definition>995313 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/StockholdersEquity" id="inmb_r_StockholdersEquity">
        <link:definition>995314 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/Legal" id="inmb_r_Legal">
        <link:definition>995315 - Disclosure - Legal</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/AccountingPoliciesByPolicy" id="inmb_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables" id="inmb_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityTables" id="inmb_r_ResearchandDevelopmentActivityTables">
        <link:definition>996002 - Disclosure - Research and Development Activity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/FairValueMeasurementsTables" id="inmb_r_FairValueMeasurementsTables">
        <link:definition>996003 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/CommitmentsTables" id="inmb_r_CommitmentsTables">
        <link:definition>996004 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/StockholdersEquityTables" id="inmb_r_StockholdersEquityTables">
        <link:definition>996005 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/GoingConcernDetails" id="inmb_r_GoingConcernDetails">
        <link:definition>996006 - Disclosure - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails" id="inmb_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996007 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable" id="inmb_r_ScheduleofPotentiallyIssuableSharesTable">
        <link:definition>996008 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityDetails" id="inmb_r_ResearchandDevelopmentActivityDetails">
        <link:definition>996009 - Disclosure - Research and Development Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofMilestonePaymentsTable" id="inmb_r_ScheduleofMilestonePaymentsTable">
        <link:definition>996010 - Disclosure - Research and Development Activity - Schedule of Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable" id="inmb_r_ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable">
        <link:definition>996011 - Disclosure - Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable" id="inmb_r_ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable">
        <link:definition>996012 - Disclosure - Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/CommitmentsDetails" id="inmb_r_CommitmentsDetails">
        <link:definition>996013 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" id="inmb_r_ScheduleofMaturitiesofLeaseLiabilitiesTable">
        <link:definition>996014 - Disclosure - Commitments - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable" id="inmb_r_ScheduleofCommitmentsPayableTable">
        <link:definition>996015 - Disclosure - Commitments - Schedule of Commitments Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/RelatedPartyTransactionsDetails" id="inmb_r_RelatedPartyTransactionsDetails">
        <link:definition>996016 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/DebtDetails" id="inmb_r_DebtDetails">
        <link:definition>996017 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/StockholdersEquityDetails" id="inmb_r_StockholdersEquityDetails">
        <link:definition>996018 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofStockOptionActivityTable" id="inmb_r_ScheduleofStockOptionActivityTable">
        <link:definition>996019 - Disclosure - Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable" id="inmb_r_ScheduleofStockBasedCompensationExpenseTable">
        <link:definition>996020 - Disclosure - Stockholders&#8217; Equity - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/LegalDetails" id="inmb_r_LegalDetails">
        <link:definition>996021 - Disclosure - Legal (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://inmunebio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfPotentiallyIssuableSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfPotentiallyIssuableSharesAbstract"/>
  <xs:element name="ScheduleOfMilestonePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfMilestonePaymentsAbstract"/>
  <xs:element name="ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract"/>
  <xs:element name="ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_UnlabeledAbstract"/>
  <xs:element name="StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash"/>
  <xs:element name="StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash"/>
  <xs:element name="StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock"/>
  <xs:element name="GainOnSettlementOfAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_GainOnSettlementOfAccountsPayable"/>
  <xs:element name="IncreaseDecreaseInPrepaidExpensesRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty"/>
  <xs:element name="LegalDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_LegalDisclosureTextBlock"/>
  <xs:element name="ScheduleOfMilestonePaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfMilestonePaymentsTableTextBlock"/>
  <xs:element name="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock"/>
  <xs:element name="MilestonePaymentsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentsDomainDomain"/>
  <xs:element name="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePayments"/>
  <xs:element name="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable"/>
  <xs:element name="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable"/>
  <xs:element name="StockholdersEquityScheduleofStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="ResearchandDevelopmentActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_ResearchandDevelopmentActivityDetailsTable"/>
  <xs:element name="SaleOfRoyaltyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inmb_SaleOfRoyaltyPercentage"/>
  <xs:element name="PercentageOfLicensorRoyaltyPatentGrant" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inmb_PercentageOfLicensorRoyaltyPatentGrant"/>
  <xs:element name="PercentageOfNetSalesToPayRoyalties" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_PercentageOfNetSalesToPayRoyalties"/>
  <xs:element name="AgreementExpirationTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_AgreementExpirationTerm"/>
  <xs:element name="CollaborationAgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_CollaborationAgreementTerm"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inmb_StockholdersEquityDetailsTable"/>
  <xs:element name="IssuanceOfNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inmb_IssuanceOfNetProceeds"/>
  <xs:element name="AggregateOfferingPriceAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inmb_AggregateOfferingPriceAmount"/>
  <xs:element name="PercentageOfGrossProceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_PercentageOfGrossProceeds"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_AggregatePurchasePrice"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ExercisePricePerShare"/>
  <xs:element name="OutstandingInvoices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inmb_OutstandingInvoices"/>
  <xs:element name="VendorInvoices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inmb_VendorInvoices"/>
  <xs:element name="MilestonePaymentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="inmb_MilestonePaymentsAxis"/>
  <xs:element name="ATMProgramMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ATMProgramMember"/>
  <xs:element name="AmendedAndRestatedAttheMarketAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_AmendedAndRestatedAttheMarketAgreementMember"/>
  <xs:element name="AmplifyBioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_AmplifyBioMember"/>
  <xs:element name="EachPhaseIIIInitiationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_EachPhaseIIIInitiationMember"/>
  <xs:element name="EachPhaseInitiationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_EachPhaseInitiationMember"/>
  <xs:element name="GreatOrmondStreetHospitalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_GreatOrmondStreetHospitalMember"/>
  <xs:element name="INKmuneLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_INKmuneLicenseAgreementMember"/>
  <xs:element name="MilestonePaymentNdaEmaAwardedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentNdaEmaAwardedMember"/>
  <xs:element name="MilestonePaymentNdaEmaFilingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentNdaEmaFilingMember"/>
  <xs:element name="MilestonePaymentPhaseOneInitiationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentPhaseOneInitiationMember"/>
  <xs:element name="MilestonePaymentPhaseThreeInitiationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentPhaseThreeInitiationMember"/>
  <xs:element name="MilestonePaymentPhaseTwoInitiationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_MilestonePaymentPhaseTwoInitiationMember"/>
  <xs:element name="PITTAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_PITTAgreementMember"/>
  <xs:element name="SalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_SalesAgreementMember"/>
  <xs:element name="SecuritiesPurchaseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_SecuritiesPurchaseAgreementsMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_StockOptionsMember"/>
  <xs:element name="UCLMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_UCLMember"/>
  <xs:element name="LegalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_LegalAbstract"/>
  <xs:element name="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems"/>
  <xs:element name="ScheduleOfMilestonePaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_ScheduleOfMilestonePaymentsLineItems"/>
<!-- [WMV6][+gjaZAClGAwQqeDY8X9YBx06+GTIvWZDOakKTxNTnoaQg7Ybh7rLZtlxNgsHOmfX7oL2EenPegBGS3KMqLQ/59JOhQJDL3yhoeFUiYdpM0j4M7VXzgGoPpA6XcYYH8e1dko9m9sTKGvUs1irzjkQxg0ZHEJ5Hmi5uzJ40mR0iSj6C5nI0fud+GerqWcB8veDPptecJME+WBmWKC+RCr7rDTh4yBCNwjVSZeAkxujJuqpF22e4FbEzfxCa7bOU0XUzktrZCHelv9l5OFXIbF5MxFmlfmLv9TKDB8vj3is4ig7Thc13VR4iFiK7TC2ubT7su2N02oWRtoHEzp1qc+NXg==] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inmb_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>inmb-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedBalanceSheet" roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedIncomeStatement" roleURI="http://inmunebio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedCashFlow" roleURI="http://inmunebio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofCommitmentsPayableTable" roleURI="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"/>
  <calculationLink xlink:role="http://inmunebio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://inmunebio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://inmunebio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="inmb_GainOnSettlementOfAccountsPayable" xlink:href="inmb-20250930.xsd#inmb_GainOnSettlementOfAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inmb_GainOnSettlementOfAccountsPayable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:href="inmb-20250930.xsd#inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
<!-- [WMV6][+9spXifuCqTrNdYNHea7GkM7eaGCw22oyXZU+6B/oy7jtVKLNX2QNQ7PogXodQfoQ+2WcLZALM8YyGGBNBwMm4Y/Ak6CzIyo7DcQopKRkNoDNujUmVtmAJed0GhG9LeS3NktAQgG584g55ToTgN+tgxn1F+8mie+yt+lKeA2ELNBxLle11Qx242/dQs6ZdKXN1fmHMbvEOaShSMbvphBims4T5goLuUB5toH5df2WCzTht6yHv+DtwOadZQBRdxcPE2ewF7edj8SuMNYwHjDJg4eVzQlWepYK7pHMKzrXwXvizeZLreyylQ8cyLC/9nnVYEuG+t+cZPvVMxTQdlusvw=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitmentDueInSecondYear" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>inmb-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedBalanceSheet" roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedIncomeStatement" roleURI="http://inmunebio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ShareholdersEquityType2or3" roleURI="http://inmunebio.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedCashFlow" roleURI="http://inmunebio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_OrganizationandDescriptionofBusiness" roleURI="http://inmunebio.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_GoingConcern" roleURI="http://inmunebio.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPolicies" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivity" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivity"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_FairValueMeasurements" roleURI="http://inmunebio.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Commitments" roleURI="http://inmunebio.com/role/Commitments"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_RelatedPartyTransactions" roleURI="http://inmunebio.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Debt" roleURI="http://inmunebio.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquity" roleURI="http://inmunebio.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Legal" roleURI="http://inmunebio.com/role/Legal"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_AccountingPoliciesByPolicy" roleURI="http://inmunebio.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivityTables" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_FairValueMeasurementsTables" roleURI="http://inmunebio.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_CommitmentsTables" roleURI="http://inmunebio.com/role/CommitmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquityTables" roleURI="http://inmunebio.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofPotentiallyIssuableSharesTable" roleURI="http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofMilestonePaymentsTable" roleURI="http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable" roleURI="http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable" roleURI="http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofCommitmentsPayableTable" roleURI="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofStockOptionActivityTable" roleURI="http://inmunebio.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_GoingConcernDetails" roleURI="http://inmunebio.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivityDetails" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_CommitmentsDetails" roleURI="http://inmunebio.com/role/CommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_RelatedPartyTransactionsDetails" roleURI="http://inmunebio.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_DebtDetails" roleURI="http://inmunebio.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquityDetails" roleURI="http://inmunebio.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_LegalDetails" roleURI="http://inmunebio.com/role/LegalDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://inmunebio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_GainOnSettlementOfAccountsPayable" xlink:href="inmb-20250930.xsd#inmb_GainOnSettlementOfAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="inmb_GainOnSettlementOfAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:href="inmb-20250930.xsd#inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/GoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/Commitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/Debt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/Legal" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="inmb_LegalAbstract" xlink:href="inmb-20250930.xsd#inmb_LegalAbstract"/>
    <loc xlink:type="locator" xlink:label="inmb_LegalDisclosureTextBlock" xlink:href="inmb-20250930.xsd#inmb_LegalDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_LegalAbstract" xlink:to="inmb_LegalDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="inmb_ScheduleOfMilestonePaymentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/CommitmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofMilestonePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inmb_ScheduleOfMilestonePaymentsLineItems" xlink:to="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsAxis" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="inmb_MilestonePaymentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsDomainDomain" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsDomainDomain_0" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseOneInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseOneInitiationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentPhaseOneInitiationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseTwoInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseTwoInitiationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentPhaseTwoInitiationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseThreeInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseThreeInitiationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentPhaseThreeInitiationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentNdaEmaFilingMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaFilingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentNdaEmaFilingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentNdaEmaAwardedMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaAwardedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentNdaEmaAwardedMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_INKmuneLicenseAgreementMember" xlink:href="inmb-20250930.xsd#inmb_INKmuneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inmb_INKmuneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_ScheduleOfMilestonePaymentsLineItems" xlink:to="inmb_MilestonePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:to="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsAxis" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="inmb_MilestonePaymentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsDomainDomain" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsDomainDomain_0" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_EachPhaseInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseInitiationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_EachPhaseInitiationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_EachPhaseIIIInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseIIIInitiationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_EachPhaseIIIInitiationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_PITTAgreementMember" xlink:href="inmb-20250930.xsd#inmb_PITTAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inmb_PITTAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:to="inmb_MilestonePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:href="inmb-20250930.xsd#inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitmentDueInSecondYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/GoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="inmb-20250930.xsd#inmb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="inmb_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_ResearchandDevelopmentActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_ResearchandDevelopmentActivityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_GreatOrmondStreetHospitalMember" xlink:href="inmb-20250930.xsd#inmb_GreatOrmondStreetHospitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inmb_GreatOrmondStreetHospitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_SaleOfRoyaltyPercentage" xlink:href="inmb-20250930.xsd#inmb_SaleOfRoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_SaleOfRoyaltyPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_MilestonePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfLicensorRoyaltyPatentGrant" xlink:href="inmb-20250930.xsd#inmb_PercentageOfLicensorRoyaltyPatentGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_PercentageOfLicensorRoyaltyPatentGrant" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CostMaintenance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfNetSalesToPayRoyalties" xlink:href="inmb-20250930.xsd#inmb_PercentageOfNetSalesToPayRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_PercentageOfNetSalesToPayRoyalties" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_AgreementExpirationTerm" xlink:href="inmb-20250930.xsd#inmb_AgreementExpirationTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inmb_AgreementExpirationTerm" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/CommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_CollaborationAgreementTerm" xlink:href="inmb-20250930.xsd#inmb_CollaborationAgreementTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inmb_CollaborationAgreementTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_RelatedPartyTransactionsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inmb_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_UCLMember" xlink:href="inmb-20250930.xsd#inmb_UCLMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inmb_UCLMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_AmplifyBioMember" xlink:href="inmb-20250930.xsd#inmb_AmplifyBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inmb_AmplifyBioMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/DebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_SecuritiesPurchaseAgreementsMember" xlink:href="inmb-20250930.xsd#inmb_SecuritiesPurchaseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inmb_SecuritiesPurchaseAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_SalesAgreementMember" xlink:href="inmb-20250930.xsd#inmb_SalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inmb_SalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_ATMProgramMember" xlink:href="inmb-20250930.xsd#inmb_ATMProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inmb_ATMProgramMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_AmendedAndRestatedAttheMarketAgreementMember" xlink:href="inmb-20250930.xsd#inmb_AmendedAndRestatedAttheMarketAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inmb_AmendedAndRestatedAttheMarketAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_StockOptionsMember" xlink:href="inmb-20250930.xsd#inmb_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inmb_StockOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_IssuanceOfNetProceeds" xlink:href="inmb-20250930.xsd#inmb_IssuanceOfNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_IssuanceOfNetProceeds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_AggregateOfferingPriceAmount" xlink:href="inmb-20250930.xsd#inmb_AggregateOfferingPriceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_AggregateOfferingPriceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfGrossProceeds" xlink:href="inmb-20250930.xsd#inmb_PercentageOfGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_PercentageOfGrossProceeds" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_AggregatePurchasePrice" xlink:href="inmb-20250930.xsd#inmb_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_AggregatePurchasePrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_ExercisePricePerShare" xlink:href="inmb-20250930.xsd#inmb_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inmb_ExercisePricePerShare" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://inmunebio.com/role/LegalDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="inmb_LegalAbstract" xlink:href="inmb-20250930.xsd#inmb_LegalAbstract"/>
    <loc xlink:type="locator" xlink:label="inmb_OutstandingInvoices" xlink:href="inmb-20250930.xsd#inmb_OutstandingInvoices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_LegalAbstract" xlink:to="inmb_OutstandingInvoices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inmb_VendorInvoices" xlink:href="inmb-20250930.xsd#inmb_VendorInvoices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_LegalAbstract" xlink:to="inmb_VendorInvoices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
<!-- [WMV6][UeqZj2BrcvFvL4//iwclo3jDHkgyAelCzeIhwwmReeMaMNCzF3lXdPX8FNRhhwPcmXayaiZrzjz/AbNoAfTUREzHAdn28l/2/XLcT3Sq3yvRl/QafHe+64xPPXUta1NofEQz+CSHTl48bK3YaDCKe5xqxouOKYANsGgMIfeb3cihPFSSAY49LoZ4lSx0mUhnd4S7MaiRLPb9i3Z2b2UGPWsVUdv8PIjry6gdlpiV5uQ2XIu/Cn6bpbyoUc/wriT35IY8qPFaHhn+sxGGVEHvKpoECjJ6vOKT2D/R18lOFp2KOpLQnzyRvCuudZRtkysYmzC/yQh9PxGpmD0/TZCIIhU=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inmb_LegalAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" order="2" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>inmb-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash flows used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Going Concern [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsAxis" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentsAxis_lbl" xml:lang="en-US">Milestone Payments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentFiscalYearMaturityAbstract_lbl" xml:lang="en-US">Schedule of Commitments Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitmentFiscalYearMaturityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of shares, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- average Exercise Price, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted- average Exercise Price, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_LegalAbstract" xlink:href="inmb-20250930.xsd#inmb_LegalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_LegalAbstract_lbl" xml:lang="en-US">Legal [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_LegalAbstract" xlink:to="inmb_LegalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Research and development tax credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease &#8211; right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Acquired in-process research and development intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease, current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: operating lease, current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common stock amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Average price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of acquired in-process research and development intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">OTHER INCOME, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss &#8211; foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Gain (loss) on foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of shares, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl" xml:lang="en-US">Common stock and warrants issued for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl" xml:lang="en-US">Common stock and warrants issued for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl" xml:lang="en-US">Reclassification from redeemable common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl" xml:lang="en-US">Reclassification from redeemable common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Accounts payable and accrued liabilities &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Exchange for gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Impact on cash from foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_UnlabeledAbstract" xlink:href="inmb-20250930.xsd#inmb_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_UnlabeledAbstract" xlink:to="inmb_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_GainOnSettlementOfAccountsPayable" xlink:href="inmb-20250930.xsd#inmb_GainOnSettlementOfAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inmb_GainOnSettlementOfAccountsPayable_lbl" xml:lang="en-US">Gain on settlement of accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_GainOnSettlementOfAccountsPayable" xlink:to="inmb_GainOnSettlementOfAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Research and development tax credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:href="inmb-20250930.xsd#inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl" xml:lang="en-US">Prepaid expenses &#8211; related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:to="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Issuable Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total dilutive loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT ACTIVITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePayments_lbl" xml:lang="en-US">Payment method of milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePayments" xlink:to="inmb_MilestonePayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="inmb_MilestonePayments_lbl0" xml:lang="en-US">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePayments" xlink:to="inmb_MilestonePayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of PITT Agreement Licensee is Required to make Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Commitments Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTableTextBlock" xlink:to="us-gaap_OtherCommitmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitmentDueInSecondYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- average Exercise Price, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted- average Remaining Contractual Term (years), Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- average Exercise Price, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- average Exercise Price, Options cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, Exercisable,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- average Remaining Contractual Term (years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_LegalDisclosureTextBlock" xlink:href="inmb-20250930.xsd#inmb_LegalDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_LegalDisclosureTextBlock_lbl" xml:lang="en-US">LEGAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_LegalDisclosureTextBlock" xlink:to="inmb_LegalDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Options cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseOneInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseOneInitiationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentPhaseOneInitiationMember_lbl" xml:lang="en-US">Each Phase I initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseOneInitiationMember" xlink:to="inmb_MilestonePaymentPhaseOneInitiationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseTwoInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseTwoInitiationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl" xml:lang="en-US">Each Phase II initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseTwoInitiationMember" xlink:to="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentPhaseThreeInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseThreeInitiationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl" xml:lang="en-US">Each Phase III initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseThreeInitiationMember" xlink:to="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentNdaEmaFilingMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaFilingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentNdaEmaFilingMember_lbl" xml:lang="en-US">Each NDA/EMA filing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaFilingMember" xlink:to="inmb_MilestonePaymentNdaEmaFilingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentNdaEmaAwardedMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaAwardedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_MilestonePaymentNdaEmaAwardedMember_lbl" xml:lang="en-US">Each NDA/EMA awarded [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaAwardedMember" xlink:to="inmb_MilestonePaymentNdaEmaAwardedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_INKmuneLicenseAgreementMember" xlink:href="inmb-20250930.xsd#inmb_INKmuneLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_INKmuneLicenseAgreementMember_lbl" xml:lang="en-US">INKmune License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_INKmuneLicenseAgreementMember" xlink:to="inmb_INKmuneLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_EachPhaseInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseInitiationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_EachPhaseInitiationMember_lbl" xml:lang="en-US">Each Phase I initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_EachPhaseInitiationMember" xlink:to="inmb_EachPhaseInitiationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_EachPhaseIIIInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseIIIInitiationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_EachPhaseIIIInitiationMember_lbl" xml:lang="en-US">Each Phase III initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_EachPhaseIIIInitiationMember" xlink:to="inmb_EachPhaseIIIInitiationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xml:lang="en-US">First commercial sale of product making use of licensed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_PITTAgreementMember" xlink:href="inmb-20250930.xsd#inmb_PITTAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_PITTAgreementMember_lbl" xml:lang="en-US">PITT Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PITTAgreementMember" xlink:to="inmb_PITTAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xml:lang="en-US">Treasury Bills [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl0" xml:lang="en-US">Treasury bills [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money market fund [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted Price in Active Market (Level 1) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair value assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_SaleOfRoyaltyPercentage" xlink:href="inmb-20250930.xsd#inmb_SaleOfRoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_SaleOfRoyaltyPercentage_lbl" xml:lang="en-US">Royalty on net sales of percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SaleOfRoyaltyPercentage" xlink:to="inmb_SaleOfRoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfLicensorRoyaltyPatentGrant" xlink:href="inmb-20250930.xsd#inmb_PercentageOfLicensorRoyaltyPatentGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl" xml:lang="en-US">Percentage of licensor royalty patent grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfLicensorRoyaltyPatentGrant" xlink:to="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Maintenance fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfNetSalesToPayRoyalties" xlink:href="inmb-20250930.xsd#inmb_PercentageOfNetSalesToPayRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_PercentageOfNetSalesToPayRoyalties_lbl" xml:lang="en-US">Percentage of net sales to pay royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfNetSalesToPayRoyalties" xlink:to="inmb_PercentageOfNetSalesToPayRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_AgreementExpirationTerm" xlink:href="inmb-20250930.xsd#inmb_AgreementExpirationTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_AgreementExpirationTerm_lbl" xml:lang="en-US">Agreement expiry period, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AgreementExpirationTerm" xlink:to="inmb_AgreementExpirationTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_CollaborationAgreementTerm" xlink:href="inmb-20250930.xsd#inmb_CollaborationAgreementTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_CollaborationAgreementTerm_lbl" xml:lang="en-US">Collaboration agreement term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_CollaborationAgreementTerm" xlink:to="inmb_CollaborationAgreementTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Payable of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Borrowed amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of stock sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_IssuanceOfNetProceeds" xlink:href="inmb-20250930.xsd#inmb_IssuanceOfNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_IssuanceOfNetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IssuanceOfNetProceeds" xlink:to="inmb_IssuanceOfNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Purchase of additional shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Additional shares purchased (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_AggregateOfferingPriceAmount" xlink:href="inmb-20250930.xsd#inmb_AggregateOfferingPriceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_AggregateOfferingPriceAmount_lbl" xml:lang="en-US">Aggregate offering price amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregateOfferingPriceAmount" xlink:to="inmb_AggregateOfferingPriceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_PercentageOfGrossProceeds" xlink:href="inmb-20250930.xsd#inmb_PercentageOfGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_PercentageOfGrossProceeds_lbl" xml:lang="en-US">Percentage of gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfGrossProceeds" xlink:to="inmb_PercentageOfGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_AggregatePurchasePrice" xlink:href="inmb-20250930.xsd#inmb_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregatePurchasePrice" xlink:to="inmb_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Intrinsic value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Issued warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ExercisePricePerShare" xlink:href="inmb-20250930.xsd#inmb_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ExercisePricePerShare" xlink:to="inmb_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_OutstandingInvoices" xlink:href="inmb-20250930.xsd#inmb_OutstandingInvoices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_OutstandingInvoices_lbl" xml:lang="en-US">Outstanding invoices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_OutstandingInvoices" xlink:to="inmb_OutstandingInvoices_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_VendorInvoices" xlink:href="inmb-20250930.xsd#inmb_VendorInvoices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_VendorInvoices_lbl" xml:lang="en-US">Vendor invoices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_VendorInvoices" xlink:to="inmb_VendorInvoices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_lbl" xml:lang="en-US">Vendor settled obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:to="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">Research and Development Tax Incentive Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_GreatOrmondStreetHospitalMember" xlink:href="inmb-20250930.xsd#inmb_GreatOrmondStreetHospitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_GreatOrmondStreetHospitalMember_lbl" xml:lang="en-US">Great Ormond Street Hospital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_GreatOrmondStreetHospitalMember" xlink:to="inmb_GreatOrmondStreetHospitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_UCLMember" xlink:href="inmb-20250930.xsd#inmb_UCLMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_UCLMember_lbl" xml:lang="en-US">UCL [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_UCLMember" xlink:to="inmb_UCLMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_AmplifyBioMember" xlink:href="inmb-20250930.xsd#inmb_AmplifyBioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_AmplifyBioMember_lbl" xml:lang="en-US">AmplifyBio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AmplifyBioMember" xlink:to="inmb_AmplifyBioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_SecuritiesPurchaseAgreementsMember" xlink:href="inmb-20250930.xsd#inmb_SecuritiesPurchaseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_SecuritiesPurchaseAgreementsMember_lbl" xml:lang="en-US">Securities Purchase Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SecuritiesPurchaseAgreementsMember" xlink:to="inmb_SecuritiesPurchaseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_SalesAgreementMember" xlink:href="inmb-20250930.xsd#inmb_SalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SalesAgreementMember" xlink:to="inmb_SalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ATMProgramMember" xlink:href="inmb-20250930.xsd#inmb_ATMProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_ATMProgramMember_lbl" xml:lang="en-US">ATM Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ATMProgramMember" xlink:to="inmb_ATMProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_AmendedAndRestatedAttheMarketAgreementMember" xlink:href="inmb-20250930.xsd#inmb_AmendedAndRestatedAttheMarketAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_AmendedAndRestatedAttheMarketAgreementMember_lbl" xml:lang="en-US">Amended and Restated at-the-Market Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AmendedAndRestatedAttheMarketAgreementMember" xlink:to="inmb_AmendedAndRestatedAttheMarketAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl0" xml:lang="en-US">Stock-based compensation expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_StockOptionsMember" xlink:href="inmb-20250930.xsd#inmb_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inmb_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockOptionsMember" xlink:to="inmb_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Potentially Issuable Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_MilestonePaymentsDomainDomain" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentsDomainDomain_lbl" xml:lang="en-US">MilestonePaymentsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentsDomainDomain" xlink:to="inmb_MilestonePaymentsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable_lbl" xml:lang="en-US">Research and Development Activity - Schedule of Milestone Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfMilestonePaymentsLineItems_lbl" xml:lang="en-US">Schedule of Milestone Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfMilestonePaymentsLineItems" xlink:to="inmb_ScheduleOfMilestonePaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable_lbl" xml:lang="en-US">Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems_lbl" xml:lang="en-US">Schedule of PITT Agreement Licensee is Required to make Milestone Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:to="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:href="inmb-20250930.xsd#inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:to="inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity - Schedule of Stock-Based Compensation Expense (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:to="inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="inmb-20250930.xsd#inmb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="inmb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_ResearchandDevelopmentActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ResearchandDevelopmentActivityDetailsTable_lbl" xml:lang="en-US">Research and Development Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ResearchandDevelopmentActivityDetailsTable" xlink:to="inmb_ResearchandDevelopmentActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US">Research and Development Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_RelatedPartyTransactionsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_RelatedPartyTransactionsDetailsTable" xlink:to="inmb_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inmb_StockholdersEquityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockholdersEquityDetailsTable" xlink:to="inmb_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stockholders Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_AggregateOfferingPriceAmount_lbl0" xml:lang="en-US">Aggregate offering price amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregateOfferingPriceAmount" xlink:to="inmb_AggregateOfferingPriceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregatePurchasePrice" xlink:to="inmb_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_AgreementExpirationTerm_lbl0" xml:lang="en-US">Represent the term of agreement expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AgreementExpirationTerm" xlink:to="inmb_AgreementExpirationTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_CollaborationAgreementTerm_lbl0" xml:lang="en-US">Collaboration agreement term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_CollaborationAgreementTerm" xlink:to="inmb_CollaborationAgreementTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ExercisePricePerShare" xlink:to="inmb_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_GainOnSettlementOfAccountsPayable_lbl0" xml:lang="en-US">Represents the amount of gain on settlement of accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_GainOnSettlementOfAccountsPayable" xlink:to="inmb_GainOnSettlementOfAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:to="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_IssuanceOfNetProceeds_lbl0" xml:lang="en-US">Represent the amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IssuanceOfNetProceeds" xlink:to="inmb_IssuanceOfNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_LegalDisclosureTextBlock_lbl0" xml:lang="en-US">Disclosure of legal disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_LegalDisclosureTextBlock" xlink:to="inmb_LegalDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePayments_lbl1" xml:lang="en-US">Represent the amount of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePayments" xlink:to="inmb_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_OutstandingInvoices_lbl0" xml:lang="en-US">Outstanding invoices.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_OutstandingInvoices" xlink:to="inmb_OutstandingInvoices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_PercentageOfGrossProceeds_lbl0" xml:lang="en-US">Percentage of gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfGrossProceeds" xlink:to="inmb_PercentageOfGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl0" xml:lang="en-US">It represents information about percentage of licensor royalty patent grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfLicensorRoyaltyPatentGrant" xlink:to="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_PercentageOfNetSalesToPayRoyalties_lbl0" xml:lang="en-US">It represents information about percentage of net sales to pay royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfNetSalesToPayRoyalties" xlink:to="inmb_PercentageOfNetSalesToPayRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_SaleOfRoyaltyPercentage_lbl0" xml:lang="en-US">Sale of royalty percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SaleOfRoyaltyPercentage" xlink:to="inmb_SaleOfRoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl0" xml:lang="en-US">The tabular disclosure of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl0" xml:lang="en-US">Tabular of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl0" xml:lang="en-US">Amount of aggregate intrinsic value, options cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl0" xml:lang="en-US">Amount of aggregate intrinsic value, options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Options granted in weighted average remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl0" xml:lang="en-US">It represents reclassification from redeemable common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl0" xml:lang="en-US">Common stock and warrants issued for cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl0" xml:lang="en-US">It represents amount of reclassification from redeemable common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl0" xml:lang="en-US">Number of shares issued during period common stock and warrants issued for cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_VendorInvoices_lbl0" xml:lang="en-US">Represents the amount of recorded invoices.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_VendorInvoices" xlink:to="inmb_VendorInvoices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentsAxis_lbl0" xml:lang="en-US">Information by milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentNdaEmaAwardedMember_lbl0" xml:lang="en-US">This member stands for This member stands for Milestone payment NDA EMA awarded.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaAwardedMember" xlink:to="inmb_MilestonePaymentNdaEmaAwardedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentNdaEmaFilingMember_lbl0" xml:lang="en-US">This member stands for Milestone payment NDA EMA Filing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaFilingMember" xlink:to="inmb_MilestonePaymentNdaEmaFilingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentPhaseOneInitiationMember_lbl0" xml:lang="en-US">This member stands for Milestone payment phase I initiation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseOneInitiationMember" xlink:to="inmb_MilestonePaymentPhaseOneInitiationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl0" xml:lang="en-US">This member stands for Milestone payment phase III intimation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseThreeInitiationMember" xlink:to="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl0" xml:lang="en-US">This member stands for Milestone payment phase II initiation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseTwoInitiationMember" xlink:to="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTableTextBlock_lbl0" xml:lang="en-US">Other Commitments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTableTextBlock" xlink:to="us-gaap_OtherCommitmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfPotentiallyIssuableSharesAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfPotentiallyIssuableSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfPotentiallyIssuableSharesAbstract_lbl" xml:lang="en-US">Schedule Of Potentially Issuable Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfPotentiallyIssuableSharesAbstract" xlink:to="inmb_ScheduleOfPotentiallyIssuableSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_OutstandingInvoices_lbl1" xml:lang="en-US">Outstanding Invoices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_OutstandingInvoices" xlink:to="inmb_OutstandingInvoices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentDueInSecondYear_lbl0" xml:lang="en-US">Other Commitment, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitmentDueInSecondYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SecuritiesPurchaseAgreementsMember_lbl0" xml:lang="en-US">Securities Purchase Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SecuritiesPurchaseAgreementsMember" xlink:to="inmb_SecuritiesPurchaseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ATMProgramMember_lbl0" xml:lang="en-US">ATMProgram Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ATMProgramMember" xlink:to="inmb_ATMProgramMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Licensee Is Required To Make Milestone Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_EachPhaseIIIInitiationMember_lbl0" xml:lang="en-US">Each Phase IIIInitiation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_EachPhaseIIIInitiationMember" xlink:to="inmb_EachPhaseIIIInitiationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Hierarchy For Assets And Liabilities Measured At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract" xlink:to="inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl0" xml:lang="en-US">Other Commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl1" xml:lang="en-US">Increase Decrease In Prepaid Expenses Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:to="inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePayments_lbl2" xml:lang="en-US">Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePayments" xlink:to="inmb_MilestonePayments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_LegalDisclosureTextBlock_lbl1" xml:lang="en-US">Legal Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_LegalDisclosureTextBlock" xlink:to="inmb_LegalDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentNdaEmaFilingMember_lbl1" xml:lang="en-US">Milestone Payment Nda Ema Filing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaFilingMember" xlink:to="inmb_MilestonePaymentNdaEmaFilingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_EachPhaseInitiationMember_lbl0" xml:lang="en-US">Each Phase Initiation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_EachPhaseInitiationMember" xlink:to="inmb_EachPhaseInitiationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl1" xml:lang="en-US">Share-Based Payment Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ExercisePricePerShare_lbl1" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ExercisePricePerShare" xlink:to="inmb_ExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_IssuanceOfNetProceeds_lbl1" xml:lang="en-US">Issuance Of Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_IssuanceOfNetProceeds" xlink:to="inmb_IssuanceOfNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregatePurchasePrice" xlink:to="inmb_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfMilestonePaymentsAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfMilestonePaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Milestone Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfMilestonePaymentsAbstract" xlink:to="inmb_ScheduleOfMilestonePaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Stock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="inmb_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl1" xml:lang="en-US">Percentage Of Licensor Royalty Patent Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfLicensorRoyaltyPatentGrant" xlink:to="inmb_PercentageOfLicensorRoyaltyPatentGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Milestone Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfMilestonePaymentsTableTextBlock" xlink:to="inmb_ScheduleOfMilestonePaymentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl1" xml:lang="en-US">Milestone Payment Phase Two Initiation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseTwoInitiationMember" xlink:to="inmb_MilestonePaymentPhaseTwoInitiationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_CollaborationAgreementTerm_lbl1" xml:lang="en-US">Collaboration Agreement Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_CollaborationAgreementTerm" xlink:to="inmb_CollaborationAgreementTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl1" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockOptionsMember" xlink:to="inmb_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SaleOfRoyaltyPercentage_lbl1" xml:lang="en-US">Sale Of Royalty Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SaleOfRoyaltyPercentage" xlink:to="inmb_SaleOfRoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl1" xml:lang="en-US">Stock Issued During Period Shares Reclassification From Redeemable Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentPhaseOneInitiationMember_lbl1" xml:lang="en-US">Milestone Payment Phase One Initiation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseOneInitiationMember" xlink:to="inmb_MilestonePaymentPhaseOneInitiationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl1" xml:lang="en-US">Stock Issued During Period Value Reclassification From Redeemable Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:to="inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_VendorInvoices_lbl1" xml:lang="en-US">Vendor Invoices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_VendorInvoices" xlink:to="inmb_VendorInvoices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_PercentageOfGrossProceeds_lbl1" xml:lang="en-US">Percentage Of Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfGrossProceeds" xlink:to="inmb_PercentageOfGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_lbl0" xml:lang="en-US">Supplier Finance Program, Obligation, Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:to="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl1" xml:lang="en-US">Milestone Payment Phase Three Initiation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentPhaseThreeInitiationMember" xlink:to="inmb_MilestonePaymentPhaseThreeInitiationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl1" xml:lang="en-US">Stock Issued During Share Common Stock And Warrants Issued For Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl0" xml:lang="en-US">Other Commitment, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_INKmuneLicenseAgreementMember_lbl0" xml:lang="en-US">INKmune License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_INKmuneLicenseAgreementMember" xlink:to="inmb_INKmuneLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_UnlabeledAbstract" xlink:to="inmb_UnlabeledAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_PITTAgreementMember_lbl0" xml:lang="en-US">PITTAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PITTAgreementMember" xlink:to="inmb_PITTAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_AggregateOfferingPriceAmount_lbl1" xml:lang="en-US">Aggregate Offering Price Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AggregateOfferingPriceAmount" xlink:to="inmb_AggregateOfferingPriceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Pitt Agreement Licensee Is Required To Make Milestone Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract" xlink:to="inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentsAxis_lbl1" xml:lang="en-US">Milestone Payments Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentsAxis" xlink:to="inmb_MilestonePaymentsAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_GainOnSettlementOfAccountsPayable_lbl1" xml:lang="en-US">Gain On Settlement Of Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_GainOnSettlementOfAccountsPayable" xlink:to="inmb_GainOnSettlementOfAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl0" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_PercentageOfNetSalesToPayRoyalties_lbl1" xml:lang="en-US">Percentage Of Net Sales To Pay Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_PercentageOfNetSalesToPayRoyalties" xlink:to="inmb_PercentageOfNetSalesToPayRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_MilestonePaymentNdaEmaAwardedMember_lbl1" xml:lang="en-US">Milestone Payment Nda Ema Awarded Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_MilestonePaymentNdaEmaAwardedMember" xlink:to="inmb_MilestonePaymentNdaEmaAwardedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_AgreementExpirationTerm_lbl1" xml:lang="en-US">Agreement Expiration Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AgreementExpirationTerm" xlink:to="inmb_AgreementExpirationTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_SalesAgreementMember_lbl0" xml:lang="en-US">Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_SalesAgreementMember" xlink:to="inmb_SalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_UCLMember_lbl0" xml:lang="en-US">UCLMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_UCLMember" xlink:to="inmb_UCLMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_AmplifyBioMember_lbl0" xml:lang="en-US">Amplify Bio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AmplifyBioMember" xlink:to="inmb_AmplifyBioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_AmendedAndRestatedAttheMarketAgreementMember_lbl0" xml:lang="en-US">Amended And Restated Atthe Market Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_AmendedAndRestatedAttheMarketAgreementMember" xlink:to="inmb_AmendedAndRestatedAttheMarketAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl0" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl1" xml:lang="en-US">Stock Issued During Period Value Common Stock And Warrants Issued For Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:to="inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl1" xml:lang="en-US">US Treasury Bill Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inmb_GreatOrmondStreetHospitalMember_lbl0" xml:lang="en-US">Great Ormond Street Hospital Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inmb_GreatOrmondStreetHospitalMember" xlink:to="inmb_GreatOrmondStreetHospitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<!-- [WMV6][G7AAkMW7W4I+4Y9I4HgkRrqP1XjB/7eHObjxVzTBV7mz1FOHTipEWTNYmFqUCI+UNn72PzCjq3HpxCst032rcNZxwfmo2btulC15zcUzisC+BTKxm5jlOl+Qj19TqibYozs9KJUow4j33rxEla5fOWcjKl7SA9Vi04JbCuXuarJzxYmuimkN3+/1M8mdrtg+lmXEGk6heNRym/JDQeL13f4DK2T9y0hDdkPg2UxNtELKAYLdcc8JUxOV7b4mdjgV0vclf3uCSxxgPgdC56reHyw94VSEchLyvxWHWBHLn4E7kGc/h6wfMaDsEUQhpnamlOsQ71mVcWQntodl1tVqHg==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>inmb-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 30 14:11:11 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedBalanceSheet" roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedIncomeStatement" roleURI="http://inmunebio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ShareholdersEquityType2or3" roleURI="http://inmunebio.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ConsolidatedCashFlow" roleURI="http://inmunebio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_OrganizationandDescriptionofBusiness" roleURI="http://inmunebio.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_GoingConcern" roleURI="http://inmunebio.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPolicies" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivity" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivity"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_FairValueMeasurements" roleURI="http://inmunebio.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Commitments" roleURI="http://inmunebio.com/role/Commitments"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_RelatedPartyTransactions" roleURI="http://inmunebio.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Debt" roleURI="http://inmunebio.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquity" roleURI="http://inmunebio.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_Legal" roleURI="http://inmunebio.com/role/Legal"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_AccountingPoliciesByPolicy" roleURI="http://inmunebio.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivityTables" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_FairValueMeasurementsTables" roleURI="http://inmunebio.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_CommitmentsTables" roleURI="http://inmunebio.com/role/CommitmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquityTables" roleURI="http://inmunebio.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofPotentiallyIssuableSharesTable" roleURI="http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofMilestonePaymentsTable" roleURI="http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable" roleURI="http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable" roleURI="http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofCommitmentsPayableTable" roleURI="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofStockOptionActivityTable" roleURI="http://inmunebio.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ScheduleofStockBasedCompensationExpenseTable" roleURI="http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_GoingConcernDetails" roleURI="http://inmunebio.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_ResearchandDevelopmentActivityDetails" roleURI="http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_CommitmentsDetails" roleURI="http://inmunebio.com/role/CommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_RelatedPartyTransactionsDetails" roleURI="http://inmunebio.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_DebtDetails" roleURI="http://inmunebio.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_StockholdersEquityDetails" roleURI="http://inmunebio.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="inmb-20250930.xsd#inmb_r_LegalDetails" roleURI="http://inmunebio.com/role/LegalDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://inmunebio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" xlink:href="inmb-20250930.xsd#inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnSettlementOfAccountsPayable" xlink:href="inmb-20250930.xsd#inmb_GainOnSettlementOfAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnSettlementOfAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInPrepaidExpensesRelatedParty" xlink:href="inmb-20250930.xsd#inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidExpensesRelatedParty" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/GoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/Commitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/Debt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/Legal" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LegalAbstract" xlink:href="inmb-20250930.xsd#inmb_LegalAbstract"/>
    <loc xlink:type="locator" xlink:label="LegalDisclosureTextBlock" xlink:href="inmb-20250930.xsd#inmb_LegalDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalAbstract" xlink:to="LegalDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="ScheduleOfMilestonePaymentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/CommitmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyIssuableSharesAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfPotentiallyIssuableSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyIssuableSharesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofMilestonePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfMilestonePaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAbstract" xlink:to="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsAxis" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="MilestonePaymentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentPhaseOneInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseOneInitiationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="MilestonePaymentPhaseOneInitiationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentPhaseTwoInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseTwoInitiationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="MilestonePaymentPhaseTwoInitiationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentPhaseThreeInitiationMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentPhaseThreeInitiationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="MilestonePaymentPhaseThreeInitiationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentNdaEmaFilingMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaFilingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="MilestonePaymentNdaEmaFilingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentNdaEmaAwardedMember" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentNdaEmaAwardedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="MilestonePaymentNdaEmaAwardedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="INKmuneLicenseAgreementMember" xlink:href="inmb-20250930.xsd#inmb_INKmuneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="INKmuneLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable" xlink:to="ScheduleOfMilestonePaymentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsLineItems" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract" xlink:to="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsAxis" xlink:href="inmb-20250930.xsd#inmb_MilestonePaymentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="MilestonePaymentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EachPhaseInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseInitiationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="EachPhaseInitiationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EachPhaseIIIInitiationMember" xlink:href="inmb-20250930.xsd#inmb_EachPhaseIIIInitiationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="EachPhaseIIIInitiationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MilestonePaymentsAxis" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PITTAgreementMember" xlink:href="inmb-20250930.xsd#inmb_PITTAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PITTAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable" xlink:to="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:href="inmb-20250930.xsd#inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract" xlink:to="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofCommitmentsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentFiscalYearMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentFiscalYearMaturityAbstract" xlink:to="us-gaap_OtherCommitmentDueInSecondYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentDueInSecondYear" xlink:to="us-gaap_OtherCommitment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockholdersEquityScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" xlink:href="inmb-20250930.xsd#inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="inmb-20250930.xsd#inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="inmb-20250930.xsd#inmb_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/GoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="inmb-20250930.xsd#inmb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/ResearchandDevelopmentActivityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentActivityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_ResearchandDevelopmentActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="ResearchandDevelopmentActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GreatOrmondStreetHospitalMember" xlink:href="inmb-20250930.xsd#inmb_GreatOrmondStreetHospitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GreatOrmondStreetHospitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentActivityDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfRoyaltyPercentage" xlink:href="inmb-20250930.xsd#inmb_SaleOfRoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="SaleOfRoyaltyPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="inmb-20250930.xsd#inmb_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="MilestonePayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfLicensorRoyaltyPatentGrant" xlink:href="inmb-20250930.xsd#inmb_PercentageOfLicensorRoyaltyPatentGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="PercentageOfLicensorRoyaltyPatentGrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CostMaintenance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfNetSalesToPayRoyalties" xlink:href="inmb-20250930.xsd#inmb_PercentageOfNetSalesToPayRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="PercentageOfNetSalesToPayRoyalties" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementExpirationTerm" xlink:href="inmb-20250930.xsd#inmb_AgreementExpirationTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="AgreementExpirationTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/CommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborationAgreementTerm" xlink:href="inmb-20250930.xsd#inmb_CollaborationAgreementTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CollaborationAgreementTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="inmb-20250930.xsd#inmb_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UCLMember" xlink:href="inmb-20250930.xsd#inmb_UCLMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="UCLMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmplifyBioMember" xlink:href="inmb-20250930.xsd#inmb_AmplifyBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmplifyBioMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/DebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="inmb-20250930.xsd#inmb_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementsMember" xlink:href="inmb-20250930.xsd#inmb_SecuritiesPurchaseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="SecuritiesPurchaseAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAgreementMember" xlink:href="inmb-20250930.xsd#inmb_SalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="SalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATMProgramMember" xlink:href="inmb-20250930.xsd#inmb_ATMProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ATMProgramMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmendedAndRestatedAttheMarketAgreementMember" xlink:href="inmb-20250930.xsd#inmb_AmendedAndRestatedAttheMarketAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="AmendedAndRestatedAttheMarketAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockCompensationPlanMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="inmb-20250930.xsd#inmb_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="StockOptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfNetProceeds" xlink:href="inmb-20250930.xsd#inmb_IssuanceOfNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="IssuanceOfNetProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfferingPriceAmount" xlink:href="inmb-20250930.xsd#inmb_AggregateOfferingPriceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AggregateOfferingPriceAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfGrossProceeds" xlink:href="inmb-20250930.xsd#inmb_PercentageOfGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfGrossProceeds" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockValue" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="inmb-20250930.xsd#inmb_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AggregatePurchasePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="inmb-20250930.xsd#inmb_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ExercisePricePerShare" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://inmunebio.com/role/LegalDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LegalAbstract" xlink:href="inmb-20250930.xsd#inmb_LegalAbstract"/>
    <loc xlink:type="locator" xlink:label="OutstandingInvoices" xlink:href="inmb-20250930.xsd#inmb_OutstandingInvoices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalAbstract" xlink:to="OutstandingInvoices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VendorInvoices" xlink:href="inmb-20250930.xsd#inmb_VendorInvoices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalAbstract" xlink:to="VendorInvoices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
<!-- [WMV6][Wch9FCGjqGuduDjfBY+cGQpBwlDIb+zTnwX7YSmvW6eNadXCotOZBQu5Xhmw9wz9ySr/KMErsameUOVmk58bLPXRzGEMMP55QJvz+o1zo5IJ/jcHoreb5pJ30MISfM75bavtTFt98PlsNb+DM6nfT2DXLOjWffKZdDcnVOlrtl9GD5TZotUMXd1k0SKWKafA0Ovg/goheVO7eSubx0IrUS+QOSXqZ3tYLnb/rdCVHAaI6VFfERXchOInRhygXynh8cxrGg15RInXzhjKQ3NdVGcDTVR9UwqiuKndzcUDDYaOl9EzCsZQIpDvmXdQSqs0ys4/MT2F1T1m03ZjSntEmJY=] CSR-->
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $S )T# 2(  A$! Q$!_\0
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M71M?^,7P'^$7Q1UK1YH#;2Z3JWCSX?\ A_Q+J.FR1$EM]I=ZC+&6P%88\L!
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M .JE\(5]55\J_L*_\F3?L?\ _9KO[/\ _P"JE\(5]54 %%%% !1110 4444
M>3?'7XL^'?@-\'_B?\;/%L&I77AGX1_#WQG\2_$%II,-M<ZI>Z'X%T"]\4:Q
M8:1;7M]IUI/K-YINEW4>FI/<Q)YH;=+&A?=X9^S/^TYXY_: N;M]?_92^/'P
M&\-Q^&-*U[P]XI^+EY\,?L?C*+4H-.EM;'3M/\%^.O%NHV%\;+58+R\CU^WT
M9V"P)9B^,-ZMCO?MQ>';CQC^R3^T3X-A^$?B#X\P^+_@S\1?"^H?!SP?XVL_
MAWXT^(6E^)?#EWX?U;P[X1\97UC>6_AKQ#>:5JM\NE:Z9+9].U#[*\3M-)&4
M_'K]E&XT'P9^UA9?$7]D#X8?MO>$_P!E#P=^R9\6KK]KCPO\=_#WQY6U\3?%
MK0M7\':_\'O"WP^^'_[0&IZAXCU_X^:7HND?%K2?%UO\+8K/P;<Z+XG\)VL,
MUXRZ4J@'ZD?M.?MFZ)^S_P".?A[\'/"WPE^+7[1_QU^(WA/QE\0]!^#_ ,&[
M3PQ<^*;;X9?#B[T2T\5_$[Q3JWB?7?"7AG1?"EKJ.O:+X:TX:AXDM+SQ5XIU
MG1O"6EZ=?W6K7!L_</V:_CY\.OVH?@GX"^/?PGOM3O\ P%\2-(GU72CKNG3Z
M1XAT[4=-U?4/#WB;P]XCTJ6:==(\1^%/$^C:OX5U_18IKB/2=6T6\LTN[F)(
MF'Y4?%'XJZI\*/VUO@)_P4;USX(_M':W\ _C+^P#J7P1UG0_#7P;\8>+?C'\
M'_B$GQ-\._'#P9H/Q#^$'AVUU/Q=HNK^.M(U74O#>HYTRXL-!\3^#[&+4M3T
MNWNUN)?J_P#X)1_"'XB_!G]BGP)H?Q8\*ZCX$\>^,O'/QU^,NK^!=5DB?4O
MMC\=/CQ\2/C%X=\$W\:W6H36.I>%_#OCC2])UK2[N^EN]-UZ#5;6>&TD1H0U
MNO5?F9U?X<_\+/X$? __ "D6_P""Z'UL?_6]?V;*_P!0U.K_ / /_0!7^7EX
M'_Y2+?\ !=#ZV/\ ZWK^S97^H:G5_P#@'_H KHQGQT_^W_U.'+?^8CUA^2)*
M***YCT@HHHH *^6/VY?^3*_VO?\ LUS]H/\ ]5)XNKZGKY8_;E_Y,K_:]_[-
M<_:#_P#52>+J &?L*_\ )DW['_\ V:[^S_\ ^JE\(5]55\J_L*_\F3?L?_\
M9KO[/_\ ZJ7PA7U50 4444 4[PX1<+N?),0/E &4#$0#3_N1(93&L?/FDDF/
MY1)7\%4W[1O[;W[..NK\&O#O["G_  4^\3M\+/\ @N/\2?VR_%GCGX6?!?XF
M:EX+^+/[+3^.]:MI?AQX9O!)%-XRN?$EF(1#H.J/'X9ELH+V[:8"!3'_ 'KW
M6_:I0KE1*[([%(Y D+E5>8!C;A9O)D^T+&[Q["%7+X/\,OC;_@H!^UM^T?\
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M2)*0D#J:AF)781@ /& YYVLTL<04*3_&DDBYQP>>N*_EM_X.8_\ @L+\5/\
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MUPH<*K,H5MZL)$,D;*49B)(\B/: A822$!2@09\P@_@)^PK\1_B#^VQ^T?\
M\%(_VE_!?[.'[)GPM\$>"_&?Q%_8Y^ 'QGN_AUH=S^T7\2OB=\++B]T#Q]XK
M^+OCG2;*^U;4?A/J%XG@ZUT/PN+GSKB."_0+.\40?]^;I-YBY0,&PF\,/F9X
MU.7#!64QF0-;,#]IRJADV%J_GJ^*O_!'_P#;!\!_&KXR?$;_ ()I_P#!2_QW
M^Q%\/_VFOB3K'Q>^-/P5UCX/> ?C?X&M/B5XL$%QXP\:?#R+QP5N/ 6N^*[V
MWB74O[ C65)ETYYY)8=/LUB /HS_ ((I_'/Q'\0O@'\8/@/\1_@5\&/V>?C/
M^Q9\?/%7[-WQ<\$?LZ::NC? K6_%6G:3HGCAOB#\--'EM;74=*TKQ?'XP>;5
M['4E,Z^*+'7;E%B2Y\M?V4KX&_X)V?L+>%?V!O@KX@^&^F?$+QA\9OB#\2/B
M-XE^-/QS^.'Q#NK:[\;?%WXP^-ELHO$WBW5#:9ALM/2UTG3-&T724)73[73)
M%W.\LDLGWS0 4444 %,?I^!_FM/IC]/P/\UIK=>J_,SJ_P .?^%G^7AX&_Y2
M+_\ !='_ 'K'_P!;T_9KK_4#G!+Q@?QMY;;AN1%,0D,C1D@,P:)$0G[AD).1
ME3_E^>!O^4B__!='_>L?_6]/V:Z_T_[I&8QLLHC*,YVN!Y<V;20"*8X)6(-M
MF8J0<PKR1D'JQ?*ZE+FZ)W^YV^[0\W SE&&)E#XE[.U_.R?X'PQ^U_\ \%,/
MV(/V"8=-?]JGX_>$/A9J6O6CZCHOA>[&JZWXQU>VC#+)=6OAC0+#5-46$A4"
M,]O#&["4*S[&V_SF_P#!9+]E3X,_\'#7[-WP[^//_!-3XW?#;XU_&;]FQ]<B
MN_"5OJP\/:IKOA/Q9'INI7N@:W:WNG6>N^'?$FF3:(C^$;75[1;;59=0UBUM
M9TN;>4W'\2/_  6R^*'Q=^)W_!4']M#4OC->:Y)XHT#X]_$?P;8:9K;9?1O"
M?A#Q/J'A[P;H^F*H"KHVG^%M.T:ST\@D&* X^Z:^[?\ @U=^(WQ>\+_\%<O@
MIX6\ 3ZA+X2^('A_Q_X=^+6E6X$FGW/@2U\&Z[K*7&H(V4)L?$=AHDMJQ.Y'
M>1EP0#3H^R4FH7Y^2K9V5G[COIVM?6]UHUU1=:->5.-6<E:-2E)QNUHZD4K.
MZN[O:UK-[F)^R1_P;2_\%2OCG\:/#'@GXF?L^^)OV>_A\-=TZ+QW\3_B?#8:
M58^'O#\&J%]5U#1]/DN!?^-=1.G-,;/2]*S'<.]M)>R0P11&O[_[?_@KS_P2
M#_8AB^&G[&6I?M>_#O1;GX+>!_!WP?T^PLCXC\3Z%X3TKP#H&B^%])L?$WBO
M1M+U'PG87]G96=A'<"[OX);1EDMG -M+%']'_P#!8KQ[\2_AA_P3%_;3\<_!
M^:ZL_B)H?P0\2G1[[3YECN-*34I+33-<U2WSU;3="U/5-0)'S!;8$X(K_%>U
M.]O[V\EN[^XO+N]N'::>>ZFEEGDG?"O,2^6R(XTA.XL=L6/E551-(\TL+0YF
MN55)I12UNHMWD^BU22TV;W9I4BJF*JQYDK4X6LUV3[[:7;\[+S_WI/ 7C7PA
M\2O"VB^/OA]XLT'QOX)\5Z=9ZOX<\2^&M5@UO1=6T^ZC,T5Y8ZG:7=Q9W$,T
M<B'9 L+P.KQ3 NH">'?MR@_\,6?M?GL?V7/V@L?^&D\7\5_+Q_P9A_$KXN>*
MOV-?VD_!'C#4-3U?X6> /C!X8D^%-[?$F#3M2\4:)KLOQ \,V;-EB+%]'\)>
M);@%GVR>,!\QR2?ZA?VXB3^Q7^U^,]/V7/V@CCZ_"7Q?_6N&HFI66UW]VOZG
M72G[2-WO3]U_+3H'["O_ "9-^Q__ -FN_L__ /JI?"%?55?*O["O_)DW['__
M &:[^S__ .JE\(5]55)H%%%% $4FTE Q&,@K@_.'WH%91R"HW'>3G (X()K^
M6'_@O;\>O GPT_:F_8B^&O[1'[;?[4G[(_[*'C[X=_M ZOX_A_9"U/6?#7C[
M5_B'X?N_APOP^U#QIJ&C>"/'_G^"9WUCQ%HLL4N@7QBUO5].,>F7)FGU'3?Z
MG)LAHV4X8'G))7RM\9D)3SX5W#:NV5A(8@64*1(R/^./QR_8Z_X*H>/+.R3X
M._\ !57P]\(IX?B%\;/$-_=7O[&/P_\ &LMYX)\>^)XM6^#O@J"YN_&MA/;O
M\(M%>?16\3@S7&NAX))$A^P$2 #_ /@B=XT_9/\ ''[.'Q,U3]D#]JW]J7]K
MSX?P_&F\M?$/Q"_:R\0:UXC\>:%XOC^'GP_5_"/AZ^UCP;X)_P"*.M/#2^'-
M6M%MK#4 =9U?6S+JLA$=E8_LE7Q5^P[\&_VL?@G\//%OAW]K_P#:QL?VP/B!
MJWCB[U[0/B#I_P $O#OP,A\-^$I-*TO3+;P0/#OA[Q%X@BU<6.K:9JVMC7;E
MK22Z;7G"+,JED^U: *5W*8C%A)&RRX\J(2R,PGM_W2@L% =#(SD_<CC>?*B$
ML/@O]G_]OWX-_M"?M4_M%?LI?#?3_$VJ:C^S5X?\':UXG^)=Q:A/AGXKG\4:
M]XQ\+:MI7@/6YY9'\52>"O&G@O7/"'BS7PQ2;QKI7B/3(F(TEV?VG]L/PK^T
M-XZ_9N^*_@C]E7QKX+^'/Q\\8>&7\-?#WQUX^.N1^'/"-WJU_8V^O>(Y+GP[
M8:MJEOK&D^#CXDNO"DD>D:A;Q^,%\/S:A&NFPWA;\:OV//@G^VC^RQ^W)\3M
M7\>_L\_!G1/V</AI_P $[_@YX"TF?]G;4OB_XVU3QAJ/PU^)?[0_CG2O"7@7
M4?'6D>'(?'/QMU?5O%6KZQ\2M.UE_#=SJMKXH\,>*KA[W5_&VJQQ@'Z=?M/_
M +:?_"AOB5\/_@9\-_@;\3OVF_V@?B+X&\;_ !2TGX3?#"Z\&Z'?Z%\,/AU<
MZ#9^(O&?BWQ?XX\2^']"T32I=?UW2?#'AZQ/V^^\2>)M7L])M(H"F^;V_P#9
M@_:%\ _M5? [P)\?/AC<:M-X*^(6F7=[IEOK^G'2/$.CZCI&M:EX:\5>&?%.
MEB+R-*\7>$?&.B^(/"?B?3+2\O[6WU70YIH+AHKI&?\ +WXG>/?'?PS_ &R/
M@/\ \%&[W]FW]I#Q!\'?B_\ L$:C\"/%?PZ\)_#.;Q=\;_@?\1C\4/#_ ,<?
M ^D_$7X5: NI:SI]YXFMM3\7>$-;U;3M8U/PWX)\3>$+-/%]Q8#6=&N9/JW_
M ()7_!KXD? []B[P)X9^+GAZ;P5\1?&'C;XY?&OQ'X"N+F&ZN? 7_"^?CO\
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M":)X]/@7P;'KL)U>]-OIX^P^'/A)\,KC7/"FA:KXH\1%&L)!I5K9#S]3NHV
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MZN8ZAG["O_)DW['_ /V:[^S_ /\ JI?"%?55?*O["O\ R9-^Q_\ ]FN_L_\
M_JI?"%?55 ' _$KP%X'^)WA/4O OQ*\%^%/B)X'U^..+7_!?CKPQI_C7PAK\
M-C=6VJVMOKGA36-,U32-9BL[VQM]6L8;RWWIJNG6#6K+,0R_P[?'W]H_2_"?
M[07[46H?"']E'_@CI\+/A5\"/"W[:1^$7@?XC?LY_".[^*6K>,?V$?$?P:.N
MW'Q5U:'3M)U'P3KWQQL/'WB'2/@CHOA4&1+ZWTEM6:.46CS?W>71PJI\_P"]
M$L19',0C0PR.TDDZ@RVZ*$ 6:,AA,T0XW!E_B:_X*4G]F;]DS]LOQ9^T_P#\
M%//^"9G[%7[0/A#Q%\3FN? OQH^ 7Q_L?"7[1%_X=CU."#P</BY^R1X_\<^#
MX/C7\0=/\/7&@WFIMX?L]<AO+2SAOM1:S:VM$N0#^Q3X*?$5?B]\%OA%\6VT
MBYT%?BE\,OA_\18O#]TA-WH<GCCPKI/B)=):.51+%<Z3'?M;RJRX61)""0I%
M?S?_ /!PIX1^!>M>,?@9#XS_ &U_^&%_B3\2_@[\7_@9%\2/B3\$/$/Q1_9O
M^('PH\9^*?AOXJUKX?\ CKQ7I-WIMA\)O'B^+O '@K7/"WBO7]4LK"XTZP\0
MV8C=!*;?^EOX=^,='^(/@'P9X\T>SOK#0/&OA3PGXJT:QU"TMK&[AT7Q/H6F
M:UIJWUA#=WL-K+#!?QVUU!%<21VTEO):J\T4 FE_#'_@N1\<_%OPMT_X)^!=
M9_;I^"G[%7P.^,+>)/"/CG4?$'[.-Y^U#\??'>O7&H:)8QZ3\*O =WX=\6>$
MO#GART\/:UJ]CXD^(?B_18-.\,W&O^'XX];TI]0WW(!]A?\ !*/]GVU^$7PC
M^+'Q2UC]JOPK^VC\6/VK?C%J/QY^,7Q[\!VOAG2? 6K^*=0\+>&?"NE>$_ O
MA[PAJVNZ-H?A3P9X8\-Z1I6G0C5[O4+JX-[>:AY4\HC'ZFU^+?\ P0Z^ '[$
M'[.7[-GQ?\!_L0?%KQG\8]$3]I7XECXZ^)/'EG'H6OZ;^T%H,6C>#O'7A]?!
MR^%?!W_"&:59VWAO1[S3="L=*GT)(]0DN]&U;48[FX:+]I* "BBB@ IC]/P/
M\UI],?I^!_FM-;KU7YF=7^'/_"S_ "\? _\ RD6_X+H?6Q_];U_9LK_4-3J_
M_ /_ $ 5_EY>!_\ E(M_P70^MC_ZWK^S97^H:G5_^ ?^@"NC&?'3_P"W_P!3
MARW_ )B/6'Y(DKXJ_;O_ &#_ -G/_@H;\$KSX$?M)^#CXG\+M=G7/#VJ6%U_
M9?B;PCXF@A:TM-=\,:U]DNET_4XX[J1!'(CPWJA8I8)40R0?:M%<\92BU*#M
M)/1_@_PNCOG&,HM2V=K]-G=?B?RR?LK_ /!IS_P3G_9J^,NA?&'Q!XE^,'QV
MD\&:Q%KWACP=\2;_ $(>$8-8TVZCO--N]6L/#^CV$OB"YM9I65+6_=H;IHX9
M(H(VBE27^HO3[6"SB^SVT*6]M$EO%;P1*(H(((;>.*&WM[=51;2*&- JVJ(J
MQCD*-Y%:%!SV./?K52K59I*;37KMZ*W6R(C1I1DI+62O9N5][W_-A7RQ^W+_
M ,F5_M>_]FN?M!_^JD\75]3U\L?MR_\ )E?[7O\ V:Y^T'_ZJ3Q=4&PS]A7_
M ),F_8__ .S7?V?_ /U4OA"OJJOE7]A7_DR;]C__ +-=_9__ /52^$*^JJ *
M5XN6@;) #LC9\SRW5P"(Y6C5O)7S$CE$[  -"("ZK<,&_AU\8?'#PY\%/VQ_
MVTOVC/V??^"<?['/C&3P^O[<7Q3M/C?^TWX\\5>/_P!H#XN?$']B'7OA0O[1
M/V;4_$$MW%\"?#%_H?C?4C\+? NF:/J(U;Q1HMG=7'V1;6WC?^R+]I7XM:[\
M"_@KXW^*WAGX/_$WX^:]X0LK"YT_X1?!NPT75/B9XS?4=9TW1GL_"NGZ_?:;
MIMY>6"ZE_;$D$UY#N@TZ0Y< HW\9/[77P7^!O[3GQ4^(?[35G_P;L_\ !4+5
M_P!H[Q8]]K2Z'XQU*P^'7P'\?_$;59+3R-4^-'A_P7\7[Z_'AO6K^PT>X\>+
MH]G##K&CI=G6#<+%!-& ?VF_"#XBV?Q=^$7PQ^+6D6%W::+\4OAOX-^(6CZ7
M>B+^U;>R\;>&K3Q!8:7<2W-QI\;:I96&HPVUT\UC;!W@E#2'D1_S=?\ !;;X
M?_#;]J_Q%IOB7]G/_@HE_P $^/AG\:_"'PE^,G[*_P 4_AO^T;\=?!>GZ3<?
M#WXF^,/A]X@\2PZ1<Z5XUM=8^&WQ7\,:Y\.M'LHKZ_L)I;K2M9UNVC2S>&(7
M7]+?PUMM?LOAWX!L?%NC>'?#'BJV\'^%;?Q'X6\(!_\ A%/#FO6VC:7#J_A[
MPL+8L8_#.DZL3!H-Q<27$ZZ081, A8C^9+]J/5/^" N@Z7\5OC-JO_!/+P[^
MTS\9K_\ ;@^*W['=S\,_AW^SZ-<^,/Q@_:X\!20:K\3=/\/:+KVHZ+I>KVVF
M?VU/J^N>,YM4LXGLU\Q#= LH /N__@AY_8FO>"/VU?B;J?[2/PC_ &F_CQ\3
MOVRO$^N?M,>+OV>-$O\ 2_V>_"OQ4T[X7?##2;7P#\(M5O(_*\<:!H?@FW\+
MW-_X[M[F[;Q%K&I7C7$K-:I)+^XU?EQ_P20^,/[&GQ8_9DUBT_8J^ NJ_LM^
M#?AK\4O%7P]^)?[._BKX9V7PL^(/PH^+^E6FCW?BG0/B-X?TW4];L+OQ5<V5
M[H^K)J\.M:B]WX>O]!61X5AC@3]1Z /+OC+XC\>^$_AMXU\0_"[P/'\2OB-I
M'A/Q'J?@;P!-KEMX8M_&?B^PTN:Y\-^%[KQ/=YM?#EIK.KQVEM=:U>Q7%E;6
MWFP26T]S=6D9_-7]D#]K_P#:1\9?M6^,/V7_ (Z:W^RY\6M2\.?!:+XI>-_%
MO[)$7B"UTC]G?XDQ^-+/PG<?L[?&B'Q#\1/B&6\=:]+=ZMJ_AVX:\\-:KJ \
M+>*;[4O">B6-SHT9_13]H+PU\5/%OP?^(6@? SQWH_PM^-&I^$]8M/A9\1]?
MT&+Q/H7A+QP\<4OAV]\0>'KB.6WUOPY-J<%K!KFE3)-]MLV*0VES<+"J?EY\
M+?V9?VP=4_:MU/\ ;#\2?!?]E/\ 9I\<>&?V<_BK\.;KP7\(OBAXI\9Z;^U?
M\8?'5QX0U[PIXL^-?BK3_@S\*I-/^'?@;Q)X;OY?"5SK6C>/OBGI<OCOQ?+#
M>6-G<PC5P#W/]IS]HS]I67]JGX=?L8_LB6?P6L?BKK/P,\9_M'_$3XD_'O3O
M&/B3P/X,^''A[QMI?P^\&Z%I/@WP/KGA37?$'B;QOXUU1X=0U!?%6G6GAW1_
M#5Q?RZ?J[SPPVWM_[!O[2E]^UM^S!X"^-^O^%;;P+XWU>\\:^"OB5X+LKY]3
ML/#'Q0^$'CSQ)\(?B5I>F:I)/</JNC1^.? WB!]!U*:66YFT)]-@NKBXN+62
M5ODGXC? _P#;9\/_ !T^!7[<OPS\%_L_^,OVAHOV3]1_9G_:4^!>M?$GQOX$
M^&.H2>(/&/ACXH:3XN^$'Q,'@?Q;K,G_  @/Q*@\4V,NB>-O!5KJ'C;PEXIU
M)K+4;/7-,TXGZI_8 _9LU_\ 9-_9<\#_  =\9^+-,\>?$*+5_B#\0_BAXRT*
MVO+7P_KOQ0^,/Q'\5?%7X@-X=AOI/M'_  C^G>)_&&HZ5HLKV>G27.F65K=W
MUG#J]QJ<:-;KU7YF=7^'/_"S_/#\#_\ *1;_ (+H?6Q_];U_9LK_ %#4ZO\
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MNCL@UW3+RZMS^_$;_P S'[1_Q"_8]_8<_P""EVO^,_#_ .U5^WE\:[7X7_\
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MY? *EOY _P!F>WBN?^"J'_!<"W:RBO3=:-XQB:VGFCCANP?VL_@@B6[K/'-
MY+/@)+;W]O.'-CJ&F3Z5?:A>:?\ UJV7[//P&\/&.^OO@1\,DLKS3;*YL[:3
MP7IU@UU;)+/J<%S>O?:-JVIZ7)%IT6I8>RU&=?"1F.I:MI?BSQ)K^G:1X?TX
MBSG'X7,ZE"@L,U&$5%XZ598?2-USQPL?;\NZC*#^*RE=)G7X<^%7"O$/!-/B
M;/\ />.</C,5Q%F_#V&RW)*'"E3!..38'*,=4FZF9U(XKF<<U<HP2M*4-)J_
MN]A_PW-^VA_S\_\ !)/_ ,3@^,G_ -"[1_PW-^VCVNO^"2@]<?MP_&/G\_V7
M>?PKCG_9K^!*WUE=S? OX7FU2X$0,?@/1[66Y:.TU+PO;Q+>0Q2:;HT,%KKE
MC!#:2VNJPZ);F?P?(GCSXH>+O".L^&R;]GCX&:[%YEM\#?AF<3I?.8?!'A<
MI<1+9O$EMX?T.]N+9[C2-,U?29+33;;51Y%Q_P (GX5U3Q#XUN]7\=:;XO\
M;V=JS]CPS6D[\M/VF>KGU:>JBMG9W6FJ5[W/K/\ B#GAPY24L^\2J=.GR^VJ
M_5N![T7*,9Q3C[26LESZ-QE:G)N*O'F['_AN;]M+_G[_ ."2O_B<'QC_ /H7
M*4_MR_MH][K_ ())GZ_MP_&,X_+]EVN0N?V>/V?[Z Z(OP3^&8N[AHK.]BF\
M!^#+M)(3!/H6LPI;:;ISVU^&EUO1/"\^FZ)/J5Q>1F3P?X1U"+Q;;:AXQT%;
M3]G[X#:8\_V[X'?#%;K6)G*03> _#]PL=M<:?:6SI)<1:=&WB%_+\-V5BVG^
M&I;4>(4TBS\ ^'-1>3PYXP\<:T?V_G;VP/#5%=:KGGRY6VDELUJW;R6NNB9_
MQ!SPW5TN)/$BK5M>-*-'@67M(VE*334XM<L5HK:R:C=6E*/6_P##<W[:'_/S
M_P $D_\ Q.#XR?\ T+M>8?&W]I_]L7XP_!KXL_":_P#$/_!)[P[9?%'X9^/O
MAQ<^(K7]M;XNWQT&+QOX2UCPX^L-87'[--C'>OIB:@VH16[7$:R?97#O&N7'
M0I^SM\$891JLWP&^&2Q7BO%'-/X#T#4A]HU8QZ.Y>>.QTV/4FN9M2TE[AK*S
ML?#WC%%M]&T*[\)^#M N_'>M^6_'+]G3X&ZG\(?BIJ^@_!'X:6\UO\./&J6,
ML/@71KVXL;O4=!N;JZN[=/"^F^'[W7XY]0T.XFFLK?4M'\4^/&B_M'PO<>"?
M!?AS7G\:Q//\YIQO..1ZSC'DP4\V>)M*5O<^L1]BNG,Y_"DVG=7-\+X*^&V,
MQV7X)\0^)F'I9ACL%@'BXX7@6/LJF.Q%/#0?[VJXRCSU%S+W92IM.*3J02_:
M?]E3PL/A]^S_ / SX:7&OZ#XFO\ X<?!3X4>"K[6_#FJ1W^D:K<>%_!6E>''
MUG2V:ULKN71M9N=(N;S2KBYL[>6>)I6,:,CQQ_1D;$22DJ1G;\P8%6QNY'RG
M&._UKYI_9*@@A_9X^"-PEL(3<?"?X?%E>.V6X=VT"T*S2&T"PJOSL5CC5(HB
MQBB\RW6&5_I:V+E>PRJDJ<]2\@+>OS8')]..E?;4)3GAZ=2I\52$))-IM*2C
M+5IM-ZO5:/1Z=/YRS?!TLMSG-<HIUL5BZ65YIFN74<3CEAUB9PRW'XG QG)8
M/]PI5(T%)I-I.4TFTDW;HHHJCC*ET\<85I"Z;02KQHSNI+Q1*$V*S,SO(B"%
M5+2@D*"5VG^+[Q!_P2I_X*1_''X;_M+?!3]F?]LG_@GEXF_9@^(?_!0?XJ?M
M3126?AWXB>,OB7X*^-.F?'A/B,GA+Q%XBLYVL=.\1^$M5\,:)X2UO0_[-N&L
MM$T_6HA?:<TJ-/\ V?W:L);6502T<C@!&VN0Z$D8W*)8WV>4\4@,2-)'>N4:
MR1U_B:^.O_!+7_@HC^V%^T9^V;\;OV#_  9+_P $D?AIXIN_B=X(\0Z???%/
MQ]HNH_\ !0'Q7IWBB&8_$;Q1\,? 4C^'/A5X*\;PIK-Y8^,=#2?Q%XA&I3:J
MRSG5YI(@#^E'_@FW\4OVC?B'X,^-F@_M2_M"?LG_ +0GQ9^%GQENO NL:E^R
M-I?B32_!_@(+X-\*:]-X!\:Q>(]8UR3_ (3_ $K4-8OKO48;:^ MM(OM&CN+
M:"4@R?I#7XW?\$1?!&D_"+]E3Q5\#4_80U3]@3QI\&/BM>^"/B=X"O->3QUI
M7Q9\:Q>!? NJ3?'3PO\ %2X8Z[\4O#WC?1M0TBULO%/B7=K-B^BR^$KB>8>&
MAL_9&@ I-J^@_(4M% K+LON7^08'H*H7/W[?ZK_Z,BJ_5"Y^_;_5/_1D59R^
M&?K'\Z9G4_6/Y3/\U3]EES'_ ,%7/^"W3J=K0Z=XEF4?:([7SR/VMO@K!]B$
MLL<L2?:3< ;;F"^MKCR_L1TV:YN[6]T[^R:Q(O;33(;SS8X[6"%8X8;_ %30
MYKB2RC:S42QZ?(C:;;:,WB0WMK'/=:Y=>#=5_LK5;'3=7^-OB#3_ /A%_P"-
MG]EB8P?\%7O^"W,JXS;Z;XGO-H20._V3]K7X+2X26RCFUJ1N@^Q:'#/JCY&J
M6-MJ%]H]II6H?V8&VEU?3M-LE:2 V5M#IQ%T;Q;.5%,?AH2Q6,<Z6!^QC7EN
MWL1<37VDK$_AGP;(WQ%U/Q+XDM?FN*KKB[&6U_XQ_!6CM>7]H8N_HK==]-+]
M/ZC\*;2\&,FA*+M_K[Q5*4]^2/\ 87"\>9)W3DW:-N7WK^_*,%RSC>9X)XEV
M011VS7:R20QVZRJNBP7S0I;#2A)?Z/'IUZVG>';J[T*PUW6_!^JZAJ?AC0-1
M\3>._&=_X\TJY?%M*E@L[<VDP5[:PG6ZC:W4JEK:Z))=6[2M-?R275[KE[H1
M2SO+_39RD7@3PU=_VSX@\0:_8-DO0;=K6*&ZC,J*_GQ>5);6@:ZL-/V0W&E/
M]GNY[1;)=$N(?!P&J6K7R>%/AU(?$C>(/%"-LR-+E>U,\MT)(8 4B73?+MEO
M+F]TN.ZE;P\+>!KB\;4FT!#X?FBTU7B;PGX(FM+M/BAX[L_#W6Z5KV:5G"[N
MUVM:R3MJE9)W][ZUOV<[*$I.?LTX2FI*MRJ4>?1-N;ES22NDG)SDX<LG38(T
MA@FN;>5(KVT$GV:TF%Y?:4EQ*Z^&$LM3M3Y>E:C?7R6DFCV.F>&Y].5S97'P
MM^$NI0:-8^/->OVV]I'?QRQ;24,@2!4GENO[8M;R:PT,SWT_A]K:VU"*>W&J
M6,8TV7PM]H7PM+\*[&XL?A)X>\3^)O$$OD3VEY;:HK-)(TZQ2Z44B>^NHM6N
M(;V*$7-BY:8R+X>?38-(TVSL5EU33]'T_P #ZWX9^''ACQ5>WE<(=6N-.+W=
MU))YEQ($N!H$UWKQOX_$5^%D%Q.T4T$R6YTR<:9?:+9^)=5\)Z@WA72O#/P"
M\.>*-*UFE)[JVUU%^]?65Y:/:W=Z7O=6;.:<(Q:IR4DE-QG5@XP5.4E2Y:/O
M)W=W9<L$FZ:BHOFA%+#<O?SI#.8M4CU"WAO&-L\>HR:Q_:%Y<2P&7^RH[1-7
M@UJQ\-VEM<7JV>AZ5X^TK2-4TVSG\'_"SPIJWG^7?'F2Z'P;^+\>EI_;(N/A
M;\0)'\V&WUYM<O+_ ,/W]U:V<-OK.K:9)JJ>(E\ZYM;6TG\-P^,-)T#3]>LK
M[P3X,\&^#_#GB_U,W(OHG@#7J22I8WKZD\T ^VH$;4UO;>:=;33C!>OX>>V-
M]Y5GI^H#3OMOB_2I?@%X7\(V?B'SCXV73V'P4^-%G]FDU42?#KQ[FQL+6^O(
MI!+X'\3:U_8<VCW4@2\N-9.MK=+HEW)IGB'Q8=*F\0WFJ6OAB#P9X-NXK6^K
MXE73OA,5+F?V6Z%1V5GTNN6UK66BT4?1RC3.<I:IM.&=97&--._/&.8X:U63
MG&+O+V<N>5M4WR3=Y3J_IM^R<LJ_LX_! 90P)\*/ <5JZ3&=I88_#T/[UY%8
MQ9W,8?W0*R>2;GS"+A8H/I2#[TGX?^C):^<OV5"I_9R^"6UF?_BUO@W,CY+2
MM_8<1,AD-M9^8>0A865DJ%/*%E9[/L\?T;!]Z3\/_1DM?:94V\#EM_\ H5X?
MK?I2UZ_>?R+Q8K<4\5_]E5Q#TM_S.\UZ=/-%BBBBO2/&*-]&)EBB968/(5("
MDIM*-O\ ,;RW1 J;I(#(44WL=J-PK^6_X@?\%3?^"O7P"_;DO?V>_%W_  3*
M\=?M(_#ZRG_:3\0^"]=^"NH>'=,7XL?#:S^*W@C3_@+\2="\4W"/I7ARX\'?
M#OQ%;^&OB)X>U]DF\2Z]XK@-G#:OHEP1_4S)NRFT$MN4XXQMWHKL2>A6-GP,
M\Y( +;:_F7_X+L?$O1/#?QU_8Z^'_P"U7^TI^TS^R+_P3C\<>#?C!>_&+XO?
MLQ/XST75O$7QTT>\\#P_#'X<_$#QKX#\->+-?\+^"]1\+ZGXR\2;DT>XCU/4
M/#R1.%%MYB '[+?L,?M+?&K]J'X:>*/&GQS_ &/?BI^Q;XGT'QM<>%=.^&WQ
M:U_PUXAU[Q!HMOH6B:K!XSL[GPS'';6VGWMSJUUI*V4X9X)M(D\MV1N/M>OP
MF_X(%?$?Q]\0OV</C_#-\4_C;\>OV;/!'[4WC?P3^Q7\<OVB+75[7XL?$G]G
M72_"?@BXT^]UV3Q-H/AGQ7K5CH?C.]\6:!I/B77M%L9]6M[!XHH8S82QI^[-
M !1110 50N?OV_U3_P!&15?JA<_?M_JG_HR*LY_#/UC_ .E4S*IT]8_E,_S5
M?V61G_@J]_P6Y5E)0Z5XI#.%G41_\9:_!';*9HB&8VW-Z+.WSJC?93JFD$7V
MCQU_9:DRV-GILVD&2"[FMK""5+6QDNOFCCN_L,,EEX8*VL$R:PEAHMA;H)M0
M@O)8O O@\V?Q&\4^)-5T[^-#]EA1)_P5?_X+<HL<KN=-\3HK1KJXV?:OVMO@
MI8,3/HQ%Q;D_;1MN<A[$@ZK!^^T]17]E]O$='M=*+QS7*SV4"3_:8ECM;=[@
M1:-%%(D$D.C>=JF#H<4.FRQP@ZHWACX?2Z3I-QXT\4:!\UQ7_P E=C+Z+_5_
M W>GNK^T,6[ZI[Z?<MW8_J7PHN_!C)E"TIKCWBIPIM2:G*61\,12:BT[:R5^
M9-7=I07-)K]GLG5+C_1VU*...XANK./2[](]LUW:2(\5DZWGB#RM,O-?\/IX
M=T&XM=6;PZ]Y\,_A[J,?V#XB^(;R9(WO?/;64+R)(]POV@^:T=VMK>V5TTUH
M7TN+5%FN[/2O#T;Z?/X?NO'/A?'A30&M?A[I^J>(_$3I;!7MHK][J66#;+%Y
M7D/+:ZDLNSPO' [>'H[07DLW]IF;_A'_  FVCWVNMIT7@GX>74/@V/5;?5H)
M67Q.46S=/]+^SZJZ:?,FH2:BM^;>P:]OG\//8Z5JD&HVGAB^TR$WHTRR\8"U
MNM&NOL_PA\/>*!KOB*3=N7^\EOK%6U:VU2U5W;757<E].Z48<]]%:G4;C*#<
M)N_N0D^:JG&[49*,;J*7+:,*3D(GEEALKMO/LY%4BT>WU'5XKQYX+*SCM!<R
MPV]A?1M]N\3PA(].\-6WB[PIHL>E:'<^$? 'ACQR9FK%) \O]E(TJB;&K21S
MZ;>RZPB6%U;6X2)%71]1&JI:Z EL^MWGAV+Q9I>C:=JNMV6B_#+POH'A3Q,Z
MYVZPDFD&5X9KYTMDOK3[%J%ZO]HE--C4#4[)K[4X;ZQ6SUAY-3L[;1O'":>S
M>+;1_A99O:Z\%H=,G$=S(ADU::*W7[2PO;B%IO-U1TMHM0B^TZP9$\)+X@O-
M0FDDU/6-+BU+Q3XLV?#OPGX<\+K*:MOK9J_*W9I\UE:UTUM>[OW:7+<J4E--
MP3I.4)*'M(QYX3BZ;J2]I?EG"5TW"48M/W5&,INH^;RK6+[5;2O;:C&3$+FU
M275KF>WN(]*$MS;->^5JLT=RT>N27/B+Q):6EGJ;^'U^)GC2V3P9H%IH%YY5
M\<[.PU'X,_&=-;2VEG_X5G\0K"YANHK.>TL-'U#PZ[7<:6_C(-;7L-_#9Z+J
M.M:5K#C3]8-S8?$KQLMI>S?"W2-,]1BA:VF_M)_-E\^WAE47&HZI?6]I$S2Z
M_*$D\0;8+B:7S1K\-]J>W5)],72_$?Q" ;3/AGX53SCXU6"ZU\%OBQ+;"XM;
M9_AWXVTY8[>W6X1GU+PUJNM237DFLI]A@>[^R#48D\1$65\;_P#M3XAK;>/=
M2\-Z7I>=9_N,6DN5RP>*5E974J%5WU=WHNKZ]M_1RA1GFV2RJ3YJ<,YRJ]23
ME)J5/'X)**Y8QA'WI1LE%?PVM9<WL_TU_9.8-^S=\#WR@9_A5X)9A%<R7ENI
M.@Q!/LEW*3]LM-BHL%VORW:J;A\S2RU](P?>D_#_ -&2U\X?LH,'_9M^!C88
M[OA+X&<EHS&3YFA)(N!(!+_'D^;E@S .3,)<?1\'WI/P_P#1DM?;Y5_N.6_]
MBO#_ )4C^/N+&GQ3Q7V_UKXAM;_L=YM\BQ1117IGBA6)X@T'0_$VG3:+XBTC
M3-=TJ\4B?3-8L;34=/F*$,CSV=XK)+Y1Y7:,@%LX.TC;HH S=,L+/2[:'3].
MM+:PT^SMX+:SLM/MK6STRVBB,G[NQL[; MD7<%:/ C4",1YPY.E110!RGC+7
M7\+Z!K/B1;#6M9&A:%KNK-H'AO2X]7\1Z\--TZ74%TKPU82-"EYXBO'M5@TF
MQENHX+R:1XYHF4"YL_@[]A#]M/Q[^UUXC_:KT3Q[^SWXF_9QU+]GCXQ>&_AG
MI7@WQQXFT7Q%XZO]$\3_  O\$_$/2?$/BVR\-MJ'AWPOKDEMXOE-UX>T_P 2
M^)KFUA>%-2U-)O+@C_1.X )7<Q$9256 CSM9MF)_.(*0^3&)<;QAR^ P*[6_
M-O\ 9P^#?QD^"_QK_P""G?Q9U/P)#JMC\;_CCX8^*'P1T.V\7>'[*7Q_I'AC
M]FCX:>"3I\VHY\CP@^J>-_">HVRZKX@WKIZ7GV@*42X+ &[^U#^UM\4_ _Q[
M^%7[*7[,GP?\(?&3X_\ Q#^'/C[XV:_#\2?B9=?"WX:_#?X,?#K6?#?ANZ\2
M>(O$NB^#_'OB6;7/&7C/Q5X=\)^$-+TGPQ/;+>27NK:Q?V%MI*&X]5_8S_:9
MTG]KG]GGP)\;]/\ "FJ?#_4]9U'Q=X3\<?#O7+NWO=9^'WQ.^&?C76?AO\3?
M!FI75O*QNWT3QUX4UZ.QU&XM=,N=:T>33-=FTVT.I[#\.?$;PQ^UOX7_ &D/
MV;_^"B'A3]E75?'OC/6_V/\ Q9^S5^T9^ROX9^*/PVB^(?P[USQ1XH\*_&GP
M5XD\(>.O&6N>$OAY\0-)\+^-_#NM_#OQO9KXFT>_BTOQ'I?BS1;#6T\/3V]K
M]+_\$X?V>/B'^S1^R]X>\%_&%-$A^,'C?XA_%_X[_%'3O#-_/JOAOPSXS^/G
MQ;\6_%C4? ^BZK=75W/JUOX'A\56OAFYUB*673M8U+3K[5-.N+B"\+B)_!/U
M7_I5(RJ;?]O1_*H?PD_LMKO_ ."KG_!;M?)^T'^S/$^+?['>:C]KQ^UK\%3]
MA_LZQ>.YU+[:/]'_ +-BFL9=1W_8(=2BFN([+4?[+M+B2:TMX;UTNX;6PL%6
M2Z6VO(V_M.XATBZO"="%K;WDVIZ9J&I^"OL&CG18O$?V1_AYX"ET?3=#\7:I
M?_QJ?LMG;_P5?_X+;/\ W+#7C_JI;S_F\+X#_P#,.MO](N>GWW_XE_\ RX:C
M^XU(5_9!':Q>(M+L[">)W6WTNTG5[FVAU:W1[W1[K2)?-&KA/#<ZRV6I7BN9
MI(=(\;Z2=6^'UA<6WP8\->)[^W^;XJLN+\6NO]@8!]+?\C'%IWO;1:O5I6>Z
MN[_U!X6W7@ODTDDXOCSBR$FW)/7(.&;1CRIOFG*T5:,I7BK1DXI1T<74UW%!
M=2M?6UQYL#6C"PO!JCZI<7T#6<S)%876J0ZHEM#%Y6CQZ'8>+CI\6E>&;71/
MACX?\4:??)J#B65$TLRS&X#W,\</F7A\00Z@)+IH+>;Q$;32+Y-:>U:]6XNI
M-#O/$7]B1^*/$#_\*0\(/I'BZ28RRL-.1HU35 ]K<FWDN;M8!>Z6]_:Q6R7O
MV6WUV*>VT*U6+3]6&EZ)XPT6.P;4I8/AYX$7P=J3+>\DTF1!%YY,UU"'$$<U
MU"K)IJ7,XADTR*'29V6SO[C4+J.]MK"^U[2[#5O'NJ6D/PGT;PQX>NO!BURM
MIMJTG)6UCKK:*C9IMZ;VLFNG+]9.,N>-*2A!\U.-.2ES4ZUHWBJE5U8M2C&W
M/)2A=U)1DY+F=>W>>2;1;RRF66]D2TF&K!9Y)9[6^34)[F2VCFM(--9?$%]H
MNFZ_+K/E66@ZD+!?$WBJR3P%H^E>'K^*W3>\[WZW,C0W"VMN^^"[@TF"73+7
M6I(@MQ&(8I#?1W.OX\;EK&2;RO%OBX_:H_AOX5CI+9VUO<C6XP@NPDRIYJPR
MSV[&'2M6,<0N$&J37,MAH.E:_#J_B63][IW]E^//BFNWPE\+_"T4TUO;:RLU
MW<K;PK:7%U*JW-ZDET(@FG:Q(\\7B2*1K=Q-JMEK_G:Q;WVGV;^5\7_$^GP>
M,UAL] +6LWNU:UEUOJ[:Z/7T?;XK4G*-6"45"$^9U')N5X*G)1CS)13G%M6_
MFBUS2E_N\<._S";I_LUK;>9<QFYFAMC:1VT<^I#6I?[0"W<$FEWE[9>)8]8\
M537.JZ)]J'C/XCZ3?>)I_#/A[2?+OCVTL/P>^,45DK6EJ/A5XXWVBMHNF?9E
MM/"G]HD3KXIAM(=.?2[[7+ZZCL]9@N[#P\-9DU#XE:Q/XZ\2^%M#\-^KRR2:
MLPT^[B82Q7$&KBWO+:_LTGO--GTO5$N6CULZA/X91KK3-*U.WTN5M6UKP'J.
MI:-\0=3$_P 3O%&@OHOEWQNNVT#X'_&:.VCM@C?#'XA:M-<QWD/AY[B32]+U
M2TN(HY;07DFA)#J?B"^:YG":V/"NIMJ%UJ*WOQ%\9ZP=(Y\8U]3QJ;<KX;$-
MM)*S=.326[>V[[-7WDN_)HU?[;R.:C%-9KE<8P<Y24U'&X:,Y-1DHPDDXOEB
M[>^I6M:G+]/_ -DYP_[./P0<2>=O^$_@20SY:7[09/#L+^?]I?F]\T,'^U?\
MM@0'_>K)CZ1M_P#EI_OM_P"AO7S1^R5O'[.7P41T9=GPI\";69YFW@^&[<%@
MD\URT.UPR[%NKS< )I[N6^EO$B^E[?\ Y:?[[?\ H;U]YE?_ "+\K_[%=#_T
MB@?Q]Q/_ ,E7Q;=W_P",LXB_]7>;:%FBBBO1/'"BBB@ HHHH **** "J%S]^
MW^J?^C(JOU0N?OV_U7_T9%6<_AGZQ_\ 2J9E4Z>L?RF?YJG[+0+_ /!5W_@M
MS$MN;UIM-\31FP%O9W(OHU_:V^"L\EL8M3DBTMO,$ 4'4[C3[.W)^VC4H;BT
MM[+4/[)8?+OK.P;0XS>W$\5E]HN-.FLKRZU:'6(A;PO)/;11F]M/%>MZ;I,;
MW/EV#>(CI*C7+2[^!/A-;7Q!_&O^RU&DW_!5_P#X+=0R#Y9M'\60DBUAO6!F
M_:V^"40VVUZ#I<Q._P#U6K@Z9,0(;\&RDN0?[)9IX-)TW2+Z>:%X]=L;-+;^
MU;F[NX$34GE\0WT=O<ZRPCU>&&P\,7NHZA?[GT[Q!IMA-XA\?I%\(/!6F^5\
MWQ4W_K=C4V]>'\#M=RM_:.+M96=^O3HO5?U#X5QOX,Y&_P!W[O'W%;BJK2@W
M_87#%U*3:<4K1=TU:[:N_<GH7,UA)'%%%=H=7U1U:TB'EWFIZS!K-W::G!9"
MQO95UN_7Q!9Z!K.L+<:XIT*[3PC<:QXL!^%?@RY\+%T2+:SO<:T^YY+8L9[W
M==I!F]N]1N19W'B4O+?.;.UTK5WU.XVM-]@'B7QF$\'Z?\.O"R.-FLDC:FTM
MR\9ADG9Q<2O:6UC<*=<"VMI?YL+^ZDAFTS7+^X\7LNG:GJ+3^/?&@N/#O@_X
M9:5>Q6A?5"+F14MY;1H=L*6TN5N8E'BV[%U'=@W,4]U#IUMJ<-OXR:+4]%;4
M3\4?'*VU_J'@O2=,\)IV5FV^5Z-)O7756WTBM>^O][ZWGA[2;E"%.G[2%IP<
MU;D4XR49.=N23E5DG!N[AIJG[&3=):2R75Y/)9:5'&;B2YE%U;Z9;K"9-=T[
M4+ZYUB&:*SGMK.'6-9&H7:7HM_M+>)/'NGQ:Q?\ A"Q\/4KI?]+B729G@M]*
MG(U2&Q$UM!IYBMF\2;M12XGN?^$?%I:>(;#Q:MUK::PFEI>GQ-XF2\^-_B?X
M72:+.MQ!<SVVBO+%"%2ZN(8WD33;LR:5>V5P-0,UJK^(XC9:AXCT^*RU&6WO
MKGPGJM_IE]XVM9/B;K'@^YL5N+Q-%E"+*L6^>4R&XG@LYH'TNX:=D4WJ7LFE
M6]MKM]%I=V=+76+;PMJGB34=)0WGQ?\ $N-%F+M_-:VZ5FG[Z6MKM;VU=G:[
M6LE5>*J\J_<\T:EU%MS]K']Q*;E%34(5(_NU)24&XOW83O"E4DB&GB-;:TCE
ML+VP,%NWEH=*>VM/"Z*R02_;9[C6=(L_"=I>:A>_\3&XNAX)?Q"XCO8OC5>W
ME[H/F/QJGTS2/@O\6TUF\MK&[M_A[XXN3]ON%T9[#1O#_A+7=)N9[&>#_3O#
M]OX6M=?T;1Y9[-%?P8OBP:=<->?%+7KO5M5]-D1=-MH[KS3:QB9-$6!8-0TD
MP-:-!HJ:?;QSSS6MI FMZZ=$VZ9<7_B+PD+EO &@74OQD\02VUGYC\9K=M4^
M#OQCU..:2"2+X>>,()FL=5GM%D2P\-:SHQ2>3PA'=W6CW%IJ6CWMC'J.C0W]
MWX5:SF\+^$-.F\0>)_BE/:543C2Q7-S1_P!CQ;4&U:RH5+:M+=M=%MRI*R2[
M<FE1>;9.X^QJTWF^4JI62E[3FGCL+?EA&I.\8*G)QNY*2DJM2I-2E4J?IU^R
M7&T7[-OP,9D1)'^$_@:214%NJ*P\.0Q+&([0_9(Q"D:0A;3%L50/",,0/I&#
M"-(I/HV><_,\O!^F/S)KYM_9,=G_ &;_ ('J3,Y7X5>!U+SP+:EB?#T3$K"D
MMPJ \%D6ZOO)8M;R7DL\,J1?24&':1B/1<<Y^5Y>3]<_F#7V^6\OU'+>W]FX
M?;_!1M:_SN?R!Q8YKBGBODM;_6OB+HDK?VWFW1;:V+5%%%=QXP4444 %%%%
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M2UO%R;N[JZ]U*S9][P/XP5N$^$</PQ/@K 9S+#Y[C<^IRQ>+XCP;G+-\OP6
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/04444#LNR# ]**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B *L# 2(  A$! Q$!_\0
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MWC#PZNC/_P ([H7Q 3PYH>C_ &?Q&DD?C".UC"VY2VA"KM7Y:#TUVOZNR?\
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M;HV@^&? _B?PDGB[_A*#K(>;QY'./&D/BS=_X)T_$OXA:Q^U!^Q@/AC\;_\
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M^4,'[5/_ &,?[./_ *TY\(:_=#0?^0-I/_8*TK_T70!NT444 %%%% !1110
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MBG\,K;Q-X8\'7/Q%\"VWC+QSH^JZWX(\)3^+=&_X2GQ;I6DC&L:OX.T W?\
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M\'-?_*%_]JC_ +&3]G/_ -:=^$-?N;%_R*5M_P!B]'_Z:30!8U[_ ) VK?\
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M$?\ X[_=_P"F>VOZ2J_FS_X-/L?\.6_@1C_4_P#"T?VB?L^>OE?\+E\1[?\
MQ_/XU_290!_-I_P:GG_C49X,_<_\W ?M'\8Z_P#%T-:YY_NG@^YK^DNOYM/^
M#4\_\:C/!G[G_FX#]H_C'7_BZ&M<\_W3P?<U_09XX\>^#_AAX(\7?$CXA^)]
M%\&> OA_X:UKQAXT\5^(+V+2_#_A?PQX>TN;7=>UW6-48PP1Z+H6C))/),0J
M;(6+L& >, [^BOYS/%'_  =%_P#!(/PE\<!\#?\ A>7B37V7Q-X9\,Q_&+PM
MX1E\1?! MXB_L1H];D\>)XB"-X;\,+KX'C3Q)]E,5O\ V#XD,8G\B/?^X_P*
M^/\ \%OVD_AOHWQ<^ GQ,\&?%WX8>(+S5+'1/''@'5X?$'AG4=1T76)-&UJW
MM]7MVDCDDM=:CE@9?E;$7FJ'C*N0#VRBBB@ HHHH **** "BBB@ K\J_^"I/
M[37_  3>^#/PDT#X/_\ !2CQ)X(M?A5^TEXFTWP5I7A'QII.JZO8^(&A\0>'
M&/BPC2;5_P"Q+;X9Z[JWA_Q+>>+([B*Y\$B*+QA#(D\"SP_JI7Y+_P#!89/B
MH_['O]H?"31_BKJFNZ5\;/@1J.LW/P&^!.D?M&?'[0? 8^*.ACQUXR^"/@'Q
M#H/BO0E^)'A;P])/XD\'>*I8%'A&6W:<>1((U(!A?\$K/&?_  2^U70_C;\-
M/^"7%CX5NOAW\._&7A36/BOX\\%6WC3Q%X7\=^//&VC^9$#\5_'5QXC\2_$#
M7_#>A^'H%ND?Q5=_\(BDGA^S 6UG8)^PM?CS_P $HM<U[7/"/QD;6OB5_P %
M&_B(MKXH\/1Z>/\ @HA^SGH_[.'B?1%.D:KD?"W0]#^&/PL&O>&+CRT>[?R'
M\B1E2$HI4-^PU !117@GB?\ :(^!'@OXN^#O@3XH^,?PQ\-_&;XBZ3?:YX&^
M%.O^.- T[Q]XKTW10?.U?P_X,GND\2:\B*'262*)PW]EE;<B2.9@ ?D?_P '
M,W_*&7]JO_CZ_P"0Y^SG_P >W7_DYKX0_K_]:OW&ML1^$[?$? \/1Y'IC2P2
M#WYQMK\,O^#FF)3_ ,$8?VJ<1!O^*C_9R/;I_P -.?"+G'OUZ?XC]A/B1\2O
M!7P:^!OCKXM?$+5!X>\!_"WX6>(_B#XRUDV?V_\ L/PGX(\)3:[K^J+I:@L[
M6^@03R/;K@8"Q.%61C0!^$'_  :@_P#*%[X&E\&;_A:?[1/VF?S\Y<?&/Q&6
M.1G[Z$'/&=N<CS*_I-K_ #5?^"0?_!RG\!?^";_[)7[+'['/C'X'>.OB3I=C
MX^^+.N?'CXN^'-?M] 7X6Z-XW^)VJ:_X?_X0OP._AZYUOXM>3X?>'7_%QN?%
M?@R6WW-:1-XKN6, _H7O/^#N_P#X(_:=?Z'IEKXG_:(UV'4Y-E[K&E_!/51I
MN@,1@MKRZWX@M==< \(/"EGXJ)7#8 ;: #TC_@U//_&HSP9^Y_YN _:/XQU_
MXNAK7//]T\'W-;__  6*_P""RMG^P5\7?AY^R3J'[!WB3]M:S_:4^"7B_P 4
M:EX7TCQ7H^EZ;JGA=-8UWP_XR\&ZWX+UCX;>.X_$NB7&@023>*GE6&T-G<?9
MKRW"B5Z\2_X-+/B_X%\=?\$M]0\#>%-2EU#Q7\+?V@/C&GCC2UT;5[1-#F\=
MZT/'/AV%M9;0X?#VMS3:%K".T?AJX\1(DI19&A!6-?R:_P"#BW]JGP+\/?\
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M?^$EO/\ A(9)K9[TO(5:!8]OZ%?M^_M6S?L._L:_M!_M:6'@(_$^7X$>!_\
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M@SQ+-\*S<!XUT1/&\Z)%XVW'][Z_#7_@D)J/P<^)?B']L#]I/PK^VO\  _\
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M_P!BG]NW3-(?]HGX=_LN?LUS_ [XR_&KQ]J'@OP=+K_Q/\=^)&T#^W=:\%>
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M;0P0Q9'0?77_  <U_P#*%_\ :H_[&3]G/_UIWX0U^ZN@_P#(&TG_ +!6E?\
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M_%R_\(WXO\#8MYY(DY#]BK]IGXV6'[9'QG_8/^(_[,/[.7[/G@_P%\--1_:
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MQO&+GP;H%Q<P^$K<MX2OI+FYM[B2Y_5NOA/3OV+-'\.^./VA_B#\//BY\6?
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MA/#;+X:U_10WAI&0^%@1:2,#"*_5ZN>NK*27=V_'M^@!1115 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #E 2H# 2(  A$! Q$!_\0
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MG7\-/VC?VI;SX^_&+7-?O?"G_"F/A+\)_P#A6?A+QAXW\'Z)XK@^'WQ6\?\
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M-XAN[#4+CPUXA73X-2T^V_LYKQ7T+0->S)I:O-M=#K861DED5VQAF8K)7HU
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MRUO6M >/4M*TVX\F1-8\/>(?#FNJT>]F4IYR/M!G6.-0%\7_ .'?O[*B??\
MA]KY[ #XM?&/GZ?\7#_S]:^I_$FD:MK$-G)H^M+H5[8W1N1<W&EQZB&3!5D\
MN5T49!.2K'<#TX!KE)_#GQ36+;#\4-.$X/'VCP%IK#\EUX8 [8) ]A7H4L;F
M5'#K#X3-'E-M/=G-1U=V[0]UO^\[V1Y.(P&78G$O$XK+E*27Q--W:6FG,GLM
MM+OU/G+5O^"=_P"R'K-O;1:O\)9-;@M'\RU36?'7Q&U06+#.Z^+:SX\F*A<
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MXC:UUNY^(.DZ%?7LAVC5,Z0/#LNTPNOR$S9E8$D] .3USXK?'30]$U+7+KX
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MVMX/+\+RJC^'-C7*>)"8GN1M%PG<?\)U\?0T!/P*T4,P GQ\5M%W(0T0&/\
MBGB7&6OP!A0#&A&<KLZ+7?C-X7\,:I?:9J>E^+_M6G6WAJXO&LO!?C#4=/(\
M7ZU/H.C$:K!X>EA:076F3+.H?]T"HD&\*%]';7(@WEBPUG!YRFEZA*I[9W_9
MR#CV[^_3Q<DR*NGF.#P_B_Q1G.:?:=2.0+V=K>Y%/(W!K22M&32LE9ZWZ<1B
MJ3Y7_JQD:25ERRQ5VEU;_M=>]K\4HWD]>B4? I_&7QDU:32=.\0_!S3= T.Z
MUWPT-7UQ/B5I6N/IJ_VYHP.S2/\ A&D;66+91<21\IN!#<CZ;+LJKE>3C)W
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M=?\ T_O?\"KTJO,O$G_(\?##_K]\5?\ J(ST >FT444 %%%% !1110 4444
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M5E)ZWCI\+T;3OZ,]\KSOX?\ _'OXL_['[Q5_Z=WKT,'(!]0#Z_KWKSOX?_\
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MHI@%%%4;N[M[.&:XO9H;:VMP";FY*A02.3R5Z>QR?2@"]7FWBO\ Y';X7_\
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M*\92ES76CC97]=$[>=[&M%75^K2M^?\ 7R/I, 8''8?T_P !^5+7E8^+_@+
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MX@DWMH08ZTWPY_9U\!RV<IBVP^,)?$ETPD^U>3#VGPK_ &-_ /P7^)>I>/\
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M(95#RQ5[-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #& G # 2(  A$! Q$!_\0
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M2/@_>6_B_0M%L!<>"O#7ASP9XD^(<FGVFD_$'75\8^(8$\-ZKXDTVVMM0DU
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MR.I#*Z,,JZL"0RLI#*0<%2".#3ZPO"^H7&K^&O#VK7>DSZ#=ZKHFE:E=Z'=
M"ZT:YO[&"[N-*N0%0"?3IIGM)@%4"2%L*.@W: "BBB@ HHHH **** "BBB@
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M OC_ %W2Y;'Q!->>';IK*STWQ'I5]< 'ZC45^4'[$G_!4_0/VQ?&O@'P-<?
MSQ=\*=1^+?P1UO\ :"^&E]-X^^&_Q.T^^^'GA[Q+HWAC4!XZB\ :U>ZM\+?$
MT][XATN71]"\8Z9:+K:+JUOIM_-?Z'J=I;_J\#D ^H!_.@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***:Y*J2!DC)Q] 3@D\#.-N3P
M"0: '45^1W[/_P#P5_\ @E^T1\(O!7Q.\*> _'FC:UXC_:R\"?LE>)_A?XC;
M1;#QIX \1?$KQ5J.A>!?B%JB?;&M-8^'/BW1[&+Q9X:US2&D76M+GNK.SWZG
MH^JV]MS_ (5_X*[V.H:IH5WXV_9A^)'@+X:?$?Q3^U#X$^"GQ);Q]\,?$\7Q
M$\;_ +*FG?$G6O&7A_4O!NCZR/&'@=/$>D?"GQ?=>&]9U73+W2(I;:SM=>NM
M'DO[,S@'[(T5Y7\"OBII_P =/@E\'OC;I.DWV@Z3\8OA;\/_ (IZ7H>J2V\V
MIZ-IOQ!\)Z3XML-*U&:S9[2:_P!/M=7BM+R6U=[>2XAD:!FC*L?5* "BBB@
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M\0/"-_<6[6ES<^'O%FD6NM:6]U:NS/:WBVEW&EW:LS-;W*RQ%WV[J]%\R/\
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M$/QJ\*?&34/B)XSL]>\;ZY\2/$_C/QY-X9@\*75OIWBK2-#\+>'DABTZTO\
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M(O"-Q9OXAT#3(-&\Z'Q9>W6KC5(+?_0&_=A.%4?[(_E[\TZB@ HHHH ****
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M/;_\\(?^_2?_ !-'V>W_ .>$/_?I/_B:FHH A^SV_P#SPA_[])_\31]GM_\
MGA#_ -^D_P#B:FHH A^SV_\ SPA_[])_\31]GM_^>$/_ 'Z3_P")J:B@"'[/
M;_\ /"'_ +])_P#$T?9[?_GA#_WZ3_XFIJ* (EAA0ADBB4CNL:@_@0 14M%%
M !1110!^=W[3?[']]\7OVP?V%?VH?".F?#VTUO\ 9C\:?%*\\?:_K5JUOXYU
MOP)XL^#WCGPGX<\(>'=9M=,O)Y=,M?&_B>/7=2TF[O+.QBA:XU*..>_BBC?Y
M2U_]AW]J+QS_ ,% ?@I^U_\ V%\#/@YJ%K>?##7/CK\2OAM\:?COJOCOQ7X1
M\!>!O''A;6_V;;_X9ZO:V?PD\<^!/%.L^)]'U_2/'LNE>%-8\-1:=>^;H>HZ
MZUMJK?M]@>GO^/K10!'LRH4LPQ_$I*'KG'!X';'8<4GE#_GI+_W\-2T4 1>4
M/^>DO_?PT>4/^>DO_?PU+10!%Y0_YZ2_]_#1Y0_YZ2_]_#4M% $7E#_GI+_W
M\-'E#_GI+_W\-2T4 1>4/^>DO_?PT>4/^>DO_?PU+10!%Y0_YZ2_]_#1Y0_Y
MZ2_]_#4M% $7E#_GI+_W\-'E#_GI+_W\-2T4 1>4/^>DO_?PT>4/^>DO_?PU
M+10!%Y0_YZ2_]_#1Y0_YZ2_]_#4M% $7E#_GI+_W\-'E#_GI+_W\-2T4 1>4
M/^>DO_?PT>4/^>DO_?PU+10 U4VY^9VSC[S%L8STSTZ\_A3J** "BBB@#YQ_
M:U_:A^'7[&?[/OQ(_:1^*VG>-M7\#_#+1)=;UC2OAWX1U3QMXNU"-#M2WTO0
M]+C.%SF6]U35+G3="T:QCN-3UO5=.TZUN+J/W;0-:MO$.@:+XAM4EAL]<TC3
MM9M8[C8LT5KJ=G#?0).$>2-9DAG190DCH) P5V7#'SWX]?!KPK^T3\$_BQ\!
M?'-QK%IX,^,GP]\6_#3Q7<^'[R/3]<A\/>,]$O- U=])OI8+J*TU 6-]/]EN
M)+:XCBEVL\,J@H?0=!T2U\.^']%\.6+2R6.A:1INBV;W3":=[32[.&QMVN'V
MH))FA@0RN%4-(68* <4 :/VJ'_GK"?0^='R.QZ]Z/M,/_/6'_O\ 1_\ Q5.%
MM;C_ )80_P#?I/Q_A]:/L]O_ ,\(?^_2?_$T -^TP_\ /6'_ +_1_P#Q5'VF
M'_GK#_W^C_\ BJ=]GM_^>$/_ 'Z3_P")H^SV_P#SPA_[])_\30 W[3#_ ,]8
M?^_T?_Q5'VF'_GK#_P!_H_\ XJG?9[?_ )X0_P#?I/\ XFC[/;_\\(?^_2?_
M !- #?M,/_/6'_O]'_\ %4?:8?\ GK#_ -_H_P#XJG?9[?\ YX0_]^D_^)H^
MSV__ #PA_P"_2?\ Q- #?M,/_/6'_O\ 1_\ Q5*+F(])(3])HS_6E^SV_P#S
MPA_[])_\37DWQKCE@\#"XL;V^TFXC\7_  Y@6ZTBY>PNOL^I?$'PSI-_;&>'
M#-;WNGZA=VMQ$P*R1S'(W*I !ZO]IA_YZP_]_H__ (JC[3#_ ,]8?^_T?_Q5
M*MM;A0/(B.T;03&A.%X&21DGCD]SS2_9[?\ YX0_]^D_^)H ;]IA_P">L/\
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M A_^2: +E%4_*O?^?N'_ ,!#_P#)-'E7O_/W#_X"'_Y)H N453\J]_Y^X?\
MP$/_ ,DT>5>_\_</_@(?_DF@"Y15/RKW_G[A_P# 0_\ R31Y5[_S]P_^ A_^
M2: +E%4_*O?^?N'_ ,!#_P#)-'E7O_/W#_X"'_Y)H N453\J]_Y^X?\ P$/_
M ,DT>5>_\_</_@(?_DF@"Y15/RKW_G[A_P# 0_\ R31Y5[_S]P_^ A_^2: +
ME%4_*O?^?N'_ ,!#_P#)-'E7O_/W#_X"'_Y)H N4551+M6R]Q%(O(*K;F,].
MH;SGY_"K5 !1110!^8G[4_[1O[1GPD_;Q_X)Y?![P=#\.K']G3]H_P 9?%WP
MG\4]2U,7^I_$O6/$_A'X/^-?'F@Z)X=LVMX-'\-^&=,'AZSU;5/$"7U]J^K7
MER-'&GV%C:W%W=_+7CO_ (*"?'_3/^"HVB? ;PSXN^&+_L]6/QP_9X_9UOOA
MO_PC-OJ?C;QN_P >_P!F#XR?M"7GQFTSQY%KR7>GVW@O5?AWI'A.TT33]&O]
M O\ 3IM5N=1NX]1-MY/[5>)/ASX%\8Z[X1\3>*O!_ASQ%X@^'^H:MJO@76M9
MTNTOM2\):GKVAWGAG6K_ ,/WD\,DVEW6J^']0OM'OI[5XY;G3KNXLY6,$C(?
M+?#W[)?[,WA3QWX'^)_ASX!?"/1/B)\-/!\GP^^'_C?3? V@VWBCP;X(E>YD
M;PSX>UE+,7VEZ4#>WR):VDZ)##>WD$6V"[N$D /H-I-JAMC/DX(3!(YZ=0.!
MUYJ/[3_TPG_[Y3_XY5@ #H ._ QR>I_&EH K?:?^F$__ 'RG_P <H^T_],)_
M^^4_^.59HH K?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH K?:?^F$__ 'RG
M_P <H^T_],)_^^4_^.59HH K?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH K
M?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH K?:?^F$__ 'RG_P <H^T_],)_
M^^4_^.59HH K?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH K?:?^F$__ 'RG
M_P <H^T_],)_^^4_^.59HH K?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH K
M?:?^F$__ 'RG_P <H^T_],)_^^4_^.59HH CCD\S/R.F,??"@G.>FUFSTYSC
M\:DHHH **** "BN>\4>+?"W@C1;WQ)XS\2:#X1\.Z<(3?Z_XGUG3= T2R%Q,
MEM ;O5=6NK2PMO/N)8H(?/N(_-FECB3<[!:W()X;F&*XMY8YH)XTF@FB=)8I
MH9%#QRQ21LT<D4B,KQR(S(Z,&5BI!(!+1110 4444 %%%% !1110 5Y-\;?^
M1 ?_ +'/X6_^K1\&UZS7DWQM('@!R3@?\)G\+<D]!_Q='P;R3V'J3P.IH ]8
M'3\6_F:6JL]W;6B-)=3Q6\2NB&6>6.&(/-((X8_,E=$\R61TCC3.YW944%F
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M8SI;)>M%X*_9W^+>NK]DE=HX94G_ .$7M()I)'1Q]CAEDOXU4/-:Q1R12/\
M:17(P2WU!P1], <_Y%,\H=-TA&".9&[]SSDGOG/!K2E*C&3=:A.O'E:4(8F6
M%:E>+4G4A1KMJR:2Y5:][O8#\Q;W_@IUI;-<+X:_8I_X*'>+0MM.]E)9?LJ>
M+=#%]?*KBULS%XLN=#N+."ZF"QG49X?LMO&?M$S",$5QVO?\%$_VJ)O#ME?^
M _\ @E3^V%JFNW>I74$^F>*[CX6>%K:PTF*WC>TU*2:Y\;_:9[F]N&EMFTP6
MT+VBPK<27,B3*J_K9Y2\<OQZN23]2<D_GFCRP,X+?F/\#U[]?6O2I8[*:4KS
MX<ABK.Z=;/LXIK?1..&PU.^F_O6>]EH3RS_Y^Z:_\NXZ=E>]WVOIW/PR^*O[
M7'[9/QB\+_$3P7XF_P""5WQUT#X6ZEX;OX4U7Q_XJ^!MG=1ZA%#:7&DZEJ5I
MI7QTF=]/L=7CDDN+.P1KV\MA!Y4EJS3,G4^&/CU\<M8TK1_"WQG_ &+_ /@I
M/H%EX3NKDQM\-K']G[P[X2U#3(X;&/2M$6V^$W[0&K>,-8TC0([)H-.:ZU**
M[U*.>3^U8KQA#&GZT?$OX:>&OBQX'\0?#WQ:^M+X<\3VJ66K#0==U/P[JKVZ
M317&RUUG1[BTU.Q9I(D+26=S#(R[D+[&(KK-,TBVTG3K#3+:2[>WTZPM-/@D
MNKF2YNY(+*WCMHGN;J4F:YN&CC4S3RLTDTA:5R78D]-7-LHG2II<*X6+4YIT
M*6?<0TXPC.,8RJ^WG.NJE2?+?E^KTU!_"U=II1G=WK2:ULG2HV7HTE/[Y-=^
MA^6/A3]NC]GSPAXT\0W;_L7_ +;GPI\0Z[=&X\4>.M;_ &'/BFT.IW#-M>35
M/&?A;2?$[ZD@\K.(;NYMPF&C4C::[Z^_X*O_ +"FD:Q'HWB3XJ>-?">I,9%>
M+Q;^S]^T7X:MH&4+O:[U+6/A3;:79)']UI;J]AB# @-FOTA\L8(W/R,9WMD>
MXYX/OUI/*'.6<Y&"&8L",8(P<CGO@#/>LGB^'9-.>09C22;O]4XEK:I];X_)
M<4[K?E22D]Y1UD.T_P">.BT_=K?S][N?E/\ '[_@J1^Q<GP5^)5_\+OVU?V6
MK+XB:7X3U/5_"FG^-?$6AZ_:7FKZ9;M?0:1J'@F]\0>%M2U";4C#]@CM%O;2
M[MKB>.8*[1^4W:6'_!4[]AG3X/#/AVR_:.T#XL>)KO3;2U8_ GX=_$;XK6%]
MJL5K&+@1P_"OPQXXTS0OM,P9[/2[_5TFBC981+-M\ROJ']HGX-Q?$_X0?$?P
M9X6\+_#F?Q;XO\)ZWX=TF_\ &NDQ+H]E=:U:26,E_>W>GZ)JVII]FBN);B,6
MMI+++<)$IV*6<>Q>&=(ATC1=.L8])TC0YH[*V6^LO#T$=KI45ZD$27"67DV=
M@9+6.4.EM)):6\CPJK&&/=L'5/$<)PR^C"&79W6Q*QU:;C4S?*J51T?88>U.
MI7HY34Q,J49^T<(QBM6W:%Q*-5N[G!1M:R@VT]==96UT_3JS\^'_ ."BVIZ_
MI^HW?PJ_87_;_P#B7)8:BNGQ";X#Z3\'[+5%+!/[0TO4/CQXV^&T=YIN&$WV
MJ*%QY0;"F0"(V[KXZ_\ !1KQ:I@\#?L*_"[X;&6&.>TU_P#:"_:NTAX(HY,%
MK;4?"OP6^'GQ%U.*^V%<Q0:Q-!&X96GP-[?HX85.,ES@ <L2<#W//)Y/J>O'
M%*8D("\@#&,<=.<]*Y'FN6T4_J?"V7N27NSS/-,[S-R;37,Z*KY;AHN-[\L(
MSA)I7AI=G))M.5>:76,*=*,?O<93UZ^\K=#\@/C]J/\ P4BT3X7?$/QU\4/C
M'^Q)\*_AQI'A-FU?PYX/^''Q(\9ZX;BZN;6TQ;?$;XG^-_!GA97+W""TAN_
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M*#^+*!^/0=ZGI,9ZDGVZ?G@"EKB*"BBB@!-PSC/)SC\.3^7>C(SCO_\ K/\
M2OPI_;)_X*,_'WX&_M^> O@OX!L_ B_!/P3J7['.C?&'POK_ (:U#5/B-\6+
MG]M?XW>+/@MI&I?#;Q!;ZYI]KX9L/@TOAV#Q3JWFZ-K8U^6XU#3KQK&VM8YF
MTO'O_!07]H#0O^"GNF?L_:)<?"UOV=-&^-?P!_9D\1>$KC1+^[^)GB;Q5^T%
M^S3\6?VC;+XN:3XS@UV.RTC2?!Q^&EKX-'A ^';^WURTU/4M9FUBRN;"&V8
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M0\KB"TAC.P?2"^>O2U/XW$1SR3S\OOCC P![TYYKD8)M<8R1^_C/3G^[]/\
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M%OQF^&_AWX\_$'3?[:\#_"'5?%6F6GQ!\5:,?[4*:IHOAB2?^TKVR?\ L36
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M_@MYI88;F.2.-V503VE $,41BW9FFFW8_P!:R-MQG[NU$ZYYSGH,8YS-110
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MFF07^C:?):>(AHFA>&Y]3O\ 2_!WA?2M,\-Z%MTVU@2+K?'NI?M$QZSXRMO
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MMX/LS_#7P"UM_9$?A_[.WA#P^8/[ BF^T1:'Y)T_R_[&BG GCTO;]ACF E2
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M:5HNG:?<PZ/!.]S!I$5Q:6T4T>EP7$CS0:<CBSAD=GCA4G- '34444 %%%%
M'&^+_'GA#P/%I;^+M7BTB+7-3BT;2&N+:\G74=9GYM-*MOLMM<>9J5ZP*Z?9
M "XOI%:*TCFE4H.4T7XX?![Q!'J#V'CK0(AIMUJ%O>QZQ--X?F5],C22^N8H
M->ATV:ZL8(9(Y?[2M8YK!TD1X[EBXSM^/OAMX<^(\.A0^)DU"9/#6N6GB;0U
ML+Z2Q.G^)=-(DT;Q#$T8W-JFASA[G1Y7+1VUU*9&A<A67A(_V;_AA;Z;_9EA
MI%SI 73]8LDU'2YK6UU47.L^)]*\77FM270LV%SKAUK1K"2*_NTN,6D'V&6*
M6VE>*@#JM2^,?PSTPW*7'B&.Y:TN_!UH5TS2]7U@7-QX^:[3PA_9LFEZ?>0Z
MI'K!L;TQ7&FR74-M]FF-[);,N#!IOQP^&&K:O#H6E>(I+[5+CQ%)X5AM;;0_
M$#A]7A34'F593I:V_P#9T']DZG'-K(D_L=)["Y@:^\Z/8><F_9U\%R:5J.A1
M:MXOM]#U7PUX9\)7>DPZQ9R6?]B^%[C4[FUCA%UI<\T-U>S:UJTFHWZ3_:S)
M?RR64EE+%;20,M_V;OAU:W=[>0)K$3:IXKTCQ=JT$%QI]O%JEWX=97T#3[EK
M;3(9EL-*F4SPS6\L&KW<DUR=2U2\^T3*X![^K!AE3D9(S]#BEIJC:.>I))QG
M&3R<9YQG.*=0!R.N^-/"_A_5M.T+5[V2/6-7TS6M7TRPATW4KZ:^LO#ENEYJ
MK0?8K.XB>XMH)5EBLBXO;OYQ96]PR.%R?"OQ1^'OB^\TW3O"_B"VU*_UGPO%
MXULK.*SU&WN)/#,M^VDPZI<1W5G UFCZA%):);7OV>\9XY"MN41G!XQ^'&F>
M,]8T'6K_ %CQ'87'AVTU^SL+;2+^UM;%_P#A(]-DTK4+B]@GL;HW5PEG(R6F
M]Q!&Q/F0RJ[J>5\!_L^?#'X;ZUIOB7PMHUW;>(=.\./X6.JS:I>S27^E--;S
MA;ZS6:'2WFA:W6.S-O86\-A;LUM9V\%N(XT /;J*** "BBB@ KC=;\<>%M!U
MJW\.ZG>7/]O7F@ZQXGLM)L](UG4[R]T?P_+9QZK<64>FV%TMS<VTM[9HFG0,
M^I733H+2TG&['95Y?XY^%ND^.]4M-6U#7?%^DW-AX:\4>%[8>&]8BTE$L/%\
M-G!J]TD@LYKF/4Q'I]I]CNX9XFMFA1D1F)) +'ACXK^ _&6IZ;I7AS5+N^N]
M7\-KXNTEWT#Q!8V6H>'S/:6LU_9ZG?Z7:Z=,UK=W]I:7UDET;^SN9C;W-K'+
M'.L?I%>=^#OAMH/@J>&YTU]0N[NV\+^'_!UO=ZE<0W$EOX>\-M?2:=I]LD%M
M:6]LAEU">:]-O!"+R:.VDD3,*@>B4 %%%% !3)9$A1I)#M1%+,<$X51DG"@D
MG'0 %CT4$\4^F2H9(W0.\996421E0Z%E(#H65E#H3N7<CKD<HPX(!X]<?'3X
M3VUEH.JW/B&:+3O%&FZGJ?A_4)/#GB<6NK0Z9<S6M_:6DW]C8;64GBD1- ?9
MK=T K6VGS(Z$^D>'/$6C>*M%T[7_  _=_;=(U2W-Q97/V>YM69%ED@ECFM;R
M&WN[2Y@N(I;>YM+NW@NK:XBE@N(HYHW0>(I^S3X+:#3+6Z\1>/K^UT?1];T:
MPMKWQ#;O#;C7?$(\476K6Z1:7%]EUN'68[6>UU*T,$IM[&TL;L7-DCP/[5X7
M\-:;X1T'3/#VE?:6LM,ADCCFO;AKF^NIKB>2[O+V^N2$^T7M]>33WEW+L19+
MF:1U1%(4 '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $B 9P# 2(  A$! Q$!_\0
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ML-X:BE2V\87'CR6/36 /[5C*1C,;<]NI&1D9 R><$>Q&/H@F)8KY;*V%*AB
M6!^\0.2 IX.0,]N*_D^_;^_X*G_\%#M4^+/_  3I_P"";_[)WP\\%?LQ?\%%
M_P!MOX::/\6/CE+\2_[)^)7AW]F?P^MAXX.O:7IMY:6/B#0]6DTR#X:_$WQ+
MJ>L0Z)KMYIWAGPI8PZ=%<:GK*W<'N'[&\_\ P7J_9H_;Z^'7P$_:X\9?#O\
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M^$+#PE\2=?\ A?XHT;X.V_C/Q7X=T'Q!%\-]3^(5[9P65MXTTB;7]+\+>*K
M64UGX6\:Z@GA_6-6L[B&Z%AWG[27_!P1_P $XOV5_P!HCQA^S)\3OB'XZO?B
M#\,+73)?C!K/P\^&'BCXB?#WX1WNJVUC<0:3\0?&N@6WV'0]1MY;^VT[5@MI
M>6GA_5+N'3_$%UI>I6FHZ9;@'[=TUC@'C.!D]N._.#VSTYXXK\;O$G_!=/\
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MTCNI+C3V0_H@.@XQQT]/:@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\R_\ @LOX0\4_$#_@E?\ M[^"/!'A;Q3XV\7^*/V8_B9H_AGPEX,\
M.ZKXK\3>(M=O=(,6F:3HGA[0[>ZU?5=0N[HQQQ6UA;7$X1I)1;S",QG]-**
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M!HT<GF0?;Q+'*B_Z1B02#S&\QCO9B$,BLB,<[BC+#&T;[BWS8D(/S'))Q=H
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MT0:+^Q/^S1^RSI?@;]N2X^(TG@K]EKQS\!?A_#X0UOQC\$]'L_@]\3-,\>>
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M2M.^!6G>"9K+P]\(4GOCXO\ #&JV^G3^)-&O]&THV.L?TG?!'_@C'^P)X(^
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M]_R/^% "T4F1[_D?\*,CW_(_X4 +129'O^1_PHR/?\C_ (4 +129'O\ D?\
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M=&^(?_!)[_@J[XF^)VNV<MFA69M7^%GB[P1J&HZS=O$T%OI$S:IX)LI/LL\
M2]?)M_\ 3F_91BTB;]F']FJYTBQ^*=KI9^ 7P7DT>'X]6X'QSLM-C^''A_\
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M_P W_P <JW10!4^Q0?\ 37_O_-_\<H^Q0?\ 37_O_-_\<JW10!4^Q0?]-?\
MO_-_\<H^Q0?]-?\ O_-_\<JW10!4^Q0?]-?^_P#-_P#'*/L4'_37_O\ S?\
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M_P#CE'V*#_IK_P!_YO\ XY5NB@"I]B@_Z:_]_P";_P".4?8H/^FO_?\ F_\
MCE6Z* *GV*#_ *:_]_YO_CE'V*#_ *:_]_YO_CE6Z* *GV*#_IK_ -_YO_CE
M'V*#_IK_ -_YO_CE6Z* *GV*#_IK_P!_YO\ XY1]B@_Z:_\ ?^;_ ..5;HH
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MG4K&XDLS<M;3B6,*P!_.+X)_X)N?"K_@GQX,_P""A6A_LT?\%A?VV_AS<?\
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MO43:2N]KI?-NR/H $'I_G@'^HI:\D^$_QA\&_&OP;HWQ"^'6K2:]X.U[[?\
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M\LN.MBE*E+ZM2>)YGR-P;2BIIIWO:Z2>K5VGIOJ?2/[77_!2/2OV4_"?P/\
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MQ6L1A2.0&2OK6*=II=@*%0) \D<F]1)')&KQ':VU3&'(<2#<S'Y25#,=55R
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M86>I,VK65E=7FFK=VUM+(@!^PU%%(2!C/<X_0G^E "T4A8#@G]#2;U]?T/\
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MDMK:&&,-)<$W,S[3)//F>5I)B79?!JG_ (1?PWM.,^'=&*O@$",Z7:,JANK
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MB]%=2Z<LE\49+[+3NFGLU8N56N%W<$$\ @@]"ISZ=\\\'@=J<)D+;02>Y)'
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MD1RQQS.6B#CS<M'"DXAS,ZPRZU?A1_P<7_'GXR_LZ_\ !,KQMXX^"/Q:\1_
M+Q%K_P 6_@G\,O%?QM\&37=EXP^&'PT^(GCW3=!\;^)_#>JZ88M;TG4(+-[>
M%=2T"\TS7;5)C/I&I6.I1VMS& ?-J_\ !MQ\'X?%/Q'\8^$O^"A?_!3KX:WO
MQ5\<>*_BAXNT[X>_M(2>%-&E\1^+=:N_$6H75S%X?\/VUI?W$=QJ4D=O>:E)
M)J,Z0"2=W/G2Q_T1?"3P$GPP^%OPU^&T'B3Q7XRM_AY\/_!7@:#QAX]U>Z\0
M>._%L/A#P]I>@1>)?&NNWRB]UGQ7KL>FKJOB'5;L"ZU#6KR^O+C,T[X_SG_V
MG_'OA?\ :KM_V\?VT+[_ (**?M >'?V>_P#@E?\ "OX'?LO?\$J?C5I/Q9U_
MP^/CK^V-X,^'NA7_ (P\0>%I9(CJOQ"^)7Q%F^'FG>(_B?XGT>>S\2WUAX\\
M'^,M3\03^"?#.C2Z?_H"_L9>//B5\2_V1OV6OB+\8[=[+XL>//V=O@EXP^)=
MM+I=KHDJ>/O$_P ._#VL^+DET*TM+"VT&676+Z>YFT:VL;6'2)))--2UMQ:I
M @!]-7+K&B.Q5565"2P7;R2 "S,@C+L0JN3C>RJP*LU?YCWCS7?AAH7_  0Z
M_P""U?P]^)]UX;B_:F;_ (+5>(;K_A'[Z?3D^*\E_/KOPK@\)ZO)#J4MOXKO
M]#2XT[XR)I%PHO%M99/%MU!'%]NU*9_].26)9E"N. RL,?>!4@Y#8RAQN7<I
M# ,2K*V"/S!^)W_!&7_@F5\7_P!J+3_VR/B-^R-X \4_M$V_B'P_XNN_&]SK
M'CJPTG7?%?A)[67P_P"(_%OPZT?Q7IWPR\9:Q:RVEM+=WOBOP=K$FMS6MG<Z
M_P#VI<V-C-; '@?[8?BW6KG_ ((U_M)? SQ%XQT75_VP=/\ ^"37CO5/B#\+
MH_%5EJ7Q>DU]/V8;RT\<:C=^%)KZ3QQ>)J>KG6;)[F;3 ^LZA>?98GNM0N;@
M1_RV^!]9\"^*_!'_  9U^&_V>M5\-7WQJT+XZ7M[XWL_AO?:6OBS1/ .B_$W
MX3:I^T7;>.$T-(]0TZTU30;;Q5=:Y9ZZ\+Z]I\7B^017\3:I<G^Z6T_8C_9>
ML_VK=9_;A@^%=F/VIO$/PTLOA!K7Q6E\2^-+JYO_ (=V/D"#P\_A.[\1S> X
MB8[:&"?6+?PK#K]S;(+>?5)(ODKYP_9V_P""-W_!,_\ 9,^/%Y^TS^SO^R)\
M/?AC\:KF+6[:U\6Z3JWCK5+/PY!XBGEEUE/ O@OQ)XJUGP'\/S>Q7%S8K)X(
M\,^'9+32;JZT:QDM-*N);-@#].ZHW<5TY0VKVZE0X83K,R_-LVX6&>$'&UL[
M]W8# SF]10!C+'K@ #7&F9YSLLKL*.3C_E^.3C!)]2:79K7_ #\:?_X!W?\
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MK?'^+MC4% (QR",9&XG)-2"'6>GGZ?CG'^B7F1^)OSGCC)R3GGFMH*!T&/\
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M_P" =W_\G4;-:_Y^-/\ _ .[_P#DZMBB@#'V:U_S\:?_ . =W_\ )U&S6O\
MGXT__P  [O\ ^3JV** ,?9K7_/QI_P#X!W?_ ,G4;-:_Y^-/_P# .[_^3JV*
M* ,?9K7_ #\:?_X!W?\ \G4;-:_Y^-/_ / .[_\ DZMBB@#'V:U_S\:?_P"
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M OB5XUU.TM+73;*]\6^._AAX7\4^)+VRTVS"V6GP7FLZI=3Q6EFBVT$#06T
M$4,0'Y$I_P &M'_!$4Q,C?LAZV#*290_[2'[2P*EL$.8X_BT]N\O&7!7RUD+
M^7\FS'[L_#'X;>$O@_\ #KX??"?X?Z8VB^ ?A=X'\)_#?P3H;7EW?MH_A#P1
MH>G^&_#6FM?ZA<76H7S:;HVEV-DUY?75S>W1@,]S/--))(P!W]'.>O&.GOZY
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HFAC;'RJ,9/W5/)(.>
MG!R <C'(![#$M%3**DFG>VCTNGIMJM0&!$50H5<=, #'(P>/3'!QVSQBG
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MC<A^ '[2&(R>I4C!QR%.?4U^E]H1D*.""I(R<X._!)Z=.,#@X^M>GFV,IXS
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MM-'EN(S"+J:R6-'D@9I$@N(YF /;Z*** "BBB@ HHHH **** "BBB@ HHHH
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MLE]K#Z]';&/4;FY\3>)QI.L^'X_$6HSQ@'Z]_!'6_B9\5_V3?A+XH\4ZG?\
M@[XK_%#]G/X?:]XAUM-)TV"\\)?$?QE\+=)O]8U630C(-.AN-"\5ZK<WHTFV
MB%NES:K8C=9Q!!_*/_P3;_9!3]BO_@Y/^*?PHU3XS_$?]H7XA:]_P3NMOBE\
M7?C7\6M5N-2\9?$CXJ>._&?AFZ\7:^B<Q:+HK2V5E%H'AA;S7K;2=(ABMGUJ
MYNK6.*#^G/3/V)-&T_\ ;E\2_MSK\9/C2^O^)O@W9?!Z3X(-XR?_ (43I=M8
MR6AC\::7X.C@C$7C6XBLX8)-6>=V2-ITA9!(3)SFE?\ !/#X8:7_ ,%&?$7_
M  4LA\5^-V^+_B7]G[2OV=;SP:\^C?\ " Q>$]+U:PUA-7BC73AX@.NR7%FL
M<DDNLS6C0J%%OU#@'Z#56GGDB*B.)9,@YW3+%M(Q@<JV<@DD\8XX.[BP0""#
MT(Q2T 9_VN?_ )]H_P#P+3_XW1]KG_Y]H_\ P+3_ .-UH44 9_VN?_GVC_\
M M/_ (W1]KG_ .?:/_P+3_XW6A10!G_:Y_\ GVC_ / M/_C='VN?_GVC_P#
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M1Q=*0"<@9VQX.>,<\<YP<9T ,#'IZTM% !1110 4444 %%%% !1110 4444
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M>G7HEMII+E9Q:@'[?Y'ZX_$X_P 117R/\+?VT/@9\;?V;;K]KGX3>+Y/&WP
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M=">]L;B$7%C970O[;"_X)$?L=_M%_ +Q=^WO^TG^UCX5\&?#7XV_MY?M2_\
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M5P"F[!Y&*_C8\3V/Q8_:]_X.&?\ @IS^Q%<?M3?M)?"KX.>,?V _@_/X3O\
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M\0=<\%1:%IMYH@TCPE?,\K6>FZG)?FZOH1':DR1(\J*5(8 _2NBBB@ HHHH
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M4E8_AY570=%"K,@_LJP)6X+FXW&UB+FX:5Y)'G9RS32222/)*6=Y)&8NVQ0
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MC^E!0C@N .6"[L9W;'.P\CH'.]2..C [32M!$[%F0%CC)R><  =#Z "I
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "^ G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEU!(!*@@'@\UH5^<7[6/PS\<>*?B;KVM:%X-U#Q)IFI_L_/X/TJXM_A3X/\
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MRR2YH\RC*SU2!-N]TUMH]U=)V=M+IZ/E<HW6C:"BBBD,**** "BBB@ HHHH
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M)5J-"B*C2/*5&#))LWMR3EO+2-,CI\J+P!G)R2^B@ HHHH XGQ!KVH:=XN\
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M_OI?\:/,C_YZ)_WTO^-9G]@Z)_T"=/\ _ 2'_P"(H_L'1/\ H$Z?_P" D/\
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M]]+_ (T>9'_ST3_OI?\ &LS^P=$_Z!.G_P#@)#_\11_8.B?] G3_ /P$A_\
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M2N[)MVNTF]E=OX$EV6JG=ZWDXI/E3/MY_P!KG]GM_"/A#QCI_P 2O#NJ6?Q
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M#.E^,/#>N:5#<2R3R:3KOA[6+'4[!=0BT[5UM9X+B\TJTM[RPFN_RS^,;_\
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M1VFB5B(YA?VL?F*.C^6_S)G^ZW(J/[=J_P#T F_\&5G0!M45B_;M7_Z 3?\
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MNQR/9QZCX;N9W8WJ&&5+FUT^YOI;4JIN%B$B9 O\G_6W?^M#Z#HK%^W:O_T
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M<BS3AY1TEF5*#X@X=:7_ "\><Y)AZ];!4GO?.<CRU4U_%Q$.64E^TG]MQ_\
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M377A_5[N'7M<^RV).I$:-#(713;1B2Y98Z\1;_@I)HZ$K)^Q?_P4)0IGS/\
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MXS_X 4;_ !'_ ,^VB?\ @;?_ /R!6W14_-_U\@,3?XC_ .?;1/\ P-O_ /Y
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MF?8:>4YE5<5>?U*&(G+!YM3C9MULES+-:?+:<J=*+5O?]_B/_GVT3_P-O_\
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M2V*^)-*N4:.XTSQ"L&N:?,CC:ZR6>J0W5NP9?E8&/YAP>*\#_9O^&?A+PO\
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M_GM<?^"[4?\ Y$H_X2'2O^>UQ_X+M1_^1*VJ* ,7_A(=*Y/G7' )/_$NU+H
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M^3Z0&KY,7_/*/_OA?\*/)B_YY1_]\+_A65_:UQ_T!-7_ .^;#_Y/H_M:X_Z
MFK_]\V'_ ,GT :ODQ?\ /*/_ +X7_"CR8O\ GE'_ -\+_A65_:UQ_P! 35_^
M^;#_ .3Z/[6N/^@)J_\ WS8?_)] &KY,7_/*/_OA?\*/)B_YY1_]\+_A65_:
MUQ_T!-7_ .^;#_Y/H_M:X_Z FK_]\V'_ ,GT :ODQ?\ /*/_ +X7_"CR8O\
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M<PC\V/>0"$\Q-V-ZY -VBL;[-KG_ $%K+_P4O_\ +&C[-KG_ $%K+_P4O_\
M+&@#9HK&^S:Y_P!!:R_\%+__ "QH^S:Y_P!!:R_\%+__ "QH V:\H\=^!?%/
MBCQK\)O$VB^)M T72_AUXFU7Q#JVDZGX5U#6[_Q$NJ^&-9\(RV6GZO:^+-"M
M] ,6E>(M4GCN;C2->SJ*:?*\!M8+FUO.^^S:Y_T%K+_P4O\ _+&HRFK+)Y3:
MWIJR^4TWE'3<2>2K!6EV'4MWE*Q"M)C:&(!.2!0!NT5C?9M<_P"@M9?^"EO_
M )8T?9M<_P"@M9?^"E__ )8T ;-%945OK"RQM-J5I+$&!DC336B=T[JLAOI
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M?^"E_P#Y8T?9M<_Z"UE_X*7_ /EC0!LT53M([V,.+VZANB2IC,-J;4( #N#
MW$^\DX(.5QC&#G-7* "BBB@#YV^+/[/[?%/XK_L__$]?BE\3/!,'P.\5>(O$
M>J>!_!WB2\TGPC\6+;6?"VIZ'INA^/\ 3X9E6\L/#VL7EKXBL7MA'-=FVN]$
MU%KG1]4NK>OHFBB@ HHHH *S=9_Y ^J_]@V^_P#266M*LW6?^0/JO_8-OO\
MTEEH MVO_'M;_P#7"'_T6M3U!:_\>UO_ -<(?_1:U/0 5C>(](_X2#P]KV@B
M\GT\ZWHVJ:0+^UXN;'^TK&>R^V6Y#(?/MO.\Z'#K^\1?F7J-FBDTFFGLTT_1
MII_@V--IIK=-->J::_%(\N^#GP]N/AAX$T_PE=7>CW4]M>:I?21^&](G\/\
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MC7='U2> SB:'3M3LKZ6$VLRV]R)8[:>5XS;W#I!.'4&&9EBDVNP4@&Q1110
M4444 %%%9_\ :VE?;3IO]IZ?_:(D6$V'VRV^VB5[5[Y8C:^9YXD:RCDNU3R]
MQM4>X ,2LX -"BBB@ HHHH ***S-4UK1M$B6XUK5M,TB!Q*4FU2_M;")A!$\
M\Y62[EB1A#!&\TN&/EQ(\CX12P -.BH;>XM[NW@NK6>&YM;F&*XMKFWE2:WN
M+>9%DAG@FC9HY898V62*6-F21&5T8J03-0 4444 %%%% !111D8SD8]>WYT
M%%%% !13/,CW%=Z;@5!7<NX%N5!&<@L 2H(Y[9I] !1110 4444 %%(S*H+,
MP51C)8@ 9.!DG Y) 'J3B@$$9!!&2,@@C*DJPX[A@01U!!!Y% "T444 %%%%
M !113&EC0[6D16X^5G4'YB0O!(/S%6 ]2IQT- #Z*** "BBB@ HHHH ****
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MW4EYR24DK-ZIR5N7K;2;T2E^F@R ,G)P,G&,GN<<XSZ9.*6D4$* 26( !8@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %8 ?4# 2(  A$! Q$!_\0
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M=*L=.U#PK9SW%Q:3W'VJRF"QRJ=XP ?O]Y2?W?U;_&CRH_[OZM_C7\OV@?\
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M_P"[^K?XT>5'_=_4_P"-244 1^4G]W]6_P :*DHH 1>@^@_E2TB]!]!_*EH
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ML* /V+^WV/\ S^VG_@3#_P#%T?;['_G]M/\ P)A_^+K\=/\ A _"/_0)D_\
M!MK7_P L*/\ A _"/_0)D_\ !MK7_P L* /V+^WV/_/[:?\ @3#_ /%U%-J^
MDVX0SZGIT D<1QF:]MHP\C?=C0O*NYV[*,L>PK\>?^$#\(_] F3_ ,&VM?\
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MM]C_ ,_MI_X$P_\ Q='V^P_Y_;3_ ,"8?_BZ_'3_ (0/PC_T"9/_  ;:U_\
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MTPF)Q&%J?SX:O6H3^<J-6FVO*7,GU3(G3IU5RU(0J1[3A&:^Z49?A8_"O2_
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M7W[,WQXT^V8HL$X\0_##Q-?Q]1+*[1WFG),!G<H(0G&.*&_:L^.'@S*_&/\
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M%K>M/X5ELIM-T..[NVO4M+U[1Y@#&%_>CXL_\$O/VF]0_:W_ &F/VI?V8_\
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MD2EK<W*7UU%);P.#\3_M@_&C]J[X*?M@Z#X!\*_M(ZS%X7^*_P#PK_Q!\+/
MA\+? 1/#>BE?'3Z3\3=$^)&O>)KW3O'.C>$%\,G3/^$7\0:;8ZI?WNLWU]:Q
M2&XM$0^Q?\%E/"NC^*_V=OAS87T/]FZM)\</"EEX>^(<^F:AJ^D_"^]U31O$
M5E<^+]<LM(\.>*-5.GQ63S64%U8Z:LNG:Q<Z5J8N8&LE8@'W=^RKX_UCXE?
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M_P J_2+X1_\ )._"_P#UX?\ M:2@#T>BBB@!%Z#Z#^5+2+T'T'\J6@ HHHH
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M8-1-NB0FZW&78JC=D UV] !1110 4444 %%%% !1110 4444 %%%% !1110
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MT$SM@ED4*V =GV?W'%?\,Q:Y_P!#1I__ (!S?_%4?\,Q:Y_T-&G_ /@'-_\
M%5[.O[0GP6:1XA\1_#&^*W-S,/[1C/DQI$T\HFQDQO#$K&9' ,3 QOB4%!#I
MO[1?P2UC6=.T#2_B/X<OM4U:9+;3;>WNRXO;B0XC@MY-@CDE?/RHK$GGT. 1
MX]_PS%KG_0T:?_X!S?\ Q5'_  S%KG_0T:?_ . <W_Q5?9E% 'QG_P ,Q:Y_
MT-&G_P#@'-_\51_PS%KG_0T:?_X!S?\ Q5?9E% 'QG_PS%KG_0T:?_X!S?\
MQ5'_  S%KG_0T:?_ . <W_Q5?9E% 'QG_P ,Q:Y_T-&G_P#@'-_\51_PS%KG
M_0T:?_X!S?\ Q5?9E% 'QG_PS%KG_0T:?_X!S?\ Q5'_  S%KG_0T:?_ . <
MW_Q5?9E% 'QG_P ,Q:Y_T-&G_P#@'-_\51_PS%KG_0T:?_X!S?\ Q5?9E% '
MQG_PS%KG_0T:?_X!S?\ Q5'_  S%KG_0T:?_ . <W_Q5?9E% 'QG_P ,Q:Y_
MT-&G_P#@'-_\51_PS%KG_0T:?_X!S?\ Q5?9E% 'QG_PS%KG_0T:?_X!S?\
MQ5'_  S%KG_0T:?_ . <W_Q5?9E% 'QG_P ,Q:[_ -#1I_\ X!3?_%4?\,Q:
M[_T-&G_^ <W_ ,57V910!\9_\,Q:[_T-&G^W^AS?_%4?\,Q:[_T-&G_^ <W_
M ,57V910!\9_\,Q:Y_T-&G_^ <W_ ,51_P ,Q:[_ -#1I_\ X!S?_%5]F44
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M7_!2_P#Y2#?\$9>!_P G-?$8YP,_\DKUH?>QG'MG'?%?N'7\N?[5?_#>C_\
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M&LZFNTJN-Q=&-+OS>RJKI:YA6>*5EAX8>7=UZE:*7FHTJ<W+TYH^I^JWBO\
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M(_C/H?QA\,>+O"ENMB7_ +,6\T>&[.NH^JJ$"A8/W+D^9@"LN/\ X*26MO\
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MKE0PC%WILTZ++M(/E/MDZ_+P:T_%WA3PK\0-#O\ PQX\\-:#XU\-:K ;;4M
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MS5=/\,6GB*6/6_AK&VB23/IR^#M4M+&TU@0ZBU@[A\_J/0 @ 4!5 55 "J
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MF6TDUZ*\M=0EE@M7M]*@TE_,8"\DC! MYK[_ #L??G_"N_#7_/*[_P# M_\
M"C_A7?AK_GC=_P#@6_\ A7Y_64?[>*:WX5\1:GXI\+W]DJ:))K>C:=XA\"6>
M@7#:O>:/)JEB0TB2>1$;;4[31=2MVOKQXFGAABN))HV3].5)*J6 #$ L <@'
M'(!XR >,X&>M CA_^%=^&O\ GE=_^!;_ .%'_"N_#7_/&[_\"W_PKKGO[&*1
MX9+VTCFC:!9(GN84D1KIBMLKQLX96N&!6 $ RL"(PQ!JW0!PW_"N_#7_ #QN
M_P#P+?\ PH_X5WX:_P">5W_X%O\ X5W-% '#?\*[\-?\\KO_ ,"W_P */^%=
M^&O^>5W_ .!;_P"%=K--%;Q/-/+'!#$I>6:9UCBC1>2[R.51% Y+,0!W--BN
M;>=I%@GAF:(H)5BE21HC(BR1B0(Q*%XV61 V"R,KKE2#0!QG_"N_#7_/&[_\
M"W_PH_X5WX:_YXW?_@6_^%=S10!PW_"N_#7_ #RN_P#P+?\ PH_X5WX:_P">
M-W_X%O\ X5W-0?:K;S98?M$'G0(DDT7G1^;"DI(B>6/=NC20@A&< .00I.#0
M!QO_  KOPU_SQN__  +?_"C_ (5WX:_YXW?_ (%O_A7<T4 <-_PKOPU_SQN_
M_ M_\*/^%=^&O^>-W_X%O_A7717]C.ZQ07MI-(YG"1Q7,,CN;9Q%<A41RS&W
MD(CGP#Y3D))M8@5;H X;_A7?AK_GE=_^!;_X4?\ "N_#7_/*[_\  M_\*[FB
M@#AO^%=^&O\ GC=_^!;_ .%'_"N_#7_/*[_\"W_PKLY;BW@,2SSPPM/*L$ E
ME2,S3,"5AB#LIDE8*Q6--SD D @&I00PRI!&2,@@C(."..X((([$8- '#_\
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M[2.-9HEPL4JJ)(U^56 K4_X5YX;_ .>5W_X%O_A7<T4 <-_PKOPU_P \KO\
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MASQYKMM++8^)O&.H6]O9Z1)I5G]LT?6\1V\'Z$>,_P#@F3%:^+O&7B;]FO\
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  = ;4# 2(  A$! Q$!_\0
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M["[FT^:[L(8[V*UOK*YDMFD2"[MY2LR?SG_\/K?VI_\ H0?V?_\ PE?B+_\
M/5H _J HK\;_ /@GG_P4,^-/[6GQI\3_  Y^(WACX7Z+HFB_"_6O&UK=>"=%
M\5Z=JLFJZ;XK\%:%!;W$^N^-?$EH^GO:>)+Z26*.QBN6N8K1TNXXHYH9_@__
M (?6_M3_ /0@_L__ /A*_$7_ .>K0!_4!17X/_L9?\%0OC[^T3^TI\-_@YXV
M\(?!_2_#'C#_ (3#^T[[PMH'C2RUZ#_A'_ 7BGQ39?8;K5OB!K>GQ>;J&B6D
M-U]HTNZWV<EQ'%Y,[QW$7E_QO_X*[_M)?#7XT_%[X<Z%X(^!]WHG@#XH>/\
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M^*O^"/WQR^,7B3_A#_A;\*O^"E7@KQMX]\4?V/KWB#^P?#&A_#KQK=ZIJ?\
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MK;_P45^+GP$\"?L)_LY:9\5/AK^P5\??V]M9ET?XF_'KXQ^(_A_-X/\ V0_
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M?#_A3P]9? 22QTZ]N]8TB7PO?ZA=)#8B!;ZRNB+X11KT\-EV85LZ4LMIX#Q
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M]='_ !$-_MI?]$Q_9>_\(OXK_P#SZZ/^)9O%7_H#X>_\2;!__.\/^)EO"O\
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M6:?>7/VW4+"TT_\ <^3]K^T211/U/[>O_!:[]BK_ (*/?L??'S]B7_@FW/\
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MS/,\-FE'#XAT8X7!U_U*HHHK$[0HHHH **** "BBB@ HHHH **** "OY[?\
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $N G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]2_C)_P '
M#?Q,^%WQ=^)_PWMOV;?!>KVWP[\=>)/!MOJ\_C+6+>XU"+0]2FL8[^6V73V2
MV^V1Q!S$9#M<E5R !7FP_P"#EKXHDD#]E_P0<^GCG6".>F#_ &?@?I7YT?"C
MX<^"_C#_ ,%AU^&?Q(T&V\4^!?&/[5GQ*TKQ+X>O?.^QZMIX;Q3<BVN?(DBE
M\H3V]O+F-PR&)6  !(_5+]LG]A']GO2/V3_VO/'L7[+'PN^$?B7X-75E-\'_
M !3\#?BG=^/M<U6SBUZ*TEO_ (E:-!<WMOX3TMK$$ZW%J,2MI-I-=71Q+8YK
M^K\PR+PDR#$</9=FO!L:F)S?*\LQM7'4<?4A1A/'XVEEO/6IUL3"M-JK-5:B
MH1DXTUI&]D?RQA,Y\2\WH9[F.7\5U(87*\SS#!PPU3!0G5E'"82KC^2G.A0G
M3BO90]E"5=QO4>KY4V<+_P 1+7Q2_P"C7O!'_A;ZQG\?^)>?SX]Z/^(EKXI?
M]&O^""?3_A-]7&/_ "GG\^_H._QGXQ_X(V>*]%_9[O/CGX+_ &AO 7CVYT"W
M^']UXE\/P^$_%&@^&+>W\?:AI>F*V@?$#6!%IGB>'0)-6@NM1N;*W\@0QSJU
MQ&ZQH;'[1_\ P1>^('P)T[P+::/\;O"7CGQUXT^(?A'X:VO@V;P;XJ\)1W6M
M>,3;BWU#PSXEU5;G1/$>BZ9-<,VHSQR12FUMKA8@7CV#LI95]'^K4HTHX/+%
M4K8K$810E5SN+A/"TJM6K.I*I1A2C!*FXW=6-W*-FTU?GGF7C7&-2;Q>8^SI
M82EBG-1R9QE&M.$:<5&%>I4YI<Z?\-Z7NDTVOL0_\'+7Q2_Z->\#CZ^-]7_^
M5XI!_P '+7Q2[_LO^!SGICQQJ^>F>1_9Y([\].GK7CNF?\$9]3^"GQI_9PU_
MQEXW\,_'/X6WG[3'@3X+_&WPO%X/\5^$ETG4->1)5LXKG65A3Q7X:O?-AM)]
M;TAQ;&YEC07+.SK%I_$C_@G7\/OBAI_AOX<_"S0/ /PLU[Q[_P %*_VA/@'H
M/CY;+7-4UW1_!'@KP?XS\1Z+X:U"S&H"PGT#3CX?6&U\F)-11VMC.[?.1R2P
M7@2Z^'A0R'"XC"5W6Y\?2Q6-]CAO8SS"#]M"=2%>\_J$IQBJ?,Z=>C)7]Y';
M#$^,7L*\ZF>8FEB*2HNG@Y8?".O7=98=I0DH.FN3ZS%/F=FXRU6C/4#_ ,'+
M/Q2'_-KW@CTX\<:O_P#*_/X_UH_XB6OBD.O[+_@?_P +C6/ZZ?VZ$^M?%?B3
M_@CIXPN8OAC)\$/VAOAI\<D\=?'Z^_9R\4WFAZ+J^BZ=\/O'>CV&JZSKLFHW
M%[)<SZEI>@Z=I%U<:I':VT=RLMO#:13/'=OCQS]N#_@F?XQ_8R\"^%/BA'\2
M=*^*_P //$7B_5OA_J.MVGA/Q%X&U+0/&FC^:TEA+I/B55FO=*NGM[U=-U6T
M5[6^\I&CEEA"2-Z^7<.>!.9XS+<NPN68.>89K4KTL'@G/,X8AU,/R*5*K&K6
MI1H3J2G;"QJRA]:2<J;C%QE+R<3GGC%@\'C,PQ&98Z&!P5*->MBE1P$X*DXR
MG*:4(RF^2,?>BDY.Z25S]-S_ ,'+/Q2&/^,7_ XS_P!3QJY_#'V#CM_@:!_P
M<L_%/I_PR]X(_P#"XUC^NGUXGX2TK]B7]GO]A/\ 8$^*7QF_8\\,_&_Q'^TG
MJ?C;0?'_ (NFU[7=!\2Z9%HGC/4M/BUBPBL[H075Q%I]Q%!%;(J%C:1!,!5*
M[OQ"_P""'3ZY^TA^T+I'@+XF0?"[]GSP%J_PZM_!6JZYX:\2_$+Q)>:E\3_#
MMAKUKX4@TKPZ)M0>Q\-SZJNGW>NW[+<6]F;*\O8S'NNQY4LL\%\)6Q*S;@ZK
MDV#IU,RI8',,96KU*&9O*<SIY1F"P\,'C<17HRHXV?(H8B$75@G.FY;+U*>-
M\6,31PKRWBB>8XBI#!2QF$I82E1JY=_:66SS;!1JSQ-&%.NZN#@IMX=M4Y24
M)I:GJ _X.6/BD21_PR_X(S_V/&L$<>G_ !+\?RSZTW_B)9^*0S_QB_X(..O_
M !7&L$?KIYQV_P /3Y"\,_\ !&+Q-%+\1Q\:/VE?AS\%8OA_\?=*^ L,^K>&
M]?U:T\7>(/%>C:-J_@>_T"6UGC/D^*%URTMK72KH126SQ74L]W&T2AL;XR?\
M$<O'/PX\+Z[<^ _C[\,OC+\1?!OQH^'?P2\?_#GPOI6M:;>^$O$OQ5U+3M,\
M%B?5M2=X;EY(M6TS4]8MF@B;3M.N;JZ$]PUF5/?')OH_SQ<,)' X!SEB%056
MV?.@N>%&<*GUB%*=#V<I8BC3;]M[DYKVCAJEY[SGQEC@Y8R6.S+DC0EB%",,
MG]HU"I6A*'LY5X57.*P]6HU['6,6HQE*U_M?_B)9^*7_ $:]X'YR<?\ ";ZO
MG'3_ *!_K_\ J[T?\1+/Q2_Z->\$>W_%;ZOG\?\ B7FOB3XJ?\$=?&_A;PKX
MRNOA'^T%\*_CU\0_A)XS\'^!/C?\+O"UMJ6E:W\-?$/C._LM-TZ.ZU&_E,%_
M;Z?=:C VJ2JEN(K);J\V.;4Q5M_$W_@CM'X \%?&GQ#H_P"US\*_'OB[]GE_
M!>D_%_X>Z%X9UR+6O"GBKQEJ>DV=AHE[=SW(MC"+74A?+J,5O$;PQ20&*)\Q
MU/\ 8_@&X49K+\OG[><H0C#_ %@E.ZEAX1E4I?5?:TJ=:>)HPPU:K"G1Q?-&
M6%J8B$DR_P"U/&CVE6#QV/BZ*BYRF\BC3]Z->7+"L\7[.I5IQP\Y5Z-.<ZV%
M^#%4Z$]']@?\1+/Q2_Z-?\#\=?\ BM]7_P#E?_0_A1_Q$M?%+''[+W@?T_Y'
M?5_?_J']L<U\E>,?^"._A'P7\<-,_9^U']N;X3S?$>/2=6\1^-O#.G>"/%6H
M^*/"F@0V&DZAX>>U\,Z;)>W^M:IXCMM3A>STZ!HYHH5FN6=H]I,^I_\ !%;Q
M-H?QB^(GPY\1?M)> /#'A+P+^S[X=_:07XGZ[X3UNPTV;P)JOB+4]"U6TUG0
M9+P7_AK4M"&CW=Q<"\%R\\4UJ=B3><(LI97X KF7]G81OZG]>I1=+B.G*O0E
M7PU&G*E[3"QYE5>)C*E**<9PB^5RYHMG]I^-3Y&\=BU"6+^IRG&OP]-4ZT*6
M*K5(S4,9)ITUA90J+24935^51G;ZN_XB6OBCQ_QB_P"!\DD?\CQJXSCI_P P
M_H<\4G_$2U\4@.?V7_ _/(_XKC5^G3OI_)_IS7 ?LW_\$I?AQX9^(?Q@\/?%
M'QW\-?C#\(_B)^PMXY^-/P)^.Z6NLV/AGPGJ<.N:+ID'CV\T_P"T?:HF\+6^
MIIJ?D^?<K=6*29@21FC7SWX0?\$T_"/PY^)>KKK/BCX8?M.?"[XE?L)_&GX^
M?"GQI-IGB/1=+2[\*VFG6UMK]CI,5T+]-;TZ\OH;O2Y;I_L3Q3.DME!+ J'&
M>6>!OM,SA0R#"XA8##87%4JOUG,\/1QU*O1A7K0HU<1"G"EB\%!S6(P.)<,3
M^YJRIPFDU'JIXWQAE3P%2IG>*I+&U,53JP6&PE:>">'4?9RK*C&2G'$RG&-*
M=*4HQ<HSG-0E%R^@A_P<L_%/_HU_P/\ ^%OK S]/^)?_ )^N*3_B):^*7_1K
M_@CG)_Y'C6/_ )7]!QTX^E?G5K__  2^C\$?!7PWXR\>?M9? KP9\<?$GP?T
MCXUZ3^SSXKO7T;7KOP=KL4#Z;;IXFO;F+2IO$=T9U1-(6.6=I!(J(T<4L@ZW
M]IO_ ()$>*?V8/V=[GXY^)/CKX7U?5M/T#PQXAO?!:^$?$6EZ5J-OXL2&6"R
M\(>.Y$N] \1:AI22![J)?LZ3,'B25&DB5_0AD'@1.M@Z2RS!/^T<?4R[ S2S
MZ,,1B:=KJG*O0P\)TY-J'MJ4ZU%-I2JJ343S99[XR>PKUX8_'SIX7 1S'$N/
M]BRG1PS>KJ1H8C$SIRC&\O9U8T:DDFXTVDVONC_B):^*7_1KW@<<X!_X3C5_
MT(T_TSC'ZT?\1+7Q2X _9?\ !&?3_A.-8)/L/^)?G-?E[^R1\&?AI_PR/^V[
M^U3\4O#-EXQ_X5KI'@?X0_"W0=1M7EL-.^('Q1U.&&_\<Q0LZ/<7WA;3%CET
MN!GD\OS9Y/*$A)7]L]1_8B_8B\2?LTZAJWP0_9M\&?'CX;6_P#_X2&/XL?"?
MXE)J7[3>C_$NWT=KZ2\UWPAK6I:;;M9?:A-<W.FPR+J($$EFND/;B*.O,SO*
M?"#(\?4P%?@2O7E1S.655L52Q52&"IXF&'RW$5H*MB,72]I5HQS*C&5",(RG
M4ISC2JS;BGZ>3YGXGYS@(YA2XQI4*=3+EF5"%7#TYU*]"=;,J%**5##U/9RJ
M3RZHDZBY8>U@YV:E;PX_\'+7Q1[_ ++_ ((YX_Y'C6.?_*?^='_$2U\4AU_9
M?\#CV_X3C5\]_P#J'_Y_ESO_  35_P"";OP,^,/['5WXD^._@^YO_BQ^U/J'
MQ#\-?L[^(/[,UR5? ]MX-\*:K+9^)S<6C);Z5;W^NV$[P7&K*OVB2TM[197^
MV+BK_P $[_V,_ 6N?L;?%_Q=XY_9:^$OQR_:"^'O[3?B'X67&F?%_P >/\--
M)L=+T"QTBWU>REU^YO[2QBFTO4EO&ALT!:^$\I4,P.[/'Y?X+X*KGE&/!SQ-
M7(LWP.4U(0QM2C]<>,]M2^MX65;&RBZ&&QF'Q&#K*5VJE+G4O9SB:X'%>*^+
MADLWQ9&A2SK+JV84:LL-"I]75##1QDL/B5#"P<*LJ%2C*#3Y9>UY='&2.M_X
MB6OBE_T:]X(QU_Y'C5__ )7T@_X.6_BB<X_9@\#''8>.-7)'7.?^)>>./:OR
MIUWP-X&\2_\ !2SP;\*M5^#'@?X6^$+CX[?#+P!XH^$7@GQ3+XR\#064EUH]
MEKMMI?B>&XW:Q:ZS%/)=3W$,SIOE="#M.?V^_;!_X)__ +-^C?!_]L2YU3]D
M;P3^S;#\+7TJ/]F+XQ^&?B4;[6/B_P"(+^[6VLM'F\%R:I<SPRW]W);Z;_9=
MU:2"Y&H1&W,<]C/(-LUR;PCR;%Y#@\9P--5<_P %A,92Y,P<EA88S%87"4XU
MU'%.=1TWBX5JWL(3<,/3K5.5Q@[<N59QXFYMA,WQN'XQ4:.4XFOAY\^!BI8F
M6'PF+Q<WA[T8I<RPDZ%.-1IRK3I1NE(\8_XB6?BD/^;7O!'7_H>-8]^@.G_T
MH_XB6OBEC/\ PR_X'Q[>.-7/X_\ (/\ _P!6#G%?$?C[_@COXU\%^ ?B)-IG
M[07PK\8_M$?"#X7:9\8/BG^S5I,&H1^*_#/@G4[7^T!.NMM<36=_>6UN)63[
M/;11W:[(#)'(;=I.D\>?\$8=9\+>'?&5MX:_:F^%OC?XT>%/@>O[0MM\$;?0
M-5T?Q1JOP_CTQ=4N;E+B:XG@MKAAYFGV7FK+%=SK&[B$R)7;')? 2<:<J>79
M>U6KPH0<GQ!347.=!.OB.?"_[/@^3$4JU+&55]7KTY<U.>QS?VQXS*K.B\=F
M'/3A&;:_L.5.?/.I24*=2.+<)585:52%>DGST)QY*D6VCZX/_!RS\4QU_9?\
M#\\<>.-7]^F+#O\ F,>XH_XB6OBE_P!&O>!__"XU?]?^)?Q7YUK_ ,$J_&#_
M !7N/A,GQA\/?;H_V+1^V,-:_P"$8U!X1I4NE'48O S6C:B93JENRJO]K(XL
MYED5I(<[X3]+?%+_ ()U?"?XN^-_V._"?PX\0^#_ -GVV\7_ /!/[X3_ !R\
M?7S:)XC\9:_X[\;>(+JXMK^]TCPIH#W6I:QK-T[1-J<FG%;*WC6)GAQ(N^,3
MDG@;AL1A*4\DPLZ>(P^.Q=?%4ZF;>PPF%PF&KXFC6;J1I5,3''+#U88?ZO3E
M:47SV2=KPV;^+^)HXFHLWQM*K2Q5/!4<-4HY?*IBL3[5TZ]*E*C*M2BL,W3=
M2<Y<LE5CRIV9[]_Q$M?%,]/V7_ _M_Q6^K__ "O'YT#_ (.6OBD<_P#&+_@C
MCK_Q6^K]?3_D'\XXS_+@UY=X>_X)"?"3X3:1^W'HW[0OQN\,W?B#X0_ [P7X
M]^&7BJ+3/$>EZ=X3T7QU%J[VOQ%\0^'(98;VXODU/0+KPS9:#/=W$-OJ3W-Y
M<I+#-!'!R/QB_P""8VE?$3XB_#O_ (1S6?A!^S7\'_!?[$/PQ^//QM^*3GQ'
M>^%[1]<;5(FUK4-.NKS[==>(]::RDFU 6D\>GPVUJ'2-Y)TC;CP^ \"\5B*U
M.CD%#ZK1]YX^5;,_8SI/"8+%1J4J,/:8JNZLL=3PU.E0HU*\Z\90A2GS01UU
M,7XR4L-&I/.L3]:J3A3A@?99?&K>>(Q&'YJE:HZ>&I4Z?U>=6K4JU(PA1:G?
M1H]__P"(EKXI?]&O>!__  M]7Z\_]0_V]Z3_ (B6_BC_ -&O^!QSCGQQJXYQ
MGOI_IS7QU9?\$9_%E[\1=?T%OVDOA?;?"&W_ &>9?VE?"'Q[_L;5[OP9XM^'
MMOJ%C9ZB]YI]M<0WV@7NFQ7[ZQ<.\]W$+$0QI$2FRO2O@K_P3A^&/A3X]>'/
M@#XT\7>"_CWX-_;._96\=>/?V=OC-HFCWVBW7A/Q)X;L)=:T77["QO+E94:=
MX?L87:CZG9SQ*X20LJ]%?*? FC"K[')</CJE+#QQ4Z6$EF\FJ'+.K5E.I65"
ME"MA\/3EB*^%G*.)I0C*%2E3K0=,YZ>9^,;DE6SC$X12J3H1EB5E2<J\<5]3
MIPC3I5*\I4\37:AA\1I2JJTHWBSWS_B):^*7_1KW@C_PN-7_ /E?1_Q$L_%+
M_HU_P1^/C?6#GZ?\2_BO@W]H+_@G9X&^#?\ P3]\!?M+6VL^+W^*UUJ'P_M_
M%>F7>IZ1JGA6^L_&?]OIJ$FG0V-G!_9LNAW>C003VIU'4;NV2Z5-06UN&,"?
MD-@8QC_#'T_*OI,B\/?";B3#8O&93PQ3JX7!8VM@*M:O+,L+&5>C/DE[%5ZJ
M=6+T:E'1J2ML>#FO''B7DV*I83'\13A7JX2&-5.G_9U5JC.*EKR1:<H\UG&+
MO=.RL?TU_P#$2U\4O^C7O!'_ (6^L?\ RNI?^(EGXI?]&O\ @?\ \+?6/_E=
M7\R6!Z#\J6O:_P"(0^''_1*X3_PLQ_\ \N/*_P"(H\>_]%+BO_";"?\ RL_I
MK_XB6?BE_P!&O>"/_"WUC_Y74O\ Q$L_%+_HU_P/_P"%OK'_ ,KJ_F2P/0?E
M2T?\0A\./^B4PG_A;C__ )</_B*/'O\ T4N*_P#";"?_ "L_IK_XB6?BE_T:
M_P""/_"WUC_Y7=__ ->*7_B)9^*7_1K_ ('_ /"WUC_Y75_,E@>@_+UZ_G1@
M>@H_XA#X<?\ 1*83_P +<?\ _+@_XBCQ[_T4N*_\)L)_\K/Z;/\ B)9^*7_1
MK_@C_P +?6/_ )74O_$2S\4O^C7_  /_ .%OK'Y_\@[_ .O[5_,E@>@_*EP/
M3W_'UH_XA#X<?]$IA/\ PMQ__P N#_B*/'O_ $4N*_\ ";"?_*S^FO\ XB6?
MBE_T:]X(_P#"WUC_ .5U+_Q$L_%+_HU_P/\ ^%OK'Y?\@[_ZWO7\R6!Z#\J7
M ]/;\/2C_B$/AQ_T2F$_\+<?_P#+@_XBCQ[_ -%+BO\ PFPG_P K/Z;/^(EG
MXI?]&O\ @?\ \+?6/_E=1_Q$L_%+_HU_P/\ ^%OK'_RNK^9+ ]!1@>@H_P"(
M0^''_1*83_PMQ_\ \N#_ (BCQ[_T4N*_\)L)_P#*S^FW_B)9^*7_ $:_X'Z?
M]#OK'Y?\@[K^GO1_Q$L_%+_HU_P/_P"%OK'_ ,KNW?\ 3-?S)8'H.F/P]/I1
M@>@__5T_*C_B$/AQ_P!$IA/_  MQ_P#\N#_B*/'O_12XK_PFPG_RL_IM_P"(
MEGXI?]&O^!__  M]8_\ E=2?\1+/Q2_Z-?\ ! _[G?6/Z:<:_F3P/048 Z #
M\*/^(0^''_1*83_PMQ__ ,N#_B*/'O\ T4N*_P#";"?_ "O]#^FS_B)9^*7_
M $:_X(_\+?6/R_Y!W_UO>E_XB6?BE_T:_P"!_P#PM]8_^5W;O^F:_F2P/0>G
M3MZ48'H/_P!73\J/^(0^''_1*83_ ,+<?_\ +@_XBCQ[_P!%+BO_  FPG_RL
M_IM_XB6?BE_T:_X'_P#"WUC_ .5U)_Q$L_%+_HU_P1_X6^L?E_R#O_K>]?S)
MX'H*,#T'IT[>E'_$(?#C_HE,)_X6X_\ ^7!_Q%'CW_HI<5_X383_ .5G]-O_
M !$L_%+_ *-?\#_^%OK'_P KJ/\ B)9^*7_1K_@?_P +?6/_ )75_,G@>E)@
M>@H_XA#X<?\ 1*83_P +<?\ _+@_XBCQ[_T4N*_\)L)_\K/Z;?\ B)9^*7_1
MK_@?O_S.^L?_ "N[_P#Z\4G_ !$L_%+_ *-?\$?^%OK'Y?\ (._^M[U_,G@>
M@[_KU_/O1@>@].G;TH_XA#X<?]$IA/\ PMQ__P N#_B*/'O_ $4N*_\ ";"?
M_*S^FW_B)9^*7_1K_@?_ ,+?6/\ Y74?\1+/Q2_Z-?\  _\ X6^L?_*ZOYD\
M#TI,#T%'_$(?#C_HE,)_X6X__P"7!_Q%'CW_ **7%?\ A-A/_E9_3;_Q$L_%
M+_HU_P #_P#A;ZQ^7_(._P#K>]'_ !$L_%+_ *-?\#_^%OK'_P KJ_F3P/3V
M_#TI,#T%'_$(?#C_ *)3"?\ A;C_ /Y<'_$4>/?^BEQ7_A-A/_E9_3;_ ,1+
M/Q2_Z-?\#_\ A;ZQ_P#*ZD_XB6?BE_T:_P""/_"WUC_Y75_,I28'H/RH_P"(
M0^''_1*83_PMQ_\ \N#_ (BCQ[_T4N*_\)L)_P#*S^FW_B)9^*7_ $:_X'_\
M+?6/R_Y!W_UO>D_XB6?BE_T:_P""/_"WUC_Y7=O_ -6:_F4P/3V_#TI,#T'Y
M>G3\J/\ B$/AQ_T2F$_\+<?_ /+@_P"(H\>_]%+BO_";"?\ RL_IM_XB6?BE
M_P!&O^!__"WUC\_^0=_]?VI/^(EGXI?]&O>"/_"WUC_Y75_,I@>GO^/K28'H
M/RH_XA#X<?\ 1*83_P +<?\ _+@_XBCQ[_T4N*_\)L)_\K/Z;?\ B)9^*7_1
MK_@?_P +?6/_ )74G_$2S\4O^C7_  1_X6^L?G_R#O\ Z_M7\RE)@>@]>G?U
MH_XA#X<?]$IA/_"W'_\ RX/^(H\>_P#12XK_ ,)L)_\ *S^FW_B)9^*7_1K_
M ('_ /"WUC_Y74G_ !$L_%+_ *->\$?^%OK'_P KJ_F4I,#T'Y4?\0A\./\
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MYJ2?'TFIT*>'E'_5RA%.C3E&<8Z5(233C&\E*[2LVTS^*/XI_P#!8WQQX_\
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M$RDX^^XM2NI)I._*FOXEOA-_P4A\'^"OV>OV??@5\3?V$?!7QVN?V:Y-9O\
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MPK\+/$_[)OB#]DCX:_#;0KS7H-.^%O@_7C#O\1)?MI3S^)-5MOLUNJ6=PEC
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MM9/;ZY?6^G??U_RZ/[(U?_H$:M_X++[_ .1Z/[(U?_H$:M_X++[_ .1_:O\
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M$K3_ .)E/^J0CO;_ )'U+UW^I;6[>H?\2^UO^BD>G1Y'B$]VMOK?=-+T^_\
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MD_:(_P""AWB"V\"_L8^+?!_PQ^-"?$_Q1\;[_7/V8?'WB[4]1U"TL(?@Y?\
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M_A,+C_GR@_[_ #?X4?\ "87'_/E!_P!_F_PHLNR^X#O:*X+_ (3"X_Y\H/\
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M4FT/Q#+"T6DQW,$VIZ<L[^0:_7]?$5XF2NE[?-8MD2S_ #D DG.PEFQR2#T
MSQNRY?%=ZS,BZ:A93@J))"RGT(V9S^5 '\ZW[3'_  3FB_X)\?\ !'G]MOX6
M_"?XC>/?BO#X^UOPE\3OBAK^OZ980>,=4\,KXH^']M\8[V6?27D?4KO6O"ND
M:]K.LWMZTCFTGOK9@8E\P^9^*?@/^WGJW[4_C;X]_!_Q!^U&OP]M_P#@HQ^S
MGX=^ /A7PQXQNK?]GJ7]@WQ-^S)86?Q%\5Z7X'LM132Y_A\GBXZ/:W&NK!%J
M6BW%@BZ-;Q&2:1_Z9-6U:VUW3M1T37/#^FZOI6IV5UIVJZ3J4*7EAJ&GWD36
M][97]C=02P7-I<0N\%Q!<1M%+&[(ZLK8INFZE:Z!I>EZ%I.@6>CZ/H]A:Z9I
M&E6/^A6&G:98VZ6=C865I#''!#96=M'%;6UND8BACBC1$&Q: /P,_9C_ ."2
M'[5/AOXG?$O_ (;$^+OA[XO?LZ?$3X8_$3P/KWP\\,_M&_M6^(=4U1O$6NZ)
MJ^APW&E>-[W3]"M[*.VTN?3KUM-N[6YM[:X-C9K)8WM_$_YZ_$[]C#XX:9_P
M1)_9X_91U#_@GQ\<_%_QN;P7^U#X)\(:]\-?#7PK\2^/OV?==UGXM^)O$O@'
MP%XR\+>/-6M+O0OA%\=M,BT+1?''Q"\$:\=?\$^$7EU&T O_ +,1_8<_B2ZE
M&Q]*5MNV7"R29P00&P(R0K*6&3P5+ $'D0GQ-(K%FT]5=EX/VF4$HZ[ 02,@
M%0N&7!R%*G H _D(UO\ 8 _:TE_X*<?LU^,K#X'^,O!7@[3/CI^R_P#M6_M'
M?$K6/"/@'5_@QX-M_AM^SQ#X*^+G@WX>_M+W/C6?X@R>#+::T?P?:?!;Q'X2
MNQJ$WVS5+_Q#=:(L4TG[G_\ !#^SURS_ .";GP574(;NW\+W7BCXX:E\(;>_
MCEANH?@;JOQP^(6H_"!1'.S2K8OX%NM'ET8%FB.B2:<;0FS-O7Z,W^KVFJV%
M_I>I:/:7VFZK:7-AJ=A=R_:+34+&\A>VN[.\@F1XY[>ZMG:WN4D!\Z$F-RRE
M@R:'JFG>&=&TKP[X=\.Z1H6@:%IMCHVB:)I,,&GZ5I&DZ9;166G:9IEA:0PV
MMCI]C:0PVUI9VT4<%O!$D42(BA0679 >HT5P7_"87'_/E!_W^;_"C_A,+C_G
MR@_[_-_A0*R.]HKBSXJE6WCG>TA&]Y%QYXQ^[7*]>?O=?T]ZW_"87'_/E!_W
M^;_"@++L=[377<I'0\$'&<,#E3CD'!P>01QR",BN$_X3"X_Y\H/^_P W^%'_
M  F%Q_SY0?\ ?YO\*5EV7W+_ "&?E_\ \%"/V.?BO\?OVJO^"?/Q;^$W@[P1
M<V_P+\1?M07_ ,1/'WB6/PK+/X,D\>_L[>(? OPFUF72-;ADU+QA;Z7\1-0T
MZ\72]-M]1ETH0-J2VT21+*GX9^*?^"2__!27XN_LS?'OX;?$/P5XU2Y7X=_L
MV:HOPU\;?MJ2^/%_:8_:O^%7[1^D>/?BG\;/ /B>/5/[+^"GA'QI\%+;6/!W
MAOPEXA?0[>S\27F@WL^@Z5<:.FL0?V%/XLED!#V,)'3 G89&0<'Y>F0"1T;
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M"Q\1:K?6-O<OH/A_PO:ZC?:[K/B.Y1;/1+:Q%U/(K>4'_ KQ=^T]^VA^PW\
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M,_YK_P#$T <'@^WYC_&KNFC_ (F%D#C_ (^8CUR!M8,?R SG^O%=?_PBEO\
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MZ;:Z0NN:3HL>I?:+W3$O[RZLM20=S9_\%1_V;=<TWQQ;ZS\-OC]X,E\*V'Q
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M9MIY^[C.<\YSP .ISZD@<>]?C%\3/^"CO[0_P]\;_';X2G]FS2?$?Q0\'?\
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M6U'Q3'96-_H\%EI5K:VNH:G"UMZU\(/V_/&NL?"C]I;QM\:_ ^E^"/B'\$_
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MXT2YO=;UV"R@\3W_ (/T%M.U"6%[+3[76]:NA86%O;V4]TJP@'Z6;UW;-PW
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M]VW_ '^7_"O)<#T'Y"C ]!^0H ]:_M.P_P"?NV_[_+_A1_:=A_S]VW_?Y?\
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MX[.E?"G61K#WG@716\8$Z[-I&FO+87,N+6>![%4LE^C\+Z#\A2\=>/K]./\
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M'N"!G!'H>>F<9KR:,#S(^!]]>P_O"I;D#SI^!_Q\3'\]E 'J7]IV'_/W;?\
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M:\\:WVK^-OCKJ8T+P_H^DZ7;6*7L/A:VL]!TW3]#T6Q6WLX])1&1A]UCC&,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM"/+EG@DG3"RJJ]30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 HZ_@W\C5J'_D'R_P#7S'_Z*GJJ.OX-_(U:A_Y!\O\ U\Q_^BIZ *IZ
M_@O\A24IZ_@O\A24 %%%% !112J-Q"X4@Y!#DA-N#NWLN&1 N2SJ0R#+*=P%
M  "1P"1D@DCK\N<9.<X 9L#'<G((%?C1\?/BO\3M+_;[TWPEIWQ)^)&A^*-/
M^(G[)ND_!KX/Z.^H#X??$GX&^-8/%,O[1_B[7]&AT^;3_$L_AR\M;JWU#7[^
M_MKSP8^C:3%:!XM0;S?OGX$_M1^'OCC<_M!_\4/X]^&>G_L^?$._\"Z_=?$W
M2X_#FIZ]86/ARR\4S>--.T,R2ZAIGAF[TRX>;29]4C@U&;3XQ?M;*)[=6\X\
M$_MN:!XT^('[+/@M?@U\2M,D_:I\">+OB/X-\<76B:>O@GPWX0TK3I-?\.1:
MGXC<C[3XI^(/AB/2_$T/A'1I9;KP]I&HV1UV?S T0 /N5B-\@7&T,!&>[=2W
MMP>!V(!S2'H!N; +-LXV%F" DKC+,$5@C%OE9TE"[X8BOP+X@_;MTJR_:R\;
M_LE>&/ 5IXC\7> ?"NGZ[J>J7WQ(\+>%;[7M>U7P+=?$>T\'^!_"6K6SZIXR
MU.WTQ;'3+W^RYDDLKK4!-<V;V=C<.OUU\)_B5X=^,GPR\"_%7PBTA\->/_#=
MAXDTF*8,MS9QW:LEUIMY&X#QWNDZA%>:7=HV[_2+21T8HZX /0/\/_U_K_\
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M[V>SLK/3;U?#?B37/#4-W<V.H7UC<L_WSJW[&OPW\6Z)^S3HGQ,DU/XIZ?\
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MI+X82?1_"R>([;3]4FDN'U@60!^Q0&"1@8&"O/08P>/KGGOGV%/K\[/V</\
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M7$8$-RE 'T_1110 4444 %%%% !1110 444UR55BJ[F )"Y +'L 3@ D\#)
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MK-CIT;7_ ,1M5MW\)->>&;A?#^H6<OQ/U2;PSXI\-7&FZOX>N-/TJXTR_/\
MI4=QR_AS_@D<VL:-\2-%^*O[1'Q6N-,O/B+\9O$/P9T7PS?Z"S?#:Q^*FJZ
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M']H?X2^*/@_XGU+5](T+Q9-X:EOM1T(VBZI;'PQXMT'QA9FV-[!<6W[^_P!
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MGPGX[BNYO&_AOQ#?>'[:_P!9\#1S^$O&G@&?2[^TTK4[ZPEO+B9EFC[+X?\
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M*9V\R)[.R8P_+-&UQDPLT9D G!.828=S?O A,9+?=Z_S??"[]FC]IO\ :?\
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M .?.V_[^O1_PEEW_ ,^=M_W]>N2HH ZW_A++O_GSMO\ OZ]'_"67?_/G;?\
M?Y_\*Y*B@#L7\3W(@CF-O""\LJ;5D<@!(U('"DYSS@_WAVJ/_A++O_GSMO\
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MOY&K4/\ R#Y?^OF/_P!%3T 53U_!?Y"DI3U_!?Y"DH **** "CMG\O3C@\]
M0>,=3GBCKD>V?PY_P->$_%3]I7X0?!?Q_P#!?X9?$'Q%<:;XS_: \6W?A'X;
MZ7;:9J%W'<W]EI&HZUJ>JZS>P0C3_#?A^QL=)N%FU'49K;?<B/R1)N,B@'N4
MTPMX9YV61TM[>YN)$C'[QE@A>0I&QW 2'85!*/'&"99L1H<_SE^'_P#@KE^T
MMXQTWP'9Z!\,$3QM^TAXCL=1^!?A2#X-^*M6\0:3\,3JOQ-AO?$^GZ>GB"VL
MOBAI36?@"UTQ]4GOO"M]8:[?ZA=2Z8='@T][C]G_ -G[]K[X-_M(3>(8?AS=
M^*K&30O#N@^.('\;^&-1\(+XB^'/B:ZU.S\.?$[PQ<ZDR'5_ _B";3-1&DZS
M^X>9[3S+E5@=';\^YKG_ ()7W;+I]]^S_?Z9X7^/NL^&_$=S\1Y/!7CG2_ U
MEK?B+6?&&I?#=-)\=6>LQR?#X>.[JR\6^(_#WAWX=RZ/I=Y::RVL:KIEG/XD
M5]3 /TX_9Y^)Z?&CX&_"?XK"]TG4'\?> ] \1W5WH5M?V.D3:E=6WDZR+"PU
M8#4]/@MM6M[ZT_LV^,EYILMM+:WDTK^7(?91UQT_J,XX'4X/I_\ J^)OV;OV
ML/V6O&WP6\::S\'$O? WPH_9M\+Z/)K.@W?AB70(/#/PYN/!X\6>#=4T?1EF
ME-UX=U_P?;C5=#$$LVIR*]RNJ01:D70Z_P &_P!N/X"_'*7P?;^#[OQ9877C
M3Q?K7P^L;?Q1X=ET,VGCC2O VF?$RR\-7\DDTHM;CQ9\/-2;Q5X3\F=TOXM)
MO8 R7\#VA /L+CMG\1BBC^G'Y?U]>F3G@44 %%%% #X_]9'_ +Z_^A"I;G_7
M3_\ 7Q-_)*BC_P!9'_OK_P"A"I;G_73_ /7Q-_)* *]%%% !1110 9YQW/3W
M_P ^E &3M# '(R2RC )YY<@ @=VPJG!)"C(YKQGXOT/X?^#_ !3XY\3SW,'A
MWP?H&K^)=;DL=/N]5OUTW1;&6_N_[.TS3HIK_4=3DAB,6GZ?;(TU]<LEO!%+
M-(B'XCG_ ."E?[.=H+'3;^Q^+=KXTF\4ZQX6UCX9S?#S4$^(W@J;0[+0]5U/
M6/%7AL3P36VCP:9XDT74+:6VN+F[NX[U(=/L+RYCE@0 N>,?CU^T58_M/?&/
MX'Z-X=^$7ASPKI'[-^F?%'X*>*?%GB'49[KQ#XLO/&K>$=0U'Q[;V]K#;Z#H
M=I="2RT;PQ:3W.K:O?VT"SWD"ZI;,GYY:)_P6+UNT\5_ #X&>-I/A?X:^.>K
M_M;W?P;_ &BK#QR[?#;6O!7PC;QYJ_@7P;K$/PYU?5;K4='^*'Q&D32_$-IX
M5AOM8M?#_A:";5;Z\#ZSI:5^JWQR;]EL>)WTOXT>&-$UO6OB-\%?&UGXDOM3
MTB\U.-/@)X,O+3Q1KK^*1:SQ2Z=X5M==U6V^QR6]L^J3^([W3X;%7ND4Q?'?
M@C]HK_@FQ9_#C]GS3/!GPYNI?AEXIU'PO^T)X*U"3X<>(M7B^&M_JWQ/U;X>
M>"/C)\5/$.M2W/B#0M2\6_$[3]0T32-1\27VJZO?3VNV_LX],ACN(P#]<V Y
MVJV"2$8Y^<*2#P1E<=QC@Y]:CS].I'!SR/7'3_/6O#OBG^TA\+?A%\3_ ((_
M!GQ?JUX/BA^T1X@\3>'?A?X3T6PFU'4M4N_"/A;6_&.NWM]'%+!%I&BV]AX>
MO+"+6+RY@@DUVXL-,B9KBX KN/AG\2?"WQ>\">'OB+X+NYKSPYXDM[F:S:ZM
MC97UI<65[<:=J>E:I8DEK'5M)U.TN].U.T?$D%[;S)*!('H [JBBB@ HHHH
MN?\ +I!_U]3?^B4JG5S_ )=(/^OJ;_T2E4Z "BBB@ HHHP3P 2?08'ZD@ #J
M22 !0 ?Y_P _Y[5\Q?M=_%+7_@Y\%-9\=^'?B-\.?A9?:=JFE0S>+/B3H]WX
MIL8[:]N#!'HOA3P7I]YI]_XT\>^)+OR=(\+>';>[B-SJ5Q&72XCR(O3?BU\:
M/A=\"O#VB^*OBQXRTSP;H7B/QIX-^'6@7FH"XDDUGQM\0M;MO#O@_P /:;:6
M\,EW=7VLZO>06\0C@,4$3-=W<D%M&\H\DE^(7[+/[47A[Q[H'BCPOX9^*W@+
MX4ZWK5UXM?XL?"N35?AKIVN>!+S4=/U?6M$U/QWH-QX/UB[\+7FGZC;RZUH1
MO9+$Q3L]Q' QE4 _*_QE_P %,OVK/AOH^I>*?'?A#X2:5K?A.Q\+?#WQ=\!X
MK:\G\<6GQ%\0_LUVGQRO?BK)JMMJ=S/:^ = U._BT>_\/Q6=W;6EE:7JWNM"
M]MY-WZ>?L<_&7Q_\7O#?Q<TOXCZ[X&\9>)/@_P#%^X^&C?$GX:6)TWP3X[L+
MGX>^!_B!::II&G_;=1@@NM'/C&3PWK$=K>3VYN--$^4FEEC7R;2OV@?^";OA
M_P 2Z>^FZ5\)?"OB71_@HDFE:RWP0&@3V'P?N?"UIXUG^'VD^(D\(6J-Y/A/
M7+'6[OX6:;>7-_'HVJ6\UUX>@\_,WKWP^^/7[)7@/]G&X^*'PM30/ GP%\'^
M(KOPK=:%X'^&EYX2ET#QI/K]MH]YX8_X5;HFA:=J]GXJO->U.QBETF/0(=2N
MI+^TNG@:&<3T ?777G&,]NN/;/?'K17EGP^^-'P]^)VHZCHOA34=4_M[2/#G
MACQ;J7A_Q!X=USPKK]GX=\92:O#X<U2?1]?L;"_2WOI="U.)B8,VTD*1W'EO
M<0JWJ= !1110 5=TW_D(67_7S#_Z&M4JNZ;_ ,A"R_Z^8?\ T-: &7O_ !]W
M?_7PW]:JU:O?^/N[_P"OAOZU5H /7H<#(!.!D<C.?4X '!SWKXL_:>_8M\'_
M +5OB[PWKGCC7[JRT7PW\(_BA\/[*QT>P*>)=$\5>.M5\%Z[X7^)OA'Q )_.
MT+Q=\-];\%VNJ: ]O:3274\[1R3PPB:.?[4 ). =I/&[Y?ESQN.X%0%ZDD'
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ML()]7N;V5G%?H9_WS_P'.W_@)(!V^F0#CJ!2DDYR>NW/N5QM/U7'R_W>U)0
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M/_"FB>#_  9J&N>(]:D\2_%GQ'K-KKGCC5KW5S9ZBUEK.H"WL[:UM[:3CO\
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MX1^"JVRZ!!XJ^)C:K\*;OXK>+;O6M-U[Q#I>E^$KCP-I-GJ]J;*^O7GU6_\
M[.L-(^VZOJ\:Q>J:;_P5=^%'B9=7D\ _ G]HWQ_;V^J>*+'PJ^C>'? VEW/Q
M M?A[X&TKXD_$[5?#FF^*?'>C:G96?P_\)ZO9MK/_"1VNCS7_B&6/PWH<6I:
MC*@KW?4_^"=O[)&J64]@_P ,KW38I;CPQJD<VA_$/QQX>U&QOO!N@7_@K2M6
MT_5++7H+_3]3N/"&MZCX6\1ZK'(M[XFT+4Y=-U:2[$T*KH^(_P!@;]E+Q%X1
MMO!FI_"Q-,\/:?XHUSQG N@>+O%7AO5[35O%OA^/PGXM2/Q'I.OV&M1:+XQ\
M,6R:%XHT2:Z.A:UI:R:;>17*,4H \6;_ (*>_"A?$/V=?A/\9;GX=0^!/A?\
M4]5^--CI_A.]^'GA/X:?&'4=$L/ ?B_QOY/B=O$'A"'5X]=AU8:%K>CVWB.V
MT*SO]:N=+CTU(+F?#O/^"LWP MM0@N(/AY\:[_X=6WC'0O!7BKXQ6OASP^O@
M'P;?^+[KQF?!.HZI]I\3P^(M4T'Q;X?\"ZOXQTO6?#FB:QI\'A^\T(ZA<6M_
MJ\5I'V_BO_@FG^SZW@;XX>&?@Q;ZG\(]0_: T35_#GCJ>U\6>,/&7@.YTKQ)
MH5EX6UF2U^%&M>*I? ]KJ2^%+6UT/POJ0TM9/"XBLO[&MXI1&IXKQS_P2K^#
MWC7XR_!7Q[)KC:7\,_@IX<^$?AFU^$<6D1BP\2)\$O#_ (B\*>"K#Q/JUOJ]
MKIVLV$MCXAOK2\M]>T35M6^V+J%CIVIV=IJ,T0 .$\7_ /!7?P'X8UOP7#J7
MP,^+_A/PQ/;7WCSXIZAXZL?#-AK7A'X"77P:\7?&#P+\6_#VGZ#XGURUURT\
M;V'@S6+(:%_:%GXAT)[&YMM9L;2ZFA@E^S?V1OVQ?AO^V7X,\4>,OA[H?B[P
MQ_PAWB&R\.^(=#\96>G17MO+J>BV?B'1M1L;[0]1UG1=3T[5])O8IXFL=3FF
MTNXBNM-UF.QO84AE\Y\(_L'_ +#%U;:WX5\+^ ]+\1-X.\<PP^)$;XB>*O$N
MN>&/$5MX)U#P=I_P^UO5K_Q!/JMKX>LO 'BZ^TC2OAI/.?#^EZ=K:0P::%=2
M?I7X)? +X5_LZ^&M1\+_  HT&_T;2-6U&#6-0EU?Q+XA\6ZK>W$%A#I&GI<Z
MUXEO]2U$V>G:3;VVG:;8Q3-;V5I"D5N8X220#V+']/UZ44?_ %_;GO@=O\.G
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *.OX-_(U:A_P"0
M?+_U\Q_^BIZJCK^#?R-6H?\ D'R_]?,?_HJ>@"J>OX+_ "%)2GK^"_R%)0 4
M444 '/./\_6O@K]LK]J'XN?LR:M\*?$7AGPCX,UWX0^(/'_PY\#_ !'OM5N?
M$SZ_IDGQ$\=Z5X3FU6]U/2;&3PK\+/"'A[1K^ZUH>/\ Q[*=-U77K:V\'16R
M7>H17*?>O^?\\C_#UR.*\"^*?[+_ ,#?C5XO\,>-_B;X.7Q)KGA6*QMK%I==
MUVPT/5+#2M>LO%.CZ?XN\/Z;J-GHOC'3-'\2Z?::[8:5XCTO4+6WU2VAO(P)
MU,I /G?]GG]K3XG>)/B7^U+\./V@O#'@_P *:G^SIX/\+_$>#4/ X\66VG:I
MX.\2Z/K^L7*Z#<>,;.QE\?Z+X<;1CI]K\3O#5NGA76-:EET>PM$>PE8_(NE_
MM^?$WX11?#2^U3X-^&_A+^S'K/PB\$_&"XU^S^'?CG4?"=[XR^.D/CKXH>'?
MA#X=\8:1J)\+>$_%=[X<7P\M]>:QI5UHTGC;Q/=V>ZPM[>S\W]!O@+\&/V1/
M!7BOXZ^#O@A8Z'J'B^P?1_AG\<]#C\9:[XMUKP78:[IEQXH\._#'4FUK5M7?
MP?X?32/$5QJVE>$=(N+*QT=-4DN+33H)FB:OEGX=_"W_ ()Y66M_L^>!/$OQ
M+\)_%3XJZ)X6TOP7\*K?6?$GB&SM/&GA;P%J?C/PE\-(O%/@FVN8_ 7B77/!
M>G0:]X,\"^(O$-E'?^(4T*_N_#=Q>RVLTD(!TOPS_;B^*P^%?[3'B_XW>!O
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MXEA\<)K^L6WPM^*OQ?UK]GG0?$^M:6FA6</AOQ?%\39O!UK=^'+6_FM#X/\
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M"OQ'U>RU"_M?#+QZG9W&H7:P:6Z7HN9=,AN[:VDBWJDTRF:.2$R(?Q3T8?\
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M8W[Q>&8_#UCXM\6?"NWU35? OB.*:/5D\+:UX\\,ZM\)C!>ZA#XNN[)H89B
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MN"?"D.-PU"; P#^XCZYVXYQ\Q/1>.HQG-(?"D6 ?[0E(/0B&+!]ADC.!R<=
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M>AC_ .$03_G_ )?^_,==G10!QG_"()_S_P O_?F.C_A$$_Y_Y?\ OS'79T4
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M$$#.U]H= U '\_7@[_@J=\==&L-=O?'GP^\*ZYJ%MK_C.Q$T[^(_"WAG3?\
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.1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" G # 2(  A$! Q$!_\0
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M<L14F\(IQA##JK3]MS23AS6Y9]/[%_\ A^7_ ,$UO^BW:KG_ +)IX^ZCK_S
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M?YY]Z3C^ZO\ WR/SZ?\ UO:C_B7?@S_H:\2?^%&#_P#E0?\ $=>+/^A?P_\
M^$F(_P#EI_?'_P /R_\ @FMV^-VJ\]/^+:>/OQ_Y@//]*/\ A^7_ ,$UNO\
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MY].OZ>U+Q_=3_OD<_P"?:C_B7?@S_H:\2?\ A1@__E7]:!_Q'7BS_H7\/_\
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M;(UCXK?'+Q#\4_V>/@[X(\+:!\']%^$FJZ=H6M>+_!_AJ[TZUGO/%&LV\%L
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M\.-;Z9]FFM!_8]@+>9(4=G5A^U+_ /!!_P#X)T2R2S3_  ]\=S2SS23R2O\
M$[Q8TCR2',A=_M.9&+99I&S([,S.S,V:;_PX=_X)Q#_FG'CG_P .;XM/\KFN
M9\5>$57%XG$XNEQOC8XS$4L5B:%3#4*5&M*D\76A3G.A4H8RI3I8G&U,12G6
MQ%3$0J4J$77J4*:H'3'A[Q3I8>C0PE?A7!3PM"MAL+B8XW$5L51C56$A*K&=
M6E5P\:TJ>#IQ;IT%2<:E7]Q&I+VJ_)GQS_P4^_97\-WO[:_QD_9T^(/CWP)\
M</VHO@M\+)]%LK?X=Z[91^&_CKX5&I6'B4KKESITVDI%/83V$@UQTDLM0E%R
MR,71%;^?SXL?&OXI?'SQ_;_$GXT>-M6\>^,@FB6$_B#5O(^TMI.CW4<EC:,E
MI''^ZLH@^T!3* 50AW9B?[:?^'#W_!.+_HG'CG_PYOB[_P"2:/\ AP]_P3B_
MZ)QXY_\ #F^+O_DFO?X<\2O"OAE8R6"R[B?$XC%TEAECL?EF#Q..H818&& A
M@Z.)<U/ZO"C1I24)IMU:<9R>Z?A9YX?^)/$$L+]<QW#=.CA:\L7]6P^.Q%.A
M6Q<\74Q<L15C.C4]^52K.+4%%<CMOJ?@#^WY_P %=/BQ\2_'&J>#OV4_C5XA
MT+]GS7/A+X.\):I:CP5;>%M?N]6@T>2P\9Z<=4U32E\3V]K>R*;8SI=?9[FS
MN#'IX56>>OIOX7?\%-/V.=+TK]G7X^>+_'_QP\-_&']FO]FGQ)\"C^S#X:\+
MWMS\-_B5J^IZ2VEVFO/KL4__  C,-N7MTN89K]XY;6&6!;I6E@CCF_6/_AP]
M_P $XO\ HG'CG_PYOB[_ .2:/^'#O_!.(\?\*X\<_P#AS?%P_7[57CXGC#PA
MKY9EV60P'%>&CESE?$X?*\NAB<="I"-.O#&R<)QJRK0C&"Q$5'$X=*^%JT9-
MM^G1X4\4:68XW,)X[ANO'&1E_LE?,L<\-A9VA[.>&]G[&I"-+DO[&3="NV_K
M4*R2M\8#]IW]F;X"?#7_ ()H?M"?&SXN?%CP3XJ\'_L_^,O%_A+X._#S0=0U
MKPE\2AXJAETZYTG79[1FL]+N=/N]1CATZ74!%:"U#.TL$,0*_,_P _X*%?L(
M7$'[$_Q6^-GCWXD_#KXH_LG77QKMS\.?#?POU;Q3H>LCXLZQK5Y'J/\ ;VDB
M6VMM,TRPO80(;,37OVDM$\$<>QZ_7*\_X(9_\$_M3AL+:_\ !?Q+U.TTJ#[%
MI5M=_%KQI<VNFVX(;[-803WDB:9:YPWV>Q2.V9AO>-9,DYP_X(0_\$Y1_K/A
MIX[0AMIS\3_%1!."<D_:@.@R0"6 / ->32XC\+7A:\,7B^-YYCBZN+;KX++,
M'AX8;#8NIF\JN&HPG[2G*%6AF^(I5:F(YZK;YJ-2E>,(>Y7R;Q'E5P]2EA^$
MEA,/'!N-'$YA7E"O5PGU&4*M1T8QG>-7 PG%4[**DXRC))2?XX_!G_@H#^Q#
MIFC_ +'?A_XL:QX[O(?@YK?[9>H^*'L?!WBB;2/#M]\:/B5J7B+X;:CJEGIT
MNEW7B_19M NWDUC1]--R;&]EB@U&,D2,/H36/^"H_P"Q->?&KX"ZDGQ<\8/X
M,\,?LU_M"? +QYXET#X->+/!VGZ)?_$2Y\%77A;Q'H_@Z)[F2;381X=O;:QM
M+.>^N-.9XKNZ>%I9'3]#Q_P0>_X)Q$9'PX\<@>G_  LWQ;GUY'VG/(_G36_X
M(/\ _!.)2!_PKCQT2QV@#XF^+,\]P/M.2!U.,G'.#73B^)/"7&8JKBY+CF%6
MI2S"G:.!RZ482S+$5L3B*D%.%U)5J\YPB[PNHRFI2NY<-#(?$ZA3A22X-E"G
M6P=5-X[,8RM@>94:;<9ZP:FXO[7+I%J^GY ?"7_@I/\ LD?!1/V-?!%KXM^(
MWCOPI\)_A9^TG\&?B-X[3P1J^D>+?#MG\4=>L;GPEX_TBWU%P^K7=Y96(GUF
MRTVZDU+3I)0-CLCP'LOA=_P4L_8O^ ?BC]D/X4^&OBG\8OBQ\+?V>])^..I>
M)OC_ .// ^O/XQU36_B-X9U;3O#^@:;H+M)XCN(;:[U(1ZA?20FS0VEF3M2(
M2K^I_P#PX=_X)Q=_AQXYSD\'XF^+"002.USP?KS2/_P0>_X)QJI8?#?QP<<G
M/Q/\6+@<\Y-UDX/8<XZ"KK<4>$=9RJ5X<<S]I2QM.M_L>!<9SQKQB^L*G"$7
M3G0IYECZ4*-"5/#UHXEO$TJDJ5)QG#\.^)E&G"C"7""C'$8*NYPQN-59O SP
ME2,%4J<ZM6JY?@YUI2C*:E1M%QC.HI?B7^R5\<?#7[1NF?\ !,S]GW2?%GB;
M6?C)\#_VK/C'\=_BS>:[9ZTUIX:^&TNO>(/%_P#;K^--21M/NXXM'NHBX6_6
M:T<O;OY7EHI^%?VH_P#@H/\ 'CQUXL_:6^%W@KXCQ#]G+X@?%+XHOI'A(>&]
M!N(;WP?X@\<-K)MH=4N-/;5[>TU74+&'Q ;9+S:EY/OB<Q *W]5VC_\ !#7_
M ()_Z+/-=Z)X/^)N@WLMO<Z?<SZ1\7?&FGW<EE=Q^7=V,EW97T4S6=[!(8KR
M!7$5Q&QCE5AP<YO^"#O_  3AC0$?#;QR @551/B9XM. 2$ 51<DX'';&.3P,
MU[.!\2/#+!9E+%RP.>8_"TX8B>7T<1D&&4\+B\;G%3.:^(=\4X.5"K["A@U&
M*=*C1O-RJS<EY6/X!\0,;@(8:.+RG 5YU:4<;.EG=>4<5AL+ET<NH47;"WC&
M=-U9UWO.=1VM"*B?P?A",^O!)+#E@H#;1G)C  VDG+-O8@$YIVT]<<>N1_C7
M]WA_X(._\$Y@2#\,O'C,%!*I\3?%;, 3MZ&Y0=0<$G!"Y'<4'_@@_P#\$XU*
M!OAGXX7<VW+?$[Q8/3@ W(8GGIM'"N20 "?N'](/@EV_V3B*]EME=%+16ORQ
MQ:2;M=V2N[OJ?(/P1XO7_,3D*C=_%F5>4M6VU>6#N[7V<M%II9'\(>QO3]1_
MC1L;T_4?XU_>!_PX<_X)Q<_\6Y\<GU!^)OBS'_I3D^W)/UI?^'#W_!.+_HG'
MCG_PYOB[_P"2:/\ B8'@G_H$XB_\-=/_ .;"?^((\8?]!.0?^'&K\O\ F#['
M\'VQO3]1_C1L;T_4?XU_>#_PX>_X)Q?]$X\<_P#AS?%W_P DT?\ #A[_ ()Q
M?]$X\<_^'-\7?_)-'_$P/!/_ $!\1?\ AKI__-H?\01XP_Z"<@_\.-;_ .8S
M^#[8WI^H_P :-I]/U'^/N/SK^\'_ (</?\$XO^B<>.?_  YOB[_Y)J,_\$'O
M^"<0(4?#;QTP()&/B;XJ&6' 4!KE1N;/R\@$Y'U/^)@>"?\ H#XC_P##92_^
M; _X@EQA_P!!.0?^'*JO_=-W?D?PA;6]/U'^-&UO3]1_C7]W@_X(/_\ !.3=
MM_X5KX\ST;_BYGBSY>H4,!<'K@CJ3GA0W6G_ /#AW_@G&&VM\-O'0P,@M\2_
M%HS^!N > 03M!"DX8AN"O^)@N";V^I\1_P#ALI?_ #9\_P"KC_X@CQAO]9R"
MW5_VE6TW5O\ <K7NM5?OU1_"!L;T_4?XT;6]/U'^-?W@_P##AW_@G$ 2?ASX
MY_'XG>+!_.Z'^%1K_P $'O\ @G*2<_#/QP.F"/B?XL).XXR?])&T$=R06/ !
MXR?\3!<$K_F#XC_\-=/\_KEA+P1XP;M]9X?\_P#A2K?_ #'K^!_"%M;T_4?X
MT;6]/U'^-?W>'_@@]_P3B[?#;QPQPS!1\3O%F<+GJ/M ([9ST;Y"2W!>/^"#
MG_!.$@'_ (5QXYY /_)3/%G?_MX'Y,/<@4_^)@N"?^@/B/YY92_^;%?^MQ_\
M01XP_P"@KA^W_8RJ]-W_ +F?P@;&]/U'^-&UO3]1_C7]WK_\$'_^"<JLJI\,
M_'4F1SCXG>+<X&,A0+@@M@[L$HI ;YLJ 6M_P0?_ ."<83S!\-?'14<$CXF^
M+,=<?>-P<\D 8R3Z'!-+_B8+@FU_J?$7_ALI?_-@O^((\8/;$Y!U_P"9C6MH
MKO7ZD]+;MVMIT:/X1-I]/;J.OIUHV-Z?J/\ &O[O/^'#O_!.7H?AGXZ!')!^
M)OBL':"=S#_2#N"\$[,CYE[D@/'_  0=_P""<+#/_"N/''OCXF^+3R,CO<\_
MB./0&C_B8+@E_P#,'Q'_ .&NG;R_YC/+Y@_!+B].SQ60+M_PHU?+O@U^M].Y
M_"!L;T_4?XT;&]/U'^-?W@_\.'?^"<(X_P"%<>./P^)OBW^ES1_PX>_X)Q?]
M$X\<_P#AS?%W_P DT?\ $P7!/_0'Q%_X:Z?_ ,V#_P"((\8?]!.0>7_"C5_^
M9/\ ,_@^V-Z?J/\ &C8WI^H_QK^\'_AP]_P3B_Z)QXY_\.;XN_\ DFC_ (</
M?\$XO^B<>.?_  YOB[_Y)H_XF"X)_P"@/B+_ ,-=/_YL%_Q!'C#_ *"<@_\
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MU"+7?#MU<W%OJN@^ )--CT3PYK]_'=R5_:&OPW^"(N?"MVGPU^&R7'@-KE_
MUQ_PK[PWYW@MKR>2ZNV\*S'2%D\-?;;J1[J\.CO9>?<S33/F61I#3O\ X6?
M35EU&+5?A/\ "G4HM7\3#QMK4>H_#CPI=QZEXV6*.!/%U^+C19$U'Q3Y2*@U
MZY\W55BCBB%UL3DY8_RQ^Y==^@[O:^G^6Q_+Y\>O^"BG[;WQK^"W[>/CCQ/_
M ,*W^&/P3_9Q\1?L2>$8_AMX4F\;Z+\7+GQY\=?%OP"\3:F\GQ;\(^*[#R?#
MOA1M>U_2S;:= %\46%];VFI"2T2[M;G@?&/_  6)_;D^("?\%._@8?%/P[^'
M/C;X=_LF_MF_$']G/5OA1X0G\87F@']GO2)KZ/4K7XBZ9XIU;4--\<3^&Q*J
M6/Q&\'>&YK7QA=6$_AT:RMG+!7]<MQX8^&5Y:ZU!=^$?"%U!XCO=,U#Q'!=^
M$](GM]?U/1OL9TG4-<MWT]DUB^TA[*T;3+J_6>YL#;6_V6: PQE*=GX*^$&G
MZEXBUNP\!> ;'6_&%I-9>+M9LO ^A6NI^*K:YC:.YM/$E]#I27>MV<\9$,UM
MJ4]RDT.5D)S1RQ_ECVV73;H%WM=Z.ZUZZ:^NB^Y'\@OAO_@J5^T)\'==A_L?
MXR_"'Q%JOQ4^'_\ P3%^'/B?]KKQ]JOC7Q/^SY\([;XM_"7Q9KOBCXL>)/![
M>-W\+:=/]LT(>&;^_M;W1%U?QC>3W/B*[N)'18?ZJ_V(_C'K/[07[,'PI^+/
MB3QQ\+_B;KGBC2=4_M'XA?!73_%ND?"OQI/HWB+6-"'B+P3IWC:&#Q%:Z3J*
M:8DK+=?:;-KT73:1?W^E?8[R;NE^%OP"AT+4/"L/PH^%T7A35[+3=.U;PQ%\
M./"R^']4L=&+MH]AJ&B+HJZ=>V>EO)))IL%W%-#IS._V-(_-DKT+1+OPSH&F
MVFD:1#I^D:5IEM%9V.DZ1I\.GZ3IMO""L5K965E!%;6L42A8TMK:*.&(+P@)
M-')#^6/_ ("O\@;;U;;=K7>NBV6IV'E)Z?\ CS=^O>CRD_N_JW^-8_\ PD6E
M#[TSJ>X:&0$#L3\IX(Y'/((-!\1:4.L[#G;CRW)R!DC !S@$'(RO(YR11R0_
MDC_X"O\ (+ON;/EIZ'GK\S<_K1Y:>AXZ?,W'ZUC?\)'I/_/PW_?F7_XFC_A(
M])_Y^&_[\R__ !-')#^2/_@*_P @N^YL>4G]W]6_QH\I/3_QYNW3O6/_ ,)%
MI1QB=SDXR(I,#W8D *O^T<+G@GF@^(M)!(^T-P<?ZJ0C\"%P1[@D4<D/Y(_^
M K_(+ON;/EIZ'KG[S=?7KUI/*3T]OO-T].M8_P#PD>D_\_#?]^9?_B:/^$CT
MG_GX;_OS+_\ $T<D/Y(_^ K_ ""[[FSY:>AZ8^\W3TZ]*3RD]/?[S=?7K6/_
M ,)'I/\ S\-_WYE_^)H_X2/2?^?AO^_,O_Q-')#^2/\ X"O\@N^YL>4GI[_>
M;KZ]:/*3T]OO-T].M8__  D>D_\ /PW_ 'YE_P#B:/\ A(])_P"?AO\ OS+_
M /$T<D/Y(_\ @*_R"[[FQY2>G_CS=NG>E\M/0_\ ?3?XUC?\)'I/_/PW_?F7
M_P")H_X2/2?^?AO^_,O_ ,31R0_DC_X"O\@N^YL^6GH>.GS-Q^M)Y2>G_CS=
MNG>L?_A(])_Y^&_[\R__ !-'_"1Z3_S\-_WYE_\ B:.2'\D?_ 5_D%WW-GRT
M]#_WTW^-+M7T_4_XUB_\)'I/_/PW_?F7_P")H_X2/2?^?AO^_,O_ ,30HQ6T
M4O1)"NS9*(>HZ<=2/Y$9_&D\I/3W^\W7UZUC_P#"1Z3_ ,_#?]^9?_B:/^$C
MTG_GX;_OS+_\31R0_EC_ . K_(+FSY:>AZY^\W7UZ]:/+3T/I]YNGIUK&_X2
M/2?^?AO^_,O_ ,33SK^F*H=IG5&4NK&&4!@K%3CY>3N!&,=J.2'\D?\ P%?Y
M#N^YK>6GH?3[S=/3K2>4GI_X\W?KW[UC_P#"1:3_ ,_#?]^9?_B:/^$BTG_G
MX;_OS+_\11R0_DC_ . K_(+ON?S,?\%I_#_Q]^*?[?G["GP%^".E_%GQW/XW
M^ /[5&OW'PN^&W[6GCC]D"SU+6_#4/AMM"\9:O\ $+P=/ON9?"%Y>QW=II]U
M97/V@._S1_(&^4?&/[3_ .V1_P $U/B;HWA+]H#]HL>/?CY\/O\ @DM^S5X9
M\1Z[XO;QA\2OAGJ'QV\<?M=>*?" \8:AX;37_"^FZSXKM_"QT_PM=?$GQ#JV
M@6=\VEQZGXDUB2SNI8)?Z];B+P5>:QIOB.]TS2+SQ%H]M?66D:_<Z+;3:UI=
MEJ>P:A8Z=JTML^H6%I?K'$M]!:7$,5UY,1G1PNVL+Q%X3^%/C!M2E\7>#?!G
MBJ76-*AT#5F\2>#M$UUM5\/VMT;^VT'4Y-3TJY>]T6+4B=2CTNX\RUAOG>XB
M19?G+Y8]E]P<TG9-NT;J*OLGNEVO=WM:Y_)A\*O^"\?[5_Q,\)_L^:?XJ^)'
M['W[,^I:CH/[5&N_$#XU_&_PWXKU+X8?%SQ/^SW\>].^%FA?!OP)HW@?Q)=R
M:3XW\2>%-5@\7:Q%X;UCQ%J!39<^']-O;$HDVI\8_P#@LM^V7X[_ &D_VO\
M]FNS\"^!/#?PJ\/>$OVF/A-I^G:3=S^$_C)X<L_"/[*5[\4_#G[2GA;6M1\5
MV'C.]LM1\1WOV>+2HO!-OING^'DMKJSUQ_$45Q!'_4Y_PJSX#&QTO26^%?PK
M;1]"URX\3Z'I3?#7PL]CI'B:Z6W6Y\1Z7:#14M=.UNX6"-+C5+."+4)E@MQ)
M=MY8"[%YX)^$&H>)=0\9W_@CP3>^+]7T6;P[K'BJY\%:%/XDU?0+B VL^A:G
MKLFEMJVH:'+9LUI+I%Y>36$]N[0SPR1G:5RQ_EC]R]>PKO[C^-G]G+_@M_\
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M)'_P%?Y"N^YL>4GITZ?,W'ZTOEI@C'!ZY)/3W)R/PZ]ZQO\ A(])_P"?AO\
MOS+_ /$U;M-6L;UVCMY2[HNXJ49"1STW 9QCGZCUH48K:,5Z)+]!;[GYB_\
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M/NI_USC_ /1:T +D^I_,T9/J?S-)10 N3ZG\S1D^I_,TE(S!06()502Q )
M!.21T!VXR2 "1N(!S0 [)]3^9IKM*$)A"22@,4CD;".0#\KXR^T]#Y:22*,N
ML,N/*D^>O"7[3'@?QE^TC\1_V8=(T;QO;^,_A?X'T#QOX@\1ZKX9U+1?!=_#
MKVN2Z+'I_A76]1MX8_%=QIES&HUJ]T9;S1K4NEI+=_:(V ^??&/_  40\!>
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M/!&K^*]-N_"Q\2+=>%]2NK/3=6U[PA:66E1V,&LRVUM9:NVCJ=.NM5TV&.4
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M_/*/_OA?\*/)B_YY1_\ ?"_X4 >-\_W&_P#'O_C='/\ <;_Q[_XW7LGDQ?\
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M@#X?\0?!"[O_ (O>(OC9X<\=ZOX5\:Z[\'=(^#UCY.A:;K6FZ'I^D^,CXO\
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M0=AVH\F+_GE'_P!\+_A0!XWS_<;_ ,>_^-T<_P!QO_'O_C=>R>3%_P \H_\
MOA?\*/)B_P">4?\ WPO^% 'C?/\ <;_Q[^808_#GWKRCXZ_"?3_CQ\'OB)\'
M-8U?4?#FF?$?P[<^&]0UW28H)M4T^WN)K><W%K#>!+.>X_T9(2+@JLB.WF,W
M*/\ 7?DQ?\\H_P#OA?\ "CRHATCC_P"^%_PH ^%OBS\!;KXR_#CQM\,/%7Q
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MBPMY)_WPINU> 1D#IDD].G4T ?B;\-_^"/5KX?\ BI\&OB)\0_BSX(\?:7\
MK7_A%? OA>W^!>F:/'XL\$6MAX_CTS5/BW>WGC/6[7QI\68=2\;Q7MSX[CTG
M3K&:'2[F&+PW#/K5S>6WKW[._P"RI\;_ (!_$;P2- U;PI?^#/A;\$/V:_V3
MSK_B&VGL]0^(_P ,/A79>-O$WCSQYIF@V&KWL7A?7I/%OB[3=!\+:;J5WK"P
MZ=I>L,#]EDMIW_5:F"-!R%P<DYR<Y/J<Y..@!X4 !<  4 ?GWKO[!>A:Y^T/
MKG[10\5Z38>)]:_:$^"OQP8IX'LKC6K73_A!\&]?^$LG@4>*&U>.^>R\0C7[
MC6'U!8$M]/1)-/\ ['O3<&]BP-9_9*\4>*M8_;,\$ZE;^%4\,_'+X@^!_BQ\
M-OB/X@T2P\67/@[7=2\%Z5X#\=PV&@W;PS6/C+PC9^&;G4/!>O)*EK$?%6FL
MLDATK4;4?I,!@8].*C,4;')13\P?I_$I)#$="026Y_BYZ@&@#\=]%_X)^?$[
MX=7WAGP'HOQ/U+Q]\)[_ /:J^$GQ=L;/69-3MD^#GPV^"NI:WXUTO0].BUCQ
M'K<=]XF\1ZHGAOP%'<^$]-\+Z6FDV,6M:GI,VHO?74_[$1,7C#$8+$G&0>I/
M<$CZ8)P,<FE,:'^$=<\9&23GG&,\^N:<JJ@"J, =!V'L/0>@' [4 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%%  3@$\G S@=3]/>LF/6M
M/EOY]*2]L9-4MH(;JXTV*]MI-1@M+@E+>ZFL5D-W%;7,BE+::2%8Y=K88$8K
M2E)$;D<D*3U(Z>X#'\@2>E?BCXR^ 'BWQ_\ \%&XO$>@_"7XR^ ? =YX!^/O
M@WXZ_$"&X?P]X?\ &6C_ ! \ >#M-\&?$/P1\7]*\3W>JZKK45_H%EX+T?X1
MP:18'P$T?B3QQLM;BZM[J^ /V@&JV1M6OQ=6AL4C:=[U;J$V<<$8<RSO=AC;
M+%#L999#*$C=6#LJ@-39=9TR!)Y)KZQBCM;7[?<O)>6T:VVG[I%_M"X+R*L%
M@##.3=R%8"L,A5SM./QNG\"^-/@S_P $F?AK\._%ND>*O"%KX'UOX/:!\:=*
MU.XN[_Q;I'P''[2GA>/XN-=:A%=7U_=Y^$,^MWFKZE)=S7C>'FU*]DE$^VOA
M;XX?LK_\%&?$_P 4_P!KOQ9XK\%6UYX=^+_AW]G::]\3?![QEJ?Q0TNX^#'P
MU_:6UG5I_A7\,?A#KNA^"["[\16'P:D2^\1>%CJSKXHOS*QU#73K<.DJ ?TZ
M/X@TB/36UJ74M.CT58([K^V)-0M$TO[+, T5W_:#2BS^RR(5=+@3F-PP"DL5
M4V[74K.\FEAMKFVG:!+=Y1!<P7#1B[@%S;>8L+N8Q/;$3Q%]HEB*RQ%XF5S^
M*F@^&/%US^P)H/P;^*G[+_QEU2ZT:]UW6=&TCPQ\-;&]U/1O".L?$SQU:_#3
MQSK7PB/C&STO5/&VE:3<>'_&GCK]G^SUR>ST*+4UBMK06FGG3;3;_P""=WAG
MXK?#[XH_"_X<^-[#5],UKPC^P#X TSXYZ=J5]<:A=VOCRP^,GBNQ^"%WXFE>
MYO8=/\;ZY\,8O&FH:WH*W][-H5FNEZ'YK:7I6C2S@'[/T444 %%%% !1110
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MW?A;2+"]U#3&TZV+Z=J\D>IZXOWE\8/A9\8OC_\ \$SX?A)XU^$'CSPC\?/
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M &O3/^N3IZ]>E &A16?_ &KIG7[=:X]?.3_&C^UM,_Y_[7_O\G^- &A16?\
MVMIG3[?:Y'4><G'ZT?VMIF<?;[7/3'G)G/IUH T**S_[5TW_ )_K7_O\G^-'
M]K:81D7]J1C.?.3&!U/7H/6@#0HK/_M;3/\ G_M?^_R?XT?VMIG_ #_VO_?Y
M/\: -"BL_P#M;3/^?^U_[_)_C1_:VF?\_P#:_P#?Y/\ &@#0HK/_ +6TS_G_
M +7_ +_)_C1_:VF?\_\ :_\ ?Y/\: -"BL_^UM,_Y_[7_O\ )_C1_:VF?\_]
MK_W^3_&@#0HK/_M;3/\ G_M?^_R?XT?VMIG_ #_VO_?Y/\: -"BL_P#M;3/^
M?^U_[_)_C1_:VF?\_P#:_P#?Y/\ &@#0HK/_ +5TS_G_ +7_ +_)_C3FU*P5
M48WD"K)GRVWJ5;:2#@]."".3U!H O45G_P!K:9_S_P!K_P!_D_QH_M;3/^?^
MU_[_ "?XT :%%9_]K:9_S_VO_?Y/\:/[6TS_ )_[7_O\G^- %R7_ %;GT!/!
MQTY/.5Q]<@#J3BOP)_;X_;__ &EOV1_BQJ*>#-5\'?$GX>>/]-\:^ O NB:1
MX6T*^@\#?&#2;[X96&@>$[K5;?Q ^NW_ ,2[:S\5>(_&?B[3?%]AH?P]M_#4
MGAU8=5%]+/;R?O2VJ:6P*M?6I# @@S)R#P1UKPS5?V=_V8M=\5>,_'.M_!SX
M0:QXS^(OAJ;P=X\\4:IX,\,WVN>+_"MS!%:W>@>(M2NK"6YU73+RUM[6WO;:
M[DE6]AL[&.Z\T65KY(!\,:!^U5\49_V,/%'B+Q->0:O\<;+]H?0/V1=5E\5>
M#="TZ'P]\0O''QD\%_!Z.Y\6Z#X<O=<\&ZTOAA/'<&L:B_A^\D\/Z]]EAL8(
MHIY)8&\C\*_M2?M077Q6^+WPO\9?$CP[\,+SQ?>?%/\ X9/>3P_\(/%?@G4O
M _PP^+NF?#I18:WH?BB*4?%S4K*\TG2]'\'^/)-(TBX\1Z^]I.L$FF36*_I?
MK_[-OP$U/X$:K^SCX=\*^'?AU\*[^V@.GZ#\.;73_"47AS5].UVQ\5:3XE\/
M#2XK>'3_ !'HWBC3=/\ $EGJ>QKP:O9VU](\LB<Q/^RW^RE<S_$34-4^"'P6
MU'5_C!:067Q;U>Z^'_A);WXD>3/_ &@S^+I$TX#5)I=38ZO(L^XC4G6^_P"/
MJ..90#X8\+_M9?%[Q=_P3*N/VC?%7Q&@^%7QQ\")X_M_'D>D>!O"_B/5I?%O
MP]^)/BKX:VWP]N?".I:A=>';?Q/X@UK3-"\/:S=:%>7^B6GBJXOUT"XO-/6W
M=O</V9/'_P >?#OQ@\)_ S]H[5?"WB[XG^-/V3/"GQU\7>)?"_A+3_",=AX^
M\/\ C0>!?'/A^XMM/1A>Z?';>)?!T.B27<QGMY]%\0?94CLKI+:W^H;'X'_L
M[:9HMGX;T_X6_"RS\.Z?H6@>&+/0;?PGX=BT:W\/>%M:E\1^&M'CTM;(6(L=
M"\0SS:YI4/D8LM8FEU* I>223/:TCX<>"M,^,7B[XWOJ%SJ'C7Q9X-\*?#M)
MKZ[5K+P]X+\)WVM:W;Z-H-L%40PZIXBU_4M;UJZE+W%[=/81R2"#3K2- #VF
MBL_^UM,_Y_[7_O\ )_C1_:VF?\_]K_W^3_&@#0HK/_M;3/\ G_M?^_R?XT?V
MMIG_ #_VO_?Y/\: -"BJ":G8.Q5+RV<X)VK*I; ZG )/''3L>:3^U=.&0U[;
M@@]&D53]0"0<>E &A16?_:VF?\_]K_W^3_&C^UM,_P"?^U_[_)_C0!H45G_V
MMIG_ #_VO_?Y/\:/[6TS_G_M?^_R?XT ?'7[?'Q'\>?"+]F[Q[\3/AQ\0;SP
M%XL\(0V4OA^*Q\&Z#XUN/'/BS7[JV\+>!?AU#I_B%DM+*?QCXVUO0-(74XF$
MMHDYDR@4M7SAX*\0_MI67[5W[/GP2\3?M#>%O&C:+\#;#XN_M;:-I_PC\,:3
MX=LB;-?!NG:7X,UVUNO[7M-1\>?$^VU[5=.6=4;3/"OAV^=H6%[;J/TO\3:'
MX!\:65OIGB[3/#OB;3K/6M$\1VFGZ[:V6J65KX@\-:I9ZWX>UJWM;U)H8M4T
M36-/L=4TJ^1!<6%_:075M)%-&KT6N@^ K/Q+JOC*RTGPU;>+]<T[3='UKQ/!
M9V,7B#5M(T>6ZFTG2M2UA8A?WVFZ9/?7DUA87,\EK:275P\$2&:3< ?CY^T;
M^U-^TX/%7Q9O?@!:Z)H^F>!?VC=1^$/B>[M;/X8#X@0_#/X)_ "'XJ_$'7]+
M@^(^H:/;^)[_ %CQ?X[L+72]'CEOSHOA/PM>:E9"R_M^_F&A^R9^VG\7?BM^
MTIH-K\2/%5]%\"_C7IWC@_LQ)9>'/AC_ &;XPL/ASX \ ^+/$FK_ !"O?#^N
MZAXX^'WC>*/Q!J.K2>&_$-C9Z3;I+%IV4N'TT77WGXD_9*_9K\:^(OB1JWQ"
M\">$/B5I/Q5\2>$?'/B7P9X^TK1_%OA&W^(7@_PPG@N+QWHNCZM97,.E^)==
M\(6.A>'_ !#>6K11ZII_AW3EN8W!N1<=0?V:_P!E?_A)O%?C-?@M\'(_%GCK
M0+;PKXQ\10>"O#,&K^)?#=F=.-OHNK7T-BD]WIR?V/HX:W=RDR:1I:3>8FGV
MBP@'X^R?\%0_&/Q1^+G[>6C>"KGP;!X%_9@_9VA^.WPL\%>+_!^IP>,O$LGP
M.^('B"3XMZKXQ7Q%I-G!I=IXWTWPW'IWP\@@D^W:/#<V7BJW9;F0+#^_.@ZM
M!KVAZ-KMJDT=MK6DZ=JUO'<(4N$@U&SAO(4G0@%)DCF595(!5PP(&,#Q/XR_
M!'X3_'#PWXE\-^+;>UA3QIHV@^$?%^M:,;:R\2>(? .B^)4\3/\ #W4->CB&
MIOX-U>]:^@U?1TNDM[BRU;5XBB#4+EV]NBU/2HHTB2\M(TB58TC65 J(BA41
M0<$*J@*O X /0T :E%9_]K:9_P _]K_W^3_&C^UM,_Y_[7_O\G^- &A16?\
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MW,,S 9*QNKX [G&<?G0!\#?M)?'+Q;\*+SX-^!?AEX/T#QK\7?C]\1;OX?\
MP\T_QEK5_P"'? FE2Z)X7UGQIXE\3>,M6TFSO=8&F:)H.BS-:Z7H\$^HZS?W
M45E;BT+&Y/D&J?MU:+\(DT/PG^TYX&U3P-\4XH(=4^(MI\)EF^*GPR^&O@W5
M_'\/PZ\%?$_Q=XMLC87OA?P9X_\ $]RFFZ39ZU8W'B/36%X=5TZ*VTN]O5^F
MOC7\"_ /Q[T#1=!\=#Q)87'A/Q/8^-/!7BWP1XDO_!WCKP/XNTR.XM[77_"?
MBC3=UWI-X]I=7-C?((Y;?4;"XEL[R&6$@#YGE_X)I?LJS3>'9WTKXEJ^E0FV
M\5%?BGXG9OC+;+XZ3XG6\'QQDG>9_B-':?$!#XGM([XV<=M=RSVT$<5A/+:N
M <IX>_X*F?LT>)8(DT?PW\<[G7=?NM"M/AIX1E^$^I1>*_C;_;_BGQ%X/M)O
MA5IKW\"ZOIEGK7A'Q&+Z]GDL(['3-)&IS/)%=6Z26O$/_!4C]E?PK%K>H^(H
M?B]I7AO0+75[75O%][\+/$%KX?M?'7AOP7_PL'7?A'->3RQ70^+&D>%OM%QJ
M7AE((8/MUM<:9'J,U]$Z5WNJ_P#!/7]FK4=*\&:=9Z;\0/"U_P##CP[HGAKX
M=^+?"'Q%US0O&?@2T\.^-]:^(.DW_A;Q#&)Y].UF#Q#XBUQ)M1:*=[O1=2GT
M:=&M!'L\ \>?L8?\$[/!WQ/^'_PG^(VN^,-+\5_M"/XMM/AK\(M<^*WC+4-!
M\9^-=+^';>'O&_Q%TW2KG[990?$Z;P&MQ!<>+M8OX[B\\R_.GVLNJW0! -;5
M?^"K/P..F>+;?2_!GQ>\,^,_"UYJ>ASZ5\5?AKKGA;1YO$WAJ;PE<^*?!\=_
M83ZC++XJTWPOXW\/ZW#:00M8S1ZI9Q-(TJ7L-4-"_P""M_[/-GX!^!GC'XO^
M$_B7\*=3^-WAEO$,&E:CH%KJMCX:AN?$?BSP[H\&I:E'JMM/JDVO7W@Z_N[>
M71=.U&.PAO;!-4&GI=6@D^@_&W[%/[*?C.[U[5O%MK</*/'OB?X@>))W^),V
MF0Z=XQ\<Z9X*T'7YM78W,4.DQ:G#X"\,VEMIMRUO##>V\\EN4N-0FW_.Z?\
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MG^(#:O\ :$M(XY(V/36__!5S]F'3?"&F^+?&3>/K;26\+O>ZIXX\-^ ];O\
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MCGT[3X-/O]7UDZFUG<7]Q%'FZ+X<_8__ &;_ (D_#6YM]>7P[XQN+'QGX&\
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M/R%+10 F!Z#\A1@>@_(4M% "8'H/R%&!Z#\A2T4 )@>@_(5<F_U-E_UPG_\
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MM0TF_O+/PYJ=[!%K\NF0W$=Q']-LK*S*RE64E6!*GE3@G*EEP2,C#'@C)S0
MW ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* +EY]^+_ *\[7_TGMJI8'H/R%7;S
M[\/_ %YVO_I/;53H 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:#QCT+ =.O(R
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M <LW4_4_SI*5NI^I_G24 %?E%^U3_P $_?C)^T5\:O%G[0>B?''_ (5[XR\
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M* .-_P"$2B_Y_)/^_'_V5'_")1?\_DG_ 'X_^RKLJ* .-_X1*+_G\D_[\?\
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M:-TX@!X<8/4^E1+X2CP,WLG0#_4#@ 8 Z]@ *[.B@#C?^$2B_P"?R3_OQ_\
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MRV.KV6HPO;WUI>PF51<1WL#O%<!B6F5B&8G!K\@_@%^T;X6U']N/XWZ1X?\
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MXAXFU0[L& E<D@6^2  &9\ DA54AF<X4@':6*L ?\)+J?K;X'4F$8 ')).<
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MWCWK^&/"UUJU_H>@VVYS#8Z797^NZO?_ &6RB@CN+R^EGN1,Z0F+LU4* !G
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M1_#7A'Q';_#7PC!K_ACPY(9]_A[P[K$6B+J&B:%_I=V?[)TVXMK ?:KG%O\
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MS[\/_7G:_P#I/;53K0O(I3)%B*3_ (];=/\ 5O\ >6" ,.G4%6!^AJIY$_\
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M^!/$'A_4X_%DT_C30/%WAG5O!'A^+P58VFI:\WB?Q/::L^FZ&8+.^MWC^UR
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M=7\/S^+KR+0[&Q752ZF[.;XE_80_:1N/A;XI7X@^./ /Q3^)EW^RMX<_8?\
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MK2]4TRSBL++4O!/B[PEHGC;P?#-;0#R8]7T*SU2Y\/Z@(]@N(=-LK]U$EZP
M!]14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "'GC\_IWK\7O^"H7PJ^(/Q!\;>$9-/^%7Q-^*VCW7P'^)_A/X,M\/+76K^T
M^&'[5VJ>+/ VH^ /B5XHDT>]L_\ A%K33?#>F:W%I_CG5/-TW13%?VLRE]15
M)/VBICQJY!;/ (X.,@D9!QR00"I&<%68$<T ?@Q^V5X"^+GQ3^-_A'5K+X3?
M&SQCXAL/AE\./ 'P"\;:/X=\1V'A_P"$O[1GP_\ VBGOOC#\2]9U"&ZL;/PI
MX?\ &7PXBT2^T3QUJ<::;XQ\&Z3?:-IOG"]>UFJ?'_\ 8Y^(VJ^$/^"F&D^&
MK+]H77[GQW\5/V;?C!\,)[?Q_P"*VU#XD>)_#^B:)/XFT'0KN/5()-0^&^@:
MJ9?.^'UM]C\/PG2;:UE@N8XG1OM+]JWXX_'GX;_'KX&?#WX-^*OAKKEYX\U3
MPW:P_ 2Y\,7NK_$+Q=X:?Q:UG\5_B)XF\6G6;'3_ (8_"_X?>"FMKC1-;2QO
M+SQ!XX_XI\I="]M+6#Y]_:]_;I_:+^ 7[4&@>#/!OA33O$?PWO\ 5_@CX.\'
M^&(O!E]K-E\4=4^,D?Q#L?$&L^(?C!9ZRFF?"R[^'FJ^&_"T>@>']3TV,^*M
M.U'6KV>>ZLU6]T( [_\ X**V7Q2U_7?@UX#\!75_8WOBSX3_ +64'P\:PU%M
M)-W^TI;? C58O@_;3WWFQ6T6LQ6E]XSN_"32R02P^(ECNK:42QAXODG2_AQ\
M8[;]C7]MOX>_LR?!SXW?!>W^-&CV47[.7@3Q7X1\4:+K/A[4_#7PR\'V?QIO
M+_2]5U.._P##'_"PM<L_$J>'K:ZU73(?'.M"\FTN[B;5?MDGM/[+/[=/Q$^(
M'@#]K/Q'\?O"EOXLU#]E7X7>"_CS:W\GPIO?AC);>(=:^'GC/Q;K'P_T/3=6
MU'7SJD?@R]\-W&D>&OB3IEV&U_1-6&H0R207/GS>_>!/CU^TRO[1G[)?PV^(
MMQ\+;KX9_&;]EWQK\3_$6LZ%;ZA#XSOOBIX<L/A]K-\L881Z#H?@;0[;Q=+I
MNEBR>_U'6FA74M2GM4(LZ /QF\6_LV?M-:I\./!=A\,?A)\1;>6U\2?%'P?\
M 9O$7P8^('@V'P^NJ?$+X;^*-&^.X\$Z)XGAM/V>/B;''9^*M$T^\\6VUCX*
MU'P?I5SJ=K;VFHZ[)8ZC]B_M/?LN?'"+4/VZH_"%E\8O$.E?&CQK^PKXHUCQ
ME-'KOQ58Z5X3U+Q//\77\#_#%[Z.'QUX4\+6UIH5IJ/P7TE--TG6K'5FC)D:
MWD67V3P!^W1\?/'O[:GQA^$L6D:5H_PUT?XG_%[]G[X0:3XC\*Q6.@^._B5\
M)_AKX/\ ';WLWQ(TG7KWQ5ISZJ?$%[J5XUUX+_X1AO#\-KINCW4^N@RWOI/[
M+G[6OQN\:0?L8K\;6\%7^L_M'1_M4>!O&%IX$TJ[T[1?#OQ1^!'C?Q1=:-JO
MAFYO;BYU2?PG?^"_"6N:'/#J'[Z;4(=&UB26*2]N[9P#R+_@G]H'Q1^'GQ*_
M9[^'GBNR\1:?KVF?L5^.X/C1IWB,W5OJ!@T7X\VT'[.^M>(-%O9KN?PUXAU7
MPQJ7CS^SO"%S?7-WX7\/NNA"22UT^,1?MNIRH//(!YZ\C.3[^O YK+AT71HK
M_4-5@TRQAU35([.WU74HK2"._P!1ATP3#3H;V\5!<W4%A]HN#90S2O%:^?-Y
M*)YLF[6 P,#H.!0 4444 %%%% !1110!Y;\5KGXJ6'A=KOX.:+X(U[QJNL:2
ML.F_$'6=7T#P]+I#WBKK=P;_ $2QU&]&I6MBQDTZ VK0W$\0BG:-&+C\:OV1
M/ OQ:^&7[1>K^.O%/P;^,/AWQC9^'OC9X9_:8\<2>'/$NJ^'OC-X[^(WQX\.
MWWP$UCP7<23RV?C?1? W@Z;5[VZU_1K..U\$>$VNM/U&XM5MC9-^\GEJ22=Q
MW=?F."/3'3 ['&?>O-/C%JFOZ#\,_&.J>%/$_@OP;XEM]'E30O%/Q($\G@;0
M=3N98;.SU'Q%%;WNG2S6=O-.C);#4+-+R[\BVGN(X)I30!_/A\.OV4/BIXQ^
M#'[6/@+4/AO^T1\-=<UW]CCQYX(^->J6>L>+_ VK?M ?M:VOB_QEK^E^(/!'
MB*WU?^T/&%AK>A-;:9>>*/#<]EI^O:!X@M/"LUR(+1(K;]"O@]\"_'?AG]KC
M]GCXNW^F?$MK"Y_8"MOAKXZ_MO7M7O/ ?@WQGHU[\+'L?"UCX<N;IM$\.^)-
M3>RUN^U26SA:_P!5N+.Z>]NFBMXT7SSP7^VM\>[G]C7XA^*O%LGAK1_VAO!W
M[4=G^RQ)J/BGPI#I-OX5/B;XS>"_AIH7Q$^(?@K1/$>I^'H=4T?PYXQMO%]_
MH^A>)AX9EE&FV<]Y;+=7:CYAO?\ @IC^U;X<^+?@7X;SVO@OQCX:^&/Q3N?A
M9^T1\3M!\#I:>%M1MY/VG?$WP'T;QWXB$WB@W7P^TGQ'X>T6VO\ 0+'P';^.
M9+CXAKJ6E:M_9.A+'Y0!C?M"^"/&?Q/^(7QZE\;?"[XE_&:#2?VA_P!J/P3K
M'@KX>:=KFOZ]H'B76_@-\(K7]ACQC=Z-H]Y97=CX/\/Z5+XGU/2/%<V[2?!O
MC#Q'J^N&XM;BXU"8?67[0_[.M[^U5\+_ -C3X/?$?X0>(?$OB>Q^(?@_P/\
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MR)\=?!'Q5T#X^?L]_&Z'Q3\38_!/C_X9^);;]JB?7_&>B#P5XX\2:5XPL/\
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MASXC77@CQ9J<_A+0[SQI=6'PYLO%/CK0[5])\+Z3K?Q 6\L_#%CK5[%;W_B
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MOB1\0+[XS2?%7PSXIM_"UTFM6?P_LS\5;:Z\ 7.DW$VM'4?#ZS>(+3R[Q#$
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M=)_X0WXF_#OXG?\ "I?#>L^.)+KQ3JEMXK3X?75A-JWBJ[#W.I^))K93:Z=
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MTM0_Y_Y_^^G_ /BJH44 7_[2U#_G_G_[Z?\ ^*H_M+4/^?\ G_[Z?_XJJ%%
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M\%<N)& 5(92J,&4@J5DSY;JP)5XY.&1XV=61@_M0!H?VEJ'_ #_S_P#?3_\
MQ5']I:A_S_S_ /?3_P#Q54** +_]I:A_S_S_ /?3_P#Q5']I:A_S_P __?3_
M /Q54** -BUU"_9Y,WTYQ!,W)8XPAYY;M[<^E5%U'4.OV^XY"D9:3D%%.1\W
M0G)_.DLOOS?]>MQ_Z+-4Q]U/^N<?_HM: +_]I:A_S_S_ /?3_P#Q5']I:A_S
M_P __?3_ /Q54** +_\ :6H?\_\ /_WT_P#\52'4+YA@WTQ&",$N1@C!'+="
M.#ZCBJ-% %[^T+[_ )_IN_=^XP?XNX !]1P:!J%^.E],/H7'_LU9Y>/S%A$L
M9N)$:1+;S(Q<.BNL>](2^^1-[JI* L&Q&$,DD(D$EAD421RQS1>:T33021S1
M!XY7CE3?&[;)T(2-K:41S+<.(" Q7< :']H7QSF^F.>O+\XSC/S<XR?S-(+^
M]'2]E'TW#^';V;^[\O\ N\=*SDEBD=8XY[::0Q>=L@N(I9#"&97G6%6\UK96
M1AYZ+(,C!4-\M/1HY%22*:&>.5-T$EO(DT5PP)5DBF1FCSN " DD_,6"$ ,
M7?MUX>MY(>0?XNH  /WNH  !ZX '84X:A?@ "^F '0 O@<8X^;CCCCMQ6:LL
M4C,D<T$LB*':.*>*1Q&WF!9S&K&00,\4D*L4W_: D&SS)HU,G'.#D9.#Z@$@
M'OC..0>5/RG!!% %_P#M+4/^?^?_ +Z?_P"*H_M+4/\ G_G_ .^G_P#BJH44
M 7_[2U#_ )_Y_P#OI_\ XJC^T=0_Y_Y_^^G_ /BZH44 :UQJ&H*\7^G7"YM;
M<XW-C)A4EC\W)8LISUY]:@_M+4/^?^?_ +Z?_P"*IEY]^'_KSM?_ $GMJIT
M7_[2U#_G_G_[Z?\ ^*H_M+4/^?\ G_[Z?_XJJ%% %_\ M+4/^?\ G_[Z?_XJ
MD^WWV[=]MFW<?-E]W&,<[L\8&.>,#TJC4<LJ0HTLKI'&@+.\DB1(J@9):65D
MB3T!D=5)PN[<R@@&D;^^.<WLQSUR7.>".?F]"1]"1WI/M][_ ,_LO4G^+J<Y
M/WNIR<GOD^M9\<T$L<4T4\$L4W$3PSPS),^&)2WDCD9+IPL<LHC@9YG@CDE2
M(K')L26>WA1I);FWA5(I)F\^XAM_W<3HLLX,KJ!;PK+ \DS[5/G*@._*T :7
MV^^&<7LPR<GE^3G.3\W)R <]<\TGVZ]_Y_)><Y^]SD[C_%W;D^IYZUER75O'
M+' UQ;">49BMFN8$N9B%#L+>W=UGG)0AU$<?&'B?9+'(BI)>6<4JP2WEI#,R
M[O)GN;>*<+DYD,#RK((4569Y2!A2C*K*VX &L+^^!R+V8'CD%P>.G\7;MZ4O
M]I:A_P _\_\ WT__ ,56>#V.5.!\K<-GHXQW\ML!B,K\RE2P;(6@"_\ VEJ'
M_/\ S_\ ?3__ !5']I:A_P _\_\ WT__ ,55"B@"_P#VEJ'_ #_S_P#?3_\
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M9BQ ].2<?2F4 +N.,9.W.0N?E4\8VK]U=N 5"@!6RRX8DE#EOO$MPP&XDXW
MAL9)P6W')')."3D#!10 @  "@ *  % &W:,$+M^Z4&.$(VC+8'S-E B@$ $
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M6RZ/:V&G6^FR7US; '0_M1W.E_&/]KOX "S^"O[37A/2WA\#^-?&_P"T=)X
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MAVI]FU6\TXVEUJ<"J5CO9ID+OM5C]&5\B?LT?'V[^*_B_P",/@:\O++7=/\
M VE_ [X@_#OQ;I^C-X<77OA1\=_A9I?C/PI::GX?8NVCZUH5]9:W:W%O,ZSS
MV-UI\SPQLKQQ?7= !1110 5U7A+_ (_;K_KU7_T<M<K75>$O^/VZ_P"O5?\
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M$W_BW\)_@!\8/V?+_P <?#73?!7Q>^%WAGX(:AIOA)_B3J&F:/X?\,_#/6/
M$WQ:T]/%%_=S)\4_'FIR:%K/C70K::W\("SM;L6EU/<!I%]1MOV,_C=XD_9]
M_; \*_$?QM\+(OCA^U)X6\'^%XM3\'6'B:'X7>%+?X9?#/PG\,?!4DD.I_\
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M'XQ:%X\\(0?\(UX<_94T[XB>*?-\=6_CZR/[,WA#6_">L^%?A[IEO<KX3NO
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MWA3X;?"WP;\+K76K6RPC6>G^*M2\-7]]I$+Q0746BVFD-<Q1K,B@ ^NJ***
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M\7]+UG5/AYKEQX4UNVUF/3_$,7A^ZL]:MH)1"3'J>FM=7&F3QB;^S[YD-I(
M?,/A/XD_\$[_  'XI@\#Z#X%T;X>>)/VKM(M+7Q-H&I_"'QKX=.L:3X^U?Q'
MHOAKPW\5_P"U]'$7P]B^)>OVWBJW\)>'_%,NA+XMOUU^32[.2>67S_1_VEO&
M?[,_A2'X=^"/'GB'6?"OB+X'^,?A-\2OAQHOP_\ #&M>*_$&E:U'J6J>#/!?
MA'1M \.Z;K,NI3_$/PZOC;PHOA1+2>\U#PE_PDU_9^5;Z3Y\?R!\.O\ @FC\
M=O"-QH>A7?Q;\!:KX!\<^(_@7XW^-=C/:>-M1\2^$M1_9Y^*_COXE^ / 7P.
MU#5KN6,?#^.Q\:6_A&.3QE?C4M$LO#$,FEH[W4ENGK7Q]^!/[7'B#XJ?M26W
M[-_BKPC\,[_]H;1?@#JT?Q>\8'7UM_#WA/X?VNN^"?BK\,_"&I^&X;O5_"/C
MOQ!H>HV-WX7\4VMI/)I$.NZ]J^EJ=2M@% ,SP?9?\$M/B;J>F_ ?X>_![P=X
MXA^+UGX3^*]U8>$?A9XVU+PFEOKMKJT7A/5O%/C&QM/L'@,1V<6NV$&@WU_H
M5MIELVI:6='M8VNK<]C\5]9_X)N:CXZUWX _$_P3X(UWQ'X)M8?$6H^&!\._
M%&H^'=/O? GPTL;F/P?I>MZ)9+X;E\5Z)\);+2=2G^&FDZG#J4O@ZUAFU'1+
MZW!:O+/"O_!.WXA^$OBW\%OB'X,T/]G#X1K\-S\-]2U/5?AM%\4H_'4Z?#+P
MKKGANS^$$FN:C>KI_B[X7^,I=1L+OQ1/XEL8?$$EK#J<B6E]JDEO<+U>J?LF
M?';1?BEXB^+=_JO@'QCX%TWXB>*?VLXOAOX/TKQ'-X]\2?M!>)?V>H?@]JOP
M\TFXU.5-#N?A=/JG]H:MH%[=LFN?9KRTTS4;5VLKN= #[F^#OPW\ ^%IO'?Q
M.\$ZBVOO\?M5\+^/Y_$ DM6T]_#&E>"-#\+?#WPUX9CLD2UM_"/AGPC864.B
M0+YL@:^NIYGCN;B=&]JKP3]E;X::W\&?V9?@%\)O$MT+OQ%\/OA/X.\-:](L
MQGC36+/2XCJ5K;2L6D-G87<DMC;*YPBP-Y686C+>]T %%%% !75>$O\ C]NO
M^O5?_1RURM=5X2_X_;K_ *]5_P#1RT <LW4_4_SI*[<^%%YS>$99C_J0_4@]
M21CZ4G_")I_S^M_X##_XJ@#B:_$S]MC4OVQ-0_:U\,_&SX(_#;QKKOPF_8/B
M^'_B+5=+L?%.K^&S\9+_ .(VH13_ !MTGPSX&M],NK?XQG1O@[)<^']$M3=6
M\6@^+KIKJW8WL+8_>G_A$T_Y_6_\!A_\54@\,,-F-1F'E_<Q"1L^8/\ )A_E
M^<!N,?, W49H _ET\ ?L9_MBWOPF^)W[0OPVU^3X6?$,WW[9]_X=TKP]?_&#
M3/V@?C7IOCCXQ>/H/!^E>.['QQXLD\!>'WTGP3';:S\.V\/^$[+4+2YF\+G3
M]3T^W:[9^'_:.\"27OA+6H_V-_AU^T%X3_9GBTC]FZU^.'A?XB>$?VA=?TC5
M?BW8?&JRN+_4X_ =SKVG?%+Q)J6@?#*/78OC7K/PYUBSTCQ7!<Z"UU?WEQ:K
M='^L%O"VY_,:_D9P0P=K?+A@, [B^<@< YR!Q3_^$:D,BRG4Y_-1&C23RF\Q
M$8 ,BOYFY48 !E! ( !!P* /Q#A\:_$/X0_\$U_BQXN_93T&RN?BGX<U]UT&
MT\%? _XQ^#=/MY]3\7>']/UWQ'I/PR^.NJ>//'<AT3PK?ZGJ5WJ"IXGTZ.:P
MFN=-T34)8!82>>^"M6_;;\:?M\?L<?$7QAX4^*'B+]G"T\!?%/PEHGB_^WM"
M\%Z3J]IK/P>2_P!:^+7QO^$EKI6B7^B_$2X\8I#HGA31]7TZP2VTJU1-"LX]
M5U&\1?W^;PW(\HF?4YWF&W$KQ,T@V%F3#M(6^5G<KSP68C!8Y:?"Y)).H2DM
MC<3!DMM)*Y)?G:68C/0L2.2: /P:\7Z/I]K^U/\ &;4?C5\-/VI_'GQZE_:&
M\":I^RCXB^#M_P"/M)\&Z9\!+70/"*:;8:)XCM+^S^%GA_P_I6L0>*S\;M \
M56HU/Q&UPUJZ7\=_I:V/SO\ !_\ :9_X*<_%_P"+!\!W.J_$CX>>#?%?Q.^&
M]U>^-]3_ &>M(75OASX;GNOC)_PL;P;%#JO@G1?"UE;VUKX8^'4$T_VCQRFA
M2ZS:W5KXPU";6;BWM_Z;AX894:(:C*(WY>,0$(W&WYE#[3\O'(/''2E;PU(P
M"MJ<[* %"M$Q 5>%4 R$ *. .@[4 ?RV^+?BY_P5#\ >&?!?Q!34_%FO^,/B
M)\*_A%=?%CXC7WP1BTS5_@YI&N_&/XY0:CX3\-^$?#/A#Q797,VB6FC> H]4
MN;_P+XH\3Q67C">]O84L-2M)=.W?%_[0G_!5/3/@MXL^+^I^+O%V@:[I7Q ^
M''A.U^&.A_LXV[0ZGX6;X+'QCKOB31-1N/ WBK7M,UCQ=\0S9Z"EQXD\.7/A
M.UU5KKPK/-X2GU)=8TO^G5?#4BMN74IU;).X0D'+)Y9.0^<F/Y">I3Y>G% \
M-R*P==3G#C.&$3!ADY.#YF>2 3ZF@#Q#X<:SK?B/X>^!/$/B;3M1T?Q+KW@W
MPQK'B+2-7L+;2]7TG7=0T2QNM7TW5M.LI9[.PU*SOY;B"\LK.>>UM)T>VM[B
M>*%9I.TKMSX44];YSU/-L#RS%F/+]V9F/JQ)/))I/^$33_G];_P&'_Q5 '$T
M5VW_  B:?\_K?^ P_P#BJ/\ A$T_Y_6_\!A_\50!Q-%=M_PB:?\ /ZW_ (##
M_P"*H_X1-/\ G];_ ,!A_P#%4 <317;?\(FG_/ZW_@,/_BJ/^$33_G];_P !
MA_\ %4 <317;?\(FG_/ZW_@,/_BJ/^$33_G];_P&'_Q5 '$T5VW_  B:?\_K
M?^ P_P#BJ/\ A$T_Y_6_\!A_\50!Q-%=M_PB:?\ /ZW_ (##_P"*H_X1-/\
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M&L_"3Q7X6T2R_:%^*&JW?QF\.I\;?A7=ZW^SM\'=6@\8^&;J[\):WXUNM3\
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M (1-/^?UO_ 8?_%4 <317;?\(FG_ #^M_P" P_\ BJ/^$33_ )_6_P# 8?\
MQ5 '$UU7A+_C]NO^O5?_ $<M7/\ A$T_Y_6_\!A_\56GI6B+ILTLHG:4R1>7
MS'Y>T;@W0$Y.0#G/&/?- &A<ZA':13W%SY=O;P)O>YN)XK>W4!0[%YIBD<:*
MN29&8("",YIHU&$LL8DMF>2!;J+;<QE9;9F ^T1YPSVX5D_?JIA+L(_,!9"W
MY*_M??L!>*/B3XV^,7QL\+^,/BA\1]0^)]G\&- E^ ]OXD\&^&O!VB:1\,-5
MAU&36?#L/BR%?#7BG5+F\CN-2U3PS\09%\/Z];ZAJ&F2W40-FT7RUI/[$_\
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M_:T>L:]8:?XOL-<U/2(+V.72;!+C6_'_ (+ACO$:!+'2]$OC#,\.GP5?%_P
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MF>.?#>J_"&_\._\ "+IHWBGP9INB^"M.UG3/BI!XJO3;>,_$U]8W<$=U9P3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #O G # 2(  A$! Q$!_\0
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ML(+*_+*R!MIE0J-TL0;Y6>)&5#S(R*"0<L?Y5]P<TN[_ *^1]I_\/&_V^_\
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M  M[C_Y'H_X>-_M]_P#1XGQ]_P#"WN/_ )'KXPHHY8_RK[@YI=W_ %\C[/\
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MXW^WW_T>)\??_"WN/_D>OE'P3X3\3?$CQ9H/@3P%H>H>,/&/BC4(-)\.>&M
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M_(H_X>-_M]_]'B?'W_PM[C_Y'KXNC,AAA,H"R^6OF!,>67"C>5"@*"'W(RJ
M%\L+R '=U/EC_*ON%S2[O^OD?IY^SQ^W_P#MP^(_BI::3K_[6'QPUG3)/ GQ
M?U![#4/&=S/;-?:)\(O'>LZ1=^7Y*XFT_5M/L=0MFS\EU:0R8.W%>&6W_!1W
M]OQ[>!F_;%^/Q9HHRS'QQ<98[%R3_H_4GDGN237F_P"R_P#\EDL?^R<?'/\
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M" 0",8PV3NW==WS9SS1IW_%!KV?W/_(:@*H@,C2D(H+L02Q &22H SZX ''
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MB'^R9X!_:&\&?&G2W^#EUXD_9_\ V;4\676G_"#P!K?A/X,_&;]M2PN=5L/
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M37/AOI'Q4\.H+9?!,GB?1HI[R*[N[ZYLM)C@N(==N=+GADA7U31?C-^SI!\
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M*<7:2NFM=#XX_P"'7'_!,3_HDOQM_P##P^(/_EM1_P .N/\ @F)_T27XV_\
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M$_Z)+\;?_#P^(/\ Y;4?\.N/^"8G_1)?C;_X>'Q!_P#+:OL>B@#XX_X=<?\
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M:.O7XP^(,<>_]K8I/^'7'_!,0?\ -)?C;_X>'Q!_\MJZ_P#9B^)GCSX@:/\
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M_P#0L^&?_!'8_P#QN@#Y#HKZ\_LK0?\ H6?#/_@CL?\ XW1_96@_]"SX9_\
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M_&Z /D.BOKS^RM!_Z%GPS_X(['_XW1_96@_]"SX9_P#!'8__ !N@#YEL"/\
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M>G.,H5JM-IQG44IG&,Z=2$]:4XVJ1YN3F6NG-=6Z_>?GA\(?A%X4^"OA6_\
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MK331]5IH^JUZFQ\AT5]>?V5H/_0L^&?_  1V/_QNC^RM!_Z%GPS_ .".Q_\
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M@':4:*O?V7J?_0-U#_P"N?\ XU1_9>I_] W4/_ *Y_\ C5 %&BKW]EZG_P!
MW4/_  "N?_C5']EZG_T#=0_\ KG_ .-4 4:*O?V7J?\ T#=0_P# *Y_^-4?V
M7J?_ $#=0_\  *Y_^-4 4:*O?V7J?_0-U#_P"N?_ (U1_9>I_P#0-U#_ , K
MG_XU0!1HJ]_9>I_] W4/_ *Y_P#C5']EZG_T#=0_\ KG_P"-4 4:*O?V7J?_
M $#=0_\  *Y_^-4?V7J?_0-U#_P"N?\ XU0!1HJ]_9>I_P#0-U#_ , KG_XU
M1_9>I_\ 0-U#_P  KG_XU0!1HJ]_9>I_] W4/_ *Y_\ C5']EZG_ - W4/\
MP"N?_C5 %&BKW]EZG_T#=0_\ KG_ .-4?V7J?_0-U#_P"N?_ (U0!1HJ]_9>
MI_\ 0-U#_P  KG_XU1_9>I_] W4/_ *Y_P#C5 %&BKW]EZG_ - W4/\ P"N?
M_C5']EZG_P! W4/_  "N?_C5 %&BKW]EZG_T#=0_\ KG_P"-4?V7J?\ T#=0
M_P# *Y_^-4 4:*O?V7J?_0-U#_P"N?\ XU1_9>I_] W4/_ *Y_\ C5 %&BKW
M]EZG_P! W4/_  "N?_C5']EZG_T#=0_\ KG_ .-4 4:*O?V7J?\ T#=0_P#
M*Y_^-4?V7J?_ $#=0_\  *Y_^-4 4:*O?V7J?_0-U#_P"N?_ (U1_9>I_P#0
M-U#_ , KG_XU0!1HJ]_9>I_] W4/_ *Y_P#C5']EZG_T#=0_\ KG_P"-4 4:
M*O?V7J?_ $#=0_\  *Y_^-4?V7J?_0-U#_P"N?\ XU0 V+_D&:G_ -?&F?SN
MJIUL1Z=J T_4HSI]\':;365#9W(9E5K@,5!B^;;N&<9QFJO]EZG_ - W4/\
MP"N?_C5 %&BKW]EZG_T#=0_\ KG_ .-4?V7J?_0-U#_P"N?_ (U0!1KX@_;Y
M\9^(?"WPG^%VC:)XXUSX9Z-\5_VJ/V<_@I\1_B)X9U<>&O$/A+X:_$CQN-.\
M5-HOBMD9O".H>)$M[+P;%XI@:"\T9?$<DVG75KJ+6EQ']V_V7J?_ $#=0_\
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M_P"@;J'_ (!7/_QJ@"C15[^R]3_Z!NH?^ 5S_P#&J/[+U/\ Z!NH?^ 5S_\
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M<Q51GJ2 ,DXK/33-3*+_ ,2W4/NK_P N5U_=!Y!B!!Y_QYXH J45>_LO4_\
MH&ZA_P" 5S_\:H_LO4_^@;J'_@%<_P#QJ@"C5JRC2:[MHG V27-O&_."4EE6
M-P/]HQL^T<$M@YP#B3^R]3_Z!NH?^ 5S_P#&J/[+U/.?[-U$$8((LKH$$'(.
M?*[$<="#R#3BO?I_"DI7;FW:*4*OO)+XI1DX.,7[LI/WM(A:Z:O:\9*_:Z>O
M0_"/]FWXJ?$;Q!\9OV2?BC>_'+XA>*_'?[2G[27[>GPL^/7P3U?QQ+JGP_\
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M^S3Z* &;!_>?_OLT;!_>?_OLT^B@!FP?WG_[[-&P?WG_ .^S3Z* &;!_>?\
M[[-&P?WG_P"^S3Z* &;!_>?_ +[-&P?WG_[[-/HH 9L']Y_^^S1L']Y_^^S3
MZ* &;!_>?_OLT;!_>?\ [[-/HH 9L']Y_P#OLT;!_>?_ +[-/HH 9L']Y_\
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M $<II?\ X0_Q+_\ F.HY9=G_ %\PYU_5O\S]1J*_+G_A\_\ \$U_^CE-+_\
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MZCEEV?\ 7S#G7]6_S/U&HK\N?^'S_P#P37_Z.4TO_P (?XE__,=1_P /G_\
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MJ*_+G_A\_P#\$U_^CE-+_P#"'^)?_P QU'_#Y_\ X)K_ /1RFE_^$/\ $O\
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MQU'++L_Z^8<Z_JW^9^HU%?ES_P /G_\ @FO_ -'*:7_X0_Q+_P#F.H_X?/\
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MW<\#U/ YH_X?/_\ !-<8/_#2>F8.<'_A!OB9@XX//_"&T<LNS_KYBYU_5O\
M,_4:BORY_P"'S_\ P37_ .CE-+_\(?XE_P#S'4'_ (+0?\$UP,_\-*:7CCD>
M!OB81ST_YD[_ #VHY9=G_7S#G7]6_P S]1J*_+C_ (?0?\$UO^CE=*_\(?XE
M_P#S'4O_  ^@_P"":W_1RNE_^$/\2^A[_P#(G=*.679_U\PYU_5O\S]1J*_+
MG_A\_P#\$U_^CE-+SW'_  @WQ+R/K_Q1U'_#Y_\ X)K_ /1RFE_^$/\ $O\
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M4UF_M]-TVS62;PC'%&UU>W,,"R2.D41??+(B#-)IK=6&I)NR_0_C%_X*"_\
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M=-DF4FV)CPQ/Z^\#SZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCL'TM(+EKZ2WEA$<GB/A3_@HC/X6^ 5G^RE'\#_#5_\ L\W_ ,$?&'P]\;^
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M7EOJMX'\.>(_$&CZSX@TJRMDT^*Z,,L[/\F?\,A_M:?]&L_M&?\ AE_B)_\
M,Y1_PR'^UI_T:S^T9_X9?XB?_,Y0!]+-_P %,?BI-\3? 7QHN?@S^SI<_%7P
MOH=_X9\>>.?^$(U:WUWX\^'M3^'#?"VZTGXJ74?B)2+2;PHY3['X671H?[26
M.^E8O#';C-O?^"DOQ?F^'<W@;2?AG\#/#&L1_#.]^!&B_%'0O"NLI\1?#/[/
MEYXD'B>+X(Z!J%WK]QI<?A"P CT#3]1N],FU^'0X#!->R7;O=/\ /7_#(?[6
M?_1K7[1G_AE_B)_\SE'_  R'^UG_ -&M?M%_^&7^(GX?\RY19#U_K_ACZ/\
M#7_!2WXO^%?B_P#'OX]:?\-O@\_Q6^/DMR^J^)YM.\9B/PC'?^#6\$:E8Z#H
MMKXMMM'U[1KO2PNHG1_&MKKME!XCVZI:>0R>77/?LB_\%$/C%^QMX.U#P/\
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MH_X9$_:S_P"C6OVB_P#PR_Q$_P#F<H ^>**^A_\ AD3]K/\ Z-:_:+_\,O\
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MX@\2>(+_ %F_N=/\1ZS%;?9$*L.2_P"&0_VM/^C6OVC/?_BR_P 1/_F<I/\
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M*6%I-,TO3[6S>1G523^NG^8'P717T/\ \,A_M9CK^RU^T9^/P7^(G_S.4?\
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MT[Q!\++3P1#X3UQ_'&M16^M^([R_MI+R\U.QTZXBN(/[/LUA .=^,_P"\/\
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M"/Q[_;*D^ 7B?Q=9?&?5O&#W6H_LO6?Q:BEM_B1>?%'X S^*M=UFW_:$U_\
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MW_O]#_\ &:X*BBR[ =[_ ,+4^)7_ $.^N_\ ?Z'_ .,T?\+4^)7_ $.^N_\
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M:>./!6DCP=XG^ W@_5?V<_A]\-/VAOAK^R[KGP1N/BMX]\8:=<>&[OP?XO\
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M2."!DD_2GB-X8]<UZ6XGAMK>&]O;BXN;B18X+:WA,TL]S-([*L<,$*O-/(6
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MI3L8P'Q$6:]+-%NEE?:2&\R1GWXXIW_"N/'9*LUO;,R;]I/B'205\P!7P1?
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M)1LDFO;5(I]*;C3_ (=.E"F<L4^91BFW-MI)-NI)2G>R7Q22?:Z5DEH?//\
MPJ[QE_T#['_P>Z-_\F4?\*N\9?\ 0/L?_![HW_R97T-1691\\_\ "KO&7_0/
ML?\ P>Z-_P#)E'_"KO&7_0/L?_![HW_R97T-10!\\_\ "KO&7_0/L?\ P>Z-
M_P#)E'_"KO&7_0/L?_![HW_R97T-10!\\_\ "KO&7_0/L?\ P>Z-_P#)E'_"
MKO&7_0/L?_![HW_R97T-10!\\_\ "KO&7_0/L?\ P>Z-_P#)E'_"KO&7_0/L
M?_![HW_R97T-10!\\_\ "KO&7_0/L?\ P>Z-_P#)E'_"KO&7_0/L?_![HW_R
M97T-10!\\_\ "KO&7_0/L?\ P>Z-_P#)E'_"KO&7_0/L?_![HW_R97T-10!\
M\_\ "KO&7_0/L?\ P>Z-_P#)E'_"KO&7_0/L?_![HW_R97T-10!\\_\ "KO&
M7_0/L?\ P>Z-_P#)E'_"KO&7_0/L?_![HW_R97T-10!\\_\ "KO&7_0/L?\
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M[MZ+W=KM:]]C]+]PSC//4XYP/4XZ?C3L'GOCKCD<YQR,@G((P#G(QUK\Y_\
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MLJS@Y5(M-U&_?F]'[[V=FK_\#00#  ]*OZ;_ ,A'3/\ L)6/_I5!5&KVF_\
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M6WD5078GY4XV@=EQA02 ,<4S^S;[_GSNO^_#U\5[W_YZ2?\ ?Q__ (JC>_\
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MH ^U/[-OO^?.Z_[\/1_9M]_SYW7_ 'X>OBO>_P#STD_[^/\ _%4;W_YZ2?\
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M:^'R\@!/F2< _P#+1_\ XJNDG=_^$0TH"20[?$6L@%I)"P4:?I.$!+G"@LQ
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M6LZCX?UFTEM;V*VO;2ZTS6=*O]-O+:[MX9XKNTG0IL$;OUV]_P#GI)_W\?\
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M3J5OGD.,JR!D=&#*P89'&#S:/5---)IIIIII---73336S_)FAYM^VCXH\?\
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MATKP43IMS\-]G_")7.D>5=:KH=_J"O>G^G-/V;OB+SBY\,@ <#^T;LJIW;B
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M3UG%J;VWAN_+\]%<:O\ PSA\2 P87/AL'E<?VI>$,/E.#G3#NR4!)8DGH3T
M];#\:0PM3!3H8"4YX7%\/8FHY8_%T:-.OPY@\7@5/!T\/A<5*#JK&0E-5+QJ
M-UI*]^6'//*[2J-UTHU557.L.ZU22K5?:SC)RK4U&,96]FU%VNT[[GY-_M1Z
MOI/Q=\*:#J%CH?[0_@?5?A'\1_@A^T3X \6:9^S;K7Q4AE\574OB6X\/Z+J?
MPEDGM=6\7?\ "/64E];?$GPX5TS5? >IZKX8U*+48+X0O#^?/AK]C7XP7WP^
M^&MZ+;XG^#/VBOBK\6OC1\2[JXLM)\,>!_"'PM^&=M\5?%OQA\%:[X\T.TMO
M$-C\/_BG:ZGXOG?X:> _"OBRWAB\<^/5_P"$IEUG3/ ^L21_TU?\,W?$@'(N
M/#70KC^T[P#!8.>!I@."ZJS<DL50,65 H/\ AF_XD;2IN?#1#%6;.IWK%F3=
MM9]VFL&*AF )4X#L!@'%&4\=8O)<-1PV P-*G26+GC:\:V/=>"JRE.HU35;!
MPJ>SKSDW7A5BW/FE=0NT1B<EABWS5:\7>G&%E3E3344E&7*IRY:BLFK2:3V9
M_.M\--1^*\_AS]@3X?\ C7X<CX8:]X)_;/\ !-A\*-!_X0+4?ACK$'PM\'_L
MS>+-=^.JW7AG6=6U?5M0TCP7J^O^)? UY\0;F\\OXE2-IWC&59;O5OM%W^UN
M . ,8QQR,' R,'I@YX[5[5<_LK^,+K5-+UR[L_!-WK>BP:C;:-K%U*]QJ>C6
M^K)#'K$.E7\VCO=:?%JT=M;1ZFEI)$M\EM MRLHB3;H_\,W?$<\_:/#1SW.I
MWF2/4_\ $L/)[G] :\C/,_CG4\+..$AA7AHYI4JQHU%4HU,7FF-HXBZBX0E[
M.G1C-1C>U.HTTY7:?5A,%+"*K!U75B_JWL9-M\OL:<J4E*^NL9.[TO*SZ6/
MVZ'Z'^5='/\ \BCI?_8Q:U_Z;]'KUK_AFWXC'_EMX9_\&=Y_\K*UY/V>_'[Z
M!9::)O#PNK?5]0OG/]HW7DM!=VEC!&%;[ 7\Q7M6+ H%"N"&)X'@'<?-E4]1
MCM9=.U&*^M6O[&73KZ.^L$MVNWO[)[29;RQ2T3+WCWEL9;9;1 6NFE%NH)D
MKZ(_X9N^(W_/?PS_ .#.\_\ E91_PS=\1^T_AD'L1J=YQCW_ +-!].G3DYSB
MJ@^6<)<THJ,E)\KY922YDXJ>OL^92:Y^6;CHU&6P='YQE'79<\90;:NFTE)Z
M7['\U$WA7Q'K7[/'[1O@3P#^S[\=_AE8W'_!07PE\:_!%_:? #Q%X4U_X4?"
M0^)_!%[H7QI^$/PRN['3K/Q]XH^'5YX0GGD^%?V&YB2VO6U+Q!HNIV*+97'H
MG_"%_$[P]_P2A_; \.:[X=\5VOBBZ3]IGQ5!XB\4^&KGP5\2/C;X0UGQC)XM
MU[XN>-OAY)))-X!\8?$?PT?$;ZEX/LXK&TT^SL[.?3=&TJRO8; _T)#]G+XB
MDX6Y\- AMX(U*]7#@$ C;I@(*@L%*GC)S]XU'<?LT_$"YAFMKIO"ES;7,$EM
M<VL]]=3VUS:RQM%/:7$,NEM'-:7$+/#<6TBM#-$SQ2(\<CJ?OZWB!5JT\/2>
M6X6G0H9[E?$,I?77C$ZV4+!IX?\ W;#2J5,3' Q2BITXPE.<92E)N;\6GDM*
MG4C.%=2M@\1A9>Y/DO64U&48N3M.,)M.2>^MDM#\9/&%]X3?]M_]D'XB^ _@
M]\0]5T1_A3\2-(\7_&CP+\&];UGP?/I7Q5\#?##3/@G'K/Q.T;3FL[[1-)TS
M3=0BNWDO'T[P39JTU]%;F]C$W'?!GQ]>:M^T3\:_VDO&7[-G[1'P_N_ GPLU
M?X+?!+X4Z1^SQKVDSZI\(_#WC^'Q+X@\6W7B.&WL/#/BOXB?%?Q?<6.O>#O
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M4OQ(UWXNZ59?V/X1^$7PYT76+C1K;5-6U(:KXL\;71O+Z*RTCPSIC7O[F?\
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:[)=$D]4EJDGLDET/9TZ;='W7>W2_;IL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %, G # 2(  A$! Q$!_\0
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M-!M-2AT_4-$\2V>H26^DOJDLT?E&;<WS*S?I9!_P6_\ V;!^SK\8_P!HG4/
M_P 3]#LO@U\7](^"GB/X;ZE9^'8_'U]XNUUI7L)--LX]<;3A9Q6]AK,UU]JO
M(KI?[(NU6(N8A)Z>9^$O&6 PN38J.6X[&XC-J56E5P-"C&I7RRM4SFIDN#A5
M5*O6C4J8_&T:E.BZ3=.\'3G4C.+.'!>)/"V+Q>:X>68X+!T\KJ58QQ$JLE2Q
M_P!7RR.:XB*<Z%)TW0PDX.,9KFK3ERT5)JS_ &JEE5$WL"0,G@%B.N.%Y.<=
MN^.O%0M+&<L"H(!^;[P4[L$,<\$8(;LN"#@\5YU\*OB'_P +3^&/@CXE2>']
M5\%VGCGPAH?C"'P]XE>RCUWP_9:Y80:K;VFMFQNKNPBOX;2:&:Z2"ZDCMRXC
M=BT;FOY/M!_X*P_M 2_\%,[;XF7OCCQ*/V!==_:-U+]F*QTF0V:^ H3#I!T2
MW\1P21P><=334Y[+QK+.)W\[2S.C$[D"^9POP#GG%M3B"CE]3#4*O#V7UL?B
M*.*E:5>="I7I1RW"*,:BJYIBJF%Q,,+1BWK1G/WDT>AQ)QGE7#:X?EBJ%;%T
M^(<9AL+AZV$2?LZ>(ITJWURK)N#I8:A2K4IU:DTDG.,':>A_8*K[UV_*V"0Q
MVD DC) Z;B 3D#W]*D@EC;*)Z;C\A7@'!.T@$#.1R,Y[$&OYN?\ @JM\7_VJ
ME_X*)_L6?LN?L_\ [1_B_P" >C_'+PO;Z;?:EX>M[34-,MO$%WXI\1VT'B'4
M]'N$4:N8+;3XK9K%KFWBN5"!W SGL/V-OVZOVI?@M^T]^TC^PO\ MD:NW[0/
MC+X-?##Q/\7?AK\0O!?AVWL/&?Q(T3PSH</BJ?PU:^'K2*PBU;5M=T&ZBN-
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MI%2A4A*RO&2=UHFM4TFFD4445SFX4444 %%%% !1110 4444 %%%% !1110
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M_#WQ1X)\4Z?/KVGV+^+_ !%H']F7=GX9U.6?0-:LGD06,F@QWNE6LFGWQO\
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M8ZM4Q%&K4CB'0QU6HU15*DIPI0472A&*_DNUG]C?]J.[A_X(91C]GWXB7 ^
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MC0_%?AWQA86>F:S::1XJ9K/1M<OA!-*I>!%M]0L+N:XDDC-G S%0J!?W5.5
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M7J>'+TJ;0V-MH]MK&H1"SDVQ-XC5HSY<BO)^K'_!:+X?_MI>,M _9UN?V:-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A4-C(Z=/Z_G2!5 V@
M<>F3_CFG44=_-IOU6S^73L)I.UTG9-*_1/=+R?7N%%%% PHHHH **** "BBB
M@ HHHH **** $(##!^OXCI2;%]/7N>_7O3J*&DU9ZIIII[6:LUZ-:/N';RO;
MROO;M>ROW&%%(QC';@FG!0N,=ACJ>E+119?<E%>BV7HK*R$DDK)65[VZ7?7U
MUWW"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 44$@<DX'J:JW-S#;QM+)(% 'R_, &."=JD\%L#.,YQS0!89
M@HS]< G&<=<9K-FUG3X696N$+*5!53D@DD=N,#OC/ZBN*U37;B^<I%N@ME#+
M@-M=ST.X Y*G'TQZ5SY ;&X9PVX9Y(;UR><T >B-XHL 3A9=@8@2,,*^"1\N
M-QR?IQ[TO_"36?I_Z/\ _D:O.\8)/<\GW_S^M.WMZ_H/\* /0O\ A)K/T_\
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M/T_]'_\ R-7GN]O7]!_A1O;U_0?X4QGH7_"36?I_Z/\ _D:C_A)K/T_]'_\
MR-7GN]O7]!_A1O;U_0?X4 >A?\)-9^G_ */_ /D:D_X2:S#*-C$-QN5B #G
M!$J1-Z<J".>N<@>?;V]?T'^%(23UYP<]!UH ]3M]8L+@X295.<8<A3GTZX/?
M."<8]ZTU96&5(8'N#D?F.*\8  8-CD'/'^1S6_I^O7=EY<4I\Z'=_>W%5)'!
M],#&/QYH ])HJM:W,-U"LT+JZD9.&#%3D\-CIC!Z]A5F@!&*@$L0%'))Z?C7
MF^O:@;RZ,)PT%N[!=I(W=B3SUSQGCCM7;:M/]GL+AL\F-@#WS@#CKR<\>_2O
M*N, @DA@&R22<GKUR>M  . !Z#Z_J>M%%% !1110 4A8 @<Y)P!E26). % 8
MY)Z =R1G YI?\^M?@/\ \%4_VS/VQO@%\6_B_H?[.'Q<\!_#3PG\ /\ @GW?
M?MJZ_H_BCX6:3\0+KX@:SX;^-]GX"G\(-JFH:GI<WA[0M8T>Z6WU.]LX[J6V
M9&>S:VGNXIXO;X?R'%<1YC'+<)7P>&JRH5J_ML?7>'PRC0>&3@ZD859>TG+%
MTE32@TWSN3BH2:Y<9BX8*@\1.G5JQ52G3Y*,5.HY5&U%J,I05ERN[YM.S/WY
M4%FP"N VUF#J0A!(=7YSYD8&YHU#D#G.T,P<(Y"<;#N.W;'SYC!P"#M( 0??
M)+LH*QLT9<$9_DL^,W[5?[3_ ,0[:;X._'CXH^'O&VN_ 7_@K7_P2TL= \>>
M O"LGPH^W^$_VAO!MY\3M5\!:EHVD:M=)?:'H5S<G1]*>]N[B[U;1VA77A<W
M:R$_1WPN_P""</[)6M?\%<_VV?A-J_A;XC7_ (#^%GP!_9I^,O@OPL?CS\:X
MK70OB'\8/%?Q:_X6#KR&/QQYEPFMOIMCY.G7)FTS34@:+3+2UCD*K]5/@:&7
M4,9/..(G0>'P.)S*G')\#A<SBZ.$Q62X6=*G4KXC!3G6J3SJA5C3J17-##XV
M-XJE!U?(_M>K7G)83+G5DJF&IOZYB*F'C?$O$1@U&$*T5RRPU2,K:IN#LU*3
MC_2,8G W$8 "EO[P5RP5PO!9#LE)8[>(F*[@03$#D9 (& <L-H&7*'?N(,:I
M@L[.!M'49K^=K_@E+^Q_\"? _P"VU_P4OU_0-/\ ',VJ_LF_M7V?P?\ @5_;
M?Q<^*7B:P\"^ O%OP0\-:QKNC-H?B#Q7J6DZ_-=:EJ^JW<5_K]IJ%]:27.ZT
MN83;QX\V_;>_X*9?M1? S]L']KWP#X&_:7^!G@/1_P!FW7_V2+KX-_LM^-?A
M5'XI^(7[5<WQN^P:7XW\ >%?$5GJ=MXA@-G/?_;;?^P],U36K#49["XO&M/#
MPN)IICP'B,USVMDN19A''UL-E6#S.IB<7AJ^$CB%CZ>45:-"G0P%#,U"K36<
MX98JM7]AA,(J6+JU\32H4'4ETO,H8?#4L7BL/.DZM:>&4*->==*<.;F;A45*
M*C[C<9*[LTDFVT?TX$ 9^96(YPC*>/XNI4[E'++C(')Q2 @YQENR[0K9/4Y^
M8!0!R23[#-?S477_  4Q_:F7]M^+P:OQ;^&>%_X*0V7[$TW_  3L7X;VA^*\
MG[/5QH*7D_[4@\8K=-XX%S#&TGC+^WVT]?AVGANTN-.E*WX>XB\#_9N_X*S?
MMH?$'Q;X(M6^/OP=^.^N?%'P;_P4.L_%O[._@CX1:9I7CS]F.7]EW0_'FM?!
M7XJ^(]0T75M5U/4H/'^JZ)X>T672-:TVQTO5H]9M8-,>>[2XFFV?A;GZP_UB
M6,R>*E@Z&+A%XG%^_*M&C4G0]J\OA0IJA1Q%*K+'UJE+*,0O:0P.98NK0K4Z
M<+/L&ZL**IXGGJ2J1C>E%*]/V:E>\[K^+&R^+>\5;3^M0#+*,J<XY!&/F.%V
MDE58D]@P(P3SC%&&#%=I+@X(QA0I4E7#'#,C@-M;8"6!4 D#/\>GQ8_X*B?$
MK]K#]C;X[>$+7XP>#_$:P?\ !&#X??M!_%V7X?PVFA:UX2_:EUSXVZ%X:\56
MC:UHUTMWX;>RT29K:]\)6L\;Z)J+1"8"25U;Z,\:?\%4OVBO"7_!1CX6_L]^
M#OB?X'E^$"_M*?LZ?LE^*/AGKOA'X?:=JD%C\3?A+I^O:UXO==:\4R?&;Q1X
M@TS7;BTO=)\?:?HFE_""[M0?"UPE_P"(;F%6:\+<]C%QCB\NH8O#83&8[%>V
MQ<906&P^'G7LDZ;C.>)IQDL)9.%6]*:FHU*;ES?ZQX-Z-5JE-*,J5+V,G+FD
MUS)IVA[M[OWMU9=#^G]U>/<)5,3!%D*R!HRB,GF(T@D52#)'\T819 V'#%"A
M%-R.Y'W<G!#'J00%7<<@88AMAP>G!Q_)7^SC\<?BCI7C_P#87@\1?$RX_:A^
M)'A3]NK_ (*WZ3/X:N]0N;7QSH>J_#3X6_$_6?#'P\NHK3Q)=S6<WC:>QL+S
M0=&\46&H:?X9T35=,TKPYI\&F6MG?)!\*?\ @KM^V/J/PP\;>/F^/_P@^/'B
M;Q7_ ,$\/VB_VO\ Q7\/O"/PNT71KW_@G_\ %[X3ZQI.F>#OACXUDT[4+JYU
MG2->EN[_ ,/W7AKX@FW\7ZEKVDW-_IQCT/&ZI>%N>.I.CA\QRNO[*K[!>VQ4
M*%)UY8VKA(QISC3=.C2J*C*NL3C9X7"S3IX>EB*F+JTZ$NA9]1:CST*UI1O2
MA2A!RMHFI)U(ZW:22YK+5V1_6YZ$$$$9!5E92/4%21_(@\$"BOQ>_P""<?[4
MW[5GQ&_:<^.W[/'[2OQ,\$?%^/0?V5?V1OVJ_"'BCPU\.]/^&=WX=N?VC]"U
M.[USX?1:=I.H:G9ZGX7\/SZ9"^D:MJ,KZO/-<W GNQ&1'%^T/4 XQD X] PR
M!U/3..I^IZU\+G.5ULEQWU&O6P^);P>$QL,1@YSJ8:I2QE_9PA.K3HU/:P:F
MJL)4H\G(VG).+EZN%KK%4IU8TZM+DDH2A6BHU+Z;*,III75WS:7"BBBO--PH
MHHH V]%U*2SN51G_ ',V Z\864\;ESP%/?V^@KTQ2& (Z$ @^H(SFO&/F_@P
M&'*DKN (YS@?SZ#J>!7J^DSK<Z?;2J<@Q@<A@=R\-G<2>6!QV X% %V218HW
MD<[50$DGH,>OU[>N1ZUYAJVIMJ-PS9 CC)C2,=L'[W3'S<'KG\,5V?B.X,&G
M.JG!E=8CQV;W(X^H((KS?\O?  S]<#G\: $  & , =J6BB@ HHHH >D;R';&
MK.W/"J2,X& 2.!DD#VSN(P*1E="-RL%8XC;!^<]^"!M 4JX+,&9&5@N#S^.?
M_!>'Q/K/A'_@G)XTU;0_%%WX.N7^-O[->FWVNV_C+Q'\/;:WT'4_C-X6LO$$
M&L^-/"5U9>(_#OAR\TJ6>#Q-J>CW"W]GX?.IW5L#/!$1\!_L^_'+QE\/_ 'P
M,^%/[&?QP_98LO'7[3/[<MG\#_'_ (X^'_QM^.7[?7A'P+X3NO@3XL\8Z3JX
M?X_^)M-UWPWXODN?!MX+'0-.O;?P_<V:VMW>PL996/V^5<#8K-\A6=T<QIX>
M,\?B,$J>*IOZA0CA<(\;B*^-JTZ%>I"G]7A5]DX0G5E64:<*;<HL\C$YQ3PV
M/>#="<_982&)J.,$_:>UJJC"G3;DE*LI2@W!\J4/>YDDS^H;DYV@L0&. /[I
M7=D]  &R6;$:@9=T!!I6&TD'(QD_,-O'.UNI&UTVNI!(*L#S7\\'[(G[>W[;
MG[6/CO\ 8V\%+XX^#GA33?$_P&_:3^*O[2NJ1?"ZXN]0^(/_  SE^TW<?!>*
MR^&$">(88O 5SX_TJ&!M2N;A]<M_#BSW&H:4L]\EO$ORM\+O^"E?QZ\#_#;]
MCWX:Z3\;O@'^RIX,M_V+?"GQZL?%GQV^'WC[XQV7[3?CSQ)^T9XA^'%S\#?
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MGB"VUO3],U"UTWQ-8V=Y%<RIU_@S_@KU\<?#=Y\$)/BY\7O@7K?P@U;XM?\
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MJE?W:VEK-.2 8XRP!(S^7J,\?X U9C<2Q)(O22-7'?AU!'\ZXOQ7<$20VH)
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M.>>A],?2N.\2NSZB=P 54"+@]0.N1VY/XUU/A[_D$VO_ %TE_P#1KUROB/\
MX_V_X%_[+0!S]%%% !1110 4444 %%%% !1SG/UY[YX_R?PHHI-<T:D9-R]I
M3J4G)M\RC5@X-Q:M:44[P=GRR2?34]=?-ZM>@?Y/N:***=H.4YN$7*?+=WGH
MHTH4>6/OZ1=.'+)=>>I_-9&JV;CZ6_R8TQQNT;LBL\9RK-'&YC)&"T3,"T;X
MX+*1Q@9ZT[OWYSU/TZ\\G\Z**IR;5.+;<*7.Z5-MN%-S5I.$6W9VT3OHDB5&
M,75DDN:LJ<9SLN:U-\T;-)6N_BWNNP4445)04444 %%%% !1110 H&2 >YQ^
M=>D^''W::B]D=U'7D9X)_6O-EZCZC^=>B^&?^0</^NC?S- %7Q5_QY6__7P/
M_1)K@Z[SQ5_QY6__ %\#_P!$FN#I-J*N^Z6S>_H 444F3G&#CN>/3/U/I1=+
M=QBM=9M0C[M*K6:4I6BVJ=&I*R=[Q45[THIURORVONO\Q:***2G&3A%2C><9
MR@KI<RA\5KV3:[7NVU9:J\K7;[NOW!1115)-VM&6KLKQ:N[I:7MU:U^>R#[]
M.Z:_-(****2=_LSVO?EE:UE+XG:*TDMVM[.UG:E%O5+\@HHS_3]>!13U;LHR
M;NU[O+/9V>D*DW9/K:WGM<Y9=G\M?RN%%%%-J2WC+[F'++L_GI^=@HHHHDI1
MM>,E?^Z[_=8%&33DD[1WT\[;;O7L%%%%)7DXQ49WG+DC>+2<FG)*[T6B;U:V
M(^4O_ 9?Y!1110[J4(\LKU%>%DW=7:W5TM8O=H>[M9_--+[VK(****<DXJ\O
M=5[>\U&[[)-IOY(?+*]N67R3:^]*WXA1112_K34&FM& ZC_@7_H#5Z)X7_Y!
MY_Z^+C_T-:\['4?\"_\ 0&KT3PO_ ,@\_P#7Q<?^AK0(R/%7_'S%_P!<E_\
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M<_CC\9?&:?M3^ M>\.67QJ^+/A'XK_!W4]&M=9\;Z1XLTCQ;YWQ"TKQ;=2^
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M4X.-1JK4BG.+Q]?"5)*5-UL+%M6I1;J*UESI->\W?:.KU:T3/W^HP3P S$\
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M_+&45.3BN:-KQ::=XNS2LWNK_JC111VSVSC/;/I]:^1/4"BBB@ '4?\  O\
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MW5-)\::7?>'/BS;>-/A?>>*[K4?#B_'+QW\8M*B\ 6D7CFS\*:;KJVGC_5O
MVK_\)YH'CCP_<B&T\2VFE6VK6<D,GTK^UQ^P[+^TGXN@\:^&?''@?P!K6M?
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M+E+MC@JRJQJ*O:"G&2I\L7:,7&\.9+5>[+73XWHN5'6(3C:>@ (/^]DG\O\
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M3>'_  C8:#;RZ[/>Z;%<:RNNZ?9K%NT^:YB?YP\8?MV?M+>#=5^)'PL\>?M
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MI'@Z_GUP^&[2R'@W1)]8.H3-RFI?MK_%KXO_ !I_9<B\?_$_X>?!5+']NKX
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MUOM<UBV\&:=I?A;X5:)X*TRTUO4M235VU35_$/BC4IF-NBY7P _8<\4^"?\
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MFY)7NTFK::,_L8:&9,;XI$+"3 9&'S1('E1CC",@*@ERJ%F"JS$-M9M()!&
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MX'^(=/\ C9XUMU^ ?A+]FWPKX0M=;\$>!?%.IQ-^S9I=OH&EW&B>(-:AEO?
MVC_$+0XI_P#A8&@>#X--&I^();?7(-2@^RFRF]!?ZD-XK!XFMB7"EB>?#YBI
M5ZN(C*AAJ\:E.,XN%+V4L9+#\_M<,JCISG&,^6,9RQ;SQJE5IT83E*,E5HIT
M:%%/W.1\KM-RUG9\[6B=DVXKU?QI^UA\'OB;X>^&MU\*OA]J/[2GC3Q+H?P@
M_:-^#?@T:4_AB/3O#7B[Q1K7AGPK\;]5\9^(-/;3?ASHOA:33/$5[KFMW$4N
MKZ/I230M:3KJEHLL'PL_X*!:5\3-6_9ITFV^#WQ.TZ3]I'QI\6O ;>-K._\
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MINK*+ASO#X9N,'+FY8ITFDMDM+I1BD[+7#^Q\O\ ^@=?>_\ /^M]S\JOV?\
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MZE%3>'H2O*<>2JI1=*S2IKW4[JHFY/5N/+:SO9?>'AS]I3X >+_%T'@+PO\
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MP?X6?L'7?PG^,_@7XP:)\8Y=0G\)^+?$^N:OX<O_  5!';^(?#_BW]G;X0_
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MX1\)^(/%!\(ZCISW:LOBKQ$_A?5/#_A>QM9KJ#6]<@CM+:4_VA!=2>-^*/\
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MINH6MK?V#WWQKU?3==^+-IJEO<WTL=O?>/=>TS1=9\0&<078OK:WOM*:QD6
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M;J5().K*4^:4NS#4JM/F=6<)S]K4_AR<X<JG[MINUWRK72R>VEDD'4?\"_\
M0&KT3PO_ ,@\_P#7Q<?^AK7G9Z-TZ9Y..A!_'IT_E7H?A@2BQ?S(RB-*\D9(
MQO\ ._>2$#K@.<#/7MBO*.HR?%7_ !\Q?]<E_P#0C7)5UOBK_CYB_P"N2_\
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M\%ZM\&_" \--XE^,'AOQ/?:1KUIH6O\ P^TO7M/N8](UB9)8K6UDD/4_!?\
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MNL7<-C9>//'[SE_ ]]8VMFJW/]%"W$Z *DKHH4(JHQ1401^2$15P$01?N@J
M*(_DQMXI/.ESDR.3F,@L2Q!B $1!;.&B  C88*  *0*4>*\KIXKZQ#A7+)4I
M5*DJF%KM5J,H3H.E&$/W4)0Y9VKN7-)RJ.:MR.,5I++\5.G&G+-,9[KOS1DD
MWI;7?H[+RMUU/R"_95_:M_:$\>_MH^/O@O\ %K7[/4]%_L;QW>V7@OP;X!MM
M-\._"4^%+7P5-I6F^-=2UG0/#_Q$\):A+=ZQK>EZ3KWB&]\8^$?B[YMOJWA&
M?0TL&M6_7I@ Q Z9;'W@<;B.4;YTQC"JY9R@1V.7H+L0P)^^(U<X&YUB!$2R
M,!ND6($K$'+"-20@4$BFU\YF^/PV88BA6PF74,LITJ-&E+#X=WIU'2@X2J?"
MK2J-\TKII-*R.W#498>BJ4ZU2NU*3]I5=YM2=U%OM'9>04445Y1T!1110!Z5
MX>_Y!-K_ -=)?_1KUROB7C42!T*$_CD<UU7A[_D$VO\ UTE_]&O7/>*8/](A
MN1OVE3'DD%<\#&.2,$<$X')]: .6HI2,$CN#@_S_ )&DH ^9_P!KWX9^//B[
M\"/$'@GX=BWOM9G\2_#_ %S5?"5[XBN_"%C\2?!?ACQIHWB#QM\+KWQ;8J]S
MX:M_'_A[3[O0VU3RW@)9;"["VE[<%OR8U7_@F/\ %?QAXA\':SXB^'/P^TWP
MQK.NZNEUX'D^)E]J5U\"/A#+^T]\.?B_I'P?TO68XC/XJTD>#= \6V\I\.S:
M?!H>L:];:%IIBTE%,?ZX?M7_ !#U;X6?!BZ\8:+-?6]^OQ&^"WAH3:9J$.EW
MPM?&WQ;\'^$=0C2]N-/U6'[/-8ZS<1WEH]D3?0$VJ7-FTHN8_G?]D;]K[XP_
M'SQ=9>'OB%\//AMX5LOB%^S_ *W^T#\+KCP=K_BG5I=+TG2/BGJ?PO30O'::
MK:6T:WFH30:;KZR^'?-MK>T:\TN2.>=8[H?<Y#F/$&595/'97_9\:-/$5*+G
MB;.JG7II3C"DY<U1QA5=9U&O<BO8ZX>53#S\/,J6!Q%14L3*OS12J/V2:MRK
M1<RU?-9*R>[VTN?%7B3_ ()Z?M50_$'P"/#GB:2T^&?A;Q]XD;X96/AWXF:=
MH[? 3PZ/VE+OXFZ5KVF3^*=(U_5;B*_^&#VG@Z'2O#HGU*T6&X\&W,]MX>N[
M>YC^HM._8S^*VB_L(+^S%X2U'1/!_P 3_C'XX*?M#?$DZ]?^*KNU\*>*_B%J
M&L?$+Q1H\FNM>'Q'K$_@"+3O!^B^'&%GH\=M?7-HT,-M;!C\B_L[_M]?M;P"
M'XB?%"Z^%WQ5\ +9?LSZ#XZTOPXVJ:5XHT[Q5\6/$OQ?\/2R_#32+&R72X]<
M$WA;1(]>TG7I@=2U!8-+TV#3Y[:0O]I_L)?MP>-_VOI?&]KXY^'.E_#+0;;X
M7^#?BKX=\1Z!XBC2\TKP[X_EUZR'AGQ*-1O;NZT[Q=X4M-,@U>3Q((['0+YF
MU%7T_=93@>YF_P#K;A\+1Q=59-4P7#]7+\=4J8=8>-3Z]"I!X1SII1E7GAL1
M7HXKEES1]M&CB9N3A69S8&63*HU!XM3JTYP<)J;2BXN3:N[7O!16UKM7LM?E
M6/\ 80_:M^%OB+X7Z)X1GUGXG?#CX)^/OVE+SX=:C\+_ (X:9^RMX^M?A[^T
M#9^"O$%OH")I.@:IHNDZ1X)\>:;XMT>V\,Z2T=L^@76AW]NRM!=QCU/]JG]D
M+XY_%J__ &=?B'\,_AWI]E\3=$T#3E^(X\7_ !EL-<MK/QI8W/@6TT+6_B;J
M*Z?I5W\3;_PWX<\/WEG:?$KP%J>A^/[/=+IFG6>H:9KFIVDGQ9)^V9^T]X@^
M%O[08G^/7BY]2^%D/PJ\)?LP^(/"NA>'/!'BC]K_ .$OC7]IO0O 6K_M6:=J
M?BK2)_#TGB&*TNG^$&GK;V;>&K+4&N?B+=Z?]A\7:1/#]=K\?_VV/V6IKS1O
MB9X1N?'OAKQ+<?''XK^$M$^-/C[PQXM^.?A3X(? #X4^%_$_B[19O$/P>\/Z
M9X4\1>)_&OC34-6M/!D-U ]QX>T>1;O7+VZ,$<8[<8^*85<-6K8WAZ6:X=8S
M 4</)4J5"M/,:=/$8QSYY2O/$+,EB)U7#DHXVKBXM4:]*MAX\U)Y7.-6BHXN
M-"HZ6*<N:HW&<*E12@FDFDU25KM633Y9)W/3/VO?V%];_:)_:B\ _$Z/P;X,
M\1>!;[PQ\#_#'Q'U;5/$]UH>M6^E?"O]H"S^)OB#1(=,B3[5K&D>*O#AEL;5
M;.>QNX;K2TM+R817\LS?*?BS]@?]L6'7OA+8>%=,\)7OA/X0^,%U;P1J-C\5
M7L]8\,_#ZU_:F\5_$?4/ %W<>(HM0U2&SO/@IJGA[PEX7LO"36,5V+>_\-^-
M=<?2+;38Y/7?'_[;/[1OB'X$_&#7_"/B3X'>$_&WP:\9_LGZ[KWCSX7I?_$_
MP/XJ\ ?M ^)/#']H> /#VHZ]-;6>A?$CP]I]Z^F:]J5W%J]J;34M/U"ST^QG
MO8H8^?\ VBOVK_VB_AC^T+\?K?0/BMH?_".QZQXT^&'P&\#V'CGX*ZEH7@OQ
M=X9^ NF^,[C7?C5X%U/PL/BCH>D)K$/B;5HO$>I^-8/"UG>3^$5UZU@\-:E-
M*^&23XKHSPM"G/)O:X"&+P^'IXA1KTN>E4PE2#2ERQ;KK'I1;C"I"AAZWUB-
M#GHPJWB/[-<<7*<<4H5ZL:DN64N:"4%32NEK]EW75VUO=>H7'[$WQKTK]@;X
M5_L]_"\^&OA-\:/A/\2-=N=/N-)\7:BWA2[\$^,_%_C/0/B!J5IJMD(+C[5K
M7PE\=:AKNBZ7>J;O3O%VF:4N?M"FZ?Y6\2_\$U_VQY?ASX0T&]\?R?$>\T/Q
M7\1?"$N@VWQ,MM,G?P!X9\">%OA+^R?\2'U_QCI>KV4_C;P=X2\.3>(_%[PV
M#^)-.\6^+M5U32[C4-2LRS\S=?MG_M4W/AGQ=!I?QE\8:=X'^$7Q!^(.L:CX
MS^(7BK]F7X9_'?XH?#[P?\#_  )X[USPSHLUSX6\8_"KQ)K/A/QGXAU".RMO
M"=A:ZS<VMQH^GZS>6RVZSG[K_:^_;*^,7P./[-?Q"^&$/A'5_ OQ!_9Z^,'Q
M'UOP3\4TNO#/BOQOXFTCPY\,=1\#Z?/JFF6DA\-W5G-XQN+K6+#3K83R*M[(
M(7AMK7[+O&IQ?EE;#8'#RR*=3,<;FN8OGHT*DX8A8.IF6-YJLXSG1I5*%)SP
MV&4WRS@J?,I)IB63XF+K*.-C"C1HT)-U*C;]G&2YHKW;W[)::*[O=?,7Q1_X
M)M?M(:GX.DDT35SXV\6Z[\9?C'XA^)=BWQ.BL=1^(>B>(OAWI'@_X)>++K7?
M&NE7WAO3KOX7Z[;^(O$AT_3-(TV_T^\UVY\3Z/:R>)G00_67[4O[%OQ)^/'P
MT^ /@V\UBW\7:E\)OV>/C+X2U;6?$'CK7]'N-7^.&O?"#PYX0^&/CF[O=,&E
MSZI<Z7XTT_4]87Q#>P?:=,G2W\1QVL6H. GCVI_\%/?BGX(^)OQ.\$_$7X1_
M#VPT#X2#XD^$_&GB.SUS7--T^S\<_#'X5:?\1KSQC&NI276NWOPI\1ZUJ=OX
M=LK?3/#&I>);72KJ'Q"TUQ$Z6L7CLG_!5WXYI?#Q9?\ A'X<'0/A++^T5I/Q
M*\ :#+J<6L_%+5/!_P $_AI\4/AS_P (^]Y>ZO?^$9+*?QU=1:]975S<W#Z?
MHMWJ&RVMXI[:#.6!\0,94PE6>&R6'U2IB\?@*E*M0A&=?.,-!SI^[3BN5TO9
M*,'4IPP[J<KFDKPFG6R6*K>]C'&K3I0U4TXJE*]V]6W*[UOH];NQO^.?^"=O
M[0&F7?C/1/!?A+PKXY^%NI:9XHT_X;_#R_\ C5XE\)P_"3XH^-OA-\*M 3]H
MR.]NKBZN;S6_"/Q$\->-M=GTJTN&\0+/KW]M:'-%/J5T@9\7?^"<?[1&K:'J
MFJZ5JD7CCQ9XM^/7Q<\8?$ZR_P"%AP:+??$GPKKW@"R\)_!3Q#_:7C6VU7P]
MX>_X5CXB.M>*H?"D-C;SZ+<Z]=:_HT4VNQVQCQ_B'_P5#^/NJ_"?XNZ'I7A?
MX.?"#XC>"?AA\8O&T_Q.\5>-I=)\*^(]/\&:+X-FTNP^$&G-<ZW++\6+:]\;
M*UYH'B6\N88X-$@U-+*>#5X!:_87[3_[;GQ%_9_U;X=>'_#>E_![48KO]EO6
M?VBO%U]\6O&>H^%M;\7OX(U;P3HNI?#_ .'MA81BWUGQSXHM_%#W^GK>22V]
MOJ+6"I9W$<VUFZ_&N'Q.%HO#Y+/&UJE-1@I1J1<\)0K8BE6E5:Q"A&NL3)N2
MIPK3E[.6,5"<*:-(QR:I&=2#QG[E*H^:4XW7-R_:WL[Z/IHMW?R3]L#]G[XQ
M^-(_V(OA':>!-1_:&UKP[\ /COX3\:7/B'XHZ]X'T&U^(-O\-_ 7AWPS\2_$
MGC6QLK2WU;7O#OB<2ZSHAO;&RU+4KF&\U;PVD5];(S>0>/?^";/[2LO@-+I-
M>C^(OCW5OC9\0_$GQ8CC^(,.G7WQ6\):A\+=,\%?"'7H]0\<VNI>'M$7X;>,
M4UKQBGAU=-CNX;G6;CQ%IWVKQ);1R#O/&'_!57XE:#I2^)--\ ?!6/1/'>O>
M+] \#^%?$'Q!UW2/''P@G\$?%[P5\+=1UK]IZU2WDB\)Z?K*^-!JUM]AL[:[
MTMK2QTF:YF75S=0]E#_P5&U;0;7XCV?COPU\'1KWPW\._$5]+US0?'E\/A_\
M9/&O@/X_>$/A"D'PPO-2=+W5]%U72_%INI[*VDU#4M*\2Z?>Z7)++8QI,<<.
MN-\#A,%0P>"P,(PK5Z[BK5G5J8C,L5*M2;56C!4X8W-*M&2I4TKPHU:W^RX6
MGC82ZN2XIU.:OBUSPA&\82BHVIWTM*+DW&G\3UU:5G-J7'^(_P!@_P#:VTVV
M\<Z)H?CW1?'OA2V^"=MXC\"Z)XS^(?B=]0UW]JCQEX%\'_"GXN'Q'JEF=)<^
M#H_!'A;5_$O@W4W.F6=YXZ\77K7]A#:)<(WBFF_\$Z/VT'\!>*-%2\T?PRMK
MJOQ-?P[I,?Q'\.7UYX@^%/CWXR_ 3XG-\&$FT_P_;>$?#%KJVC^ /&WA[5=/
MBTY_",=_>S64-O<Z9J<DS^A^&?\ @IK\4O"3?"3P#?0^!_B-J_B7QTOA#QOK
MOB.[U+2_$NBZA\4_C=\6/ WPTO)I+*+2O#=AI7A_3O#&ES6T5M#X@U3Q#86=
MU:2?V'<LMS>X_P '/^"CWQ\FTSP#H7B?6O@KJOQ,\??"7X:^,M3^(?C_ ,57
M?ACX#:->V7PS^+'Q&\6:?;V&CV,&H:-XX\2P>#-.T.>RBU=[2+5K#4M2AL8[
M;1AIM_WP_P!?,)3G4JX;AN\974X4:'.Z:<J=63485DDDG-\T)R<I0G3@VH./
M*_[%JS7[S'Z75E[36^VM_*R?35-]^I\"?\$XOC?!IMOK'C"_%WXO\-6_P=NO
MA%;:Y\5[_5+KX4PZ5^TMXA^(OC_PW83^&K;0?#$,"_"K5;/PI8+:Z9=V<MK<
M-X7T^\AT>"UG7](OV(O@KJ_[/'[-_@_X/Z[X;T#PUJ?A#Q%\2VD@\,:H-6T3
M5[/Q#\2?%7B;2/$UM<-''-:R^(=&U?3]0N='GWSZ+,6L;B625 [_ "+\)/\
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MG?#_ /P3>^-'BA/!WA[7?@%IWPK^%MK9_L?>#/VD/AH/BOH^L0?M0>,/A?\
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M4J\*BK5/:+WKN$)I1UT2YI)ZK>^GZ4VO_!/#XT67A/PYH.G?M<16OB;PS/\
M!O4K7XCO\)4N/%/]L_#3X ^._P!F[7_$$%O-XD;1X]8UGP'XIT+7/#4UQ;W5
MMHGC3PY-?:K%JVFZG):)X)+_ ,$:O&FIZ/XBM/%?[3'AZ]N_%MCH!U'5K3X;
M>,]2O+G6/#G[/'QE_9WCUB76O&WQ*\6ZYJ\VM6/Q33QEKC7NHK;V^OZ9J.EZ
M#IVFZ#>VEM!YIXR_X*+_ +9^B_$/XXV'@Q_ WC+2? L?QLM-*\,R?#BXO-<\
M/_#WP%I?@G_A7?[2T7AGPU9S^-M0TGQ59:]JOQ#N[/Q&\'@7Q9HDD&B^!9I+
MO2;@3_0'P5^/?Q=T+]G_ /X*<_&KP1\0/^&I?%7@KXPQ7GPE\>+X$U31_"OB
M/3M-^!7PL6?Q#X<\!:9<R6VN>&O!US-KFO:QI?@"6.R\7S:+JMCI[C6I[F:L
M*U/C#*:3MFF5J56K@(4/8TL#6J1>8XC#T*;E4K4'"G*C6JT*E:$JJ:IJ<Z-*
M7LJS6L:>3XN;2P&):C3J-2YI4%R4HN3CR*2=[-I246FW:4MD?2%W^P!#=?&6
MU^+D/Q)M;6.UTC0M,AT)/!\8F@.C?LJ^)OV9%N;;4(]0B%N6A\2S>*+>-( ]
MO! VBPS11S>>GBVN?\$J[JXO/AOXE\._%W0%\:?"?X??L\> O!</B'P7XNA\
M#7TOP=^$/COX,^()_$>G^ _B#X*\82Q^,=+\>3:QX8@T/Q9I]UX8U73Q9W3:
MUI^HWJCYWD_;W^,Q\1>,_!1_:^\ 1?"GPQXX\;Z9I_[9*?LU6\=GJ>J>&_@/
M\/OB7X3^$MSX%:63P[/JOC3Q5XC\4I::U:);7_BK1_#+^#_!B/XDNO[4C\X\
M9_\ !1#]J/QAXCO/A[XF6[^'UOXZ^#GC;P-\0/A(_@:'PUXH\ ^/M3_8KU3X
MI6?B#PUJ=H^H_$V"2\^)TBZ;X2\3:O+H_AW4V=_"?A[3+WQ1HUQ>DHY3QKA>
M>$,VP-)+"2J3<ZU1<]&O0E.G3G1J4H-SK4XU(U\)+V5;!ODH8UX.IB<*ZLRK
MY2Z*J_5)J/,XZTXU'[DDFWR.3DG:RFDU+XDVFVOOCP5_P2_T?P)H>F^'=&^)
M]C;V-A\:OV1OB[,-,^'%IX=CE;]E_P /7>D:SX>L].TW4UM=(M_'VJ:EJFI:
M4;5FC\)0736C'59#+<S>TM^R9\3;;]D+X8?LW67QG\%3>*?A>FB:0_B7Q%\&
MK'Q?\)?BGX$\/R:GI\/PZ^+WP@UK6YH=;\*:]X:O+&'Q"FF:Q:7L/B;2;+7M
M%GM%B2V7Y*_8U_:O^-GB;]J/1/V>_'?BFT\1>#1\+I_['\.:'X/LY+SP/;^!
M/AI\,;_39/B=K6J-IGQ%\%>+M7U#5?$#-XA\867B'P!\3I;NUC\%:O:W>GW4
M!\#^)/\ P4A_:>TWXX_';P=\--=T==%LK+]I+PI\/?#GC[X068O/ 7Q&^$/B
MGP'H'@*34-!T>Z/C*]L?%NG:GXT\26J^-M5L_P#A8WABPM_$O@G2K#3K#%[P
MRP/%V/Q5>E4S;+ZE3"4<)GT:E>I3E1E4JTX8>%&<^3GEBXTX\M6,(PBJ<(*,
MO:4_:5.I8W*J="G6C1KMRC*E!4\//W4W>2E=*VKO'=;Z=#ZS^'?_  3;^(_P
MEU(^*_A?\??AUX'\6>,8?'OAGXGZ7IG[/%CJ/P?T_P"&_CKQ[X;\?R^%/@-\
M*-;\67_A_P"'$NFW^@7L$[>(8O$GA_Q%/XBO]2O]#M);&RB''^$_^"5GCW1?
MC+8_%KQ3^U$GCFXTRZUZQ$^N>!?%-WXOU[PQJ?[2O@']I/31KFLZG\0=4\/6
M'B'2M2\"67@2UM?!?A?PSX-@\."VU%=%N-7$\Q\M^)_[8O[:_P ._''Q ^'G
MA'QOI'Q3^-/@GQK\3?AI8_L^M\"]*L?$6N_#7PI^S?XA^(OAO]L8WNCWIDN=
M*USXFVFDV=CX+L+]?"-]87T'@2%SXHAO;AM_X;?MM?M*_M/?%_2_AI\%OBOX
M4\(^"]2L_@=:ZC\4['X"GQ>NF>(M<_98\=?%+XL:1I$GB.[TSPY/?Z?\5=%T
M+1)C>-<1^%8HM1\*M:W6JRN]GV*AQBHXK%4\TR?V-:C",\7[/!RAAGAZ5.LG
MBN;"+&4H3IXA4L!4E>6)EST,-.K5I5'3SC'*Y6HJEB/><::O1:5ZLG?5Z))W
MYWM'1RLG&_UM^QC_ ,$_K?\ 9,^(EUXSC\9^'?&=CX=^'>K_  O^'<6G^"=9
MT?QEI_@35O']Q\0;N3QYXIUKQ?XFL[R_M;@Z5I7]F> M)\#>"[LV#^(M2T*;
M7[U[D>9^&?V(OC%I%GI$WA'QQX)\">//A%XI_:?^&FD7WQ.^'\/Q=^$?Q]_9
MC_:$^)5Q\8K73_&7@FQ\3>'-;TG6] U_4(M*AD.KQL+S0];M[NRU'1->M9D^
M-]6_:R^/WQ?^(?['?ASQ_P#%"T^'^O2_M+?L!:K=? 3PQ\*_$>A:[\5O#'C3
MP+'XO^)GQ>N/%AN8]4TWP!'XUNM6T"Z\*@2^$O#MOH#^'?%SS:SJ-NL7U3^T
ME^U]^T%\./VA?C1X0\*>(](TV_\ ACIVAO\  W]F&?X)Z]X]UK]K"QU?X.>+
M/'>O^-+/QMH8CUKPQIVC^-M"M_!L5]I@&@^&Y_#EW9^*$N]0\8^'3'P2P/$=
M7$Q]ICLLKXW-:%2M%UJBITJ5'#XEY?@XU9.G*,HU*>85U5JN,<'0IU)5:N(H
MQBW3IK+G2:G1Q*I0FXQBGR2;C!VE>DY-+EA:*DU)Z*SYK/#\*?\ !&SX<:IH
M.L^$/V@?BIKWQ>\*'P9\:O#W@G1_!MAXA^!>F^"=?_:$\9WGC'XF^(K7P_\
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M&3T)X))P<')'08'IQQ70PP0P($AC5%48 4 ?K[]ZEHH **** "BBB@ HHHH
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M?-!8SK%+J>JV[3RW>+MHX0_]KW]BY/VJ]=^&OB&'XEI\.M2^'%IJ^F0:U9^
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MDDUHT@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#(UFQ-_92Q<[D(EC ."Q4<J#VSV]>G<$>6A2I<-P5
M=D*D\C;QTZX]^]>TG\OK_D5PWB#13&)+^V&5SNGC QM4]77&2<$G(P!C'/6@
M#D*4%@058(P="K$E0) X,66&=@$PC)<@JN.0>*3\"/KP<=OS'-(1D@@LI4G!
M5BK8*E6&00<,K%6'1E)4\&DTI63=ES0;ZJRG"34DM90:C:I%:SIN<+KFN--K
M5.SULVKVNFKVU[L_GK\2:9K<?[8_CWQW:>'_ (P1?L$:G\6_B;IO@6QCCU5_
M"<'_  493X7ZKH&I?%L^&X[#^WH/V?-;O3J7A7P=>7-S-X,;]I,W?C"*WM;:
M_P!'N(_*OV9?V8?VD_@'^QK\'/VG/AM>_#CX%?$G7/V9?@#\/8[3X3_#[X@:
M_P#$;QEK?QD^*_P5TOQ%\3/VBO#/Q"U&Z\.^)/'OP]\)3Z_>6UM:Z ;W3=8U
MGQ!JE]K46B1KIR_TUEG+!_,?A!$5W?*T03;Y;#H\><2^7)O0R[G<.&VAYE?D
M@_-EBKN%DD!=PS-YCAF#LNZ,NFP["@&#&"?N)<:U_JU'"4L!A?8TZ>$IXF%>
M'/\ 7*>'C&/*U&4*4*L_?EBJU7#8KV\EA7&--X;GGXT,G@G5<L1*\I.=-^^E
M"<I<TMG>RLK1V6NK3L?C5\*?C%^TOK?[6-A\!O$GQD^)7B"]E^)WQP^$7Q.^
M'T_PJT'PQ'\-O@)X(^'EVOPD_:FT?XH:?X+L=/?XB_$GQ=%X;ODU6'4=5\'Z
MM?>-+S0]%\&V,W@]KA?D'QIX<UW2OV./V8=*^)/Q=\9Z'9>"?C'^W1>7<GQP
M\#_'OXRO\8_$&D>//B/IGPN\+_$'7_A=K_A/Q/9Z]JME&UQX7O=6(T_5OM#C
MPEI]S?Z=:64O]*?FRB-8A+*8T541&DD(VHH50^UER0P+_+Y:[SD*/FW"RR1[
MFBDDB>1461T?;O$:QI&=JA5!14,2'!*P%8LY3>W-2XJCA\1"MA\KPU!\V E6
ME3IX649NE2Q\,2H1>"IP49?7*MD\.I/VJ<Y5ZM.-:GJ\!6=T\7)W33:YU=/H
M]4[Z)MJVJ=K)M'\O>AZA^T!KW[1>AZE;^%OB)X%^*^M0^-/&?Q@L=-U#XY:K
M\0_@7\!]8_81N-.MO@A;_#_4=.A^'?BWX;?#SXO7GAO4? OBG0?%-UXH\:_$
M"W?1K/3U\9:7K=P/M;_@GC#XB;X$_M1?"CP'?CQ1X4\/?"_P8/!/[4'@CPQ\
M6? ^I?$'XG:]\)-7M/$VA-X4^.VN>,-8D^(OPYN-,T:ZU/Q%8S6NF:M?>(8K
M+6=/LO$>EZC'#^UPFG"",32; _F!2[LH<$,C;79UQ'(JRQ( L:2F1RC%P$)9
MI)2&=Y'=00A=V8)E=IV]'#, -[^87?D$A2%&V8\74<QP<\)+)L)"C+ZLU2E2
MHKW\/5HSC-U8T_:OEC2=.$'4Y%&I4<XSFX3CGALJE2K1G/%S:7.FVZDDN:$T
MK1YFOB:UM?16:LS^:SPK^T-^W'X7^ <GBGPS\7OB#KOP[\,^*OV./@C?Z_XM
M^'&CZ-J7PZ^'/BS]GSPWXV^,GQZU7Q3J7PZU_7+OQ-9_$^>U^%=[KVN>#?$F
MB>$8]1U#5-3TI]1#ZI;=3JO[;'[8FFW/[+T7B+Q]XHTW4]5\/_!_5O'G]G_"
M:72_#'Q-\->._P!H+6/A_P"(?&8TW5?ACK/BO6+O2/A;%I&M^*)X&^$GASP1
MK\EGXNA^VZ;K]II=O_17Y\_F"3SI-Z9*,'(8$[]P9ARZ,LC(5/5=A8NZ*U*M
MQ,K._G3[GSO8SR$R':4!E)8[RR;%<MN.(42'R(GFBEVAQC@G756IPOETYQGB
M*D:O^QTDN?"8;#TZ;I_4*FTJ,I\ZM&]23C&G-<[RAE6)5.$5C73:OS*TIW?/
M-Q=VW]EQMJW'ON?S!_#3]H_]NKX9Z7\ /A9H7CKQ?>_V5#<VNDWGQ8\%:CJF
MM_&SXJWG[67Q$\+?$OX3>+IH/A?XCUK4;/P5\/K;PZVEGP_KG@>X\/V'B&T\
M>7NMZIX8T9(K7Z]_8E^*'Q<^,7[;O@CQ+\6_'7CC7_%NG_LV?'S3OBQ\,M5^
M%U[X%\%_LV^/Y?CUX,L[;X4:#XC70=+MO%LMKX?T:V.G7>L:CXBU2ZTZRF\=
M6FI+IGB6&SC_ &^\^;+GS9&\Q5#AI' =D01H[%"K%DCW*-S,K942*Z1A"OVB
M8^0&EED6W:-D5Y"!^ZQL 6/RT3'I$L<?_3,')...XOPM>GB_J_#6!PN(Q>%K
M49XBC/!*HIUJ<82DG3RZA/XG.:]G4H34XW]I]5DL$M(Y974N:>,Y]%IRR3;B
M^:.NF[23YG)6N[<WO'\U>K?MI_MFZD_C+P_X;^,_B[3_ (P^(O!7B/4O$_PF
MN?V==,?3/V:_%-G^VA\'_@UHUA\/]9N- BB^(MC9?!3Q?K>L:I9ZE=^,K/4K
MFYM_'=YJ>EZ;<1:9;^B?'+]IG]N3P+J_QP\(?"3XD_$?XE?&7P&?VAO"UW\(
M+_X$:0VE^#OA/\+/A@-=^$7[2>G^*+'PK86?B+QE\2_%-MH=]=1V>JZKX8\1
MWGC36O"7A[P=I]QX5>XA_9_X>_LY?!#X3^+_ !)X]^'7PYT3PQXN\60:E9ZU
MKEM<ZW=W+Z?K&MW'B75]*T>WU+5;S3_">B:QXCN[K7=7T+PA9:#HVH:K.U_-
M8_:ECF3V_P Z?:J>=+L')4,1\Z\(ZC[JL@+)@JR&,A2O!+;U.)\EA7IQH<.X
M:MA*5./MHXQ8:4\74E3I.4;_ %'$2C0@X.DX\U.M-0P\U6YUBI8E++L9-59U
M<=:K4Y53Y5-1HJ,>79.SE)I2;LTM4EMR_P \GC;]OOXH^,?B#\19= _:,\?_
M  ;_ &?KKXI^*=(^&/Q1\/?L[ZCK>M:]HGA?]DSX=^.]*T?0+#Q/X%U'5/[!
MU?XT:SJFGR^*)_#6H0W=R[>!].N;.75].O8?V0_9;^*GB[XL_!/X>:W\5-!_
MX1#X[:?X%^'!^/G@:#2=6TFV\"_%?Q-X!T+Q5KOAVR75(!%+;01ZO&\L&E76
MHV>DR/\ V1)?M>6$\">X7N@Z1J7B/P_XNU&PAO?$WA2#7+7PSK4KS_;-$M/%
M$-G;^)+>SVRB$QZS!INGI=+/%,JFTA>%8V05L$LQRS%L9$:DG;&"23M (^;D
MKS\NS:"I*!J\3-\WR[,*%*E@LI66*/LY<L:E*IR.GHHRG3H4>><E&,ZLXJ%.
M59RE1I4:?N2Z,%@Z^$NZV)^M2E?FERM.[>_O/:/1)+=[Z6;@>@XQCCIMQM_+
M QZ8&.@I1P-HX'H.!TQT''3CZ<=***^>LE>R2N[NR2N^[MN_-W?F>C9=E]R$
M(! ! ( V@$ @+@#: >,8 !'3  Q@"E/)W'DXQD\G&=V,GG[WS>QYZ\T44-)[
MI.^]TG?UNG?9?<NRL!WSW(P3W(],^GM1[=AT'I1157;NVVV[)MMNZ6U]=;=+
MWMTL%M;];6OUMVOO;RO;R"M+1[-M0O8XE_U28>8XQA005Y..N#TSZ&J4<332
M0PQ*\DLQ("JN0,''7Z9))P!BO2-&TD:;!AF#SN 6<#Y5Y)"#/)VY(]J0&RFT
M* OW5&T>P7Y?Z4Z@#'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *8Z!U*,H*LI5@>FTC!&/<<>U/
MHH Y74?#-O-F2T)A<?\ +(9V,?PY'X9QSCTKD;G2[^U=D>V=D5=Q>,&0 #N6
MQOV\\DKM'0GI7K%-*JV=RJ<C!R <CT/M0!XT01U!'?D8X]:2O8%AA;=NAA.U
MBHS&AX'0<BG?9[?_ )X0_P#?I/\ XF@#QVBO8OL]O_SPA_[])_\ $T?9[?\
MYX0_]^D_^)H \=HKV+[/;_\ /"'_ +])_P#$T?9[?_GA#_WZ3_XF@#QVBO8O
ML]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B: /':*]B^SV_P#SPA_[])_\31]G
MM_\ GA#_ -^D_P#B: /':*]B^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XF@#Q
MVBO8OL]O_P \(?\ OTG_ ,31]GM_^>$/_?I/_B: /':*]B^SV_\ SPA_[])_
M\31]GM_^>$/_ 'Z3_P")H \=HKV+[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_
M .)H \@2-W*A8WD+@E0@.6QR2N!R .3CMW%;=IH%]<L"\?D1]-Q(.._*D GM
MV['FO05BB5?EBB78 %*HH(SP<<=\<^O>IU.1VZXX_"@#'TW1K;3B'13),5 :
M5CT)^^5'8$\@'D?6MK_/^?SHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH :V[:VW[VT[<]-V#C/![^Q^E?SG_\
M!5/P]_P5*U#]O7]A+4?@?\2O'G@;_@F[>ZEX>\&_M.K\'?&^C^ OB!;>/?$W
MBKQ'9R7OB;52+;QM-X6U#2)? ND^'+CPU<W%GIFKOK;:G!:275O>G^C*N0\;
M>!_"_C[2K32/%NE)J^G:=KFC>);.VDN+JW6+6O#E['JNC7H>SGMY2UE?V\-P
-D9D,3L@$B.O% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $: ;\# 2(  A$! Q$!_\0
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M?>#/&OQTTGQS\;OA+^S[\=K_ /9QUK]I7_@Z#_:<^#/Q$^(/@KPYX-\2:D/
M^N?L:QZ_KFC+H?Q \.>+?##>(P-#T0C*,1XS!D"@J&7SZ_\ C-\7_B!\1_\
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MY0V[5=9+[%.=F5+E>2Y9E4#9X/XH_:H_9?\  O@GPO\ %GQS^T;\"O!?PO\
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M@88#(^GMV]JK^8 "P \DCKVZ?3I_7BMUT^7X#3_V;ZK\U+U:\NZ[]_(_B?\
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M9;*"+]]]G;[5;$G[/:\W@*XXVAL]B%)[]1@8!FY1110 4444 %%%% !1110
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M9_!OC'7?$;^!I&\?-X.)_JFHH _ ']N'XQ_ML^'[K_@G%X-^"/B+Q-^S5?\
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M2[:YM0V-..7*#>&&S + 8*]0,< @'\O?B'_@I#^V'X-\5^-_@S\3/C+^S_\
M#CPSIW[8_@'X1^+_ -MO7_A"J?#3X#> ?BM^PUH7[6(T37_!.O?$D^&4\0^*
M/B/KC? KP-XH\6^+_P#A#D#%_'2?\)VXW^-WO_!5W_@HM>?"T?'B_G^$OPPM
M/A1^S+_P3O\ VC/'7PF\0_"352?C3J?[1W[9_P 6OV;-<UG1M8U[Q&/%'P_^
M''Q7^''@O0?B=X'=X_&'C+PB-=\-QJ2PEQ_7/=:=ID\6H0365M<+KC,MW;7
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MPLN_!'B_XE>(_AKX$\"?\% OVA-=^!&B_#+XX<#Q,/C-\*BO_"3-_P (FO\
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MH@2"/++'7^43J\MC_P *FN)O)^S'_A$ !:#U_L;^7?KSR:_U9?\ @CU-(/\
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M?%,B?\)GX-C*Z*8W\:^%!)O7Y1\(?\%*O&6@_LD?#7]IGXF_LC?'[XLV^O\
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M;_<X_P",^M*/V7 ^7/P ^////''7!]* /T\_:(_X+]?L_?LA^+O#W@']I_\
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M@U3XC75MX.73'UEO&_P4^,7PF0QZVNMKHXT5/C#\.?![:^&_L9MO_")^;&@
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M]H!;2& D$CQNC%"<EF8!WV"0^PTP/SE_X*>28_9]^%I]/V[O^"="\#_J^KX
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M\IFOV4/^Q(_:<_\ 5-Z\/Y5^@7_!V;_R>Q^R!_V;-X]_]64*_/;_ (-ZHO\
MC<O^RQ^Z@G!^'W[3&<D$Y_X4YKN%/KG.P\<!B/>OQC'Z^)^6^=.:_P#*;/\
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M...N<9K _P"",L5P?^"E/_!3>:>#[./^&>?V #@].3^TQCKZ^G'0?2ME\/\
M7<:W7JOS1_GA+_R+5C;C'VC_ (3$@?:1QC_A9W3'8^OOGM7^T]:_ZFVSUE4
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M^A>,O!3>(/#GAF+XA^ #XH\%>.O#0\5^$#XJ\&R>,M!\21LY\H[_ "W]DO\
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M:9X:T?P]:6>J:=I6B:5H>D1:'H.D:-HHC4C08!&JH V"JKN>1U#Q_FS\1/\
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M\(C9XO;0P4WB-#& ?J[^R[_R;)^SE_V0GX,_^H1X=KZ"KY]_9HB$7[-W[/\
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M;6N_B]XM\/KJIU;QCJFN?!;^WW;6R&V8D\1$>),%(<,CD91D8 '[BT444 ?
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MK5O'>C:CJ?A+X7>.M;.@?'+1OBMX'\/^(QXH^'WP\\5^&="51XH^*_@WQ?\
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M_;?[;&_/7/\ PSV,9SQC;G'XXK].Z_,/]J3]Y_P40_X)5D^2V-:_;9SCJ?\
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M@_L?_'_3S_:7]B_V%_9# ^%RI7G!&TEL']V>E?Z;?_!*OPOX@\#?\$V?V'_
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M4?\ !:X+/_P5O_X*.&4SX;XB>%;0;;4.,?\ #/W@(#!.3VXXY7#=",_WV?\
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MPG_S5'_943_-']1?2<?N^%%O^C6\-^GP+;5]/S->BF1_<7Z4^ON3^7 HHHH
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M_%T=%XX!S@=P",?AGX)_X-^HA#_P6:_91@^VVURW_"#_ +315K6VQ\J_!CQ
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MB?M4?\I$O^"5/_8=_;9_]9[6OT[K\P_VIH@?^"B'_!*_SH()_P#B<_MK$W#
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M]"M%?CEKG_!67X7>&_%W@CP1KW[&W_!1;1O&/Q%NO$Z^ ?#UU^QGKHU+Q8?
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M2%S(4;S3Z?\ %_\ X*3>,O@]X13QA\3/^"9O[>'AWPPWB;P'X+756?\ 8?U
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M0\9>"_&/@O7O#7C8$,'  /UI_9?_ .39/V=NO_)"/@W_ ,?/7_D2- ^_[_\
MV%?05?D?\'OVI_V@?AY\)_A1\.M<_P""7?[>-SKG@3X<^ /!FLWNDZQ^PS_9
M[:CH7@[1-#UG5=&/_#:^6C60RK&/E888!RXD9N:^#_\ P51U3]H*'X@7OPD_
MX)V?M]>+1\-_B[\2_@7X\NVM/V-=._L'XG?"G6VT#QUX/)U[]K51_P 4QXB!
M"MPH920&^9* /V5HK\X_^&X/C[_TBU_;T_\ !M^PY_\ 1KUX]\'O^"DOC+XR
M>$V\9?#K_@F?^WIXD\/6WB;QWX*&JM_PQIIBKXI^%/C37O 7CG15.O\ [:J-
MN\+_ !'\$:YX9.6;#Z'A<C:M 'Z^X'H*3 SG SZXYK\LO$O[?WQ3\"^%-9\5
M^*?^"8_[>MOX3\+>'M5\5>)-5L]0_8(U%=/TW0]";QKK>LNB_MMC<H"G*'"F
M93(H61<BEX)_X*#?$?XD>#O!_P 3?!G_  3,_;RU+PMX\\.^&/%/A#Q!_:_[
M NF"^\+Z]HIU[0]:7^WOVV5QG0-;WDN'+9=<X8;0++LN^R/U;HKYC^!/Q6\1
M_%G1M9USQO\ L]?%/]G"?2M6.C6?A[XV77P=?4]?TQ-&&[6-#/P=^)7Q<\,'
MP^PX5#XPR2"<, 5'TY0 445\G?'WXL3_  E\+020^$?'FN6VKV7CFUG\:^%O
M J_$;3?A1'H7@[7-=E\;^-O!!\3^%?%/B/PZC:1K'_%+^$X_%WC'QD7BC7)<
M-0!]8U^87[5!AD_X**?\$JL^2Q&M?ML8'!;C]GL#CZG)/OG%?D1\+O\ @HE^
MV'XEU+]EG1+#XJZ+XUL/'?[2&J^"_#/B31_V?/[-T_\ ;>\"?\-G^ ?A1KPT
M'7"#X9T ?"C]E/QMK?QW\;^)O"G_  B"MXS\/^)D8.OA'QFI^[?VEI_V^?%7
M[7G[/7Q3\"?\$]W\2_#_ /9@\8?M%:=9ZO\ \-3_  '\/:E\6?#'Q3\$GP)H
M>MZ)H7B [M 8$GQ-)X:\5LK%E6-F\Q0  ?N/17XP^(_V]/VQ-!^+OPW^".M_
M\$NM=M_'_P 6?!WQ2\9^$/#Y_:T_9L.G:AX:^$Y\ Z+XZ/\ ;2L,;3\4_!0:
M+;G&(^ NQO9_^&HO^"B/_2+;Q'_XF=^S50!^F](1D$>H(_.OR$\;_MF?MW?#
MGP3XP^)GB_\ X)<>)-,T+P%X0\5>,_$-W:?ME_LV:EJ.G>&M#T(Z]K@T=0R;
MU"Z*#L8@'AU*MM98_ ?[9O[<_P 2/A_X+^)OA/\ X)<^([CPSXZ\'>&?&?A?
M5KK]LC]FW3M0O?#'B'1AKNAET5U31F&A:TS,RE60,R;D+,[ 'R+%_P &P/\
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M/@[QL/&I/_">>.?!_@%2]>=?L&?LA>*_!7PL\/?M,?M3:O!\-/"NJ/\ %_\
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M9/&OQ0\4HO@SP=$2Z2LQ02?G5IO[ /P"_;=\:_#;]L6]^$?B/]F#Q@?BFOQ
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M;QWXRUWQ[XW\9>-==,CMK?B3Q7XCU[5_$\KL%+-J[-Y*+Y?E_05%% !1110
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M_P"&VK_"_P"".C? 7X9_!GX.C1O#Z2?"[X6Z"OB+QCXG\-^&_%/B;P4OQ/\
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M5?!/XH^$/%_@_P 9^-/!7CJ3X'_'?_A-? 7A!?\ A-/HS_@F)^R -(\<:_\
MM/:'\3/BWJ7A#Q/>^)M'^''C?Q9XQ\:K\3/VA_@W_P 5#X&T#1?VBM$\?_\
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M?#&C>(] %WJNF:M>^!-%5?$'@71OVC#H/B$?#+XR?M2?"<:SK7PP\:?M1_\
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M/B%=LGAWQS\5]4\!^"M=\1_V+)KKYF\0/X6\,Z)K?B1O^$4+,5T#>=C>$]Y
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MS\4_VJ].\??%3XE:CXB^!_P]?P+XH^#^K6OCWQKI?QT\"Z1X"\8:_P"//^%
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MB^*G[;OQ]L/V0O _P8:Z\/>,_AQ\>-:^#W[1_P /M7\%_%KX&?&CX7Z]XU\
MZ#KG@KXW^!_'_P 1OA%XG\0_#OQ;\.==_P"$6_:D^ GA3P@?C1X+QX7^./P%
M\<?\(+_PAOC0_MW^RO\ LM^&_P!FGP38Z?8RZYXL^(VK>&O"^C^/OB9XA71=
M5\;>,-+\#G7_ /A5FA^./'!\.>$O$WC_ /X51X:UL?##P9XH\6)_PFC>"]#\
M-'QT6?>1B_LK_L0_ +]BFQ\?Z;\$=+'A.'XB^+SXT\0K=6^D1*%T?2#H'A_0
MM)C\/>'O"J/X>\*>'(UC68+)XU+&3_A-O&WB\,V?O"@ HHHH **** "BBB@
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MQ/UO1M";QYXUT/P4I?PQX _X3/Q"-:\5MX4\*,/!J>+=?\1DQPR%G/UQ110
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*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #X 0(# 2(  A$! Q$!_\0
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MWIXL_80_:(\<^#?^"A>F_$"Y;Q9_P3IL;3XEZ5>R?$KXM_L\_&']H[X_> _
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MS_P6Q\4_#K0/"7[1WC/P[X=O-1T/7? FN_\ !,/1M"T >*HUT#PY+XB&O?\
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MFOT'_P""$_\ R<S_ ,%A/.M_LI_X7I^R?FT^S _8C_PR;X>PVWZ87)^[C/\
MRTK\P=-\=> O _[7G_!52R^(/Q+\ >$-0O/^"B/Q0OQI'BOQWX/\-ZCJ&E#X
M,_"1#K2:+XA\1+O561E#@8RI4X(*C]-O^""VJZ7J_P"T/_P5UUW1=:T;Q'H^
MK_'7]F%]/\0^']8T?Q'IFI(/V9=!0NFM:#\D@#J4+?,%8,N0=PK:?P2_PO\
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MDQ?\)S_PN _\+.'B0+M+CQ>#XP)QE2N* /P1_:T_9/\ VW]9U7]K^;0](_:
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M#_Q+^$OB*63PFBCQ0OA/PUXR\)3^-O%^@Q^"PX_X2MC)Y-_P2]\#_M)_#?\
M9[\8:9^TUX:\2>'?' ^-?CIM&'B+QCXR\2+>^&%T7P+H']N1?\+!^-?[17B?
M^P'\1:+KR>"\^,U'C1-OCD^!_!P\7$'=_P""E?BVQ\+_  $@T;Q]^R)XO_;"
M^!'C7Q'I6A?M ^!_"GB?1_#NH^!/A?&)]>7XG:W%XA\2^%(]?\.^%/$>C:)+
MXVDC\7QR>$$\OQO,?+A5:[#_ ()\1?L]W/[/MMKO[,7PR\>?";X0Z_XO\1ZS
MX=TGQOXA'C;4M>U3_B0Z!K7C%?$#?$?XL"303-H;>&$ \7 @Z%XD ACW[RAG
MP9^U3^PU^UM\7_'&N?$:+QKX<\6^/M=_8&_:(_9T\7V7ASXA>,_A3\-M2\<:
MW\?_ ("^// O@SP-\*_$'B+Q9)\/)/BM\&?!'Q6^%_CCXEQ>,)2ZZZC,H\$>
M4B\7\>_@9^T#\&_^")7[4'@GQ3J_A+X2Z/HO[-W[=WB;5/@[_P (]_PMQ/AQ
MX!\=>,?C!\0?A+\&_#_Q23Q/X34)\*?AQKG@SX7"1O!OBXRGPWU=%B-?T;U^
M=O\ P5AY_P""8G_!0<F?[-#_ ,,>_M%9N@<[2?AAXA&<^A^9<CT[\T ??%J#
M%8KP/M M1D%#I^<?A\O/\7.,<GFMJLRU_P"/)/W?V3_13\N1_HGRMQGKQ][@
M=AQC&-.@"L>D/T;^0K\G_P#@N)^[_P""1_\ P4#$IR3^SCX\Q^/EX.2,#.0>
MG?WX_6&ORA_X+?8B_P""2'[?J&8C/[-_CNW-PWO'&I#8QSC*G!]<'K48G2G/
M_KW4?WPJ'5E'_(SP_P#V%X7R_P"8BAU=E^)_#[_P;I_\IBOV4/\ LD?[37_J
MMM;K_35;_7Q?0?\ H-?YF'_!NJP_X?$?LJ2-]T_"S]IZVM<G/$?PP?)QC^ZS
M?YZ_Z9_/F'_7>5@?3(49S_%UZ>V.U?/<,JV59>FFGSU-&FK:S[I'[G])62GX
MO\1RBXRB\+PKRRA*,XRMPUDB=G&4HW3;32D[-.]GMI+T'T'\J6D7H/H/Y4M?
M2'X$%%%% !1110 4444 %%%% !1110!^(W_!6.7P_P")/A3HFEW":7-\1OAU
MK+_%KX0?#WXF?!]OBS^SY^T/XI_X0WQ[X$C^%_C71=?AA\,>(O$!77F\6^#/
M"^Z7QJESX&\.^-? '@SQH(SX,;ZS_P"">/A[6_"G[&/[-WA37K7XD^&_$'A/
MX7>%?!FKZ5\4!K5[XZTS4]#1=(:/6!XA\+^#O$^B6WEZL'\%^&O%7A/PM_PB
M/A)M!A;P5 ML8X_F?]N+]G;XQ^-?VC_V?_C%X>^#WBW]H_X8^!O"/C_1/&'P
M>\,_%#X;>&]+UW5->'B%DT;7?A;\81X5^&'B#P[XJBUM5\;ROXP'C&1_#_A8
M;$/A1?%P^WOV;-.\;Z%\*M'T#Q=\%KKX!G1;MM'\)?#$_%S6OC9J.A^ T"1Z
M(OB'Q[M\N+Q*0^KC_A%/"_B[QGX0\'0KX<\GQF^PF( ^P*_.+_@I;_R2W]G6
M/LO_  40_P""; X]/^&T_@\?_9?3I^GZ.U^;W_!2O_DDO[/G[WR/^-B?_!-?
MCCG_ (SF^#/R<\?/TY]#G/< _2&BBB@ JI+_ ,>S\9_T4\>OR]*MT'H>_MZT
MFKIKNFOO37ZC3LT][-.VU[-.U^E[;]-S_%:^&!QX,\,"XN!]H^Q:G:?Z7CD_
M\3T@#^WL@$#.<D8Y! ; K^ZG_@FT9I?^#4;]H6>Y/D0G]DO_ (*G"Y(M/L)&
M=9_:9W>P5$P#WC VD96OU-B_X-^?^".NGSQ36_["_P ,!$A(51XE^)FW+<!E
M9_B$R@9R20I'][/2NG_:N_9\^"_[+_\ P2$_;R^"?[/OPVT7X8_"CP=^Q/\
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M^Q=\,?''P*\':/=:_J?PMTJ\\"^$?B;\4?B=JFFG4R$QHOC;XI^/O#!^)\B
MN-_BKQ5X.;QD,L&\$@*R#XN_X*^?$?2_#7PV\$>!_#MQ^RKXE^)!\8-XFO/A
ME^TCXZ^#^F>.;_X8:YX.\?\ @/Q!K7PKT3XQ_$KX2>&=GBQ]=/PP\8^)V\8?
M)X)\0>*1$S>-RI'W1^PT;BV_9+_9X^S:%\)]"TVV^$/@,?\ "/\ [/\ =Z/J
M7PALA_80^;P)K6@>)/%_AG6_#BL!M_X1;Q;XP#.C$>-?&0=9& /PB^-?P^_;
MN\7^,?VP-=\'^$?^"BNB^#KSXJZ7HJ_#_P ._&S&H^/=3?P;\?1X?^-'P.\<
MGQ-X2'@#X>>$_P!HO7?@;X6_X5=X2/@X/^S+\(O^$Z^/*^,?^$O'@D?7_P"U
M]%^W+:>%_P!E'1/C!I7[+Q^$%O\ M@_\$P-'\7^*] \?_$T_'#4?'@_::^ (
MUPQ^!_\ A6[?# 1GXBC6C^[\8;?^$,9BP\S?7[Z5^;__  4K_P"24?L^?O/^
M<BG_  36]L_\9S?!KC\>G_ >.M 'Z04444 %%%% "8'H/RKS#Q5X/\*?$#PW
MXG\$^,-+TOQ7X.\8^'-6T+Q=X?U6T35=.\5>&]>T4^'->T76M$.^/7="\3Z
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M/Q-^#OP:;X=A_"9/A8>+H_&?QL\>Q?&[QW)X0\#_  J1!'^U%^R_^V%\*/\
M@C=\:/"@^+?@O]GCPCX)_9Q_;;UKQE^SA=_#G2?CYJ&@_##QYXQ^,/CSX3_!
M;0_C>OQ(\(IH;?";X*Z[X(^!#>)/"O@_QB5&@)-X#48@8_T[5^=G_!6-0?\
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MI.KZ39?$K3R/[<_L1&4'XO\ QJ^,/B@R(NBZ0,1^,!X-8MY?_"$[7)K]#J*
M"OSM_P""KDH_X=C?M_L?(R/V2?CU]KST'_%L=>S]2>,9/3D5^B5?G5_P5B /
M_!,;_@H*?-N./V0/CY;?Z-<D,-WPQ\0@E>@5COPQ.2RDC R: /ONR,45C;V^
M )A9\6N>3T/3'8_IG XK:K)B/^CM%@"4B^Q!Y& ?F;C R,#([_O ^WJ#C6H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_XA:IX[T;X<^*;_
M .&7@=?B)XYTW1Y)?#O@G5O':^!].\5ZG]P:4WC9U\6'P]Q@M(ZD#&"60AA[
M!10!_*)^T'XF_P""A$_C;]K@^#_#O_!1[PY\-]?\7^!M9^R>$O#?_"2>.?AI
M\3E\&_M.!O!?[+&MZ!X</_"P/@SXI^-6B?LK>)G\4_"?'@L?!G/_  OL>"_'
MA^,ZU^AG[2/PS_X*<?'3P/\ !WP5IO@#]CFVN?!GQ%_8[^.FI^,/'OQW^,'A
MOQ-K_COX#>-/A#\>/'7@K6? W@#]F[Q;X6\.#Q3\1_ VM^$U/A;QEXNA7P:R
M^-GPQ3P4/VOHH _(KXO?'7_@IM\&OA5\3OC#XA_9J_X)^ZAX>^$G@3QU\6/$
MEGI/[77[05_J=]I?@;0-?\0ZX-$5OV)$ U\)HH W819/W1(F&P:_PX^+W_!4
M/XF^!_!'Q+T/]FO_ ()_VFG^//!WA?QIHUMJO[9?[2)U2QTS7=$&OZ&-9'_#
M$1RP&L-\H0D!VP,A/+]5_:^_;"^#_P"Q]X#@\1?&!-2\<7_C_P 1#X?^&/A/
MX7O/!\WC;XDZKK;G1!I.AZ+XB\2>$O#KL[2#PQM:?9XP\9:YX5\"P*/'GBOP
M?X-;ZS^'?C;P=\3O ?@GQSX!U:WU?P+XQ\.:1KOA"]M1JFG1WWA;6=(#Z*>2
M&!9<@LWW0H9 K8W 'Y<?';]I7_@I#^SMX,TGQOXY_9E_8,US2]=^*7P:^$IM
MO#W[9/Q]&J_\)-\=?C3\)_@+X!&[Q!^Q*O\ Q38\2>.?!B^-,$G:6?#%LM[Q
M_P )G_P5C\S=_P ,S?\ !/7&/L^?^&R/V@<[<YV_\F2],?P?>]L4S]HS]O/]
MFG]G/XE_#;X'_%S5[CQ-XR\3:O'K%UIFEV>B>(F^&VE:#J_A[7)/B?X\&N^(
M530/#WA1M;T3Q9NBC\4^,O!_@P)XUV)&BLWZ+3RPVBW$TY_<6X-V3Z'!R1TX
M!SCM^HH _&OQ[^U;_P %(OAU\8/V??@3K?[-7[" \;?M,77Q/LO ?]G?MK?M
M )I^B#X4>"?^$ZUWSEE_8G64X\-E@1X97<67)7D-7T1_PF?_  5=QYG_  S/
M_P $^,^O_#8_[0'Y[O\ AB+'3OG/:O-/#G_!3G]D+QO^T;\*/@SX1UW4O'M_
M\1_ OA;Q_P"!?C%H"^$?$'PTT!?BH^M>'_ VAIKFN>)H?%#>(?%GB'P]K_A:
M-_"W@Z3_ (K31/\ A!_'3_\ ":$Q2?J/J,PTZUN=3$-PWV.TU*]:SM<'[;@*
MPR!SNQ@CD8)R,X (!^/UO^TY_P %(Y_VA?%7[,UO^S/^PW_PL/P)\&/AC\=-
M:U]OVR?CZ/"][X5^*OC+XL^ = T:)F_8H_X2=O$#>(_A5KS,%3:/^*8*L[.R
MQ_5WPVU[_@HI?^./#]G\8/@C^QCX>^'MRRCQAJO@;]I[XR>-O'.GZ:NC?>T3
MP1K_ .R7X/\ #7B'/B$@N'\9>#U9%&%(;YO(OV1O^"B7[-W[6_Q7^(WPY\'Z
M5XQ\%_&/P5<Z9X-U?P[\3/AMK7@SQV)/#_@_P]X^U_P;KSG0'T#0O$?PJ\0>
M.?\ A%O&7A*/Q>0/& G\;>!_,\!^,? _B_QA^J5 !6=-YT4-P8.9^"#P?UP.
M.?P]JT:* /YH?VG_ -D#_@HC\7OB[J7CBS^%GA:W\<W7[+GQ3^$?Q(^)GP?_
M &@O%WPY^$/QG\!>()3KOA[X+:%X&\<^(_\ A9OP^^(!715\,1E_^+-B+Q_X
MF\=S>.O!OC_PAX1(]QT_]A']LGXI?\$]K?\ 92;XQ>$_V7/ _P 1/!'[3OP\
M\8?"?XA?!8?M0?$OX:_![XM_$[XMZS\)OAAHOQ4\/_M)>#_"S_\ "J/@MX@\
M#?"X1N/&19M 4IXV:383^]M% 'XH_'Z+_@J+\(? ?AGQ5H_[5/[,'Q%O=<^-
M?P*^$X\/^'/^">7Q,46&F_%?]H/P'\)=:\;$Z%^WSXKE3_A4_AWQKJ_C"Z@:
M%4=? IA6?PGN>XKZ*_X4U_P5'_Z/\_9%_P#%<GCG_P"C_KPW]K_]N[XP_LI_
MM6?";X<S? GQ?X]^ /Q.\">%UTCQ=X>T?7/^$G\6_%+6_B<OA_7_  7HFN2?
M\4T?B)X5\-:UH?B?P/\  @^#S)\:8_$/BAH_'O@P?"8>#O&7[+4 ?BS^T;;_
M /!4_P"!GP ^._QCT']J/]E[XHZK\&_A!\2OB=X<^'>C_P#!.7XDC5_B7JW@
MCP;KFOZ-X(T?^P/V^O&'B&*3Q4=&C\+QL/",[2;BR1D !_<M(^$'_!3F_P!+
ML;[_ (;H_9-M_P"T;/3;NTM+G_@G%XU4Z>616V[5_;]&6PP*Y.Y.-I!.1RG_
M  41_:]^,'[']I\$_''@;X5VWC_X9^(/&/BFP^*WB&].LG2_ 9713_P@6C:_
MXT1]OP@\.^+=?.M?\73\7>$/&/A#P=XO\/\ A3P))X(_XJT>,_!?OOQ,^+7Q
MKU7]CWQ#\</V??A/XDUOXVZG\%Y/B?\ #?X*?$6S&F>*&\2:[X-'B!/!&O:'
M'KT*Q>(869HH_"I\9>$MWBN/_A"9/'7A-Y9)(P#XB^!5U_P50^,U[\?K3Q5^
MTM^S3\-+CX3?'_Q-\&O#5UXD_P""<7Q)<^//#.B:%X"U_P#X63HG]M_MN>%R
M^@>*AXW_ .$78H)(V_L M&\AS7TU_P *<_X*A?\ 20/]D?\ X]_^D<GC7_OK
M_E(!]S_9Z?[-1_L$?M?^*_VP/@[X@\<ZY\-/$7@'4O!FK^&?!NJW'B#1=9\-
MV/B[4O\ A#/#?CG7]8CT77] B\3>'?$?A8:\_A7QM\+V/C$>"?'&A^(_!!\<
M^,A%_P )F_WEK]]JNFZ/?3Z(EIJ6O"RU)O#NEWEZNEZ=K6ILDC:)I#ZPX 4%
M@$RI+'>Q.T*30!^0G@.?_@J=XQ_:%^-WP1OOVIOV7]$\-?#'P%\!_$^E?$V[
M_P""=OQ-.E>.]2^*R^/SK>B:#&W[:Z>&5;PBW@G1@S#Q?XQ=QX@C5E7RZ_2/
MX,^'?C%X<\'WMM\=_B;X ^,7C0ZOJ5\?&7P^^"^K_!+PVNE*R-H^C?\ "$:]
M\2/BZ[>7OUCS/%/_  F)1MR*>')/P)_P35_;E^,7[54?B_P5\=?@SXK^'/Q5
M^$^C:???%*[7PCKGAGPW8^*)/&/CO0=;^&>M_"[7_%'B_P 2^ ?$GA,: R>!
MW_X2[Q@_QE\"R>&/CA#)$/%;>"O"7[%4 %%%% !1110 4444 %%%% !1110
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M9/C#\9_A7X>UH_$_XW_ ./Q9X,^,7@KX,E?'7@)/&)7_ (0\^R?LF_\ !/\
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M:_ '5/AOXF\ V>B^%-;73/'?Q*^/&OKX^\/M\,-&_P"$<^'7Q=^)>A?$./\
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M_L>/H/B;PCXG?Q$/C;X'?X8>-OBH%\6#]C#XS: J_'KP&"NX_H%^Q!^R7/\
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M:)_X5SK>O_ 'QIXK^%'_  AO@WXR?!SP_P##&3Q]X";QNIW@',?L/?L.^,?
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M444 %%%% !1110 4444 %%%% !1110!F31BXA\F6*W/VBV(-K<X.2!@J< Y
MSSCD$=L9&G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INMUNE BIO INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5205835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 NE Mizner Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">710-0512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INMB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,585,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,734,000<span></span>
</td>
<td class="nump">$ 20,922,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">1,704,000<span></span>
</td>
<td class="nump">1,181,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other tax receivable</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">472,000<span></span>
</td>
<td class="nump">331,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">30,670,000<span></span>
</td>
<td class="nump">22,662,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">878,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease &#8211; right of use asset</a></td>
<td class="nump">1,064,000<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">746,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Acquired in-process research and development intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,514,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">33,358,000<span></span>
</td>
<td class="nump">39,562,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">6,875,000<span></span>
</td>
<td class="nump">6,539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">517,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease, current liabilities</a></td>
<td class="nump">457,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">7,357,000<span></span>
</td>
<td class="nump">7,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">623,000<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">7,980,000<span></span>
</td>
<td class="nump">7,465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">229,888,000<span></span>
</td>
<td class="nump">195,754,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(764,000)<span></span>
</td>
<td class="num">(575,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(203,773,000)<span></span>
</td>
<td class="num">(163,104,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">25,378,000<span></span>
</td>
<td class="nump">32,097,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">33,358,000<span></span>
</td>
<td class="nump">39,562,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities &#8211; related parties</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="nump">22,280,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="nump">22,280,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">7,115<span></span>
</td>
<td class="nump">7,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">10,067<span></span>
</td>
<td class="nump">18,330<span></span>
</td>
<td class="nump">25,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of acquired in-process research and development intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,514<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">12,286<span></span>
</td>
<td class="nump">41,959<span></span>
</td>
<td class="nump">33,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(7,433)<span></span>
</td>
<td class="num">(12,286)<span></span>
</td>
<td class="num">(41,909)<span></span>
</td>
<td class="num">(33,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">OTHER INCOME, NET</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (6,472)<span></span>
</td>
<td class="num">$ (12,093)<span></span>
</td>
<td class="num">$ (40,669)<span></span>
</td>
<td class="num">$ (32,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic (in Dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (1.68)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (1.68)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic (in Shares)</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="nump">20,185,676<span></span>
</td>
<td class="nump">24,141,613<span></span>
</td>
<td class="nump">19,176,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="nump">20,185,676<span></span>
</td>
<td class="nump">24,141,613<span></span>
</td>
<td class="nump">19,176,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,472)<span></span>
</td>
<td class="num">$ (12,093)<span></span>
</td>
<td class="num">$ (40,669)<span></span>
</td>
<td class="num">$ (32,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive loss &#8211; foreign currency translation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (6,473)<span></span>
</td>
<td class="num">$ (12,416)<span></span>
</td>
<td class="num">$ (40,858)<span></span>
</td>
<td class="num">$ (33,101)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 159,143<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
<td class="num">$ (121,022)<span></span>
</td>
<td class="nump">$ 37,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">17,950,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,779<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,025)<span></span>
</td>
<td class="num">(11,025)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">160,922<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(132,047)<span></span>
</td>
<td class="nump">28,224<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">17,950,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">159,143<span></span>
</td>
<td class="num">(799)<span></span>
</td>
<td class="num">(121,022)<span></span>
</td>
<td class="nump">37,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">17,950,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">193,575<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
<td class="num">(153,886)<span></span>
</td>
<td class="nump">38,675<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">22,172,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">160,922<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="num">(132,047)<span></span>
</td>
<td class="nump">28,224<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">17,950,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (in Shares)</a></td>
<td class="nump">198,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash', window );">Common stock and warrants issued for cash</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash', window );">Common stock and warrants issued for cash (in Shares)</a></td>
<td class="nump">1,557,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,746)<span></span>
</td>
<td class="num">(9,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">178,767<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="num">(141,793)<span></span>
</td>
<td class="nump">36,281<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">19,706,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash', window );">Common stock and warrants issued for cash</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">12,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash', window );">Common stock and warrants issued for cash (in Shares)</a></td>
<td class="nump">2,390,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock', window );">Reclassification from redeemable common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock', window );">Reclassification from redeemable common stock (in Shares)</a></td>
<td class="nump">75,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,093)<span></span>
</td>
<td class="num">(12,093)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">193,575<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
<td class="num">(153,886)<span></span>
</td>
<td class="nump">38,675<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">22,172,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">195,754<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(163,104)<span></span>
</td>
<td class="nump">32,097<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">22,280,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (in Shares)</a></td>
<td class="nump">649,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of warrants for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants for cash (in Shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,739)<span></span>
</td>
<td class="num">(9,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">203,103<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="num">(172,843)<span></span>
</td>
<td class="nump">29,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">22,930,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">195,754<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(163,104)<span></span>
</td>
<td class="nump">32,097<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">22,280,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,669)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">229,888<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="num">(203,773)<span></span>
</td>
<td class="nump">25,378<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">203,103<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="num">(172,843)<span></span>
</td>
<td class="nump">29,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">22,930,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">22,267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (in Shares)</a></td>
<td class="nump">3,654,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,458)<span></span>
</td>
<td class="num">(24,458)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">226,904<span></span>
</td>
<td class="num">(763)<span></span>
</td>
<td class="num">(197,301)<span></span>
</td>
<td class="nump">28,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,472)<span></span>
</td>
<td class="num">(6,472)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 229,888<span></span>
</td>
<td class="num">$ (764)<span></span>
</td>
<td class="num">$ (203,773)<span></span>
</td>
<td class="nump">$ 25,378<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">26,585,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents reclassification from redeemable common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and warrants issued for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents amount of reclassification from redeemable common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period common stock and warrants issued for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,669)<span></span>
</td>
<td class="num">$ (32,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,594<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_GainOnSettlementOfAccountsPayable', window );">Gain on settlement of accounts payable</a></td>
<td class="num">(626)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">28<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of acquired in-process research and development intangible assets</a></td>
<td class="nump">16,514<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Research and development tax credit receivable</a></td>
<td class="num">(523)<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other tax receivable</a></td>
<td class="num">(532)<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(141)<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty', window );">Prepaid expenses &#8211; related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(667)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued liabilities &#8211; related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred liabilities</a></td>
<td class="num">(517)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,638)<span></span>
</td>
<td class="num">(22,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(899)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(899)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock and warrants</a></td>
<td class="nump">27,544<span></span>
</td>
<td class="nump">27,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants for cash</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">27,545<span></span>
</td>
<td class="nump">20,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Impact on cash from foreign currency translation</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="num">(2,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">20,922<span></span>
</td>
<td class="nump">35,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">27,734<span></span>
</td>
<td class="nump">33,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 702<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_GainOnSettlementOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain on settlement of accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_GainOnSettlementOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 1</span> &#8211; ORGANIZATION AND DESCRIPTION
OF BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INmune Bio Inc. (the &#8220;Company&#8221; or &#8220;INmune Bio&#8221;)
was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical company focused on developing
and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. INmune Bio has three product platforms.&#160;The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases and was used for its Alzheimer&#8217;s
clinical trial (&#8220;XPro&#8221;). The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem cell product currently
being developed to treat recessive dystrophic epidermolysis bullosa (&#8220;RDEB&#8221;). The Natural Killer Cell Priming Platform includes
INKmune aimed at priming the patient&#8217;s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio&#8217;s
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors
and chronic inflammation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2</span> &#8211; GOING CONCERN </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant
revenue from the commercialization of its product candidates. During the nine months ended September 30, 2025, the Company incurred a
net loss of $40.7&#160;million and had net cash flows used in operating activities of $19.6&#160;million. Given the Company&#8217;s projected
operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations
through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In response to these conditions, management is
currently evaluating different strategies to obtain the required funding of future operations. Financing strategies may include, but are
not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding,
collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. There can be no assurances
that the Company will be able to secure additional financing, or if available, that it will be sufficient to meet its needs or on favorable
terms. Because management&#8217;s plans have not yet been finalized and are not within the Company&#8217;s control, the implementation
of such plans cannot be considered probable. As a result, the Company has concluded that management&#8217;s plans do not alleviate substantial
doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 3</span> &#8211; SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US
GAAP&#8221;), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. </span>These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s product candidates are still
in development and, to date, none of the Company&#8217;s product candidates have been approved for sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the Company&#8217;s
research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products. The Company operates in an environment of rapid change in technology and substantial
competition from other pharmaceutical and biotechnology companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company relies and expects to continue to
rely on a small number of vendors to manufacture supplies and materials for its use in the clinical trial programs. These programs could
be adversely affected by a significant interruption in these manufacturing services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparing financial statements in conformity with
US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures certain assets and liabilities
in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following
three categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;2: Observable prices that
are based on inputs not quoted on active markets but corroborated by market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;3: Unobservable inputs are
used when little or no market data is available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities are classified based on
the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification
on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets
or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of
the fair value measurement hierarchy during the years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial instruments
such as cash and cash equivalents, research and development tax credit receivable, other tax receivable, prepaid expenses, and accounts
payable and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash
equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation
limits. The Company maintains its cash deposits with major financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Research
and Development Tax Incentive Receivable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in Australia (&#8220;AUS&#8221;), participates in the Australian research and development tax incentive program, such that a percentage
of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected
as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is
reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration
can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information
at the time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in the United Kingdom (&#8220;UK&#8221;), participates in the research and development program provided by the United Kingdom tax relief
program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government,
and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax
incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred
and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to
the Company based on available information at the time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment is recorded at cost and depreciated
using the straight-line method over the estimated useful lives of the assets and consist of scientific equipment with a 5 year life. Repairs
and maintenance costs are charged to expense as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined and the in-process research and development intangible assets will be amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair value, an impairment loss is recognized in an amount
equal to that excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#8217;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#8217;s fair value
at $0, resulting in a recorded impairment of $16,514,000 which was recorded during the second quarter of 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,195,342</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,296,807</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,238</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,139,480</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,241,045</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires
the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can
materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally
require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined
from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate
weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for
forfeitures of stock options as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development
costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies,
clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead
costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development
activities on the Company&#8217;s behalf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the
periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the liability method of accounting
for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable
to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements are presented
in the U.S. dollar (&#8220;$&#8221;), which is the Company&#8217;s reporting currency, while its functional currencies are the U.S. Dollar
for its U.S. based operations, British Pound (&#8220;GBP&#8221;) for its United Kingdom-based operations and Australian Dollars (&#8220;AUD&#8221;)
for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#8217;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has one primary business activity
and operates in one reportable segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s chief operating decision maker
(&#8220;CODM&#8221;) is its Chief Executive Officer who evaluates performance and makes operating decisions about allocating resources
based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed
by the CODM are consistent with these financial statements and footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,&#160;<i>Income
Taxes (Topic 740): Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024 and for interim periods
for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact that
the adoption of ASU 2023-09 may have on its consolidated financial statements.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40):&#160;<i>Disaggregation of Income
Statement Expenses</i>&#160;(&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company&#8217;s current financial position, results of operations or
financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act
(&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as expensing of U.S. research expenditures
and eligible capital expenditures, the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications
to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The impacts of the
OBBBA are reflected in our results for the quarter ended September 30, 2025, and there was no impact to our income tax expense or effective
income tax rate.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Activity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT ACTIVITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 4</span> &#8211; RESEARCH AND DEVELOPMENT
ACTIVITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to AUS tax law, the Company is allowed
an R&amp;D tax credit that reduces a company&#8217;s tax bill in AUS for expenses incurred in R&amp;D subject to certain requirements.
The Company&#8217;s Australian subsidiary submits R&amp;D tax credit requests annually for research and development expenses incurred.
At September 30, 2025 and December 31, 2024, the Company recorded a research and development tax credit receivable of $1,704,000 and $1,181,000,
respectively, for R&amp;D expenses incurred in Australia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Xencor, Inc. License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On October
3, 2017, the Company entered into a license agreement (&#8220;Xencor License Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;),
which discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. On June 10, 2021, the Company
and Xencor entered into a First Amendment to License Agreement pursuant to which, among other things, Section 3.2 of the Xencor License
Agreement was amended to change the due diligence milestones. Pursuant to the Xencor License Agreement, Xencor granted the Company an
exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license
agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor&#8217;s
proprietary protein known as &#8220;XPro&#8221; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants
of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients,
in any dosage or formulation (&#8220;Licensed Products&#8221;). The Company believes the protein has numerous medical applications. Such
additional alternative applications of the technology are available under the Xencor License Agreement. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
also agreed to pay Xencor a&#160;5% royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by-
country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid
claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product
in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#8217;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#8217;s fair value
at $0, resulting in a recorded impairment of $16,514,000 during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.75pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>CORDStrom License Agreement&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2025, the Company and Great Ormond
Street Hospital for Children NHS Foundation Trust (&#8220;GOSH&#8221;) entered into a license agreement for the exclusive commercial use
to clinical trial data associated with a GOSH study investigating the potential of CORDStrom to treat RDEB in pediatric patients (the
&#8220;MissionEB study&#8221;). The Company owns the intellectual property covering CORDStrom, the investigational medicinal product used
in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the manufacturing
of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing authorization
of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include a milestone payment
of up to &#163;6,000,000 (approximately $8.1 million as of September 30, 2025) due on the first to occur marketing authorization to be
granted by the FDA, EMA or MHRA, which had not occurred as of September 30, 2025. The Company was also required to make an upfront payment
to GOSH of approximately $0.3 million, which the Company paid during July 2025 and recorded in research and development expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the GOSH license agreement, the Company
has an obligation to provide CORDStrom to the MissionEB study at no cost. While Part 1 of the study is completed, Part 2 of the MissionEB
study is currently uninitiated due to a lack of funding by the National Health Services England (&#8220;NHSE&#8221;). It is unknown whether
funding for the study will be allocated by NHSE or its successor agency in the United Kingdom. The Company has not recorded an estimated
obligation for the supply of the MissionEB trial with CORDStrom as it is unknown if the MissionEB trial will resume.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>INKmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2015, the Company entered into
an exclusive license agreement (the &#8220;INKmune License Agreement&#8221;) with Immune Ventures, LLC (&#8220;Immune Ventures&#8221;).
Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate
any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company
agreed to the following milestone payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase II initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each NDA/EMA filing</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each NDA/EMA awarded</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company agreed to pay the licensor
a royalty of&#160;1% of net sales during the life of each patent granted to the Company. The License is owned by Immune Ventures. David
Moss, the Company&#8217;s Chief Executive Officer, Mark Lowdell, its Chief Scientific Officer, and RJ Tesi, former Chief Executive Officer
of the Company, are the owners of Immune Ventures. No sales have occurred under this license. During December 2023, the Company initiated
a Phase I trial with INKmune in patients with metastatic castration-resistant prostate cancer. At December 31, 2024 and September 30,
2025, the Company recorded $25,000&#160;payable to Immune Ventures within accounts payable and accrued liabilities &#8211; related parties
in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the agreement began on October 29,
2015 and ends on a country-by-country basis on the date of the expiration of the last to expire patent rights where patent rights exists,
unless terminated earlier in accordance with the agreement. Upon the termination of the agreement, we shall have a fully paid up, perpetual,
royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days
from the Company&#8217;s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not
make this payment. On July&#160;20, 2018 and October 30, 2020, the parties amended the agreement under which the Company was required
achieve milestones pursuant to the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2023, the parties executed an additional
amendment to the agreement under which the Company removed the due diligence requirements to achieve reasonable commercial efforts to
bring INKmune to market. This removed all requirements of clinical trial timelines and the filing timelines of an NDA or equivalent. All
other provisions in the INKmune License Agreement shall continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Pittsburg License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2017, the Company entered into an
Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh.
Pursuant to the Assignment and Assumption Agreement (&#8220;Assignment Agreement&#8221;), Immune Ventures assigned all of its rights,
obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh &#8211; Of the Commonwealth System
of Higher Education (&#8220;Licensor&#8221;) and Immune Ventures to INmune Bio (&#8220;Licensee&#8221;), (the &#8220;PITT Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consideration under the PITT Agreement includes:
(i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone
payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company owes annual maintenance fees under
the PITT Agreement in the amount of $25,000 payable on June 26 of each year until the first commercial sale. At September 30, 2025, the
Company owed the University of Pittsburgh $25,000 for annual maintenance fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon first commercial sale of a product making
use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar
quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, under the PITT Agreement the Licensee
is required to make milestone payments as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">First commercial sale of product making use of licensed technology</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensee may terminate the PITT Agreement
upon 3 months prior written notice provided all payments under the license are current. The Licensor may terminate the PITT Agreement
upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after
receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to
the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 5</span> &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">September 30, 2025:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,238</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,238</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">December 31, 2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,588</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,588</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 6</span> &#8211; COMMITMENTS</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In April
2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing
space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $76,000 each quarter during the
first year and $152,000 each quarter during the second year. The lease commencement date is August 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">As of September 30, 2025, the
maturities of our lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">68</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">729</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future lease payments</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,080</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: operating lease, current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Long-term operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">623</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Weighted-average remaining lease term</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12.0</td><td style="text-align: left">%</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2025 the Company recognized $134,000&#160;and $229,000, respectively, of lease expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2024, the Company recognized $40,000&#160;and $120,000, respectively, of lease expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2025, the Company&#8217;s wholly-owned
subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments
to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,449</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 7</span> &#8211; RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">UCL</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During
the nine months ended September 30, 2025 and 2024, the Company made payments to UCL of $132,000 and $252,000, respectively, for medical
research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company&#8217;s Chief
Scientific and Manufacturing Officer is a professor at the University of London.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">AmplifyBio</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">At September
30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed
on behalf of the Company. During the nine months ended September 30, 2025 and 2024, the Company paid AmplifyBio $41,000&#160;and $324,000,
respectively. During 2025, AmplifyBio ceased operations. Amplify Bio&#8217;s former CEO is on the board of directors of the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 8</span> &#8211; DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During 2021,
the Company entered into a Loan and Security Agreement (the &#8220;Term Loan&#8221;) with Silicon Valley Bank and SVB Innovation Credit
Fund VIII, L.P., together (the &#8220;Lenders&#8221;) in which the Company borrowed $15 million. The Term Loan was secured by the Company&#8217;s
assets. During December 2024, the Company paid off the Term Loan in full. During February 2025, the Company entered into a letter agreement
with the Lenders whereby the Term Loan was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
three and nine months ended September 30, 2024, the Company recognized interest expense of $145,000&#160;and $752,000, respectively, related
to the Term Loan</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 9</span> &#8211; STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Registered Direct Offerings</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During June 2025, the Company entered into securities
purchase agreements with investors whereby the Company sold 3,000,000 shares of the common stock in a registered direct offering in exchange
for gross proceeds of $18.9 million (net proceeds of approximately $17.4 million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During September 2024, the Company entered into
securities purchase agreements with investors whereby the Company sold&#160;2,341,260&#160;shares of the Company&#8217;s common stock
and warrants to purchase an additional&#160;2,341,260&#160;shares of the Company&#8217;s common stock in a registered direct offering
in exchange for gross proceeds of $13.0&#160;million (net proceeds of approximately $12.0&#160;million).&#160;Directors&#160;and officers
that participated in the offering paid a combined offering price of $6.50&#160;per share and warrant, and other investors paid a combined
offering price of $5.50&#160;per share and warrant. The warrants are exercisable until March 16, 2030 and the exercise price is $6.40.
The Company determined the warrants were equity classified. The fair value of the warrants was approximately $9.1&#160;million and was
calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount
rate of&#160;3.41% based on the applicable US Treasury bill rate (2) expected life of&#160;5.5&#160;years, (3) expected volatility of
approximately&#160;92% based on the trading history of the Company, and (4)&#160;zero&#160;expected dividends.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2024, the Company entered into a
securities purchase agreement with an investor whereby the Company sold&#160;986,000&#160;shares of the Company&#8217;s common stock and
warrants to purchase an additional&#160;986,000&#160;shares of the Company&#8217;s common stock in a registered direct offering in exchange
for gross proceeds of approximately $9.7&#160;million (net proceeds of approximately $8.9&#160;million). The exercise price of the warrants
is $9.84&#160;and the warrants are exercisable until April 29, 2026. The Company determined that the warrants were equity classified.
The fair value of the warrants was approximately $5.8&#160;million and was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of&#160;4.97% based on the applicable US Treasury bill rate
(2) expected life of&#160;2.0&#160;years, (3) expected volatility of approximately&#160;77% based on the trading history of the Company,
and (4)&#160;zero&#160;expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2024, the Company entered into securities
purchase agreements with investors whereby the Company sold&#160;571,592&#160;shares of the Company&#8217;s common stock and warrants
to purchase an additional&#160;571,592&#160;shares of the Company&#8217;s common stock in a registered direct offering in exchange for
gross proceeds of approximately $4.8&#160;million (net proceeds of approximately $4.5&#160;million).&#160;<span style="background-color: white">Directors</span>&#160;and
officers that participated in the offering paid a combined offering price of $8.445&#160;per share and warrant, and other investors paid
$8.32&#160;per share and warrant. The exercise price of the warrants is $9.152, and the warrants are exercisable for two years from the
issuance dates. The Company determined the warrants were equity classified. The fair value of the warrants was approximately $3.0&#160;million
and was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1)
discount rate of&#160;4.89% based on the applicable US Treasury bill rate (2) expected life of&#160;2.0&#160;years, (3) expected volatility
of approximately&#160;78% based on the trading history of the Company, and (4)&#160;zero&#160;expected dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Common Stock &#8211; At the Market Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During March 2021, the Company entered into a
sales agreement (&#8220;Sales Agreement&#8221;) with BTIG, LLC (&#8220;BTIG&#8221;), as sales agent, to establish an At-The-Market (&#8220;ATM&#8221;)
offering program of up to $45&#160;million of common stock, subject to certain limitations on the amount of common stock that may be offered
and sold by the Company set forth in the sales agreement. During August 2023, the Company and BTIG entered into Amendment No. 1 to the
Sales Agreement. The Company is required to pay BTIG a commission of&#160;3% of the gross proceeds from the sale of shares. During the
nine months ended September 30, 2024, the Company issued and sold&#160;198,364&#160;shares of common stock at an average price of $10.56&#160;per
share under the ATM program. The aggregate net proceeds were approximately $2.0&#160;million after commission expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During August 2024, the Company entered into an
amended and restated at-the-market sales agreement with RBC Capital Markets LLC and BTIG (together, the &#8220;Sales Agents&#8221;) relating
to the offer and sale of shares of our common stock with an aggregate offering price of up to $75.0&#160;million. This amended and restated
at-the-market sales agreement replaced the Sales Agreement entered into with BTIG in March 2021, as amended in August 2023. The Company
is required to pay the Sales Agents a commission of&#160;3% of the gross proceeds from the sale of shares.&#160;During the nine months
ended September 30, 2024, the Company issued and sold&#160;48,762&#160;shares of common stock at an average price of $6.96&#160;per share
under the ATM program. The aggregate net proceeds were approximately $0.3&#160;million after commission expenses. During the nine months
ended September 30, 2025, the Company issued and sold&#160;1,304,707&#160;shares of common stock at an average price of $8.01&#160;per
share under the ATM program. The aggregate net proceeds were approximately $10.1&#160;million after commission expenses. At September
30, 2025, the Company had $64.5&#160;million of common stock available under the amended and restated at-the-market agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During July 2023, the Company sold&#160;75,697&#160;shares of its common
stock at an average price of $10.56&#160;per share under the ATM program. The aggregate net proceeds were approximately $775,000&#160;after
offering expenses. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior
to the time the shares were sold.&#160;&#160; The Company reclassified&#160;75,697&#160;shares, with an aggregate purchase price of $799,000&#160;of
its common stock as temporary equity presented outside stockholders&#8217; equity as a result of potential rescission rights. As
of September 30, 2024, the rescission rights for these shares lapsed and the shares were reclassified to permanent equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During August 2025, the Company modified stock
option awards held by its former Chief Executive Officer to extend the post-termination exercise period and provide that unvested stock
options shall continue to vest pursuant to the severance agreement, which will result in additional stock-based compensation expense of
up to $2.4&#160;million to be expensed over the remaining original vesting term, if any, of the stock option awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table summarizes stock option activity during the nine months ended September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Remaining<br/> Contractual<br/> Term<br/> (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,203,307</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.49</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,218</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.88</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,965</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,195,342</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">8.29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,379,014</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">8.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended September
30, 2025, the Company recognized stock-based compensation expense of approximately $3.0 million and $6.6 million, respectively, related
to the vesting of stock options. During the three and nine months ended September 30, 2024, the Company recognized stock-based compensation
expense of approximately $1.7 million and $5.8 million, respectively, related to the vesting of stock options. As of September 30, 2025,
there was approximately $8.0 million of total unrecognized compensation cost related to non-vested stock options which is expected to
be recognized over a weighted-average period of 2.63 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued&#160;warrants to the Company&#8217;s
lenders upon obtaining a loan in June 2021. The warrants have a&#160;10-year term and an exercise price of $14.05. At September 30, 2025,&#160;45,386&#160;of
these warrants are outstanding and the intrinsic value of these warrants is $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During April
2024, the Company issued&#160;1,557,592&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;1,557,592&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $9.59&#160;per share. The intrinsic value of
these warrants was $0&#160;as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During September
2024, the Company issued&#160;2,341,260&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;2,341,160&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $6.40&#160;per share. The intrinsic value of
these warrants was $0&#160;as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock-based Compensation by Class of Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the components of stock-based
compensation expense in the consolidated statements of operations for the nine months ended September 30, 2025 and&#160;2024 respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">677</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,375</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,042</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,473</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,984</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,848</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Shareholder Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2020, the Board of Directors (the
&#8220;Board&#8221;) of the Company approved and adopted a Rights Agreement, dated as of December 30, 2020, by and between the Company
and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of one preferred share purchase right (each,
a &#8220;Right&#8221;) for each outstanding share of the Company&#8217;s common stock held by stockholders as of the close of business
on January 11, 2021. When exercisable, each right initially would represent the right to purchase from the Company one one-thousandth
of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001&#160;per share,
of the Company, at an exercise price of $300.00&#160;per one one-thousandth of a Series A Junior Participating Preferred Share, subject
to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered
persons) becomes the beneficial owner of twenty percent&#160;or more of the Company&#8217;s common stock without the approval of the Board.
The Rights Agreement was amended in 2021, 2022, 2023 and 2024 to extend the expiration date and shall expire on December&#160;30, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_LegalAbstract', window );"><strong>Legal [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_LegalDisclosureTextBlock', window );">LEGAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 10</span> &#8211; LEGAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Dispute</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
had a dispute with a vendor in which the Company believed that the vendor did not properly provide services for which they have invoiced
the Company. The vendor invoiced the Company approximately $1.6 million, of which the Company recorded $0.2 million. During August 2025,
the Company and the vendor settled the obligation for approximately $0.2 million. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes
that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company&#8217;s
consolidated financial statements, these matters are subject to inherent uncertainties and management&#8217;s view of these matters may
change in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_LegalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_LegalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_LegalDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_LegalDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (6,472)<span></span>
</td>
<td class="num">$ (24,458)<span></span>
</td>
<td class="num">$ (9,739)<span></span>
</td>
<td class="num">$ (12,093)<span></span>
</td>
<td class="num">$ (9,746)<span></span>
</td>
<td class="num">$ (11,025)<span></span>
</td>
<td class="num">$ (40,669)<span></span>
</td>
<td class="num">$ (32,864)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Basis
of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US
GAAP&#8221;), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. </span>These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company&#8217;s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s product candidates are still
in development and, to date, none of the Company&#8217;s product candidates have been approved for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the Company&#8217;s
research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products. The Company operates in an environment of rapid change in technology and substantial
competition from other pharmaceutical and biotechnology companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company relies and expects to continue to
rely on a small number of vendors to manufacture supplies and materials for its use in the clinical trial programs. These programs could
be adversely affected by a significant interruption in these manufacturing services.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparing financial statements in conformity with
US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures certain assets and liabilities
in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following
three categories:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;2: Observable prices that
are based on inputs not quoted on active markets but corroborated by market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level&#160;3: Unobservable inputs are
used when little or no market data is available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities are classified based on
the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification
on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets
or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of
the fair value measurement hierarchy during the years presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of financial instruments
such as cash and cash equivalents, research and development tax credit receivable, other tax receivable, prepaid expenses, and accounts
payable and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash
equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation
limits. The Company maintains its cash deposits with major financial institutions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Research and Development Tax Incentive Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Research
and Development Tax Incentive Receivable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in Australia (&#8220;AUS&#8221;), participates in the Australian research and development tax incentive program, such that a percentage
of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected
as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is
reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration
can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information
at the time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its wholly owned subsidiary
in the United Kingdom (&#8220;UK&#8221;), participates in the research and development program provided by the United Kingdom tax relief
program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government,
and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax
incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred
and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to
the Company based on available information at the time.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment is recorded at cost and depreciated
using the straight-line method over the estimated useful lives of the assets and consist of scientific equipment with a 5 year life. Repairs
and maintenance costs are charged to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined and the in-process research and development intangible assets will be amortized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair value, an impairment loss is recognized in an amount
equal to that excess.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#8217;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#8217;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#8217;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#8217;s fair value
at $0, resulting in a recorded impairment of $16,514,000 which was recorded during the second quarter of 2025.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,195,342</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,296,807</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,238</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,139,480</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,241,045</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires
the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can
materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally
require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined
from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate
weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for
forfeitures of stock options as they occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development
costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies,
clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead
costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development
activities on the Company&#8217;s behalf.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the
periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the liability method of accounting
for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable
to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements are presented
in the U.S. dollar (&#8220;$&#8221;), which is the Company&#8217;s reporting currency, while its functional currencies are the U.S. Dollar
for its U.S. based operations, British Pound (&#8220;GBP&#8221;) for its United Kingdom-based operations and Australian Dollars (&#8220;AUD&#8221;)
for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#8217;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has one primary business activity
and operates in one reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s chief operating decision maker
(&#8220;CODM&#8221;) is its Chief Executive Officer who evaluates performance and makes operating decisions about allocating resources
based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed
by the CODM are consistent with these financial statements and footnotes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,&#160;<i>Income
Taxes (Topic 740): Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024 and for interim periods
for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact that
the adoption of ASU 2023-09 may have on its consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,&#160;<i>Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40):&#160;<i>Disaggregation of Income
Statement Expenses</i>&#160;(&#8220;ASU 2024-03&#8221;). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company&#8217;s current financial position, results of operations or
financial statement disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act
(&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as expensing of U.S. research expenditures
and eligible capital expenditures, the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications
to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The impacts of the
OBBBA are reflected in our results for the quarter ended September 30, 2025, and there was no impact to our income tax expense or effective
income tax rate.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Issuable Shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,195,342</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,296,807</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944,238</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,139,480</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,241,045</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Activity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsTableTextBlock', window );">Schedule of Milestone Payments</a></td>
<td class="text">In consideration for the patent rights, the Company
agreed to the following milestone payments:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase II initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each NDA/EMA filing</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Each NDA/EMA awarded</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock', window );">Schedule of PITT Agreement Licensee is Required to make Milestone Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, under the PITT Agreement the Licensee
is required to make milestone payments as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Each Phase I initiation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Each Phase III initiation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">First commercial sale of product making use of licensed technology</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ScheduleOfMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ScheduleOfMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">September 30, 2025:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,238</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,238</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted<br/> Price in<br/> Active<br/> Market<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Other<br/> Observable Inputs<br/> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant<br/> Unobservable<br/> Inputs <br/> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">December 31, 2024:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash equivalents</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Treasury Bills</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Money market fund</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,328</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,588</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,588</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">As of September 30, 2025, the
maturities of our lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">68</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">729</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future lease payments</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,080</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: operating lease, current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Long-term operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">623</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Weighted-average remaining lease term</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12.0</td><td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Schedule of Commitments Payable</a></td>
<td class="text">A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,449</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table summarizes stock option activity during the nine months ended September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> Remaining<br/> Contractual<br/> Term<br/> (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,203,307</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.49</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,218</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.88</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,965</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,195,342</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">8.29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at September 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,379,014</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">8.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the components of stock-based
compensation expense in the consolidated statements of operations for the nine months ended September 30, 2025 and&#160;2024 respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine&#160;Months<br/> Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">677</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,375</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,042</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,473</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,984</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,848</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,472)<span></span>
</td>
<td class="num">$ (24,458)<span></span>
</td>
<td class="num">$ (9,739)<span></span>
</td>
<td class="num">$ (12,093)<span></span>
</td>
<td class="num">$ (9,746)<span></span>
</td>
<td class="num">$ (11,025)<span></span>
</td>
<td class="num">$ (40,669)<span></span>
</td>
<td class="num">$ (32,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,638)<span></span>
</td>
<td class="num">$ (22,348)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">$ 16,514,000<span></span>
</td>
<td class="nump">$ 16,514,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-5<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Issuable Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total dilutive loss per share</a></td>
<td class="nump">11,139,480<span></span>
</td>
<td class="nump">10,241,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Issuable Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total dilutive loss per share</a></td>
<td class="nump">7,195,342<span></span>
</td>
<td class="nump">6,296,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Potentially Issuable Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total dilutive loss per share</a></td>
<td class="nump">3,944,138<span></span>
</td>
<td class="nump">3,944,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Research and development tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,181,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_SaleOfRoyaltyPercentage', window );">Royalty on net sales of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">$ 16,514,000<span></span>
</td>
<td class="nump">16,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="nump">&#163; 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_PercentageOfLicensorRoyaltyPatentGrant', window );">Percentage of licensor royalty patent grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_PercentageOfNetSalesToPayRoyalties', window );">Percentage of net sales to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_AgreementExpirationTerm', window );">Agreement expiry period, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).<span></span>
</td>
<td class="text">The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inmb_GreatOrmondStreetHospitalMember', window );">Great Ormond Street Hospital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_AgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the term of agreement expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_AgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_PercentageOfLicensorRoyaltyPatentGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents information about percentage of licensor royalty patent grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_PercentageOfLicensorRoyaltyPatentGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_PercentageOfNetSalesToPayRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents information about percentage of net sales to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_PercentageOfNetSalesToPayRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_SaleOfRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_SaleOfRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inmb_GreatOrmondStreetHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inmb_GreatOrmondStreetHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Activity - Schedule of Milestone Payments (Details) - INKmune License Agreement [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseOneInitiationMember', window );">Each Phase I initiation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseTwoInitiationMember', window );">Each Phase II initiation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseThreeInitiationMember', window );">Each Phase III initiation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaFilingMember', window );">Each NDA/EMA filing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaAwardedMember', window );">Each NDA/EMA awarded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfMilestonePaymentsLineItems', window );"><strong>Schedule of Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ScheduleOfMilestonePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ScheduleOfMilestonePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseOneInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseOneInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inmb_INKmuneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inmb_INKmuneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseTwoInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseTwoInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseThreeInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_MilestonePaymentPhaseThreeInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaAwardedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_MilestonePaymentNdaEmaAwardedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details) - PITT Agreement [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_EachPhaseInitiationMember', window );">Each Phase I initiation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems', window );"><strong>Schedule of PITT Agreement Licensee is Required to make Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=inmb_EachPhaseIIIInitiationMember', window );">Each Phase III initiation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems', window );"><strong>Schedule of PITT Agreement Licensee is Required to make Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePaymentsAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">First commercial sale of product making use of licensed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems', window );"><strong>Schedule of PITT Agreement Licensee is Required to make Milestone Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_MilestonePayments', window );">Payment method of milestone payments</a></td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_EachPhaseInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_EachPhaseInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inmb_PITTAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inmb_PITTAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=inmb_EachPhaseIIIInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=inmb_EachPhaseIIIInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_MilestonePaymentsAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_MilestonePaymentsAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details) - Recurring basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">$ 27,238<span></span>
</td>
<td class="nump">$ 20,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Price in Active Market (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">27,238<span></span>
</td>
<td class="nump">20,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">10,556<span></span>
</td>
<td class="nump">10,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury bills [Member] | Quoted Price in Active Market (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">10,556<span></span>
</td>
<td class="nump">10,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury bills [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury bills [Member] | Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">16,682<span></span>
</td>
<td class="nump">10,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market fund [Member] | Quoted Price in Active Market (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">16,682<span></span>
</td>
<td class="nump">10,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market fund [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market fund [Member] | Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturities of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease, current liabilities</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">$ (140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Schedule of Commitments Payable (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentFiscalYearMaturityAbstract', window );"><strong>Schedule of Commitments Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2027</a></td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Total</a></td>
<td class="nump">$ 2,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inmb_UCLMember', window );">UCL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Payable of related party</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inmb_AmplifyBioMember', window );">AmplifyBio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount paid</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inmb_UCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inmb_UCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inmb_AmplifyBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inmb_AmplifyBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="nump">$ 752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Exchange for gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,544,000<span></span>
</td>
<td class="nump">$ 27,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_IssuanceOfNetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_AggregateOfferingPriceAmount', window );">Aggregate offering price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_PercentageOfGrossProceeds', window );">Percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Average price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,984,000<span></span>
</td>
<td class="nump">$ 1,719,000<span></span>
</td>
<td class="nump">6,594,000<span></span>
</td>
<td class="nump">$ 5,848,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.05<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">$ 14.05<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investors [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=inmb_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Exchange for gross proceeds</a></td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_IssuanceOfNetProceeds', window );">Net proceeds</a></td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=inmb_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_AggregateOfferingPriceAmount', window );">Aggregate offering price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_PercentageOfGrossProceeds', window );">Percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=inmb_AmendedAndRestatedAttheMarketAgreementMember', window );">Amended and Restated at-the-Market Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock-based compensation expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock-based compensation expense [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ExercisePricePerShare', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,707<span></span>
</td>
<td class="nump">2,341,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Exchange for gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_IssuanceOfNetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Purchase of additional shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,341,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Average price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Securities Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold (in Shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Additional shares purchased (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Average price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_AggregateOfferingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_AggregateOfferingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_IssuanceOfNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_IssuanceOfNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_PercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_PercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inmb_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inmb_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inmb_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inmb_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inmb_AmendedAndRestatedAttheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inmb_AmendedAndRestatedAttheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inmb_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inmb_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inmb_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inmb_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details) - Stock Option [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding Ending Balance | shares</a></td>
<td class="nump">7,203,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Outstanding Ending Balance | $ / shares</a></td>
<td class="nump">$ 8.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance</a></td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending Balance | $</a></td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable, | shares</a></td>
<td class="nump">5,379,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Options granted | $ / shares</a></td>
<td class="nump">$ 7.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms', window );">Weighted- average Remaining Contractual Term (years), Options granted</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue', window );">Aggregate Intrinsic Value, Options granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Options exercised | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options cancelled | shares</a></td>
<td class="num">(107,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Options cancelled | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue', window );">Aggregate Intrinsic Value, Options cancelled | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding Ending Balance | shares</a></td>
<td class="nump">7,195,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average Exercise Price, Outstanding Ending Balance | $ / shares</a></td>
<td class="nump">$ 8.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate intrinsic value, options cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate intrinsic value, options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options granted in weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,984<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 5,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">$ 3,774<span></span>
</td>
<td class="nump">$ 3,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_LegalAbstract', window );"><strong>Legal [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_OutstandingInvoices', window );">Outstanding invoices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inmb_VendorInvoices', window );">Vendor invoices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement', window );">Vendor settled obligation</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_LegalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_LegalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_OutstandingInvoices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding invoices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_OutstandingInvoices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inmb_VendorInvoices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of recorded invoices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inmb_VendorInvoices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in obligation for supplier finance program from settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationDecreaseSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>166</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Research and Development Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ResearchandDevelopmentActivity</Role>
      <ShortName>Research and Development Activity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Legal</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/Legal</Role>
      <ShortName>Legal</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://inmunebio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inmunebio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Research and Development Activity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ResearchandDevelopmentActivityTables</Role>
      <ShortName>Research and Development Activity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inmunebio.com/role/ResearchandDevelopmentActivity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inmunebio.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inmunebio.com/role/Commitments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inmunebio.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/GoingConcern</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Research and Development Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ResearchandDevelopmentActivityDetails</Role>
      <ShortName>Research and Development Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/ResearchandDevelopmentActivityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Research and Development Activity - Schedule of Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofMilestonePaymentsTable</Role>
      <ShortName>Research and Development Activity - Schedule of Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable</Role>
      <ShortName>Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/CommitmentsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Commitments - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable</Role>
      <ShortName>Commitments - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Commitments - Schedule of Commitments Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofCommitmentsPayableTable</Role>
      <ShortName>Commitments - Schedule of Commitments Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Stockholders??? Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Stockholders??? Equity - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ea0261356-10q_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Legal (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/LegalDetails</Role>
      <ShortName>Legal (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inmunebio.com/role/Legal</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0261356-10q_inmune.htm">ea0261356-10q_inmune.htm</File>
    <File>inmb-20250930.xsd</File>
    <File>inmb-20250930_cal.xml</File>
    <File>inmb-20250930_def.xml</File>
    <File>inmb-20250930_lab.xml</File>
    <File>inmb-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="523">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0261356-10q_inmune.htm": {
   "nsprefix": "inmb",
   "nsuri": "http://inmunebio.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "ea0261356-10q_inmune.htm"
     ]
    },
    "schema": {
     "local": [
      "inmb-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "inmb-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inmb-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "inmb-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inmb-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 203,
   "keyCustom": 26,
   "axisStandard": 12,
   "axisCustom": 1,
   "memberStandard": 20,
   "memberCustom": 17,
   "hidden": {
    "total": 95,
    "http://fasb.org/us-gaap/2025": 85,
    "http://inmunebio.com/20250930": 6,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 166,
   "entityCount": 1,
   "segmentCount": 38,
   "elementCount": 573,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 523,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://inmunebio.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://inmunebio.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://inmunebio.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c40",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c46",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://inmunebio.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://inmunebio.com/role/OrganizationandDescriptionofBusiness",
     "longName": "995306 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://inmunebio.com/role/GoingConcern",
     "longName": "995307 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://inmunebio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://inmunebio.com/role/ResearchandDevelopmentActivity",
     "longName": "995309 - Disclosure - Research and Development Activity",
     "shortName": "Research and Development Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://inmunebio.com/role/FairValueMeasurements",
     "longName": "995310 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://inmunebio.com/role/Commitments",
     "longName": "995311 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://inmunebio.com/role/RelatedPartyTransactions",
     "longName": "995312 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://inmunebio.com/role/Debt",
     "longName": "995313 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://inmunebio.com/role/StockholdersEquity",
     "longName": "995314 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://inmunebio.com/role/Legal",
     "longName": "995315 - Disclosure - Legal",
     "shortName": "Legal",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "inmb:LegalDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "inmb:LegalDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://inmunebio.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://inmunebio.com/role/ResearchandDevelopmentActivityTables",
     "longName": "996002 - Disclosure - Research and Development Activity (Tables)",
     "shortName": "Research and Development Activity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "inmb:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "inmb:ScheduleOfMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://inmunebio.com/role/FairValueMeasurementsTables",
     "longName": "996003 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://inmunebio.com/role/CommitmentsTables",
     "longName": "996004 - Disclosure - Commitments (Tables)",
     "shortName": "Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://inmunebio.com/role/StockholdersEquityTables",
     "longName": "996005 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://inmunebio.com/role/GoingConcernDetails",
     "longName": "996006 - Disclosure - Going Concern (Details)",
     "shortName": "Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996007 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable",
     "longName": "996008 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Issuable Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
     "longName": "996009 - Disclosure - Research and Development Activity (Details)",
     "shortName": "Research and Development Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "inmb:SaleOfRoyaltyPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable",
     "longName": "996010 - Disclosure - Research and Development Activity - Schedule of Milestone Payments (Details)",
     "shortName": "Research and Development Activity - Schedule of Milestone Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c80",
      "name": "inmb:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "inmb:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable",
     "longName": "996011 - Disclosure - Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details)",
     "shortName": "Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c85",
      "name": "inmb:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "inmb:ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c85",
      "name": "inmb:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "inmb:ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable",
     "longName": "996012 - Disclosure - Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://inmunebio.com/role/CommitmentsDetails",
     "longName": "996013 - Disclosure - Commitments (Details)",
     "shortName": "Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c27",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c27",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable",
     "longName": "996014 - Disclosure - Commitments - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable",
     "longName": "996015 - Disclosure - Commitments - Schedule of Commitments Payable (Details)",
     "shortName": "Commitments - Schedule of Commitments Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://inmunebio.com/role/RelatedPartyTransactionsDetails",
     "longName": "996016 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://inmunebio.com/role/DebtDetails",
     "longName": "996017 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://inmunebio.com/role/StockholdersEquityDetails",
     "longName": "996018 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c143",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c143",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://inmunebio.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996019 - Disclosure - Stockholders\u2019 Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable",
     "longName": "996020 - Disclosure - Stockholders\u2019 Equity - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://inmunebio.com/role/LegalDetails",
     "longName": "996021 - Disclosure - Legal (Details)",
     "shortName": "Legal (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "inmb:OutstandingInvoices",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inmb:LegalDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "inmb:OutstandingInvoices",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inmb:LegalDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0261356-10q_inmune.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "inmb_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program [Member]",
        "label": "ATMProgram Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities \u2013 related parties",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of debt discount",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r43",
      "r91",
      "r436",
      "r453",
      "r454",
      "r819"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r13",
      "r347",
      "r350",
      "r406",
      "r449",
      "r450",
      "r736",
      "r737",
      "r738",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r593",
      "r849"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r751",
      "r752",
      "r753",
      "r754",
      "r820",
      "r852"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r783"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_AggregateOfferingPriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "AggregateOfferingPriceAmount",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price amount",
        "documentation": "Aggregate offering price amount.",
        "label": "Aggregate Offering Price Amount"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r656",
      "r691"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r659",
      "r694"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "inmb_AgreementExpirationTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "AgreementExpirationTerm",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement expiry period, description",
        "documentation": "Represent the term of agreement expires.",
        "label": "Agreement Expiration Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r686",
      "r695",
      "r699",
      "r707"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r308",
      "r317"
     ]
    },
    "inmb_AmendedAndRestatedAttheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "AmendedAndRestatedAttheMarketAgreementMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated at-the-Market Agreement [Member]",
        "label": "Amended And Restated Atthe Market Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "inmb_AmplifyBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "AmplifyBioMember",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AmplifyBio [Member]",
        "label": "Amplify Bio Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total dilutive loss per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Issuable Shares [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r594",
      "r595"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r69",
      "r87",
      "r115",
      "r118",
      "r119",
      "r151",
      "r159",
      "r170",
      "r171",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r337",
      "r339",
      "r382",
      "r426",
      "r427",
      "r431",
      "r501",
      "r566",
      "r567",
      "r574",
      "r593",
      "r596",
      "r597",
      "r608",
      "r776",
      "r777",
      "r834"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r93",
      "r115",
      "r118",
      "r119",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r337",
      "r339",
      "r382",
      "r593",
      "r776",
      "r777",
      "r834"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable",
      "http://inmunebio.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r636"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern [Abstract]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r85",
      "r550"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r49",
      "r112"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r49"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r840"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r88",
      "r89",
      "r90",
      "r115",
      "r119",
      "r142",
      "r143",
      "r145",
      "r147",
      "r153",
      "r154",
      "r177",
      "r199",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r226",
      "r227",
      "r229",
      "r230",
      "r232",
      "r235",
      "r238",
      "r239",
      "r241",
      "r244",
      "r250",
      "r382",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r489",
      "r509",
      "r531",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r730",
      "r747",
      "r748",
      "r755"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r120",
      "r251"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued warrants (in Shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in Shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "inmb_CollaborationAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "CollaborationAgreementTerm",
     "presentation": [
      "http://inmunebio.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "documentation": "Collaboration agreement term.",
        "label": "Collaboration Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r63",
      "r433",
      "r488"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r195",
      "r196",
      "r545",
      "r774",
      "r775"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r751",
      "r752",
      "r754",
      "r820",
      "r848",
      "r852"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Average price per share (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r489"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r489",
      "r507",
      "r852",
      "r853"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively",
        "verboseLabel": "Common stock amount",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r227",
      "r234",
      "r435",
      "r593"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r97",
      "r103",
      "r424",
      "r444",
      "r445"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE LOSS",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maintenance fees",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r115",
      "r117",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r197",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r219",
      "r220",
      "r221",
      "r345",
      "r394"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r649",
      "r663"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r106",
      "r552",
      "r553",
      "r555",
      "r557"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r649",
      "r663"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636",
      "r687"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636",
      "r687"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "inmb_EachPhaseIIIInitiationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "EachPhaseIIIInitiationMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each Phase III initiation [Member]",
        "label": "Each Phase IIIInitiation Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_EachPhaseInitiationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "EachPhaseInitiationMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each Phase I initiation [Member]",
        "label": "Each Phase Initiation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r104",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r140",
      "r142",
      "r145",
      "r146",
      "r147",
      "r150",
      "r225",
      "r307",
      "r332",
      "r335",
      "r358",
      "r359",
      "r425",
      "r446",
      "r560"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r104",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r142",
      "r145",
      "r146",
      "r147",
      "r150",
      "r225",
      "r307",
      "r332",
      "r335",
      "r358",
      "r359",
      "r425",
      "r446",
      "r560"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r149"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact on cash from foreign currency translation",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r76",
      "r77",
      "r78",
      "r99",
      "r100",
      "r101",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r137",
      "r139",
      "r152",
      "r178",
      "r179",
      "r185",
      "r224",
      "r252",
      "r307",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r406",
      "r443",
      "r449",
      "r450",
      "r451",
      "r467",
      "r531"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r656",
      "r691"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r653",
      "r688"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "inmb_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "documentation": "Exercise price per share.",
        "label": "Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r372",
      "r586"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r371",
      "r372",
      "r374",
      "r379",
      "r415",
      "r416",
      "r417",
      "r549",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r586",
      "r588",
      "r590"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r586",
      "r824",
      "r826"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://inmunebio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r367",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r423",
      "r586",
      "r589"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Price in Active Market (Level 1) [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r261",
      "r266",
      "r268",
      "r362",
      "r372",
      "r379",
      "r415",
      "r549",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r586",
      "r590"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r261",
      "r266",
      "r268",
      "r270",
      "r362",
      "r363",
      "r372",
      "r379",
      "r416",
      "r549",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r586",
      "r590"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r362",
      "r363",
      "r364",
      "r365",
      "r372",
      "r379",
      "r417",
      "r549",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r586",
      "r588",
      "r590"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r371",
      "r372",
      "r374",
      "r379",
      "r415",
      "r416",
      "r417",
      "r549",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r586",
      "r588",
      "r590"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring basis [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "inmb_FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "FairValueMeasurementsScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value assets",
        "label": "Fair Value of Assets Acquired",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r695"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r695"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r695"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r695"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r695"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r647"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "inmb_GainOnSettlementOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "GainOnSettlementOfAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on settlement of accounts payable",
        "documentation": "Represents the amount of gain on settlement of accounts payable.",
        "label": "Gain On Settlement Of Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r511"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "inmb_GreatOrmondStreetHospitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "GreatOrmondStreetHospitalMember",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Great Ormond Street Hospital [Member]",
        "label": "Great Ormond Street Hospital Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_INKmuneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "INKmuneLicenseAgreementMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INKmune License Agreement [Member]",
        "label": "INKmune License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r624",
      "r636"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow",
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of acquired in-process research and development intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r105",
      "r183",
      "r184"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Incentive Receivable",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r192",
      "r194",
      "r341",
      "r342",
      "r343",
      "r344",
      "r366",
      "r368",
      "r373",
      "r383",
      "r384",
      "r385",
      "r447",
      "r448",
      "r516",
      "r547",
      "r549",
      "r580",
      "r581",
      "r584",
      "r585",
      "r587",
      "r590",
      "r816",
      "r817",
      "r842"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194",
      "r341",
      "r342",
      "r343",
      "r344",
      "r366",
      "r368",
      "r373",
      "r383",
      "r384",
      "r385",
      "r447",
      "r448",
      "r516",
      "r547",
      "r549",
      "r580",
      "r581",
      "r584",
      "r585",
      "r587",
      "r590",
      "r816",
      "r817",
      "r842"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r458"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r51",
      "r743",
      "r814",
      "r815"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities \u2013 related parties",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credit receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred liabilities",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other tax receivable",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "inmb_IncreaseDecreaseInPrepaidExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "IncreaseDecreaseInPrepaidExpensesRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses \u2013 related party",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for related party.",
        "label": "Increase Decrease In Prepaid Expenses Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r686",
      "r695",
      "r699",
      "r707"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r711"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r711"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r711"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r422",
      "r559",
      "r764"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r770",
      "r771"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r218",
      "r223",
      "r572",
      "r573",
      "r851"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest expense",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110",
      "r111"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r652"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "verboseLabel": "Investors [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r832"
     ]
    },
    "inmb_IssuanceOfNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "IssuanceOfNetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "Represent the amount of net proceeds.",
        "label": "Issuance Of Net Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_LegalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "LegalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_LegalDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "LegalDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/Legal"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEGAL",
        "documentation": "Disclosure of legal disclosure.",
        "label": "Legal Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r115",
      "r118",
      "r119",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r338",
      "r339",
      "r340",
      "r382",
      "r487",
      "r562",
      "r574",
      "r608",
      "r776",
      "r834",
      "r835"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r64",
      "r438",
      "r593",
      "r596",
      "r597",
      "r745",
      "r749",
      "r763",
      "r828"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r84",
      "r115",
      "r118",
      "r119",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r338",
      "r339",
      "r340",
      "r382",
      "r593",
      "r776",
      "r834",
      "r835"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowed amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r62",
      "r116",
      "r123",
      "r215",
      "r222",
      "r429",
      "r570",
      "r571",
      "r591",
      "r839"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "inmb_MilestonePaymentNdaEmaAwardedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentNdaEmaAwardedMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each NDA/EMA awarded [Member]",
        "documentation": "This member stands for This member stands for Milestone payment NDA EMA awarded.",
        "label": "Milestone Payment Nda Ema Awarded Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePaymentNdaEmaFilingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentNdaEmaFilingMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each NDA/EMA filing [Member]",
        "documentation": "This member stands for Milestone payment NDA EMA Filing.",
        "label": "Milestone Payment Nda Ema Filing Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePaymentPhaseOneInitiationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentPhaseOneInitiationMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each Phase I initiation [Member]",
        "documentation": "This member stands for Milestone payment phase I initiation [Member]",
        "label": "Milestone Payment Phase One Initiation Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePaymentPhaseThreeInitiationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentPhaseThreeInitiationMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each Phase III initiation [Member]",
        "documentation": "This member stands for Milestone payment phase III intimation.",
        "label": "Milestone Payment Phase Three Initiation Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePaymentPhaseTwoInitiationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentPhaseTwoInitiationMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each Phase II initiation [Member]",
        "documentation": "This member stands for Milestone payment phase II initiation.",
        "label": "Milestone Payment Phase Two Initiation Member"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable",
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment method of milestone payments",
        "verboseLabel": "Milestone payments",
        "documentation": "Represent the amount of milestone payments.",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_MilestonePaymentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "MilestonePaymentsAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable",
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments [Axis]",
        "documentation": "Information by milestone payments.",
        "label": "Milestone Payments Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market fund [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow",
      "http://inmunebio.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash flows used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow",
      "http://inmunebio.com/role/ConsolidatedIncomeStatement",
      "http://inmunebio.com/role/GoingConcernDetails",
      "http://inmunebio.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r52",
      "r65",
      "r78",
      "r82",
      "r94",
      "r96",
      "r101",
      "r115",
      "r118",
      "r119",
      "r122",
      "r127",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r144",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r225",
      "r228",
      "r231",
      "r236",
      "r307",
      "r332",
      "r335",
      "r359",
      "r382",
      "r442",
      "r508",
      "r529",
      "r530",
      "r554",
      "r556",
      "r558",
      "r606",
      "r776"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r652"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r660",
      "r686",
      "r695"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME, NET",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r554",
      "r558",
      "r563",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of future lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, current liabilities",
        "negatedLabel": "Less: operating lease, current liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease \u2013 right of use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r592"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r79",
      "r80",
      "r81",
      "r455",
      "r456"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable": {
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable": {
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ScheduleofCommitmentsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Other Commitment, to be Paid, Year Two",
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r750",
      "r837"
     ]
    },
    "us-gaap_OtherCommitmentFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentFiscalYearMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Commitments Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Commitments Payable",
        "label": "Other Commitments [Table Text Block]",
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement",
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss \u2013 foreign currency translation",
        "verboseLabel": "Gain (loss) on foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r443"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r593"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax receivable",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r658",
      "r693"
     ]
    },
    "inmb_OutstandingInvoices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "OutstandingInvoices",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/LegalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding invoices",
        "documentation": "Outstanding invoices.",
        "label": "Outstanding Invoices"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r645",
      "r661",
      "r696"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r645",
      "r661",
      "r696"
     ]
    },
    "inmb_PITTAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "PITTAgreementMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PITT Agreement [Member]",
        "label": "PITTAgreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "inmb_PercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "PercentageOfGrossProceeds",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross proceeds",
        "documentation": "Percentage of gross proceeds.",
        "label": "Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_PercentageOfLicensorRoyaltyPatentGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "PercentageOfLicensorRoyaltyPatentGrant",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of licensor royalty patent grant",
        "documentation": "It represents information about percentage of licensor royalty patent grant.",
        "label": "Percentage Of Licensor Royalty Patent Grant"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_PercentageOfNetSalesToPayRoyalties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "PercentageOfNetSalesToPayRoyalties",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales to pay royalties",
        "documentation": "It represents information about percentage of net sales to pay royalties.",
        "label": "Percentage Of Net Sales To Pay Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r238"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r489"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r238"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r489",
      "r507",
      "r852",
      "r853"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r227",
      "r233",
      "r434",
      "r593"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r180",
      "r181",
      "r551"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of common stock and warrants",
        "verboseLabel": "Exchange for gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable of related party",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants for cash",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r405",
      "r430",
      "r441",
      "r593"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r73",
      "r440"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r653",
      "r688"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r176",
      "r267",
      "r271",
      "r410",
      "r411",
      "r432",
      "r439",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r506",
      "r538",
      "r850"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r410",
      "r411",
      "r412",
      "r413",
      "r432",
      "r439",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r506",
      "r538"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount paid",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r410",
      "r411",
      "r833"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r833"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r176",
      "r410",
      "r411",
      "r413",
      "r512",
      "r513",
      "r516"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r176",
      "r267",
      "r271",
      "r410",
      "r411",
      "r432",
      "r439",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r506",
      "r538",
      "r833",
      "r850"
     ]
    },
    "inmb_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r414",
      "r464",
      "r465",
      "r466",
      "r514",
      "r515",
      "r516",
      "r535",
      "r537"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r813"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r547",
      "r554",
      "r555",
      "r566",
      "r836"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT ACTIVITY",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r546"
     ]
    },
    "inmb_ResearchandDevelopmentActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ResearchandDevelopmentActivityDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ResearchandDevelopmentActivityScheduleofMilestonePaymentsDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Activity - Schedule of Milestone Payments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ResearchandDevelopmentActivityScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Activity - Schedule of PITT Agreement Licensee is Required to make Milestone Payments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r654",
      "r689"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r646",
      "r662",
      "r697"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r57",
      "r437",
      "r452",
      "r454",
      "r463",
      "r490",
      "r593"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r137",
      "r139",
      "r178",
      "r179",
      "r185",
      "r224",
      "r307",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r346",
      "r348",
      "r349",
      "r351",
      "r357",
      "r395",
      "r396",
      "r449",
      "r451",
      "r467",
      "r852"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r548"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r102",
      "r115",
      "r118",
      "r119",
      "r151",
      "r160",
      "r161",
      "r169",
      "r171",
      "r173",
      "r174",
      "r175",
      "r177",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r382",
      "r426",
      "r428",
      "r566",
      "r583",
      "r596",
      "r597",
      "r776"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r592"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "inmb_SaleOfRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SaleOfRoyaltyPercentage",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty on net sales of percentage",
        "documentation": "Sale of royalty percentage.",
        "label": "Sale Of Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock sold (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "inmb_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement [Member]",
        "label": "Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Issuable Shares",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822"
     ]
    },
    "inmb_ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Hierarchy For Assets And Liabilities Measured At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of PITT Agreement Licensee is Required to make Milestone Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of PITT Agreement Licensee is Required to make Milestone Payments",
        "documentation": "The tabular disclosure of milestone payments.",
        "label": "Schedule Of Licensee Is Required To Make Milestone Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfMilestonePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfMilestonePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Milestone Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfMilestonePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfMilestonePaymentsLineItems",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Milestone Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfMilestonePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfMilestonePaymentsTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/ResearchandDevelopmentActivityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Milestone Payments",
        "documentation": "Tabular of milestone payments.",
        "label": "Schedule Of Milestone Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfPittAgreementLicenseeIsRequiredToMakeMilestonePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Pitt Agreement Licensee Is Required To Make Milestone Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_ScheduleOfPotentiallyIssuableSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfPotentiallyIssuableSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Potentially Issuable Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r58"
     ]
    },
    "inmb_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_SecuritiesPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SecuritiesPurchaseAgreementsMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreements [Member]",
        "label": "Securities Purchase Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r172",
      "r174",
      "r564",
      "r565",
      "r568"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r778",
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306"
     ]
    },
    "inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options cancelled",
        "documentation": "Amount of aggregate intrinsic value, options cancelled.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Exercisable,",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Options cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "inmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options granted",
        "documentation": "Amount of aggregate intrinsic value, options granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Ending Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Outstanding Ending Balance",
        "periodEndLabel": "Number of shares, Outstanding Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- average Exercise Price, Outstanding Ending Balance",
        "periodEndLabel": "Weighted- average Exercise Price, Outstanding Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of additional shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price, Options exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price, Options cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price, Options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278",
      "r297",
      "r298",
      "r299",
      "r300",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Remaining Contractual Term (years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Remaining Contractual Term (years), Options granted",
        "documentation": "Options granted in weighted average remaining contractual term.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Remaining Contractual Term (years), Outstanding Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://inmunebio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r88",
      "r89",
      "r90",
      "r115",
      "r119",
      "r142",
      "r143",
      "r145",
      "r147",
      "r153",
      "r154",
      "r177",
      "r199",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r226",
      "r227",
      "r229",
      "r230",
      "r232",
      "r235",
      "r238",
      "r239",
      "r241",
      "r244",
      "r250",
      "r382",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r489",
      "r509",
      "r531",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r730",
      "r747",
      "r748",
      "r755"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r40",
      "r41",
      "r76",
      "r77",
      "r78",
      "r99",
      "r100",
      "r101",
      "r124",
      "r125",
      "r126",
      "r128",
      "r135",
      "r137",
      "r139",
      "r152",
      "r178",
      "r179",
      "r185",
      "r224",
      "r252",
      "r307",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r406",
      "r443",
      "r449",
      "r450",
      "r451",
      "r467",
      "r531"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r152",
      "r226",
      "r227",
      "r229",
      "r232",
      "r396",
      "r421",
      "r457",
      "r468",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r556",
      "r558",
      "r601",
      "r850"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r152",
      "r176",
      "r226",
      "r227",
      "r229",
      "r232",
      "r396",
      "r421",
      "r457",
      "r468",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r556",
      "r558",
      "r601",
      "r850"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatutoryAccountingPracticesLineItems",
     "presentation": [
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r657",
      "r692"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Member]",
        "verboseLabel": "Stock-based compensation expense [Member]",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for cash (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36",
      "r37",
      "r57",
      "r459",
      "r531",
      "r540"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares purchased (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "inmb_StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from redeemable common stock (in Shares)",
        "documentation": "It represents reclassification from redeemable common stock.",
        "label": "Stock Issued During Period Shares Reclassification From Redeemable Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable",
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants for cash (in Shares)",
        "negatedLabel": "Number of shares, Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36",
      "r37",
      "r57",
      "r284"
     ]
    },
    "inmb_StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and warrants issued for cash",
        "documentation": "Common stock and warrants issued for cash.",
        "label": "Stock Issued During Period Value Common Stock And Warrants Issued For Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for cash",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36",
      "r37",
      "r57",
      "r467",
      "r531",
      "r540",
      "r607"
     ]
    },
    "inmb_StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from redeemable common stock",
        "documentation": "It represents amount of reclassification from redeemable common stock.",
        "label": "Stock Issued During Period Value Reclassification From Redeemable Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants for cash",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r40",
      "r41",
      "r57"
     ]
    },
    "inmb_StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash",
     "presentation": [
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and warrants issued for cash (in Shares)",
        "documentation": "Number of shares issued during period common stock and warrants issued for cash.",
        "label": "Stock Issued During Share Common Stock And Warrants Issued For Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r818"
     ]
    },
    "inmb_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://inmunebio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet",
      "http://inmunebio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r40",
      "r41",
      "r53",
      "r491",
      "r507",
      "r532",
      "r533",
      "r593",
      "r608",
      "r745",
      "r748",
      "r749",
      "r763",
      "r828",
      "r852"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r345",
      "r356",
      "r534",
      "r536",
      "r544"
     ]
    },
    "inmb_StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockholdersEquityScheduleofStockBasedCompensationExpenseDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity - Schedule of Stock-Based Compensation Expense (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "inmb_StockholdersEquityScheduleofStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "StockholdersEquityScheduleofStockOptionActivityDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity - Schedule of Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://inmunebio.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOING CONCERN",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "inmb_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://inmunebio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligationDecreaseSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationDecreaseSettlement",
     "crdr": "debit",
     "presentation": [
      "http://inmunebio.com/role/LegalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor settled obligation",
        "label": "Supplier Finance Program, Obligation, Settlement",
        "documentation": "Amount of decrease in obligation for supplier finance program from settlement."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r569"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First commercial sale of product making use of licensed technology [Member]",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r772",
      "r773"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofMilestonePaymentsTable",
      "http://inmunebio.com/role/ScheduleofPITTAgreementLicenseeisRequiredtomakeMilestonePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "inmb_UCLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "UCLMember",
     "presentation": [
      "http://inmunebio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCL [Member]",
        "label": "UCLMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofHierarchyforAssetsandLiabilitiesMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Bills [Member]",
        "verboseLabel": "Treasury bills [Member]",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://inmunebio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r155",
      "r156",
      "r157",
      "r158",
      "r426",
      "r428",
      "r561"
     ]
    },
    "inmb_VendorInvoices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inmunebio.com/20250930",
     "localname": "VendorInvoices",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/LegalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor invoices",
        "documentation": "Represents the amount of recorded invoices.",
        "label": "Vendor Invoices"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://inmunebio.com/role/ScheduleofPotentiallyIssuableSharesTable",
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r602",
      "r603",
      "r604",
      "r605"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://inmunebio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r147"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://inmunebio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r147"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001213900-25-104141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-104141-xbrl.zip
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M@WJ_/QE-1/**K.)KC<8V'W+3@;N"&99SZ)#\3X?,&_,V1U'NM^&M-4W8*7^
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MSP4Y"P"O#K7)Y0X&X;4A-OE"^J94*>T&YKD0J,1!.']""&.T>!FCF'8DY@1
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M*F@7*NF;FE(I7,HB'D=,V0%3U4-AZ@BZ[88APS]4NS_TXH5+)[5F[-2;9MM
MX$*- H%KA:Q2S"77]!8?<$>)*RMB^/2NWHD30>OXD=!%C(3.8H!C8D&VF@_G
M#Q?AO)89%T&U+N>V<8T<VCBP!F8GC%DNHANADE>JQ2.VH-C/\<P?+A!Y*;1
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MB@. .IF2/C  9,K-!X: B#YCGS#^;*U;]!W#X8X/]+[^D<^"</L>\_;9+J5
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M<"X@6P*RY<ZC"\B6@&RYL?RC@6S-%7F28/12%H3FFE(I[C'L]/P#> XHS.R
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MI-4(?@X7H)87NXG6(F2M$UNDZ_8F#A"!([3NL\<NDY(/7=  ZPF5-L:(2'T
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M*/8DQL<\"<3A?81XZ"KS84'+T$':>%5U Y]7_/O,&R5TO&&L$><NG6B3ZN7
MV\!,!^HKP +>3KD<U63VC0MM/*"B@"T9JBDE+D3F%(8CR0N79)"=@OILV.)G
M!(6^F+^1+F\9@@9TD*1H'L)("N!-Z!.3 =1PK!Y1N(/:(7;IL*T>+OF*U?&
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M%:IX*FJ:P: O-A>>8NS1XY+8(9X2 :.?9"$,2D(P^ OFI''ND#SLAI<L?6/
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M&MT2H:NBL^;L@5S("0N5]+I+(^[!+FS(" YH=ZJ["SH.$3&)NJ!1]4]+^4?
MF%+#%N(&DMY41R;S)BQS=R-8XY5,;<')""U;T9/0[XE.0B:D?B%C!Z0G[],U
MMMQSA[BI["_7+/X&Y8C.6,7J;;C1G]=I:E#NVMZLP$BI9(VW<R&4I5=V7)^#
M3K1'.BXP(U@UCF=H:-6G[08B'XJZD??]^6#7Z&<6K8^6#KA(*%XO5$<H<G;9
M"]<HP!V9?''+]_@0/2S4\ON'&I[<_0#K3'9;/"YIP*KF0C'LE]ZG?+:HY M5
M)5\J?9X_D)(G5,J_+&%='1?8#[-$+9/9'7D<Y9?% )Y]*CJ%P0?N,L3*5VHS
MK]@()%\I66Q9J13#II5FZWXSX\IN5W.=3-L+;3'B%HJ88ZKIFXJ2JY640C$_
M9XU9"NN-H9@L])3.!CV@6Y:5?*VL5+/S30*W1L\NY_D?(K0JQJVZE!'^@QI_
MN7-'>0.^&94TEC+!^.2TV4BQJ*Q\+E16S:9O"DJM6%1RA>I:*EMRA<0%]#M#
M<N5LD)SSD)P_%)(/*R:LD8N6,ITBDE?7<E5CW2:+VQ BO$0=-@V^(QTN&R@.
M&6;/A@I!4<_E@,_4E&)UWOT3 T/;<YKS16_U;-!; /1FE7PQIV2+I4.@U^,Q
M7\@"$:/72B)L<E$CV).H_BA C]5J^^X_='=X"P-;\/Z6+HO-1@W;[:J';"0G
M<SQ%B>,G$8<3;1"74)_%EECR7!A;(_E(U8EE0)3CEY_V<H%87RY15O#VF\[*
M_@TC'>WK+Y8E.N%Z%7^52&25" .124[.@A2?2)!&4!]9IA3A6%QV7Y.=JRR'
MST\Z6X]I;E/1-ML#&#KCN'S,1I;&#?(Q]&V]YX7TLGKGEG6M,9S@<K;\E7W*
M?09D4OH!)?(3%C\YG[W\ P]2U^Q3/GC2\YH0CZ:.%CW A SE\0HTR\'@S<+G
M('Q&9!H%C=Q$Q3EXJ/@9G2,61C.F%C[CN2YBSXL&[$^ESP'0/)@Y@A(^437"
MSQ%$.3"8,Q#=7WEJR53S.+$U00%>W9]P++.'*'U%MJM\3_$VX;F(,$8[Y0_Z
M1DZBI.10S)O7M^8G1V,(B">-#SC%W$>I@2I(C-5IT"'22_[#XZ@)!*K:JR"&
M09@,PSU.O%I4(LI'YD'"T3ML[;P=KFH2@;YA'",""@A-2$ECV9S0+T^ N4,;
M5B?>8NCPI5VK'OK2)K-KAE;(PDM,X,TM(DMVPE6"2L: J"[28)#9D?:0Z?2'
M%G8O%49P8OEXGL0UAFED,LYQ0;2V$[*>,_5-Q5,^4T;F!<UQRDSMXI0(XL1"
MB?"(+%8C>U'):'6OOGBTC=%8Y#6_6MB8R>]$[G\ODN2B50^=H.CF3(GUOFJF
MO%8'?G>"</U<7%P0Y3D?C$]*2D;D^/9#=.'U0@A/)MIZ!#N$M?CM:E,+VR5Y
MT?/XZ+\GVHM7.%Y>7R(QQEL?%:8/Q:H[?I/TZ#*\;!(O,5DA'NN'V*8PFTFA
M%DLV%@>B*J14*YX"A\,CR>H](-H0JQ9I4 "4H0Y485,D-N+%UKE?UYK(1<)+
M,GQ&]MJ7< E,JL4'5(CRB+#)X*['0*O4P&OQ^ @G+&4D0S<]>"E!!K:?0XZI
M%C(55+?[DQ%&:<S)>W[Q(;AJ4$H<<)FE/T/UY'<'V$R9U0?QX.SJ!"TN ]$0
M@L]FETZ,H4*73#Y[!,TP)/2%EI3 2V9[I 0ZX2:(/!CDGY8)VEZACJ?_5D?C
MZSNO6D<JR%Q>G/VW=$!1&M07&$4\MPR!\T]Q[/H78AU7[ <5 4-F;IE<EC9=
MD]OH]=FFDF+A:T"),+SH+^)5D3<QUY OM;@AGU!L_-\BW7%"(U)>2VB9H9^"
MQCXB#U7T_%&0)7J54/%9A=+JAUS5!%B42&\L4PLWWI,/X+>8;LJH"JM(&<$T
M M7KNRPN$)227-TK (<!]]3V31817HH<*G<NBZPN;L'<XT/5&"12-=OD+"=(
M4@Q9/$B&HYM.Z/AKU>F022!(]8FT#P^:8\HV55,'?H1O^J)VM5_8(>5IY-3Z
M3.^+K#^BHXA5!A;GJ^OA"KZ"]M'.$[SM[<<6+<NI*[>(J14GE/N=RR_9'W&S
M/W(?)ONC=LG^V(QBX^: ;)/#4=PPAP,T==",NNK/+3TAR]X/2[:%@[=I$ZO
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M,G"&A'4AZE?D"'.IUV59'$\D), _#>(':H0[#9'"SF$S5$!5UL://*%X#AF
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M>$2B8$ULA2R$PHZ'T:28O3IEXZ$*$E&?3ZA.%U(29?O(U)\1D!4UHT-6A"%
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MXQ$>M,P#R,-NE.M.YEC%V2UM]I:4OF8']L"F!LPMLOX1B5D2L< VLO$J"SA
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M4).F31)U?1(Z) =24TEK_*[CN0[,.AY"*]@7_.F^VS?]@&>GD_3R)LFTVDB
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M1TC<)/>> <Z)SSG1CA(!,H,9YIS6$!TS)CFO6C9/VM"64&N7C7\RH#E@BHH
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M7!\Y%F%1E++8 X?=<7619D44;6N*42_D,LS?P-'9A?M6UGH;I"7(0I&:K-'
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M0Z0U0UFI9) .I2,1R<3%E\IP1Q!/\">8H>O5DU0&R;-4H2)9/<><K)'2&>
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MP%Q1\YH&1VT#PK+U>DJ[&X?2[OU"%MQZFWJMMOWVSY=)J/K+)-3JTK)H,KL
MNAL#E^%NHG3\MN[LUMA_&7A /8<9$]0#X(II !T>CV335\BA]"9ZIG 62AO]
M@;.#)W3WMZ&Z!@$[9&,P;GX(Q;'&Q9L9H * L5L[['M.%,E@^6$0=ET Z]!3
M@M \&P673:*T'8\%T&X4Q#P]!FAOGCT1T,<!C'5^H $@'+L/])MD!C-#[Z6
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MNZP0V?]+/#S+] .] %(P_P66*[A7CS#T':<?Y9%F-6AZHA1DO/U#@,YJ&?Q
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M3MTO<?+4PCBN(RX(!S9H?0B6>2['-%U5" ]!H#S*@<MQ(_Z)7O,O<?P\%#O
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MP@>.CF)OM*@F( )HCCB_NKZXB2%=IB%F7VAC./-:&L-^$E[;@ROW"/Q7#M1
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M^ ]^$3<MX<(*J,@3AZKVETL?;1UZ5H!J B%WX-_.!!O[@!_@/Z+O*&"(KR*
M[^JY&L "\J5WPZ-W_%&RA/#K&EV!?B52Z+_!#*-A%4^@B@S',C7BT[MHJ:,@
M^.\)V%\_3JDVVNC&AWE$M9CZKP^)&LN0,'D<%97CPK4& :F..+^5#&^:X=J[
M?O5U&+IU2:P+@ZOV%,@NMK4/Z, ](-7K.MX%)*V1"H;<U3SR]I[YP &B*^\2
M&8 C5F_3W5\0* L%RD$%CN<*Y-X%3 (,*I%)L#E>D(YY;-C0TWQ%\7Y:5';M
M+XZJMWT6KXFI HX_$T1<60R&!7B=^PY]P3-1P8<]HW1TQ'F%D+S<J,7)/GR
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M[Y'K=/!JA><_<@^/G]H]KG-_]="[:SYV'NXSP0&LC$TM27J$/^%N44E_0@(
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M@]@D3&I0+B\-8B1(8^"&P\1%J/U&H,!K!HZ )+ETIQ$J?O.*:H\U"4Y1PS0
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MQ! 2/#AD+/A28"S\3Z(8BS)[8[&$BRC'0F!M+$3?W$4_%F(:8[$P'^ )>96
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M+%#:H5Q"JLP%'90IUYR08O- #F6'0XA-C>E005D=#:9KV33A:Q55<QUH=?I
M=BWH7X#=GLJ:JP#ERC)UA',70A]^[6'H@[H+K/Y(LL#%C/Z"Y2G1UL>:.0,
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MV >G%0AV.X^/!=S"<&.2CMX";O"_31%7X"T!O#')9K^%MSD8@#PR3,U\FEU
MW"D=PX&H4 <::-HV<-9G%13H2P!]3.>,MB1[U#04]!?*:)E(6AB%7_N/%I!L
MUYI=J)JVV##9</]U&W&N)-7Z)FDNN)C=X28QV*XL\(\+#'FV+-?\X<"C=@^)
M9VVP"F*09F9Z_R"[2)O_\Q/LM63)H]DMF #M%;!UC+'KV/@)/GH#7$R -R;
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MY,_[<- .*'0&LMX!3-,1W 0NL"C=\?PRG&RQ^Q0]AS\F=DG$*@,Z&&@S- 0
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M_?1_HTY?*0S?,:2O(OX'4$L#!!0    ( %B!7ELIS3N9U@,  -\/   <
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MHS@<:5=K/B)I&_H%??/&KE_L_P902P,$%     @ 6(%>6T4/UY+1 P  .Q
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MG/]GSUDY_,%M3?_Y7[T-T"\-_@%02P,$%     @ 6(%>6Y! (/?59   =FL
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M>\1H1"_>X?CZ8,O/C<=%WDV8?O]9+I+)[4AN>%.'Z&K&TG4494F%K685Y=!
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MT#!MN+6+1Y0'VK2*3H^20^R;^\.,='?&K-$?V-K4RP@Z:I.7D"+,^/_BRP$
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M=7^/_+!M<$<E?KHXV)SU0V7?X5F4TNK8Q@K6*JDN,A@L%ET.?PD8=12F2NC
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ML)/(@>(G*0,">M0I,7#7)/KZU2D +!7OY^_W9^FI(PW2*)H3,S$FWR.U>QS
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M[WSW4MR V</\24Y.SO;%=\G.X27+N]ODL4^G? N\&RL- QY]":Z>R'J=GVT
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M6$Y&L')Y@.&XTKU4"^=M8YD:SPOXU=6+B3.0S7;+R35(\21J;#TD"G7!2RN
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M?Y^F(4MAQA-]?W[ML'O?E3Q/EJXE_<V28^;K^]%?Z/;*);BAIS1F32B++5E
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MD;IBBD@>EN#+G>&3=_-7(ZEAZFY$D&Z1L8L\G+%GG%>.Q;^7"&\;2>ZX/71
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M1BDG%#_GI/8Q6B1G6LWCO#CN=V:@86Z1EP=?ZS+PCK?K:#EF[]' J@K(HL]
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M^JQW]S&:NL6R_Q@UZWZU^=^7JGU:1SFQK=M>[.'_<5'\W,W^SY_KW0<.,VU
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M]&']<VZ /EDRA]EX1&K'780&K0,5"#NZ@V'+W?N&-XLSUS8QI)4>5T9,XGA
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M.5)YW1^I,8Y(.[V2-5=<$Q:85@'FZ*?C]492E6"(JE;V1&H4^:/01&Q*FR0
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M44=DU%T+[S#:+2(/>4LFT#WP\]-+)S>MICQWOSBGR1E?0IR"%1]T?]@A6[3
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M%9P^151%R19)%CLN\?.@#^Z1& CV#IBTJ.C ;][1GEZE,?C@MNYU>WVCY$V
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M^X&%V@>WT^[5_]EH6_>KN%0OSO32E$JSAXMC2LL0^"D_<^!>VT3_Z9=TLM?
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M9Z"WP6*G8=E$23Q'68*0MI?Q,\-PN 1&G\@V"S2;=/6;Q$!""-+^_$%">^_
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M-Z'%:^>/^AZ?-J7]V%Z+5(?SECJK)VOC-!JZ*>=N&53IU55LJ;GQY_N;]F+
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MVMG%0S2T0<;WC=*Q'9!D$-T,SCOF[D>WR5NS=<_XRR3<MVH731^)@Z?J//Y
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MS?#Y[("M=^CV[_Y2S86@=*GGS"FJ"[#MH?K=1MV$-P!-5EC 4>\"\?5_#7F
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M.WPWRQ50)R\LGBIV#B@*MELDQ]>8![;HV<59KPX/+)[$8 >*EO)D%E BGD5
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MLP2W2*5^O"((YYFF.=[B=FIA!WI]G(I*#.RI>67YF/N!)>-9/6L"8;_G6$3
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M KG?B:+CDFY&=6 S>KA-HO0-N-74);:O7,I%!4EANG@_@-+BY'9<9Y'":KC
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M(CS>SE\.8@#Y L:]2!W027@?M.(6Q?(IJGCDX-/7X*:2,>?"'TC9O4$[UF+
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MN)KDC?NG?1*[N>%W  H=0T6"K#Z4!U>A%N8V6&RAD&59[>__XV"[*U"RIS=
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M^43^NH^@+ :#9L:"6:2DDFHX4H)N3G7J 1,09(6\%[LO\XM"ABU#WJ*HN.Z
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M@=(!2WWOKJ R],^?ZUDO76PB^>\_^F^?8S,(>X$ZU4_Z=G5W<XO_O5WRX/<
MU/:2<]G].+_[^COZTFT[C+WM3T?^]1+)1"G=)!TS77:EYHHRCC!A<X&S"6''
MSH:YW+\E4[KX_E H!]MW$,?\I?'_Y>'LL!,#[S+.+"0\]Z?O+#1MH[_D 1>G
M5AVH>F181#[P-2-7#G"@?0#'$.OZHZK;%1E"-,=\:C_Y:!MIR(H>"K@4Z']
M-IJ.O+% ?NDWLM'!0,') DO-$_U1V_&&\GJW<[O,S?5W&^$7F7CH[UN%!Z#:
MSCTEU,J]( DT/-KKG\HZC4&O:R=UK.5=[#[2WBT.9^)O/19](_OPC>M]M-$7
MGK22F/R8PI^G#:?+;O%&/#)X]%,X<'1NN UGDYM;A'T%K2EA52'U.2(RFA3=
M;:1 Z&\><*2I]:($9EVUM0$LN6E6U7J(K!BGK=(RI>E6*D]@[EHIKL7X?/[A
M*#AY^8ZIRBY2)RS$\>QF^, W5.L+V.DSNP_Z=V![0XQE@TU9<LWUB$EIL=B>
M9S3>B/,KS]PFJN[KGKH?82>3+C5P3'>TY(1KCKJ7@?(2+NZ^F:>-8*R5?8NB
MXD1->;YWTH(6B&D34IRC(Y!J(#,@F7DGU68N5JJB)<"5X+G6T%%<&SZE&8#*
M=1DW&4MUJ2C.<FL.?*]980 \O9!-"^]A0<B\OA )[ $H(KG3%D*]8WNBJ7&$
MK]M2*C/:U\;,HF%<F1#O(0[F&2RU)KIE=<_FZ%FT8IPW!"]6?;!R0RE..'^H
MS]$?_[&0J5978IR@'/>S1/\:+NQG@N>'PC'/WWX[1=*.J?H>$[.[;=_OZPBP
MG?A,.Y+.+'J_8ODRL](:"'R('<-PRJO!ZS"U;2TCVYP5^D]J)];<,1=+<&@%
M94)FW&]1*^!"[:=4@:CE2V?]>59&;T!"H> #T'PV'(/M@A.BX/B7L%CL2:BS
M+ (\"Q#(W])I8/*9$E)_'SJ6!2\TW?:@@!T=Q:)"-I0*Q&'D"=@1)(R4^\J.
M1 2,W'U1)RUL):Q5\XJD(YXTQZT\S/S2?@[5J81RQ<:W7]PO87C08//8U9SJ
MY78E('8^?C@4K_@J1)UA!DA_ !#S&Z':$D!=/Q["JKPDOVXN#G,JNJ=-KV_N
M4A,P11F.W<VHH8Q2$#'ZXFD*T85++S/\8O<OS=N=/KVU]N?!DP"P;<Z^,ULW
MRA$.8N@"%GM:# ' @X8B'V8\!DKF85'B)Z@E/8JQEYSEA/K%%4>V1+6@-C09
M?$1,GXK1K>/K;/K\#[^>AFEZ#4I<I*/K&AF,X0-0L")KU::NUWG:06?M-%/>
MG1$K$>,6=?/E2#BLY'Q8\5_/TILF,$.<#D#MF0>@6/2"!-EIK>6O[-B$ U!"
M(K(Q.WX[[Y9T06/PPM3<QI*<!U/&P-X'))R,CM8\7K4DHD.O51&5%^VVU6B$
M"2+7T&^%3.))P1DYW@[!=A6NAOX>VZBD$#DF(:M_[>T>-P&0N MD.U!%^^%<
M0:?0#/,Q#^U3W<4,S:;Q[2%%LL!"'PRP4F^,\5!L-609,80=4P=8J74G<PZ1
M9356VNS,)K8&A'I>Z 32GX._)__;991]&,YX^VS!>?#,S^1JL(1V3O/]LQ=4
M06N23]0<[$:33KR[U'GMR?-K9^='V*%.B#]_\IB[<.:%_W$_^%!_+YB0S.2\
M7:E' ^M1%5?YH%$JB @X7Y"T6O2VVUU?"Y^\9'&QT1!I2'2[]*A<\?C3\8=&
MU,88TDB0!4W0R'A$KZRQ6PO6,>Q0ZKQ;W+R; '$$%L@'H#6,[YX/LZ<AA(\Z
MW".,<D"),<Z,J23'J39+=S=M<1X%HLD:*/YA\AXQ3BWW+/47%MI-0(%<&MHY
MFW$,<#E0T=U^MFD<$]@B+[YC@ZT?EWO-MKVRNG8 @EX] !$-_^-#^)<'H+RW
M!Z"_NE5DUR&DV9H\!<X*!"[FT2!CX!75J2.6=IOL](HAA2(/<S*N<7I++21?
M&+$/?S"N*5$H]2[%NC%&9>T\P037>HWM=%*;5W$L)97M/ _8?4\#-?SU /17
MZ(RF')R#7?B%VEM" 5G,@!#>D&DLU319."AH/Q<#C\NKF2RBELQC8[<1IQA7
M@(4/>*0;G'8$V_VSD6;67>$A2Q&HESD_Z?LYZ'9PI:NM\$C(8)E."6#6=1G(
MZ\\]-^J;'2R@@W7:<V<8[[>U0Y E]%Q<*P<%@C]5'_R0C%HM*V%^%6(Q))3C
MVM6^++7P^@T^0(\L#)0():L<8UREM+E9 PXD,3_]$885S;#GI;KO<.RV5=2(
MMACR&:$;0GVMG7^,8P/RKVY3\#^L.*[^<$@ALWC &XKWE/Q8%QB?XDP_3'9J
M3"QZ9_[%TDI1]=98<*JN4\/LCR:YB*DX)HYY'2BA]L\+]4)BB$="("P\/@7D
MS"-.#I/1G RE.TVI._V_G3,%=_ E$3[F:U)1_IKZ:.?7RY:H* GPSP&R\%9/
MCOVK(EW0#OC_(SX+2!QK::SXM*<1U[3VE(B,Q_NO?;$1D$.:-M >:"14W,<0
MQKG"/%=#M2TI0&))ZYDD8L+E;S3"\I@Y<O!1^Z0RC'-8?DL='A5TY *6DA.H
M/_5D[/$:'>HY'(.E/B2"@'A*(>20"CQ.^^PH;$V(>A@1:99[&) M<C45%P4>
M!E*=^BRGXC7!Q^-OT*J+R#U3VG(N3)'1[0.0R)R%0II3A9M@%C1.1?$P\L[L
M\N0\A%55_DV(W7>IDOV.;^OZG,F%8+.6_'!%TOL?NZMZ9V-SSRY=\O4257[Z
MZE3::4LJ&I_=3Q30%@QB!W)HTO,EW0M #4VZ(T0,+K@(/>E1M:&P#8-8.6=%
M%JUC25J'\7UN_C]INHVDSYA Z(FRU]T'H./\6<Y-289V,CS@@'_KP<$AAT*^
M0ZFF$/&0B3R0/3"[)^F:=YP) E@$1J\;%;]KG$X*1IB-,<60F;=HNNE//S >
M1M')=[>#'^#(@HT+SNI2"X2UK>0C#.V,C;ZL7^'E'D(-<UY[-UF4B/HH$,+#
MG#9A#N9R[Q=KGUU2AZP)4-.ZVD7$-0 I$I33M9T;\"L(NI&!B)N3V7^WAK$1
M[<Z"]4"CVA6HV]_BJ8/=:CN6Q!ZPH)7E(@LD=5=9+=(#JE.<WT/&LCJ^="9L
MJFI<>0 >]RA;YO3/<B[PBUR;_9 X=]Q2-57(]TC^R]@?L;D79D7K'^B+*J6)
M-O/T!8!D1&/FG"\D76)7:O6LN6?'&^-@?_YZ4.TC_9\UX(^U47VSW=?Y[M^
M#)6P4O(%M;5A"I0 [LCC"[*B(3KRZK5?D1&\(0,ADC3LVB'__$4(6RN<JG9O
M/[E=$]E"<2AYI2E [==)ZZ&M-.0)*6_P$%@DTFHTZ';Q@-CJ;AO+DZN.Q%ER
M)OM.8NU1^.'>OS+%\' 49BZ-.G@/N(2J4NMR.P E'X!XE(?Q?@]IO\)"!)$<
M'42>5B@9/?V!,E\U%5Y?)60VCB$*(-.ZF=*L5(H%P]P\G,Y8]A4$^,P^-LZK
M"%EY$L#=Q-"[O5T VA8^ %UCWHD#O<IW-*JXVKOI%&3E)S!P[L7R//?S8\(=
M9]*&=.BZ?_MXA_?6%9E7S2Z^/X&R1_QAM+(BCY6T*<K!*=B%WYO,O?@#4,+$
M<%6(2L@LMG%X+7!//BB$BNAB82=(S:^"O9M(OCZF +6AQ8F2<P+7J]3]WE7[
M+$T[G]I T:4)3.8A+F0+K&?3)'J(Q[>S6WR1]HW TV!*,J^^#"M?:!) T&<A
MGXF;?U@<.)AEE3[G/0G4\,^%_1U6JA-&+Q#F_=;26=%_A.:WZKL7H-8#CE;?
MB4(YPT.QU(^%@#29;9[+>,\6>#M?QI0(NHVK"I$#$'?5'VF+3IZCYL9^L'71
MYJ&*-;QEH8M<+IPOBD^ALOT*+@.. P/2:CV0> @_U'X#!/13Q"O(,%YDU@'(
M&DAWR$?B^G+Y86S(83)'MX<062].&169JTU#A)-'6Z]#HEMODC= T\[JD_E/
MLHXFM#L0\4=S7)VN7.0@0/^]";]<_-MAS40I0C<^88$AR+^>J?(B//?[,'9E
MU^0(M%:-P;1%$;U0M"SM?[6,&VV%>0*\%\*<@M1"^]!L -M\_ZIO1<CH'"=M
M.-(G[]3?"2ND"BC_##3R9QI\7!OBNFO;<B$=H1+:'MYO*P-HE5M:1B=9:+(%
MTD0M4]);540KL51C&/XV?1Q8>1^"R^-".6\<OTD=)*.[(4+(!7U GP+C!Z0M
M,N\"T>_AR#VR=B*)Y<F"5 (7FVX[%1:-V#*$GF!9.&J9T"<DHO#*B0P[M5PE
M%+\U^/'0WJ%_=2^]?UDY2AU:M[#V>,_6C2C.@K19>9SM4D$.0$.N&FVA"R4$
ME-#_&?'=F%[F8IL?CI>K3PPD?PMW]M1\6 R([#T<T59"+CP>8\A6 %9=*V04
M!V#68<M&K?KYJW*77D!NTY8=7EP.O;3_+Y8?_?_AYU\ %/T M/^^_1IS\  $
M\@Q19+ #<@<@",.J&)CJ"A'% @B'HQBO2KA+KNJGO"YUW:IBG?Q^E2^='X 5
M"VKP1MSZ0IRAAV)'"K+ ['GM]SLW./!Y__;OIC8)>^H'H,Y;6$1R' IS .HP
M5(S-J]/%4M%T+V"-NN3NNXB!<B(SEL$1XDHCFOXTIVX1^^;6FB6:ZR13"FBI
M!"YX7#4<WTZ\I7@<">]2S169].4\5(IL[O.C*>(EZ'/[[3YP/E3GO2W4M-("
M9:HO?B/JH0N3FWHAO3ID&"^8XTT-M*AOIAG748;CX&Q;K#6# 4<"N:1KF ,P
MQ;$JR<EZM?%6."69GP7E<KX54)R5-<#'%E.M5FY < >@?^O/@XQKD[[@4P!;
MI_;9B:TVJSL3F.'C2(3YA(]-P-S<E/68BA9,M[:M'>>;[691+5^U;:7Q]D<8
MD]._*$KTGQ]):@XF,)<;/+VGXE\Z9GE\/P!9?B9XY;5@^*K]OP6<M'LW]%=_
M5(?_T&_8FL7>X^F0(2QWJPV9" ;4IR@<"9H"Q26Q07I4RCT@G;K389D9%<2&
M.#*[WD13[,L:3O+-T>[NLCU$W4],Z-N$8Z/^"GXHS\ITS?U:,8D6QU&MR!YY
M?7GAV!/,*R[XHUB2%3@NC[M5B"8XV*TM6Z?N%]NJY4*!<B_-G6\<#;KYS# X
MS0)W;OS!\/U0WIK9;IDRF4/H=U W*"#=N-J[Y^R\@X?W08_.62RK5VU$**A@
MSP2I32JTGV'HT[CSYHUL@FZ38)Q =#]3V K&NZ)]<DQ3[TATS%-JXC8#?[)Y
M,KT(/F-A*!6ALDV,:+W.$:$I3QH^3G -6,=XD*K !B,>V\G\;D*YYV@*94?3
M'(Y$J$>S@.S-W#W+2;3$*T\5K0>TN64F7;^ZQ#'55)+-'7;\ )111BS@[LL<
MCF8&2.]OR=P#W_QSXA:(??[Y\060UT9X<C47Z.I_';SXM^<PEP6D@T\4J%:5
M6%U/^O7[RW17AO-"&R9*YS[?<%/*SP?\G?QUGM#?7Z33Q"VO*KX&DNEO@.,D
M<"2*VJIIQ"J>(M)=;(*9Z@R=-II"#B32/MJJQ8I+C#P^:1;G..$Y^P17$!^4
MF7J9I^+%#8X&?^H!:/@.RXTBQ8.@?Y5H\Q_Y),*-IK:&H):C&^[;6M*F-77C
M6VTP6%/4#FR\?E87+SO(N2<ZZ)<ZM_R-/N;LZ5%]+H6<>]PN0_7B%^,,CO>,
M2)#>PE\1*S[F+O__O;WAJ\6+'5O\AX3RP'\EC1?-^@Y C;"X("T2,13F3^9R
M,AJM)%+45H?8S2P39TP_#LBAZIVZ9F\],DMY<U7'SB[0_ZSUGY<O,\V4^*/F
M7/A6+:HE0@\/B?R<O/++X'6XQ(]RV>N'WH5:/1D48"^U"T7V I'SG$3!.>1A
MB #@NMG7_#+Q Y!L0GT34!39U^24#R0M/*X=P?AOC<H:-V153497W7YZ^99"
MTMN I]P-OU.JQ>NZGSW_GBX,^_[LTL3/B *.=34G_SZ#@1:,1Z!6V, B/7!+
MX[3G.9^3M3V??]3?JZZLU07L?9]VFK'SZ-X\??;US;*@Q6@+'E1']'9OT'0Y
M<QI2FQ%>/KW(HJF<U)#N1^U MC_UV=PD0ASP+X0*^GSWN;0-C:Y55JO509"#
MY8-@I,_;1DK^YS.-6J9\LD4[N7[NU_,&RR2WJK$_C=LD@OAVWSW9?.UV3,&\
MJ#K3LGX6+6M3F#9&D&JLZFS_KXW4^R]+/_K$]KZ7G6V<;;O\L*(VY*^,]$C!
M?WOC@T/+AW8GK?'5>9X[QU4FWABY\ WYU-I:Z=)I>IPSFG6ZZ^(7)]FO7KU;
MSG[C<XC.A5#%/__+8VR%R'GX<'H 5:]K$)PDK@ ,4%>ZB<=4=$:YLVFB#VBF
MZ>!(%AXG23U&@>.U3(Q'K55K^#CC^>.]!UUK;=QY;LN6/"5!$B"<#!09P8?4
MZ&!J4Z/C6XWFVZ0[LW;BZ^'<R'"C25\(ES/V5'UV3F"'2"[&XZGF1@D>.7RG
MKFE24TV^KW?"YU-2OK-]/;+H-=NHYF+SG]AD&^*^N^].$6\!C\#X0K&H)/,T
M$R/%#WKL[YD?&?=Y,4(7)_9;]Y_$8]P_-,J^9V<&AC[FY/KII^!NQH+OI]M!
M,)I5+Y@L00:O8FJI7#M1/E9W^,Y7MP0&^RO2,XKD9!>&"_L=D-2A8BLC3\5?
MI[(IFI=OBX0&RU5:>->7+80GO//9(([,AW?V7>+5>4$RR$G$A#XQ:)@(KCXD
M9>4F^V0^W<']25B(4OP\>NV,7@S7<-_BG>:<A43'$<NQS1YJ)\E^RF=?E8L[
M,-!"*MTW"G<!@TWTF36UD/.I'R\<]VD2-4G2JE=.GMZD%+]NIG33@G]^FO3P
MR1QWS.P1ES7,XX'C"4#(ET57LP83\P/0LP&QZI273V@<T6ORVVVZLI^W]F&^
MK?*:H1#$J'F(R,<)92QX,<L34Z[=6.&RJ_O6KFQ%Z7S/;D.^BQ._4'-:3\&I
MMNTN_1>?KST\MY$U\_Z84Y8H\FM=LYX(.$M/IC1T/NAKSQ&.5P-_8D\H?7W?
MH!'CZ)<H;%C,'B/,F7_.G..QX\5>&W/9M6>59T[RP)*#G@/>9'BL+82ZGDU"
M\%@B4?='6I\6 ^E%XT_5+(-73=5#JAS$VGYF6]D2B/UN?J7X99JY+=[(R<^[
M^.9)M.N0V \!;0Z&$JL\RT(%OB,S>U69EY(M:"K,QA(;^7;"3\/IA5QRL,':
MVOM/GYI;7#X<GG1!4\;(&$,WC26/0O-\T([!L;^!.A\^DGR;5==L#?^Q>WWG
MZX<'E4O"]F8^-BVS O_PG0E\<W?>_5;'%6$!&:7FZ/O=W@QIK>M?,AX2V'G!
M)G=[@_II$O-.\0PO&J<%*]-2>JC,5V@DKR('W))3<8U+]Z( !M8PO<2T]Q)3
MPEF*1$#Q65'9Y1:NO+==/42$4^^68'80;(MJMH)4ITC-JX&^1]:(T:T:'Q;3
MYBR[I=HP7YMM<SSL-ZTZE>N&3BJ,\)UY,207EWW[\UKJ#?6L8QS"?[\FK-D6
MCTYC/3][(T_7,POA1U][SYW\7#0CH?UYXJT%\5F+1\+5(Z;/#H?='IWX].#:
M-]77W5$RW3)WCY@_2:"^4 ^W/4*#DJ )02X4(@<2W9VK CMIN:BN4%=@4YB1
MXGH5WU[AY:;<W)#LX.NF4N!:9W4#[]P2F*-.,8Z,[*W? 0VZ*#I0$1U_)_B(
M(0,[\%$5W(UJT7UE)UR?W_8&-36T3BINB]X_;VLS-ZM,[7SY>L9(9;Q*\_/O
M]3^T&^)Y.OPF1US6GX8??E8N%J:PDWB[Q>?F+_5U[W'=EG=A)\H6V,UX[MF<
MM_<6K5>24?;X^>G$L&BD'2;JYUP"VV'=GP(_L(+M9Y:9FFF=0@'<^4\+E^=.
MT1RJL8CRY4,;$K6-QQIV0^/OI'Y9[[;XU/31+=L0B7; ];ZITT.Y!7,--7N6
M4*^22F*90H#C >@&33'6H_7>;[>IK,C$U9?SMBI57Z1SO,OA6IB_?;*EL]%M
M36J'?U8),P<%]F<,:D%@3Q W".3; ?)>Z3UYXTC,MQ$8E@TC?^X;]_5KUSB*
M YW0O]^?N+\L6/NZ3,ZXSS2TW(@S/>?A5^>[O/9?)+2?)MY$R"KQ"%VH7GOP
M*)T=/7M-V/;*[UVO?K%/Z%B]U4'**Q:DXW![V2X_LC7+U@7GVX:>F5[T2KQ%
M_RGG:Z1G-.Y[3$'EMMU3;8Q7Z:!;P""BM%S[]90+.XL>%>FIIGO19T%G03X@
MI[17"6D#T+S_'B5TTHG D.L?U85YS@9N]RD=D_3*=$J8W^Z[)EU]M1,*AUN;
MI3', 3=?FFIWM^6]D/-8ZFQ2&KG""/7HT]B[WK*YZ>FEYIS6EX+>[_K=-."S
M^%FIE8H!Q\D/;O9"QSD5(Q=9K!'KW";2MV>( 28<Q/,$,_"(J#'E\?C%'?WW
M^B66*P^S6ZP&?#FB_@SA%AO5P"5#5XQN%@L)T@C7.*9=.Z."]?MOOSY^J/;X
M:7=[IS^X"DJB+"LS'BE:-MNY$N2FZ%*ZO"M8XI/)9VMC;2B?DY3C4FK<O2<S
M-\87+RRPM:(1:*31<W@15E:5V-ONJ=UK<F.A3')?2;\_)$?IFM;SBX?&0P_A
ML-(-L+)^;T,=T&UE6L>I(IF8;T*!M><KKN##Y70MIL/.)UED._^(M(]#%ON9
M4X>$9<\]2*SIF^D]I^N16BKA@\!T=,H<8@=8:#7*5A:(50SU#+I$SD9QS2#U
M>KFJ;*JV/[;7M$89JF'TB;!4_/*422M.+($NV)C2>RA#-UU1;OU\&$D:.$4E
M].1Q:DKXD="\R"A"3YJ8Z_INW^[I&Y\$TPC3_1*N:LEN+MZERT)35%O7M"%D
M)A\^N,UG8EQQOBZ*%*I5&_>?0KF@=X>#KY</^YY0UUW-__$GA?/]2Q."S02G
MIWU"^EP'3TL46:;S!X_Z/+G],6VC R8,=/>W7Z<=B>XYE(\,[)MC#^\24KWU
MU7;9]/YM]TG<=Y??FE<,B\Q=W<=F7,WPIE4N?M<^94Q7YMYI;(MA6X[P.BL)
MSGPOS7Y9XFR"O8#,S3-;FKB55"HD>J/UTCSQ!-+M?EOT_786-(C2U,JW(1+Z
MY01W,M6UT]Q*8+[L?(.:([U>\BWW8I4W#00Z4O6>9JW\YQ"^0M#)^4.YG\1"
ML&\92\[O3VQ:=WI>U4SIBBC?2*<D<FH+""D,;FH$Q5R?Z1:[.YCJ7"AA)['F
M"$]/:5 /%38_;*"^?NA-Z&#+R:/^OU$)4/ V.D9$(=GA/=P%[UA5 "0;LTHH
M[*&B5OM;+\<T/3IQM:%F7&[[[3F+?_J+X5*8UN0&^_:ZICC9B"^ "C7;!'#P
MHC2A?=/'Y1EF9*^*I>:@A];6O473G2=K*C/5_$RLC (KEE]\F5(O&D]13AKP
M8+.>E6_^>D/K,T@==%WZ59+^ /2!OW13T?\SMOHTT.)&,V92.C(@)U4D1VU1
MO-:#Y&#'7QK^]7M<(CB]MD\Q1,*@FY_*#S.U%0\/@<1R0MOX;]U:HN6-6GU;
MZ;_CC.OKA;P6 XC=!%+1M*NE6-%4W+8\YY[APRSB_:8)\=V[E<I8WNG>LEL)
MRO%L959%'Y !>/*"R7@EYMC:Z6L<>!^S+A&_'CC^=["9\81BNXAYWXXZ/%;.
M4U-:/">0.Y;KU]M2:R,G7R^R:%4 1\UX9+.D>O!7_;(E;;D&I'SEP[M-Z>MV
MNXVD8@QY-K K0R0O43FE8,6/CQB-40_N2Y1KN.1[WB6S;M$L(*K*+W]FSE+&
M4#O=N\QVR+DG5GJ0W01\J_#)W;-VDJ>&87T9<2!&RSX:.Y]^ #J!=8<G0[BU
M-0 L.;,WF9W(@.*"-$IL (V.K*JH'!)4C(O39MP^"R&,MYZ>,2I#N2'!/7/7
M 1<__A>W:I"HWBFUUTK+69[9FIJH,-1\:BXWX+"GA-R@NU(Y^J$Q(C9Y<2%*
M+E#Q("U*CO=-*LMH&T>#;C:(H.@])A;+BY-9"^&^$D[* 7H1OL)VM=3@=!).
M4\O+HQAOCB<PPQ@OQMLEE[(4HQT CQ+X<B:,''B'QE6<\<S(P..8N>L#2<%,
MODY?@0B_K)D K=RBLFS#*%P](3X[X]0MJ=QK(1S+</YM6;" 6J^\^,:]B?<T
M^2\6AEH]1_O(TV\'\8L9KZUZ?R[NNM_"STW=WT0_FY2Z.G?;]ZQB*'?+_$ZW
M&-M\25=R5!Y'D+345KL@\'@>PL%0I\XTYPRTC!>-,(1(>V#NI1?+0E)FW]I2
MAV&1ZPZ/'_M;?#FOP!^@]9]OP3F&H)B%U=$/(5-PD*87%6)%BXYK%RN)QWY<
M]R%" )&55=O+U)=UI'T_(U9\(+IW+MP=TY@(UJHLY!.,LI(=+'70TS^1-WP
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M!^\NI.ZP>G*"7NB0I2P?ULM? PJU8O,"_7CU;E[\QOSF#?#?,H+.;9=E(#$
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M):=$FQ1SW$M-<1MU/!((FBDI,$@FCKCA>^5.:N&(N9;A$B.X@OOR%'GFI*E
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M7^3T;K)$O4F2!#(9\Q#&V;V>/<OY)!KZ=0;F7C.%!(T>*F%K5 E!;:>0[_N
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M0&#WA3XGU@&B1JXQ>:C,V$3$_HR@.XN)9A[--=4#M5SOO=$;T[O_;!)_P)E
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M['J@MXZ'Z,C1N!]9!$9PCO"V)),BZ)<KGGR(+/:=)&5&[;"391+F[PM\PHF
MRP)HN )+(JW SL'I%DC>2"J>V?08#A(YR-630F7PR5DV0TYHW]!OZ .FL9'R
M$YA@^TAG(':3HS(ON.3LFKSUC\_ T2K4[6;+S@8JBN;-%-NQ3*=-U9O7_]CZ
M42Y*]X?)K]/[%3]=<NV"N,7A%=@9^%@'VYXH5+,6*\3Q:+D.4MA]M9];S3":
M[:TZ(()-5A*:\$Q*\WG(0\,.VL*PC*Y">$=0R+'/*N-4[\*[Y5$LC%6.XKK
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M:H<//\L9=WU9:2EX).G/,R4DOJ2>93?)Q[0?G;4)?J!14#'KKU':B'S$CVM
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M["$HU4\LLYH33['MCW78B.^SX"H-J5C7Y],)>7=3V7TE,W00&&Z(4W4LFT,
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MZMWF9@?3VJ:6ZFJW/?=)&K($[@+?%$2S&:FHUTOS]X$,*E]IYK$=B!188M>
MD9S$7?W+(\?K!II13%1:JP;0D'7>I,YMS55Y#UGW4&13BOS^;I?:EFQ$+;WI
MW>PAZ<'C1P_"U/XW=O-JG[(XVA[JI[VT!O_OS6[E'XIG&A(>ZGB4507ZC@5]
M<2D)^SP^,:>Y$"57(%,V,SSBX^T]$#19ZW#<')D8*GEXDVJ@P<G\@9LW7,KA
M2>]IBU;$"\J&F63M\V;=2%M#J5O2^[446D1Y,:>-UMIXE:_MU:??BKATX;#7
M\V+M&,/8P8FHJ''O+SOK!@MB?R\4DYF5H2TT&@,T>L2OD6Y;@>E-)]!2FGU8
M'PKXCT1UPBOASR/OUBO/Q"_CNVCC3IR%+GD+U]JW-8,+H?F!0&\!)])>LFOG
MA/_!J'!VHK5OP^O'?(IQI(#T^3>LJ.WK2167_3"I6!B/6N;_)X/OVP8&/+>)
MWLK0(H>;-.\^W,"5Y>U8Y1+R2T6B3>O] LJCZ-U4^>F."24$!,5FI]WCOQ\N
M_/3+"JFHHYR^W3/[A.&)-Y1'\E.VAR<F^FN6CD491K$UOF:[QE]V-1XS#FB,
M7/Y\-WOK2[=_(]W/C/2REN4^K^IS_R+^B#L^^\]_AKJ7--77PYYF;_5"CC0$
M!+^#PK+SW]YQEH=0Y&VA)D^52@8.,S(;I9/M3'C&E.4-X%M@LQ?8Q61<\[9>
M)G::J0@5!QP,PC7ARK$,1=_PIK+&!_.RD7$V[NOKMT6B=]"S2V['J[@(OOF-
M\"RS'YS9)J[;M^- E$&VU#GDHQ,I-_9=/UXHHUYHG;+?$Z;X:Y?H::NJN)=<
MBVQCC'>(UZV&N+F/Z!DAJ75+&X"$>"Y4K'O  UA#WIH!]F0&&YZ*6FM6V6S%
M"7)I\_=^6@%E?_"C4M"H?9A?F,8OY_@)#UZ,XQD?R#@TB/59]<5=G,%X34MO
MW8XQYB-%]^QT>;TKL.-##A88)SX6-&.1LT>6OU=/&O)6CW1&R;[SU\]G_Q$Z
ML9%<O5"QB@DN*D&70YHK]AG2/#[XM&EH33&N(.4<B.<_AHJQ20R)JLF@PJ\S
M5BT&$*4PQ12B! +"8CG$>C5Z8@-%$1:>L) I/ '<3;PTC?NTC$@SW3)8EZ.8
MH[\9Z,VZR%FK?.KMT'F[/5%QLB19Y/ER._SS%9A<<T@D3Y=%A<HZ\ZYW3/AP
ML!V 3+,+#RVEQ>A];8QKR+;4U8N6W6O*.I'](R"L;G5ZP&U=4SVY]ZM>%2E\
MSR;%;#ZHM?6H:VQ0K[.ZZ\<HN>Z2]ZL]+;:OV7B/ZU7VIQ*$&H7T#JP,^/?_
M!4< <]%]!QO,'-\/E.=QVO$U2*Z$X (FFN.,NH:2%9MC;LWJFASKH#HUU63X
M\>0+4HUR_)#*/5&)(54+G\T4[K/FP(78@D$8HN3%+D0@;B_U5U4T4LEW/"Q>
M1_2CN(P^HU$8V-@U_-KPR_/^C?VG:B,_Q)&Y%AOJ@O1,3C_FDKZNRXL@ARD;
MG']*UL:?A8.F&?,T030$-P_B-N#:$34:#QEJS<; %)-?S-OL+2JI-5,A@(Z+
M!)7IR0U]EGFA;3@UX-M(>A&QT\:#J/$VTDAH-#QID.-.;G)[X&Y\:-#D*>'$
M;4G^<O;6HE7_V9XOJ46%?^TW?V>P:K(HI.S8R.B%/1\V7'Q(@(F*\.'H:_ :
MQ91GX$U>#<43(_WN,LW2)B/;2EZUL["UH$0V,K[U;<MPE=W>D@CNDQF->J4)
MVI6J.>6QL,9+3WN>H]I488MK/9ZQ/&X;>96XMC_<N/:MQ[&'MT\7JU^QOESK
MVG* ?G@ALN17]/MEF%("_K&$^.G=YGP6@@)?(XP$HO-XLJSARBTM3.Y5[@IL
M+*&E-Z\*Q 707J,F9OJC^K&N)6'TVK6F+ZN*7:-W/$V?M71KVA8];VI""EV\
M;?#BUL[#*2Y/$&6@]V'D_3:*YZU+7KEW'@9N/UZVM=NZ\=:CO171=Q[,'_-V
M_6+)?S6[?]]L>+B%D'=]!88JVR!0: 9V.+[[L!SZ9YW6#1G*!1E$$HU36#5P
MZGY,;4I1J/2+E$LVA/=3&YARA6U#BW-!JLA!JSSOGQU'^GZ/ZWYQ\QJL,WY>
M*S"6=^C6>#S[4_QSVC#O4=I+&8-?$9K6]<,W#U3];#Y:<<@BSR-<L,?YA ']
MZ''V]V]&AOJ'GO^RMJU]>SQZW#6H]MY\_NW";%?RE7'W'XWVUU/\.L^<P9;(
MWJ5]&4^Y],9>0BKFPSO.\V]V+NQ$XX[AD<+2UW&1)3,ZWD0('3:VEE\]6Q;N
M'TT,5RNP]BE86AH8]_7W;XO2Z_FT-!!D6-+L:1N$1&O_<OE.I2+!K1,C#-@B
M(GL%!B!1UV[^)3O8LV7"L%2F]Q,6.H6LA$6430?#>.Z4U"LOYO0->%,Y9U*]
MQ#T *6U#HIZ5[".;D<2?<_0K[MX=1UIR?/*G:,DH27+4@MXTL5;_[U_]?, Q
M8)R]D"[>*U3B;;EI+50-8)*O_7Z/507FVJP_\>E==PHZCY7/K,"4'#9B;HG[
M"MH22H36-\-N,A@3+1DY<2'VQ=3Y'>DEV#5FZEF44SN/MK.WG2I)J["IZ8D8
MR<,:S+9?1SGGS@WPC[^(<5.^[GMD?<#AN(>!#Z]L/\W]T9=:OFW_I=Q*04E8
M_43IHWKZMMWTZ4260!U[%O3A*;((F98K,)CP$ "_7A6+SF;H+"R> ? YENX)
MB=9NO#(*' X.M"V7?'G\X(K)O$UH3K/1R^G'VX"N7^UWZ1#FJ,O1BSE2..=6
M2/^!?ZMR<G]NRAZIU(<7UMB$;FQ,[;7(OW$0OX-139Y_)-"'.FZNB"BVG<97
M3W$M!.;8PT#&=:P/"R&'/0):L^&J?MB]O*F46((:6- FU@+->0L=C<'%B1=?
M3K=* ?R,(J'EX'E2;,OAB3',?NVZ%K\=]S7&1X1(R,71HN?DT\0\E*I04W %
MUY-@1L"'TN3!@>-O!E9@D8A14D 3F%^,-0%V%[]T44@-X3&8E,JH<)YLQP)K
M;6F4-35X>TUFXGVNP=O/OY&:XS:SE?Q EW?WLBYJ(.0[\'Z?$*/XVJD,ZHGN
MZ=.SKC9X7]^#R9\NWK]LWM_WIH]RM,M@R.;>">^',]1UF+%C)1Z^SXI[K-6W
MNW9O&^<R;E)=6@J]HUKNBS:>"=7C$=NSV4)[]G&> K$LTAM3<'BX=MP]P*W1
MO#O/X1%>+F8TT%+52>H]^K39A9M0M]'+_O@]ZX3-[=MWSGV@GM]V[,YYI7A8
M B#Q;ORA7E/,'V+MA=LL+Y6TPQ:WC8]%%L8^#/#R.NH=M>>#@^OQ>/>@FCZ/
M70T[6*9GGE4:?"'BNHH<OWH-'G7XZN5J\&-V)^;TWO6<Y EQG$FX]K9G;(9Q
M=OA815E-C6NE+6E+E6V !SVQS=-U6V;NDY.CO<.P%(NW#RX/^@YI7N9L<6V?
M__#AWN^I!D2!U7[NJW?1], -NDG;U[G=.('\N+E);5]:?OI[ Y;K-D<_C\#R
M,=2)R-J[%9%D<//A'U]^"ZB)=5J26LZV?.9[\Q09;^^L<]*7F$F7%]OL=%I0
M=QV4FT0U"^3S"W",DS=8!_R88]*N5<4NP ,Q0;$]OK/]0@L>OX+=A)*:KK?X
M4.8DP]O]<%+G#2&PX.@;\<?=W\U+/UB66Y3->JGLLXO56[.'XFP^_E!A0O]/
ME9 JL;Z^2O]!%^OUL<Z3K^Y-+?KG/R\_1O'B#Y[R*53Z]N()/ESKE\&/M_?O
M;']=H=V]W77_LQF',W>^R>MZH]WF5V"K#F]]^N:_4?;>X6R^X=MX6BTU:K3V
M;$MK4[4)Z4)1NT:M5,U0%%5*)"VU5^W62ENK1J@1FR!&46*K4224VHD1J42\
M/N_WG_?]XW>\Q^_/YWC&O:[KO,[SN*_GOA+_=^CXFM+E+>9R,.R7D&$>>GP2
MREI<5#8MSE3H?"T"6WR7%GRBB?_JN=X7),M%,G'9.:B!V=$N2]>UU+7OJ>2E
M-^P,+BTYQ;T-9G(1T'XBF_*QNP+P^WL"WF.5]0G7K(O#<FY$W[4P -_1EC0.
M.UN.FW[?:K0L\M8VJ0I2KA^(]TT(80A77G;&8[D]1C8<N1"="UKH+-W\:9VI
M+5FK!<,?UYL@!5&:M6(&"\%2A6&UGN%*[WADN('A*[4KWW_,8ZX)OW<O9@!.
MI17I78[LL++(74M*DK*O%&R-9W;D?4.9WQ[,+JP2N"]Y?ZCEKZQ NN6N@./Z
MG&68TAX\1,GC:]S=_Y@\UU[5=CQ%'[V50?#?7TY8/$_3HHV$R$>A$K6QW0L,
M)SE D9+@4P ^$X';-O,111,CHR-VJ?JXH&FE9%8E]D&DW7K#$7^=2A;HQ?=Q
MGS_UVM:3EKI[8.E![[AN1<Y!";%(@?IPBQ2.C(__8N+YU?V?Y +@7/"ZW>V6
M4P#]"6T"S'X*@)C,FO2(H$#AVCS0N^11"A/4\20VT)>.W$*2(6I"O0ALW56Q
MV"J9Q3J966]L^ NJ'QX>FR],("$A2\@[<X:N7FT:/743Q,2BRL^B#;08^%(V
MN![^'N2%B&Q0 3%IL] F'<^3C0B@KO_R"L\M81/ =25=.?#WMJK;]-4>_)D9
MI6=RG(FJ%8@/L^@Y.M:-=\<-L6XZ3+;J%Y&]^2D]S?;\3S20=1H1H!XT#V@)
MMTN^OM8E'^\H10 GHR%L;/-4([)WI9<V^R0*P4;#@KE:/8]O514O]+/%OD+*
M]YY):?=2F]\? ]7D9)49QI6?(MW142Z)509*B91/A%J\7@3L#E2)[$L,Q?46
M'D]C%N-@=(3H;M"Y36_WT*(\ZTY'U1$E+"<9;*EA>5)4M)H;J,7V9-RG)^F+
ME_LW6\9V;*"W;P#GA]YS?Z]\2,F:Y[),^12;MI/8FAH=)'A%W=K4C%#Y$_13
M$X_HJ3I'_2^WPP3>^>Q,58MPE#1&D^:))53N!U934&:"RJ9AB[ V,3]V>0B,
MTT)' MV7?@M[.$T #8L]$PD-W>%\!X::#0^GH+*2"0_P0Y)_3@$FS!\31CG/
M,;MXN^F\+/G0Y_5!_7Y_)_9G0,:/JARH#N4&[2=-AMR 6YQE[@'5)G> K]!&
MA#FBNMB8H?[3[:Q4Y>EV>;*CEL V^)<T+CDVI"]J!P@IN,PMW1+O(&CCE:E?
MS!P?59=T(=OOY;E]; <\#D2GY""*PU*O2N.3>T",P0A2$0&\%4# CR^+=PD8
M^=HW3@>*,,Q250B[;UO!^,;#1R\JGOP-R5AOL@F4WTY4M'*9$&TSE)"3^YR-
MYD"[L86+7(*[RY/5]WO.#!)&3U4B!'7Y1FE?/)LFBV!I?4)?>"OS5]N_V4+O
M)9>UV+%!8BH_7-LF?8OOS'L>[Y0$PI%>V>_3/$.&2[YY6@=9FY\"C%["L* +
MVS19$^+.W-)T5ZA\DG4^+_B" ]2KAOQFB0*/WP^^(QZY3;VNVOVW+KC55_Z]
M=R2JU8HF0IMSD%-;BE+^SJ'#:\B]"&AGF87:92T?B##0N#J)"[N8US3F"6T5
M.ZH6 0KB08G08V3N]"UM(F+-/$;)P[Z,=D#V0=9W<HVSMCG!'VRV'@+H9LI:
MB=CK#UA6V;\T .(H_7-UU-\J2P>;+?7JU3H MSKKNTL+/QYMQIBR.=YF\PQN
M:!6]\>][B-NE_:29H\/R U/Z-^';NK;_?JSO880#DLA"&K3T^,OC+K*;X1H[
MD9H'O7K56)RMDBF]E\XKULM;[Y,:(P&'RP!2R1N>8.Q<CH\B[:O6K\U_RX=(
M)@DZQ<&F4P!B!KX[ (]4=VI^$=GV4L]AI 3V\0=)G2JM&P<8\JA\U]GV(66:
M_;-PZS/AB=T;NWR4 .]>^(1>BQ <"$-].>OR/\6&A?;T<\,//5H30MV%VPNT
M#_^=,>N+SQNRY<FWW+?_U>_<MR/ID'>87XF"V Z+7FP+9NEZS(G]861(B#OA
M3K_2&A"1ZW<R15=5>B;0)[.I?\\6&FDD>PJ@7FTA#1#R\I!GGXN!AE'4H?8$
MD_=*;1I=1V;-4U +/-O%#1*_=LJEVH8\[T)T4[9:0?XALF(2N^OC#$A9=[F=
M9WSMQWJG-%9M\,9D6G.FRGO;:32L_U^:A4% ?OZ*JUC>Y+S5$"D(A:W5%NQ3
M0K-1F58W=)R6$(SYSM;S:YAF2-#@^9Y/[V1,Q' !:0X;?7X==LNHNTL/N.^*
MJO5=. 6\>N8.?.:<+$=6QFO)=X-9H'1ED#M#6A\(F?'NTD/NH:XR0;9NGR"N
MH3ZDHRG2M-34T>U^OEOLJ2_DK[:"U \8JY8;GM[,7.6,4LZTBT)(?7A CU-*
M4S_W+.JFKEOF_>J+NND-Z<AK>^6.F?)"C/"K%#T^@UQ[AS]FRW[0]+0$=SEW
MR;W>T2!OMM]^[XO,\]0&LK_-_W&%R#H+[4PV(U^-C+A^4E?=8GQ6QJ_V]KGQ
M2'ECI4WJ^4I_$[H /[,!N7M,#;6:TE(&U7HO1-9<F$J@9:(7?A0V?PE+N'3-
M&91/XSI;AAQ:WR)?N^;F*:"F9.N0F(-!"Z ]P&QDU1Y'^9PN--LS(EM,Z]7G
M0.7G/U]A.:%V(Z]R3@'1PD)AQB3\5.^(9_N-RW[ H@KGQJ9Z)O1YJ-1)+'SI
MVR+*NOL4<('J?]9 .&RZX4SJ)V.J6,AI^L2&]Z< )Y%?Y>!60ON[(ON_1UT4
M#(V?C*'<\T@LV<S7:HCFCL>+L*PK;-+8)Y@TUYN+&B]9S&-<4$U^5X?+,=&N
MNI$:!]^;$C4&13Y*C>3^A;L_*\7,61=9W?8_[CZ)U# [*O.< -]\;+Z:X&&1
M?VMGN.@FC[Z^IM):J(.FPZNVZ:P*VM0BX2DB"L30?OL,R(Q//M+8J6XGC>@7
M;1=UDDH( 4MNX=/:K.2PRH6G_5J1B%YLW&SA][_M%VLN?FU"1QN@I@*1*FK\
M4\?CC[VB4Z1IDZ#ONL@S9SA/".H4X8'-HP5ITC0LG+$51*AZ-('V /W"XD#=
M@]X\2[06HK69D<JNA4F,"->K32.-4T!?,T\4ZB'BX<AVI??*&&S25>@H^O6\
M W,I#4,N(C;@HK?6EKU],2(LM*N89<0LV_+%%4>Y*2 ;H:J+7RZZ*KC6PDAC
M4!\L C4BRA;GN/L%^@IEYK@7JJ"1^A6;76/#8UU38E%3W,9)H+>JH#K$6R"S
MZG8@SD'&:Y8;51J<"HZ"L1*%VWC>&6PPC:QKZ"5>R_B<W#N;G^PRVC:1MFP8
M;\D<4"+:>M_VZ'M-Y\K!'1E:U/D&%HM(S_1JOC^/W9B5\0E=CH.91= 2V=Q,
M 89W:ZN9K&TOE#S-2LUS%VZ@; ,2_$F6?E?*^9$#TMD3LW_^M$U+0UI:GFJO
M:XI!B12UOW#F ]^9N1[0&?(O?71D(^AU^K(%TW7/.F9]\6INP&R>B.#JVY0W
M==S/Z-IZ2'NR5[GG(D?KTYN1V3?7XEN-+@_12K_-S,DA81>LIDG@1U3 25J=
M203M^B1,E!S1(RQ*1A#[ND.\?@4WX!'Q*SS66=S3,E4!)>3GW:W]7R"F-_,1
M[KX0SD)41D;=?8AH(C>HO%4+-R30U6R9&8$[$3<>J7-0F14P4GTTYHW<JO"6
MQ3ND]' AZVYCN$?[I7C;535W^)#I=Z-]].5F'%M34W'W.FX.)'Q0Z!"G4UYR
MR]5+./,"SZ6]+5W-BQENY+]X+[R?1=<4GJ5'77(@R3GG :,AA_G[-2.KTJB2
MK6\&%NEB9;H<#8$:!IQ?*Y8'!23F*&52PSO]<LV_-56@_12YF0'8E0UMG?4K
MH+.X.7N7>\_.4X3LX1L;1_R6<N3$Q-71M0UJDN;_#+3N@?^R6%+M ;,[!L^9
MCBHG7X+>FRB&H.0%J:H354"!2K#C,%[_4//O05^62?.$?%&2ZF0@GTSJD>G>
M:)5/D419&/-_)Z*E6I>5+( (37#(M9=J+" /4&S%FR46P#F&#S/FBCUAP-QD
ML[FD;I:T_F&3/^-3:4/[CTNT?E8W^8"NONWI:GL!:NB:R.!/2L<90"OG"7[0
M(:-032.(=%WVL$V(I429?QRD?B$^#(B$*[O_$\'N;FN=048V.0_4"P; )L[P
M2&^;BYC5<48;HX",A51MXEJR#^T..<VHA5R+0S ;E&#X@Q):>;[]S3["R(N4
M_6N ^S80TZU"O'L+E.M;7D;;5M>TUA\@6."=.MI2L,$0MBYT]"+!%!QQ"A#8
M 0;BT<)>8%9?;2WJ#;(")_K"F( F!"7$U@OFR,;T\G\CZ+17>\07(X??<:.]
M*CQ_C/_Z&_)$]<:"_!S/.U5Z\=4ENJ1_/QC:Y^5],+F5][JFZ[14P=6MHX>A
MTD+6^A-(\>J)NCSS,>8317-4L_ZUQEIT3=,5NT6;^8>KFN6:'UWK\X$5<>2>
MT$"UA:?Y3\,'U IN#08DR(&M B&K3V'\F6;=KTHGLA'5F<X17Z#>EXH\E12"
MWXP7B?BSWIYT!HJ+DC[J+C_5N<D]]SX;W;JS&Q1:GSUGE^]+6%X&8^3CCL-0
MBQAL#$V8>,?(9_J.S7IS989?F6U?)*2@?<PE?\ZZ;@_8N?9O:FK?MGJO<KD^
M0RQ6RZ8%.A#(!Q 4E'&*$A1WZ X'K_1C@2ZUS]%2VFKPSCM41<@27& 37JU=
M^ADVA*[#> GS$%6[L+&V)^AXF&CPU8[LZ>C -I!9CF$\KN@4$'=C% F4K_ @
M93GRUX\KD1&&A/N>H+E\7L+//<B^ARUV=:T#/FM-8WY 6"8EC:/=36;=E[A(
M)4B'JKC#JLM4UU'O P0G[ =-/;E+PXA456X/0;"_.A''9)\".BB7 W0;L^>Z
MCAU17D%RG[1Z2J)1>?(8%>ZCYGDALAQ'?V-VDFL2+DER\*42@=<]-M.HEPOB
M\F_2*W0\B?6)I3W]K43E4&/+4KS;US\R,A:K-L"P%YHE+#ZLS1GZO4Q%%[<A
M_?U%6/$2&;L@M,YD&]L&@#&&J3GJ3:_!_9\F8@D)8:.=N[UAZ^U/D(VHQ6S,
M,RL;/"^?%2#C\CSW!5;_QK^7H1<6&]"8RU<[%UFH$+QTZ"X[6:!7^&JT*=&Z
M!_L^S89J1U9<8N.U37'"R]-[+<@3\LN1"R9OBC<A 25\WC(^R^^^WGM%_#2A
M.K7(W'X;JD'N^SJ$9XMJEQF%.G^])_9Z.LA6<-QX2M7M3,HYH^N#;^1WX2S?
M)3$Z6RN$]^W<%KD:VZ\6P1!]3%*5[+88S(.,)CGSWT&^R_ P>/4GRB9CI\(\
M7:NLR#Q3:""A=)C)+_>F_'W>!"U] Z6R_8G(79Z=PJGF]M]RE7FMGW#MK&^3
MYT26]V0*!DW>G0( T&]=%VUR**%XJD$GAR6/PLY==CE134:IV]K--B4=<] E
MW%UZ"8+:!7:-E/UG%)CRGG6X2SQ-0)ST=G;@3SL##?ONTC-H;WPWF-_*M!7W
MB?\.K]S=OL<IX*>R _4 @1RF&:8M@!1O7L]K B.#Z"7=\8@40_5O7Q(Q#WY-
MF+^1>[2XT^0J@3FWJZZG6R D0PH*>LW%9!ZIDO[YW\;$MT-;=:W,AIKI_5KQ
MO4KTVBE@/TJ!VG%\/ YM27@[/93?:./,D#_/VF92(N@NSM$3*' *&#11N.1Z
M^<.=@=<9+*!8F&OO=F>$Y+GTB1K[!^S>V[5_+D3]J8YZ-B-;YPX!I/5W:%EK
M6T]E22&:2QL&L9)=S-G&(TFMLP/& UCKFE A5NZ-_*Q1)!*]^&>?\\$K71V*
M<W(;BTL"03%E_H"Z_E4S(A<,4NO<*^@U5D!DE=B_^ZM!TLE6,<6%ER[<[LX<
M4'_*+L'GEAC!8"EC%C5VCW,4Z&1][NX'!:.?7/;>"9FFCQ;BQ!RM(\5<SM-;
M=!O(2NKLJ_[ ETZFI],$BOA]".U[!E,3QK*!R8[EL#,W<2PL%D")*.\[EPRR
M/$M^?,S":G(**"O(Y$N *T]4S'3<4#)OE)X#N#Q#F/O]O?= 0>QMD'/>%V;.
MM>MVOM?8=143WNIW7(B$9*C\2[C7(=T);H4B(V-Z\2Y&WQ[YF_!M6O)O6.7Z
MK/<6&!LH-J<+-N''X_1URATIZU[1LJEI7KIY:6T'S3-'HQO0)HJNSC6BR-;/
MB]V%#=LBN'=1C_I9@ Q$]FT6==-?X@#AI8A\6%XXXP_>YAR9SU]<[G^^.L&2
M.* X\LQ?[4</M(_R4"WK+)36"M.YP$87^!I=)08&.6$7R>$YOSA2O_SFROGZ
MAS-CX?.)R?D/Q*NG &#,=K[8C@;KOQWU]7<.'_.#LEP<Q^2N),K@1])M_2.&
M"@:E44'!/9H.<SD#O7Y^:;EI+= &ZYFGLP,G<U.+(7079Q-0^RGC?Z* :T($
MC< 326[F>CZ[::&DOQ;?#GX,@_(\1I_VU%>> G #BK8"7S[X%@YKQ%B(1&FA
M'2>+=+CN<GWZ)C'4,&PH\Z7@77*_4DJKB<#MYZ(049?S7!\+O95BN.U"(R[^
MU C\]$TA<=L5XR0&7[C1C>7P+C-VF^.7?NB:T/A!ORWEH7_O7B2 !@#R4.QH
MTVB"X2([;111*X_!SB)HEY1Q(*;UQ3I0+S8F4^0R3 )J3XZN@NJ17RX B<6U
M> J6;J-AX2KY=69#$+_71JF7%^ZWP9KI%%6E#*@L4WHSHH?G2)IRFWSTA%Q*
M48=AX9S*<XL7/+.GNZO>H1F!H<@-Q&41LQQ<>WD%>;PCA"TV4/9!A[D7]VO^
M[GRVYO8)\19"77,]PO6;X6=["#;,RRMH[3ZBP[H/0;X5V-!U^2J^KV.7R?,4
M0'C$EB2"<DLNHRT@6-KEGD)-R:4X(1#>*I%RAS:9KTB^AZ^:62/5$!>3M*__
MG:4O64+/FI"LR8AR<@,F;6.ZN9F,T"&LQ5+%<6ULID2KB%#U9AH-Y(:@H]XE
MNU.TJ!?)?D3K;@W5^'9Q*(@L32CO%.& 6N!^4!%LP1%]VEP$QXPOY'*[D2^T
M/@*!7[L4^0N\ !D&:GWFJ<_GX;^5U#B.?*NU\?^UR14GR7P.X8,N(2</9TQN
MA]UU^G!>3Q!>QP#T.US;*V[]?-Z:Y:Z:X(='G7P=/_[^ZC5YR8@O'533O3G
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M'+RLT-@</Z/3*Z5@*3&>8<M>97NY43?W]K;>?)WE.$3=T-IM96LL1$4< XH
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M*S6VPD8$^0Y$G6J/T%6[*1"D)9G9EGJ;N(:AF+! $+4[L9['J>O-!CK.'%-
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M3;EX"NBTU[X"FZ2IM)U\:I<EZ_6<D=[MH26/HAIR&D4!:OM^UG-Q]MC^ZBG
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ML2]^T1WL?/O=\^K/Y?*Y4E/<^TU%^:%:'VX^'(. G>;1:SHZ]38=@+-,R!)
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MCEE'WG)=K"SPL63>%1#)-DG,/0SZ<F@[1'2D+#Q4/KFIJ)#-D#7X(+]#)$:
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MI7PIM!-5M!.P> P/7I*<7C5)P(7^)5]>4O!'HJ.[ ><WHF&/-<BX"$=Y?6X
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M EUA,<95C N3@^1 QK@O54>&&]05$QX/LQ-F8SS+!.9#$;TH2ML^;K% 3Y-
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MJ J@^%)_W0&3([Z5OJ?>#2T&#$38!735JWDVJ?Q\5MH3< =E6WT?]^;X.:D
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M.*2!B%-EE%U>F;NYGI$416($7PU[K9?DJBQ7=X==4.8;K:/<IA<"NU4#1 M
M>V6*T<68C.TK<@_1OIC[\=VWX7-!91D>:^K'2I%ZZWT/YQDUU/IVM>KL;]F:
M)C=V,NOIL ?K3E:#3$A^]L23N/ZX=UDQ)_;_]UCIY%M&/,%;.ZYYZ_6.MJ,)
M*QU^.R]U:ZA=7+?X":_(:9*0A'RX:O8#)E+F-.%8RHELJN(?X-Q_5L+_+B\
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MX+)L1%ID92EGN(Z)^53:@DK+^LS>7V@%6E4 Q1JJMW[]ZT?C_!&L^J8:]C;
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MJPZ&[1[(D<5UQK 6 /^^UM,X-X'.6%GX96H%A+&H\7';ZB5Z(R5BH<ZJ# B
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M+1"503H[/TX ^A,?EW8# Z69T_DJ\X"=>*PQ!%$(M.A(#\\2=M;!T++/^,<
MG^WF&^./]/_8\]XP.4XJ6=8QU_N>=Z[VOH[A?+NS8_,/!:")B;V.;#=%'UQG
M9 F'9Y/<@PZ(;)KJRE4J['WY\+<+9D"C7_K)R)D&<[XK6]4RXE.<F6_$L9@F
M3HN'@Z5'%.V>],GVH,H)3>+0,%]5 "*@) 4@8;0 ]'M'W+^<4_5WMRPQU]?<
M32T71#GFU[9*0^4&3SM3]$._KD&V)=X'.MW'J@"@K@4/Z$B3(%%C5](6^$IS
M P;3#G49>NCXDQL58^(+L9OG0NG7ARPY8>R(R#),K.TNOU'0+!7!H381Q%RN
MB#.TL.9CXA*T/$S^M>0^FJ5QPDQ$EQ%!>_+RR87F-X^2'S]K[#R;K6CJDT@G
M&_C]Q;Z3[E'Y.N/]:MN=F=;#2;9.5O;?GPR580>>%SI"W(9J8Y]@_4\>1B'8
M3QY.(I9_IJ[)!]IZ.#2[X6Y$''W2,-D[?G_X8<K9#L0RXTF^M19L=!W \T,J
M[7AB5 'HY[X)?1T51)!!&19<@BEF?4\DBIV<<C4ZELN>0RJY/$A&J*4$-="]
MLV-6$([E-,VA61&5CQ=?7>WY5O32,MMI4GQ!9?, L#2.:Z:^S%2K[#<^C!K#
MO<3M-Y4##OU>\AM&6G./Q8*?8LV*O-9G&?Y)8^G,4K=6-Q(5II;9SE8)[^G1
M]1'CQY::G;GY2_Z7!?+^Q+<E#N-$60;,:\G">T'E^NO ^TQ$LT7+"=>.:J@5
MJBB^MG3]H^=T54:Q%[3Y;5!$(CB<!-F;B6%1Z*3HI8<3P<AHE/>-"^G(\W<"
MR#7/D8@^ES=E?R0?WM&F4)"P+ #=IB_DU5/18C\&F7\DL!=_W:JIJGI^^J*.
MWB]G-?LC:CN^SU8?\4SCI0+HS5VA_81],ITTOO16H3HNPN@HUJ"2(P#1SO$@
MX]0#"/F0B$B1/*SCD7X]B#M; ?:"*_..KQLW<*-:Y1#:M<YPW)^NATF8M$UO
M@I?++ESD"P.B8RH[^5W]F4I=H0K8/X PS@!;.;((&7J6*QMI^H<7=&(I@X63
M<D/4)+T=@$94(!6O7V,DDPJ&Q/?7CMR>J?&NEZHB)P<=;UX>\3[Q_:UK?_G+
MZNHI35=H6GQ;&_F<6N5?3W*/56?U3*XG]7H@GQ3\TMP<V+0^\:2]SGDCD=J$
M^[60A1M#"4 "T!%'K=88L;=!O0-!Y.>E=SD_XNHLM%JCZJ)6=J7U7YB.KUQF
M%LU<@IUX7_=R5$Z8T:[4.*GA!,X<W0GVH#(E&W"26)-Q>#2\\@A7X_F"+T$A
M/\KTT&VL%9!8BH$N-2FK Z]P[!#MS:M]/*MW%FQ-&]6+G(G%I-SI&H?5A17&
M*;>#51Q.KSY*L[EF\3T"UD+XT-H4XC6^]@&EN0T08BGX@<HA0!/>@\):(HFB
MP058!>[N6P!!.95[M)]I2XEUJ:+4]W72_&!.J0^Q0MDS/B]JT_EJ!MV>]Y:*
M7_SLZT^,S6T76?#\GFN?5[DU4N7=^+'6J=MZKVG\V<G)!#N'+Z_1H66,8MT5
MY%6N[%I+=B&BWXCP@J29(;*LH"+A/"._M!:1G>72N6/8 EGH3!.VNA.H7Q+M
M(T9:'_R9O-OYM=R/,W-(-O7'YMI=KN%\GP D>I;FP#T06?0@]!25D[&8BLX>
M N+Y<[<&?.-D@G6D>>9<]<X8]=IZ.A8R7EQ8XG2=T_*J8!2 6<9>)-5VWZL*
M<5MKI"]8YR60<CM\T_U)A'H_M*;&C'KPA8(R8EME9DWQE4[7H$H>O0+I:&\A
M]?0X\0W/E7.S:>3(5BY%D7>/5,]A8((;3953;&O3%E&N6,]\(V=,__>YBYR?
M!V$&L3H16*1.K%[<S>8>N!O3S2+D[U5\5-35RNV\'OY=^N7HU/1-2ZA":KJP
M8^T^PT./WED]S3YW_1P(=$XJY V%F,;EPZP*Y@;23D"F?C8L]O2I*Y@N-!M0
M%P86-_)_HNQO$WX\QG5!8 )00_W4=A//E5>\&+:57:IX\)$?LO' !8G))R86
M6L&A8 Z(7#B;=C_6PS2_Q,M WC;=*].C_WWA".R',^S88TIP;>'1YU)MPKX)
MQ]M:D*RE* +GIOB/?-9(L4X$OJ5#@:WSLKON$T^<XV333]'%? Q<_WUW6&\T
M4AX7E?T<?>'@QU$7QJD;IR6-_]3];]R]9UQ37;<O&BLJ(DH5$% $46D6BM)B
M0T2$"$H+)8\B)<00D18@$!4! 0'I D*D=R(E1"F)=!5I 1()0B @O21(64)(
M;IZ]][WW?=YS[S[G?+SWP_HPYIIKEC''^(__"#_&U$CA^/- +^YP>[ UJ->^
MRS(82R!NRP2=L&'?H!./QEH#764(0X'>ZH,6@FJ[FG6[DKEIA;.EDWF1#[/'
M8SH7#I37!.Z)6S@VNJN_ 9R#V;G]/N0D9R>+&S:.%&U)='?:S4IM-NI?F^]2
M$#TXJDR[,[HG:F4#1GT5&^R$)72@]-FJ\5?WVLJ7O?^HO/]FV)W[0*I!^^WD
MR]3F!_!?#9=3+<I/7[,ZK1]RUFX*$15SYE._[X<?!X]Y%/VFW'T]@4K$J^NT
M4?$004CX4]5C'@-A!YW.%KBT!L1XG'\W 3G\X:CMI)VUA-5?N186K5-'OUH^
MG2R9/@W)>,T#A7_E!ZRS ?$AW; / JWUCKI/R _9TXMFS.5#F+V]$LI_K '@
M@C+;IE4&$$][M'4!GA[\_8-+4O'/P^"=X+$\>4D=7#2Y5KEE^9FN^ ]K7+-\
M%:ZYB"#K=^FGRZ(D$]<VM!9\F^YNTLR DR2(ZL:;[P]!JA%D$!:>PF*$:N+W
MA0R-*E$(/<+#B'- 1JNA(@ 9BQ,%QTR1!DBT? >G'VU>N5=S:B.=,]4U*79[
M5M%U]6I/SE1QSF_7:/;LN%H(!]> 6\"'.3?BVE)U$H&,-I@@(1-\[2,+ 7_2
M@L@6$FP9/7<SVB;:UFXYGVK]M,JN4_85P3JB)Q&V5A4K?"<Z["/B#&*L[>$3
M7W3&!6M"_EJW4FE,R[4<PI^B1SX)*9515;7@N4R,ZZ=E,2]M3UQ;6/,$_$FW
M[7)#2'Z+Y@?;M'Y_HOI)@Q*Z=5*^/_9\'W8LF0>JRMN,0H=.*.%;&?3HMJLI
M-C0R7"/*4!U($Z9?P*L, ]9,;DN3=J7^YR\I?<#CMD-^QL\NA"RP("VX"(:0
M3U&-1D3(7E;$LU5;"^?HVRS_\%6L$'PF"@2"NJ_[/1%=>6&;[7K26^0G[;NN
M>>C64WB6,-MY/GUZ@<U<EE/KB>"!Q@5BFZ>9^#",YOK#N0?,>*;W>HSE'T_H
ME^',W?#L'-/X2R3G(Z\MT1#K;8*$O(1.'%<$<RS%4:^Y+FSCY4F61H>P[ FV
M?/1X5I_/B* EGP^G-@]K.IY=&5EV^3B(Z8P@I(SN>WE!=8D=<+E0Q&NO[]%[
M7=[O>N1O9FQ3)4@72IHL%C[\"98O^?71I_9VN*.18H(Q/IG%$)Y,R+Q3J-CY
M1'Q.8Y19]-=LL!_1_]5W1##J0JM./?KUMWI4T.I:7)SZ#%E NUI].0YVZ$AM
MI<R;SA(7^]TNYGOO3QX[&+51PBD$,I@POF+3-YH0PI&PW1P8R[Y%&M4.%IRC
MD=0!7S9MG =J_:1EVJAG3EVN61:..X"0._216OB1BD+>,^V?[.]*:/'&5#G]
MK+FJCR\*$>8.8$%<S;GR<8@PL-P:(@5$@Q3X2H2T^E'U=[$U(&F[I(XG-I..
M:Q-ME@_;7##-^5H"#8N]*;G'XBTZ_>]_<I*C(+CRYEENV1C+[;=@-W ,M=\>
MXP#(L/#,HYG7&FE1#<+CB_<L[QXRCB_M^<O7].&A?8B@+QG'CTWN-+SUD0\Z
M4(X@:^"WAWPU?^$X^O5U^X&,[^B3P!EV?=LZ23**>?U[ B#?[F^HP2IC[_DF
M>+__+^(!OY<'[.Q7C;<.:6SN1V !G08>:"()^Z"-![JJQB>F>S=PG*>D" UF
MM_*WHFW['5E324^"GXBV0R133?Q2[-ZV7.Q\E-6E3](Q*RVMGOXM)S+^FDJD
M5OXY9 .3ZI<_J'@N+0DSGO:+\NWW)5)Q63-TV!@AGRDP1N2(=8X'Q)"DN33R
MOA"P^WI4N_RA$ INKW"8[Z>)*YA2DY#C&/F!,I>/:2S]KFL;+8=^O4T\O#,I
MA"I?N]QR)9[SE+_=8 #7IGVXTAXOR>V4%\,HL:$4VURI]"7AG>A<[F&<=/-+
M;Z$B^^$TT.>O(\15^_]VBXW":[4I*G>FP] V6N2V5RV_UM HN>6@SGG,Q:C.
MF<OS(1Z?#(R"'>2*?O- @V=_.#YU.LLL*]:($'[UW9U]:@>4&C=X";?_K<U=
M:Z*:ZE1&;13B)D;@/;;I/MDY.O.V@0!3^37&><L0G6.26XL2XO9AA?11K*AU
ME303>;?@>ZV!NN@'DV:%W]VU_F1?_2UU>S(NF^R*DP1@;=A#^E83POOF-XVC
M.1K%&&O@:PD<NARF)0@[ @]LC$;SCUJTPRMO%'YAI*FHC#WV64W.^FU5V8.T
M9X9-Y6C1EA"E_FD*QO0A29%289'[L5__V@=$.N;+!*(L)3!/QWI!*L1Z+_CM
M$S1^UW8&5PHPY>?"A_3=QN7WVH&?-QB@V&X3+K&X?/3Y;-9B;$(BP)_N7-IJ
MJ:SVOL>/*Q143X7?6O3+FZL2^TN;EI%N,_[NIA3D=*=W0[7\XLF>B+:I'P<9
MJCX.;MTSM"S[5->!N?:0KGLQ:.:9V_S#+DF(3BU,[F4^-E1JN?2]2K]_Q\*O
MKZ^:72YQ<C6MDK*_E-Z-=4ES$3]S6ZYO('G_@[EV#[GNQ%"<^C<N#;9#J9[%
MD2"=KR-5LH\5R,"._$ [M^EDB?2G^:I=O.;*EH\ZWL>XP1HXCTZTJ6(1OF\N
M+K[4-E3><@H-5JK-+_307F_\M=&!"K66Z!TAMO;LA1D95H^1A=OKY.J=F2IQ
MBZA7=3&DQ+$@.-)'RE>E2+1U@W:W(]^QYZ#UO>9'#3J";KLWC@#<U"WAD.XZ
ML\',@1#A3V2DS&VV7-HX>JW1>MX1LA?\VC5VJUVZ(Y1AO>72_AR/+H7:XX[,
MTPE)L][!3#73^U39E.6[G_P_O>>V,_9R=/S+1N#7V\^=JA8.?;^UC^VR:0OW
M E1L6-WDAYIOC]M"A[<@=BQL!'XM6S55T$LI(ME=%5FAGIW1XD!TH!$O//7B
M.KD[JKL$K133S;>:9S]^!0?"$,G;./\TC:C^:C\_PG8F95%+TDVB(&*]=_M=
M04W= ';<\#S<S]])N_;C8#Z?F;UJ3Q;A@!&O,-<#M//J[@W9VVJM94ZEYHPX
M0G:'* PNNE%JP$1&X9O@Y<\DS=X0!0#<0M)E-=!L#&79YJG(LAFB3HH.%-G6
MGNF7OUBA6-48)5.TNX]I2W6/3U<V 9V=@W16<9L8H H" NEM4<UV*BX:FC<\
M24,6#NC?Z/\C'?%*\XOFJRPEB5M\X'P90J$.UM@I#'DI#3;H!*YN3LXV;&NP
MIC]+"S0O[YT9W<OZW*AK&$7L.E@7TSP"&QF92T^>JBR!C9H>TU[G@=S)@UJ"
MPT,/JPDUE41X5V-89OZ[N_8WDC\%S_^FR]BGK#MP@QBI.=8VG@M/B3J?0NP[
MF4!YP%,US<"GQ8;E.H_2C9%&8I9')DEZ/%!"!.LZMQTOR0/-U;)= @<#-&(!
M((QU->XZDR'1+KR%9/6TBYS=OFUT,O"!<&VPQ[,#*_B8.H%8#H35T9JNT^)H
MXM,C94Y7ZDY?Q#. NQ[6=6ZO?#+O.;!FV-:IA1[TU#!&&U0HJW"\B&/\H #F
M.(,J52_<TY  +<);X<\#7?DM91PU-BG#:^P35^&J882>V5@&ZK C&CK=ZC5L
M(MX_2Z5O)^:/9CZ9WY\BI3;BDFY+'8(LESRB1".'C+QUAE,H)$J= Q&18I+7
M'VU6:&&39..7RP,]#ZH%<LE:B5,Q&9 TS726_%!U,U@$<V)".,I0"JB>2&1N
MHZQ9'2T\D/@\5(D6Q3&>4)'2XH$D'-%3,'%TQ+5J]MX,>"&@T20ZTHH[I*\V
MEBD54S_# PDYLV\6%LRF1T061J$.;[\EG9^M6VX7CB7O?\P5X"@!-[/VRA_6
M_#C)THEXC#E?(N.H8]4OWT)W'/G5H$U'O5[2VK(GB\QOYM->3B!U;GSJ\YOS
MNNZ+/>+9LWZ$K=',$"ELM>^)@.U]'"+AV%7 T1W0OQI<B+D?P00&#Q7RW3=:
M6! 1<CSB[@ _^LJP_9]/2K\T/,'2&FG5#8\^140&>#^.+FY1)>MRN^7WA<@#
M]1/XV :[(#?Y"%^^U1DJ Z45P,6F]HX%)VU6/0-SG2TS7XFN;H6P])HL@6HC
MMBM!%UU ]V:KM&_$_W"TFZF<\]^4'26H%^9@&UXD)ZR+0)*5'N5K21DI!YQ6
M.CKTZ3+4\JEIBJ_KZ.0(XT)9>N/(\&N'G*5R.031)R'JEXGVNS/<+(X%@)1L
M@^P>!ES67/I.Q?Z^,ZCFN]\'J=>JW?<5*9;RN\,[U^/]C]&R=4G_>/N:?*?F
M/XN^>D\]57.L6UG"3>[ZPA/EWNT=K4_G5CS292NB$0\WU3,?&)0H$2,6-3RU
MA%SW)EK2H CL@1E$80OV>+2QRZ#9V_-S>%ER#9T'ZB"0MY_P"9]1.<2RIK%N
ME >Z5 0FG=%(WA HQU.H?TR^!E.0G.^1-;[I=DJZ*?@C\=$!3^9$C$7< .?7
M!Q5BOUT2O\;/Z_9CG8,>^C)$AZ*']3(N^C\HAR"#/=3_0AOVNSPMZD(%[.6!
MM.F^E@\R1:[L=[ Q,Q*\F3ZB22N!ER\137UHB=#SI05979K;TO#U&8;5'!&6
MM,@#[49MQVF-/(6(82P:@3_LEC:1;D\EMF0;.0YV6&O1TN1.^)TTS>#K+;VG
M;2[?B-UM^V7/S@\C3N/C\L"IB(638P'4Y2O;:89'"2OGWG@8GN@;;D]_GG3X
MQF+0Q&7.U2=NNW<J_=8)[8L0WS 27SL:JS-QS KL;!/E_>MJ!:QTO/J.-2S\
MUW#JW-#]*HR.6LVO=8D5OF[4(L9"A)H'K&98%5?8^W^KFBNK-$\=K4!-;5(1
MQR9$?FTOH[J"44%:TZ.R@/T85F"X SXN+#SK)%H;J?\QF]6=F.NN<@P]7&F>
M7 @]YTA6UW'V%+BR)T!^T6!L^QX4N%X\6R<%%)=Y6*)QGVV\[##Z@Z/RHEJD
MM DS8<L!I1<V67W6U&%S0GW=Q[U_V8V]5&C($-O6,\(,WDY6,1LHM\SW2/!/
MOCUXUKI8N:*J&)H/30@D1ST=V3!,S]3UR9;V*>[/-3_;5W@S4U>365L#[RN\
M_<[2!'[4R+W^V$C6JX+N7A[( YV$S1EF!Q1WK3>]NHO-GQ3Q)$^/)9AD!"BF
M5VZ'DU?%:6"6FP8/)&J?9.WG&'V.!_I X[ZHF^8>_,4#,1'3<9'^4.M4-G$]
MF.+IBQ+?+EC9ZOB(0$!$/"2>Q%QOILS6J@67S-*M1N/SRMNVU&K42F&V$?%D
M/WO%N**9G,X/1[$_$'QVYNC-9V=\IL?6Q#[ ;^_Q[>%(=?()"/67F)W?+N$M
M(>R,2@5VK!O&/45ZQ'+$O?JU740Z/^R$"#EA*(4"82X1*;O0QFV!]T48</\0
MY93-?1C_ !6TOT.JN33%U O^X, =&YOG]\/[47=P]GWF7PZ"%_CH]K[B$P\4
M>AD+I/_1F1!8B.6>8B.7VU$O<*(8.Y;-!*=6PMK&Z6)EPT<:1F4B0^W4R%^4
M5?G(D/WDM!K<83@?+\4S"8ME?M#N-) PW/M,U*72A;G3'[2\F28\$!Q[B',9
MB"[@*&R_YX.3&O"@?,[/2;Z&U='F:&FG&B*(@;#%NQ.=3WU"C&-%H^M_8#3\
M]Q*T1LI3(QH>>!?.:2"/0<1^U\1'ZH&'<L<WPANTQK'R5\>)@S7#IN08F*2Z
MDJW6MOF:NA-8>B[EP\_]*$_\_A'$;L$Z2=M?P].'NQ<65X5?-XB/"[\*.3;
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M*A=W76JV)>H1-Y__=Y"(L6/KK . /VO:@EW[DB0]X!OC/;X16P,!H5,$\>*
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MI8N'AD>N5 F6_M&(OI $/U[[K!W4=%=MXO4YYVY;D?//O&Q.>ZY3Z$ISE.I
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M03M-=.^!0),)YKG/0).)E+1C@0U\_"04_A=^9E!OO7-1O.EX*SRF:8^LB;7
M\?@K,C76.D.$GDU!.^P8/]W^XVS\#^F*C*:5WJUEYT,:GMEUBL6O6SR0UT"'
MQC[_A#0DOCAD<[3]D+?-?_X%81H5#:[>PMP#\%M@#@06!1/5%Q7XO"R.CFX-
M+'S.D66:=BDW@R74"#A!CT"YC&R !X*$N]AW"@LC)%-("I5!#X[17.G+-P:@
MT\:#ZN7S,^FG_\/^=_[;Q92W_RF[[_SG50][_E5:!5GKO%J- V[I&^#=%5:"
M]><#M8OS!+><U!]C:\K<JK9</AV,Z*G]W3#S9'ZK%986&)-^1C,=OM /Z2O
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MF#T+BV[LC Z<* ICQ=2KUQ &C%NUZ;@6_/ZF,3.1Y2N]^H_(PC5V/@;"K?W
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M4:.E@(2]Q**$'4/IH6M\"'BDD85[#:+F8$E*B:TT6%#U%/[D0(LBYR!0D<^
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MR_]N(??_INT^<T++Y(/C=9=728Z.-[*^7 .!=ENK@?;;(GRZ<!3+V7FF:CE
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MOVA%/Y/? 7C"-DC 7 +0O<(N?Z;8983S38\R(N1I)+K='J^VI\RLN5^Q.?Z
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M,_C9%;-<P+Y(X@O9[ACIZ 9' _"E"NV8Q:_5K*:X''F'M8^Y#>H5D]I/FFL
M& S(06"$N,I3I \*4"BV,HDT-"A<(1T+$W:'D8VRJMLL?P_RI#"]$>:E93QC
MP+','6$.!ON9GP5"V#IJ[/)4I OKBV[BNIV,->OK.'0?TH[U5R*A\!"[$I%+
MB AIEVW*P<JDEO17Z)24C=L?W[.,F3!RJ6,++"^QRF^1UDW</<8W\-9'H2X
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M6+D&'CQ;6UW+6'<@S?U@4L^,-63SFD/GUIP[)/L( I& 0"PA"A#M-8ZV&]<
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M>=B6W2'9'QAC91<P4ZG[<H7G2JXS^-Z<Z"]2?;/?&V;BI&PWGMI,^H#)7(5
M7>@(*S#!^FL["2+0]U!A1]V=?G[47(OOM)>VCUGA#HZWQ59HI3DLCAUA&EEK
MKC"_T9>,W.<22AY__S+RT[_5?Q#IUR,9O I1%CCS#+^Z#^5\I3,S;T<ZA=LX
MSTW#"^P(TF-!RVJ,AME(OW"##[G7\KP?.EVVRKV1_]3WE7^CG#1\+FZ7]&;%
M:]+KE'KCWR(S-NQYODOA;+K*C6N[;]EOUGU06J*W.3WKKIW]Z<+)\9LP(E(.
M#^N0HB-E9K.Q7>PKGDPLA;.O):H<M*?]&!^;R8N5R]# F1=_*[/\:'+P!"R
MS(!]V%/6$A(;ALT]XZP1_U.WU1ZPF"-,$-<(3F5R<NYQS!0+G,QUS@@CKM:K
MK<!E< W5]/)/7M3ULW(2PN+(V(HW<@3:5[?=P<8,O$?]O=G4]6VIVQ_9?Z#
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M8DN@BT=+W53\A+>/%D8)AVSI%]&?@6ZG[W#DY$AS([,5.Q#G5^)_J0@+K0R
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M&)$,:I$W$ S!GE)QSM_8RXA4V&&N$/<35F GT<)MTI2<5FR1S-8:!\.8)>W
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M3B5OFZ5DZTG 9+)J/9+14UV1R7C',@=IGT@W=P=I =[,?P-02P,$%     @
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MRGT#PV$#JEFJ/;/'_K@[HBS-AG5#2CR-0'.>9T:BOB$^'NE?F29E8R-8/#Q
M!OGPW<V 'U-UR.YEOJ]@#!G>MLP%KI.SDYX.&9@7STT*#^!"]E31(05M0G[K
M&4^G_-8QW+[0<=B);SUT]\0\.B@L\%Z'MF#[VRT=$NWAC1$TVL^ Z"XVZ#QX
M?%.'@0 PBR9 #[6_>RK)!F<>08XP)TF=2:RO-+%I:MX,(=U>>_;RGM\Q)[1L
M/G]]:7#JMURY:P9&'&W-#OOK]?6XX.4#ZWE&9VM1'OIHGN@NLV*5@_0'Y3^?
MUPP#PW.G"^V:%[I/QRG_.BX3HAEUR*[#K.C7<_1HN8T(^1;]/,YG$IMBAL@I
M]DG+D\S4QSOF.M6K#*?L,RV;,DO'0\"'O(,?J,9N-;B1F&K4&IR^7K1UF*7$
MA@U4@])!:;B BK2 O U\B0YM))LAF-^531 ,87(1O)%Q]*F=?FR8UT.\-V8G
M+H+5/?*3(4&92GBU$9>:]W0])[*^4W><Z^<CT<T%,8%?7SO53F@6G7C6NUH=
M30!L$/%&(N :N?^FD38M-)IE".K2/S(SFT.H4V,3U,.)A5-7&MR$:8KQB_*C
M=:Y1Q.Z5&4^S7/*FN&OI1NYCFFKLG9?5IKB2MIR#%8N!+D;ZQ6H& ?;%L5G^
M"J6!'RO/VQ1[&M]7=0=69VY7QSTN3"S>V2NJ;%_)?6JVY"'8_2WS*E4XUJY,
M7S!+WM.BMSD 8U^R<ZC8KKD8+>Q:ZDZ3M"NO5)I46^__&VVC@$:H=OW&F/]5
MC+<CTE/78O)+&%9@=0S^"A)4A.0;/P0[%(YKT\K9UPB)3R(Y)71LXD7GLL/S
M[I9C'3;ZN_$3<Z46)28>7MSTJTTRDZF<PN.YYK9O7ED56Q_WNR;>EG_GLW@W
MJ@.![FW-V ^L$Z\=Z+A(>XCFLZ^(:_?PO: R6JW6QROA6&AD$2'J5AYR<=7'
M=J!,]2I6KUH:FYUQL<Q=DV%ZQ+$B-E['OH29>[9<*RFK^:YWK\%H0'++T,L:
MI@X;ME6="3\@@F7#XEIKV+#>>0R8Z+5E):2A(7PWC*)^NV+>9W$_893YCD.I
M8$+N80HUHAEJ/6S8"K47.E+80UBUHQ" 1SS0U_OGJO_>R*4SU-?268YV6\N@
MMI9AP/^V#.O2"T/N&2MSAC%" /7C/A%/OH9BP[+AK/WID(@8L$IBPXA7%2'8
MHIX1_K8CR/%_;&B*#2,E_1\WVA+."KX0O@M%V0U"C>2)9\)0-D-_,!I1%"7:
M,E.DL9JA0,2OU&Y<W4KMJ*V,!^6V,GY+Y0X3_JO59,,XV#"R__,H_ K$K0N;
MCK_D;_U J;C T?B>T70PUD@:/Z ,D1_Q"P0<#3B89!#!AIEJJ$*MZXM\QG-6
M#ANVU=MOR<>M.R%3YZ!&+03YM^[M#[V-R&;$$#8FUQCO+H3#>[,YAB8 J+[M
M@R<@5BW=(5LA'/;%_!N/]/^KZ>;_-#.CJOJ[%<<GVUL_E/X:M0=HAOI6U*;_
M-6@-?PT:83HJ?_7H'QMK8N6MXO\E<#^_LF&G2%N^T/< 5C>@^5%,5Y3*?W:V
MW]^=C?B;L_/_YFQ.^&;N6OI<B23K$F#()<[QA /XSYY@PN=J_[[S/]*MCW5\
MBND?_F^28X(PE_-'UI783-Z'_,V&.:)[_P>!?(3_KSBRN/\61\6_ _]/89P.
MWW7P+PO@._<!5%;B*476'DB?_+Z.[[2E3FTH!V! :VBM&:_5"39,4(VQ=7,:
MJE&L/1M09%1+_XV/1K9FM?L?Y?,_NIC ^/C'E&_8L V:Q3^LM74CO&<&DDS+
MK(86_"&L; QA@?1KV8S[R>K<Q.#_TA^(?P(-?J6)\-  ;GD*?OR?$<[-,)6%
MFH"GV:)02?R,9CG@K?\%<I@_(!<Q\&]<5/$[HVV5SC!4/FC(A:#MQ!V!IK*'
MDCBND0UCN2!H(MAU5I*+(TO8'?7[///POZ,>]+_P">9]L0)$'*7_[Y""_X=\
M^]<YH?B.Y+ \#QH:$O[PP^_PX/_5 OU;"^!]_KK ^M_W_(R[A$!=L-ABI?][
M^.'_1'7*T*R&X:%K_Q,RFOI7J/T]W_[RX.4O@;M?U+:*R/S_*&BHW]SX->9_
M39I=C?GX[S.7E!B _ROBQO[I<= ?NR(9P?#M[= 9EA8C&#0$XMDP>C 0%>=!
MTZ4@XQB"895.8,_9UZ\'*YN/EW9YZC!;GF<I96M-F'T_2;Z\:_&))F\&YETK
ME#P5\X3/9_#=/E&]&#K&2 K>!B8-Z?5<U-]TS'T$6I%GI"NTJTWBKZ^JDE<6
M(\-U"I*Z;8+G/[5?K" &I%I6\7<'7UPZ0'+\M-B'.T4M_YV%,:L6O.@S6)G>
M/E!FB<5I>QQQZ#I=K&1Y9OI91JICE$.QYZ6U4+J?(X5%V-3"MULU!]#8,#2@
M,Y52923&&D0)-:.]R7V9K4/J.B_'XUN*;\<7BZ9^RZJ)*7WHT9@V'CEILYT,
M;ASM1@%G6@ZC>''!0RP.5H<L#!2EYH]K[IFBY'?Z^OEVRVH/KTWHK=VJ\*G0
MR*B8HX][Y]MY(_='/E6],DZ;W3S:9,9-AYCP#"@%/&K/4P)+:-ZMDJ!86ZOX
M*_W^9$80]2A:8$Y2(/GRNB!Q(^_U\WF'/G]_X2]?3 0;&S.0!K0G'@>2X'DX
M0;!V<S]KT,FFHCJJGW48Y*<5FGU:I@Z%5"PGB$7MI)W1UUFM2;Q8.^)XLN'U
M/6)8H><]I9^Q_BJ"*I[\48))M*!][^6SAS^ 8@N-S6^VQ?9YC[J8)[7;59AP
MNXDWN0WQVF@6NIJ+BIY7&:CD+;IO.$$85\8ZYE[(\Y"N2&ZMN-E#I9W[_2G+
MQ$I*)20 Z^VN*I]8^F6N(>%Q&>'BG(7BAX\3YBN>-#R+UY2"24;QMNYC&+8P
M[]8M&)I0$N)PB"?81W:O:3UI.LN\$U^Q"K_0+0-3)P"!L@L;.S(*ZK)0M(,#
M=:LUD58?\ VN7PY5C.([_4%U5%?^;H;> $,"F*"'OP2#RL? 7^VRABTC.D@1
M+)4BD.B.GPZKFUL*)G!C@SIK3K:*#*R9#8VJOK&R-KL4K5PE^=6TLWH?:RB;
M# 'O 0)\:G! ?+>X;KSVH>-R1_9Z%S[>C7=[/ B!@0 <@? 6JTJ4,[AI@'SZ
MC5J-&/M"1;E9A[V@<=^<ZWU<2$X],.=0=CL.+!0[4E[OKF^?D5*@9''DC&_6
M:6^C\_+!=S^#8BG?B_(1%F6?2A+NXT=Z!6U2]<P"TC+W'1A*\9=7K7L^<8JE
MQ%*&!*\'+@"J=V(,35I\\N9A%_#:,A$CP5"GE?0<=B0(12EB\R:ZPPEQ%U.<
ML;XGZD:+'ID#R'C%ID0=B6"FHGECO&KCJ#.V,+31&ZSD8.UZ36V!=^9QT029
M>1??^'.RQA"B>-_&Q?[;.JO."U-)LJ(T=-P,H/G@A]H[_Z?F%(\(@=<J_3H3
MGWM$LC03>=-_GL"A .4#>*(H6<CL$'>\MO%Q:C7#ZJ5A[=)H-@LJ0+?ZT5Q8
M*XD>1M*&\G(*_NW14@/9QVF9 U:=53R%">><W"2'XD2>W??HK/_Y>_ZBC\7K
M)ND5W.=>FMW]1RF*DCZ]C]6%IF4/9NVC8&2B?C=:]#%=4UMZ@\M,OF[TJ]]7
M&FRVJ[T?EONE&#\]1=9EB$Q1>MKQW-ZM,H!C^\*5^D@M>A>->^EJSFA!6/57
M)U>$\)BOOEL-,#I[ROKPUX^91IF57YV>O<JNN/'RHOM5@HJ +YT"T=]-;#:]
M&^A/P D6,P2'67NP018TAQ)J*F;)2 ],I<G9D@S,R^*9@R[8JC"UU72X]W>+
M;T-UUD;=2GZN(WNQ?J1WU<L-6\9'Z[%A2:I$-RI+,%($__-HB<QU,]];GZZU
M<F,S(."#D4],@+[SM*F..& U#P5D91>!%Q<PP%4WC=K7P\T:.-,2TTM#<QZN
M+^J:F@=9P[NGG(ZM"ZH\N7CT"EA/;+PZ!,^U!2@I0=(Z3O6E))S)X5RGN\4"
MWH/GL,3"HC+S^?69C>;7Q98?[8YXD4.%2'T5,V>QDR&'-CZ=KC0.XWM6PCES
MI==?6/G(YD]URWF+HN7>')9\JS"^_20.,5T]MD"/!$5ING1!P+''-W^LROHR
M)!T:4II]*0@19Z@+76@BW*ZN_ZV305XP%%Z\=S(]R)?CN&$GT#3.IY)X, (=
MCP#.(],VX$DL U^4&$O8@F9_')RA^@M@:0S=)V!V#X%7$= H(QLJ6GX*MD9T
M-$&5Z+R.1;.F;&J!]Y[0'+\O[6O(E[W^"CE2#R]4+ZZWV3/XP/PBS$(^O #T
MHKHB+&D";\B&:'O@>P:YQ::WITM6C)!M29.-"3*L3.[94?;4Y_H'C[+SKW]5
M:GA@/7\/DZ[@N*9M$MJC!)=Z&/LWD MLF-!0_TS_D267>@9Z^HO=>U&\@)R#
M7J939LVN$A%*N5FNY>=2JJ^!M$]W>5OYY\;R-0<A[4S+_,X@M_D?!>0&$;(L
MSVGJN=-9F)WV3W\ 'U2T'BN[E\06U006VSVN24O;<RU.+"E$WB:W4.!,!BH6
M+@*AUX9U .SI<%I.6,-$[SZ0T[ 4 FS2*QJ:7HTPSFKK.S)4WUBK])F#H5=S
M<E\5E*+=#^B?\E=H"2C3&;<R:%=KKA'Q]NC$ &?020U#40,Y#7$L?E,R6A@7
MSGQJ),0:."Q)P2PXW0/A+J!Y6(&;][C(#?]"9\3N<PNHS]'CK+#9FC'?R*#M
M[0><'0AOW*>1V^&_[S'D0"S&%+&9!DFB6'B;5SIHW+P_J(>1+(G4H[8^YI[M
MJ?*] I81-6=F ,J];V5+0FS8N?FQ_G&RJJ^HJ9DM_8$:ZHU28V#WZ=JS/K^^
M,[0ISTK$>D+N>Z''&I\GO3,9HWB?1UV=X7Z74O6[4,<H3"6QS#XFG8:DHD%5
MQ]LX5S^**C(^O]8KCG Y78SA#SX"?G5/U85V5_,Z@QG=1GMIGOVQ]5]5:/57
MM&7,1@?'QQ6BW[\K/W]@4>.YG:]HB.XA&Y0EX2IB DZW^83W0H\G.X%!%'2T
MFQ98LFGJ@M,841LBRR90%M"R."L:,EY'9M?*9B="1#V$-^(V3OL5W<G.>7R.
M[JC%*QJ6Y_SF4?97S.!VAB&P7[HZ&K>WLN=CJ_BG6]WZ0J_$C\RF/0:"3N;!
M@/V08$I2;)]^L:^&G,LG)'#D@#?U!O;(1T/?V0"&?X=XBHVS(S=1_$LU/'LX
MSNES.,Y4<K"[*:34H<1*,+'2$IMH5Z)F*#Y0-*NBK=QE7VB95.OV43@:S$E#
M(- 27>=.$5\=%DI5&3DD>9\<'U3L='_>OF.H3')WQ1&'TOF1E'UV=>.YWB/W
MS($Q<CJH0DA9A4\@H)*PY!&QJ3<QU;YI O(>!^")S7!?"E+DQWAU@EHP7.!*
M'@)27L3\W74?#DTX#?G[[TA3R/%U]O6^:!7]:NA 35$FW9&(!U4<.U!)&]E+
MZC0.*JH=#L<:R8C1%898/%AS,C*QV9&RO/LS[GJ,#2VK]KGY]._Z%GN;2+_E
M:U=UI)*E)EY?T_"OZAH@O&X,:Q!AU4QL%<YA-NQM-MGP,8X I%PY?G+IGO:O
M[G"!B*W68R?RUB=(T>YTC!4)X85^CZ;L0$N]T ;,S#G7YR;ROO1TR@J_]U:J
M@G5=6!@B>CZ\AA S24(8!#;7#]@5O%MTD=<?_F$?6\-O5B<T&T//>AQV4)J[
M2YP'TL959P).5Z1W70Y1ZHNGJN!=NS9#W8J<2TO$&Q(?I<HK6NK+BXF0D602
M!*6SRWM\'*,.#C"4-[7FC+A VU+6.R,=9D:K+ ,Y4(\6E,(DY"#3KEW]&>(O
MQN_@JF$14NF@Y>DO?=C.U%=\M\)"F<RSL+!\CBUH,[RF";L82D!35/]<:0FQ
M__,L!;Z8Z!^I4%_9KE#I3AT>S$)+U?$6O..J'$F@.RT/I 29!"MFB 7XI?NO
M0^W"3L0M339L/R;6_)F!YM,[6EOO,$R:E^#M@B"3=HK=PO\X!:2SA#:06[)Z
MT$WINL_3'TC^TDUE4V,KIF?55X=2JUT59P-CZ \>NL\JG>FTB+!X_3$0MQ*H
M-T,F[=&OK9#5+Y.P#"R]?XA;O*NW4K_23%6H4/S70-'K,V$N[GW7S"AXWO$2
MA@@-9PTDF'PR"-D48NP%;VT:@T'3K0\!.0N0#:.BX5_ G#- 5.K.!.OAJ3:G
M[HS0 BBO3*[6].C/\QH$F6(][TD(C9MXNZ(Z\:!J: K#;U,#2Z)?_T2XG(MJ
M[Z?QMH?#;QE8/U=,9/A3$#L_>SN)OG169\-B6#*^MJ[>LF+#RX(B7W1226-N
MEY*FB9?C%=(WPR%JXFV+9(B2MT?BR6(#D81YJ34&LU1V.R#.ACU$$E$)<:NV
M;%CCT'GSSH]\J2Z&5\ @;W=-POB1*VQ8)?:=74&2G7U*F6UIN6VQM:6F3]P1
M^R<YUL;4*)F 2V6CS\"O2I2#5LCJ:Y(%W(Z\OD?.Y*K<+]&K&P_Q4LETNA'T
M:JHM?S&.ANQX-?72?*EV4P=+=<AH=^I)":Y.F))JY0=C,-%,[8G^1,3.D+=5
M,T!(8];@E:VW#DR*K7E>1I]D/'POW&UU26G#9HK%RQ'JO:>0)G>2>=M(]@JJ
M/JH&J,+$228L<9>X8I\2K7(%9JU=]7WG<#+>[K*/205"1Q]0[U'<989]*C1?
M;9\DU&<!NK>.4]O=!/D;1?U!LV"_]Y\-:O1OB%5<N)773-7S >%MTZDL'B!:
MZ-Q5#-^56%$9\1=#$]PE$NV&W*)5R*ZK"9K=W\]]Z8BNP?Z@TH(#6+TNMBK:
M9109:5&^2)5TN'%,]X6:@+X7;A,\B7&6R@,V*X$9FD30/7=F]>"90RSEPNBR
MA'8T9PUO/-6IL,.V,KGRN'W>_LHP=U^[LO0NRUP?X6+G]>I[5EF*0!<% ZK.
M+GE[A0&JIT!1CTH&!^@)V'?("@%+/<1E 0F=7&Z*=IXT(7[]3#/-;[20W!XA
M!-Y3^C;TD_(".WG4JB)1TD*#:.U2O00I*2ZQ$=05_UB\)$O(&U'K@N +7DXE
MR 2CTL,G"XNQ,9B11VB:4>Z3.7VC6G^N^TU<*4'(VS^#:\LG77@NKORLOG8L
ML7L0WUPXC=J.__20C&#(K]IMO:YHAR=R36,VA WDH"1K3=YJA4G\%,+."PO3
M-><P?, #G,WVEE/6^L-!<\;%X6N:9S73L+]50M^[&I@Z912L]3C.TS+B9,]=
M46%)!EQ6A#OSW*9^,9.#.R4]*7"4HR?%R9O/_SRBJ]+\V2;\<(DMF9E?E^+^
M\5&T+^.#$3_VC2N(H@61T[MN&RB68>.IY.IT')+Z(-BY44?JQ.AW8+12H#0G
M<K10]'[&1$_P_DV]IG/?\W0FHD_KRV[2[X*SU*EQ,7H<&+-YS((\M1MKL]D=
MI8>1F<L335IP&UWMY_79L^2EGML2\Z7=6_KI).7CT;B[?DN.'_;=TU:!@%/D
MS]CKQL6&%6@14:#5#P*CZB\:(+=9C*R!1=%._2ADPP+R"Q@+X_GI>M:G_-2Z
M2V"#U<D%T6&1$J3^W"M#1/WRAIHXE3I/:Z>BB]0#]ZG KT!=,<H 8'ZH("9O
M>[K8<$%<66*\1I'2MS3AW/#@63,=F9,.LW[&13\?O[XT<3\C/+\3T0DI@?04
M Z_IZMOK.8C%BNE\+M9@OD3K'F\,5ZMRU,!&\.2!1A+#9-KJ*#9X3GT)A]+)
M.3='"G*JN'L@--#47\%36?-D%K*,X(<$E:<ZT+NPA6XOF8]8W*!J#U[(P'U3
M%72>KLNO-RPFW9YR&@AVQ7=4>U((W%9/(1F+OSSEXR9]3SX#W7CWZ3VI,KX3
M3:K<K/J$F\T"KY6GJW?ND>-,Y_N1U FWTP8T[\!)]0C@)KA7^>MT/G=T3P O
MN7)W]#%RXF%Q1>E 'E':((T[-HH0WVW>L7&GP%@KJ&V$$EY;Z%94DI I3I%*
M-[RJ(>I.Y3N\W>Z<_IFI6CKN;G3ZJ/UTGFI);"<9(Q5TMEK)6:C1)];3YKYA
M86E9UY%N'9J.2H03&-M2Z9/XT6XVT!]\,DB8KG:\$258RQI@IAIH5> \,^B7
ML^E.HT:'JA-Q9SW+W7"H=.-(R3:G'XF%_26?[V=^K(BX5O!AAO33X;NXJ/$
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M+X-;.<6K&4.LDVLDEE=="_X'+TOJ4SO(H<.&Z>CCUTVKV; /^:0REBOFO]O
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M:F:0+ \X>%,4_Z,8 WI"P?[0@.IK^$]<LNH"$C:=M]Y-:X7AC@^U"N-\P7J
MFUS267EQZF3S($Z,4A$IT.,Z7*DS)RDCZRN%7 PD&3.I 3OC<D<<<16201@;
MGW$4,1W^8X'"CS<'(PM^7-L(9,.N^FR@XX.7M*TJOCI_GCO]:*)"_(GPO&-#
M5I:#IIB0RU>7B?'. XTY1\8@5L2/(*2@'9'#L[+'E^<=UGZILN195:DTG?NM
M4M\>I$<,,6L=-M29\%_<_\9_/0SBWS5+0U)P>IS;+J#_MH$7I86[K8D[KEFQ
M8)YU@&9$* ?QQJ\&5PTYC%_DVXV&I%K.U;6]HH>[QE5V+7WIX9%IUMJ#R5:=
M#9_M1(Y%=,CR V*=<,$%/(\V9@?#+MLXF4RZO;RZ+&#Z#/NA&5V(NHTS:N*<
M&GLXO*/L29="S=4!A9&APGOS%^_*[8:",N'83H, J#7NNH1?5X]#P%0L1RF^
MDW/.!SH-_? ;?$M@N!9C"/_?R1J(VRT(.Q@7F7=8^\XS%(:;^:GH6RR-H2B#
MXQ0]%M\4-@JU:_X&&R9$ 6Y>IEF!-A%6RA='S!-$972*$N#/>N,T8B_%R>AV
MP\59[]FPVN48#$6LQ]!_NI^(Y#0O/3?'W847=&R?%/Z$KU\S"QZJZQS6\?6]
M<H#P1M/JP.$:@PR#T_T*[2)"35#]M4:R2DHFQY84LBLVLG)U/2$M<[8)LZ#S
M:,S@7LMDY7G\*Y^?.6OFO_/_HY;)"$5($#PJT)(X+3 HA"9&#TGH(8BO/M!9
MCC."Z_??A-\VDON1??!=@&\YB+3^? UWO&2R@Z_VW->YF@_\E!.4L6*ESJ#1
M_#K_19W223"IPPJLW]3U66\5I)$2C"3 9T,F(\W<SUVP_CVMFB/]"3AULFN(
M]H^J1U8C:_V[!0L_=X1]*\JYO2GUME:HC@W;J@YWTNA0)JTA75G%]6_"$QA6
M2_X;RK*YLN:WT3=>;4P%#ZY"F?91# +.-\B:+]?QE/^33$N<1G-<=9WD!1Y<
MY6\#O4Z\-1Q>&K+\)BO (R']QVT&Q)_8(PY!.Q0)&J' R&(\TYA1A68<DX2$
M#8;UHY[@<A'55_W/6"TCN+<<M6]@UK)AGA;%@VM*Y&3J5(=7ED7PYN>!W=CX
MX5JMEL94XW5O"3F8T,>C;%CA=6!K22L@O1%B*HSI'.@]8DB(QHGZ!W#2)W<#
MS<+M^_LX 6SHR?@KETT>S"2=6Y2[IR<R75A8H0R+R9GIB=R?I<652L27^V23
M#F*?*]:'#:NHX)TZ2!V_-G5B;'#E;^XE^?Q4=KT6/,W8F2<L$=MEM'_VW%4'
MA.#BJ*W#HT<%;KE7JJ_0 E,,YWU6 KR=S]7U?TP'U4.)Z$2$#&HZ&U$_2_2/
M-8*16I5QIK3L: --3W)^ DNB-MF6U&QKF-!)X%P0&[^1[1&@MOOKEU1%&\+K
MW19JWBK'WCK?Q?2S83WI-Q' :63B^/J2ZZ9#%!'_TKS'_W-H1Q-I<793D;&#
MIMAA;4*,X@7=-X]'?>(EHU)/@\F0;C/@!I;)#:G("T,A_&)DSYF>A,40=XHA
MLGM2<4CLS*=5LY?#"C6:;)B'F)'BW0/W!"^GT*P;9*-X.K83KGME],@<Z\&=
M5<99'5YY.;?P^GRHW)>WA\Z$VMV,B<FX><BXYMUV0D[_CUIPHX7Y@#!=&:4+
M*@(9'9-[:0E+!+K_KJV[- "4#A)8@Q^2H\5 3\\GG/F@L\THX2(R?DID&+O0
MU?2]IJJGPLF<.^YYLW65JT_.S'T+#TI$8VW@AT'?_.VHZ8HI?H8.%;7+>8HU
M11"*XO+-(2URT;3HT4:2-&9\V:8UEF ^VBHXA5H*(R/&J)WZK;4E7[R=1G-I
MAG7)_J)8E%G+8-0[+__0'0DW8-Z>K$;GKD--+WR5WJ*P4@]M+,9A'<H7VM*S
MQ6'?IK_-H,A*=Y80[LF[HL[J:ASSN./,*?U-:*>>^ %9:QB>#U-OWLF&36S2
M(T Q8#^)7@;F;[I@D1W"#!$H<:/!9'H4@$B(TL=RDQN6#*?]/,S Q!+7J%ZC
M@\SG]7[.74ZF":E^!F+ LQ5KN4[)&\GE8,GIP64=_J,VP]J5F'.-T5BC)A %
ME+!VH2CPL5IZ._-9-8G^!<RD(6U!B<W]6&>Z,QA1P+@T8B!<A'W3SC("I8"G
MZ'0V3!#'7V#"M3993Y4YZBSYGC1H+O"04E'1Y^HVT1&:XTFOD2WD7E.D:9'[
MVPFI'":8% 072YQAA^&;DD%WY ,OFA7)4",MPWM:WNKKG")F" )M[?<@:=/)
MH=Y??%<P1\5D,^&WY5ZE3?+Z*8Q.\IY[&C\^R>.DM#=:]-QT_$X[G33Q@A-I
M1PH3;3U.G!R^>M8)QH)_'T%-%QK!']&O,G.CC+;^%</*7YZ&3$5-/\T =<GX
M=OQN5]"+RH:E14G,Y0O@Q"I8_4V+JA3D[::\AK#I=&Z<2>,]UB9ZM-DOLO+*
MAN/$_A&S$D_#[[E!:Z&W"!XH4"4MG8I.S*\72WF.\O9%C)/0V2P>,5^=]8[J
M/<[G0%6J%/9R]T0'HN[K<IJVM=&*(9QBP(;!FZ5"@HJP8_5\Y^?&8Q:R)8-#
M4X-X%==^8?,DAW'FA5C":2 TP;_9D?Q6QPH-Q^;0B;T+G9)<50TBIWT/CVO4
M&-;EQ&?OJ.1JWNUS?<S%1&;U=)=,[]M2+G](Q=BQ88H;0D(WR_/KWSXO/_;6
MX?1.SEMWBLU[-6^M#+P:W\9(QF9/0R),)(980GP!3I!UEYB5.)X,.M2]1B=@
MHR?:"#7IR3@$T$,UQJ%IYMV;S""Z.VT]N=[0_'3=BX3I&3;LU@MM0U_[&-?!
MU<3OC^QIY@G(=F??](5?Y!7? !#>K@EF\3M,=%J0$?S/6ORJYIVNU58Y+Z@6
MGM<HVU'__ H]/.INA<\ AH<Z7&^HBJX9\E_>XULA==3Y_,5;6@2R6L;C<T1=
MK^MB?!S7]KYR]+9O_":<<@>]]Q<:8E7B]'6U)VUSFW2#R( /JNJ+K=^X(TRO
M8X '+OC^^XCUWP1B.GA* S7;"]]D3)%MVCU:GC8B_^&(.4-!#/%KAIO)\@>>
MMH4^D$:<HM(6K%S$_N%X(4N8-_WW2@R+#=,%;3T_"]"3I@GD@Q"IYRNAEG_A
MXQ#_L%QFMN<Z<H7COUNF[^5F]N]MDU0&4ZF*]T]S0S(VKH?Q^S@;AG_$4'JY
MV#I]=%PU>LM,*@OWA TC?&")X(GN 6R8T6G\U'<V;)?[I= Z1ZX_?^_/US]_
M@WR-OR.S)-K^YV^B_M&"@_]I'0?7["^$MUN6D[K6.6_1M[X6'JGRB7:B>\^=
ML<[#?9*"L\#9#N%ACKP=<#GN$DNUORR;*4K439[E:[\ZO5>6)S?-?)@/\6LJ
MR?\?W%'B.;;MMR$D\[N8>49:4<.(ER0B(AZU'8<LQR9W0P+KE?\BB3*Q^0;.
M\R-/]Q7@'X<SI*@;1^)[QF=CFTT,)"$I>)1\16-_\\CJ!(7F=L+Z=9(I)[P?
MG90/6&'2$"^YEA=K*8B;9=3^<2KE&M2^</& I,T+#!^:;BQ.#-B<=HLAMT38
M,Y-:U7!J0#C6JYTET? :0!(K!2+##.0*G'VRZ/H5KF#"&5<S.F]9<9HF4QLA
M^K;_NTZ*/*U.,)#*4;5CAV9>P#RZ:CLRJ=A10^U33=OOJF\J(M)Q9[N[.';Q
M\+Z.KOI^X-)-O!"!AX7 MU]6;Y5AN TU^P++K%W"B+8E/!6Y&$2#4P@=2[R=
M^B^C!B1[B'KHSD@M^@, N<BD$"2QE 4W NV2FR(;%A>&I_0O]O5S]E!0_&.N
M\T8R0\$?]*_?V\Q>TH1XFI>'@I&(ZO$'K/'^Z0E3N[2AL(9S1FU+Z):5^V2$
MQ#F!OK1[$]0/]1\F2S;/3&$5N_(%FI4K>D*!V")>5 JI2U(AD]RX'&Q5TDI#
M9919,2,5$Z\=P/64).ZZ,[&'XG!V;\J1LW9GTM^T[QK[/?+@>Q[.(O#VV-!9
ML>V'C:XF?JG2>@&+T T,6\B!L31;!:,^8("S^'A\':'['!MVN3J.#:O/)Z*2
MHE29M83I)WB1M7X9[*83L)2P*$=%1>,%<9J4WRQ1R"B@:^IVO5@"1?$V2_4=
MN=+WU.LW T];T[KWE;FX)AN6XFT(T\F3<.8; QU:#$5TMGL)3G\/)+3])G@A
M8G)".]61= K-(8$"5=ML^ORKX?J'47K8B6GG*TW?WZB7M+O:?'@N]_)UF#9S
M#]WV6G#D?J+X,?Q4.\5[A(.74W#/],-O@O<:B2G/!HWC3O\_[+UW5!/[N^\?
M1$&DA([4J*"H- N(4A(5I8@T"U7(5D0($2+2 H1$07J)PA:V( 0%1$1 I0D$
M H2B6^E-@A"2J$B3&8$P0@B_^#V_>]8^Y]Z[UCWG_GO_^*RLE36?F6<RS_-^
M7N^9Y)/M6K#B,.-N>[3,YT._#&O^*+WC[.9:Y),BH5Z"./+E\/>+J0I3PK_D
MH A G)L/,=D>9!C>Y<I&(57=MX0X*J -]W(T]^,0400_L,H:J0L&[5?,X&7\
MKC7?])4RU><UV8-FIYZ0=W0 #9]+DS=A]/M=?AD>,U]>"\!8E-1J\ALW$-2C
MZYJ$0)#2M14*XHCC[B)@?T"] ME.0JFC,&AAWID$ME*<KAZ)=9PD QFPR@5,
M(&5?%ZQUHG''@-7+*S_(;JK*[_G9RWXAZDH7P7UU!?BC9P=6<$K,<?]\O6'#
MQOTW%ZE69:Z8K :C9R657NX>74%E_HH,\[3T1PI?>9F]"G%YY2]OZQYZFIX*
M/04OR3TKN& L@KF^WG1;[/R4Q-6[C"-2?F]^J^]/@0W?.K"12KNY./:!6P+U
M/B-<W7C(PX&J+6O:L:3   \.LA(,9W6U+DKS="%:.?X#VZ=2@ N^$PCN3;!(
M!*>._[;$-B^N0.[%($V5G-T#-F%C 9K'["2VY\\ B]R+PR1?AWLDP/(+2FJ>
MKTYDT-1)N"@4(YA32RZ"K*R K)H2+%K&;!N'+$/L0VJ,A* DBIPCM>.(:H3#
MP[K-ZC:%X[_6I/(T4@K'$S)^>D3X\//(2<P'W)V_3!/6+C6>FI90$K(\WBDO
M=\<UT]7%ESZZQD]AERV*^1DW[P,^JS35)1 L(K !P>5^A[#O)2(_FQPK,82'
M/SM;UH7;&ODX['9;=C]=/KCLZ<$[J K:MTBH%99^3\*WPGRI6^^61<<J#"9H
M6#L1S8',DZ+?D7_^1YF%+?I5**(4/]MH8;C'158OO7OTQOB0LO+.=[W$@S8\
M-UW[=[4/9-]8%QDRV\KC4/H1NU*Y!<Z>Z8R">A]7_LT_7EU1F\JD_'G_I8+#
MZ>Z:DSW?G+J#4/]H3CE\O;S.D3<IRJ)?WX:<4$?^82RA@=_U12KHOJW4._[%
M39@?9<R;FP&2>8J*@_P=YBSF)U0[?\]&-E^4X >9 R6=3#'5A6-H.4'.*<YX
M*8/'DI06%EF+\4DO.E@.\F/\WD&(;@.LWOL1&JM!8\/AF(MSSH[BN6)[:LC<
MHP*>0!(BZONH-NOG"-Z@51I2#4^?LEK8NXXGW-YXC/*UTYZJHPL@Z^P0 0NJ
M?&"+)A UH"HT]/5J1!"HU,Z )RZ8G<OIC)NJK] UQ.B/.RC=%M-;0@]3>'MO
M"S_P5A0)XM]GZM^R=I2'%<=;G]AZMQ,F5-*A/R[T*JX65M;PM>=PR]3^9>4N
MK3N1Z2=1]RDJQ(\(X (JGO+&85X0G9A"%T^^B]U1DH84YIT7V 4[%B*&I/"R
M8A.&04L0Q_F[ ?-[*!%XTC2(2#1T"ZF,(2J 6ZXP_%6./2SUG,GQ*E&H>%+!
M\,\R,)/ET_Q0P/G%1$H-?/YE VZA"=2819!I")HW9:Q7<,Z:(@E/\227ZBH0
MT4:3GX V8>TJ';5/5>2'J*?8.AL7 N#M1]KZ,8<_MQXK*=%=_**R04++>.T[
M-Q-%&-%[H+L).P'+"'Z5=?.VM3FL5_7-5]!S[NB>F>=N]CN2M'1+^M(>]7X]
MB>BI6Q"XJ*W?4OABH. U8J.6K\C3AM(XS&0 6O< LML7DU7XM&>NISCJ%^DZ
M;'("E[EST8=B$X&XT#A"U2G",GJJHB('3E3GKXW=32+0OQ$/0/#UB%EF#2JM
MV9R' $47+&EP08%.%2*J* E$&.1"USC<4+>17[P12[!;/^+JQCL+>F5/1>F=
M-:SG([13TLG8H(J7,O[N>ATQ^FDXF0P,8NWZ< TV(-Q^*,0NF+X66%GL'^;B
M'E96-.M8_#7^2<GDF9'56A>NL:/MMN[B=GW@RJD@U;.Z@>]F__[T;*;A8<7=
MXIE(Q<P"M^]K2/)5[#.,RF7RFD)\WC/7\>*\M+B'18>[MAYS#NOO" @(?)#X
M)'U_O_1-=QA/8N,O0=09B!J'>+XVP783%M\.-;(64YA5)>T.\2@9,W@EP0SH
M75!==Q8T_F'5=O<?267?;WW&>!DW#2[K1.U?J*Y?GAL9#%P(#%BHD$S+>>\=
M19+C1_+L-U*1QS$4X QEC,-U&D)-41!J/#183U5:=X2TVU16Z6A)@@YH0*;Y
M3H2[075LG"PDVN)U!*@C&V%MF\192ET!1_3$SX)=[09;L5UHP.&>EZ=EG[C
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M_K8GN">X1;BTMW17T"(Z%2V'FBJD5:/H3%5>&'2.=*-;NYTD;Z8NZ!()EZ&
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M+CQC0B1CPPQ6<E4G;O2H9V+(\^@JW *BC( =1NZ!;#N)V]Y"&$YE0@.NC:R
MANRY$8$&NF8Z(+EEAMTKOJ_$,#%&+_S\T$TS)U;>;<8V&:LHUO2C"S)A>@6P
M-7;R_H(M_VF(9 F7[9\92O\B]#E42VA4Z^Y(S'<I<5A0QM%W.[4?C#^92_]K
M#BU-G*!H((_S>Q%29N8<7 Q2&G(!A=$" &<M)JRYW.'OQN;K]1O1U/!S78QO
M#UDX&.30*@MASPV5G^66O/2_\'G.A3''F%G3CRUA^K_\J?<RR<L-,.6.0 _!
MHYR>!(#9B9 @( 0[0TG7D,@";QC,IDA!M,LC!">#=-*- (MS T@M6M*R;?>.
M49LW0&5B1>5BH)ED1(F_L<G]5X.%*FR];AYVI^C,G:PCXQ9;/@?UV-L*I:9*
MGWO5$]2R(A^1U*..5T:.]1RQ@86<V!H[E\S#09F;L&W[H;L%_I-2PP1-X ,]
M;!,F2K %Q3G/4DIY&)"8#5HY ^@8JC!@P0Y\!$2NMA,/#35KX+'H!'JVAC[8
M79?"/!OM,6^RMR0A1,?S]-H,[_T9K^YU(^(X7Q<: V\,TO/W0>$L W&" ?1H
MBIQ"D^&+0(U68"BWDNU!V4&0ALH0;6A% 0?W#.HO8\TUSS:.:C>^ 9WOHA)6
M/.T[F><:^1^;LCS&(_3?B<Z@_WHD?#LFZ.X#9HF:M/5,_L;1V',5%6(7MF^-
M36\/W1JZ-6ATU/PPI:MW.ZGUDB$ZT21A09M-$H&LZ(R$5M+8-!LQOU%TEN/'
MN^KS'$N1;9;GN8(BQ5.]2@27OA#)(V$!\'- 2?("*]<JU@6)2S0[X1U-,@M+
M(SV+V[B;>.B"ZO/CG./O'*4^9YS^T=-G*WU(;!ZF]31Y/^R?H^#^"6WAH?XK
MJRF59J=*('2[\:1<GR[O,CO*#N'X%EB-KU'W(9A>K9@[[&&]%O@PNK(F_D6#
M7O'*I^1)SB7^QR&[5/U5'9^0_D0U8?R[V%T-,4=;S>X4;;&>6E!6-A>Q=(C<
MFD@_.'M*>:M:JLSCS#ZIIHVJS&2>;9U M_,(SO4 HI66>)2 @,(EBP1T1U0B
M>&\\,:1 YU=^X9:;CK(I723(,0>7@!1WV$B3(.X6-+!RBV!VM(<3>#[,V7C-
M3-']<GEYQ9/2MI')&B"6RP,K7@.%W"RPKI,F/$/<#B4 #BW9:/EJVKTPO@)8
M$E<3U2LT6\;V(XB^],2GM->MI3]@3RAU1L;'RBOR=8%<MQGNP-Y96Y_$:QF.
M\&'*,=2?BQ?4[A3=%M,2BCERR&:G^?9=L>F8UJ$O/W:*;EW6:'+8R:D\Q\L'
M$A;JP1^K'.,TI!R^CH6."<GS1XG.E0-HFRB$NE^D02<3@;=B46+-HCB2* OH
MPZU00>YB5.P?!+'U[!E+-DW ?/[>FH'EHL;+#?68\B<+WAM51*U9RNN2>298
M9PLHW5D@&O$')O=!M@#S#/"LG&T>B([C2X'3'9)$SIGZII&53[H%H/DF+%9
MG#5B5Z/TD*,>(Q5Q<7%-37^NGGMUAYB%\QPWEFS98F6^!)'$."?4UU(;:$B2
M-WQ<M1U1_:RN$HKJF-S11]4LF\D7 J;3YAT20K$3_FT@I3,?!5WEV)+J)NE"
M]55O0 K]PPSOQ/.S\E:. +_0/]M);SBURF%-\N0V>:=_#?GNC9R,9[.?I6^=
M>ACNVY=>L)0!>[?<B2F\\!KU<S6@4VSC)V#BRSN:FO\08"X\6C\]SO^;5"4@
M=0&8U[E+Y;*MJ9+!K..YYT9J()[>DT9\71=2!3CG-=>LF2/^UW*TZGF2C/Z3
MYTS#(Q''N/,M<G&X=+ZZH(B:I=%X<3:)W*PSPU4QB$>J0&QFZ[%F)'2@;!:!
M:%;$SUX&'HZF\,X&LW!*>+1U7;SWE+GV^2%F5^UH&+>$/OJ@Z[I//I>EYR?,
M?3Q[3/1@X,*=$Z*K'Z#TH.5*XU&D!L%TA+\/C^"(%,O:<2@)1 TP.XYJ\.)9
M69"\L[LQ^7J?#ZA7Q BY7?YP#FW#RMM=F#.CXG'QIEUC2>Z^Q;LK..@ ?![W
MU -?>;D)>A+\^YEA;+6'GL<EL*8RANH3,>616WZ:?GJHG*#]%&IF6F2?'N;=
MXGII [PREJE'Y_"C&@]L2%*%LU_AVM$I6A<\'ET-IZ>@D@7-?V6I C+YL=3N
M?GY5227Z1_8+C, 6W@LUG5#J\%(?#8EZYTT;"*V$SS:$?LTJ] V5_77[Y/6T
M+_'6Q?>%$T%1GMP<UP&T(C?O)IP>KI:\'6#%SGH=P7:0]U/T,AZ]:88P2*DY
M03@:6HD7Y&)3WF=%12]M<"M?"ECHJ2LM"&]Z^R8C^D%W>+@6%[F'WX)ZD]VA
M$W$-M$H(37C$LP5%.\-&U]!IH>.2%G:@<7NE$J3:Q3\X&C+VM.%@M@$;ET"4
M&0KYKA4?96ZN6Q3#^#SN];GH\70+>=R#&[I1.-J1P3, O>HC J9Z)>B<Z O3
M[4@)$'7OVA!5#%G(5M]M%L3"$*R>?:*SR3N>O6:A9&<<RC&2H;X*_ >&^J0H
ML>RODA?Y.Z(VR"\@\U#TG4G-6J"W'1TGRSL+*"7N'5'76_FP*#V;TU'9UJ3!
MTC?\OMRT!Z&88J>A9^%8/UQ8#TQ653!:1K+=?1X.=[\5[<NB .=(GRCG@/7O
MD<;Q/)_B253B M56*?DF4AO*1ZFXSIVB!AH4#_)L]\Z/<E/*&01KL#RK!AOX
M5/UTEW/&<-9NR2<)RT?;5%!Q!#B++ F9TBU5$7"\A\4@P?R)6\U\G>6H37_Y
M[L'Y@JBR1_O>UF?IX*^YY$1H8(*^6?\\K$N\T$<\,=-0V6D Y^UJKAY(6TPE
MBEN!X:W(O<!J8@#!BD63]?!C=*>G<2:V]*Q-2%;/L:*Z;<_2:H=W/V(/+8]W
M9:_J?@B,_G*W5Q@0%D4,#MPQ]UVWI_.)"[3%GYNP. 0C#+&T&K )(V7S=-[?
M,A?]LK]E&7&_ .[.'WRU":,TXM9Y-)85-R^!MS%.8GX59-_/*_!3OWXOCOYE
MO_ (K7H>-?UCG+\),X"<-DJN"GQX&'/U%ZF-FBW<1SR=^GM3V$KE@BG\UWKM
M)HSV@2]/PGPB]4[4;?#10.7>WP<K_+WE'7/L_XOK?QD7Z[G;?5=/CX6M6PA?
M6[2UMD1N.:DE]59=YUU;[*?P>5.)X7<MQ^34)%3_PK<L2+;,"*ZPZ?\^XD3E
M[R8&5[\?^"^%0UE0-WN\4?$IX]@FK$(M)E(FE4@:&FU;6-]*[#:(8N=%BI.3
M%)%:H[SGU0C%,<(UL(F6C%1V[>#(<:J*"0=&+%^MYF_K]^C<.E>%4<%^N!JL
MK^=[=_ZR;O9WGD$!+\Y ';^V<7P3-N<HFC2W"7M#HGNB6.A6@[A-F/CB D\\
M !!EH^X1-7GF34U9)%G%X1"["UR2O 7;9K'B++_>.-V0*0UEC:.'?NBG+3.R
MWC)RLS)D:SA$'0%X>!'?Y1\9_&$X$<EA+PS:L,FB>++],(T5@8?F3+;5T3\T
MX2X!J-AE3^< =X\4M!#DX09*E;[\SH?71^7IFU]P#3UQ+8?]=W?!NL7.]\*5
MZ"5^U,#5:-&2E:[I7WVBW30YU%7X7<K.:O(6/R(*I'7976U6@9CGH92I\FNH
M].:C=:/5B\K?^?(I;8KN$QT\X_Z-YF_C#LS(6,?T'_MKYAK+;^_D#%W'/I@5
M\&ZS&&83)D;%@@E=X?E'&L! &HAU _R1)663MA'1)9 !:S2.!53>I9I'/??J
M#HIX.7OL6C3N\HC1>&F6G>W%D:*/U@_J Y<T)DCHI8Z=7+7,\5)S$L5^;+4
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M-V)VF$.3AB@N0#A/EYFL<0(8C:>>X*!D\$?/9;92E'BW*/)4-)#=U4!,*?7
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MJ0$%4(PYYO739[%!\+_6BAB?)AE7%%]?N?)9Z^B[^PUG-;N&( ,VCLY,? I
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MWFP' 0UK: WS/%@?HO,EF@"KQ)NZNB%,27SQ2ONP(;T0Z.+OB%Z_SL- I4$
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MPJGK#H[FBIRRX._JT\G;3PA^WY]XKC9(&4AIR+Y"V;S_D5]IMBW9)E1 G5W
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M#[/NKMV,Y,IO64U&!YF]4>^3*WNL_7]<-WFW#[&<^O^&!'.:]")UCB%+WA9
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MS\8TNH/=Z@J+<&Z9MS!EEGUUYB\R;Z4T=8CWKV[PW>FZ'?3W"PK\?.A.D%%
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M.W6]SJ]?M]#/],T8*\ZOX<M4FB3.4*]@+!>PYIE:@HYM>,4)A^6EK'D+ZOH
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M,G*/>0A5!W3H^_O6U?:YW0Y_YL-0 _D<?'JNK,O0(1]0%/K.GGE(Z?$/G>D
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ME+@L!IV$T2\9#9E3V((SJ=9PGEGKJ$G]JY3A">^U.6XI?V_\+DPG&&+U*>J
M+%W"2C?=V8,Q*B SVO,UH:B' :%+):YV3"/*OO[I1B>EM2!#ZK*!-]%1<>43
M<[?\>&;7VI8=$41?WAMF]"<FDY!"J.9/'Q#/F(Z9;@$XR51+LH;X:'V%/[E6
ML9UBF74"(I80\Y<U]D8N$'R[[' F8PZFR'YKV.IJR83]WY.^:YLR>6U.SKR+
M.^[NP5G"YQ81RW<NE&&-QN9STI0OB;R>ZU4O=D)I4)S!Z&9R!<L";"OA$=8H
MWEUA&K.HV]X\'0J-MAF$5/?TSDBZ9F"<;MY(;='=HHG1R7VR47=A";.*WTY
MP0& L.T=6H)])2(9D+.4+]4F9R1G@!;BHM0>BK;TE0:3SE:%XD.>AAC2AJ+6
MK6_HXM\X"XQ6F51\E'V6NFM_VIQ]4O"FAC6HJE![)5Y$:(W/%(\3U"B6$G^4
MZ)%K$=$*V!.L_8&">@G4EF0$07&/H53,AM",CQ#^5%7_5X5>2'V. S@V6-0H
M"#!-Y/\UV@3(I8*INR+<0+M40F_M[<2H ?HMBHVO@(K^)!$M.2=?*V</^'A^
MH8YQ5<R 3C1L3BH)E5&W-0IJG=85=0=V;NBM?,RI:2 ;&O"^+YD5!%RZ(9MD
M7)CKJ-#]Q$2R;2G.4-Z3"4=TDIW)<7GL(>!+,L:OE$SCF9H(,):L 2BZW3,4
M@")^8[H(IBZ@NT?G_36.IZ8FVG?ONSU\E71)O;ZT\]^<ZG\HT;#M5;$2*^Q[
MJV"?641T]E\S^)>2U'UE0DBNI$2L9$6MUS5D %UEO7;\[=?OXXXBC(WG6.FX
MD)D/]2V+B%I2>J-#)5E*:*CNHC@ # F=*[<T,6TN28W$ZY(G3P !K\2T5/9:
M$,%\W]GH#PC] /_*TH?.38^[_?%.+N9 Z^:;M%J$N<CD,?CJTX^(=ND+W24Q
MF7N;E\7_X?V9,#UPJ:@%),HHBXBDD2CP=[YL+TV#XI_5D4G9DB4Q]GP'%EC9
MF@%L0<<<2OWA"["<:NJX"\10C>Q?Y_XZ:B4WS[U/O%/MA?BAND_I,K:1'QR%
MHHG  QZGAD.'_0KX>O$2@A[TY02$#F7JSZ+23$VA$Q+D];*%'"F9<BC]$<6\
MK]SNN<2=((;U(M[B4HQ.ZCD6)3]@$7R85Y5L5)0]9^C-> 3% YP.@MIWC=GJ
MKD:;1<3*Z RLRGB #; \)\E/%,1=1"0JT)QNS#J[=^C#]5!Z'/K:!0Q>/*-#
M:#&W+WLRT6!?%5CF-Z%_@6H%=DSSY6=A-"A(9)O JX#Z]G?>XO8D8/[M@2[*
M;OE^RH:7 NRVX7&!<!G&0TI;3=D',E(:<<7^;A+_PR@]'S)Q?^;?<7ZM,H!K
MCEW7'VGES:NX5.8R045#54IC- (&W2M'0]/!5]X044I+Z,]7!^PXS4TNXG+3
MG2#I!NT\"D4)!"W2:S-(OPJ^?O4^U 5?M)U)MMB3;\G2'.#+8BO.T5-)VRLZ
M52H .KR6?[P*XA=3CH =';15T-S!;CA$Q%P[0@[_)CX[KI_^G;],T6FZ!IHK
M.@GEN#QHZZ$X=H>?)ZDQU#J028W:CT/"JWTF&_YPF*MZ8YNGSV-"9O5TS"71
MS&IR["'H[D,HR!NHK )MVO1R8J*OD6S#<#RJ-<B:-GM,[70\HMB5WL*V &2<
MLN"&_2&7(.OY]B&_Y[V;;L;Z$US[;%,O)#6 N"KAM)WRO9= <BD_WG0=*$BI
M8:R&T%X@C>=/DSC<G*:NG/A,6SL6H E=%>&T7(!JU\;]!63+0P#EK=0_XB2P
MB(#-KW@UO.OK^R.L^("=HB@PPI$Z8[QC>,7N/V].V-]1N<W,WAEHLG+?;Z>U
MMJA\X\MV+,0WXN1FD_.+B'1:?:.S1+@&HC>;&@"'^8%BOR%+%C)/OPV[$PRH
MIMB4DW-X[)V@XYCAW47$C<I"^I$7@J\SF^N?)<0%?)9Y72(4,.?XL*H3361^
M[<K\696;#STSCUZ.F>:_/!6&.]'Q=F&T]P["P^TFLLXI_H\_$#L/'HU=)3K[
M!\+=HC/QC;'QS=5(LT1^T3\:0?P/8\LDY/"W72CJA^I;)4#;L8@8*YUX\E^O
MC2TM_4>EZ1*6B//:\Q]0+6 #6"(J@-KB )R'?TCD?H D95U7V/JC9;_ZEN=;
MU &C25)-38K-9TR57:9_2:HHC[19WRO!W;E\<\W&\;-X$LPQ9=Z,]?[H NO<
MI.E8\%@#<H5N?BF8*92\SY/RK\\I4  _>0-$1R51(D17V5;DRZ@4A2%PLT)\
ME[!T3 D!HY":;V+U4V<)-RQIXK=X^B\3SX/KZN8+VR+6J!8I_D(!1YW1LA@V
M]*-B@FK939IE9A!6%4)VORO4.AL)X@H-+@XY=1X,F[V>G8M,@2])XXM"JT.Q
MO^2[*H'I<EP21:WX@X_? .37VN#_Z'WU57P"YW?D(*.- [SW%FJSMY/U]P&X
M9E*\TG]8%,+:'&!S4SE?I.0#!*XAB^M/DW[ASNB/<=;8TC0F4%J4D(+*O JR
M!0$D79]]1:,W''\36!S<GWNC/MHF1G\J$2@\ 5WAU-$[&.H#\,&J=![; ;HM
M8L0+-1JC)#,F4+I[#1#=G,6"H@^#8>P<Z?3A^0F!'_1<FF?C!YH-<TUJ:X5T
M:XI-B6_K!>G5!]^P81'2.]3U"P\4%K ]Z'V3;0<?!3E3;X#-I"7P]L8NK*VO
M;SVC,4Z,2AFUAFK!DB/0W4)R-OZZ?GT $LIZ6LR4(%= <N[3R!$<=U"?OB$]
M>L#P&+(+=VT1 ;@[$T7HUID,G!IL ^YO&5W=274.-HR.;PPD 3WBX@*1?-=W
M?PWQURK124Q<T6"HZ8X^?ZPM-#'IT5-+2 MP>/DBYU<08^CI<W+,,>*VU>^P
ML=)37U5&]:,%P/Y6K/$+X!AP_K[\6#"J1G!S Q0B]L$:4W8 ZK 9M+N4@@.*
M4W]6" PU_)(R6XIQ X-X,>\J7THS?.>\[6/2?8B.U^J?U]76UV7=5-[V-TC0
M\8SLT!&P%"JL@"1?3H%*\:I?B.2G.ACBVUVZF5(O#O#<LP]K2?;5U)?J.#;.
MNZ13#4-E2R=Y"O.:%S50H.35VSRE>;O5Y0Y*NC\3$L) /['77;G56*[PIF(;
MQ.\0X "/F4$7\?+/A:"WQPN:+NP"K65U@ ?E/-^9E+"SS[NGPB/YR)!\5"?%
M7SRTX.12W5-^IF=]37=27I+XYD7DX,[+KK.;TXXKXPOSFR+"]=_2^Y'_776[
M+8N(?A>%TM&,[2M2PE!_W +%'<Z\9OG/4S)+>/#A;DRL!$G/W]5)U86X1Z!8
MT-(7J*PO@E =N7RZ2WJ-< 4Y?_[-= U)YQ39?R9RK'81,>5TW\_#?7/LY"ZT
M>?W-K96KK*P:A1F^'?!::1O;&BA)7 \&M3$2Y_EM).083A>S54)+RZ&I-H:5
M$T<M>J@[ \@1)T!2FZP)1+8Y$WCVBXB:.P'K@0]]L!FH'A9 0([IG1\ZTM-H
M%W*NQ-?/8H(^[1TG#7.0$18>D=B&OE#^C,08M9RZJ3Z^$#B2_0QBX_1PB;-/
M(IV8J]Y>U9&-LT+FJ@^4CEO9*B-M\<G'5_J_$=Z$TG]4=<ZB!O7=(9^?58U3
M FRA60E!,\0##B,-E+1S5F['XL9&M4'O:2ML*O#UF]CY)J.$G&VTB$B3-:S.
M*7.7I >E2X;KL6M>@+^ VD/.;(95??:2!2T"92OHQ9#[*M6-4^C[3L)0/2#'
M0H4B0D9)'SK,.BI/;Z+#O[/QC!BG?VI[V^D^;4+O=CLK,]Y,\!O+4 ??L]T%
M]?6A$*.-";BFHPV"<4LP*!9\L/-KHQ.0.QJ+- P-4:JO;K 2VWLQP\"Y$]"W
M0I^0&"8=OEHT)ACT9Y<^:7DT&D+3@IU #==NGW"[&0V?X(;^HHA8JYDATF_0
M<Q:4@$Y&2SG:L$.OGTP'HDO=G4X!5](KH!P/4KI^S$P"Q0@TXQE&)U,VE8X-
M\M/LD$N@_1Y]UE.V&4C/-*D[X^0+@>TG!]\8#.&>9RBGYN\1RN9$\1JP2#X
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M9->8-F/FZ,1;X9)$GI/%+61B':$Y;X"?5A-K%2$)RVGE)S9,MW1A/"0D3;*
MRU2'-TE0AFY +"_W(.?QZ'C.X/(B]LLGT-]&)B2W%PS/5VY-Q]W9+S+?K]-M
MQEJ@ %]2HLPP*/WG:8<D@LX&X,1<!KQ!C$HHN]"PS'0;=&^0U?J DS9J]:J_
M9B26YQB0([9DJ(38QS255K.;KL[Z*;'0I*;9= .;9=@VD4N"=:/%+JDYWEG-
MN*6T8"%J:&@B?TL54#8V:@+8YT2 2P7BF?@:5BI.NY:P.H2]%1S-*!WP@7%
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MFTW7I9]Z5IW.S:XZ&=)@PBX1-:G[9:BX)+P?*%_K.7ZC :O5C]TUXK>(:''
M;AD3FE(WDYG[H0*Y/>P'>F<TKN\/] ;"*T 7GG"%%*)'20EZPT,?WDK<AO)4
MVW.[ $YBX\8HIS#M?=5=*+>>R-Y^@Q;$O+R=L\+NI,(9MEFHM*/1L<CN6<Z*
MG\7^C3$HD'D(F%+U 7/2[6@Z(:.:KP!F8HVS[Y"+(>M&9,;N[U81![O[3R=O
M;CI4$=EJGG^HR4RV$T"F*]91_R0LP:A*7U>&4?P>DI>V6P7B7PT+'&US[WZ2
M59T3_V@..>7^R&?"/M?X4B8W[LZS'_$5>99_RV6&T&28B!'/K/&B@\IHF 'O
M71TO'EGZ7=$[:%H$QK;5L\W!*T4 AX>UAA(?018M3-WRJ'2^)L4#.M5P*C>Y
M7KR@X4;GOHN++?Q0?%NO<G.= :$ZJ)VO1[1G/A?P:,O@0/#+#8H%Z";KKH<"
MQ?SK2B+4SI+.&$/>(D8&56URCKVA%BJI).K-QT[D[PR+;JD3&@B.U.@?@YVR
MSP-]2<-Z@]FLH,M+Y$,'MK8?=?Q'FI"*]+_-^$[[1W;X"^7X7VW,%Q%*MKQ^
M;GJ/[M@_/W[NNP2;P^7#J[Z<'MZK\MG ?^B09LZ2E?XM91)""JW:@MX8+7>?
MQ.FC,1K VQ, /8.F5'ACBBG$.%<Y9A@W6B;E&(3F6P*C3:*W''W?X1"!7KYY
M9Z2FT?[4C2_ZPDE&[M=:@LZMNO)NX_#"$G".UZ"?2%U!.0,&I<(A$@8=:P+,
M<$GK0N<%C$;-TW8$8_+.UHY]G$R2%F1Y5/&^'SL@&;$Z]4X\AG+E("M,',XU
M9F[;JC@-QX%"&:-7@820;<RE2G"!2JDS72G G  9$M7XQMT2? K;&<2GPZMR
MS^>)-@!\T>?G4G]+M]PYB>JT9OEN$)D1B4H.V-GP @HB6:3;H9 3#MZR0?_R
MB]>H75")R)O'2.8\^S(5!XQ^.8S7(Z?+SH*HJ8(R^ CP)3%](KM!D03DSW/=
M0<=@KQD2\5+I!Y]A5U2*544_?UK_=G"9SL7[!?&/_F8,:,M0"P]QYUCI'%WJ
MEH['9'1;AA2O&1JPNK<BBI&:^[ZHA#Q%SI*6W*1N.05Q6A6H7AAGS014N;ZF
M\5+MD@F:&L;:O OVD&RM]8\X]LO[ABB>@BX_2[F 7TG9DR:4X'CXM$7$<O9:
MR$^V TH"65Y]6-V#XZ##;V#>7!K&3M3D<J0[4FY)A$CP ?&"Y4FBD?\O(8+;
M(?."U!Z_&J)=#U88\B-,C,J@&=J9B1_("8-(J>["YR=L73!Z*A"8XU)W@<P;
M4TR>8M-"X902X.&6**RA=G]MU+K&$\",J+8O'C2"VMTRT-QY0HK=ID[S^]^'
MW/<@XNC(J3[Y;V[*Z&0T2@F'3HB(2 ;!2+%;\9>I$<!,8VN2^]':9'UQ22OA
M.FH=GA>&:LW7!>[2K\-6YP!^,V$5Q:R$G'.2W6==N:D/$R0EK#6*.S! NC#]
M:*$SHL'5:%/B[K@O9E=I]__8>D*]_%.*^B]7UV_=I ]P9(\@+IAU8N$%57T_
M@)/HI\)X,=X$8LJB.V$S,7(UF<]3: &?TT5$1IJI/5 _C8^MA'=C30Q);>G.
MM-:Z%:.+B#9!PTA^ ?"8[&O9IQ=XO'M3PX+10BHF2$(S5O 'SQ=(*GR_\:*Q
M*"@1C&TVM$B/,LB?/ ;F)"I0E,.@Q748)7DP.8"[^B0@M&%%SODYWSLOLX[E
M.C10;*\?4^V/_&=BX'_(-*BDO7V,FIUU4*0>+OE'Z5'4$:H%(C:3C(BR>/;F
MT:W,)>MWF*]-6F^\9F\+9K7:F^\/5^&TQ^Q'MP'\%'AW5&#85;WG!:'SO]T.
M-:3$Y-TA/1GWKKOTSOE.Z7:; V$8X/V15MO(#^,;J_83<N;1L#97@J(W^LDW
M0XDN4)+(WX2M MLOY#4B)?P4QTUTGK.^Y$K].6"GE6L421.Z,)YOGM@2TQ%/
MW5S$'9A<0W[+G<\O*!AX<+<J\SP'O9H/ZS3@4C6+*-NRQ(8PE6#Z@9QXI!%(
MA0XJ'/ K"*$>9&%KX6\]C9[YRU_4W7RK]*.ZC!.)+0WUO$^]5+UQF6<H0Z+I
M&&+85?@#+[L($J9S'@J5468OQ5M"1-^HFG@&FT$]$N:R$,6N.G#H).0D"<\
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MD-UQ[\UX9JL1(3 2W. +XM%@.I;$42'3BW8='/]@F4JA%]<;%'>_ZR">XVM
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MOVQKX5N!W'Z!HM@FC/J;M/PA[+]LJ]ENEVB:,*B<\9LP]*/TNTD[Y%\>_N=
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M)JIF__W]^/_3E\3FV'\ 4$L#!!0    ( %B!7EMLA"&R4WD! "^6 0 -
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M4ZAI=<\\@/K0>P^ WVDF?Q0X(BCM@D^OX#/-5YPK1TGWY2@Y/. ?K!"T;#%
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MF4&TW\2B* I).V>N =@RYXX=RXD1[:$WI"L]Y[4?6-0V?Q^RYU2)AUQ-9'
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MRC\$AU8^^$1!Y7-H8JS);FMYM#W+;=N6Y_MWT([OO,(K\U*H-Q7D"DJ3<QW
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M(NAD1'=G&NWTX_'"8^\]^WI$V][TVU0B_LW\Q%>0]EZON1ZUAH0[!LQ'L=W
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MJMZT6QF<@/>_\ /.\YZWKLA\04IPMFH]\&G95]P+3O;;B]U](<=MM[^ZLV\
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M:DI8?G=ACQ&G)L6X*E/>,_7A(](HM+9 PE$<D/VE=XPSC$_ L](> UL.HZV
MJ&,]L+:P+?&L[6Q*=!$TWQ :4A[PG!1>3UD-;F%8QX8RH-B37%EO$8]/R+"T
M2;_ILFJA7Q0J-@5H<Y[=% 39"E0I?QI,3\:JPT8 7E!PCZR=FRL'RUSHF_PX
MM.,K]WJM$-EZ*$*PK](UN8=Q8_V._;?,RQ_X7^E:O^\ITO7:KU*^7(W[%C#-
MK*,"I]3N9F][VVU,707O!^9B%0SUP"V)0ON0%H>*$M"FCJ8%G^F6K:P'4X^4
ME_4P9_6)JT;Q&C.$("]/7"\C:$K=J0#O,7[C'./>J_J9XR+CI4>2 B_^U9_N
M5V^Z1\/2M^@0;FCM7-JW.\K_JY(K+JBC6HD_W>Z_NM*^=M=V>N<[CS'VYD4$
ML@(_.\99V.NW+/WZGPU73;Y=VX^^@S-:&?%N]&<"$3M A,,7$<F]FR6.E$Y#
M=>D3(>2?,1*%V0A)O""&B(!!0LC:1802O-='B-486X"]U_? ;K=DT1%RZ=OQ
MF?<]V["KN-@WO.Y]LYZ3T@?1>MT[V&O8OHKF(8/4I@=0+7F=(,O&F5,#RD-I
MB#-'*Y,-&*/>N[O(RQF0?J.UWN"7L)AD4:!)0\:91L90[ U_H7N?Q564;X*C
MPC+>.YF(*N+#USAV-?;4VCT4/5D[59\KHB>@;PBE^J=3&["K9PU.'>@0E[$Z
M9_FKX=V=Y/VY 5A5J\<6NF);VCW*QF;&Z/S0]K+,I:9,U=%=^T['J"VHA$J<
M*9]"]"IBR_3YR=15C&"FCM\.**=>[^C0'N!/?[FIC+4P*[;:8U6]I7W,,&(N
MTSJ3$/K",?0:3?,SS\NK4#_\=NY1B.I/ZPN3JSNH'$FCK[@$M,['T>Y=97V%
MH@2[\[Q)C]4WVVJSIN;H#VZ\--O=?#WP8NA]3U>#3^CXLX<0\-6*1<1=$[(9
MUVIY9;O,DL0]J $AZ\)4/A7X"M24/PH_D&\/MT4_@+>40O&YI#0A(0^8*/4+
M>3#D;ZN:>>%:I]=[[NA"<G*6Z#/6#>B5K90.JR$(6&U&,6475.C514&1;(0C
M]X(#WK(-!*V&;8[XQ#FZ(L.*@=M7]G#J1,U]ST5$769[6H^=])CP]I5NEDT5
MH3;^@I30PR&@(C,H!2](E+;FH36]LV*U)CW%*#3N^7>]N4CJ2Y*+6V_QE8JR
M](9R#D\=\YC@:WE*?R0=%;C)<M?!S691'GS12*T73M";2$'Y8=? !D)J+$6Q
MM!>%/B.DJ8PM4%CYHXF"JKU6!B>5$A-7Y2=Y]7O$?8WIZ_,.?EN19CZ*/O8>
MJ0W_)DU'GQ#1$BN=$LD&H@AJK1XVGGJ%J$EIK=D#AL80Q3-M^M"^48HIP&Q
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M?^L'(P6MDRMGC-8:?>Z\O698;8O9LOOHLO>8G!2UM_(JQJ^1??#HC98M(5L
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MEOVE09INS"B3BXN\P@#DZM50>+/,LH>RF50H-(DOWL1%VXFD2@V&2L 7L=#
MSKE] KU3F$E5)U@/Z9?N)KV2&3B=*L^<7YVZ+-MV!/-S?!^RI0*V59R[ S"3
M:]; 2X'BEX+ T&%,XBN2W:__/XJQAZ+J#-<&ALG-WRI8%6("^2ZXE8VA(K%3
ML[=A.1'"S8R3*,B6RPR_A:*SH6Y<:.18.:<K2,(I0LL74>%>)PNW%DKTA&Z
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MQ12CJHY9&M=)EX6RC B7]4&3X @QO[5WXD[@WR&-5%=08]C+V:JDH7$QN5-
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M?5(JGA_6=&Z!FWOJU.D>\^J2?%_X\D,7<G_3$(]+C&7>Y('$#KQA%!GF/U&
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M5I!P8&S&Q:RDV23Y!O$23/]#66')\+2/HZG9P*D@$]^CZ2,>+2WX,H:]7!N
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M@!=-&W*6,J&[LIV6R73G>(( >1-C!ZZ@IH^P?6Y/.XUWYBPG.0Z1?PJG:)0
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M>O'B#^UUP:KWDO=GJORFY;]-;:>+QL=MK^>0MTH?7[,9AIE>A&'[(ITIST\
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M*P$^FZ_.T%&^(2,'Y@(H:X,@E)#9CDR+PV7.>UJ*R=FWOA?X9%T6<.HX-O(
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M1IQN<R"O &JA@U/K;[ZY]#NOK*SB2<#IR68/U)^]RGX\<,R8>HU:IZ*/:@<
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M-99]5? \>[N+!8*ME#JU87[<7O2WSN/LHU;9R'+KPM('J)YH.BJ;N;UE-RX
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M<VN,>5/ECPC<0?!] (_H#2QO0N+Q>V?(0*7^@Y4KP"=*S5G /<T@P92D;$\
MFNR0J:N-624-X3OZ(?CU8,&VOJ4F:5D#IR#3#1/'ZMJ^I6;+?_KVQ]A8./?/
M<VI?]\]5/MNO4EE00#UD*TL]?:_S'BGW%B>,T&X@+/=W^+L)")LOPU]S^4I-
M7%+GHIH0K&NR$WDF'?!=O"@ABX]T=;:8@!FJU%S18#]S\.CZ,02=)@NNVA?^
M'.O\.45GJ@AS6+'<6]?4+2W]IXL '@IL0C(PD1\M7!H'#7OF.&'C*?L\544I
M2.J-0R/)K?#?3^1._&_I<>\[[JFF[[\]#--P.:!O\O>*?'2***[KLP!1LJ$,
M<?&+V(1(ZI<QDG_*J3^,D+_B\..-^(UKV]5U]#DBA[_G"P?-2V>OG[UQ+,UD
MU>FKUOK%4,T:=5S"F_<ZY\2?>[2A- BL0H+0[G5A,LW)&OP[.'^+C#E^,)#?
M>5S6XF)"M]U;3%(.7*^_EB*'&HM-L&\$R&F5?,>#O.RL""MZ17?)CY_[QVW^
M9BYC^'J-Y!WCK/LF7V6V*GQM:S-8L/L*D;1RV,&)YX2ZRB#OQKMYIB3;_S/W
MKC3E2+<NE!QT9/;^DSA\A/<FI$U'.%$'CS:TS7"']"A.IM%[NL%#>V]UVK*T
M#8R5DPL<[CH]U#=N=W)PB=%;ZZS;<6-Z6.0]L>M.5&ZJHDU]=[!OY)^M8 A)
M%M%XZ*L!_%Y<^!!\!ZBQV-ZXD@P4N?,LB'4(R6F!.8"B-V%2QA 9M:'"KZ4K
M@>/TGHTTM'9Q&3:0+I2H5,UR="=ZO4#R0U_K)N06H=WYA2+DH%+3]I]'Q:T?
M!^KMZ3YTSN&<@[C8/1RR_-67RK +D)L[IQ_+5YG\G6^P/;\;DJ+^S[UC,%V^
MSD:&M0< :YN$ 0@Z9BR7:SB5@C.%:_YHE+O'C=5E^\[79[#(HB#983 * ?6>
M /W94\G+'^VXC$G5_@6^KLU*4WD(9EMAD0W?)\JP0;9TW4[0WK)UXSG?M2SD
M3X-*'OHD4)IINB@=C%+ J_[P'DJVB./?#F8U^YI-B'F]Y-NR-S"NP*T*E5;Y
M&6]F?!1,=F:MF)R[K6/@M>V.Q!D73A:R/"9@>O696^>RW-/X2Q?>O-\2IU<1
MWO8$F^\Z%[K!@[3J_"PE4TL7Y2KN%=9N^3W+,0;U4'/W**#KZ5[.:QX^@_.C
M%"0;9,(-?]PIR4?S$)R_4.HH+S+'G<PS8"@%]9?0 CBA)SP%O86JKXESJ][7
MR&;W$N?0Y!J!,4X:&.XPCJ/)PT7LAM;$[G%1(DSL6=GC_[2/[>ZGG"T0O6->
MO;N@CNH^K.0YZ>4Y^<^M/?ESFY! MU,_'UK10,?E V'7ZL^=';R6!/D@O34]
M(B5*\NV@T_;>(B/E-\HTX$%(7.PL_K;(^QW9$I<L(N?)Y^Q=CL$*[I3R%8?9
MI0R".I-_%:SDDE/%.3UI."A[8K_'&^ LY<GTF'B*=?1S1%R=&8^2;/"@O=1G
MZ'LOU07@VO+$$R-[8%^P^0Y W7B(XG0>#AISV,.?@P'U2>TP+:P]!T;DQPAY
M.@-OQ3-FC"\FMN@.XW>!76Y 21,G'Z6!D^&=K>%"MV!KSO:'\?<(E+WFEBLC
M7+,7Z:M^VLW A\8SO.F[P?(^G3-PCK;^H-S<=LF+][>U.$#$ EOUDMUV/OJD
M''<K9U\K#+@_@Z\'M1R3+FUYKS<%D7,TB#\&>YR# !Q@H\33/(MD:Z3_"^R"
MK),ML)#Q%)NT"RN+)"U03<I HB<@H%5^L6>5+2P9.IUIYID!GC@UB^3:V7&G
M&&FK6:NR2C=R&8_$5^Q:B> UYQ*O1X5B.-=5!6J@/XN0M.8S+=#MGR^PM@#6
MV9/E0(_M7\3> *%03^LUB\G/Z+HTM)I;$7AX_&1]N_GZ9VSNA:/J<7<2(=Q7
MXH4?I/S7612_/=J[!R6WG)%!2JE"G!ZL'O\U\/C2?<B, ^3NEM\[U]V$0+"?
M:L]#<TKJN*@$IK(X/0.6.?8]+7S]E-^,Y4=@D&__)*AP+^A!\<;&./55\BT(
MQ3,"6$H_^Z9]2; K$[RSUN\]7"<]6QFV?J:1[(QXCJ@I;?N(9&\K9:SW*,XT
M7JOFPC*8V_FA/'^&A^5)#\D2SY+Z%4N/E"5-,>JU1FPD2BKHSJGG/4<_-,R7
MO0]S+LMNMA(H^IZ+NS#^3OKPUKOE=C\[+[Y,3CI3_M9.Z H.W5.UF6.Y(M.6
MK97^AAH(? 'LV-&)N*:,>.V?)>=WG(0%/X$Z/J-^ ?-=I;;_O;6 FN^^7>;6
MPE&1;XY2'3O5]^]_=FE!UEX(G"6W2#75-H>D6!O]]][F9AZZ?A=^X>XF1.22
M2-\>BIGVGH$TD0W878</+C]-:F4PG[X3[NEV_?TQJ^Q"P@60[+K%,_78E:T/
M,'&.HG%O=<,O2;KY?KCU>*^N\I9I4X]\DE+(R:T:(XGO=BDD0(\?MFV;.;RE
M*^0$)_1,8#Y^B^ZJR.-+ER+>?PU?V"/2%T2Q$*K"?->C7?='1._6OV3(S*M+
M/\BY608130GXHN(08BO\V)38E[C34^_]PN_=?4X4R9;>-T7RABSE[?^X"6'O
M'M@(W80LMOY9B/_O+R!+Z?^_C.O_S[<*,0HA3BIOW3-,3NE:+#R /,^D7IU:
MB)_/@RQI_!?/M0F9CE^1WWI[#?9A2>3^,=%>(5T:E>>@O@1$=-T]2O]]^[R#
MC+1"@F4Y=%5N!K)@9%II/A/PYFUU[9L"=>^C4_4)7MP])W32 [.*,W6S>']%
M!3'_"N \SKM&5K]7]+HNK>0-^KVW59!\-_8?Y4D']T,MBR$O-HIKS <A;R%;
MVH5Y(2PMV&1*;VPGO;MWVMI)R#3K1P\<C_\JY[1CRV-6>,Y17:F7,>?$PR(+
M#H[U!&R0 U;V%[_QJ3B$WCKVI7+,.OHX9\)?X8R1?W0VR^&EOMU^G4O.-PNE
MP  6BEBH#JPF\G>RFTT<A'HDV?1-)!+J65P;46#L4*]I&#F+SG^8]\/;YT0&
M=E?P(_^&"TFXU/B@34@[LCS\(VW?=IC.30EQ$3VM[L>6W'VMV:/%PJK(=?UD
M@A'Z _&!!SU;[+Q(I\YYI9YS@"QV%+R"2/A#["[#FLY(2'2-MNYS"^7%?RU3
MX!?M"^_1@6N">EBN$RBT&Q++)+Z^)2RYSGA;4%YG)[0(1'L-S)G%HL[TS2=*
M.RD/&B\U'_:9KF0Y+JBVC^W=?4A7-U!X34XOHG]NT;*-VRIW5%118M_-4EUU
MT?* ?1^$Y%P^?^UCRZ"4YV\M"S%$Y-TI3<W=?QY/S_QV%F*S*_T7 72LT]F>
M4[_E[/:_+\ROOYVH2SO7E'L+>&. F=QF^R?9)9+J#:**1^-$NJIU2 RA)'+Q
MP_QYOW3VOT\5[/WW%Y__#,>*IT;M/9-^1O?Z842W5.)/F<+2?NOH(V4$83U]
MDKOT520G^:8M)+%M08);_>X)U/X9E2E$$.004\"'\HK^Y^$3J$-98$/*-YF(
M7>^2#@9]=;MO+G.(F$6W8]TX%G5IN\@LV49[]\![W0U89J"\F Z,LR>YX%QX
M;H"$A9'GU?/&:77FG=;93GLF(.=\P]]:U$CP6QWLCJ\_?&>W)7N/2(.SIF/6
M)8>ECW"S^OQY\VZMAR^D8[**X;T03^(#>)]]OO8HY(AL@FV=5B7U5&:XO;KP
MWKAYI%_,_K##A5U[9!8Z)JH?:<I\^UODHO@?= I?SVIE448[6?077.N[6*Y.
M85*Z>)K9>>DMDN=2CK<S]\GK.GAEWWB3?51OYZLVA9',O:9;[LRR*?&+U' H
M(X8F-[T*-\UHOX_5JAM]]LLH#+=?GZ)*;;3A'#KH.S:.5M Z_@&IU%S 6$5>
M[XU]$6[@IOJPU"=)=<A]J$)#@NL3M"O^_,$^BQQ5/9=O"SGG=76>/=*ZY_8H
MC4UC[QZ$7T]5+KH>.L3:%CIN]]T@9#^L<<%MQ\U,>AX*=(PZU*0_>CSE@+?*
MEN-?J_7JC[1-/U[Y= H2B=<!2$2JRS-T(6RH=L2HEJGPP[(T)2KJ7.A"F*GS
MM4]H6;LVX] /T>X\)#I\'[2F6R'M;VL?+;=D&A2,.054)3\3ZL6\T*HLH4&2
M"W;7T$Y^[FFG4]VWE&74IZEEA:Q-QF:/?>J;W+[S[*W.N*L_D;LF]08]RHC@
MFW6XG$IZ->3NV;ZC4M([RB%?7?X(^/(<]?IM#CL8^6?/'KGQ34++<T'3WK ^
MSD8[_==E3JC#:L,BZ8NQSJ&+\4U'6-HW;C4J0BX[_=]*\W]5N8C4J.V/CAW"
M??9Y)YEVB'ALONLB[-"1'JW&'6W_>^>*>ME;-'UE:IYVJ<:B*4-ZJ*X!77TO
MTY!^,L E^^_+S,*SV$1.["GLM7KQ3!&IKPMZ6R%ZO^IXCZ_JWGM\SMJY7.'-
M=HG%C&L'CDHGQ*F+B.T\$V/]<73+D2.0!?^^VI'[1YY6UR9L3THX<KF^(5W/
MJV;J6>>];1<>*]:\B-,_?S+_U:$>D-(*E^-U)=8M$@7[ $'^2]"$,?;G"=IE
MIMR7\9.F'T\X##R[K]ET-)3CV:LP9!>)/7GSE/DH-^"12J<%7V^LT$&?F>WX
MTQ82]>7X_?7C(GNM;NYROPD1>XQS?"$GV2#JK_M.W;<M/6SJVV2ZGELHY1LU
M[(+XQ;@H=[C&YZ59=(R/K^7@^<F^R8Z ^Q(EC3EC0\H)>HU-#[6_S\UEWB9%
M'*"8J 9[C:95E#KV^\Q[5==VK%H\\1Z?IX8F& [[=W=T2SS4=?_[J&>ORXTG
MB?0_"%>^-KX)8<8+3 G"X_@W^3?>ZCP0_^=0YGWZOD-O'7W'6R-_WV:)(,^"
MT:P)@\X[3(:5EMP03!TDTH7^(J>4 YVTF07]VX>]ZP3$)^-A$;+9N0&$JIE5
MH:MZG2ZQ8&Q<7/CUS+1D1HV;%$2]=5GOP8+C#/+.KV0>_/GHV!"#DOL6]US&
M^L,<Z\V![7'*5=^N_% N&.!R?,]%_10?@D!+C]\\>%-"1]Y65 JR=.=_E\@G
M/D?%?#S.P9;^?)<-.W1+Q_8^^\:-VST4#..S.(O&5UU<H6T4T?R-DQ U& 9J
MM(EAOF94^@+?9^E+Z[ Q"M5T&BKFE;:1I+%.*!Z) 97TMB\?G926;K:W[]//
M8[K4>&)VWN\]Z:HC2^YFCA(%TI7K9YQ9A$SX4?#A$ZQFUQJQ S-FT=6X.,>[
MS$-UY-FW05.8DD(O 87B).K WT7@_HN\Y&QB1,1+_G$>,AEVM@:P*R!H^J''
M)@8_K*I)!P1-&R^3.1@1K&OGW;$QL+L-K\E++B&'1T1<1G,HLL'X7?75C4VO
MW_8M+!Q@#1V@[*I[T]@?MK T^^B)P]?"]IGOG]QC;G_+ GV=5K"@0F60(NCJ
M"4H#!%>@-G?,J-P@A2)0!O5_'<N_ 'S*RT,0S?1[JTPE3;EE/S1,78(U=J^.
MMO07!X>?*AUQVO8<+15',">HTUAOR.IP'? 7Z^PC -GNC6PE0]!X^.<#_.A2
ML(&Q9LJLM4A;HB@+.LC*M* W<X9PS=D6K:;:7ART%)UG0:R=A:8>/!O0R#/*
MVI:Y<HWND==[E)+X9T^I\?-<;E4NAYGN9TYV!U7$4VE7F5)!,#F^DEI"  ^:
M?@DDK>^9_=/KOHJ/U 2U]S>1%,#OPT[95CV@G9GTD:7*XUC3>>T^*S/%]QO6
M,RB(0&JV< ^Q2X/9NIBT1LL*C?P1F8'9'D*6H<+*L<_&'>NKW_3-+W5CY/V"
M(D*&5N2#HZ/O7+QU=^*YPO2PAZJDQAA2#UD1"!#8M_+#@V^7\@W Z,O1EV.*
M0FZIN?M!@([BCIQB=O-.*H(]<;PO)G;744,*%?'$Y(?W[B\'<C7.IO<4CSAN
MBP_:(_+[?C^-Q::E(10%8CU56-3*#<" CH%AVWL8&N1$JA>7F7%/*(*D:S&R
MQJWK0B>W%M4\65/VH\'C,/]:GZA"T,JD1'._ZYGANG<G<UY&UN6Y+ =VPL ]
MJ"YR(OFU.%\Q8R4]%U7/TZ_D-;46[@03>9L0Q_O=)ZLS.)6T)-K53<@.G _9
M-IL[1Q%Z%E>>>UKH#4RM<HJGF\<5T_-[$37&ZX?QGVYB[Q D&N9F 1>^013'
MG)<UG-S3CMI*ENOA3-FG\<^M[0065]"S/=+6A]&R(5&J69EVK,[3A=TNH!<P
MY=&[!)6;H<E0I5]@H]MS^D9!CV,#.!7VQHF30$=!9V[XTR]"ZW2ZJ>_;J\_S
M"Z96394:,;%&TD'%?6%5IJ,J+Z=RQ"""&\N+H*']O',TAYG@;=/5!DMDRE;F
M<X;;-9D98_[\$RV\$&P%:[63-JK+@<[;LL@R(,*UY?-+#SLP(P*:;!3I>R*@
M\MU U.(<06ZZY:IE\L=_T#BM34C"3_YE<)V-(68(9V '^#8PC#,0RO/6*JQ0
M*P9-E1*Y*$I_$D+;BM^%B\R>8G@7E*3=KAH!&^CU,.@"U8+CJV6:7)/KUI@\
M5W4?TF>\M#,&0+ $3T+'-B&L'KKT2NV M7'%6#Z3J*W\=MV\DA6C;DH3G3E7
MVVA2:]$BU_?UP1F@^6M (+#RZ$ C_L'NXN<DZ5-/^!*@"?OJ!:"K#9E<J.E
MM2W'OM[]N44#1#K(@Q4>U6_[EC&*;2N&&E"#BP.U3>,31K\\2=>>1I?X^8Y\
MN6A3^:'WB/@O'S84-$3,2_(L.&K)?/_HYV!T*V$;#O5"T"[8#Z#HPLNP=&_@
MA2'%!9]ATGQ;+E,#2_ E>?4:P1AW#">++YOG-%:EUUN8Y_9ZCGI/V,VQFWU:
M:8 O,XVF^!R@I.!TUP_R#P_"=?D^/-0<4[R]P,H9Y)I7LSYJTFFU @IOOQW
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M]VL%JJ ;P&QMI*513[!0*7YB "K5.C1*=A.2N<R4!$V. 0MUG/$1:5,UO-[
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M2TRU ]Y7>\&:#LOZ?*[F1YCK [KK9.D WO(500;?B:KYE!@,='4R15J@3/P
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M+:?_^+"G>XEV=1$G.FA2)L(E+L,,E ?&E",J+$*OEI_*$GTE[P.\6N82\@]
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MRH?!"76@8'H+,*_"O,'Q1*5Q2Y3,F6P/_,RHKQ)W%JT$?2CO?"9""\(=BF'
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MYH-P-_N;W]Y\SRNAM(QMA>[+["A=##C9.TA$35R&Z5+4R*@!M $^ %/;$T9
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M(C&U)N]R5"2M$8)9*364_0&Z?6.(5=!PNXK.1^;#H(*H LB9B]8"2Y(?D'6
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MH(9UG9P:L; BY^F2,7ZT[VQOA;@KLDY04Z7,Y"J0>=0"2\@;Y"S^W4LTYC]
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M"D,H67557OD1$G ,NNK>E.B<>HK63.^M>$QS]3]P<M ].I.##L<.]0I*9RW
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M0XC82/I@1[LQWS67JH5F.5B;D7F/8VRP<&T,F%)VE:]YL;*JM@&Y>FPRT&+
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MFG,CN^'-MB -AP]']V\0FQ.C(2=):NRLZV4$X^&D#UI=$W:Q3$ZB>--'TLX
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M2E</ENL>X9VF;R<(]G"3>ZW#0_J7V8X?PH_#_N\CB/\GO]8^_5]02P,$%
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M)I.9)T ;0(SB^B2/\5U/"HE]S='9O-/N^ 09XP:TYR()U,;L)+9G: 4*-="
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MN9>AO &EU=IX2M4#(P8AHUTQDHK=/N_^W*,B>4F]I?'E4*,2+&;'MQ+V*AA
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MEHA=EVG_E:K=F#G"0MH_%.C9&TV%04\*:PP'5KT"-VJB'T#W#"!\_B$AV?_
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M>JN"YAK3IX(+.39MR85 :C'@"/3O-_!9I;W:+*CDM2"3TUS(:RTLQ\CZ'W9
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MN"*$W+2Z=Y;E_IR-(0M\J[U&OR[E;:N]/Z=&:OH%1N$G>$60&=]Z.G5D\TL
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M2R]X<'E;YG##@M2E7083"=Q]G]U&X(\P)MCA-!5HCX(U( E'9&7FW P%X+?
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M6T&X&M1I)U?E?^P?^<:VZZK6")0=>0@;]%A:%-HF!Q?89$\^__Y!7<\+<J!
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MX,)+ (X5%@:F-FJ![?';'YP")6-1)DF*AZ$8SN#B^62/GO$!DV#3*9/=[S?
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ME3]Y?M7>#48(]$0(I6E7XM878&8J^2G$:%4AK@/GX@5ZP:7L*;>E*Z;7FJ?
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MN:7O##GNU'C.BQ^=;FJVE,JBQ;I'"<?0_;4VIV[M7IPXE'?V_;&\G6V6+P<
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M-)4P]F-63BJ]O@01Z7NONKOD3<OKV+_D%.L:_F<)0H*2;O(UHBPXR:^HLK<
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MPWOW\YG6[]WOYK$F6E=\^_;XD/A$.@QL 2)9E)Z&>)[*&%&0%9Q<+#.%/DA
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M/OLZU68_(=+"B^Z02^? .(OL.SSY9F!V+DE[YLL$VGB70.!M=TI8[9*X!ZI
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M?-Y:^'KX\<LSOUKXD'8L2W0%NB((V]1!E $U608I*SZ.=YOZ#(A:SB!"P,A
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M;?M?&:,,;9LG=C5&41_GQGW@(KF^<>=$E!'>0;B:* H"E6QK =-DI+H0*T-
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MGU,1$I,_S5^P6G.A#-MVHJ7$^PG6'^J\Q>IX&M<54A*NILW7/WPY3U0/:=R
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MZ[QVX$N2+X)['[0?UCM;8?["?;KO4:&TTXM;.0I4DP-E/KW.3B'+ 1S=]I3
MOZ5O-5VB-VZ=E%7,NCW8\S'F_$]T![^V*[U=G7#-61ZO)KQ-*Q<A0 -V $]I
MHI%#W<37K_E6!6X2#G$9D+5>I"S,OL"O517+"DA:B3E:([0\QB*(#_:W6M\)
M#",=:E#L== \Q'Q&9=W!4MI1T%0YONK\LWKHN? .157D# 6%CP<D^._[V.HB
M;+/M^ LOX]MOM %+1NT'%(O!J(Z8J.1(-743QXC30%1&9*ANX>5W]:$J1EVM
M;0W4A;[WELD'A^[:& XA# G,R"]9)QP5NG;,F92=?%MDW+OR]YGQT'X:N40'
M:C5RWWLIE7ZH:=*IQAR'L3<H.!%'G+,?TE-4C9QPBIPPEK9W;\I:'Z%RE$O;
MU>[08Z>^*F9+*OP<NB1%9HCTA0Q*0)T79>E.P#U_A?7"=A7JKM"B+7W+B#@^
MG*A.. OT<)B)C?Z_]2,MQFM,'!C*^$U<C5W ? -1$_0);8P14TL_>4-Q:B_'
MKV:1%/_]N ZE3'!\.5@O47#J7A12=!84,X48XI$0"53INW5JJ S4H,R">7 R
M01-(F_ DE^ -6:I*Y+H 1<)O0"/Y2R]*'N/I*2,H/.HL!S$\!I;>^;H-C@GA
M?2&ZM>O7A6<<W4L>"K7<,\PZC;5Z.USI2O PK3NJU.'ED$LG*]W=V.O^3WY-
MI ?Z'SV7EE/-W-J7 "Q-RO;:C5HV+XV$7:^N)KI*DEW'0>)V3A3HL^@.=8#Y
M%[(EA(OEP069]3A+2N<[PX 7O4P,0PZC<0S*9SA.R")>W?;7!:/2]H$:6=D0
MVAWDU@@ML#+3WQGDR'<HOD-=0T8,6H[482"2F0CFGP>'%K: /5TD^5)P\2[R
M\@9LCRB41M@'&B_QT"PX#%\ER+\GDJH0H090>]\!C;X?EN [\'SVK\3RFFK(
M?I6M/='V)W[!8&)PH>8LHGS)DY(&W7>2]VXXZO^NT=JIR&=@6Z=KAH(C*1"S
M1E;V]')Y](2JFTK1VX %!HI>4 8>3UA$6,V_'XG0]>-]&_48_KGX6-)C$[',
M-%H:Z0A<&^'R]R!8&KKK!>*=Q.Z"(IK^5-+(A0; H .MAG_8A5(%91\XRJD;
MM_I5A/CK](?5-TW6.FHX;*OI'3K;<.O,2@5J,SY;B'VU <LD29%"2$J(E )2
M5PUI8LO3^O+I$ZA<&H00H"GU:@^=MXH, 6+YH&)!-BT.J;\UV\CG:TGPZBU\
M49CGU1]&2W7)L>9_7#SU16/;EZLQX;]^]:5H+J-39L/[-.D'Z5^^VSW=_O-;
M>,K7W O8NJKE GRS\=RY$C?Y>#:W6N?]4[A<L<I'W(4#E6ZT[9&E](^I"9><
MCOO8;B&GK6K;[%E/>SQ=ML8,.JQ<'Q9PPN5"6WT0Z]_3I2XQ9/";"7K9KA!5
M2%4-(""@CP)2!DJ>B8:CI E&H35>G>B=A$M G^.'5H<@(%LP%7]=9!T46PJ-
M> S@VD+=,B?8ILW_*%*"2.6?Z@<>B;$5I([C8M6'LLYG 1J7G\F'Z[6&C3.2
M-V#;Q2>Z!.I6'0<"TC=@TNU'1-X@DROK^ZK]<-,@0;/264#^B&,FMY_X]\ ]
MT:7Q:".T@@_>P;_?J(N9%7V@-7ZI/'4Z7VZJLBSFKW^>[\9]*^^+N^W17N]T
MX47B>9WG')_:;)H9W48^_4*QFF;^>$'CP,Q(KLW@G</=HY&>09-,R4W'LZF;
M"-Y1$WXWX"E,%:2ID)IRXGP'*'^AST"D3S\/3;'\I4&O!((+H/L*I0U(!$G6
MJU.UZRXIJ *YNQ3O(!A*.KJ4_Z(?J5*!+[$"*2NKHD/YC584B:*3G^(#./RM
M2Y0$:IT7!YLD_AW()Y.NKS&2$;L)!@C)(A)ZU@A)O%H. KZ\[L R]THX"-WD
M[Y0HX"8[Q12AYPM'.*OY<%<<]GJK:<23UWT^;.<YCI99E[HAY?I?3I8G_M!4
MOVGHEP/UI&ASN-Z%/DO]AYT*]1QW*,1$-I6X/M+IB'5-\]!VJS*/=,\]TPG/
M-8;?Y'K;_.Y9OT6&=+!^^>-J<XO7?,\_$@PG=>B*?\<;3B!8S#2-W2"%[:?8
M);C=!N2SVQ6@V,/,N[BV$_INXT.=0=!Q0:@G^*U6(-.3ZMF^IPE(DUEWZU#%
MIE6+=$W35><XF'+]A?5^9_YL .!,3>#1.IT3$%N_(:^ NY%HX,H*$9I;.PE%
MN:?.G3(?I O@O$V=BNT[P&M--1:8 ^]$CB4S@T](\ O>([Q/AS]G'%[.?:O#
M"<"[\,VFE'N>;<#04^FW^H5%!ZITY(NP:0]9IU&<DX>W]8?3G>H^7ZZ)=JUR
MW=7P_!:Q/.?[9UGM_D?'^OMGOS=GA1+=<TA;UB] (^[K?R-=GA"\ 3Z;FH#>
M4\_8TL"L(+XG[H4^K](O144(X?&(6C09&8UYC-_4V?"F-%JQD;_'F*KD,TPX
M-6"L-G+UV8>%:_FLR[SU ?CPH2_9K]YHRA2V9A$O?%F82G\TH3)EA)MZ-)[^
MY4M0/.6T[>;TO>&/7/QO&"#2N96ZNWV,+3/0UV@Z[I,^I9?Y!PH]F^9+--6-
M[0XQ;K^OC*3WWHHL?OVUQJB!2,7Q_W:Q5N &[W&QAEWX=V,7ZCH!\^_&+@.O
MF5]4Z!NP(>X#T;?*0AB>W[48_YT0 ]E.!,1+(N;SUDM XUDH_DD(41$T31%)
MT2!G%U!]**'UU*4[I7@J:Q"$^OX$=V9@E)+K'OZ<OX%3KMN +>AN&0XOO^#S
M^9[63[Z$+)X-@XLL!!F]N7T_L9>O*KH"D#J*]DA689S(>]RW1FK\O<0@94)9
M8TK]^M^,,@PX1.V/XKTC>!KKME*,<6;^N$301PCH_E8C@H<@3$?-TM6SJ=_8
MH8K9HL5PD'YT#;_-C2;1J'2MR\0VLH/LO4>"])4;\54+<^/'E9,-KFC;H-[7
M^9VL\"BE]\=5-%6. P./)CTEH?:O]$,#(<_2,DPF-PNDWO9FA_&%CN75/7\3
M#0E*H&TZ\:3X+5JU5;8"H^I4#%BP20JM%L(UW\90FR;("LP7U(TI#L&3#OCZ
MSMF IHD$-\$&['<HS:H/M\W-KKVQ;UGKQJ'1O<?M?F@F,,?__@4GH_9 M8*M
M-6NNQ ]%QA^0SJ"F-32YLU$8JSE>772LCV@)D80['X*:SA"G!I_:(RA5XLN)
M'(\VE9V?X67F@H=;K05I#-EAS"\=S#'?F3R4[4P'#+ YM7E7].N#FXG[[L_%
MV9X^Y5_?H)1L2-B)D+:225U!>R0>]:DLTGAZH.P"2J?=)*'J\O'S%_Q\/I2D
M<(25IWP>9=<<#7*QL FY>+.VRGR,8_>F3-F^QOYF>:&R*SW0;K3I>YAN:59]
MX2(8%,^\#-^$)['&# !F&FH_?DW(((N/07/"'K8SSXOE;_(,4&#&,S&(72(_
MX&FB0/_TB% JH?6XP!+N\!&)%O@B9&>\VM4^$G8@T7M^O;@0 &5.^!9]^VKW
MDP0G=9B1@IBPF0U8W8ULX!&>)CCR8,TU0(2LAPK#QF-='3 "*&H\5M/^0STI
MT5^A?_%J2W^=P0Z"=6_D7 M",20T IV\$$:P>MI1/'M;VY+ZB;CV)+NG-B4V
M$,G:_28M5^6R%G'F''6@LO(EOOEFHIF3>^7IPC->N6;]9:KN0,Z39\_2+^=M
MDE+N366Y93TNIY_\X>0^8-UMQL5Z%H3YK;T+66[Z&0IFBZ4;GX1H**Z77H34
MA-IU^J255""O$2A@=;;O<X0[0%% E&"*ZZQ,,'H)_0P?9PD696DIN"H)JVV#
MMFX!T&2" SU@AJC65-OXH<ZD3Y+;:<[]NA86EN;ONQS[2H[-_ K,+<JG_<DG
MZJ,=&Y*X;TU/7KSJX(OW/$W#W.3<W*80A-S=L>/8*5C<";C5_0Y8?'H2+&[;
MN\-!&>\-][[-T%'^?';.)GW.@V:R <//>K$N 1Y[OHRT*L)E[7,"C$KY%MF$
M=VW!@IM0:/.> =,C(P[6T=BK+1NP5S[!J?_K/3KW2@E1O#9!K$F/;<!FC NC
MDR9UN@>7AG$9:N=[+P[@'+?&>MGW&[TV7M@>K%\_NC-TSF[ATF"=P\.6T+DS
MQAE'[097G0J^<5<^'@TK5C+)W_7@8)B]EF-Y:8Y:FJL+W<D8\X8S:E.J69)V
M.\K_.\9(,3VGY#!.ZV5=BZ5$!ZC;AHF=,5=_*2T8(;%KIT37(3)HL5(#^0JP
M<0&[4:8A?XDL@)[,2$IBT<X70W7K2BS4SMY6^7\?^T"V=LTF17J@SZS_@::/
MC.61D4)BZ*=%?9\NI[B13RA+8H\& JI9.RQR7,\5Z:OGQQO!Y0F[VR&'\5-8
M^0W8->B/&0U$XW/H]L>1D8KL-5/6KZ?9CUM!ZP='&AKOYQC-%[=GEFS:?''7
MJ<V[_[+Z?=L^X);TW/*</VUE[/K<I>=RW![>./CR;)>LEAM-N9<S?H5,([N4
M9I5/NQ4GEIURPX@7^CTO+#[,4T8B]VMIO>'T5=D=#5)ZX]WH<M)VS+%A06LV
MOXC6B5);IXB"T N;!!3>%)M?9\KFPT4!^0(*"P&#6(*G:>4$/9#2&0:W ]J2
M'D1-\&$$\P&)3O_ZP6U7!@+86"5?_] Q@_Y(=5];4"JE+-LYZ_OR@;[(Z;#G
MR-T2$ & 1E;+ZQO(@Y*Q)?6&B> "@S2-;>L/JWO77KG!AX-8&S U@A<-WR+<
M2]IQ]"E2Y?!4<KW,2,;1/M:OHS3P %:A1[ HS3;R,[ZR_T;VDN8S];NOU.^J
MPY8V]:9.T]G1;.',>DB_ND%5K'_A7G7SW1W<FI"<9_?3G^&^T"\)TKB""IX+
MR8LS2$,%:FM??3%OY.YA9J]84;[H6>8[[/.F/ZPJTC=@C.\F]'7^%/0JCZ26
M+?P$Y8+V$YV>3(T;Z) :TW&% 7X20N!)7;,?A4XX;_8C>&7.(-%*F7Z3SXKF
MO+%2B#V,A*[412SAC^:;!1/S;]Z$H@$G@X1VK7Z1/ -ZV+4!DS=&*V**#(=$
MH: OYSM"VIDA(O0C[4 # 9\36H56^SRK@6@CR8Y@- Y"CL"B#9#3_MM#5@$Y
MJ55&<,=@TTS^A^G:"Z74QTLW;9V:>MK#'ZV']S"(.9+TV$@[7'!YPOQ\S'E\
MO[.,]/M'^W4_5E1<!#Y_\/#8GE4]J?.)?JX,Z1[HFJ'"G<P?_U(-+)6)C48R
M?W5Y87P=9DHPWL'BP/4<XDZH<5P",Y&H V/!450Y\5$1 1* JUT+@JJ':7SX
MIU#$'E'XG8K@YJW9T5%AF(BH4$'/ID]XAS_S9GV#,[C%@;%:Y])E8HT=LF(M
M(F&1R@OS:+T85Z\':1S/KLM5$\=E[=L/A.#V1OHOZ.RY6$-C.<C:R#CN.="L
MOH?>F6'6&Q>RR]$:;<+_.DRRWX!1P V8?_X&[)=5A/>;5:7U ?'IND@&M %#
M+,^0-F"EIL:/J.&DT8 ONH\^X @I$]AAQ2XAC8.&2_QAE<M,0\NC-" UKL\B
M6Q(#:K\VPN\:,9-0,F 2<[PFXI5<R"9W21I(,.(C\-G.O4BTD"*G28[$[L8_
M6>ES;!LZBKUV9T9_/HL_UZQ;)9W)&=<Q?VG>Q^I_%'W8)^OQ7*<^C\CU *#D
M3K<R\_[/3^AOM&<L_%0\BFUWY>AR7<NIQD]ZH^KS9@>;O9RFNA"UIO-7!*3A
M*HXJ-OT 1 =]A>)&@61R[%VGMBMV@S:+G>4&B=3?6S49&[!.AR<BLP]H@0*P
M2A[Q'::S:/H;L'2DYR]&JK&%OKQ-?7/;+IY](\+BU+_[2 P2/ "6'712R,\@
M&D%WQDD)B/HI+IHG/_Z.P?)%;X;(]B")W!HKG..G,.'S[<<A"V% ?*NM8#3"
M!7*<"%"$GDRP8@Q'QJ8#>#Y19)''S4;3Y[Q30;^*;:$LYUM.)^R^.<$._;@K
M]<?Q:59*+0\7(B36J_Y=R7?)J?),U#9W>V5[/#(VP5_5O5C!S?2?;WD:NL,3
MNER=0CN;ZI.3^0*:TZX<G\G,_?YPN^;:!'K3Z-B%S-WM:[9Y;Q#H&6KMMQSB
M,9$N-#<1H([O%@:Q$0GH;1)\S6<IH;0IK-OF%X:(YH-&&0Y".,=BU) 5<^1^
MJ!*;HG9^6M4T">?0=E3?POH%,%#&?5"&,:'RO'J[A0@ETJ4%MPFI%-1.J,5S
MO08=;'F0C=A$" *5NL:VOJ2<@8X+8X\8*.#G/-M:/M2W6;$TCD'AU="M-6_(
M^K'_F_&>A%_]OR(+*$F1AL:S/0;)1Z\-](PN>1GOF#(J]BSTP7.G;!* .IH7
M/)'NJAS3/MK_I&P'2G5[OHF!?+=R;YI]]4CVK3IC>@++T1[YXAS=TSADN*J)
MN^=)07UN_S1=ET]S)V#!*RO')""9<87MKP,.L2F($ U3ZA^0LR3.)8F/A:*W
M^;T#+J'VX!M/0:D\6AS!N&(ZJDBNO1]U2&0'?,T7;L!2I87JFN>>@<@8XGU!
M,2;H<3 /5VI&JMV S:?S-XG-_/#M[W^I4<AH.#.0DA3P8K%#[<[#K^U@X/L'
M-/P0FRDOUH,:N4)UM%-OM;$LB6O^-#ZT^-/,;N-2GQN%-UTME(D]@4J?<V+N
MR)'D'V7/.CG9?2ER-J[L^8$7A(Z+ZVB)-:=K#"[.G'ZT_SW02VA_U]CM.ULW
M?5GQ.VO@Z9.V&J>@@E>"]1?5XY.N^J8N3"+6=K&ML( IDMV\"0:W9Y9+K-[V
MK"2EYU+$N:?<0_[WZVUX,#75Q;$N-_MV6_Z=VR,?#0R??_NG)Y4$-X*G\ (H
MK5LFJ-M'H,971:8-@TA+(6-GR.T^AS)\_*E^!U9L^5A:]*7<A:,36X[L=I0_
MMOG&WE00C2"^)L%0VH[5HX13D.YC?,$:6T+ K:>J0B+*6VBAAG,DF3I]KTZ)
MG=<[A&&M!R)' \ZV ,PDW+L@UN"M&:\&FRGK 8.E!8>%AJ$3^Z?:#ZE0V :J
M3Y#ISJFXF_=3KLI0ZU[OV7+BXO&UU/N)._XQH=_N^,G#4A!;]44R#(+K2ZAI
M?%N[*M[+?P"I*\0B2)U^Y>B$);A\</-GXMZ!5HNJ4)=1RT))4Z"DT-BM$W;1
MLKPY^9'S\R<N_/F.'\<HZ*WM#KGF,LEV2?#\_7QC=QI[[>]@+4%330K[+?F(
MQO:'5<F%"JHN55K6>J&5>VN$"J;*'?WKPK2Z Z,F\\LO5E[X13XJ&KGC6?_O
M09;KZ2)K&AYA.\@,I)*C>+8L['9OO%*'JDN?<4NLJ15P(Y]Q :JR ?J\O><4
M5WYQ<Q_CB[XOLE'JC>#FF.> ^'FXOCAST.WYE1F-8^O9[9LEBMQ)/ R8IA-E
M@U6G$EL#0/,?$P')1C,7!_6>'FTWX'?O&:+*S>,*#5R?#T4BE/\!3J,;6BWI
M,U['V0RLO"W6DNTJNE=!_$B"+5')/E&<!><)"DL&G1C#65WQSP9W!J@'DSMC
MRJM??+8RN5\V"_+?;"VKMCI<R',H]8[FE2*N/?H\_.K9ZS?.;%)=S_R/\7^C
MKU676!M:!&I/ :;L+4VDW_'M&[ N'W/H#K?JRO5&'[+H *_:*\LG-(S6^?$-
M0>\+Z?FAE!7FH<*2-H?4$/O4E59KE/TRYM*D]I0;9?#RI'^K5G_(S=S@IO<X
M0<_"E7=F _'Q=,>K,^,8>Y>&W19=#VS<2Q^&)Y1$*?:%'-TY%!9<4T:Q RDB
M>;65"^ B!:486J0)G7H<(#*"3 %?#EH**0LXZ<N)61T%5_WUP6^Y$PM7.'(!
M,S[U2312!/T-[<(,ZO#'^A2< UR95>U_ <K%G2PX%YM_;CV%><W/2Q@ANL:$
M?A-HBS6-IU;^ NU]0DW*U=TA$Q+9N7HD^'9,J89J_5 0(,O"GYBZT/CQR< W
M@JEZ0Z[Q'(_G>\A?.AQT$(P^+0;6SKR$[@G.&Y/2;OKYB71[::!LJ7D^.]1!
M5AUYBA0QWB)]S:%GE^_YZ1O-99.<!#FKL&N@LP4W>[]Y'M$$>+<!R\#UD$U\
MEDQ19L!04J2!RIQ8C;R0M %S !I3EF5][3X85S4>E[&N&S#6E_)YT3@<?FCL
M1J$VWD7%_VDYAJ- _^C&_;I$M]V2<HZV_*CST=@6SX>< 2SOAXX<>\W:GX'6
MFWL;66A[9)Q#?M502A?<F'6)NUW^J/*E3=LVW463&C-K?R?[-Q&:"DM'FM:.
MB*1 @R2"]O@[TC@C"8?=CE<3)-4"OIVJLJ.9I8,:&I"S4(T$]PDM^KWOOD'O
MGQ]P%B1I_#6UOR?S')X4Z/_ED#.B^:!PPF#82K"8@3J$1PMQ[\GTZ>95,E$7
M;S5AF_SD@Z>#%O$(M"K(OXNCD@.D;XBB;XU\NU&WF%2PLQ$741S\ZWI>0_XJ
M,-,[%S[&"5-%/[Q,TK,_*Y#9\OGLWX>FE$]RI:=C\67?O\4LO%3>DDGXF'@A
MRWG?;Z(_?G#MN+K=F8%_<\:414%&TW7%>_V\[=U#?SB660_=J@_ :*_519=^
MF>7\L.N/6=LNY^+_]J$G3<M'FZ"M=6A(=RHUCG+X9\G;)P-+EO%"Q#P#L!7V
MI$[^:RP)Y@9IHH (@,]F2C'J%VPL+\NTN0FP:7DSN W8[Z'',<T9N46U@C5F
MHW];6T-5:/31?./) 6ZV<?JJW&L1.@5]L6?8BJMQ""2GM3JOF>$-O$ X6U::
M<'+"8B3-+\8,>8IVY$%9,#TBJG0D]-CT!R@C,G;3J3YY[FT?'",]K]NZ5Z@J
MOEX<.!E^T]W,\+I^G4D@[SRPQ^3F^2*39=J)S\6LM(23L*TGZ&_>2QVZ=?.F
M^2,-,^.:O3VF+"TK^(-KD0=/'Z<Y?)IXWC].[XN<<!Y^KY"5:U9Y,[+2QDG'
MZ.J,N_VCOEO%=G[=.Q]FYU"_-95IZIYL\6X8S3=9-_D$+&8P ;L-6+P_.O[5
M('_[0B0C+H^XRSG=X$[Q9X(E0J%.G>0/C91#M@X@F4W/Y_AK]BW/(=(5\\9V
M])*>$2(,4@PT% N^^GF=Z0\,_HKVF$8_IW58H@5'Z$ $FPF'LZD[\2VGH(@R
M@N,@:O_#A2@.26&9FDB4 _CQ!/4)IMI<YU>9-Z*HLAFBPH<O=2 J _6@PIL_
MLS(TZ+7;[\\C3Q5*7IX7=39:; K37$UTG\)\/O4S>J+(^::A_>4FN6T#-U0]
M8=6A7_/#6$B#L:DA]1>A3QAR02\KSY\]3)A0\"Q2K=<>I[FV!5\NO. 8DUKH
M\Y+NOCIJ_RV\V&4@\>1+C*F.R[E.Y1V'=7)U])!7=-X>FZQXG+-?^>V'=-]F
M5]?L6F=AR"\)^A.[J+5C#XM]( Q*.EBUB(P97TSFPQ,IJ5N9$T=: 6?.W.A!
M5ZA8T.:_RN&U-U;,Q41EXF2EK%N'DAC1=XQJ,7G7>*&!R=H_%KS$TC_7S"@)
MQ,,0>IR4^$%TK ]YJG(,*N_C$/<XNKF"3#(A.F)\U$TPV<A6-V"WZ_;C1IVF
M.#RE>[BV ):&0OO@MV4'M.PG_\0^O4N[;$K2GX.-"<N60;[ 5ZKPG=Q< ##6
MAA7$WK&A>*;@+ W8^3$[_+7K@?6!1UFE-=6?\9>#15:R&96?[2-OFUZ'97I0
MRK%F-SY?\TO0S?A.2.?C[%YW("?VR?=[8HU[C@WF@#_+M/KIMBI*YM#+SGIK
M?YSV4"I]K7E9V[-RTI50;YE>U><AEQ@2?IM^<5:K?@=R(4;[J(VPX-S-<*^L
MM RS+H]0&Q.,=]&PD#1<(I"BH';,H&OY%*+"#.HDI%\23-P"+.=+R%:1QY\S
MMYH)D$78/'S5N?SMAORYEM8/-UHM2_A6L>$W#33;:N5'6S.,ID7_/E"XW#/,
MX.2-H>N&Q+]!]@LH;<*Y7J()7BQ\W^WUT1B]6^3WH0X'K%! 1<?04_U+;5?.
M@HY)"8@SJ1NP/YE]A'<HX2\>?M+Q-'0A>FQ*9?W+H^7UB0T8Z(XE_9S17!>1
MQ#K/: 5?Z]S<#<^^38W 16M]59X]M_*B2N<[?7[F<K%#D0=-)XOZ_&O._!>^
MGH)%GD9"DWM%7_Z!R0SAPU2OVXYS5]<:;V3HPS& U'P+X"#P*,LELTCQ16J
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MRR3+6^[9+DNS.J<*LN=/D?F"?$-4\OE ^[.>>7RS!0=SQNSR(61HXK)MJ?5
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M3 A6%6P"UEE,2*U(]QT0S/,@M=5%(RSXR8(_P3K@KC_@)CPWAC.:]T1_%"F
M9X#9,Z-&IE'1[I[#1!JO3S- LV>NED&2F<].WGSXGP  _B< /!+UPA0AA_J
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M=HGB^_E8-9B]$:(:,:-9@GA>$J=V[Z;+@]]-^98/!DJOOK:ZPS>N'5'W*M4
M:[N;OVXT6/7F6^]=M8ZI!0M<U08(>RZ'OMOC096[BHCT-7M<:3-0\CFF:%VI
M^,OD:AB/VD52?<=OVKXANZ:SIFZCM1GP-&UY/J6=Q+%AHY4O;9%;/!)IPM]
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MZR*'F0O#C2!.Y1>OBB^)W&[LXS*?)(JJN#Z.9&3BYN'EXQ<3EY"4DE954]<
M:6KI_75'W^"NH9&%I96UC:V=O=M#=P]/+V^?X)#0)V'P\*=1T3&Q<?$)B>D9
MF5G9.:_?Y+XK>5]:5EY16=74W-+:UM[1V=6/Q0T,#OW]<7AJ>F9V;GYA<0E/
M6/NV_GWCQ^86:?_7P>'1,?GWGW_AH@/0_T_H_X^XKISA.G?^//UYAG_AHCL7
M]B^#*^<O7%>Z>/66&8-+$,<-Y1>7.&^_*F[L8Q11,2=RN3Z>9.(65<6+D?X%
M[=_(_AFPR/\M9/\3V'_A6@*PT-.=)8_^"@ "H-$DWR4"_J\E_6Z$UZ+UL;+M
MCC68S?3N.-24[J/(\\";[;!<#-%BCX$VK;6R4[T&XZ+]?0K@I+@0Y]<T^K_E
M#74]RXD!FBJL8=@WL]O9"1"F%7OGS:6X@F#JZU\^N5<=:C08S*>+FVT80XR.
MW6TOY'[O?&)+@M]CF"=9-@0.KFGVI# MY+XLCCM*U3V0LJPW+Y#.0O+[EVI
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MC<?.%M_2W->@HG G\1*^D<J\Y[37ZK=3#1G*-*M]X#N*=T&;9)M?&B<2J+[
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M5&GIIFCR2RW_:QPO=:C2=\52FA(V.R@Q<(;SN]<NJ[SZ>SSBLN_OSK-"J4;
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M)[OYG:^]>Q]*_&?_+HNK0[AG:U?\4+ ?^.5P]#,@3"BIW[6!MT:?62"N-GH
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M=4[06GOR-!ZR@)#PK+1UP@:$$4 A4+8MK1AJM1[[XD!/OVI>R1*JQ3P*<,Y
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M0J8:KH=KW+1I\LXMV>3'L?K!L[4R;ZTW=2S<2L5SC?I7&:DKRL13[,=!9;%
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ML/[ZZR])^=,22K]>LT?4RM^H:"X79)<3"7$3Q]Q\SFHK\/S=%\47'<0W"1!
MEJMWAFVR"U//AU\8N&0$)!R;$T"B8=UD(>XC@4HOJF!<I>YU;24>@>IPKU#@
M,$H%5PR4DB/<J:TX-N%_+])A0BWGYMUAUYC9Y>[,S\.5DC^P'5R #'C#_4"?
M\=^3=$\18CK $8@,/0$/-63P1-)S#M^AI5R0QKV=UY'\"TH99*[8=.WE%^LH
M=^4(!@Q#W;,:1YFX!T*B4"I\D66K+N QE+E_";*AT]:VP<8F/3,V4)FM=O\M
MPBHDW?&\J$"?W:L[;8*4="E!;_?W!R*JKJPV%3'/^U9=0\9XG[S"&>MU&I5N
MCU&<1+7N8&O+M--\+T3)&40;%!A81CEF9QH9CWAM/:Y<QSA\KRQ*>WF^:?;:
M\X(3;Y<)OSU^]Y[GN]>WG3('>UBRUO()O'Z<3D68JT+N#)Y1>B*@>W -/:@M
M'8668P@<9NYXL=.O G,'EAZYTL @V0M#R8;4[75#3S.'Q%2HZ/<'*DBN!S18
M8EX7'VEJI#*_:?SRIW&&_@)B.@?=H<AE7#MZS+A2TZM0_F//9@3Q1J*O(V.[
MCR^V@QA[!#JG)X9"'<?2C:% <U_?HT"B&[1+NH1K#P*17%\<YKI,A;8IJON[
M,?D?5L&<>-REU>=__+BX="8U^.#N:&NWE!/'AOS"],W%(K7$OBL&]4($J;<T
MP4B+C$_9^>M6^;$Y<FF>FG@6@RI/JU6_H2[KSLF4PH CD/?#'#OS$A%]^X'I
M7Q]'XIGPID8'[:*/7CNFGABC *N&<U>;&I/\%WM5WW1!)=,$(LPT^Q9MDUE/
M;^=>Q0U62=+TN^G>BD5!Z9_]'$AKCE,5/^F9^/H).8>@E.9_]]AD/KX\=^MR
M9'9PCPK@GC@93&Y[\#7/[5W25Y:W78GS*>K9N;XO_$<E7CHI&^=.S).<NI]7
M6O6L#OSB&?RNOO,'N9+\\85N%)5UI]QV#P%'J/Y^X9;XZ70BTZ5 !_-"[:G&
MQ:X492-Q6U$@\#1&F\*P?7[O-2GBUD.)ARK;7O/G]P.^_N *!2U*I2VE+;Y)
M4*E?SYW?Z97&,MOT#?W"S<)C/XG&?OJ_)Z^X7+)/ADAPG@VY?/U4\GW+ES\X
M4%6T03KY\,TQ^F($ !_R$:@7AR6  .<%+CZ2PZJ#TBL*XJ!TV5ELVR+!H'YR
MM^F9PM8'*C%V>7S168[#O\L/'OIX/PYAM_G^S12Z_(?6*5_8.QDY]AN,OE,:
M?86?0#?/6FD^$N H^6_- ^( C!Z;XV%"D)$4['HW-0PVIF.]@)G:[L2P/M-3
M!/@7E"-0NN26#9-[-*6*"D<D/[T* -,B.W.O4G%8)JM==1E?1:$3TNPG4&Z2
M565IG$D2S"71]!)B_+Z7J'UG%N0L>#[Y:1V15UN^*& >XZ7!''0IG&Y]_MDB
MH<*&S1(K;YS]<:;1W[BQ55+(KZ/;NCQG55\#;N H4X>':];GU(?]/ 0.[IT<
MFA-.>%)W *;'-6E<4R32,:_WW![ IR;4/ATH^/A-ECZN-_%=9G6^!LUB@($!
M*H[^@JJ418/,-R3M^+P"<ZE5&3J.!& $D/#EQF/"N=N9F4@RPW-$#WQ7+UZ2
M%S68I8QOD@UKX:ZIE_[U'%'>[OIO"GMCCP*;7F$J &OM66A!F!-RZPOQ@L[=
M>5R"I1U*FS;9 >-!?W_#T!U>5\6QS@!5^!EIHTA*J)&?#@?\PY]F<&3^@5Y!
ML=.<B<1?VQ<0QL54.D#-BR:Z@MF08H/=!+$A A_SQQ&(BR$?[$I=7I!*+0!/
M[=&3/P&#80NX5T2>S44:.,[K&9Z=BQ]IX2SW0_=N)\DV;F F-Q42#?FTT\]A
MNNQ3DW?J^>]2RR);K-\^LOF=IV9CLV8HNB.S<UY%Y =>J#'9P[HB+E?E1'2T
MDJ<OE"2K9V]JB7;RS^Y1TFER-O[\.[.T+8=4GDGWP@3]F@P7K2J:.GR(=.]A
M<M"R<Z42.L2DAUI-E2-:#</GY_CU/WJJDZ((0C1T9CT60P[WO!DB6G<8U'/S
M0*-M=*FKOGA)8$[Y:N3XPV366U\^!?ZZ?2=?X[QV@4AMZ2UK!WTI?4L!1=BW
MX W] PU4\&&\SJ5CBG< 3,AKV-@\,,/^6/0TFFFVZY]]BX$]%YK>FP,3))2>
M#6""J;6.U%[&U4S]Q=_[WDWS=ZL]9W734.9N7F>*>A+@_HARWIJ(^T>@XJVI
M-;)HPQ?(2S +@=5AM6%_!\/&%$&:M&=H;U:5.JWN%S>4>Y!TV^H;JE:%DC:Z
M9W:[ESY7)?0W230W-[X9*]U6?R&_U)@1^W<]CR.JY\G[0X5^KN0>VP[+V''*
M9\YB,&MD-Z7"RIB6Q);FFR8[5,66\G;U3N43-K\B^;TG4\GB@A8!UY'ZT57&
M4?(#[4J&&Y)JYS0*K'7'%OGJFFN#=>./H>ZU[JV/_P\M_7><*J0N;M\.4GS_
MXUN/-71&0%I")%'D]T&N_% [RVF1B!OG5GH@/:UPIYY@V<L1YUSW8D8X>79!
M"Z\UM;367'#% _0$^9!7WP*^+91)ZP1\H8L\.*L1[U05Y:&W7EN]Y52ZS<_8
M=L$X+\<3%_KFF 06YBNU]J'_F?=UHI>1P><0(S.F%/ YP!:693X\UTFJZFD@
MM_';-(XQM"0'2;^IB^O-24G3SG]4G IM4SQLA7=BQQ*;H^K_WK\S>5=?L\_<
M\\';?-7-$E;C2R8F/;24O2=/ON=L_;412DRQ2'S\EGS3R-G_=H-P]61H==L/
M8Q@(R4:Q]U;289]_7^VM9BKLU-J8VJ$GG(*8">[T#1$3F%223C72X-<NB5&D
M3__13L2=S2^X)28J%Z;9(>[5^?'/:P0_X4JD_H@BXVZ9_=0**;?M['LWOH:R
ME7V$&2D\FEF3/D<*3<IYT]R8"JTC-GL\<\_]ZR$HT<CA8&4]7F53Y^1N4V%J
M9+*'5UJ0E)1I&2CA^R4U7KEL\+9J$R''LR M,QKA7<36K(^R"YDL,\7$["X5
M$L:L;-*#OXW6B;(;M4VHB<K?'E8]]O(79KI+U_;V7=X4PR?WZ87IPZ0B)A'S
M!.X3@G/I1/@@GF:0ZAHT$%Z@&"U403P5PH[^1CRM(TU;7N#?D/4B:ZKA$L#"
M.(+0:J[LA(XU9P9%V)G% K F5]EVH/G&]$3;2^&I@_/A)@?"5HT-QU^KM**T
M:\"G)!6Y'B:_(B=O;/?=F?=5DHZ+%'>/3._%?)<J:8=$&[&?(3^2C*U=1/O9
M#2P*-GCD_!JM+(JT+'SE>(K+RCI4DN12*\Y]<]'9%:NJKK<UGRK<"&[Z@65!
MJJ&<<B%BG-17-,K/)&7FI08J(4+'(]/2\/>W(EP\_S\8;J7<^@W)NJ!(NY31
M=>QOX8=-+,?"_Y1KZM*\^_K+>7F?V+DS.I)\:4_.%E!FC'TN(>#%J[-Z8\?F
M3)V&KEKP\C<=;_7(]*K^7/IG")'9/4:22@U1&\C-$YKJ^E)5?F;?,[X<N1ZH
MS7MMJ.=1NA#^'U%C(#"NLM06R:962KYB\=93)HQ-;+;JOFM9.1(YEIU9\/7P
M73B,<W6TDKH3LJ+5&!8_UTIWFK0=1R^)VCIO5K7;H>0 V^+I59MT"+N>P$^'
MU8G)(.TB/+9SCL5^VI.$S@\-=-R V#3@AR_'VM2TC1^!*%X8]]"('WN6LN&Z
MK0UQWB3$5@R,(U#7AWG1"THF=@Y N[I6.&<EQG38R:9WN_2"7D H]RQ=VD:D
M)D[^>:_XL6^OV(N;7OSN4\<+6Q_]IY\U";;\B=W&%DXUI6M6])2(^(AB4J9Q
MIK%Z1#RVA=>=M\^VMJ2_;V7T[;,,^2B%$2.)C=,[-6M#BXJ,,_,FBHX'&"A5
M(V(]\!@\PG 7JHEP,I1K:JVS2SNZ?&4_(P[F4#\R:2%$+WKXL==ZPF(1MQNN
MTY:VGL22_LIA\+BW"6=IT)]H422+&5341^\FGQ@;M>HC\(=(TL E6LP9)B(_
MW/?V3NQUX9\-GGZZ?8K1=UC$:\+[RMPW<,WX1G&956+YN&>5:J9O>9K^!D_U
M[S&<P)@G7G,4)V ==<#&6B:G2ID8T)?"$_)T@WYUU5 '8P+:[BS8C3 TR!LW
M[5I'Z@XYUVQ&ZSCXS<9+A@-B_#_^F12*3GNKD0H7$@BY.A+0I$3J_:<AZ^E[
MT4\S;-YB1GHE<_LIF!O0,EVX3'7 ZG$%P"/\9 WT2.C1= [5_."*)#7&S?J%
MQYLS6^5[/H_Q<Z:,6=*_T3SFM\X<'Z!5R(_GK.+YJR=P=Z@UGSX]<OITH]$:
M\G?P*>_;T BS]66BKOR@H?D1Z.01:$BH[5+'$>@O%V27YGL$RJ\"/04^9ZBO
M;&^>SG7<LUOK"$(7-J!UUY*J6[H-]VC*K@(^J!3#Q?C?'O]3M,6=J4>@6(9Y
ML9-'KLR0*O221\,3H2T#FMB;8@1);>IEU.OP$I/Q]:WUIRF"$?U>"NG50_^T
M=)9^U=26[H3&S IR8SK4J&ODK5CT8)EAU73.J2^Y/$,NT_;QI#!-M3#WD8 $
M'VF[>GQ+*][4X$Q]JWJ&/^GP<_[KJJ ZZW)\ :\9[^IHT>#&$^-+GI?*O*VU
MY!E&\$+GD5HOYPLKYF\+M,R+9+N)H>9F%C8UB7EVO0%UM4;9]#PR%^N?0?8_
MN;S4XE>2^-S\$D=H 8 P&%52K%23'RWWM E*_?ES&HIPK?#\'NAL HVXO[&%
M,TI?_&=YXV0%P/[%GXOC7\)IZMV&2"6]J?D:%)A<XG-V[I^_:MU;4:T#LJD=
MDQ=OUOUU\F!U]7OR)NY-W@VQZO@BEYJV\G'C!SE:Z/T&U7R+[!7-YMQQ:YO$
MMEZA-V]%O/CRY5Z7SFA;C 3 38.RE5)7)*KQMD'A2OXK9*YS$DN+*$5R89/0
MKUP9?E\@6-^D@>9HJ%B!K/LG_<YCVN/Z5*@GZIZ[E_MZPXT[^^D:3^4Q9Y!*
M@\R+4;546*1" :UKCU]/TT29%8G^ 19V<NFBNOP".F:GS>*5^6:<]24^_R+&
MI0/]/K[!E_HVU!%%'PM(-FWCH7VVG>H+%H662'L#J\F:)#OS153#6UVLPM/#
M_YW^-B_RSS&N13@W71[9:75DF(7=I6(B&8I/0HJ1T X]7FIN5CCX3: ;&<KY
MARF(SY6L4W_0YQ5@(BS#L8C_V(V *W0LKT_TBSS0D14;_9U7F['^C>I.MP)<
MR<2HO+,ZLF<CR7GG/;Z1#YR-F3<YH#W:/2D9>_O9? 1%FL]/13R$1S)M(O]Y
M^N=5RJI\F*Q0SR\)<<6MMS;]@HE6+N U9(:!?\=8&8M+!;VVO;R"2V[$_VV%
MIMR(Z42:H6I*GMKO1;DD7CG+ +AQ@*M<P+*,@=GU[.RB9OQTJNVBPTW'>X-Y
MS*OH_KQ3:"FD9;L+RX0.RT<//6XJ2P_D)"KT..=C&*S%*WJL0UD4]\XJ!U.?
MSN;<V@(/!V="3O6*_ZH22YQJQ9\(9*09.[RT7^9![(0D%?Q"8C@ QM'P L4N
M'8-2T2U:CFZ]+AW9JB4=VWH]^-$Z/5@,/.1H)J3^RO^Q_4#1;"H"'I3[++'A
M0=.O&7T><E*O@6I9J[=<0*EUA46:7%J)S"B='NC*5V)6&%*82B\OZ))(4XM+
MDER??A#O5=H+VP^&#C)SYLJ^]E/WR(?=:3UIRB]:S^V;+L5R16^I?FL5)+^J
M]&E5/M/I3 (>T;__F7O42)U)ZN_W/1LM6;'"&BA-<AT=N=W&QP5"GIR8%1:&
MQ,Z"ZNKJ)ZITH$\07O-$CG97-TJ.MEJ""4VW+:?^O1>/B\2HN7C\(*PA9LZZ
M-N(Z1U7'1\G .BL%LRN&&6N\<\0?BQMKW4U2#;]QO-Z.[45/R=H)F;M2O\<>
M5?Y[F11L.EJ\OM>\I^HN'G;<X=FB)Q_AI&.).K'JX!Z]1<2WRA=[ZIVGSNS&
M1N_>F9XVIRX6362I54>7W4R5G_U#I_-[74>D$U(H]@XXY^/TRTP:V)C-)\/8
M768\0V.R*CP;;&=%AZLW\8JP>[Y*L96SOZ!N:MWTBH+[^75>!INNX1\)4ZHM
M6;X"T<UL<M:>J]<2NFQ2(FK:C HG\=&.,CT?$Z_^XGDB9%XD]*K)*G&5Z"%M
MQNGTX[I/2<L9'[5^ 6+W/J?F%^'W]=3\5Y*VJ0W2.,UOJU!5DDQE@4#O_2+>
MXGBZ3:+;>$-YO(^SHT^9JSZ/):A0_#+66CPR9AD<,#]_,#)\2ZSHX]<4>%"T
MR8*;X4%GTY[\I\L-6LOY.[TCC5L76_0^!H-X'UR=WSU5;>@-77"&QA)_7T(<
M@9PECT##."=<W!%HX9 X#SM0!/GO_']7EOIG'X9LY4*^,60^ICH-EPEJ*,/-
MBJ2EYFXDV6EJ\%7!]6^V3_W])CUJ.0G3J'!YR80V?8R7)7%:9D4YE?0'A_PI
M,.8)<=M:X3<3J7$.6<6HO2F?:MQW9+P;%?$>;KE:V^-7.=RS=,. _=YW=@-@
MON9-S]G0T9:]95WH*$XG[T>\7':6%67Z>=&/%4NO1DM_F]0HQZ"@X9M_4B0-
MK@<^3EFJ+.OQKUG":PP(JZ95,Q4W6XZ5S.+!_[E/T8?'+\*RT8$K>B+A)$_E
MQ\'FDV]R60\1 QFE^]AEEP1RWK\L7/M_YKX/G8'Q8GK3B(<HKL.+B,CJ[6X8
M;='G" 0[=02ZESF_HOZQ^J"H-FS_N%$I,]_(Y&7L/X?0(GZ38(&JP*P'V!;C
MJJ=OBSSJRX;+Y*7#NO7#1N(#^QCUA#5&]W% 9'O,N"V2E@7[V%;\95 V;:D(
M_.:TC4-%WZ1/"^[7<: M3$G#Z=5]-,_-%7A8( *6^U7O\&8Q434B7J8PA_F=
MWO;O$X2]"24H?L0DJ*$6GU.FWV;!B(A7.82XG.'9]>Z[X;T1UEH[-;7"EAH$
MK:I:QO^P#\(H8N2/Q=VT3'%!N2E6H062FY=SW-Y'8W/\@B1FL^5PXHR@ZN_4
MNN#1']/>N^O'O9 ,T>PV",YN$D?696?Z&6_I?_2QJ1=?5&:<A?T^_IAS]0%6
M 6?NPF<ZXUPU/C*A'!3;@L\;4"70*X_;+9&@X)0#76:WS5O64^'$%+ "SML>
ME8K8,IZ+.[X1Q"JULYG#+U8A\[#]4[8?D3#F[64F00FRHX:[*6K(8#\"W?+<
M@1Z_?-4Y DUV]S)CZLY]I=DR4-U'(*>,(] =M6^VCA0<\&\"LTF9&85(^7 R
MWL]0(O9<(D/K5_SW\@NRSUXW!9FV%\9?_GN5QZ_%\4HEV_RUJ983)J]Y/M_Z
M\MFY^XKDZY!-7GY_E?5[3UG[V)R2B]3DN_VV*[;-?KTA_1II-L>J34^[PRT2
M?(V*E\HUJZLL4+6C)?*CSOMG>&*#GI=^_^>IOH#U4S96WXAV;JMW[3F_[4!>
M2Z99)O=IK>Z(@C*)C:<6KRZ[B!3/@R,,!E9;)B7"1V1EI?E5LR)J_1;ADO)_
M&\)N&H\L>MX@*A S; /#E$/HV-;=O[:"^IJ@VQ(O$P-7#3_NU_M&;PV*\_!<
MWKA<\8)=_-3;P9GMDYN/.:;JWQTZ<7I6XY[(]/M$UZ=M5.Q9FC@[&DED3:FS
MKHZ:*7H79XM-#AM/AJ?,KBCV#-_Z8W(!).Z_O.BT'[G])K>2!]>T>O?O)Q;-
MR_-I@9Q?#G].O96/C A^?#YH1QQN7YSBW6>!>D.43VLJ\IC]-@6SW:RH3[VT
MY*E38]JBY-$GVS#RMZ;1_-:WT_/S<B*O?=,E.*IOI$B9]RQZ0X+N=U7HWZDP
M/0+U?Y7?]3,*W^P['-]L?CMJ6H*H$LT,W2\>,M<7RU:Y:'WG<O_%KC._R3Q\
M5Z_]^!)2<R_V1+]2>EKJ8EI6O!E)0^IMX%*H^D0]/M.KD-5Y>CN(369M=&E5
M[Y:C[^G(VE/+IR/KL*W7#!V@[\J>%Z7=5WI0\2PIRR/MY<,#UO-Z\P^':]X,
MC<UJ^%I&>GXL',EVM/1[JS#B];?,P&D$>)CVFX+GM%W$9>Y,.I_YB.W7V=$Z
M_7A#SO?KDTZ_LS<,S0U+GKV^X?\R-6G@Q7WKU5X6SPCHR:@M7M6LR/C,TK25
MOAOQ*6^?YA1F/\X9WZ\:O36>948**2;LD!AWXJ^U"]TA7O[*$A >_.S!$:CU
MYMWKU@*S)D8";'[3=\+./+V29N?F<7X^S6"NKJ,3P7)P*Q80NZ[@U<II[M@G
MM_;>Q<A9KYS.ES.Z V?>UM<QZ T:LE-B?5C=9"/\\L0XI_7MV9+3(E[GB6JJ
MB6YG["X(VIO=9BEQC5R]&3J4&5J<2?IS^KC O#@>82=67,2.0*]-<8<!Q^/%
MH,V/('X$PM*/0"\QZ_AQ9!CSMCIQ=P1V*+3;!V"9D&GFF2-0S1 +1%]&\,>Y
MKX,L+U]$)UP:-G^NTPMY?N'G54(PE-1/]PO9\7@,X,G3,JWZ.#A!8$A-U&&P
M*U,]MA*Q/[XRJNHLU=LE5!_MGO\MK,KSJ>Y-H\35$VKLW_AF289O/MH'%<1T
M/](B5$5U4YH4?WQJ]&R,92_#_R@S,-.P6C5ROMF38Y"6+U7L'\6[+,D;YCG2
M\G>5Z0B^.^R4A]4)G#\"13.%QUK=:5Q=S9!(U)4"TQ+]2F1&E^U=T^&=M'&\
MB3/8+,^J-0U5P1Y6=8<^\<W;V^'FX];&9*WB9&X%VK^0+C"IE^X)0#$5\+R+
M>NI(KH[,F%B*//2<YP1_9O3,;/X3RO36^9+$#8::9/I[U_#G^]^HB9^ 8D>9
M-XL-U,/NZB*_*_&4Z_HB>M(7/E !E,%5-4F9'BL9ZRKV]@Z5UF/L?%36_';<
M4%;_+LG2QZB,6V['5:8CT%70R$7.(M[485]]9#R@;3!?ICJX?5:1VML%/?_'
M18UZ;/$P0LB;W4(H[9(8AB6YXN>N%Y=3S3O16O@DG?#8]IR(ZGG7&SK!UWY-
M#_*H?!G.TAZ,"X!Q)JFN928*N=-_M!0!;D:.+Y76CD#<B*CJI,(O5Y,MO //
M_AQ.9^?Q-<8JQ-\MOU<V'K5L7"0T5MYA=J/$)LTXD"<5WIOBFYC]MD"SL>A[
MD=E'7Z>4)V6W>W/,..5Q.CXX1Q?ZMKI'F0/KFPB=&P4WF^^)&K\WOC^<$F?X
M#OW\\X8,U_NK('O6U^+ZUQY]%#1!12FGM[]W4GEBH'7N<W/+;P-!HUDW(Q>M
M>+^4>"!'WWAPQM.O1+O\AMDO8DN)EHN-@\,>7#TS"%Z<6U:<B?$7_]@$80'6
MVN<NP+IEY['<*[FR1Z HZ6Z'O)<,JWW5%.?.?*!%/UEZ0@<2KOG*52CF[:3Z
MI]7KTT8!]?[&;HT>)(U3Y1S9Y[G3.+ENF;\Z=TOS$1BAK5WV*O6,4[V5AJ#A
M0F)9BU2!A5)V)MQ(L\=3R3;!8ABEJ)O3+7C'US**K%E/R787],0%C'@55V[Y
MCIGK&]W^_WFJXR3.?!?\HXV_$_*7$[P[3'R/TW8I6(7DA"K'8'Z+0-8*,"JW
M>%'61R QFR/0+A6R8U3-V3+X?]J(XLJWU:E[D@5;7HI+#2YNL )BRM;?7_^&
M46QJ:>ZP_S:KAD1AN/2N.J(TAM6X(F9U@+3J5<2\(G^O=G5)Q1\Q+6IPC.JT
M3*I]:T/#: !0I7,[4+7,AV=[YNOG M5GO6*2!^JH<*"_&CT-KL>L)]$,G8=T
M?#^B!\5 AUGHRX!\;SV:.[+=17*,JR>)JTM#[\J0VJ&\Z9C/CF.+L]3!W60O
M9?-:OE'*:IA6BOY+";WW!];,KKGS&,1['>Y28+#W" 1F\B%3OW"OV81"$C'N
M/HD.>^V#/+,>F0<DTW*D#VPLP"3LW>X@UV"8:\GJ:SL7QY )AZ)$6YL]U%N1
MAO571Z#3>\#U T'D*&6RRR>6H'OX@2")7%YX^F:^BJ771>[P UIA%<P7^&T'
M$YM4GL?Z$TZJ+BNVFW/H+NFM=.GH5^S^[L/]BONJ;!.A.$;Z"@KR/BST72:P
MM4Y2_81D>6V#B[$;Q^9;%"N%C.LXR9#+#=G-\"S19=&ERV9UY4VE?@4]Z6"P
M+3<_JR,76[EOZ>])'8L)=0>)_;JY_';T#.8"! &-FI4$."H9%X!!ZF2'"S<P
M>&# .'>8N43%)J)9I+%J8"X8RIHPN:$&C7N S$9.W@F_-W4$>M(IF1%=7:E8
M:?NM,<;D"'1C0P+[#75L%<^P AG4T05L+R8*4I?Q4@TCB+H)V!Y &5</,Q\>
MEJ#8/P*6'7JGJ7MQ:$F&*!!&2;H,C'Z9=)$?8[CY2^$68-RKIRS:J(NY)85(
M-X,)E&:#Q3>!UG3(""R!>)K!2_NL)Z"_@,1G))#Y>["Q>6*,*X=)9>J9&/)#
MAFJ6>0NU?7Q)?5+>]P.KFDG>AJ+N:0N7@B]GOI_/%_ZJ8WC A6*E64]V)VQX
M<_'/-/1 21IDS(;A0FE&ET>]!NP2\X('DV-81Y[CK;19BCSLE-.*'LMP_D2K
M;O-BX),\B[OETPI-R51!PFT%41TEKQ>!<(-D*34$^9K+X"49JU[7ZP_2P=Q"
M*4G&==1WQF-D?K"[Q&J99:W-+.&2L-9$ ,(BVJ#$)C,0+.=G^R#TH$Q7&&BN
M</I[!)IR9[+I4B/I." '0>UOGQ6@<<66T Q?XH] KS#L.OJE )&<$5]W_.XX
M;H065_*&FT73,(J5,G<1R"/GUG#B"H#X_D[(!075))\'U(D/@297"#U_?RB%
M;C'9W,BZ*EVSBI'VA[EZ6AYY[*T:-,B"QI=IKF2A-]2;R$M=1R!!-!O@TZ4G
M2Z1ZYY38 Q$P7CA=[,8G*N%S,1+2HYV>Y?5A#ED]Q5#S7YR1;<(\/,PCNN$B
MC[5S.<ZGU9$,$V7HMU$GHUNE*Y$:'00>6D-2P"N"&(,/"/?%.2(;'(<";G*H
MZ \_?_:TKB:"([@W,[V)XL7502?^='CZ&5YP6"5-Y8J>HYING9^;1>G38#U<
MKXC<.NX?CL=)QH8H+:,=PM&J3#LIJW?NC]O"TGL<TN<N$%T(]T6&*P]BGZ&%
M@!)S4SW6P!GW#B%H'%X8R[NR?W=-P\0??*>H'>+T?6V\)#F9+4VDVD[;,E=Q
MLDKDGJ\US:5/+B"?;4RFGV50KFK$+_ BMLW4,//ZP)IEIZ4383JS#G&@9>EY
M_4%DB=2R3)._28Y$Y8C1["3A[)OC%-=I:<SH1$N,'8&>$K'-*/ E!O@ XL*0
M!/A]2U#7(9?P:X,DKEZT)G7P!0H6AIM&KCJ#_QEA&#TA]\.K&9"J?C=(E&I6
M$$VJ1.((Y!,F[U)!7F;P<G7,JJ5;TZ37!V@'Y$H-PJG#_%8HF95Q.Y#::X,1
M!6KIUBT1G0L9G<H<TQXNU[.GU\1$V[+!7$"+<YX1-3;!RRUSP6S\:KTF-*SY
MOTE?]QSI'@Q+JWYX!2+3_15:8"4/1!!%J=<0:/@Z, EZH-60$#@7W:RS[U3_
MV1F9X)0"N0BD;#O&#QF&4#CDOLXXDJ9)]G7CW<=%FLG:='"#\8#Z-&L><LF!
M<2>ODZ26MR&(>)B)27KZJ2T./=:\D4ND25%,XNKV^"WMUD*=DWJC%"4,(DT.
MV$FK]/VJ-ZTO\R8T)<N1H?^Z^$0GA0Z4E;K)_5 M2.@RR"FK-$Z<>:9PK998
MY[=48:\<P2T[.F"MW=KX3K;#Z5.TH:DZR2G>[")<0]HGB+F6,%Z/Q$5CYBMS
MV6DC/Y%A7XBUN&Z?N#P^/!AK0ZS]#CN/%@:VYS.2JB9[@N?.^!!T'#S=*#%I
M"_<)@OWD+-C)GRZ=E+!2-=NL3K&KHTNC6_DM*?J*.[@OX&E_\A%HXQ*%&$,X
M1W6/9/BX4F B#!G@)0W:G2[4&GH;._\3\*7=1PD3J(98TJR;*D%FLA7C1DF2
M[MSVB%GJ?U!/S:TJ;?UL;^2FUJM(+6&R3E$19%BW+GA!Q$4'&%B BL%G=48(
MTDZ>>C=HD-A-U2I8;Z9A!^0"@S7!I9$Z%],J3AZ0NFD#.%+NU_F3,5SZA1Y\
M*7^:>9>RW$4WBG8R8Y37>ZG@CKF:V.0C$ )'XE^0:J!6D&'8(Y!G7J)#0[>B
MB7$#$+^-A+9#N%HON;N[%I&F@(2>;_D\3>-;.!^F%.H^<^!3#?7'>\J6<-9S
M]VOM.MM8E+!#NIZ@HDY8E8C2R6*7PEI6"FV<ABR;IPF$/-1-K!CN)"\:% 7'
M1?K%1[E:RXR9J1EHU=16N,3#(9Y-(_0P>Z5#G+Q2W_)[H);)MGN@ ]SMR;N
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M0>"6QSIRKV,.D%.+'HS=)=-LYX-[BVC!,9MZ2HQ;-'H263EV7XT&B%*5VX]
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MC]:FIB95\?V0I]@R>):_$%B'T.+JD52?!<,X/(YMA2A21SR-<,#%J,*X4+I
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M\<+5!@?#Z%;'XI^WR3-G%^QH4K64:5-$9ZAWEN)2QDU<"+6 O@VHT2H6DHY
M7^9B2<K80%T3T_KZ,)S@#%Q;$AO[L+F9*A5+NRC90MV8BW,%L(@/3DC_KDSQ
M%32DD6K,@(SCUYH8DJX4OO$J 9,%]F/H^'3XNE6?ND#.BT5QX%#_##,$R<["
M"X'%+RG04PS]$?Q[E./\%LG$Y9@Y4RDNN;.7QP.X+JX@W$,D@C)]8EK=R<+.
M7-UB8M3#:&*L*NR"88GJBG012OL(%!&" A]K((+LT_T3Y4.+[";UMB.T4LFY
M"0L^%P!_FY%6V8I!*GV.C,X/=ZTD(:&FM-"5AER>>FN?V-YN%O)F%L[)"9G2
MV:%.2KU%#7I4"J#_N(G'A(PKW-W_]?Q3UX,RP6$SE1@NDIE \OT^/-)SS%K;
MMT+>H+"L=#"77=M:UK]5XD,1JZTY3EJFO;'/4][,O5^Z+[=JNDDZF3C_$7**
M*8PRHQEV$H61&$IP; #D%,,<%JFG#/2'DQU9 /-"QH,LLO5@3Q@7JW[IW:H\
M;L^:.8#?9 S'65"$#%V[/QIX3GQD5[YQ4WG#=S%TC\$S=\=(YT0ATG(>W'.?
M 5^ QLW5FKTCG*$=QD8S;E)8T>?0(X2KDSJZ\X/)V@HV8LICE.::EK:AK6-Q
M 0S5A!,48?],F+:EMQ3#%QD+.^ N[$^W>:[N)M3M(Q#K['M*^*/.;@QX)X\$
M[0J]1A-W@(?BNA2%R=%[[4!=TZ.(+\:Y9\=0_.&^G"5D8,FDGIBU4=]<>>E>
M%L !9K)^HP:;U=XM1QD"-,H6WPH)]P6!94-!:9"D.O:\N%Q6:N_Z,$6>> EU
M!0@F;UA"J4%9Q1H1.SF6%N.;@=/A,*.Q71C/K]6&#(>>$K6IF"4Q3S7-V^8%
M<N\<MKM&2KY9_\#;C[X=UY2!SK;A[,?IPVEY-4F\=\R\J_8E1<B3;=JT&%Y\
M_^F/TWMY-S)#<<$9Z28X#?7LDC\B"9^G6*7/']RW$)=OPO89IY#]/E>\3] R
M8DWD2/Y>HM?Q??5-E_/[64TW[LZF5VYX?K;2]_)"46=N^]EM@M0)-KZ)GE:_
M:Z)*9-L5WSYYFL) M<#=1GQ]:[PT'D^;K=3C3XQAOA!WSN+N48F,R,%#E!/F
M#\(E2!L+\#-?C/_)Y3\"O0XY N$2L(<<GO<>(RN8>H^.0-7'E)HO]%O@M>9:
MWC_[D[#_ZZ=TKGY<\IPH\5%>++$.VPUF9TY"ZC9?4OT=8>=0U\;UQ)#0;D@=
M.(EYH6@PUJ<NQ_W T&%859D#:.FL#WVKLO;Z776@-;ZI+643_%EPP>J!PA&H
M75CO&NH6L/'?5J< +TV>HI&L!GWE(C^NADL@Z:!O3&RFVH[O;IT_MGJ3B77@
ML_BER@DR_E4!M9OP'GZVS$_)6SG?KJBIL=E-=6.?E3(8?00ZKX/Q1P0O'%?.
M.2Y48*#;,WJ0+?H&%1*#L@QQ?Z+Z<E-!87.W3?WOTL3$TY.&,5J$[R-/#2.1
M9YM%66X-Z<@6.OS1XQL*@'%XI*,][?_H"8\H!.AR?I_]1ZK%Z^;]D7Q\7=VV
M9$J(1 2[S8%CRM^3(\VVHX_\OW.@4@^DHL^CMHT>^3W3-TZ[KJ5 _8E2LH_J
M<?4<[ARR<DLH.X^9@%M5&0<6V(AUWW8Q(1G^*(G!06\DBZ\)A P5W:FQLBK7
M^F&=IY)@IA/_?,FSW] ]J ["BC(\5@IZ7OU6%U<DG2A*N-JP'EZ,N@N\IT#.
M,F[=F,47';OQS\4,"<(Q*!UP'8$ZOCD;.+808UQ8+PW2@N\-.\R*ZFWU\F5
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M=W4XG*?6L(@04P/6J<OK,_"T LO\2"*HP[9)A<*X%EEE=\-XD@)M%P=_3$-
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M2-5C0P9AT:(&$LROG;>VHCO.IS5/!+R)J__GSYJ;VC\!3)E=QO-<B3__PSV
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M"::I3!#;AH8XQKM+IVCQ;H!AT<"V_Q!%'V,%!.(S>2JXF6H^)-0;LOP8,.#
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M@XCJQ;Q-;X>ZV"N*A5]#36(4HRX&M;6WI<SC)Y;X(CN5V/?3%G3H#8FL.^1
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MM];$=;-5B/T#,SQC?V@A"16]N>EPPPH_RM@5Z-.F!.T*'*XBE&*2-PN[IKY
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MSW@1K ^@:\=]WE[R$?DN 'D4JHK1O3J!M.OLC4VM;QA,&/>Z.FA,', GE.B
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MVO8EPG]GKY1=./GJUBOE&76L$,L 6&P:&!H_DSTXK2#:"<96K5ZTU=T5\,-
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M_!D#226+B=,MMP:G2X2(KD#E3GMI*>S!]R%*LE,6C%E37Q\LTK8I:2AVWO;
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M;&-(G_VQ )6+4"=!C]Z+2"4J;!!CYRY!>0#C)F"9T*DGD#*A]X[&NM /M=L
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M,[ O$ 5GM1L"GP+^*]$63C\N[$?(()VY(]*#CE_1AY GN41YZ+9^1I0N)<$
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MD0L 3VEWYA1?'L3".]5Q,WUSYT%$)D%*6:2W<!<*-MXB#R(O<>%B;R.\&SY
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MAYB35WV]>729742ZCK\5.@]/0$E!/L @/^H5'<K90N.<YN^,;%D0)DL4(?/
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M$^V>!ZNX=1A[:6BX.Y\D29#_.G>&VAH[[PGPONZFRW#$H9%Z_\A&V]K%0NK
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MEK2)E7Q/&[M7%QY%]M A=<3@KG466 'H9#RF7'#NE:V^(X#.^H8T*Q78O\K
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MLW-XGX:L?M8M)&\39KE1QI2?Q6H@^%N64$*D48C*_J:".0Q5 L$"'5//_4U
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M[#Y2CH"XPS='2:7?04!3A&(6W=53?>NX;O!8XV9,)]8"B!4IJ+!S]KYC5M9
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M'(JAPM\=0V8_8_.FZME_-J13&4W6Z\=$2F!L&S&6NE/DPE=;WH3%C.\E.T_
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MA7.UFW58QXG'>%M@<U FF0K0F:R'XKTD+:(:).&1ND+D&$G,>^?SQ ._R8;
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M;8!%V@]N66P,V0:E,=)8;MXQIE3#.3#X'3R0TO4'\_: R]+&D//#A=N;L-E
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M2S%2^UP^GVL'9&$O $(;1GQ06A64UVO)@)]>I9YO'6V@B2RUX+N1:7/B!D+
M\$]?E=?#%)V[91B<-="3I]7@- C%.H!"\85CI80O$2I-.N_W8'S(^9(YQ,41
M@T/%&((KI%S)O0EN=:(3J%=&]Q]Y#];M'",)"95X3&(UH#KP='=^=%M"AN?1
MXA(,J^LM1L-Z</%=BG/4#;*_D*5=0H]^@*1OT^X^BM"7LA?M:D\GK$NY6Y_R
M"6GQ_5CHHB7I9'[AU9RFO+SB]=#YJ=@,95YWE=;.IY@\)X\1-W8-MYI@91^]
M33B(Z]"EZG243Z_*7J))Q*@#8[2.:5*<T]1B=]2NW2KCIIXS6Y6)2*0B@9DX
MGG3C(/:RX'&@RK$>*'L^M9P7_GCJJT[\QL[?H1A5;_2P^I>4^5K2CD%,/P\.
M(6NAH-^!<2(#+HRU]/T-Z'FC%2#J7 _"NPABF((;H!:9;G9F_!V$-QW;V+V^
M:$; ;JMT5P?*93J<V(.=X_ZKI?!<&PC/0A_T:UFGP_&R1R ^YGHBCP]R?N.G
MUY1,'H,R&"1AS!SG<2SK6]'%MN1?UO5 35,LUU#$'1,>WHQ95]=<OCO^.G-H
M9AX];AE5$-6'46/+)_P8_BY9JZK&+DMGCO\89U[(GUT99E[$!*H&_I:I^-?[
M^%G%XLRKY\--[=%2W4\2HA149,,$3WG:68J9%@F9Z#TN+[G68T>4-%'XH&B=
MGV+WJLS^Y<= L^9<F[X%Q7N7<+?\CG^A^2LJ-ZW_<K5T&+'\.#YR+S!GB2?-
MLD9%9"%C8<C")Y_Y&:;F\]&H0QDWMY8]JDK==C,[C]WH.%;[Y>II0J[4RJ,H
MP@):I"#3+IR2&?CQX[J[!,IX4L*^04+;ONNQM=0$<79%+V-A@%CVQ#[!28DE
M2%-<E$^_:OA9>=+Z\G-^OG0DJ:GFR5:BYCCYSYD_)-9^-@WD2#E? $HS?NP>
M-6/>.M-_JNR1!O<" T4J'L!N#]OPL?9@[(E]PN4+38,IW47G@(S.:!UF)42:
MQ],S8-A#T(L(UJY\QPBO>]_?]4$)-Q">:J3>042CI_SM=1+7UK'Z3.4@$8RT
MD%FWZ&WH@,'9D(?Y^]QQ R[$ZXV1 S+6FG:BH9 ;0'JA!%MJQ]X/3;X]A(F#
MDJ^2X;*$?TOX>=X%7 WMNYQU,H(8_=HCEN,L:>UX^&3#NN#%*ESCC'S^SR=1
MJ"E[3B\(7]L$WTVT3Z&>&AB#?HO=TA)KOUYCD(SO:6\@L\Z*8!8I'2>)#0+^
MJ^! [CL/YNP4/T6+:%1#7'FA]M+W+M_TPPLZ$A)OK4"=KB!( <]&,5%)>O<1
M)[ABQ=C3@-ESJM1 "&A)W_Y>PX GN59RT6]W213$CBXF@P[ZRUO%KQNH%KO.
MK*PS:OROZ6$FOH%"175A1UI\,Z_/E2Y@/!0_/7H2)JAZ1DSEB-(I<*-JO-N^
MS,[RD$><[W"%==C58NLVZQLC6XH]9+?WOP;RO9\Y+FSX.U4HY2S8-53:/K(@
MJCSX^NJ?5ZX-H3FE4Q;:YF\FS^0T<446F>K/M'PI*,"2T1L?(X4U'J*>XW5%
MDN@TF64/'>$9KL$0]RK@SI79<?*?"L'Y6H5XAE1!'Q;>@W%.R]HUH.%\BNV+
M,.?GXBF%^S&#*QK%,DL6[9B5G8@YX#LGP!.?FN3US@KNEAI)PY.WC>KXV-=8
M\/@]F/1<#TX:YSOC[3"H]0R'V28\=W8>S$<)DPE=ZC+&S'XWR_&&7R<R#LNO
M9(C@.NY@E1D[M'3Q%$"T2_:W%@C-*+3LD14<YFJ &IWY,W/IFH7RG%B N+;Z
MY/7*5&%1H7P\5I@YPD1*+QF=JQ]1X9JS%%1#-4*"F*K.-\;9<B,CUUD\@0HF
M4L@%:ST6<R[F@ZPB$)W7.8/FX '9LB=WP:@.#R6]B5[$Y$#'6^XU,(C>KS3;
M9UY7)"3J!J0N(_&\L^Y_C92-Y32TLB\:5@2KNU7U6N=(VW_\^8\C4=*.CA)+
M*JU3GQKLM/6]7GLN>T7YNEI6MM*N!\7/Z:\EIISK@\N\[N"@5=W$TJE]LI%9
MFH_M+Z_-"N3V6\ZF95EKF\%WKO"ZT#)&IV*F]V!  \6$,6-F!<SA*;X[U_QT
M$*(;-%&LP3!7F347/ZLWXCU$%<#JI%P;9HT:R:VVZ-!W%3<40FD'H$Y5>"=!
M,-#@@CI6/:*R;?EM!AYZL2/$?03*LP_M_($A=>+J/? E&$(ONL&LBY;B(;I;
M6PSUE4SY;1,[V/Z<\/=0L#=@Q97WQNW!^&6JBRZ#*87:T8<<WF9TB$=B1Z Y
MAU;<2=_&3S%I (E[:@#]'LKD'81R=A2@ D9NQFMLP C.&RV%:>!Z0M',%+0@
MU@Y$MZ\2ID09O-Q\K/;V0YU\V5;@IRY?"M=1=2;AQ7R&Z(S0)342\5I(I7$G
MQHPGD,5"ITKW/J?H Z1Y>;RS:QZ+U#YP&/JN/) \A4X*/0PY[PMFJB%XE,"$
M\T.-$[\/;]0X]^0[#CS]4;VIK*S.[A<8]S=U1[A/U&A)M-;;W ZROU*5?$NP
MI;1BX<\S%U9Z):PE747HCABNH:]%@I&N^3737YRPJTLT__VH4(&X\Y>URQ\*
M?;EM;LVFEP.%1A<"%%W,KY9G9=K%_/2=+,<N1NP<Y(TY^[Y9SN0JC\A#'=H-
M6-MRWCC(M1DJ;AVA"O3N*,EW?MF#W3_6\$3K%&AQ+81UAR?L#Z_K!Q9"IS>A
M_TR]:DGN<3;N1 *6&;+<*[P.,((.CRTZ 31U#1QUQW5HDP>.8)[/]5+=>_%<
M%$"WLE+F#(VMK4\X94]Z0/G=Q<.4H.I;26'J25,WD=[FI-G9#XSMD/DM[JF>
M/5@7#LZ58*FB&.HI7&]@PG24>H)K""V"O%].@'></$#K1J:K$YMBJQL&XEH<
MG"7T./'^B&3N<4^6N_/UT37FH+J!FV"^>SJU1;9.,V9UY[>8&3T:VXH9 +\V
M03V R9H?E;T*G2$TF'7VFSF <PD&X47J@!PM_0$4P=0-<W,_^+D'=]P__T%#
MHS,G5R<-)UM2XJ\<<680?8L<Y\*J/Z%%M^VYIS3_R.'1J!QZU4'.7?>>LD6Y
M=$WDE3(!ZM!4CIZCAW2VYSZRABLV(T_V.!4&VWU4=LTYXZ1<Y"=P);CRU;D%
M-9<*PX*LX,>1'WHN!_R\/I<M"]L_XB-X8]NS!!;B./8&=+P$PM$18C_V8%X?
M8E1\\Q%=R$,^5.$Q,CQNCNP"Q8)%*W+ 0&(0%\<,T.\B"&FQK;!7681$HXMC
MO N8)NN1, 0<\\K'RC A3Z<":[QO/9PW-N54OV-*ZGROV;H'.X[U&#;2PVC,
MX_ ,T!3/$-O--E#8@XEHJHLO;<O3;_V6/_L)$\*I@B*(JP@X-JIRH+4[YNC8
M7T X0;O,>[YIU Z^=/-G2,=T6NE/TZ-#?8*OU& ?/L-8"Y(H:[Z/U^Q^OW#R
MTB64H6[O39'+'P8R$EE??SA661\_7.)^;:S,K_;,QW+9ME</*G4=XF]K'1G@
MOTZL+Z_07K:NT9NA??GS5IF$JZ-[SHJ#W>,L<E%C#)O<1 ^?,I\DM:/C$8 U
M/-'9-3T%QUJ/V](+>MJ@2/-#GM[GB2@F+LE($* 2@'HF*@4K"D30"7S$X8:@
MYZO!\W-X;UO0.8[BPM(_P)@FG5[F\8."C52]'%6*BV$9F42+::>]:V(? .SG
M<6P=8,X!(#>U]Z.9\#BN3C'VW,2FY3J?!S3;UZN]OW9:""&_667P)>12B<:<
M=M&32%%;.Y$#(BP&L7*L]<2Z6[=7>9<'/S?+$A[CT%<B[[,."V<]/RUUV/OP
M&<'%MX?^DKQTR517_D+HX87T&\MC?VZLA(R_!['>!:PQS+VRV%!_2W[-5TH?
M+U7$=MEU=?H1E-(6G3+#GF2E1?5-]U1FF38\_F3(7W&]>MC:^L/HCD6_*]L%
M;=+@E'2!S(ND'-G7^B!45KF"/$Q2IWD%'>$B@ $Z.@E1=[0&Y.O()W:KPGNK
M0'4FH@,GA:'90:P=&W[V^GKHY.;Q]1-^N:X!Z145T7E,=)=7:Q%.>*I#.XUX
M;@]F+*+_=_=,BH9!^J=)M?[S@7(99Q9),N;+1>=[KRX:-5^=7Y2)]&Y"^;G^
MTGBX*%80[:KEKCO4>;WZ$EBL-&3N]*;*Z3$G*[N@T*$LXB*[3\S'KDP@BO$H
MN/,SA64[L"H25SCM]"TE>>2/AFCQY;;I9I-3SAF<5[73P<$1@;;9KO5VL8$B
M+4/-)C2->K;B;FFS?>1.6_6/_,V;-Z,((S^7]V 36V6ODXLL<+^^XRN+3;26
MQC0G/M1H*A>VJ2*X!PE[L-].V9K8O;M=EWI>HLHF[C?2V$Y=.BE\/7PS(C*I
ME?//A;ROF>BGV,D#,)4N!<G/$6>"US]'.5<M.^W!'KQM2GU^^HYJKNHOX0]2
M2X8T:<:&D.)ZH-&0.C?R^C]V9FKT[(X?&A_8J:*ODC>>PN;OGSAZM;T=!H,'
ME1W41?]?V@*K/!ME/A7(%%=4"7KU,"RX*";L[L)_KAAY9?F?710\=(<E-A^Y
MV$TZK9[!O3N//(0],TH)QXJ50WZ_7,;Q&0:*#']<(Z;$FC*JJO+P(?G-]^9\
M_RAEE_N9SL+MP]G'6I^^>+P?PH.F@MKG&LW:$8=BAA#PAHR34%0G5;L9M,[-
M5T^N87M.:+I[=E 5Q[@R3$-]6W^I;_74QECGH=I:E:#J"QGL7+AX#RQY0RZ7
MR8@GIFQ3RDS#%#H=/3U2Q_@\Q)1M<FZ9?+3A-"PY5%B+B617=%:7A%D$"DMG
ME]G:?Z\L'RW,]FIPR"YMZ_U1TTP5B^88/:S;3<1Z>3/7)3$EG33QS8QX(U6
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M(]MXK.$QYWC%<9N\^C"&1-\ XF*A0<VOD2I)4YLW"_T>@3E?"4K!(156VNP
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M3-^?:LMH?D-2A:Z";C>@OGD,U[/,MVG[2'=>$L5K/N,4QMD%@W #\M(H?,P
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M^/MQ&4:_P[[HL?:+HLOC;43$@$$PEX;VV+S.LJQKN3/B5GR7\-*T,V27^7[
M>N, F)&!]$;&TD2PN&*N%9B7L#C*]684S"5$)N KC4G^3I=OS7#/@N%DU@#L
M4^B.Y=\/U9#OL,Y,57O']\]]#-)NG?:7<5178=P8P>=Q5';SB:,4L\J^>7]Z
M-+-W5&Z"**L*7MUYF$_H449G1$S;DL_E@E^Q#G7UX(4DV$VWSBF!%R66<G4[
ML^@3RZ0AV?,KU43DUI>[W):81_ONKK4?[L)9O&W\/I6LG7J2ZWG=H$'CC)7N
M&P6%FI)C'ZPOI7SW^':_-G=B?&*TQT'1,G_CSM>"@,;-(-.I1K9VS!TX=!&W
M%JA6JX9ZAO57"5EN^8P_FA<&%C +?\270FZNT(N_N.[O >O8U[-0_B)JD"O&
MUT43]*'JU@'?7QXA%Y:W^:V?U-ZR_R-:OHM6AUJ;8:GJ=&^CDK@2N(HOT"^F
M?'=0,E4A#D/KXM "P8&>.3[B4ZK<2IVE_QNZ:JGT>GR)Y?'H*_TU&S/GK"8B
M#6OB/UPAM-$8TB-[L-;@/5BT\1ZL:V@/=FR<L#N=L;."X%VL?$(-<0JN,A@X
MN7+]Z[OOV66G+>RLS#^NW!Y^W/:C]"LI?-JV\^Y93$^<@[15>5YW0\/4N+EJ
MN+G+^?D!<5[7?S6^RI 'LV<O08%%OZ$2$6(-N+2B2_6C!F9,J="9$*9V+)".
M>J874Q5!5-UVD[G$52Y:[-RBGDF[-Z3>M6C7W!!MH=5LH!.'FR]$OLM[]K&?
M\6]19DZ</5?A?:SK&$^7ZS1!N7:8<$@]S)(4!TZO1O8FK:^SJ[DR7C4K5(F&
MNG>YX\-[L(X(S\Y\BO/V'Y8!Z#("D.:[!YMYOP>C_K4'8^XC.<X?Q6/W[F[R
M[<%$K8N"7PVE%EMJ=/6(J1#%%$U<%$SD)/MROS8PQ//K4^\1KJ0Z/+AE<#YH
MZ]3FNAANA;W[8[SYG^Z_<!V&M/L9QS&QG4;G!HUD5EI"($6LE-%+1A<4RRH'
M9,DU7)V1]8TY?(PRV/2,UMB;0/'>5T>'7.<H'A*@>N(&&V4_<K[I[7&5C#+?
MQZX<:<2:[XX^QM,*$,]CD 2A+/H@]@IP-!:H[XB01G2AI'U=T_/FX2>PQL-4
M)5^>;('=R*:_Y>[UJ2#I)4Y39'M;RY^K4U?? ]])<I_3GH3XRL_0_J_/;7)S
M0J,RO^I/IM_%:3^KUF:33I1+Z]5K[\U7OCXL\#7Y(QTN)($93G4EOW(L2E^.
M1+M%3$Q\]GCTXW.WCKZ&]J#PXUYY/Z5XDX$91TG;G^E'=#ZA';D#^W8]7OQ_
M#@7G7<R 3!OV8#^^XN9L<*#6XK33]H?&N?"MH/Y"P[P_JMO@.K\DQG :__KA
M=_5*GO<^T$@W_O=$S;CG77%;@<CU-T@H'_8+=SG:^1>2:R5[;YOT'0?E;_RO
M$31Q_PW:V'U;?_V_VS_XN_4!.Q0L< 4GG/R_Q] ZAPFY:=/QXIO*97S8D<?P
MK8,_-58B(_;'6F^",GXWNA?2?N@0B1RZ'8%74_L]JG_P=U-'W1,AGX-'O:4^
M&,(7)MV6<[4[#%HQ6Q<?K17_*?NRS_M5!)OM_/20T6Y(%G<G*O34@5,GY1K\
M!2VJI 45#O'-!?^(#.G0_5[^.AG&,/A?U1!4= 2]SWQO6?^?;VU@,=B8(72]
M,[N N9ZBU]1%FD1RY@#:6G\)IIX><WJ8&S9/DN!]EI6 AO.;$BD*>>&1SHFA
M[B$V$YK19N9-[X=^[,'JUS>:/5_:^9C,Y'29.O,-[L'NH":M=SCG=K.-3O/Z
M(YNZ='E**QZ':>"/JC?0-N($XM@UD@?$ZG&=2ZW]CJ?3@F@9-Y*'W?V8BN?=
M\IY>\+B#*9$DU5WK.'Q'^.L!0A=+'ERV2/EN"3].T#:H@XD),F(X7Y4:V>_J
MSURX^4/D@:U@4=O#+<TN+YN_=\NEBXXX%+N&E.0N.(!A*XQ+7SZ)"Q3>OO]H
M [0NU)-*/W>E2NE'>?+M=P7-?[^]A6$J,DNDDRF^S+N*!B9F\-F^(NV$KZVS
MJA<*S+6KL2] /,<5E[R]Q9:H^<"$&C T'\2DT03G@;_4QD4:2O"U!\3;X8DJ
MENG4F55/#4AD"+7Z -W' T?<XW=JVH6QDR"-QU\6!CHS<TO +#I"M,%=OB>\
M:<H&^)[#S."#6NT!Z[R_$$\C4>T#8E/^X46'P<6G6..HBIE;/M+.R12E *ZY
M+_'6/Q)3:N1R?U>CJD><N?-8T]UJVD,TODAUMUP>"L*50KAVPL&L+II8 /9L
M%(!V!L,6N]O0MW<;N-> A%6Z/:;$=;0V:$T3#3ES*FJL$+%VI]\$E9''0T??
M#K+\I2CK702R6>\^.13%ZE=">3UOYZ#ZZ\U0R6L,G>,S0I6&"DR1]91P7./<
MV@XP0)<.2L=>^\MO7 -:=1[CR;A^8.Z>V(.YY"HGE;:-&I@3I\WG\056>>QW
M7^L3WP9FMB]BSJA))XADRVDAJZ.DQ1YOZV(-!;Y$9N]FY]P4NFJ;77BK4ZQ9
M42FY-4WGFS/I>7Y(53QIW<%_EBC5I&2W8*70K!^B\V",_42N+SRF 3/",1H-
MI(K']!6=AC1 A 44#9IQ]-SXC42@/ALHVKL&XG.H(S!V)^A(&4Q4#^ZX9D 0
M?;RW@Z<-C%>%O:/3\S?3YN+(QQHF-PIMB]_E!!JA #Q7E(])?$K..,TU U!L
M"8!&)XCPY#Z 9L833G1.('F8QP]%M1.D#.#SR&.85CI:*$9Z*>;2B#-]NR<^
M:EY5M*OE*.E)U:R,$V<+_1:D%E04_/U#%8ON03?RL0LK4A)&J=*3$*$+5Z_>
MVZ\\3TP-=4/B996&_H+Z=JXO1:KW#IQV@TK:=:2=RH0^(>!AR(1M]4[D.V-1
M"$^O]Z>=U))1Y;*#+!N?JZ'F!]C-X"$Z07J@:^XT;S!?OAL1[Z$#(M;B&>II
M2.%[D%DM9-F.%FH@B&/AN_N,@8DZO)P;KAQ6!H6X#%(O+!>) APB4_=NGG-C
M,V7$0(YU5K;50-D^MC,X7"#ABN3M"96X%9L*J>$<Z5L41T=G491&X1$7F[R&
M3D^_>S%-@F+F(T1VW:D9Q8^/*BQ>43S<G5X7WM:6L]@8\64JEN8LF[PIK2Z1
MU/WXX>?*0LMC3I PKD-V<[HMBAZ\A&X8^Q1S$( 56$.^Q9CI3ED5T"R)HL-P
MVX--IN_!./=: *_N;[+(>N"^GFQ6\8HS3WLH: -]^ N490,>61AK2M)JG=%]
M8A== DYP#D)1.Q90$^-[,<AR!9&),3)<#>@XB2L#]-*M^-S ('HI^A2&MJ-O
M!O9VN5MVQ1P#9?&XJC2WSGSM/(89$%["H<&[?;:RW)_LP7RFT=DM"*Z8*.?/
M<:[OSI7RXF@O(7QZ&&YRCDX3XYZOPLK%=HQ+D^)YAGY4#?(H]8+/?]"G"8D]
M YU3-X"'.M*< @G\OPF-H5]]>/)-8_OQ_);!3@>M$=Z+B\,).;?/RD+D ,"?
M24OEHG:N0LH=,6H0"2AQ!;=B25@CW ,:7O825  B6<Z)7*^*KXTY)5PC*V/[
MA'$XOUI&%;3:HR.+ $K%G75^K;H6YA$3/^K^$K7.5:)ZY0WWSBLX8M1<LVDA
M!EXW#"Q?+=NG-C=7](14'/OP,T3?U/&45YJ*$XK?.5U"R.6ZHQU)()F,\FE;
M?7_=U\Q=Y'MF9,TZ<=F*Q!6ELTSRXKA7_UJ>(W<Y42\"G_9@1S>5T8GK0(Z:
M@?UN_;]I(ON[]("-ZSKIUL\T'6*-:Q$.0,3K$P9:6MUM8XU)+-0)J^C*[BK?
MEE>Y2?.9^\1*FN);L<0[UP"BV9<9J],T\2]+?+9C-4:G,0-VE.9Q@ZL[!EBO
MW4+6N-PX)0!4[F[Y3M(F>X)6!EZU6C]>-W*V>2_?+$>>*"Q?TFG,'7Q"3*7-
MO]Z#-<:D@'!6&CX6T3Y[91A['-'39Z5,OX+5?4^9,$ "6^VNZ.<XACMO> CC
M37<*@:9MAK&.7B0_VLD?:UQ3 "/1G7_A/S[4(_F6;1?G41M\'>@,G$2H^N0>
MC"<0 E9U($XB&158QWE2ZF4/K!S(A$0=AKC*3$-]*T@,J/,&X7B#(^6W/P34
M8OP[)C3\\SEU9=#!6VL4M'9*Y9?E'UH5/QY4*]NS!,NS&GUS*ARKGL;#/2T/
MN99Z>";2!\L7[,A\ H]+7&L$<HJ5*BK]0DHL/#[6N_84H5(*+ \D^6FN:*GY
MVMS.?OV-]7=IX=J4G:UODZ_E_>BS$3LPXS P=X+Y#2D2$.!)'M94O2+#;X"0
MS#]4$O.1>G'WI?CW:9L,FT2W7'Q7/>;UK.930\I)[13!(3.=HB+56ER'TH]:
M=:/34!Z=)A%Z!-R7O_BY^MZG% EX(E:"N805BE;OF(LSTH<TF/Q<,R($9\*?
M4^ZJQ%P>YC[1KF,D:B+%?;<\),="0>_0J7'"F]DW_\RBIN=8ET&)5.XIG/\Z
MS 0@TF5U0>I+(F]2<4?+K=>[8F4_3L.!'28ZCB?R%1(KRZ+7KU UP7T_M\O-
M'WOMAH:JS( ^"-F1R+O0PAO-^&RP3[N.G-Q]P[W+U!_ 4R^ZT?#C/#WH*BOH
M$/9WZ ;O*)[NH0# ,\C(+R0'J,R;"1?R"\]XP[5Z;CF0-*Q6P% 7]?NYQ),9
MG9SKC)$=4<?:EMSVR$RW[WGO@3'6;A^VY%?*"JFQ#1DB7;<G6H?ZV<6&U%AK
MG4?SJWNY'?U'P=/C1+F\P,JGJ@6UY*I-\S>_=%>MM1#-%PJPZ=;F4Q]]M=23
MM O\US..X#K4-W '?2*#\*%!21QMCC9"FG8_**5>2(/13<1[YM"\]F!P]V7I
M 7SU!EO'WLW]W%SO5'E9I9^K+?E!1J>-NU:)C).QZJ?9X;EWWEW309/'&?BU
M&2^0T&&/(3(B??*-H;PN]-%J+!K(8Q*>&2 O$HET8)6YU2GD[Y8O$]29OY5
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M@Y;(QRX'VAR 1I"\((L[C7R?T\$IO6G,;?1W[J0__4>I-_WUTV43.D+G]3_
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M MG&%_I7FV(_6MQPG"2^!&]'H;8_L*T_Y PM-Q&UN:,CA)?*#-F;P<9=5-D
M.5T [69(Q#NT)>@9S2[6>H16]C5B&D06_I #QBQR=]#Z^W_76\[=.,Y5E<4W
MG^$?VQK[>6MVJ:9Y_YSW PW^=,1'C.VP>: C] ^B>!EZR$T!&&_D>QMF?!#W
M_A(H%+7FJ8^\HQYG&+!VPN26)+<A17XV>^%^I+2%[])5O^+1_A.#*[K0E;?
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MAJW5"-"Y? MV5+V'!P1D%3?0/*%-9"+[;\0/\V%7R&9X+@W&,F)_/C ^I1_
MFPA,IJNN13JU8?,X<XQWJ96D>N#^]Z=0A58F!CI>;D,,JKUWV4[:*.D'0$:?
MN/IO<"*Z'>]CH\;L,]M)2M+(D= \3T=80K;P3T?EKMR[HS,D(=!1XR_L39)E
M3JG"I:,S_&SZFAI(ER&DW(@I<<6E0TS4W9C.K3DWHQ-7[?!(NQ'=.:M@3<MN
MV[NE5JEWGY2$;("Q0^@J/(A7<5][6+_%Z-]VA*1@B]'?VH H'<_2L 3I%=-)
M7#<<?K*'Y),%#<TLK2R;D>I;<(H)78[%R! @B7.2><R"L[([PN6X%Y^2>JLV
M:8-I-L D;CK*0+9#O5I>NA\OD^]()5]C#]>/5%7>5/;2'&''BVV^7;J^Y=&Q
MC^<6%JY$2Z:V2(X5)6_NES?#NB82XL5OH!0ZD5W](HY)^<X<+P$:AX!J5CXV
M XZ2*+-[Q)@?),CE.$)CZ?M*.59>J.<?@'AY*5*N*M</9Z"QML1FEBU29%V6
MLY7X)Z8DV]'<V3K](818R=XI7>;7#/+HAP3(C/""FJ2YW^K9O$BH"30D<)\O
MT^?<Z]TQITBSBV]]>\\-EMF9&U%>'XV'!8TL9)97WWG#?+:_.J&O7ZN;R)6#
MQ+FT66B L9*NNC"ZBAG=]AAW]5X3(:^;_&:0T16J3X)F9I5%CZY8:N%+?UN&
MG)1EO%-(4Z8Q/IS//C\ '([^=UG<?Y9R@*IVPT\E%$Y"9NF,5'0UY%[,9'28
M"/51L'RI>X4!IZ;4*< +3[J*WP7@1BP)0(@_G]<IJP#C%M0":(BE\I%3+-2A
M4%WVO!;)44T<X2,/1&;/98_&*(8_X!Y'-Q'.K08:\!_Q:;B9P2IR'-AKK6M,
MT MRU/WLK%P3H;?/=S!O)Z=FZ&'/$*60^>, EW?"1+BV-QN8_(,R!.2,=.$)
MM(O\,G3_%] 3$F 3[JLN<EA:<H=$W.V-A%Y#BAJ<(MV1@9/WT.U"XT4PEMZ9
MM@DY^(QJYH8N;*\A=9 :179P2!9W,KH=^EY;Q7?%\VJX=B;$* BOISE!&Z!0
MW3_ >C!*D$6VYD[B>$%.R5PGY%0P5)=>>?S8/2LO23>Y7>AW\^JFI@?T['@C
M$[/5V9"0-4*J:!8\\\D])$,8H#DZ]TG.VOGP 9",H\\#Y43<I7^'Y7VM:D;>
MCF$9PYI-W 21^VF=(3S,!;5'I+!!+4BG>44GRNN#6_S 7.XX9#G/ 1 '=KLS
MW-E[ZS\]" 7$OYG_?D+0%R[YR:&HZ"DE$^C065]L/!(/*246\5J>ZUCH0S;T
M,$,E)A4(XW"WM(!J=CBAFSYQ-FH9"S:LNF?0%[29#69P3AJ Y[SW._7OLVX!
M^RB=\U5Z>8/ @TNO7RHXAWD!#;]RW-2L7+HSS87M.3JQ)YH=BYDA0:,S:,A1
M;9A7.!YYN*Y82V)=_W:X>!5B"U%"D"W:YJ0K$M>>++[&^FDI((Z#-YR'HM+&
ML>$T9)<9'B5JZ:@#4Q\$UZ'V@&8XGS:5LQV)@"PU_OV.!C?L327^36F ,S:3
M[2\Q$>Q ]2P/:R0%*M\!<?/*P&P)DBR#/5>TH_-*ID/9'1I]2T.8QG=!,K<*
M>PG^.,2O+C:>YJ?11]+9)T2I CYP(#N=69W0A]O<7[QB58@8BB,:<W:8=2E<
MGA/@!JW <="1 /@H(69$@D1D:Q0 JM-<3QC(%0:H!*2OKK+^?X:Q:3 INX9E
M]?7R'^3D2/,M>ZMB)0>O+ZW?F[EG _U5,)<=0Y[$=437&/\&5.<?,B>*YG#F
M(47W8LAU!XJ33MU O#2T/&U<$.-M5CTYS]-P.,(M$+9/S_^8BBS9<WW, J)A
M/%)K6(K)R35C'Q;%P09<42IY+=%!&Y]"P^@\>::'#9*G_C!VZ(^"RH>YH@!(
MEZN0?*S*3PW\Y7O0Y$.1T^X*&<G ;L%[0!V5=YPUF;/0F#.Z1"N+M@SZRZG$
M'<F AO5'$'\5SS[Z\J4Q62VU2A*RG[JV=/ZS?W[_O6[ZI#T.-B1M-6;]:CK6
M17XP9MJ>+?0#+/</27RJO8E@N:B*&/'^4#R=,GER>(\.=6OE(YRZ/D'V+1M
M;&4(VUV$4W18K'"O@DQA/OW);R$C >OPQ&YUQS!E50#V2A1 S^.L8W(&R3V.
M/W_B^6X0>+$?W \:O)0U<NS.R8H?<U>".3\/F@CEQQ)_;@)1_[U&2S6.OI/=
MI!Z<T+!$)C45)0U^C$S[0C_O,VV0O *]$SO4B@[2+P;P,YB60#0N[RBXS,K
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M5EG244<0F[!D_R*U:!I[:TM<K?6"T1D=U93YZQF'EWPZ\F&\?+CC/\;B\=A
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M2%XC-EUQG&(M=@P\,W1[>.U?U?YO_-"A6'+=G_2'_";=.*SY,:GO0YQA)=!
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MS&_R'JS:3QI..8W?@/<>ETR.CQ+RD-M:,P3O55>J0AI)>9XRGA@P2IU[JE-
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M=]$]O"  -U#S03,9NY&,K:!$Q)NMY/WFJT@H7BT3OH=]@I3;KM^X"'S1#<*
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M9C]+\^_<U*;(;GWQ2UUFZ\)M=#M!2>?TO+XD=GWABL?\X9;Y[4R6N>^EI;X
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MD1\6%)7=D)U$QH[NM81P4GHIIP;4OS<YE0P@?J/>)6HRTR9;U]SFN3-57S(
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M[KEX(^RPZU"7A>/,)8I9R,_2_J.R_V^%G?C_5=E_%?9_U]4+6!H:$)MG: .
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MN0NUTOI$N"FZ1PX9-K1G$,N-J3=#22:OZD_+NU0A*D<$Y#J)(^3F!OPO=PL
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MX^R+*$:8TD+'.6<LQE$!67V'R ,VZT*'J\EPO\8,W+^S@HX'SP.V+F(6,9U
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M,FR^EB,(%<Z6KL9RX!NMUNU J!=Z*'LF@YG7J\^CXFY5/&-<N"HV'J)LII?
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M"11BN8/TFWH]D2VE3#[^(PYO^#K!R^!AN8"^S@RS#P?62O/,><'\T89SFTC
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M570UU1TGQ0D=6BAEHQ)WBO@_PY=1_']02P,$%     @ 68%>6W-[D'^$"@
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MW[82>*X$XG 6_&6<83BU_"S%VV(]SR([=/DE^V!RDD24^=7]$YCJS$6*JZM
MZ?7L$9T45-A9POFR9><2!:QK/# \Z<[25M195C[5DB0D=Q29$P\^. G.GE%3
M#:I^I9H$X"@VWVZ"MP>7 35,E'V;A+YXWFM[YU06:RX@THQN(-;B:ECRP$KW
MQ12^LR!YB(\?@B0N2@UK&BH0-ADKDT.Y=(E,0:(R%_XP.A<D\[D5+H+)K3OU
M^<U:/\[R==CE6SK5[4)PM&*^Z%YW6Z. -%EJ".G61JJ3$]H,D2-J-D38#&II
M;DC*T<12D;?*M4JM<K/8]D(X&?0.B:JZ\B+-A@9B^DM'/G!Q5)_?G$WH=O V
MF,3/O)\:MD.GSX?)A45.!ZIZ.6O(V] Z<V&Y(2_B<$VWAI2CTOUEF.W7DL3J
MO;&6E5I2+8XAJL;%FBOUM Q&)F1P+$Z&!J$94GB6$N+&"&I>&)C/>;YP$I\M
MFRL!8.T]E&BWZ^S12 =K8B@2-W>@H:4)ZYU"5,0L690$W!M;7>@JU#RLW91H
M>C'5A-"\L09RVD=$HI&[<,#D*9O=K<B"77:[%.0JU_P >*X4\\S Y@4;%'UI
M$1#1G@/E\;#T743%K&[7 U:N\2&0DA'M%3?V@ H\I:,BJ?#:X/K-&M>E<!/$
M'6R>Y>F:[ME4&U>2EYX1';\B4\L3JK5RX0 ^7+4^"PH#E)_0K5W%1VG4R3H6
M1&:S8\T22W%9<D#\KF8<XLUXZ<F"_U5C+K^R*/V)%;G1<%(\G:0['".Q^U:L
M&#U05@OHMQ,Y5KU+?M#FQR'G9^Q&GT]#XK@Q^PL\;""F9#*ZK(9BK;P:BU_J
M('0?D>'D/(K=.=U;0>>JK@UN,*JI!L.Z4"0*4+:*-Q=2-P8^92OA0:'RH@(=
M=ZZEV9\9(RE#E+*5U2D)*4FT\*@4S?[@)RG#QOJ7>HG$_')B%%4? :+,/SF:
M_<%/4H8H)2Z%U_)QIZ TV1ZYC_*BE.F+I9G57ZJ3>L'$1:[<)^(@3<0F>GW*
MYY&0'DX/JKSA\XB$O&@[[M1KHF8N-*8&5Z/49+I7:1Y./1$_(>PV/CMQ9 Q^
M<N/9:1+%P9R$N/ I$N\+FJHR!>]IM8R^5K9-2'L;4J,^X)M+:A.8E<?97NAP
MT!>8M:3;7#@3+F\QJ\&* JP,Q1[Y.U("E.I8U>X6*:Z]%9+I321&+"BTNI7B
M/I]1N=$G\DY?GX_^[!Y;R%JBXJ76$DJFS!*,R2-K49.]Q0(7:3F:_4%54H82
M-2[UB@X]%]@- Y_^:9-"-! 73&7R?=IFJLM6INBEJ7M5=Z5&&F )6ST^N+VU
M9\1)/#*<'--Q'==+F$-[2^PDY&6ETN8UQ$FW.NR^0W;U='U#BV8JX1GLD5U%
M0*?QY+?K^UU-D_+KN^:5=F9=8G_M4OG$@4^696J9Q-12@.1',[<YE[^7I2H@
M&9W71>?*M=D6D@RB,>&U@YV[X-KZ3&!1TZ5B=(>N#:BV3"7:A79VVZ[1V?A*
M+]VM8%Y22(\PJ)H46AQDHG2&_IBM=ZPW-4]YJIM&@-X&!&\F'0W56WW J!C)
M]2W<KT*9?%_#5< K0E$G@LI2UU;,/,\%ZAS4X:#'EP*U!(Z5OLE[@:U/([1R
M4/7$C+HNK6%MDJ1<8W/T"S]($9%>W/M9KGC5YWQ<6.EA7U3:J^([']H,;?5-
M(0!YR[D5+52AR-!I$,470;CB-MMU'+.>!M.LCIO'1^9!E^K78J.P"R.>Y7>D
M/5V^@TD75T7E.L559A>*8-RSEPTFHR FO J:M^ ]4RAW_!W214AH[+5"W^WB
MDO3UR" F<^A["&!L 9B4MJ%;A+[MP,PA'FA1'18$TH$5#R?L7NH87UBUJ#])
M)]ZYQXW-AS=1>GX*GG72DOV31?4 QR_NEDW86DZ1G*(9?3*TDP>R3S^EJP(=
MMEI5<4Q!46%1<9;J! VGG3?6G)SQQ;\3%2N0P_-E<OW8=THO!FK19"9KL\X4
MI8\59&BB_,=;(\BC8T\F5N+%O0"?0=#LQ6I%!N:/7K @I+#;NR[Y^%!! B$=
MLTFKDC:O='= +#+98GO*,&6-^U"@*8]M.!M* X\UV<A%\KKVW8[G+,]DN[RT
MC">3N<B(NP8@P,S4.%D%#ZK/V(%.TIH2-P3Q /6DEM(.7IG#^H2E&EF=D=AR
MO:ABSRYX!1A*6#-J8_>MC-\RN0-(I!!;:65UV.!I<P,L@+?Z25,;4GC=7L(K
M$!'XWK&:6+I65^T:97$IC8"V0-7N YM532SML@# O<)FHNM[-FVY&]F%08E>
M;MNDY0[>T=\,)X4C"H0@7#6-W;)6#?*4N &HY<P7CY9\YR;PK=4GQ4M0*!LN
M5>J& V&UJE[RN%6EBA;14F,$/L"E [#1>!<6QO"!JTJK/YI9$1E27Y<)SA(%
ML2070>%@1B)5\AZ6<$T42P<^$;^2]MUS (=,U6"]1J92.J"U!FMH4_D#SIKJ
MX4PDI8"!4RT@X(*$E?1O'.M\;EVX](?3%L!4#&.JSG [/*KDT5A6$&1KE5(^
M?K8H-:<U%.5Q^FJZ*F4"6B60DQW<_,2"H]D-I.,IG8V,N@((]2.8#'[K;4*6
MB#2(!G]MUXRYF5L/M"*E%6]MJEGI*J-P<'>W!#R_G><N;^?%5 ZBVWDU)P>M
MS@ZD[PCJGBEH$-",9\H&.?100#N3 & '*;;4=&ZAKSO*YQD0F'6>/_CUGGK
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MM6!OAV>/"35>3:4EQ8'_F,019_D=BG=71VDKNAVHV+5*)*M$B%9EJ8KJ86?
M'>XJ<(<JI[Q@P!UU!MS1K@)W)'VVJPO<_>U=R!E>G+B>MRK3A()= S'3O9E:
MAPR*<#8)%JER^W7@D\6U%7XF\47B.S@X"HB8G'[0\(GDB&]!B_9C>:*&:TKK
M2)KKH*!P>M+H@VX($FN7L1X@B4^M,%Q0PIPEA!AS#3&C]A3MS%A6TL;O"&:]
MBNCK!I-2%R.WJ?& INY5]TRBU):)9@E6-RXETKK;NMK.4#FA,6&J2:$?3B[<
MR+:\WX@%;3A;,&*VNJN.ADCWYFI  &W3*,44?;$;.L/NGHGW1.CB'L^@H[S:
M;)A;83M1ATK)(UU^DF6(:>3=<V!( W+J)OWEKJ!?2EIF!XL)N2&LS3IA7:$L
M4P<&'-Q[WZ'+"RL239SS%YO^%*7&MQX/.[S.B^7>6'T&UK-==.+$+GJ.I5!V
M&5K?=H76*=W9$?#IV4"LU^:W29 9@M_!&ET!5;H[M[M$L$!O)R=@49X9D/]"
MGHJ?B#N=4:M]_$0_G9)THY9_>4?"^3M4:"7([Q+2,M+.@/^^6^#/LO5[;,5D
M1$(;>TY+D-]AX"NEG0'_WEATLM"*F[XD;]B*$I,LM_U>!83R3NY8 4EINIJ7
M M8(G+%S6^0(DQ1)@]$D5:AKVL,+Q(D60ZPB?TOLP'<0PL<-Q,RZK- @%J6(
M=:ECC2XN7+N#CW10#FT1*G3P*W6XKUN%M#3DC$P(];5+#<L+90$^N?%LX#N4
M 2>QO(U&Z&CWI<'8TKLJS<4_"SRJ!%':/+X6&N5[T&W&[_R2,[2*+.\WMY*R
MH<O+O*PT*ZJ$T=JZ-+;Q6P\ DZ!48*HL.;1FT2L-%"AL=++8T%+.W(I#WQEY
MEH_68!J%13,U-VOG11%^'%B0D@4QF 6_.8&F16;[6YM0)*D;%UJ*A-R\6M"T
MVI /CFEZ2RJ@U]\:Q1*(WBAE+QHF<11;U#WRIS<)A@* \V<N3H+A:"+BB%)2
M Y#/M6CK^0OU^=R(C$+7AD[ZZ(IKL\'PGNAG/>Y("6:<N8=F_A^4^5\>#YW2
M#1X+X%#ALD.B0PP=[O@-C$;,T-6Y:W5 NPL&.#D'E&F7NL$VQK4'/#X-%BGM
MB=5=!U:F_YL)7;RD/XRC@3\BH1LXEV$008>Q,#A\7?B5\)3(-^PV+%+)[#8Y
MJ("<F]R!&]542/2;<S#5#W5:^B2<?;+.M\@?D6PBUS%/N[6Y-P-K<W*IIFZV
M705X!7RA=UFG@>"4=VYC@XE2<Y*K=NAY$$4)<<X2=G,X-;N<P:@008URR^M@
MQ*;5&-@YM6D#!EH*;.N%/&>REYZ<&O.[JY$=*X%L7F_G&^*-][@+8LO;ZCB-
M%,M?K^:" (Y3^+XM[Q=!."%NG(0K[K=,-ZLX?(W>*.&)UAVSM<VO8+=/2[\J
M^Z^1'"@]D*E3W/FF^=3R;>)Y1K;-(MJ[IG*X0.5J57O*TGVD4/WTLI-@H09;
M.W;N9PS=7%%K3F0,[GU8RO969J=M\K=; 6Q$''.- SI!0>!TFSQ'(*Y?-SJM
M<<_UMNYXQ4B&FO@-1&8?NFB$B3?8[2A2U^J0*[?XJ,>P9I<=["U6X'5&7_54
M ]Q<'<5'3.AWG#>6E/,7]F=SS0VMF7(^?_2"!2&W)'RBJXU@4?/X(/2OX61,
M[&#JNU^H:'F4XS2(\"X]0W.GER73=.M3A!C\)6@I2IU?AT;2(?E;T7(  -R/
MUIMC Y_.=7(;6S$G=)7) >&^=!TEM#@:T-UIE5E47 YJI2MSIQH04I2[T?6T
MS%YREE!M":SD[RZ#8P5^![D9+:.7B2$!0VV_.281H>_&.K&<L?Y&P2-C(+,)
M6.UW&RD:=:JEC,Y:;]5F&>),NDOBTZV?1RD?.W,J)E9I*':?"": <C1-GB<I
M(R@I1JQJ69G31IQJGR[C AA&2:)F(XN(/J^J\ UUK[D,TH".34(_\]' =Z>"
M5M(X=2 ;B.G/HAL2IQ/_"OYJ67ELLW-"#JVBBJ])!J5^ *7!.!J%P9-+M?%D
M<1^Q8_-E'=:L6I-+$*"1)6QR3=)"35JBLOXA=$PMF<^M<$&WEBXUNA/7MOSX
MV.:U=5FJ>>"Y-F6OR6SI73*PXH1^O2B08X*DBP1:F$R.IF9*D8HD%4)=ZL/B
M^=["R)82F*MXE8;((()3.NI*)S&=MO&"E1B*J1E@)H#O$NB<GB3>E3N!=N]D
M*!K=9BF#KB1+_(;8PTG61]&F]$/P2TQB.OU$K49N:,$-3F@P?Z2DF7Z<4@=_
M"NY_"(@8+8>F"Y)(8,T%3N!]BSRJ8I6B*FM%/VNV0G#1L,*99WZR?A?0[>4D
M".<70<AK.*,Y'2 LZ>:C2F$@[XTH#(<V?81.""3V2Q]%18#M?1,]E?=8\&-D
MT17UCKYKQ.Q$X$<GB^(W"(=H"H0-GZFISX)R=%A>P#AWOXIT4([.*@A@ADBD
MCLS4]5H$FO2Q&0PVX$=E G0,GHY!8R-[0J:\_EV&Q(J'X3SPG=LX)"3^&$2/
M;FQY50<K@D6O:0QSB>5BN[!<OQH%@%7^-O-<HS&QB?O$\\M)C-.OL):4V5 O
MM$\B)UUH3--HC>71K=\X6%@>W;JG3;>LJ6042_#L;H%3+R:4*N%?>3 #:WHU
MQSK$.^G7.(=Y_!K"('67/I7MXK7KD2@.?)(G94M9Q,VG=@D'D6#0NEGGZV'6
M=Y'E@=@V'=,I-)[$=3YD*._6<J<E>YD.V<I3<+7,#B=7+OTS"L)\!:8.LA_S
M\FE2\U)RJ-U"4DF(C44,8>8O9W=3D=!GKXBNR5U>5_-6*'.<.H,LM>N:OCU5
M+E:F 3I-:6WTG714-T386/JOE7&EFTRVOXDHE]8B-0X;<U+"L J&,5@R MVB
MBB377-Q.&;#C:4A(EL#LACP'4KI0B.C9'5SOA&*2N L#?UBZ:B';F&VEZ2(7
M*+ TMH"?*A.?I]BX$7O%)-SHR YFBU5HM^A:7&H:7[TA:]^\N)J(T=Q$'6Q+
M;8P%@L/K#EXBB),@7TW#G",'C-)Z8COLR<EIX-%_!JEA7-I*Z86DYO$> M H
M$9FH('AZ3?497./R 9ADL+&ZXJ867+7,T6T0F4H>C,1 2'I>D_\BAU$AMT5&
M',:N@PO8ZRZ393M25^155B)I1:&#-B1FZ$DKF[3,WO>6T%T)M'#O>]<214UB
MJ49K&S-:M !#N>_-K<']Z95"XLKJUT8C*Q(68;DD%5X0N$%[NN>?/WKN9''B
M!@IBW'AH.Q)^FH6Y^;9HB?JCD#Q:KI-M27!.VJII;!T8M?%:@9Q0,A-'86 3
MXD07E.M2IAAY@(>FAI3IV*$.2G620^J#+%J!YOR09C@I?-:1^UM%N7]@*LE5
MHA$P_$Z>J17*KIT/C!W;%1#1G@=7@3]E014$,U4:VFR]_#I@BMI;E@96X:>8
MA"2*EX7$P 5?1<%H@7A9\5>*1C+>"GU5?Z,P',JU?-UJS5BA0 "&=$Z]A=)N
M4Z72^#5],'!K:DZ"1P]UJTNDA[N<)_:Z@<_C_O#1PWI:6&9.MYID4^"P07(X
M%]S6:*&$"ZMI8&T?I:*$4EI:!$<@)Y3M8R4M\+"@$!6CT4 88#!NM6UP>.I9
M$=W%\(F.:=PVZ."M7^BF;5-F$HWSM')N"H10C%H% >,7=QM5LY3 6"$AK"N)
MF[3 S9D CVTP97IHR-DPK91OYEC>T1\B6*WRV(@S LM4K0E'I@EBUXT]5RSZ
M#JOD=&/-"8J-0V'1[/%PI>[#]-FL@P7X2 V367#+C*9%1JV[$4626A->2]EL
MR5*B4[ZFMBOJ:P6;UPHVKQ5L.JA@L^:5?[*8U8Z'X9@UC4.P@F(Z_=OKU\@,
MJ:-N)47,37\EI2XB9S4FKU%5&S%"]E5K:&(% \0X&;6 4%"A>8.W)'1)=#P*
MLQZ)W B@-$2IHV3T6I<P?%AR\>ODA)%%>4OL).0WPT<)JZH8D>5MF$@AKU)B
M&(,Y IB!D=7IJ80D41!D5Y&7I%0PJWK0;#WK3G"JE!?*O;OCN^M1&$Q#:ZZ2
MHKS^D+FLV$[PV!221.*>5KXXSZ6A#(U)Q +ISG$<S\BU%7XFL<[\41IPUZV?
MFG2!:W>MSD?H:EE\2<8TCI=10\EHL7EDK*4D+5,93"^W\8D5(0M1$%T;?$MN
MV8@16!<&^.W^U68]ZR&NXEIL/K8]R>8BOZ#B55'V0NSF>N#C[8 VQS=ID6K3
MP<KECS;$@A(BS?:]**(OCVVX,UUS#*LH_C6Q8!TO\HJZ'.2;A%&B_V#+432(
MHH0U5,.[&:-$>IO=-:7$7CW!(Z%?O(O%Z+(R9\-)8>(#0]Y,S^P4Q8%:0LJP
M64!\^5Q1NB%QSH*4LU#]Y!;O>M4SZP7"D>KDU-VUC]0@Y-$KYR((^<==)V^H
MLK?=(2L]:PT.H<2.6U_91J$+7O*S,/"N IR)#6N[7.D GK^0T':CE/;RRRC[
M-GK7Q;%9(P^[N"IKHM%<8[M5JXECY\\DXE745M2!5:">ULXYV@VB;:RXW?&:
MOV*7NBCS-/K!KM.R"_5T]1@%4<SB3*X_97%=JJ;\%]OB$FARORN^I3'TFVN(
MM]'CA^8W>9!Y$W;1VXZ)P^[<0R]LB(SNJKN#!&MCE?1M,*DYS[\$'AW&<^/%
MV(I17&9DCG=NO>X$YN;*\-NCHF?ND^L0/__]5J_U0IY?5W@MI'$J O"@8QIG
M/DM"UO^<A&Z0Q2IX:7^,T_EZ@KMGQR2$+'$S6JM'Q30D4VKGAI,)X939;C:M
MR2672%,WP"[% B3$!7\[=*-]R6481)%2A%[\] [YJDURDKA/U3(;8&2%PY#?
M\7:XR:;,</[Q\@.$%'<(5R5!2]PG 3C[9*7';D@\G.3G0JSU$[2C)4%PYQ9!
M&2'G$(.U+:PX8N<F'6GZ"LGL')IB@>88UH51VV)X2CUEZAZG+4+2WMS$&7:3
MH")!>P<MM*+P<R6 CT(6E@J^/N MP.GPN[9;W91?CA5@+\.E'YV?=E><0C=M
M.,J/;G7B=HN-QIJ <BSJHE%Z58 \_CUQJE\&IS&8)-%=VD:JRCM/,X).YSN?
M/WK!@I!;$CY1S:KFXB;@B>HDO6 0W06QY16_9U[931#_1F)JYH.I[WXAT!E'
M>'SNG,N%"&FNA> E%=!X3B-H%T&8?<1^!WV.V#'S.^@U=@U_KL?P]=OR+!%V
MB8[G_PR3.(HMWW'3NO' JM=(;G?\(7D)Y^A"1_FJLK\*Q+M(NRN2VSUHFR6<
M0PM<*T8[MR&]&37P(TJ>G[_Q4YJ[F>5GM]"6#OS CT.7;HAMOIM:VK)M26EI
M_R*[IXXFM2)7=."DT<H9MKQ,M*Q^<6IY'G%.%NO)K%V8. 5N=G%#V!JA7'.V
M)CVU<38LU?X38>] ';PG$EI3<LG>[(S.DF4"Q+;DL4"^TH[:3=-B7<Z#FM"R
M9F?%0EFGCHY[)8GNHCV4E7<.=UT.J7)\NG2WHQI;07BZ^LE=.22H$TX.1$.B
M)' WKBOJ3GF-3?O4-8"/6]VI3X!\^0G=9)_"KF?@/P54PG)I/E7/&8APBF6W
M5)_*-X1N-<$I_4+Q#T(E,:X]LIT27'\OM-XVR>.CYY+PPO59#D96Z6OXX+E3
M;D7.B!T2:C=N21RG;<2@_31U!K*W_?'O^_M[__?I^I?O_OU_]^2OW_\\/ GM
MIXNGJV^H%7FF\CGZ\^SCY^GBF'BG7\A@]OP\'Q-R;5W?G'ZY./)^=4:_?G]Q
M,Y[-GD?V_%=K8;F_AU_^_')P_' 3'$_N[L?G7SX>._[A]][!X<&O5_;=T>U?
M1XNGL7?PLS7Y2/[QW3<OH]&O]['U[B:8G/_\Y1^GMQ_OO&^^?_CIZ#?K[/0G
M\NW+7R]!,OSIM^.;Z')Z/9B0AR/;G8TN;F^/?_OF_57P^S?>[<O;^?W,=[ZY
M_=>UY8ZO1@_OW:/?#Q\.[R]'GZ)?[IVG[T>#/\/%=U/'>W1_^3;Y^?#707)P
MZG_W\/BP".[M@^?0O3OZ=O#;]W^-+JR/,_\?T<OEY2_G'Y]^>@S.3__\W^^>
MAC_='9X=C-]][PTO'@]_&CY>_>Q_68R?3I/$^7T<?UY$O\V_G!XL?IZ]'[U<
M/L[/WA[<_7XZ&,SN/_Q[[_1VO+]OQ/>HGR5M%+A5Y]D?#Q@/+"[ #,?_ U!+
M P04    " !9@5Y;H'Y0*YIK   K4@4 %0   &EN;6(M,C R-3 Y,S!?;&%B
M+GAM;.V]:7/K-KH@_'U^!2;WK5M)M4^?+>ETTLN4;,OGJ&-+;ED^Z4RJZQ8M
M0C(3BE1(RL?*KQ\L7$ 1&T$2H.][IZ9OCFT">#8 #Y[UK__G>1>")YBD01S]
M[8NW?WSS!8#1.O:#:/NW+^[O7DWN+F:S+_[/WP'X7W_]WZ]>@0\P@HF701\\
M',%%O-O?K0.P2KPHW<3)#GR9[;X"K\!CENV_?_WZ\^?/?URC;])UD, T/B1K
MF.)?@%>OT(3%E!<)Q!-^#U:/![!89^#]&_#VZ^_?OD7_']RO+L"[-^^^H4/^
MUU_#(/KUP4LA0'!'Z=^^8%9Z?DC"/\;)]O6[-V_>ORX^_()^^?TS_D7M^\_O
MR==OO_ONN]?DK^6G:<#[$$W[]O6_;J[OUH]PY[T*HC3SHC5>( V^3\DOK^.U
MEQ%**N$"PB_P3Z^*SU[A7[UZ^^[5^[=_?$[]+RC= /AK$H=P"3> 0/Y]=MS#
MOWV1!KM]B $BOWM,X(8/2)@DK_'XUQ'<8M+C1;[#B[S]$U[D/_)?7WL/,/P"
MX"_OES,A3M_5YJ*#7I=PAOCG:P1/#A7^5D(>,E7.# 8S^)S!R(<5_GCF>%W[
M)L3$CY-B(%GX;U\<TE=;S]O_UR1-899>')($1EF31"F"AD"R\=(' DX^\#66
MOM<PS-+B-Z_P;PB=^'-3W L@,10U,(N=\$4+@F1QYH4Y.]38_5?X$!)91E_A
M;0RC5_=W7_Q]M5A-KL'%_7(YG:_ Y.YNNKK[ZVLRT=_K\$Z2.F6]9%VLB_ZI
M #C_XO4Z1IMCG[T*6; W2;Q3\"2+96B]_GLG_@_"> R4 VY+V3P>]HKY6C'4
MB*-+&.(#Y]9+LB.Y@;PU/GO3\R/[E\EST#?76RS\^N\]GP2A1"STX1*(3OX9
M\"(?S.,HR7_$PP*8@I_QT'\S,N5"J-ISG16\EB2J-G8KR;P.O(<@###1AKEP
M. NXN'6:8&A=/=>SR?GL>K::31T?4&(^L3(CP-+X)F+F&TXLK-])S-I2(1@C
M\Q5<[WA/W67Q^M?'./31*VOZVR'(CCVSG;. B].@"894$.Y6BXL?/BZN+Z?+
MN__\CS^_>_OM7\#TG_>SU4_L#>-",L0,8P5$@&[O-_X>)D'LWV7H8FI/_3<<
M\I][(7ZW5E1^821^4]^+/1)Y&OGM2?Q6A\0O3Y#?=CCQF+-S$OF#GW_*Y7K?
MDVUN0RY(NE<DF,PO1WQ2ZC):<+&*26.H>"_VV#@91-OI\QY&:>\*5G-^^Z+5
M@$$D2W@B$!=? YA_7LJ, WD1\H<5$#Z"725B%JWC';R.T\%D@EGA]=]="44%
MA$ LKA=W=^!JN;@!B]OI<K*:+>9WCI_T$AYQY>($Q[JNVTHZYC ;3"[J<[M0
MR&L0",1A/D7O<202+D\%+A=8SC<1Z?W8?8+)0YS"5N3D*=?H(Q"BOSO>4NU)
M^J:#OH?]@ E\1(=U\ 3IM&C^Q6;E/?>\J60KV;^*)=!(+^4U.ZXN+@YD18-[
MK.2HD#:\J.\>/<2CQ2'#7E7L?N[;2-*8W]E+_102@:SDCTCP91 !.N8KMV]V
M$8=JCTDN<CT;(_5>ZSQ()/80+IU?%)G?L'IG2Q.EE\$=C#+Z!,-;/([0C^D
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MN$+?+#:3),&6:R)(_=_,_#4LWJE< $0FWCA$HV,<#H&N0V8,.4S8GQ?9(TQ
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MENI;>PKU%T"/C\TJ-9V8'>Q<H*>+VGU#M -.>I>>-.T=QPDGXZO&1<K#WSA
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MIK0^P!;LGE6<>2$H9J=M$?8PH2TLW199Z56":N:0WNC9P897Q,Q>5N&RZ*5
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MFLLC F3G^J(VE0>QH&K2:Q@)+LJNXC8VMQ )1N^1E*V7'YT$<X#4E>"B=B]
MLSNV[IN*@;;@BLAD+KAY FIA*QO42*58S$5FGA0B#>L3,Q;<GA3T=2& 6NRL
MB9N: J;6^I.ID;8YBP9^7FLM:?LIK0/4B)_-;=@HD2PQVN;/8=X2=Q#AY ]@
MB%0LYO[T.H%(YW$['HEJLDTE2R>8FIY2;%FG%6ZSZ*U)FPL;L?[Z*[LNY*6
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M!F!9*Y'H"$';@1HOS<)L+LF]&9D-F=HQL*N[YH]CS6A4P#C?PPQ\UD,A^\9
M.RB#&7DV:IN5J8P-\(0](?,H-M:8'JH]0?T2XZ,T<3-^F#+SC_Q)VJ_H#K2+
MM:S*3H*AQ4"*+OF^BX6XP. %!D,;H-FKCLT_$5YD]','F>\S^MF4HYWLUOW
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M)7R"84QZLP]R\NFM:5_NM. 2*5CY$")[S""P\I[1\8?5EN ) IHM@+MKN'P
MM&)ZO6:Y+H7,DPGW2#T]WH;XV1 1RSTS]5 GH?:R#EZDNK")S/'%YXY#-=IR
M]B3-4)\$IH_)&7JZ1ML -]/%?>13=,\'&;S&N3T#G8*J]5S$,BBA$L<(Y>,
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M$6&8[\K%)F_ ]3NZ#F 2Q.B[=#@MIF_H;![U/<.NJ]+(=M18C$L#"5TM;W<
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M31>;W(NR2(@C<7[ MP("NVQ0>.'AKNSGQR+[)/]0G&Z I\6L+OQ)<4*S<,X
MG9R(0=73D<Z/S^\R<:<8X=QFW9%$W*W=!]7;]V\^Z7#1J(-BV%-%/(^3[GY"
M<#0ZHG Z](VHT8F289PV)G)JV'IC$N/"@]KI\J".]CZQQ"_AS@MP>R]TO!*\
M#EY8Y,$)[=\/<@?<>>Z >VCZWXI ?C9,N^D5*8$"#%2-E$/K@F2="4VY="0'
MEOUOQFCR?(S8!+=&B&)LWCIP+!?KCR)E=CC*"GW% _+1;IV%.$%;)J)UM-9'
M1N_$R<3DQY#@EVJ&L^83@F)&5FVGB=?LI#JO,A?)B:94X<E+1Q([JN8J=QBS
M(?]CR2AM ,]_/W,QM$ED_=*.'>Q<)N4RQVWGDM"GA9U+2>41]$TPRG>D#T7K
MR:IT6:<6M-Z)V&N F)Q3EE5053%Q28X*+W3AI.RHVZ)6<LST A1XU&"N!A-[
M"KEJ1!YT0]N*WIQ63C(3R#1,+E2QX)Q71>9:PP#CT +3BL4<:XP^T6Q7F$$D
M0'=H=6=&?NDGFF5PIU10\@D8;00_ "H?')ED1/5LM1'F:ASMJ.7\Z"=EE*L^
M4M)>P:+8-5)CF@EV.VTI/(ZK@(>I9L2:D$:68WK1 S+8!&M<:X7V+47@D.<B
M4F"5;W)F-*B&@V*\H*.-$UU."T^N@M:"0G9YMX0T[V[J)=@4F2+P#KL#:=IR
M"1'$@:0X6I[ 6 P%7S*#03[Z*]=9BTK\>/S2I8K% )2BJ_-I;7(<?2<VXM1M
M.%7D<%'17/0D*WM>BVO!RVQIIZ8T4*W,%I%W+!O#D)0G3T,RSX6CH'MM9=PU
MH'IK6BJ5C1?];V$5:!!Q"*N @%/6^UD_P>@ KQ#]"C_9CT'V>('V MI B:;A
M/Y\%8#:4'D[P&4T$BIE&%WS5#G/^-=:>=K:/DRK:J)&:HQ&0)4Y#<AU\)4Q'
MTL/<HF:!O0Y!1B,M(O^"F-ZWZ"J2U6:MAI"KOC;(>8,\ 3(BCXL4=ZMY/Y66
M*5(8%&'@BXN9L"_/*+(DM5'D,:LE?2R?9$6&!CYMV;:7L@+3Q1AZ+]6:@M;+
M3;NIN2K$A\<=-?Z6K1)PB_?U$N[CI'QN'S7UA7PP*$>/M_R5%I[<"TB?0&W=
M#%66,Q(#O,AB@_V=5V'\61"RB2F1(E(0,FR\]('0(I_G-?8WO(9AEA:_(1X(
MXGW06LJV4B.!1>1?*(9@Y8:XSLDHKOG927:[FI'U]'8%!=R'C.OT A;'A/-J
MWHXETEO5$UB+&J,H67Z?PLTAO XVPO> HG(YG0#@&49:P;Q"47"IZE'&ZGZZ
MAFD*H:!J4A&U?7F /T$O67V.1;RCTYR=5KRKE95""NP#S#M9X>D FL^QV; E
M]CRV&A'06D60O#R,MT7OTVOT,HW2.%G&1R_$L&7H+Z2EL\AT7(W&OO)B/,@G
M '0&VE';96BY'I(-QW@;VKCI2<;TH'AOVHCC_5C")B58\?:5D@AVXU73[,8+
M(B05.(U?;$O!7?B8#]U>5"=0\XTF',3&T V7:;C,=6I)[IG3%M3.2X"=(L5U
M*VF0P2I?;N(('F^\Y%>871TB/Y6?/^1K0#\'Y/O15"O@(\+C@0QE:S>V)'EN
MA>V RC82BHQ",@FOM<2(,@OKB#8N[I8DLI@'>@H/*;Z+M#Y>_5V]]A.T^#":
M0E* V+[&I8MG@W7M"&2UQ@#VWN Z/="_/.!FI[1=,"UB3OYXTE'8MQ$#SVD,
M[?)>:T\DOD7)C-1V2\<S=F\VE4K0X(;OJ6:= +7\-*;+CR HSHV;6AMGOH^Z
M)<DLGLP7<8A^C&D"TF2;0+(-9;G:M1&@''*2B&K[Y!7CT3AK52B_X!K813;K
M98"3KJ+B>Q>5K\L$Y0*64M5ZJ0WUVA"\UV"E]IRV[ PJGF6X.@I]F*D2$Y@1
MY<.4GX?@POHI1(=KZ%0@;]TQ5^H)BAX>OQW00SI7J4;S*FV +U24FCA:58O+
MM]8DR@(_" ^X]555)6CZC'-]H4\#TW;[0T9V^V)3Q%L7L5!J/WWQ;HTW@%V+
MK=14K%8$_Y7KX4%E\'H90X9TJY/7KGN^]TY/KN ,Q#6KDF=ZC=!W1%'ZT[^*
M$_+K 76#O'57N23I@D'^]E)U  $->[WNI7RR^M83Y/!7^5BUKNS<QT+K$NTO
MKL,]AQH\<6A+2^M'2H<"4$P8?;WM\Y"5D?B9#Y+FW2^J,I*2LL(C9T ^6CU\
M:!YOG,@MP\57' 762>HK"S./13RLK-7[8TR(\K<!3?\OJNHY[NO7!+OI^1!@
MYM!C*ZJ$1_XHK1JG[N]453*D_3-/:L Y=^RJ<5>[>G7I9[.:*4EG*4)ARB@9
MH;_#H\[&,BRH'.&P: 8?A>:&DJ'J)NAGL<FK.7CA+$JSY$#L73266QW^@Q_"
MY7C 3* 5]>XR+$B&MS1 2$TP>\Y[F6=K"=<X7)<4#\ G.,VN\"':\4@180K&
M"3<:N:WH](#.G_L$BQ?HZ1+@BB:C%(L MIZ>P]W9"YGXMV-/U+<F,ER/^"+B
MMNQM$S* IAA_R  '3[V0 2&!7H2%JOD,.=$":BWNK+\M&WI8O57@2[5IM:-Z
MKZ8N$X8[:.8I.CM)BJ;\#<6[E0K#Z!FMWS3:P!4"7>M %88H5A^V37B(%C2D
M=D$U2T/EPL%=TPN==-4+$^I;]I7R8NG?FB84O!US0L';=@D%;YVY50\/.$</
M*3#A97QXR"8/\2'[$-,. FN81&IW:34#(%, #\\!R"0@GV5,%=>T,>:>Q"WI
M94U]_P0C/TYFT5.,+FZA>XA^!8K/W+V\ZN VCC@>-L[K1^9E]E*D4.'#=!+Y
MZ#<).H69B)26]22+*4$^)\DUS6<%S+1NMXP9*?C6>'.B6BQ?8ZQ?TQ@?QOI#
ME+/5HQ?EFO<\)OX(Z)_HW23%[]++8'D[#/C:RB.1&##SPJ89 K1ZBY6P<EYB
M!%Z  68"$AT?["-@6J^/M=Z%R4FV[X<D3E-50^5Z@B\9TFRJ[#*=MX9%X[I2
MX&L]?>0Q#GV8I%2 , SOA/&(9X+B3JZ-*PTTA.]B#K)V318:-:1P44ZVQ":W
MTA93Z5:C5BJ_Y.E("W"Q^/,8:41"F]LJ+WLHU.^*OX^ANB-7\ZHCX"#E0FU"
M/K7JNM(AY&;74\NHO9?Z?A\&,*$^1@1&O$V\W>(A#+9$H2A4ZCN892'1*\0O
M=CI3[I_%="=SG8%JMC-0S>/Z*FB-./_A;D8^NT6EO/01UXQ$_\'7V9,75AYD
MI2&&A'Z2RIGX'\SXL7K<M;#E\;(%F2S7VE0^99DZ"@(=0,L>T"PNX>KFU\58
M<.NW(]@H7%'D027,#F[KF<I-V_4 P')&QR_JM@1HX;M24=&BM4=8$$WSX%74
MBQMKD4]=M'E,;4<R>XVY^&4='A/8.8R%3"(+9!E%' L75;U(%@F5;+<D6<(U
M1+<ZNA+PBT]Q9=*G,C.$/(U'<D&*T>'M*A7RECT@'V $$R_$U[*_"Z( )]GB
M]#U%[\1\&%5=:@/'T#=1@12/+5ITL,0;?@  >9@RSGT$:EZ*-:6?7<4)UI;;
MA%S0)WFM[S&:MBA;FQ9?HYG)@V-$09RZU% '5K2CJX/.37FC@4L<3#!'E^[J
M,PR?X$T<98]"4U5I6\P'<PJB+B+GB5PZ& K/4"W*V-RQL_D/NT,$:75/6-9
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MXX9L8'&_$2+WVRE9''D('W'>^ ^"2<&@2Q:(;K.T]4W!E4?<F*L]6P'\6^H
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MFR8-'ZQ,5/H.=A;T#,>DPFO,4AJ0QRT:<RP$OD+]1G/Q&.XM8OH7X@C=(;K
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M-8DZ" +(T[7I:I5+L/YYJTK\^KT6+M'4\6N.+2K*)<8JU_N*QG[%;V@<NL4
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MV;N[ L%<"YA:TF=JBT2?<>C[(RBV[)@XC35CYBXET5U]@^:W2FMKR?WQLGR
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M,:BTKTG@=BGP'+W]7=IY4"VW="IR^!'AZ0/3I<&"_7:*DI-O]L<QHK-71K5
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M+Y!),<O1M!NI5)2S)(QP;R/LSYX$[D="-&S2LY@IE\@KGT0*"/!JDB1J.QO
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M[FX/#]=/(@+(=1![.!H&$T)G3C[C:EO$3,9'_$\\&L3_]?]02P$"% ,4
M" !8@5Y;BW6(68#W  !KGPD &               @ $     96$P,C8Q,S4V
M+3$P<5]I;FUU;F4N:'1M4$L! A0#%     @ 6(%>6R@44/FD!@  9R@  !P
M             ( !MO<  &5A,#(V,3,U-C Q97@S,2TQ7VEN;75N92YH=&U0
M2P$"% ,4    " !8@5Y;?])4HZ0&  "1*   '               @ &4_@
M96$P,C8Q,S4V,#%E>#,Q+3)?:6YM=6YE+FAT;5!+ 0(4 Q0    ( %B!7ELI
MS3N9U@,  -\/   <              "  7(% 0!E83 R-C$S-38P,65X,S(M
M,5]I;FUU;F4N:'1M4$L! A0#%     @ 6(%>6T4/UY+1 P  .Q   !P
M         ( !@@D! &5A,#(V,3,U-C Q97@S,BTR7VEN;75N92YH=&U02P$"
M% ,4    " !8@5Y;D$ @]]5D  !V:P  #0              @ &-#0$ :6UA
M9V5?,# Q+FIP9U!+ 0(4 Q0    ( %B!7EN3^Q3+JCX  "-#   -
M      "  8UR 0!I;6%G95\P,#(N:G!G4$L! A0#%     @ 6(%>6_N=.\,>
M4   %54   T              ( !8K$! &EM86=E7S P,RYJ<&=02P$"% ,4
M    " !8@5Y;*VLD;!2)  !3E   #0              @ &K 0( :6UA9V5?
M,# T+FIP9U!+ 0(4 Q0    ( %B!7EO!0T$RF;(  %N\   -
M  "  >J* @!I;6%G95\P,#4N:G!G4$L! A0#%     @ 6(%>6YU#$J\5F
MV*0   T              ( !KCT# &EM86=E7S P-BYJ<&=02P$"% ,4
M" !8@5Y;ZD7=]#*J  #_N   #0              @ 'NU0, :6UA9V5?,# W
M+FIP9U!+ 0(4 Q0    ( %B!7EM56,WX^BT  -4O   -              "
M 4N ! !I;6%G95\P,#@N:G!G4$L! A0#%     @ 6(%>6VO?GO"Z(P$ "SX!
M  T              ( !<*X$ &EM86=E7S P.2YJ<&=02P$"% ,4    " !8
M@5Y;;(0ALE-Y 0 OE@$ #0              @ %5T@4 :6UA9V5?,#$P+FIP
M9U!+ 0(4 Q0    ( %B!7EM)@M9ZGAH! ,A! 0 -              "  =-+
M!P!I;6%G95\P,3$N:G!G4$L! A0#%     @ 68%>6VMONKRVW0$ TNT!  T
M             ( !G&8( &EM86=E7S Q,BYJ<&=02P$"% ,4    " !9@5Y;
MV?CFO@S&   9T@  #0              @ %]1 H :6UA9V5?,#$S+FIP9U!+
M 0(4 Q0    ( %F!7EO?L09YT&D  .)P   -              "  ;0*"P!I
M;6%G95\P,30N:G!G4$L! A0#%     @ 68%>6]/O^!>Y#@  ,8\  !$
M         ( !KW0+ &EN;6(M,C R-3 Y,S N>'-D4$L! A0#%     @ 68%>
M6W-[D'^$"@  V7   !4              ( !EX,+ &EN;6(M,C R-3 Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( %F!7ENSZ4*GQRH  "VB @ 5
M  "  4Z."P!I;FUB+3(P,C4P.3,P7V1E9BYX;6Q02P$"% ,4    " !9@5Y;
MH'Y0*YIK   K4@4 %0              @ %(N0L :6YM8BTR,#(U,#DS,%]L
M86(N>&UL4$L! A0#%     @ 68%>6U4@S_7F+   #]X" !4
M ( !%24, &EN;6(M,C R-3 Y,S!?<')E+GAM;%!+!08     &  8 /,%   N
%4@P    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>ea0261356-10q_inmune_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:inmb="http://inmunebio.com/20250930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inmb-20250930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2025-10-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:GreatOrmondStreetHospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseOneInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseTwoInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentPhaseThreeInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentNdaEmaFilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:INKmuneLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:MilestonePaymentNdaEmaAwardedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:EachPhaseInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">inmb:EachPhaseIIIInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inmb:PITTAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inmb:MilestonePaymentsAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:UCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:UCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:AmplifyBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inmb:AmplifyBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2024-08-31</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inmb:AmendedAndRestatedAttheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inmb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-6288">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-6289">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-6290">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-6291">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-6292">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-6293">001-38793</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-63">INMUNE BIO INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-76">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-81">47-5205835</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-6294">225 NE Mizner Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-6295">Suite 640</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-6296">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-6297">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-6298">33432</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-6299">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-6300">710-0512</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-135">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-139">INMB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-6301">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-6302">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-6303">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-178">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-185">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-191">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-6304">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-6305"
      unitRef="shares">26585258</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-6306" unitRef="usd">27734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-6307" unitRef="usd">20922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="-3" id="ixv-6308" unitRef="usd">1704000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="-3" id="ixv-6309" unitRef="usd">1181000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="-3" id="ixv-6310" unitRef="usd">760000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="-3" id="ixv-6311" unitRef="usd">228000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-6312" unitRef="usd">472000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-6313" unitRef="usd">331000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-6314" unitRef="usd">30670000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-6315" unitRef="usd">22662000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-6316" unitRef="usd">878000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-6317" unitRef="usd">1064000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-6318" unitRef="usd">307000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-6319" unitRef="usd">746000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-6320" unitRef="usd">79000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-6321" unitRef="usd">16514000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-6322" unitRef="usd">33358000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-6323" unitRef="usd">39562000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-6324" unitRef="usd">6875000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-6325" unitRef="usd">6539000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-6326" unitRef="usd">25000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-6327" unitRef="usd">25000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-6328" unitRef="usd">517000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-6329" unitRef="usd">457000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-6330" unitRef="usd">140000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-6331" unitRef="usd">7357000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-6332" unitRef="usd">7221000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-6333" unitRef="usd">623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-6334" unitRef="usd">244000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-6335" unitRef="usd">7980000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-6336" unitRef="usd">7465000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-6337"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-6338"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-6339" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-6340" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" id="ixv-6341" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" id="ixv-6342" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-6343" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-6344" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-6345"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-6346"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-6347" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-6348" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" id="ixv-6349" unitRef="shares">26585258</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-6350" unitRef="shares">26585258</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" id="ixv-6351" unitRef="shares">22280451</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-6352" unitRef="shares">22280451</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-6353" unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-6354" unitRef="usd">22000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-6355" unitRef="usd">229888000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-6356" unitRef="usd">195754000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" id="ixv-6357" unitRef="usd">-764000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" id="ixv-6358" unitRef="usd">-575000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-6359" unitRef="usd">-203773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-6360" unitRef="usd">-163104000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-6361" unitRef="usd">25378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-6362" unitRef="usd">32097000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-6363" unitRef="usd">33358000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-6364" unitRef="usd">39562000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-6365" unitRef="usd">50000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="-3" id="ixv-6366" unitRef="usd">14000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-6367" unitRef="usd">2546000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-6368" unitRef="usd">2219000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-6369" unitRef="usd">7115000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c8" decimals="-3" id="ixv-6370" unitRef="usd">7369000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-6371" unitRef="usd">4887000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-6372" unitRef="usd">10067000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-6373" unitRef="usd">18330000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="-3" id="ixv-6374" unitRef="usd">25813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c0" decimals="-3" id="ixv-6375" unitRef="usd">16514000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" id="ixv-6376" unitRef="usd">7433000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-6377" unitRef="usd">12286000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-6378" unitRef="usd">41959000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c8" decimals="-3" id="ixv-6379" unitRef="usd">33182000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-6380" unitRef="usd">-7433000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-6381" unitRef="usd">-12286000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-6382" unitRef="usd">-41909000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c8" decimals="-3" id="ixv-6383" unitRef="usd">-33168000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-6384" unitRef="usd">961000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-6385" unitRef="usd">193000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-6386" unitRef="usd">1240000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="-3" id="ixv-6387" unitRef="usd">304000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-6388" unitRef="usd">-6472000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-6389" unitRef="usd">-12093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-6390" unitRef="usd">-40669000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-6391" unitRef="usd">-32864000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-6392"
      unitRef="usdPershares">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-6393"
      unitRef="usdPershares">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-6394"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-6395"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-6396"
      unitRef="usdPershares">-1.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-6397"
      unitRef="usdPershares">-1.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="ixv-6398"
      unitRef="usdPershares">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="2"
      id="ixv-6399"
      unitRef="usdPershares">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-6400"
      unitRef="shares">26585258</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-6401"
      unitRef="shares">26585258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-6402"
      unitRef="shares">20185676</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-6403"
      unitRef="shares">20185676</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-6404"
      unitRef="shares">24141613</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-6405"
      unitRef="shares">24141613</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-6406"
      unitRef="shares">19176853</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c8"
      decimals="INF"
      id="ixv-6407"
      unitRef="shares">19176853</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-6408" unitRef="usd">-6472000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-6409" unitRef="usd">-12093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-6410" unitRef="usd">-40669000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-6411" unitRef="usd">-32864000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="-3" id="ixv-6412" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="-3" id="ixv-6413" unitRef="usd">-323000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="-3" id="ixv-6414" unitRef="usd">-189000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c8" decimals="-3" id="ixv-6415" unitRef="usd">-237000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="-3" id="ixv-6416" unitRef="usd">-6473000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="-3" id="ixv-6417" unitRef="usd">-12416000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-6418" unitRef="usd">-40858000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c8" decimals="-3" id="ixv-6419" unitRef="usd">-33101000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-6420"
      unitRef="shares">22280451</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-6421" unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-6422" unitRef="usd">195754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" id="ixv-6423" unitRef="usd">-575000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="-3" id="ixv-6424" unitRef="usd">-163104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-6425" unitRef="usd">32097000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c14" decimals="-3" id="ixv-6426" unitRef="usd">2076000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c17" decimals="-3" id="ixv-6427" unitRef="usd">2076000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c13"
      decimals="INF"
      id="ixv-6428"
      unitRef="shares">649860</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="-3" id="ixv-6429" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c14" decimals="-3" id="ixv-6430" unitRef="usd">5272000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c17" decimals="-3" id="ixv-6431" unitRef="usd">5273000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c13"
      decimals="INF"
      id="ixv-6432"
      unitRef="shares">100</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c14" decimals="-3" id="ixv-6433" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c17" decimals="-3" id="ixv-6434" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c15" decimals="-3" id="ixv-6435" unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c17" decimals="-3" id="ixv-6436" unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c16" decimals="-3" id="ixv-6437" unitRef="usd">-9739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c17" decimals="-3" id="ixv-6438" unitRef="usd">-9739000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ixv-6439"
      unitRef="shares">22930411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-6440" unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-6441" unitRef="usd">203103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-6442" unitRef="usd">-610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-6443" unitRef="usd">-172843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-6444" unitRef="usd">29673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c24" decimals="-3" id="ixv-6445" unitRef="usd">1534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c27" decimals="-3" id="ixv-6446" unitRef="usd">1534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c23"
      decimals="INF"
      id="ixv-6447"
      unitRef="shares">3654847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="-3" id="ixv-6448" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="-3" id="ixv-6449" unitRef="usd">22267000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c27" decimals="-3" id="ixv-6450" unitRef="usd">22271000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c25" decimals="-3" id="ixv-6451" unitRef="usd">-153000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c27" decimals="-3" id="ixv-6452" unitRef="usd">-153000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c26" decimals="-3" id="ixv-6453" unitRef="usd">-24458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="-3" id="ixv-6454" unitRef="usd">-24458000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c28"
      decimals="INF"
      id="ixv-6455"
      unitRef="shares">26585258</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-6456" unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="-3" id="ixv-6457" unitRef="usd">226904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" id="ixv-6458" unitRef="usd">-763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" id="ixv-6459" unitRef="usd">-197301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-6460" unitRef="usd">28867000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c33" decimals="-3" id="ixv-6461" unitRef="usd">2984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c6" decimals="-3" id="ixv-6462" unitRef="usd">2984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c34" decimals="-3" id="ixv-6463" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="-3" id="ixv-6464" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c35" decimals="-3" id="ixv-6465" unitRef="usd">-6472000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-6466" unitRef="usd">-6472000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c36"
      decimals="INF"
      id="ixv-6467"
      unitRef="shares">26585258</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="-3" id="ixv-6468" unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" id="ixv-6469" unitRef="usd">229888000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" id="ixv-6470" unitRef="usd">-764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" id="ixv-6471" unitRef="usd">-203773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-6472" unitRef="usd">25378000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c40"
      decimals="INF"
      id="ixv-6473"
      unitRef="shares">17950776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-6474" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-6475" unitRef="usd">159143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-6476" unitRef="usd">-799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-6477" unitRef="usd">-121022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="-3" id="ixv-6478" unitRef="usd">37340000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c46" decimals="-3" id="ixv-6479" unitRef="usd">1779000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c49" decimals="-3" id="ixv-6480" unitRef="usd">1779000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c47" decimals="-3" id="ixv-6481" unitRef="usd">130000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c49" decimals="-3" id="ixv-6482" unitRef="usd">130000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c48" decimals="-3" id="ixv-6483" unitRef="usd">-11025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c49" decimals="-3" id="ixv-6484" unitRef="usd">-11025000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c50"
      decimals="INF"
      id="ixv-6485"
      unitRef="shares">17950776</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-6486" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-6487" unitRef="usd">160922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="-3" id="ixv-6488" unitRef="usd">-669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c53" decimals="-3" id="ixv-6489" unitRef="usd">-132047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c54" decimals="-3" id="ixv-6490" unitRef="usd">28224000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c56" decimals="-3" id="ixv-6491" unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c59" decimals="-3" id="ixv-6492" unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c55"
      decimals="INF"
      id="ixv-6493"
      unitRef="shares">198364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c56" decimals="-3" id="ixv-6494" unitRef="usd">2032000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c59" decimals="-3" id="ixv-6495" unitRef="usd">2032000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash
      contextRef="c55"
      decimals="INF"
      id="ixv-6496"
      unitRef="shares">1557592</inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c55" decimals="-3" id="ixv-6497" unitRef="usd">2000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c56" decimals="-3" id="ixv-6498" unitRef="usd">13463000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c59" decimals="-3" id="ixv-6499" unitRef="usd">13465000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c57" decimals="-3" id="ixv-6500" unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c59" decimals="-3" id="ixv-6501" unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-6502" unitRef="usd">-9746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c59" decimals="-3" id="ixv-6503" unitRef="usd">-9746000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c60"
      decimals="INF"
      id="ixv-6504"
      unitRef="shares">19706732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-6505" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-6506" unitRef="usd">178767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c62" decimals="-3" id="ixv-6507" unitRef="usd">-713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c63" decimals="-3" id="ixv-6508" unitRef="usd">-141793000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c64" decimals="-3" id="ixv-6509" unitRef="usd">36281000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c65" decimals="-3" id="ixv-6510" unitRef="usd">1719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c7" decimals="-3" id="ixv-6511" unitRef="usd">1719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash
      contextRef="c66"
      decimals="INF"
      id="ixv-6512"
      unitRef="shares">2390022</inmb:StockIssuedDuringShareCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c66" decimals="-3" id="ixv-6513" unitRef="usd">2000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c65" decimals="-3" id="ixv-6514" unitRef="usd">12290000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash contextRef="c7" decimals="-3" id="ixv-6515" unitRef="usd">12292000</inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash>
    <inmb:StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock
      contextRef="c66"
      decimals="INF"
      id="ixv-6516"
      unitRef="shares">75697</inmb:StockIssuedDuringPeriodSharesReclassificationFromRedeemableCommonStock>
    <inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock contextRef="c65" decimals="-3" id="ixv-6517" unitRef="usd">799000</inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock>
    <inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock contextRef="c7" decimals="-3" id="ixv-6518" unitRef="usd">799000</inmb:StockIssuedDuringPeriodValueReclassificationFromRedeemableCommonStock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c67" decimals="-3" id="ixv-6519" unitRef="usd">-323000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="-3" id="ixv-6520" unitRef="usd">-323000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c68" decimals="-3" id="ixv-6521" unitRef="usd">-12093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-6522" unitRef="usd">-12093000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c69"
      decimals="INF"
      id="ixv-6523"
      unitRef="shares">22172451</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c69" decimals="-3" id="ixv-6524" unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c70" decimals="-3" id="ixv-6525" unitRef="usd">193575000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c71" decimals="-3" id="ixv-6526" unitRef="usd">-1036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c72" decimals="-3" id="ixv-6527" unitRef="usd">-153886000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c73" decimals="-3" id="ixv-6528" unitRef="usd">38675000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-6529" unitRef="usd">-40669000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-6530" unitRef="usd">-32864000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-6531" unitRef="usd">6594000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="-3" id="ixv-6532" unitRef="usd">5848000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c8" decimals="-3" id="ixv-6533" unitRef="usd">-73000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <inmb:GainOnSettlementOfAccountsPayable contextRef="c0" decimals="-3" id="ixv-6534" unitRef="usd">626000</inmb:GainOnSettlementOfAccountsPayable>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-6535" unitRef="usd">28000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c0" decimals="-3" id="ixv-6536" unitRef="usd">16514000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="-3" id="ixv-6537" unitRef="usd">523000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c8" decimals="-3" id="ixv-6538" unitRef="usd">-796000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="-3" id="ixv-6539" unitRef="usd">532000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c8" decimals="-3" id="ixv-6540" unitRef="usd">-226000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="-3" id="ixv-6541" unitRef="usd">141000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c8" decimals="-3" id="ixv-6542" unitRef="usd">-646000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <inmb:IncreaseDecreaseInPrepaidExpensesRelatedParty contextRef="c8" decimals="-3" id="ixv-6543" unitRef="usd">-127000</inmb:IncreaseDecreaseInPrepaidExpensesRelatedParty>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" id="ixv-6544" unitRef="usd">667000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c8" decimals="-3" id="ixv-6545" unitRef="usd">-49000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-6546" unitRef="usd">962000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c8" decimals="-3" id="ixv-6547" unitRef="usd">2689000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c8" decimals="-3" id="ixv-6548" unitRef="usd">20000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="c0" decimals="-3" id="ixv-6549" unitRef="usd">-517000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="c8" decimals="-3" id="ixv-6550" unitRef="usd">60000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-6551" unitRef="usd">-61000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c8" decimals="-3" id="ixv-6552" unitRef="usd">-18000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-6553" unitRef="usd">-19638000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="-3" id="ixv-6554" unitRef="usd">-22348000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-6555" unitRef="usd">899000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-6556" unitRef="usd">-899000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-6557" unitRef="usd">27544000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c8" decimals="-3" id="ixv-6558" unitRef="usd">27789000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" id="ixv-6559" unitRef="usd">1000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebt contextRef="c8" decimals="-3" id="ixv-6560" unitRef="usd">7500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-6561" unitRef="usd">27545000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="-3" id="ixv-6562" unitRef="usd">20289000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" id="ixv-6563" unitRef="usd">-196000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="-3" id="ixv-6564" unitRef="usd">-237000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-6565" unitRef="usd">6812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="-3" id="ixv-6566" unitRef="usd">-2296000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-6567" unitRef="usd">20922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c44" decimals="-3" id="ixv-6568" unitRef="usd">35848000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-6569" unitRef="usd">27734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c73" decimals="-3" id="ixv-6570" unitRef="usd">33552000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c8" decimals="-3" id="ixv-6571" unitRef="usd">661000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-6572" unitRef="usd">702000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-2948">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 1&lt;/span&gt; &#x2013; ORGANIZATION AND DESCRIPTION
OF BUSINESS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;INmune Bio Inc. (the &#x201c;Company&#x201d; or &#x201c;INmune Bio&#x201d;)
was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical company focused on developing
and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. INmune Bio has three product platforms.&#160;The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases and was used for its Alzheimer&#x2019;s
clinical trial (&#x201c;XPro&#x201d;). The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem cell product currently
being developed to treat recessive dystrophic epidermolysis bullosa (&#x201c;RDEB&#x201d;). The Natural Killer Cell Priming Platform includes
INKmune aimed at priming the patient&#x2019;s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio&#x2019;s
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors
and chronic inflammation.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0" id="ixv-2957">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 2&lt;/span&gt; &#x2013; GOING CONCERN &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant
revenue from the commercialization of its product candidates. During the nine months ended September 30, 2025, the Company incurred a
net loss of $40.7&#160;million and had net cash flows used in operating activities of $19.6&#160;million. Given the Company&#x2019;s projected
operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations
through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In response to these conditions, management is
currently evaluating different strategies to obtain the required funding of future operations. Financing strategies may include, but are
not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding,
collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. There can be no assurances
that the Company will be able to secure additional financing, or if available, that it will be sufficient to meet its needs or on favorable
terms. Because management&#x2019;s plans have not yet been finalized and are not within the Company&#x2019;s control, the implementation
of such plans cannot be considered probable. As a result, the Company has concluded that management&#x2019;s plans do not alleviate substantial
doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited condensed consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-6573" unitRef="usd">-40700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-5" id="ixv-6574" unitRef="usd">-19600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2972">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 3&lt;/span&gt; &#x2013; SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US
GAAP&#x201d;), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. &lt;/span&gt;These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company&#x2019;s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s product candidates are still
in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There can be no assurance that the Company&#x2019;s
research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products. The Company operates in an environment of rapid change in technology and substantial
competition from other pharmaceutical and biotechnology companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company relies and expects to continue to
rely on a small number of vendors to manufacture supplies and materials for its use in the clinical trial programs. These programs could
be adversely affected by a significant interruption in these manufacturing services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Preparing financial statements in conformity with
US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
Actual results and outcomes may differ from management&#x2019;s estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures certain assets and liabilities
in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following
three categories:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;2: Observable prices that
are based on inputs not quoted on active markets but corroborated by market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;3: Unobservable inputs are
used when little or no market data is available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities are classified based on
the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification
on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets
or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of
the fair value measurement hierarchy during the years presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of financial instruments
such as cash and cash equivalents, research and development tax credit receivable, other tax receivable, prepaid expenses, and accounts
payable and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash
equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation
limits. The Company maintains its cash deposits with major financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Tax Incentive Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, through its wholly owned subsidiary
in Australia (&#x201c;AUS&#x201d;), participates in the Australian research and development tax incentive program, such that a percentage
of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected
as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is
reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration
can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information
at the time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, through its wholly owned subsidiary
in the United Kingdom (&#x201c;UK&#x201d;), participates in the research and development program provided by the United Kingdom tax relief
program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government,
and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax
incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred
and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to
the Company based on available information at the time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment is recorded at cost and depreciated
using the straight-line method over the estimated useful lives of the assets and consist of scientific equipment with a 5 year life. Repairs
and maintenance costs are charged to expense as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined and the in-process research and development intangible assets will be amortized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair value, an impairment loss is recognized in an amount
equal to that excess.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#x2019;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#x2019;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#x2019;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#x2019;s fair value
at $0, resulting in a recorded impairment of $16,514,000 which was recorded during the second quarter of 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,195,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,296,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,139,480&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,241,045&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires
the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can
materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally
require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined
from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate
weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for
forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;)
costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development
costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies,
clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead
costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development
activities on the Company&#x2019;s behalf.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the
periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the liability method of accounting
for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable
to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial statements are presented
in the U.S. dollar (&#x201c;$&#x201d;), which is the Company&#x2019;s reporting currency, while its functional currencies are the U.S. Dollar
for its U.S. based operations, British Pound (&#x201c;GBP&#x201d;) for its United Kingdom-based operations and Australian Dollars (&#x201c;AUD&#x201d;)
for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#x2019;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has one primary business activity
and operates in one reportable segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s chief operating decision maker
(&#x201c;CODM&#x201d;) is its Chief Executive Officer who evaluates performance and makes operating decisions about allocating resources
based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed
by the CODM are consistent with these financial statements and footnotes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,&#160;&lt;i&gt;Income
Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU 2023-09&#x201d;). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024 and for interim periods
for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact that
the adoption of ASU 2023-09 may have on its consolidated financial statements.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;i&gt;Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40):&#160;&lt;i&gt;Disaggregation of Income
Statement Expenses&lt;/i&gt;&#160;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company&#x2019;s current financial position, results of operations or
financial statement disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 4, 2025, the One Big Beautiful Bill Act
(&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as expensing of U.S. research expenditures
and eligible capital expenditures, the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications
to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The impacts of the
OBBBA are reflected in our results for the quarter ended September 30, 2025, and there was no impact to our income tax expense or effective
income tax rate.&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2977">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US
GAAP&#x201d;), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. &lt;/span&gt;These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company&#x2019;s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-3005">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s product candidates are still
in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There can be no assurance that the Company&#x2019;s
research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products. The Company operates in an environment of rapid change in technology and substantial
competition from other pharmaceutical and biotechnology companies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company relies and expects to continue to
rely on a small number of vendors to manufacture supplies and materials for its use in the clinical trial programs. These programs could
be adversely affected by a significant interruption in these manufacturing services.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-3024">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Preparing financial statements in conformity with
US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
Actual results and outcomes may differ from management&#x2019;s estimates and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-3032">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures certain assets and liabilities
in accordance with authoritative guidance which requires fair value measurements to be classified and disclosed in one of the following
three categories:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;1: Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;2: Observable prices that
are based on inputs not quoted on active markets but corroborated by market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level&#160;3: Unobservable inputs are
used when little or no market data is available.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities are classified based on
the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification
on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets
or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of
the fair value measurement hierarchy during the years presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of financial instruments
such as cash and cash equivalents, research and development tax credit receivable, other tax receivable, prepaid expenses, and accounts
payable and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-3070">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash
equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation
limits. The Company maintains its cash deposits with major financial institutions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c0" id="ixv-3079">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Tax Incentive Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, through its wholly owned subsidiary
in Australia (&#x201c;AUS&#x201d;), participates in the Australian research and development tax incentive program, such that a percentage
of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected
as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is
reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration
can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information
at the time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, through its wholly owned subsidiary
in the United Kingdom (&#x201c;UK&#x201d;), participates in the research and development program provided by the United Kingdom tax relief
program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government,
and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax
incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred
and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to
the Company based on available information at the time.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-3091">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment is recorded at cost and depreciated
using the straight-line method over the estimated useful lives of the assets and consist of scientific equipment with a 5 year life. Repairs
and maintenance costs are charged to expense as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c2" id="ixv-6575">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0" id="ixv-3100">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined and the in-process research and development intangible assets will be amortized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair value, an impairment loss is recognized in an amount
equal to that excess.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#x2019;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#x2019;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#x2019;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#x2019;s fair value
at $0, resulting in a recorded impairment of $16,514,000 which was recorded during the second quarter of 2025.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c0" decimals="0" id="ixv-6576" unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="0" id="ixv-6577" unitRef="usd">16514000</us-gaap:AssetImpairmentCharges>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-3129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,195,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,296,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,139,480&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,241,045&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-3137">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At September 30, 2025 and 2024, the Company had
potentially issuable shares as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,195,342&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,296,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,944,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,139,480&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,241,045&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c74"
      decimals="INF"
      id="ixv-6578"
      unitRef="shares">7195342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c75"
      decimals="INF"
      id="ixv-6579"
      unitRef="shares">6296807</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c76"
      decimals="INF"
      id="ixv-6580"
      unitRef="shares">3944138</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c77"
      decimals="INF"
      id="ixv-6581"
      unitRef="shares">3944238</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-6582"
      unitRef="shares">11139480</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c8"
      decimals="INF"
      id="ixv-6583"
      unitRef="shares">10241045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-3187">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-3198">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires
the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can
materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally
require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined
from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate
weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for
forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-3207">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;)
costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development
costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies,
clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead
costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development
activities on the Company&#x2019;s behalf.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the
periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-3234">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the liability method of accounting
for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable
to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect
on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-3242">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial statements are presented
in the U.S. dollar (&#x201c;$&#x201d;), which is the Company&#x2019;s reporting currency, while its functional currencies are the U.S. Dollar
for its U.S. based operations, British Pound (&#x201c;GBP&#x201d;) for its United Kingdom-based operations and Australian Dollars (&#x201c;AUD&#x201d;)
for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&#x2019;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-3250">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has one primary business activity
and operates in one reportable segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s chief operating decision maker
(&#x201c;CODM&#x201d;) is its Chief Executive Officer who evaluates performance and makes operating decisions about allocating resources
based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed
by the CODM are consistent with these financial statements and footnotes.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-3261">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,&#160;&lt;i&gt;Income
Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;&#160;(&#x201c;ASU 2023-09&#x201d;). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024 and for interim periods
for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact that
the adoption of ASU 2023-09 may have on its consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03,&#160;&lt;i&gt;Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40):&#160;&lt;i&gt;Disaggregation of Income
Statement Expenses&lt;/i&gt;&#160;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company&#x2019;s current financial position, results of operations or
financial statement disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 4, 2025, the One Big Beautiful Bill Act
(&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as expensing of U.S. research expenditures
and eligible capital expenditures, the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications
to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The impacts of the
OBBBA are reflected in our results for the quarter ended September 30, 2025, and there was no impact to our income tax expense or effective
income tax rate.&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-3284">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 4&lt;/span&gt; &#x2013; RESEARCH AND DEVELOPMENT
ACTIVITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;According to AUS tax law, the Company is allowed
an R&amp;amp;D tax credit that reduces a company&#x2019;s tax bill in AUS for expenses incurred in R&amp;amp;D subject to certain requirements.
The Company&#x2019;s Australian subsidiary submits R&amp;amp;D tax credit requests annually for research and development expenses incurred.
At September 30, 2025 and December 31, 2024, the Company recorded a research and development tax credit receivable of $1,704,000 and $1,181,000,
respectively, for R&amp;amp;D expenses incurred in Australia.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Xencor, Inc. License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On October
3, 2017, the Company entered into a license agreement (&#x201c;Xencor License Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;),
which discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. On June 10, 2021, the Company
and Xencor entered into a First Amendment to License Agreement pursuant to which, among other things, Section 3.2 of the Xencor License
Agreement was amended to change the due diligence milestones. Pursuant to the Xencor License Agreement, Xencor granted the Company an
exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license
agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor&#x2019;s
proprietary protein known as &#x201c;XPro&#x201d; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants
of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients,
in any dosage or formulation (&#x201c;Licensed Products&#x201d;). The Company believes the protein has numerous medical applications. Such
additional alternative applications of the technology are available under the Xencor License Agreement. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
also agreed to pay Xencor a&#160;5% royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by-
country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid
claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product
in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the second quarter of 2025, the Company
released the Phase 2 clinical trial results for our Alzheimer&#x2019;s drug candidate, XPro, which failed to meet the primary endpoint,
though a subgroup showed potential benefits. Due to insufficient resources to fund further trials, the Company has halted immediate plans
to develop XPro for Alzheimer&#x2019;s or other indications and are instead seeking a partner to continue these studies. As part of preparing
its interim unaudited condensed consolidated financial statements, the Company determined that the intangible asset&#x2019;s fair value
was likely below its carrying value. Following a quantitative impairment assessment, the Company estimated the asset&#x2019;s fair value
at $0, resulting in a recorded impairment of $16,514,000 during the second quarter of 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.75pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;CORDStrom License Agreement&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 6, 2025, the Company and Great Ormond
Street Hospital for Children NHS Foundation Trust (&#x201c;GOSH&#x201d;) entered into a license agreement for the exclusive commercial use
to clinical trial data associated with a GOSH study investigating the potential of CORDStrom to treat RDEB in pediatric patients (the
&#x201c;MissionEB study&#x201d;). The Company owns the intellectual property covering CORDStrom, the investigational medicinal product used
in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the manufacturing
of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing authorization
of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include a milestone payment
of up to &#xa3;6,000,000 (approximately $8.1 million as of September 30, 2025) due on the first to occur marketing authorization to be
granted by the FDA, EMA or MHRA, which had not occurred as of September 30, 2025. The Company was also required to make an upfront payment
to GOSH of approximately $0.3 million, which the Company paid during July 2025 and recorded in research and development expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the GOSH license agreement, the Company
has an obligation to provide CORDStrom to the MissionEB study at no cost. While Part 1 of the study is completed, Part 2 of the MissionEB
study is currently uninitiated due to a lack of funding by the National Health Services England (&#x201c;NHSE&#x201d;). It is unknown whether
funding for the study will be allocated by NHSE or its successor agency in the United Kingdom. The Company has not recorded an estimated
obligation for the supply of the MissionEB trial with CORDStrom as it is unknown if the MissionEB trial will resume.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;INKmune License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 29, 2015, the Company entered into
an exclusive license agreement (the &#x201c;INKmune License Agreement&#x201d;) with Immune Ventures, LLC (&#x201c;Immune Ventures&#x201d;).
Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate
any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company
agreed to the following milestone payments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Each Phase I initiation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase II initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase III initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each NDA/EMA filing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Each NDA/EMA awarded&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company agreed to pay the licensor
a royalty of&#160;1% of net sales during the life of each patent granted to the Company. The License is owned by Immune Ventures. David
Moss, the Company&#x2019;s Chief Executive Officer, Mark Lowdell, its Chief Scientific Officer, and RJ Tesi, former Chief Executive Officer
of the Company, are the owners of Immune Ventures. No sales have occurred under this license. During December 2023, the Company initiated
a Phase I trial with INKmune in patients with metastatic castration-resistant prostate cancer. At December 31, 2024 and September 30,
2025, the Company recorded $25,000&#160;payable to Immune Ventures within accounts payable and accrued liabilities &#x2013; related parties
in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The term of the agreement began on October 29,
2015 and ends on a country-by-country basis on the date of the expiration of the last to expire patent rights where patent rights exists,
unless terminated earlier in accordance with the agreement. Upon the termination of the agreement, we shall have a fully paid up, perpetual,
royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days
from the Company&#x2019;s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not
make this payment. On July&#160;20, 2018 and October 30, 2020, the parties amended the agreement under which the Company was required
achieve milestones pursuant to the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2023, the parties executed an additional
amendment to the agreement under which the Company removed the due diligence requirements to achieve reasonable commercial efforts to
bring INKmune to market. This removed all requirements of clinical trial timelines and the filing timelines of an NDA or equivalent. All
other provisions in the INKmune License Agreement shall continue in full force and effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Pittsburg License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 3, 2017, the Company entered into an
Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh.
Pursuant to the Assignment and Assumption Agreement (&#x201c;Assignment Agreement&#x201d;), Immune Ventures assigned all of its rights,
obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh &#x2013; Of the Commonwealth System
of Higher Education (&#x201c;Licensor&#x201d;) and Immune Ventures to INmune Bio (&#x201c;Licensee&#x201d;), (the &#x201c;PITT Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Consideration under the PITT Agreement includes:
(i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone
payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company owes annual maintenance fees under
the PITT Agreement in the amount of $25,000 payable on June 26 of each year until the first commercial sale. At September 30, 2025, the
Company owed the University of Pittsburgh $25,000 for annual maintenance fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon first commercial sale of a product making
use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar
quarter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Moreover, under the PITT Agreement the Licensee
is required to make milestone payments as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Each Phase I initiation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase III initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;First commercial sale of product making use of licensed technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Licensee may terminate the PITT Agreement
upon 3 months prior written notice provided all payments under the license are current. The Licensor may terminate the PITT Agreement
upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after
receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to
the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-6584" unitRef="usd">1704000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-6585" unitRef="usd">1181000</us-gaap:AccountsReceivableNetCurrent>
    <inmb:SaleOfRoyaltyPercentage contextRef="c2" decimals="2" id="ixv-6586" unitRef="pure">0.05</inmb:SaleOfRoyaltyPercentage>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c78" decimals="0" id="ixv-6587" unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:AssetImpairmentCharges contextRef="c78" decimals="INF" id="ixv-6588" unitRef="usd">16514000</us-gaap:AssetImpairmentCharges>
    <inmb:MilestonePayments contextRef="c0" decimals="0" id="ixv-6589" unitRef="gbp">6000000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c0" decimals="-5" id="ixv-6590" unitRef="usd">8100000</inmb:MilestonePayments>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c79" decimals="-5" id="ixv-6591" unitRef="usd">300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <inmb:ScheduleOfMilestonePaymentsTableTextBlock contextRef="c0" id="ixv-6592">In consideration for the patent rights, the Company
agreed to the following milestone payments:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Each Phase I initiation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase II initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase III initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each NDA/EMA filing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Each NDA/EMA awarded&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</inmb:ScheduleOfMilestonePaymentsTableTextBlock>
    <inmb:MilestonePayments contextRef="c80" decimals="-3" id="ixv-6593" unitRef="usd">25000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c81" decimals="-3" id="ixv-6594" unitRef="usd">250000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c82" decimals="-3" id="ixv-6595" unitRef="usd">350000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c83" decimals="-3" id="ixv-6596" unitRef="usd">1000000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c84" decimals="-3" id="ixv-6597" unitRef="usd">9000000</inmb:MilestonePayments>
    <inmb:PercentageOfLicensorRoyaltyPatentGrant contextRef="c2" decimals="2" id="ixv-6598" unitRef="pure">0.01</inmb:PercentageOfLicensorRoyaltyPatentGrant>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c2" decimals="0" id="ixv-6599" unitRef="usd">25000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="0" id="ixv-6600" unitRef="usd">25000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:CostMaintenance contextRef="c0" decimals="0" id="ixv-6601" unitRef="usd">25000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance contextRef="c0" decimals="0" id="ixv-6602" unitRef="usd">25000</us-gaap:CostMaintenance>
    <inmb:PercentageOfNetSalesToPayRoyalties contextRef="c0" decimals="3" id="ixv-6603" unitRef="pure">0.025</inmb:PercentageOfNetSalesToPayRoyalties>
    <inmb:ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock contextRef="c0" id="ixv-3405">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Moreover, under the PITT Agreement the Licensee
is required to make milestone payments as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Each Phase I initiation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Each Phase III initiation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;First commercial sale of product making use of licensed technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</inmb:ScheduleOfLicenseeIsRequiredToMakeMilestonePaymentsTableTextBlock>
    <inmb:MilestonePayments contextRef="c85" decimals="-3" id="ixv-6604" unitRef="usd">50000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c86" decimals="-3" id="ixv-6605" unitRef="usd">500000</inmb:MilestonePayments>
    <inmb:MilestonePayments contextRef="c87" decimals="-3" id="ixv-6606" unitRef="usd">1250000</inmb:MilestonePayments>
    <inmb:AgreementExpirationTerm contextRef="c0" id="ixv-6607">The PITT Agreement expires upon the earlier of:
(i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement;
or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).</inmb:AgreementExpirationTerm>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-3451">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 5&lt;/span&gt; &#x2013; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Quoted&lt;br/&gt; Price in&lt;br/&gt; Active&lt;br/&gt; Market&lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs &lt;br/&gt; (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;September 30, 2025:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Treasury Bills&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Money market fund&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,238&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,238&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Quoted&lt;br/&gt; Price in&lt;br/&gt; Active&lt;br/&gt; Market&lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable Inputs&lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs &lt;br/&gt; (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2024:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Treasury Bills&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Money market fund&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,588&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,588&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-3456">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Quoted&lt;br/&gt; Price in&lt;br/&gt; Active&lt;br/&gt; Market&lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs &lt;br/&gt; (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;September 30, 2025:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Treasury Bills&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Money market fund&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,238&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,238&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Quoted&lt;br/&gt; Price in&lt;br/&gt; Active&lt;br/&gt; Market&lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable Inputs&lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs &lt;br/&gt; (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2024:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;Treasury Bills&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Money market fund&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,588&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,588&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c88" decimals="-3" id="ixv-6608" unitRef="usd">10556000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c89" decimals="-3" id="ixv-6609" unitRef="usd">10556000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c92" decimals="-3" id="ixv-6610" unitRef="usd">16682000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c93" decimals="-3" id="ixv-6611" unitRef="usd">16682000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c96" decimals="-3" id="ixv-6612" unitRef="usd">27238000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c97" decimals="-3" id="ixv-6613" unitRef="usd">27238000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c100" decimals="-3" id="ixv-6614" unitRef="usd">10260000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c101" decimals="-3" id="ixv-6615" unitRef="usd">10260000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c104" decimals="-3" id="ixv-6616" unitRef="usd">10328000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c105" decimals="-3" id="ixv-6617" unitRef="usd">10328000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c108" decimals="-3" id="ixv-6618" unitRef="usd">20588000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c109" decimals="-3" id="ixv-6619" unitRef="usd">20588000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-3691">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 6&lt;/span&gt; &#x2013; COMMITMENTS&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In April
2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing
space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $76,000 each quarter during the
first year and $152,000 each quarter during the second year. The lease commencement date is August 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;As of September 30, 2025, the
maturities of our lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Present value of future lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: operating lease, current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Long-term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 88%; text-align: left"&gt;Weighted-average remaining lease term&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended September
30, 2025 the Company recognized $134,000&#160;and $229,000, respectively, of lease expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended September
30, 2024, the Company recognized $40,000&#160;and $120,000, respectively, of lease expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During April 2025, the Company&#x2019;s wholly-owned
subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments
to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c17" decimals="0" id="ixv-6620" unitRef="usd">76000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c27" decimals="0" id="ixv-6621" unitRef="usd">152000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-3699">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;As of September 30, 2025, the
maturities of our lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Present value of future lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: operating lease, current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Long-term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 88%; text-align: left"&gt;Weighted-average remaining lease term&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="-3" id="ixv-6622" unitRef="usd">68000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-6623" unitRef="usd">729000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" id="ixv-6624" unitRef="usd">405000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" id="ixv-6625" unitRef="usd">1202000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" id="ixv-6626" unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" id="ixv-6627" unitRef="usd">1080000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-6628" unitRef="usd">457000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-6629" unitRef="usd">623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-6630">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-6631" unitRef="pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense contextRef="c6" decimals="0" id="ixv-6632" unitRef="usd">134000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="0" id="ixv-6633" unitRef="usd">229000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c7" decimals="0" id="ixv-6634" unitRef="usd">40000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c8" decimals="0" id="ixv-6635" unitRef="usd">120000</us-gaap:OperatingLeaseExpense>
    <inmb:CollaborationAgreementTerm contextRef="c112" id="ixv-6636">P2Y</inmb:CollaborationAgreementTerm>
    <us-gaap:OtherCommitmentsTableTextBlock contextRef="c0" id="ixv-6637">A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-6638" unitRef="usd">1449000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear contextRef="c2" decimals="-3" id="ixv-6639" unitRef="usd">1177000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitment contextRef="c2" decimals="-3" id="ixv-6640" unitRef="usd">2626000</us-gaap:OtherCommitment>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-3829">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 7&lt;/span&gt; &#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;UCL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During
the nine months ended September 30, 2025 and 2024, the Company made payments to UCL of $132,000 and $252,000, respectively, for medical
research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company&#x2019;s Chief
Scientific and Manufacturing Officer is a professor at the University of London.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;AmplifyBio&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;At September
30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed
on behalf of the Company. During the nine months ended September 30, 2025 and 2024, the Company paid AmplifyBio $41,000&#160;and $324,000,
respectively. During 2025, AmplifyBio ceased operations. Amplify Bio&#x2019;s former CEO is on the board of directors of the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="-3" id="ixv-6641" unitRef="usd">132000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c73" decimals="-3" id="ixv-6642" unitRef="usd">252000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c113" decimals="-3" id="ixv-6643" unitRef="usd">26000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c114" decimals="-3" id="ixv-6644" unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c115" decimals="-3" id="ixv-6645" unitRef="usd">41000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c116" decimals="-3" id="ixv-6646" unitRef="usd">324000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-3850">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 8&lt;/span&gt; &#x2013; DEBT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During 2021,
the Company entered into a Loan and Security Agreement (the &#x201c;Term Loan&#x201d;) with Silicon Valley Bank and SVB Innovation Credit
Fund VIII, L.P., together (the &#x201c;Lenders&#x201d;) in which the Company borrowed $15 million. The Term Loan was secured by the Company&#x2019;s
assets. During December 2024, the Company paid off the Term Loan in full. During February 2025, the Company entered into a letter agreement
with the Lenders whereby the Term Loan was terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For the
three and nine months ended September 30, 2024, the Company recognized interest expense of $145,000&#160;and $752,000, respectively, related
to the Term Loan&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebt contextRef="c117" decimals="-6" id="ixv-6647" unitRef="usd">15000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt contextRef="c7" decimals="-3" id="ixv-6648" unitRef="usd">145000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c8" decimals="-3" id="ixv-6649" unitRef="usd">752000000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-3863">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 9&lt;/span&gt; &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Registered Direct Offerings&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During June 2025, the Company entered into securities
purchase agreements with investors whereby the Company sold 3,000,000 shares of the common stock in a registered direct offering in exchange
for gross proceeds of $18.9 million (net proceeds of approximately $17.4 million).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During September 2024, the Company entered into
securities purchase agreements with investors whereby the Company sold&#160;2,341,260&#160;shares of the Company&#x2019;s common stock
and warrants to purchase an additional&#160;2,341,260&#160;shares of the Company&#x2019;s common stock in a registered direct offering
in exchange for gross proceeds of $13.0&#160;million (net proceeds of approximately $12.0&#160;million).&#160;Directors&#160;and officers
that participated in the offering paid a combined offering price of $6.50&#160;per share and warrant, and other investors paid a combined
offering price of $5.50&#160;per share and warrant. The warrants are exercisable until March 16, 2030 and the exercise price is $6.40.
The Company determined the warrants were equity classified. The fair value of the warrants was approximately $9.1&#160;million and was
calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount
rate of&#160;3.41% based on the applicable US Treasury bill rate (2) expected life of&#160;5.5&#160;years, (3) expected volatility of
approximately&#160;92% based on the trading history of the Company, and (4)&#160;zero&#160;expected dividends.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During April 2024, the Company entered into a
securities purchase agreement with an investor whereby the Company sold&#160;986,000&#160;shares of the Company&#x2019;s common stock and
warrants to purchase an additional&#160;986,000&#160;shares of the Company&#x2019;s common stock in a registered direct offering in exchange
for gross proceeds of approximately $9.7&#160;million (net proceeds of approximately $8.9&#160;million). The exercise price of the warrants
is $9.84&#160;and the warrants are exercisable until April 29, 2026. The Company determined that the warrants were equity classified.
The fair value of the warrants was approximately $5.8&#160;million and was calculated using the Black-Scholes option-pricing model. Variables
used in the Black-Scholes option-pricing model include: (1) discount rate of&#160;4.97% based on the applicable US Treasury bill rate
(2) expected life of&#160;2.0&#160;years, (3) expected volatility of approximately&#160;77% based on the trading history of the Company,
and (4)&#160;zero&#160;expected dividends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During April 2024, the Company entered into securities
purchase agreements with investors whereby the Company sold&#160;571,592&#160;shares of the Company&#x2019;s common stock and warrants
to purchase an additional&#160;571,592&#160;shares of the Company&#x2019;s common stock in a registered direct offering in exchange for
gross proceeds of approximately $4.8&#160;million (net proceeds of approximately $4.5&#160;million).&#160;&lt;span style="background-color: white"&gt;Directors&lt;/span&gt;&#160;and
officers that participated in the offering paid a combined offering price of $8.445&#160;per share and warrant, and other investors paid
$8.32&#160;per share and warrant. The exercise price of the warrants is $9.152, and the warrants are exercisable for two years from the
issuance dates. The Company determined the warrants were equity classified. The fair value of the warrants was approximately $3.0&#160;million
and was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1)
discount rate of&#160;4.89% based on the applicable US Treasury bill rate (2) expected life of&#160;2.0&#160;years, (3) expected volatility
of approximately&#160;78% based on the trading history of the Company, and (4)&#160;zero&#160;expected dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Common Stock &#x2013; At the Market Offering&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During March 2021, the Company entered into a
sales agreement (&#x201c;Sales Agreement&#x201d;) with BTIG, LLC (&#x201c;BTIG&#x201d;), as sales agent, to establish an At-The-Market (&#x201c;ATM&#x201d;)
offering program of up to $45&#160;million of common stock, subject to certain limitations on the amount of common stock that may be offered
and sold by the Company set forth in the sales agreement. During August 2023, the Company and BTIG entered into Amendment No. 1 to the
Sales Agreement. The Company is required to pay BTIG a commission of&#160;3% of the gross proceeds from the sale of shares. During the
nine months ended September 30, 2024, the Company issued and sold&#160;198,364&#160;shares of common stock at an average price of $10.56&#160;per
share under the ATM program. The aggregate net proceeds were approximately $2.0&#160;million after commission expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During August 2024, the Company entered into an
amended and restated at-the-market sales agreement with RBC Capital Markets LLC and BTIG (together, the &#x201c;Sales Agents&#x201d;) relating
to the offer and sale of shares of our common stock with an aggregate offering price of up to $75.0&#160;million. This amended and restated
at-the-market sales agreement replaced the Sales Agreement entered into with BTIG in March 2021, as amended in August 2023. The Company
is required to pay the Sales Agents a commission of&#160;3% of the gross proceeds from the sale of shares.&#160;During the nine months
ended September 30, 2024, the Company issued and sold&#160;48,762&#160;shares of common stock at an average price of $6.96&#160;per share
under the ATM program. The aggregate net proceeds were approximately $0.3&#160;million after commission expenses. During the nine months
ended September 30, 2025, the Company issued and sold&#160;1,304,707&#160;shares of common stock at an average price of $8.01&#160;per
share under the ATM program. The aggregate net proceeds were approximately $10.1&#160;million after commission expenses. At September
30, 2025, the Company had $64.5&#160;million of common stock available under the amended and restated at-the-market agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During July 2023, the Company sold&#160;75,697&#160;shares of its common
stock at an average price of $10.56&#160;per share under the ATM program. The aggregate net proceeds were approximately $775,000&#160;after
offering expenses. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior
to the time the shares were sold.&#160;&#160; The Company reclassified&#160;75,697&#160;shares, with an aggregate purchase price of $799,000&#160;of
its common stock as temporary equity presented outside stockholders&#x2019; equity as a result of potential rescission rights. As
of September 30, 2024, the rescission rights for these shares lapsed and the shares were reclassified to permanent equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Stock options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During August 2025, the Company modified stock
option awards held by its former Chief Executive Officer to extend the post-termination exercise period and provide that unvested stock
options shall continue to vest pursuant to the severance agreement, which will result in additional stock-based compensation expense of
up to $2.4&#160;million to be expensed over the remaining original vesting term, if any, of the stock option awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table summarizes stock option activity during the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except share and per share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,203,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,218&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Options cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,195,342&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,379,014&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended September
30, 2025, the Company recognized stock-based compensation expense of approximately $3.0 million and $6.6 million, respectively, related
to the vesting of stock options. During the three and nine months ended September 30, 2024, the Company recognized stock-based compensation
expense of approximately $1.7 million and $5.8 million, respectively, related to the vesting of stock options. As of September 30, 2025,
there was approximately $8.0 million of total unrecognized compensation cost related to non-vested stock options which is expected to
be recognized over a weighted-average period of 2.63 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issued&#160;warrants to the Company&#x2019;s
lenders upon obtaining a loan in June 2021. The warrants have a&#160;10-year term and an exercise price of $14.05. At September 30, 2025,&#160;45,386&#160;of
these warrants are outstanding and the intrinsic value of these warrants is $0.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During April
2024, the Company issued&#160;1,557,592&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;1,557,592&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $9.59&#160;per share. The intrinsic value of
these warrants was $0&#160;as of September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During September
2024, the Company issued&#160;2,341,260&#160;warrants to investors in connection with the sale of common stock. At September 30, 2025,&#160;2,341,160&#160;of
these warrants are outstanding and are exercisable for cash at a weighted average price of $6.40&#160;per share. The intrinsic value of
these warrants was $0&#160;as of September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Stock-based Compensation by Class of Expense&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following summarizes the components of stock-based
compensation expense in the consolidated statements of operations for the nine months ended September 30, 2025 and&#160;2024 respectively:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine&#160;Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine&#160;Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;677&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,473&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,984&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,848&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Shareholder Rights Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 30, 2020, the Board of Directors (the
&#x201c;Board&#x201d;) of the Company approved and adopted a Rights Agreement, dated as of December 30, 2020, by and between the Company
and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of one preferred share purchase right (each,
a &#x201c;Right&#x201d;) for each outstanding share of the Company&#x2019;s common stock held by stockholders as of the close of business
on January 11, 2021. When exercisable, each right initially would represent the right to purchase from the Company one one-thousandth
of a share of a newly designated series of preferred stock, Series A Junior Participating Preferred Stock, par value $0.001&#160;per share,
of the Company, at an exercise price of $300.00&#160;per one one-thousandth of a Series A Junior Participating Preferred Share, subject
to adjustment. Subject to various exceptions, the Rights become exercisable in the event any person (excluding certain exempted or grandfathered
persons) becomes the beneficial owner of twenty percent&#160;or more of the Company&#x2019;s common stock without the approval of the Board.
The Rights Agreement was amended in 2021, 2022, 2023 and 2024 to extend the expiration date and shall expire on December&#160;30, 2025.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c118"
      decimals="0"
      id="ixv-6650"
      unitRef="shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c119" decimals="-5" id="ixv-6651" unitRef="usd">18900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inmb:IssuanceOfNetProceeds contextRef="c119" decimals="-5" id="ixv-6652" unitRef="usd">17400000</inmb:IssuanceOfNetProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c120"
      decimals="0"
      id="ixv-6653"
      unitRef="shares">2341260</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c120"
      decimals="0"
      id="ixv-6654"
      unitRef="shares">2341260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c120" decimals="-5" id="ixv-6655" unitRef="usd">13000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inmb:IssuanceOfNetProceeds contextRef="c8" decimals="-5" id="ixv-6656" unitRef="usd">12000000</inmb:IssuanceOfNetProceeds>
    <us-gaap:SharePrice
      contextRef="c121"
      decimals="2"
      id="ixv-6657"
      unitRef="usdPershares">6.5</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c122"
      decimals="2"
      id="ixv-6658"
      unitRef="usdPershares">5.5</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c121"
      decimals="2"
      id="ixv-6659"
      unitRef="usdPershares">6.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c123" decimals="-5" id="ixv-6660" unitRef="usd">9100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c124" decimals="4" id="ixv-6661" unitRef="pure">0.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c125" id="ixv-6662">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c124" decimals="2" id="ixv-6663" unitRef="pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="c124" decimals="0" id="ixv-6664" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c126"
      decimals="0"
      id="ixv-6665"
      unitRef="shares">986000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c126"
      decimals="0"
      id="ixv-6666"
      unitRef="shares">986000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c127" decimals="-5" id="ixv-6667" unitRef="usd">9700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inmb:IssuanceOfNetProceeds contextRef="c127" decimals="-5" id="ixv-6668" unitRef="usd">8900000</inmb:IssuanceOfNetProceeds>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c128"
      decimals="2"
      id="ixv-6669"
      unitRef="usdPershares">9.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c129" decimals="-5" id="ixv-6670" unitRef="usd">5800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c129" decimals="4" id="ixv-6671" unitRef="pure">0.0497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c129" id="ixv-6672">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c129" decimals="2" id="ixv-6673" unitRef="pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="c129" decimals="0" id="ixv-6674" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c130"
      decimals="0"
      id="ixv-6675"
      unitRef="shares">571592</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c131"
      decimals="0"
      id="ixv-6676"
      unitRef="shares">571592</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c130" decimals="-5" id="ixv-6677" unitRef="usd">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inmb:IssuanceOfNetProceeds contextRef="c130" decimals="-5" id="ixv-6678" unitRef="usd">4500000</inmb:IssuanceOfNetProceeds>
    <us-gaap:SharePrice
      contextRef="c132"
      decimals="3"
      id="ixv-6679"
      unitRef="usdPershares">8.445</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c133"
      decimals="2"
      id="ixv-6680"
      unitRef="usdPershares">8.32</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c132"
      decimals="3"
      id="ixv-6681"
      unitRef="usdPershares">9.152</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c131" decimals="-5" id="ixv-6682" unitRef="usd">3000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c127" decimals="4" id="ixv-6683" unitRef="pure">0.0489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c127" id="ixv-6684">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c127" decimals="2" id="ixv-6685" unitRef="pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="c127" decimals="0" id="ixv-6686" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <inmb:AggregateOfferingPriceAmount contextRef="c134" decimals="-6" id="ixv-6687" unitRef="usd">45000000</inmb:AggregateOfferingPriceAmount>
    <inmb:PercentageOfGrossProceeds contextRef="c134" decimals="2" id="ixv-6688" unitRef="pure">0.03</inmb:PercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c135"
      decimals="0"
      id="ixv-6689"
      unitRef="shares">198364</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c136"
      decimals="2"
      id="ixv-6690"
      unitRef="usdPershares">10.56</us-gaap:CommonStockParOrStatedValuePerShare>
    <inmb:IssuanceOfNetProceeds contextRef="c137" decimals="-5" id="ixv-6691" unitRef="usd">2000000</inmb:IssuanceOfNetProceeds>
    <inmb:AggregateOfferingPriceAmount contextRef="c138" decimals="-5" id="ixv-6692" unitRef="usd">75000000</inmb:AggregateOfferingPriceAmount>
    <inmb:PercentageOfGrossProceeds contextRef="c138" decimals="2" id="ixv-6693" unitRef="pure">0.03</inmb:PercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c139"
      decimals="0"
      id="ixv-6694"
      unitRef="shares">48762</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c69"
      decimals="2"
      id="ixv-6695"
      unitRef="usdPershares">6.96</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c120" decimals="-5" id="ixv-6696" unitRef="usd">300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c137"
      decimals="0"
      id="ixv-6697"
      unitRef="shares">1304707</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c36"
      decimals="2"
      id="ixv-6698"
      unitRef="usdPershares">8.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c137" decimals="-5" id="ixv-6699" unitRef="usd">10100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockValue contextRef="c140" decimals="-5" id="ixv-6700" unitRef="usd">64500000</us-gaap:CommonStockValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c141"
      decimals="0"
      id="ixv-6701"
      unitRef="shares">75697</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="c142"
      decimals="2"
      id="ixv-6702"
      unitRef="usdPershares">10.56</us-gaap:SharePrice>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c0" decimals="0" id="ixv-6703" unitRef="usd">775000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c143"
      decimals="0"
      id="ixv-6704"
      unitRef="shares">75697</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inmb:AggregatePurchasePrice contextRef="c143" decimals="0" id="ixv-6705" unitRef="usd">799000</inmb:AggregatePurchasePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c144" decimals="-5" id="ixv-6706" unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-3911">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table summarizes stock option activity during the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands, except share and per share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,203,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,218&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Options cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,195,342&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,379,014&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c154"
      decimals="INF"
      id="ixv-6707"
      unitRef="shares">7203307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c154"
      decimals="2"
      id="ixv-6708"
      unitRef="usdPershares">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c155" id="ixv-6709">P6Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c154" decimals="-3" id="ixv-6710" unitRef="usd">1218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c155"
      decimals="INF"
      id="ixv-6711"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c155"
      decimals="2"
      id="ixv-6712"
      unitRef="usdPershares">7.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms contextRef="c155" id="ixv-6713">P10Y</inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c155"
      decimals="INF"
      id="ixv-6714"
      unitRef="shares">107965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c155"
      decimals="2"
      id="ixv-6715"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c156"
      decimals="INF"
      id="ixv-6716"
      unitRef="shares">7195342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-6717"
      unitRef="usdPershares">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="c155" id="ixv-6718">P5Y9M18D</inmb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c156"
      decimals="INF"
      id="ixv-6719"
      unitRef="shares">5379014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-6720"
      unitRef="usdPershares">8.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c155" id="ixv-6721">P4Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c145" decimals="-5" id="ixv-6722" unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c146" decimals="-5" id="ixv-6723" unitRef="usd">6600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c147" decimals="-5" id="ixv-6724" unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c148" decimals="-5" id="ixv-6725" unitRef="usd">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c2" decimals="-5" id="ixv-6726" unitRef="usd">8000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0" id="ixv-6727">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c149" id="ixv-6728">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c149"
      decimals="2"
      id="ixv-6729"
      unitRef="usdPershares">14.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="0" id="ixv-6730" unitRef="shares">45386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="0" id="ixv-6731" unitRef="shares">45386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c2" decimals="0" id="ixv-6732" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c132"
      decimals="0"
      id="ixv-6733"
      unitRef="shares">1557592</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c150"
      decimals="0"
      id="ixv-6734"
      unitRef="shares">1557592</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c150"
      decimals="2"
      id="ixv-6735"
      unitRef="usdPershares">9.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c150" decimals="0" id="ixv-6736" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c151"
      decimals="0"
      id="ixv-6737"
      unitRef="shares">2341260</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c149"
      decimals="0"
      id="ixv-6738"
      unitRef="shares">2341160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c149"
      decimals="2"
      id="ixv-6739"
      unitRef="usdPershares">6.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c149" decimals="0" id="ixv-6740" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0" id="ixv-4088">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following summarizes the components of stock-based
compensation expense in the consolidated statements of operations for the nine months ended September 30, 2025 and&#160;2024 respectively:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine&#160;Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine&#160;Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;677&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,473&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,984&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,848&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c157" decimals="-3" id="ixv-6741" unitRef="usd">1363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c158" decimals="-3" id="ixv-6742" unitRef="usd">677000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c159" decimals="-3" id="ixv-6743" unitRef="usd">2820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c160" decimals="-3" id="ixv-6744" unitRef="usd">2375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c161" decimals="-3" id="ixv-6745" unitRef="usd">1621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c162" decimals="-3" id="ixv-6746" unitRef="usd">1042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c163" decimals="-3" id="ixv-6747" unitRef="usd">3774000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c164" decimals="-3" id="ixv-6748" unitRef="usd">3473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-6749" unitRef="usd">2984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-6750" unitRef="usd">1719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-6751" unitRef="usd">6594000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c8" decimals="-3" id="ixv-6752" unitRef="usd">5848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c152"
      decimals="3"
      id="ixv-6753"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <inmb:ExercisePricePerShare
      contextRef="c153"
      decimals="2"
      id="ixv-6754"
      unitRef="usdPershares">300</inmb:ExercisePricePerShare>
    <inmb:LegalDisclosureTextBlock contextRef="c0" id="ixv-4180">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 10&lt;/span&gt; &#x2013; LEGAL&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Dispute&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
had a dispute with a vendor in which the Company believed that the vendor did not properly provide services for which they have invoiced
the Company. The vendor invoiced the Company approximately $1.6 million, of which the Company recorded $0.2 million. During August 2025,
the Company and the vendor settled the obligation for approximately $0.2 million. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is subject to claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes
that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company&#x2019;s
consolidated financial statements, these matters are subject to inherent uncertainties and management&#x2019;s view of these matters may
change in the future.&lt;/span&gt;&lt;/p&gt;</inmb:LegalDisclosureTextBlock>
    <inmb:OutstandingInvoices contextRef="c2" decimals="-5" id="ixv-6755" unitRef="usd">1600000</inmb:OutstandingInvoices>
    <inmb:VendorInvoices contextRef="c0" decimals="-5" id="ixv-6756" unitRef="usd">200000</inmb:VendorInvoices>
    <us-gaap:SupplierFinanceProgramObligationDecreaseSettlement contextRef="c165" decimals="-5" id="ixv-6757" unitRef="usd">200000</us-gaap:SupplierFinanceProgramObligationDecreaseSettlement>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c6" id="ixv-6758">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c6" id="ixv-6759">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c6" id="ixv-6760">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c6" id="ixv-6761">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c6"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c7"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c6"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c7"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c8"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c15"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c15"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c16"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c15"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c16"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c13"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c14"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c16"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c23"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c25"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c26"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c23"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c24"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c26"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c45"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c47"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c48"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c45"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c46"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c48"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c46"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c47"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c55"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c57"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c58"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c55"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c57"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c58"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash
      contextRef="c57"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedForCash
      contextRef="c58"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c55"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c56"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c58"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c55"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:GainOnSettlementOfAccountsPayable
      contextRef="c8"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="c8"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="c8"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:IncreaseDecreaseInPrepaidExpensesRelatedParty
      contextRef="c0"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c8"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c8"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c8"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c8"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c8"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c90"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c91"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c94"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c95"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c98"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c99"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c102"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c103"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c106"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c107"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c110"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c111"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
      contextRef="c155"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c155"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c155"
      id="hidden-fact-86"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c155"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <inmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue
      contextRef="c155"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c156"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c156"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-6855">0001711754</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-6856">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-6857">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-6858">--12-31</dei:CurrentFiscalYearEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
